"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CA,A,CA 688637 A,028-586-326-903-929,1964-06-16,1964,CA 688637D A,,CA 688637T A,,DRYING APPARATUS EMPLOYING RADIANT PANEL HEATERS,,GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/028-586-326-903-929,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
2,AR,A2,AR 125324 A2,034-589-570-842-76X,2023-07-05,2023,AR P220100899 A,2022-04-08,US 201261596202 P;;US 202061625621 P;;US 202061723048 P,2012-02-07,COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN DIMETILFUMARATO,"Se proporcionan en la presente composiciones que contienen compuestos o sales farmacéuticamente aceptables que metabolizan en monometilfumarato con determinados parámetros farmacocinéticos y métodos para el tratamiento, prevención o mejora de enfermedades neurodegenerativas que incluyen esclerosis múltiple usando tales composiciones en un sujeto, en donde si las composiciones contienen dimetilfumarato, la cantidad total de dimetilfumarato en las composiciones varía de aproximadamente el 43% p/p a aproximadamente el 95% p/p. Reivindicación 1: Una cápsula que comprende una composición farmacéutica, en donde la cápsula está caracterizada porque dicha composición farmacéutica está en forma de un compacto con recubrimiento entérico que comprende fumarato de dimetilo y uno o más excipientes, y (a) la cantidad de fumarato de dimetilo es de aproximadamente 60% p/p a aproximadamente 70% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; (b) el uno o más excipientes comprende un relleno, en donde el relleno es celulosa microcristalina silicificada y la cantidad de relleno en el compacto es de aproximadamente 20% p/p a aproximadamente 35% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; (c) dicho compacto tiene una resistencia a la tracción que es igual o mayor a aproximadamente 1,5 MPa, a una presión de aplicación o compactación de aproximadamente 100 MPa, (d) el compacto está en forma de microcomprimido; y (e) la cápsula contiene una pluralidad de microcomprimidos. Reivindicación 14: La cápsula de la reivindicación 1, caracterizada porque el compacto comprende (a) fumarato de dimetilo en una cantidad de aproximadamente 65% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; (b) croscarmelosa sódica en una cantidad de aproximadamente 5,0% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; (c) celulosa microcristalina silicificada de alta densidad que tiene un tamaño de partícula medio que va de 90 a 160 mm en una cantidad de aproximadamente 29% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; (d) estearato de magnesio en una cantidad de aproximadamente 0,5% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento; y (e) sílice coloidal anhidra en una cantidad de aproximadamente 0,5% p/p del compacto, excluyendo el peso de todos los componentes de recubrimiento.",BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/034-589-570-842-76X,Amended Application,no,0,0,1,68,0,,A61K9/48;;A61K31/225;;A61P25/00,,0,0,,,,PENDING
3,US,A1,US 2005/0181041 A1,088-571-296-918-410,2005-08-18,2005,US 803404 A,2004-12-09,US 803404 A;;US 52823203 P;;US 55986204 P,2003-12-09,Method of preparation of mixed phase co-crystals with active agents,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.",MEDCRYSTALFORMS LLC,GOLDMAN DAVID,MEDCRYSTALFORMS LLC (2005-01-26),https://lens.org/088-571-296-918-410,Patent Application,yes,12,128,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,424/456;;514/179;;514/2;;514/221,3,2,081-851-849-852-645;;113-841-170-481-614,17455356;;10.1002/jps.20949;;10.1007/978-1-4757-3092-0,Zhang et al. Journal of Pharmaceutical Sciences 2007 96(5):990-995;;Reutzel-Edens et al. Solid-state pharmaceutical development: Ensuring stability through salt and polymorph screening. Pharmaceutical Stress Testing. Ed. Baertschi et al. New York:Informa Healthcare 2011 p254 and 266-267;;Drenth Principles of Protein X-ray Crystallography 1999 New York:Springer Science+Business Media p19,INACTIVE
4,CH,A,CH 456230 A,111-656-518-448-835,1968-05-15,1968,CH 1130266 A,1966-08-05,CH 1130266 A,1966-08-05,Machine à laver,,TAYLOR HOWARD D,DAVID GOLDMAN,,https://lens.org/111-656-518-448-835,Granted Patent,no,0,0,1,1,0,A01K1/035;;A01K31/00,A01K1/035;;A01K31/00,"45H,1/01",0,0,,,,EXPIRED
5,WO,A1,WO 2019/160894 A1,154-352-264-011-947,2019-08-22,2019,US 2019/0017756 W,2019-02-13,US 201862629921 P,2018-02-13,PUMPING SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,"Systems and techniques for guiding or advising users as to how to control motor speeds of pumping systems are detailed. The systems may solicit input from users and provide recommendations as to settings users may employ in connection with water-circulation systems of, principally, swimming pools and spas. The systems also may permit a user to retain control of both the duration the pool-filtration system will be active and the pump motor speed while providing suggestions to the user that may maximize efficiency of the system or minimize its power consumption (or both).",ZODIAC POOL SYSTEMS LLC;;GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/154-352-264-011-947,Patent Application,yes,4,1,3,3,0,E04H4/12;;E04H4/1245;;F04D15/0066;;F04D15/02;;F04D15/0281,E04H4/12;;F04D15/00;;F04D15/02,,0,0,,,,PENDING
6,GB,A,GB 1080288 A,141-581-641-389-492,1967-08-23,1967,GB 3086265 A,1965-07-20,GB 3086265 A,1965-07-20,Washing machine,"1,080,288. Washing machines. BETTER BUILT MACHINERY CORPORATION. July 20, 1965, No. 30862/65. Heading A4F. [Also in Division B2] In a washing machine particularly for animal cages and comprising a casing 10 for receiving the articles to be washed, water is circulated by a pump 84 (Fig. 2, not shown) through apertures 24 in a pipe 25 extending along the bottom of a V-sectioned sump 28, and discharged through a number of reaction type rotary sprays 111. The latter each comprise radially extending perforated pipes 130 at each outer end of which is mounted a nozzle member 135 having a stem 136 extending into the pipe end. Water discharged through an axial passage 143 in each stem 136 impinges upon an inclined surface 142 on the head of the nozzle member 135 causing reaction-forces upon the ends of the pipes 130 which rotate the sprayers 111. The washing water is heated by a steam coil provided above the pipe 25.",BETTER BUILT MACH CORP,GOLDMAN DAVID,,https://lens.org/141-581-641-389-492,Granted Patent,no,0,2,1,1,0,A01K31/00,A01K31/00,A4F F29A1E1B2     -;;A4F F29A2D2       -;;A4F F29A4B        -;;A4F F29A5         -;;B2F F10H3D1A2D    22;;B2F F10H3D1A2Y    22;;B2F F10H3D1A4     22;;B2F F2M           22;;B2F F8E           22,0,0,,,,EXPIRED
7,US,A1,US 2020/0041033 A1,020-294-729-604-637,2020-02-06,2020,US 201916529234 A,2019-08-01,US 201916529234 A;;US 201862713069 P,2018-08-01,VALVE ACTUATORS PRINCIPALLY FOR WATER-CIRCULATION SYSTEMS OF SWIMMING POOLS OR SPAS,"Multi-position valve actuators principally for water-circulation systems of pools and spas are detailed. At least some actuators may indicate position of an associated valve in a non-electronic manner, as by using a handle visible externally of the actuator and directly or indirectly mechanically coupled to the valve so as to move therewith. Hence, even if power to an actuator is disrupted, positioning of the valve may be determined by viewing the handle.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-09-13),https://lens.org/020-294-729-604-637,Patent Application,yes,0,2,3,3,0,F16K37/0041;;F16K37/0008;;F16K31/055;;F16K31/607;;E04H4/1209;;F16K31/53;;F16K31/046;;F16K31/05;;Y10T137/8309;;Y10T137/8292;;F16K31/043;;Y10T137/8275;;F16K31/055,F16K31/60;;E04H4/12;;F16K31/04;;F16K31/05,,0,0,,,,ACTIVE
8,AU,A1,AU 2019/222656 A1,199-185-533-202-379,2020-08-06,2020,AU 2019/222656 A,2019-02-13,US 201862629921 P;;US 2019/0017756 W,2018-02-13,Pumping systems principally for swimming pools and spas,"Systems and techniques for guiding or advising users as to how to control motor speeds of pumping systems are detailed. The systems may solicit input from users and provide recommendations as to settings users may employ in connection with water-circulation systems of, principally, swimming pools and spas. The systems also may permit a user to retain control of both the duration the pool-filtration system will be active and the pump motor speed while providing suggestions to the user that may maximize efficiency of the system or minimize its power consumption (or both).",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,,https://lens.org/199-185-533-202-379,Patent Application,no,0,0,3,3,0,E04H4/1245;;F04D15/0066;;F04D15/0281;;E04H4/12;;F04D15/02,E04H4/12;;F04D15/00;;F04D15/02,,0,0,,,,DISCONTINUED
9,CA,A,CA 379018 A,035-537-241-853-187,1939-01-17,1939,CA 379018D A,,CA 379018T A,,YARN FABRIC PACKAGE,,GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/035-537-241-853-187,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
10,CA,C,CA 2548281 C,072-462-552-386-457,2013-11-12,2013,CA 2548281 A,2004-12-09,US 52823203 P;;US 55986204 P;;US 2004/0041500 W,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.",MEDCRYSTALFORMS LLC,GOLDMAN DAVID,,https://lens.org/072-462-552-386-457,Granted Patent,no,0,0,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,0,0,,,,INACTIVE
11,TW,A,TW 201818925 A,141-942-579-408-082,2018-06-01,2018,TW 106127330 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/141-942-579-408-082,Patent of Addition,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K9/20;;A61K9/32;;A61K9/48;;A61K31/616;;A61K45/06;;A61K47/02;;A61K47/14;;A61K47/38;;A61P29/00;;A61P37/02,,0,0,,,,ACTIVE
12,US,A1,US 2019/0297699 A1,191-802-739-284-189,2019-09-26,2019,US 201916358412 A,2019-03-19,US 201916358412 A;;US 201862645380 P,2018-03-20,BINARY SIGNALING VIA POWER SWITCHING,"Described is a lighting system that includes a lighting device and a switching device. The switching device controls application of lighting power to the lighting device. Further, the lighting system includes an automation system that includes a non-transitory computer-readable medium having instructions stored thereon. The instructions are executable by a processing device to receive a lighting profile selection. Additionally, the instructions are executable to cycle the switching device to transmit a binary signal to the lighting device. The binary signal identifies the lighting profile selection and instructs the lighting device to emit a lighting profile identified by the binary signal.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-09-12),https://lens.org/191-802-739-284-189,Patent Application,yes,6,2,3,3,0,H04B3/542;;E04H4/148;;F21W2131/401;;H05B45/20;;H05B47/185;;E04H4/148;;F21W2131/401;;H04B3/542;;H05B45/20;;H05B47/185,H05B44/00,,0,0,,,,ACTIVE
13,US,B2,US 10728975 B2,036-306-445-268-164,2020-07-28,2020,US 201916358412 A,2019-03-19,US 201916358412 A;;US 201862645380 P,2018-03-20,Binary signaling via power switching,"Described is a lighting system that includes a lighting device and a switching device. The switching device controls application of lighting power to the lighting device. Further, the lighting system includes an automation system that includes a non-transitory computer-readable medium having instructions stored thereon. The instructions are executable by a processing device to receive a lighting profile selection. Additionally, the instructions are executable to cycle the switching device to transmit a binary signal to the lighting device. The binary signal identifies the lighting profile selection and instructs the lighting device to emit a lighting profile identified by the binary signal.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-09-12),https://lens.org/036-306-445-268-164,Granted Patent,yes,8,0,3,3,0,H04B3/542;;E04H4/148;;F21W2131/401;;H05B45/20;;H05B47/185;;E04H4/148;;F21W2131/401;;H04B3/542;;H05B45/20;;H05B47/185,E04H4/14;;F21W131/401;;H04B3/54;;H05B44/00;;H05B45/20;;H05B45/37;;H05B47/185,,1,0,,,"International Application No. PCT/US2019/023024, International Search Report and Written Opinion dated Jul. 16, 2019, 13 pages.",ACTIVE
14,TW,A,TW 201345520 A,129-630-755-941-541,2013-11-16,2013,TW 102104904 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID,,https://lens.org/129-630-755-941-541,Patent of Addition,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/255;;A61K9/14;;A61K9/30;;A61P25/00;;A61P29/00;;A61P37/00,,0,0,,,,ACTIVE
15,TW,A,TW 202231268 A,062-344-577-720-490,2022-08-16,2022,TW 110139187 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/062-344-577-720-490,Patent of Addition,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20;;A61K47/02;;A61K47/32;;A61K47/38;;A61P25/00,,0,0,,,,PENDING
16,US,A,US 706231 A,082-799-121-459-729,1902-08-05,1902,US 1901/0076838 A,1901-09-28,US 1901/0076838 A,1901-09-28,BOX OR RECEPTACLE.,,GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/082-799-121-459-729,Granted Patent,no,0,9,1,1,0,A45C1/12;;A45C1/12,,,0,0,,,,EXPIRED
17,WO,A2,WO 2005/055983 A2,138-529-164-208-815,2005-06-23,2005,US 2004/0041500 W,2004-12-09,US 52823203 P;;US 55986204 P,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.",MEDCRYSTALFORMS LLC;;GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/138-529-164-208-815,Patent Application,yes,0,27,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,1,0,,,See references of EP 1727520A2,PENDING
18,TW,A,TW 202102205 A,172-806-741-785-934,2021-01-16,2021,TW 109108318 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/172-806-741-785-934,Patent of Addition,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K9/20;;A61K9/32;;A61K9/48;;A61K31/616;;A61K45/06;;A61K47/02;;A61K47/14;;A61K47/38;;A61P29/00;;A61P37/02,,0,0,,,,PENDING
19,DE,A1,DE 1628823 A1,003-222-929-358-048,1970-05-21,1970,DE 1628823 A,1966-08-19,DE T0031873 A,1966-08-19,"Maschine zum Waschen von Tierkaefigen,Gestellen und anderen grossen Gegenstaenden",,TAYLOR HOWARD D,GOLDMAN DAVID,,https://lens.org/003-222-929-358-048,Patent Application,no,0,0,1,1,0,A01K1/035;;D06F17/04,A01K1/035;;D06F17/04,,0,0,,,,DISCONTINUED
20,CA,A,CA 832112 A,059-072-319-081-660,1970-01-13,1970,CA 832112D A,,CA 832112T A,,ALTERNATOR WITH ROTARY TRANSFORMER FOR SELF-EXCITATION,,LEECE NEVILLE CO,GOLDMAN DAVID,,https://lens.org/059-072-319-081-660,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
21,DE,A1,DE 1628822 A1,102-002-433-520-472,1970-07-09,1970,DE 1628822 A,1966-08-19,DE T0031872 A,1966-08-19,Tierkaefig-Waschmaschine,,TAYLOR HOWARD D,GOLDMAN DAVID,,https://lens.org/102-002-433-520-472,Patent Application,no,0,0,1,1,0,A01K1/035;;A47L15/00,A01K1/035;;A47L15/00,,0,0,,,,DISCONTINUED
22,US,A,US 3277906 A,143-125-200-235-010,1966-10-11,1966,US 15425461 A,1961-11-22,US 15425461 A,1961-11-22,Animal cage washing machine,,HOWARD D TAYLOR,DAVID GOLDMAN,,https://lens.org/143-125-200-235-010,Granted Patent,no,12,10,1,1,0,A01K1/035;;A01K1/035,A01K1/035,,0,0,,,,EXPIRED
23,EP,A2,EP 1727520 A2,141-371-862-187-389,2006-12-06,2006,EP 04813765 A,2004-12-09,US 2004/0041500 W;;US 52823203 P;;US 55986204 P,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS,,MEDCRYSTALFORMS LLC,GOLDMAN DAVID,,https://lens.org/141-371-862-187-389,Patent Application,yes,3,0,10,10,0,A61K9/10;;A61K9/146;;A61K9/148;;A61K9/4858;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/146;;A61K9/148;;A61K9/4858;;A61K9/145,A61K9/14;;A61K9/10;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,0,0,,,,DISCONTINUED
24,WO,A1,WO 2019/183135 A1,167-629-017-873-751,2019-09-26,2019,US 2019/0023024 W,2019-03-19,US 201862645380 P,2018-03-20,BINARY SIGNALING VIA POWER SWITCHING,"Described is a lighting system that includes a lighting device and a switching device. The switching device controls application of lighting power to the lighting device. Further, the lighting system includes an automation system that includes a non-transitory computer-readable medium having instructions stored thereon. The instructions are executable by a processing device to receive a lighting profile selection. Additionally, the instructions are executable to cycle the switching device to transmit a binary signal to the lighting device. The binary signal identifies the lighting profile selection and instructs the lighting device to emit a lighting profile identified by the binary signal.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,,https://lens.org/167-629-017-873-751,Patent Application,yes,5,0,3,3,0,H04B3/542;;E04H4/148;;F21W2131/401;;H05B45/20;;H05B47/185;;E04H4/148;;F21W2131/401;;H04B3/542;;H05B45/20;;H05B47/185,H05B37/02;;E04H4/14;;F21W131/401;;H04B3/54;;H05B44/00,,0,0,,,,PENDING
25,US,B2,US 9682043 B2,094-656-592-342-620,2017-06-20,2017,US 803404 A,2004-12-09,US 803404 A;;US 52823203 P;;US 55986204 P,2003-12-09,Method of preparation of mixed phase co-crystals with active agents,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.",GOLDMAN DAVID;;MEDCRYSTALFORMS LLC,GOLDMAN DAVID,MEDCRYSTALFORMS LLC (2005-01-26),https://lens.org/094-656-592-342-620,Granted Patent,yes,23,2,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K9/14;;A61K8/63;;A61K9/10;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,11,4,034-143-250-253-919;;081-851-849-852-645;;113-841-170-481-614;;022-229-833-191-061,10.1016/s0378-5173(98)00348-2;;10205617;;17455356;;10.1002/jps.20949;;10.1007/978-1-4757-3092-0;;10.1016/s0168-3659(99)00172-8;;10640575,"Lide CRC Handbook of Chemistry and Physics 2003 p. 3-246 and 3-480.;;Meyerson et al. “Crystals, Crystal Growth, and Nucleation” Handbook of Industrial Crystallization Ed. Meyerson. Woburn: Butterworth-Heinemann 2002 p. 33, and 38-39.;;Payne et al. International Journal of Pharmaceutics 1999 177:231-245.;;Zhang et al. Journal of Pharmaceutical Sciences 2007 96(5):990-995.;;Reutzel-Edens et al. Solid-state pharmaceutical development: Ensuring stability through salt and polymorph screening. Pharmaceutical Stress Testing. Ed. Baertschi et al. New York:Informa Healthcare 2011 p. 254 and 266-267.;;Drenth Principles of Protein X-ray Crystallography 1999 New York:Springer Science+Business Media p. 19.;;International Search Report for PCT/US2004/041500 (Oct. 6, 2006).;;Khan et al, “Stability characterization of controlled release coprecipitates and solid dispersions,” Journal of Controlled Release, Elsevier Science Publishers B.V., vol. 63, No. 1-2, Jan. 2000.;;Japanese Patent Office, Office Action in connection with Japanese Patent Application No. 149502/2011 (May 7, 2013).;;Japanese Patent Office, Office Action in connection with Japanese Patent Application No. 182177/2014 (May 24, 2016).;;Japanese Patent Office, Office Action in connection with Japanese Patent Application No. 182177/2014 (Aug. 18, 2015).",INACTIVE
26,US,A,US 3102007 A,092-337-177-585-560,1963-08-27,1963,US 3160260 A,1960-05-25,US 3160260 A,1960-05-25,Drying apparatus employing radiant panel heaters,,DAVID GOLDMAN,DAVID GOLDMAN,,https://lens.org/092-337-177-585-560,Granted Patent,no,7,6,1,1,0,F26B3/28;;F26B9/06;;F26B23/04;;F26B23/04;;F26B3/28;;F26B9/06,F26B3/28;;F26B9/06;;F26B23/04,,0,0,,,,EXPIRED
27,WO,A3,WO 2005/055983 A3,099-257-885-549-485,2007-03-01,2007,US 2004/0041500 W,2004-12-09,US 52823203 P;;US 55986204 P,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.",MEDCRYSTALFORMS LLC;;GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/099-257-885-549-485,Search Report,yes,6,0,10,10,0,A61K9/10;;A61K9/146;;A61K9/148;;A61K9/4858;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/146;;A61K9/148;;A61K9/4858;;A61K9/145,A61K9/14;;A61K9/10;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,1,1,022-229-833-191-061,10.1016/s0168-3659(99)00172-8;;10640575,"KHAN M A ET AL: ""Stability characterization of controlled release coprecipitates and solid dispersions"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 63, no. 1-2, January 2000 (2000-01-01), pages 1 - 6, XP004185066, ISSN: 0168-3659",PENDING
28,US,A,US 3277907 A,153-220-280-080-992,1966-10-11,1966,US 26500663 A,1963-03-08,US 26500663 A,1963-03-08,Animal cage washer,,HOWARD D TAYLOR,DAVID GOLDMAN,,https://lens.org/153-220-280-080-992,Granted Patent,no,11,13,1,1,0,A01K1/035;;B08B3/02;;B08B9/0861;;A01K1/035;;B08B3/02;;B08B9/0861,A01K1/035;;A47L15/23,,0,0,,,,EXPIRED
29,JP,A,JP 2011256175 A,018-518-274-927-330,2011-12-22,2011,JP 2011149502 A,2011-07-05,US 52823203 P;;US 55986204 P,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTAL WITH ACTIVE AGENT,"PROBLEM TO BE SOLVED: To achieve increased apparent solubility, increased dissolution rate, reduced melting point of the active agent, and decrease in crystallinity of the active agent.SOLUTION: There is provide a method of preparing a mixed phase co-crystal by producing a mixed co-crystal material. The mixed phase co-crystal material, which is prepared with the active agent and one or more materials that allows the modification of the active agent to a new physical/crystal form with a unique property useful for the delivery of the active agent, produce supersaturated concentration of the active agent for a prolonged period of time when suspended in water, which facilitates absorption in vivo. The change in property of the active agent is particularly advantageous for the delivery of the active agent, e.g., in an oral dosage form.",MEDCRYSTALFORMS LLC,GOLDMAN DAVID,,https://lens.org/018-518-274-927-330,Patent Application,no,2,10,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K47/02;;A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/4422;;A61K31/496;;A61K31/56;;A61K31/573;;A61K38/00;;A61K45/00;;A61K47/04;;A61K47/10;;A61K47/12;;A61K47/18;;A61K47/22;;A61K47/24;;A61K47/26;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/44,,0,0,,,,PENDING
30,DE,A1,DE 1763920 A1,055-851-238-301-251,1972-01-05,1972,DE 1763920 A,1968-09-06,US 68412967 A,1967-11-20,Selbsterregungs-Wechselstromgenerator-System,,LEECE NEVILLE CO,GOLDMAN DAVID,,https://lens.org/055-851-238-301-251,Patent Application,no,0,3,3,3,0,H02J7/30;;H02K19/28;;H02J7/30;;H02K19/28,H02J7/30;;H02K19/28,,0,0,,,,DISCONTINUED
31,WO,A1,WO 2020/028664 A1,087-973-296-152-756,2020-02-06,2020,US 2019/0044667 W,2019-08-01,US 201862713069 P,2018-08-01,VALVE ACTUATORS PRINCIPALLY FOR WATER-CIRCULATION SYSTEMS OF SWIMMING POOLS AND SPAS,"Multi-position valve actuators principally for water-circulation systems of pools and spas are detailed. At least some actuators may indicate position of an associated valve in a non-electronic manner, as by using a handle visible externally of the actuator and directly or indirectly mechanically coupled to the valve so as to move therewith. Hence, even if power to an actuator is disrupted, positioning of the valve may be determined by viewing the handle.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,,https://lens.org/087-973-296-152-756,Patent Application,yes,11,0,3,3,0,F16K37/0041;;F16K37/0008;;F16K31/055;;F16K31/607;;E04H4/1209;;F16K31/53;;F16K31/046;;F16K31/05;;Y10T137/8309;;Y10T137/8292;;F16K31/043;;Y10T137/8275;;F16K31/055,F16K31/05;;F16K37/00,,0,0,,,,PENDING
32,US,A1,US 2013/0216615 A1,131-078-961-414-844,2013-08-22,2013,US 201313760916 A,2013-02-06,US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",GOLDMAN DAVID,GOLDMAN DAVID,BIOGEN IDEC MA INC (2013-03-28),https://lens.org/131-078-961-414-844,Patent Application,yes,2,57,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/60;;A61K31/225;;A61K45/06,424/451;;424/489;;424/490;;514/163;;514/547,1,1,023-769-150-733-128,4881918;;10.1002/jps.2600571102,"Finch, ""Particle Size of Drugs and Its Relationship to Absorption and Activity"" Journal of Pharmaceutical Sciences, (1968), Vol. 57, No. 11, pages 1825-1835.",DISCONTINUED
33,US,B2,US 11268625 B2,169-329-566-164-702,2022-03-08,2022,US 201916529234 A,2019-08-01,US 201916529234 A;;US 201862713069 P,2018-08-01,Valve actuators principally for water-circulation systems of swimming pools or spas,"Multi-position valve actuators principally for water-circulation systems of pools and spas are detailed. At least some actuators may indicate position of an associated valve in a non-electronic manner, as by using a handle visible externally of the actuator and directly or indirectly mechanically coupled to the valve so as to move therewith. Hence, even if power to an actuator is disrupted, positioning of the valve may be determined by viewing the handle.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-09-13),https://lens.org/169-329-566-164-702,Granted Patent,yes,16,0,3,3,0,F16K37/0041;;F16K37/0008;;F16K31/055;;F16K31/607;;E04H4/1209;;F16K31/53;;F16K31/046;;F16K31/05;;Y10T137/8309;;Y10T137/8292;;F16K31/043;;Y10T137/8275;;F16K31/055,F16K31/05;;E04H4/12;;F16K31/04;;F16K31/53;;F16K31/60,,2,0,,,"PCT/US2019/044667, “International Search Report and Written Opinion”, dated Oct. 23, 2019, 14 pages.;;International Application No. PCT/US2019/044667, International Preliminary Report on Patentability dated Feb. 11, 2021, 10 pages.",ACTIVE
34,US,A,US 3522520 A,179-029-534-220-35X,1970-08-04,1970,US 3522520D A,1967-11-20,US 68412967 A,1967-11-20,ALTERNATOR WITH ROTARY TRANSFORMER FOR SELF-EXCITATION,,VICTOREEN LEECE NEVILLE INC,GOLDMAN DAVID,PEI 1991 ACQUISITION INC (1991-10-29);;PRESTOLITE ELECTRIC INCORPORATED A CORP. OF DE (1987-07-06),https://lens.org/179-029-534-220-35X,Granted Patent,no,3,15,3,3,0,H02J7/30;;H02K19/28;;H02J7/30;;H02K19/28,H02J7/30;;H02K19/28,322/28,0,0,,,,EXPIRED
35,US,S,US D0439029 S,043-607-459-383-633,2001-03-20,2001,US 10555799 F,1999-05-25,AU 199803878 F,1998-12-07,Jacket with pouch,,GOLDMAN DAVID,GOLDMAN DAVID,,https://lens.org/043-607-459-383-633,Design Right,yes,10,47,2,2,0,,,D 2831;;0202,0,0,,,,EXPIRED
36,TW,B,TW I697338 B,090-294-502-075-928,2020-07-01,2020,TW 106127330 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,,BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/090-294-502-075-928,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,0,0,,,,ACTIVE
37,WO,A1,WO 2019/236316 A1,117-424-250-072-405,2019-12-12,2019,US 2019/0033746 W,2019-05-23,US 201862680360 P,2018-06-04,BLACK LIGHT ASSEMBLIES PRINCIPALLY FOR SWIMMING POOLS AND SPAS,"Lighting assemblies principally for swimming pools and spas may produce ultraviolet (UV) radiation (i.e. black light). They also may supply visible light if desired. The assemblies may be submerged within pools or spas or located externally thereof, and the light sources may be controlled either collectively or individually.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,,https://lens.org/117-424-250-072-405,Patent Application,yes,11,0,2,2,0,E04H4/148;;E04H4/148;;F21W2131/401,E04H4/14,,0,0,,,,PENDING
38,CA,A1,CA 2548281 A1,122-508-541-686-035,2005-06-23,2005,CA 2548281 A,2004-12-09,US 52823203 P;;US 55986204 P;;US 2004/0041500 W,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVEAGENTS,"This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful fo r the delivery of the active agent, as well as compositions comprising the mix ed phase co-crystals.",MEDCRYSTALFORMS LLC,GOLDMAN DAVID,,https://lens.org/122-508-541-686-035,Patent Application,no,0,2,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K9/00;;A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/56;;A61K38/00,,0,0,,,,INACTIVE
39,US,A1,US 2021/0002913 A1,057-090-535-182-892,2021-01-07,2021,US 201916968663 A,2019-02-13,US 201916968663 A;;US 201862629921 P;;US 2019/0017756 W,2018-02-13,PUMPING SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,"Systems and techniques for guiding or advising users as to how to control motor speeds of pumping systems are detailed. The systems may solicit input from users and provide recommendations as to settings users may employ in connection with water-circulation systems of, principally, swimming pools and spas. The systems also may permit a user to retain control of both the duration the pool-filtration system will be active and the pump motor speed while providing suggestions to the user that may maximize efficiency of the system or minimize its power consumption (or both).",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-02-20),https://lens.org/057-090-535-182-892,Patent Application,yes,1,0,3,3,0,E04H4/1245;;F04D15/0066;;F04D15/0281;;E04H4/12;;F04D15/02,E04H4/12;;F04D15/02,,0,0,,,,DISCONTINUED
40,CA,A,CA 742506 A,100-280-256-402-519,1966-09-13,1966,CA 742506D A,,CA 742506T A,,ANIMAL CAGE WASHER,,HOWARD D TAYLOR,GOLDMAN DAVID,,https://lens.org/100-280-256-402-519,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
41,US,B2,US 10859214 B2,099-360-916-723-075,2020-12-08,2020,US 201916679891 A,2019-11-11,US 201916679891 A;;US 201862767681 P,2018-11-15,Apparatus and methods for retrofitting incandescent luminaire fixtures principally for use in swimming pools and spas,"Lighting assemblies principally for swimming pools and/or spas are disclosed herein, as well as related methods. The assemblies may be used to retrofit incandescent luminaires with light emitting diodes (LEDs). No need exists to move (or remove) elongated power cords associated with the luminaires, nor to replace any Edison-style plugs of the luminaires.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-11-21),https://lens.org/099-360-916-723-075,Granted Patent,yes,2,0,2,2,0,F21K9/235;;F21K9/235;;F21V29/70;;F21V29/70;;F21V31/00;;F21V31/00;;F21W2131/401;;F21Y2115/10;;F21Y2115/10;;Y02B20/30,F21K9/235;;F21V29/70;;F21V31/00;;F21Y115/10,,0,0,,,,ACTIVE
42,US,A,US 3463173 A,097-110-815-652-71X,1969-08-26,1969,US 3463173D A,1965-10-23,US 50352865 A,1965-10-23,"MACHINES FOR WASHING LABORATORY EQUIPMENT SUCH AS FLASKS,BOTTLES,TEST TUBES AND SIMILAR ARTICLES",,BETTER BUILT MACH CORP,GOLDMAN DAVID,,https://lens.org/097-110-815-652-71X,Granted Patent,no,3,28,1,1,0,A47L15/508;;A47L15/508;;B01L13/02;;B01L13/02;;B01L9/00;;B01L9/00,A47L15/16;;A47L15/50;;B01L99/00,134/145,0,0,,,,EXPIRED
43,US,A,US 2190873 A,115-778-401-238-632,1940-02-20,1940,US 29373839 A,1939-09-07,US 29373839 A,1939-09-07,Sewing case for thread braids,,DAVID GOLDMAN,DAVID GOLDMAN,,https://lens.org/115-778-401-238-632,Granted Patent,no,0,1,1,1,0,D05B91/14;;D05B91/14,D05B91/14,,0,0,,,,EXPIRED
44,GB,A,GB 1080289 A,148-410-146-034-035,1967-08-23,1967,GB 3086365 A,1965-07-20,GB 3086365 A,1965-07-20,Washing machines,"1,080,289. Washing machines. BETTER BUILT MACHINERY CORPORATION. July 20, 1965, No. 30863/65. Heading A4F. A machine for washing animal cages, racks, and other articles comprises a motor driven pump for supplying washing liquid to spray means within a casing, means controlled by a motor driven programme timer to control actuation of the pump motor and a drain valve solenoid to cause the pump to pump washing liquid to the spray means and to the drain a number of separate times, and time controlled means other than the programme timer for interrupting operation of the programme timer motor for a predetermined period each time the pump is pumping water to the spray means. In the machine particularly described which is of the construction described in Specification 1,080,288 the programme timer comprises a motor 206 (Fig. 9, not shown) turning a shaft carrying cams operating switches (1 to 6) controlling a pump motor (33) and three timers (204) controlling a washing and two rinsing cycles, respectively. The programme timer motor (206) is deenergized during the washing and rinsing cycles by circuitry controlled by the timers (240) and by a float switch (160) responsive to the level of water in the washing chamber.",BETTER BUILT MACH CORP,GOLDMAN DAVID,,https://lens.org/148-410-146-034-035,Granted Patent,no,0,0,1,1,0,A01K31/00,A01K31/00,A4F F29A1E1B2     -;;A4F F29A2A        -;;A4F F29A2D2       -;;A4F F29A4B        -;;A4F F29A5         -,0,0,,,,EXPIRED
45,US,A1,US 2019/0368213 A1,152-512-761-524-329,2019-12-05,2019,US 201916420839 A,2019-05-23,US 201916420839 A;;US 201862680360 P,2018-06-04,BLACK LIGHT ASSEMBLIES PRINCIPALLY FOR SWIMMING POOLS AND SPAS,"Lighting assemblies principally for swimming pools and spas may produce ultraviolet (UV) radiation (i.e. black light). They also may supply visible light if desired. The assemblies may be submerged within pools or spas or located externally thereof, and the light sources may be controlled either collectively or individually.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2018-06-26),https://lens.org/152-512-761-524-329,Patent Application,yes,0,2,2,2,0,E04H4/148;;E04H4/148;;F21W2131/401,E04H4/14,,0,0,,,,DISCONTINUED
46,WO,A1,WO 2016/014414 A1,183-926-742-075-008,2016-01-28,2016,US 2015/0041149 W,2015-07-20,US 201462026916 P,2014-07-21,"KIDNEY STONE REMOVAL CONTROL DEVICES, SYSTEMS, AND METHODS","Embodiments described herein are directed to devices, systems, and methods for removing kidney stones. A stone removal system may include a kidney stone removal tool and a removal tool manipulator connected to the kidney stone removal tool. The removal tool manipulator may control capture of a kidney stone by the kidney tone removal tool. Also, a kidney stone removal system according to at least one embodiment may facilitate a single user or operator perform a kidney stone capture and/or removal procedure.",BARD INC C R,GOLDMAN DAVID,,https://lens.org/183-926-742-075-008,Patent Application,yes,3,4,1,1,0,A61B17/221;;A61B1/0014;;A61B2017/00199;;A61B2017/00212;;A61B2017/00367;;A61B2017/00398;;A61B1/00042;;A61B17/221;;A61B1/00042,A61B17/22;;A61B1/307;;A61B17/221,,0,0,,,,PENDING
47,TW,B,TW I676475 B,095-549-291-468-37X,2019-11-11,2019,TW 102104904 A,2013-02-07,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,,BIOGEN MA INC,GOLDMAN DAVID,,https://lens.org/095-549-291-468-37X,Granted Patent,no,1,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,1,1,010-268-447-997-047,19721818;;10.2174/157015909787602788;;pmc2724664,"Hassan and El-Sakhawy,「Physical and Mechanical Properties of Microcrystalline Cellulose Prepared from Local Agricultural Residues」,8th ARAB INTERNATIONAL CONFERENCE ONPOLYMER SCIENCE & TECHNOLOGY 27 – 30 November 2005, Cairo-Sharm El-Shiekh, EGYPT. Moharregh-Khiabani et al.,「Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis」, Current Neuropharmacology, 2009, 7, 60-64",ACTIVE
48,US,A1,US 2020/0158294 A1,036-781-524-693-014,2020-05-21,2020,US 201916679891 A,2019-11-11,US 201916679891 A;;US 201862767681 P,2018-11-15,APPARATUS AND METHODS FOR RETROFITTING INCANDESCENT LUMINAIRE FIXTURES PRINCIPALLY FOR USE IN SWIMMING POOLS AND SPAS,"Lighting assemblies principally for swimming pools and/or spas are disclosed herein, as well as related methods. The assemblies may be used to retrofit incandescent luminaires with light emitting diodes (LEDs). No need exists to move (or remove) elongated power cords associated with the luminaires, nor to replace any Edison-style plugs of the luminaires.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID,,https://lens.org/036-781-524-693-014,Patent Application,yes,0,0,2,2,0,F21K9/235;;F21K9/235;;F21V29/70;;F21V29/70;;F21V31/00;;F21V31/00;;F21W2131/401;;F21Y2115/10;;F21Y2115/10;;Y02B20/30,F21K9/235;;F21V29/70;;F21V31/00,,0,0,,,,ACTIVE
49,JP,A,JP 2015091773 A,163-617-272-736-451,2015-05-14,2015,JP 2014182177 A,2014-09-08,US 52823203 P;;US 55986204 P,2003-12-09,METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS,"PROBLEM TO BE SOLVED: To provide a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, and to provide compositions containing the mixed phase co-crystals.SOLUTION: The invention provides a method for preparing mixed phase co-crystal compositions comprising: (a) forming a first solution of a first active agent and at least one crystal lattice modifier dissolved in a solvent; (b) mixing an anti-solvent with the first solution to form a second solution; and (c) forming a mixed phase crystalline material, where the active agent and crystal lattice modifier are contained within the mixed phase crystalline material.",MEDCRYSTALFORMS LLC,GOLDMAN DAVID,,https://lens.org/163-617-272-736-451,Patent Application,no,5,1,10,10,0,A61K9/145;;A61K9/145;;A61K8/63;;A61K9/10;;A61K9/10;;A61K9/146;;A61K9/146;;A61K9/148;;A61K9/148;;A61K9/4858;;A61K9/4858,A61K47/02;;A61K9/10;;A61K9/14;;A61K9/48;;A61K9/64;;A61K31/56;;A61K31/573;;A61K38/00;;A61K47/04;;A61K47/10;;A61K47/12;;A61K47/18;;A61K47/20;;A61K47/22;;A61K47/24;;A61K47/26;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/44,,0,0,,,,PENDING
50,US,A,US 2116570 A,079-293-070-983-97X,1938-05-10,1938,US 16708037 A,1937-10-02,US 16708037 A,1937-10-02,Yarn fabric-package,,HILDA GOLDMAN,DAVID GOLDMAN,,https://lens.org/079-293-070-983-97X,Granted Patent,no,0,2,1,1,0,B65H75/00;;B65H75/00;;B65H2701/31;;B65H2701/31,B65H75/00,,0,0,,,,EXPIRED
51,CA,A,CA 742507 A,138-730-722-134-051,1966-09-13,1966,CA 742507D A,,CA 742507T A,,AUTOMATIC SEQUENTIAL WASHING MACHINES,,HOWARD D TAYLOR,GOLDMAN DAVID,,https://lens.org/138-730-722-134-051,Granted Patent,no,0,1,1,1,0,,,,0,0,,,,EXPIRED
52,US,A,US 2114376 A,034-076-739-392-116,1938-04-19,1938,US 16190737 A,1937-09-01,US 16190737 A,1937-09-01,Necktie construction,,DAVID GOLDMAN,DAVID GOLDMAN,,https://lens.org/034-076-739-392-116,Granted Patent,no,0,4,1,1,0,A41D25/16;;A41D25/16,A41D25/16,,0,0,,,,EXPIRED
53,CH,A,CH 459653 A,126-789-759-159-245,1968-07-15,1968,CH 1130166 A,1966-08-05,CH 1130166 A,1966-08-05,Machine à laver,,TAYLOR HOWARD D,DAVID GOLDMAN,,https://lens.org/126-789-759-159-245,Granted Patent,no,0,0,1,1,0,A01K1/035,A01K1/035,"45H,1/02",0,0,,,,EXPIRED
54,US,A,US 3101729 A,151-759-958-948-393,1963-08-27,1963,US 17852962 A,1962-03-07,US 17852962 A,1962-03-07,Instrument washers,,DAVID GOLDMAN,DAVID GOLDMAN,,https://lens.org/151-759-958-948-393,Granted Patent,no,9,2,1,1,0,B08B3/06;;B08B3/06,B08B3/06,,0,0,,,,EXPIRED
55,US,A,US 981636 A,015-937-990-789-191,1911-01-17,1911,US 1910/0560265 A,1910-05-09,US 1910/0560265 A,1910-05-09,SANITARY FIXTURE FOR WATER-CLOSETS.,,GOLDMAN DAVID;;GOLDMAN HIRSCH H,GOLDMAN DAVID;;GOLDMAN HIRSCH H,,https://lens.org/015-937-990-789-191,Granted Patent,no,0,2,1,1,0,E03D9/032;;E03D9/032,,,0,0,,,,EXPIRED
56,US,A,US 984272 A,125-206-779-541-739,1911-02-14,1911,US 1910/0560264 A,1910-05-09,US 1910/0560264 A,1910-05-09,DISINFECTING GARBAGE-PAIL.,,GOLDMAN DAVID;;GOLDMAN HIRSCH H,GOLDMAN DAVID;;GOLDMAN HIRSCH H,,https://lens.org/125-206-779-541-739,Granted Patent,no,0,0,1,1,0,B65F7/00;;B65F7/00,,,0,0,,,,EXPIRED
57,US,A,US 923165 A,127-894-977-026-249,1909-06-01,1909,US 1909/0474971 A,1909-01-29,US 1909/0474971 A,1909-01-29,DISINFECTING MONEY-DRAWER.,,GOLDMAN DAVID;;GOLDMAN HIRSCH H,GOLDMAN DAVID;;GOLDMAN HIRSCH H,,https://lens.org/127-894-977-026-249,Granted Patent,no,0,9,1,1,0,B65D81/266;;B65D81/266,,,0,0,,,,EXPIRED
58,US,B1,US 7631641 B1,002-263-535-131-531,2009-12-15,2009,US 99997007 A,2007-12-10,US 99997007 A;;US 80338307 A,2007-05-15,Solar heat absorbing and distributing system,"In a preferred embodiment, an apparatus, including: a highly radiant heat absorbing material placed closely spaced from and generally parallel to an inside surface of a glass panel disposed in a wall or a door so as to form therebetween a plenum, the highly radiant heat absorbing material being at least partially visually clear.",GOLDMAN MICHAEL I;;GOLDMAN DAVID A,GOLDMAN MICHAEL I;;GOLDMAN DAVID A,GOLDMAN MICHAEL I (2008-08-21),https://lens.org/002-263-535-131-531,Granted Patent,yes,30,31,1,1,0,F24F7/013;;F24F13/18;;F24F2005/0064;;Y02B10/20;;F24S20/63;;F24S70/60;;Y02E10/40;;F24F13/18;;Y02B10/20;;F24F7/013;;F24F2005/0064;;Y02E10/44;;F24S20/63;;F24S70/60,E04D13/18,126/629;;126/595;;126/628;;126/701;;126/569,0,0,,,,INACTIVE
59,US,A1,US 2015/0000094 A1,036-211-207-749-120,2015-01-01,2015,US 201414316464 A,2014-06-26,US 201414316464 A;;US 201361839465 P,2013-06-26,CONVERSION OF A MECHANICAL TIMECLOCK ENCLOSURE,"Systems and methods of retrofitting an existing mechanical time clock enclosure to an Internet controllable, electronic pool and/or spa controller with improved, multi-functionality. In some instances, the conversion can be made without the need for adding new, additional enclosures (and corresponding wiring) and can expand the functionality of the controller to operate one or more valve actuators, one or more circuits, provide two-way communication with variable speed pumps and/or allow the electronic controller to access and/or be controlled by the Internet or with interface software.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID ANDREW,ZODIAC POOL SYSTEMS INC (2014-07-17),https://lens.org/036-211-207-749-120,Patent Application,yes,2,0,1,1,0,E04H4/12;;G04C23/00;;Y10T29/49721;;Y10T29/49721;;G04C23/00;;E04H4/12,B23P19/04,29/402.03,0,0,,,,DISCONTINUED
60,US,B1,US 6397120 B1,094-100-157-854-580,2002-05-28,2002,US 47624599 A,1999-12-30,US 47624599 A,1999-12-30,User interface and method for manipulating singularities for automatic embroidery data generation,"
    A user interface and method are disclosed for manipulating singular regions (termed singularities) for automatic embroidery data generation. A method is already known for automatically interpreting singular regions within an image so that embroidery data can be generated to recreate those singularities in an accurate and aesthetically pleasing manner. By using the present invention a user, with minimal effort, can gain greater control over the interpretation process. At the core of this extension is a single mouse click interface that allows the next best interpretation to be chosen easily. Additionally, the user may more precisely adjust interpretations, and provisions are made that allow automatic re-application of those adjustments to similar singularities encountered later. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/094-100-157-854-580,Granted Patent,yes,7,42,1,1,0,D05B19/08;;D05B19/08,D05B19/08,700/138;;112/102.5;;112/475.19,1,1,078-345-120-020-617,10.1109/34.177385,"Fridtjof Stein and Gerard Medioni, ""Structural Indexing: Efficient 2-D Object Recognition"", IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 14, No. 12, Dec. 1992.",EXPIRED
61,US,B2,US 9936899 B2,137-628-166-920-280,2018-04-10,2018,US 201414502090 A,2014-09-30,US 201414502090 A;;US 201361887675 P,2013-10-07,Tremor reduction system and device,A tremor reduction device has a mechanical flap having a flap portion arranged to apply pressure on part of an inner arm in order to reduce tremor. The pressure can be manually adjusted by moving a rod in a channel in the tremor reduction device. The tremor reduction device has a case for pivotably mounting the mechanical flap and the pressure is at least partly determined by the angle of the mechanical flap relative to the case. The rod has a tapered section and the mechanical flap has a pin in contact the tapered section for changing the angle of the mechanical flap. Optionally a sensor is placed near the pressure applying location to sense the tremor and to provide a sensing signal to a driving mechanism which causes the rod to move in order to adjust the pressure.,GOLDMAN DAVID A,GOLDMAN DAVID A,GOLDMAN JOSEPH (2017-10-19),https://lens.org/137-628-166-920-280,Granted Patent,yes,13,2,2,2,0,A61B5/1101;;A61B5/1101;;A61B34/75;;A61B34/75;;A61F5/30;;A61F5/30;;A61H23/006;;A61H2205/06,A61H23/00;;A61B5/11;;A61B34/00;;A61F5/30,,0,0,,,,INACTIVE
62,US,A,US 6098325 A,193-419-740-884-473,2000-08-08,2000,US 17089998 A,1998-10-13,US 17089998 A;;US 83736797 A,1997-04-17,Display having selectable simulated illuminating means,"In a preferred embodiment, a display device, including: a front panel and/or a rear panel having defined therethrough at least two apertures; and an index panel(s) disposed behind the front panel and/or the rear panel and moveable between at least first and second positions to vary what can be viewed through the at least two apertures by an observer looking at the front panel and/or the rear panel. In one aspect of the invention, the display device is a book, with the front panel and/or the rear panel being a page(s) of the book and the index wheel(s) being disposed at the front and/or the rear of the book.",GOLDMAN; DAVID A.,GOLDMAN DAVID A,,https://lens.org/193-419-740-884-473,Granted Patent,yes,4,17,1,3,0,G09F11/23;;G09F11/23,G09B5/00;;G09F11/23,40/495;;40/113;;434/178;;283/15.1,0,0,,,,EXPIRED
63,US,A1,US 2004/0243274 A1,001-399-294-145-962,2004-12-02,2004,US 80686304 A,2004-03-23,US 80686304 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
   A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/001-399-294-145-962,Patent Application,yes,14,12,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138,0,0,,,,EXPIRED
64,CA,C,CA 2694208 C,016-591-695-278-605,2015-05-12,2015,CA 2694208 A,2008-02-21,US 76786707 A;;US 2008/0054550 W,2007-06-25,METHOD AND SYSTEM FOR CREATING AND MANIPULATING EMBROIDERY DESIGNS OVER A WIDE AREA NETWORK,"A method and system are disclosed for creating and manipulating embioideiy designs ovei a wide area net-work. The method includes steps to transmit various embroidery design data ovei a wide area network between a client and a server. The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic rendeiings of possible finished products, and more precisely adjust interpretations through a provided usei interface with minimum latency.",SOFT SIGHT INC,GOLDMAN DAVID A,,https://lens.org/016-591-695-278-605,Granted Patent,no,0,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,G06F17/50;;D05C13/00;;H04L12/16,,0,0,,,,INACTIVE
65,US,B2,US 7587256 B2,032-561-867-263-374,2009-09-08,2009,US 80688004 A,2004-03-23,US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation.",SOFTSIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/032-561-867-263-374,Granted Patent,yes,20,20,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05C5/02;;D05B19/08,700/138;;112/475.19,70,63,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp. 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Anaysis and Machine Intelligence pp. 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;Ji-Rong Lin et al., Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp. 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours, 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm For Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp. 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions On Image Processing, pp. 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmenation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions on Image Processing, pp. 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions On Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p. 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions On Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable,and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, pp. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 1140-1153(1995).",EXPIRED
66,US,A1,US 2004/0243272 A1,053-932-495-614-373,2004-12-02,2004,US 80660704 A,2004-03-23,US 80660704 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
   A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/053-932-495-614-373,Patent Application,yes,18,12,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138,0,0,,,,EXPIRED
67,WO,A1,WO 2009/002571 A1,042-931-797-205-475,2008-12-31,2008,US 2008/0054550 W,2008-02-21,US 76786707 A,2007-06-25,METHOD AND SYSTEM FOR CREATING AND MANIPULATING EMBROIDERY DESIGNS OVER A WIDE AREA NETWORK,"[0038] A method and system are disclosed for creating and manipulating embioideiy designs ovei a wide area network. The method includes steps to transmit various embroidery design data ovei a wide area network between a client and a server. The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic rendeiings of possible finished products, and more precisely adjust interpretations through a provided usei interface with minimum latency.",SOFT SIGHT INC,GOLDMAN DAVID A,,https://lens.org/042-931-797-205-475,Patent Application,yes,4,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02,,0,0,,,,PENDING
68,US,A,US 3549877 A,008-426-244-884-199,1970-12-22,1970,US 3549877D A,1968-08-28,US 75600368 A,1968-08-28,UNILATERAL MOMENT PROBABILITY COMPUTER,,DAVID A GOLDMAN,GOLDMAN DAVID A,,https://lens.org/008-426-244-884-199,Granted Patent,no,0,5,1,1,0,G06G7/20;;G06G7/52;;G06G7/20;;G06G7/52,G06G7/20;;G06G7/52,235/193,0,0,,,,EXPIRED
69,US,A,US 1568064 A,093-724-048-513-495,1926-01-05,1926,US 74194724 A,1924-10-06,US 74194724 A,1924-10-06,Antislipping device for shoe soles and heels,,GOLDMAN DAVID H,GOLDMAN DAVID H,,https://lens.org/093-724-048-513-495,Granted Patent,no,0,22,1,1,0,A43B13/26;;A43C15/161;;A43B13/26;;A43C15/161,A43B13/26;;A43C15/16,,0,0,,,,EXPIRED
70,US,B1,US 10278880 B1,110-556-022-649-612,2019-05-07,2019,US 201816156074 A,2018-10-10,US 201816156074 A,2018-10-10,Head tremor reduction system and method,"A head tremor reduction device includes a frame mountable on the head of a person. The frame has two frame arms, each mountable on top of the ear of the person. A mechanical flap pivotably mounted on each of the frame arms to apply a pressuring force on a head area about the rear side of the ear. A section of the frame arm has an arm channel to accommodate a control plate for movement. The control plate has a tapered end portion operatively connected to the mechanical flap to adjust the flap angle in order to change the pressuring force. A control rod slidably engaged in a slot in the frame channel is used for moving the control plate along the arm channel to adjust the flap angle. The frame arm may have a rack movably engaged with a pinion for moving the control plate along the arm channel.",GOLDMAN DAVID A,GOLDMAN DAVID A,GOLDMAN JOSEPH (2018-10-17),https://lens.org/110-556-022-649-612,Granted Patent,yes,42,0,1,1,0,A61H1/00;;A61H7/001;;A61H1/008;;A61H2201/1604;;A61H2201/165;;A61H2201/5053;;A61H2205/02;;A61H1/008;;A61B5/1101;;A61H2201/165;;A61H2205/027;;A61H2205/02;;A61H2201/5053;;A61H2201/1604;;A61H1/00;;A61H7/001,A61H39/04;;A61B5/11;;A61H1/00,,0,0,,,,ACTIVE
71,US,A,US 5716330 A,169-661-463-726-180,1998-02-10,1998,US 50213695 A,1995-07-13,US 50213695 A,1995-07-13,Body and limb position/motion detector and power assist apparatus and method,"In a preferred embodiment, a power assist device for a partially or totally disabled body member, including: detection apparatus to detect position of the body member; and power assist apparatus, responsive to the detection apparatus, to provide powered assistance to move the body member in response to detection of the position of the body member and in response to the rate of change of position of the body member reaching a predetermined limit and/or in proportion to the rate of change of position of the body member.",GOLDMAN; DAVID A.,GOLDMAN DAVID A,,https://lens.org/169-661-463-726-180,Granted Patent,yes,14,24,1,1,0,A63B21/00181;;A63B21/00181;;A61F2/54;;A61F2/54;;A61F2/70;;A61F2/70;;A61H1/02;;A61H1/02;;A63B21/00178;;A63B21/00178;;A63B21/0058;;A63B21/0058,A61F2/54;;A61F2/70;;A61H1/02;;A63B21/005,601/26;;601/5;;623/24;;482/51,2,0,,,"Servo Controlled Exoskeleton Measures Muscle Forces, Control Engineering 15 (10): 92.;;Miller et al. Weak Muscle Control of Powered Orthotic Devices Proceedings of the 23rd Annual Conference on Engineering in Medicine & Biology, Washington D. C. Nov. 15 19, 1970.",EXPIRED
72,US,A,US 2922579 A,027-114-481-308-511,1960-01-26,1960,US 57815656 A,1956-04-13,US 57815656 A,1956-04-13,Electro-mechanical vector solver and resolver computer,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/027-114-481-308-511,Granted Patent,no,4,3,1,1,0,G06G7/22;;G06G7/22,G06G7/22,,0,0,,,,EXPIRED
73,US,A,US 3011715 A,093-635-836-797-631,1961-12-05,1961,US 80045159 A,1959-03-19,US 80045159 A,1959-03-19,Wind computer for high speed aircraft,,GEN PRECISION INC,GOLDMAN DAVID A,,https://lens.org/093-635-836-797-631,Granted Patent,no,2,2,1,1,0,G01S13/60;;G01S13/60,G01S13/60,,0,0,,,,EXPIRED
74,US,A1,US 2014/0094952 A1,061-465-837-698-336,2014-04-03,2014,US 201314011452 A,2013-08-27,US 201314011452 A;;US 201213490194 A;;US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,AUTOMATICALLY GENERATING EMBROIDERY DESIGNS,"A method and system are disclosed for automatically generating embroidery designs. A described method includes identifying vertices in a set of chain-code points defining an edge of a first object to be embroidered; filtering the vertices by: determining whether a height of a first triangle defined by a first one of the vertices and ones of the vertices that neighbor the first one of the vertices is at least a threshold; and when the height is less than the threshold, eliminating the first one of the vertices from the vertices; and generating embroidery data based on the filtered vertices.",GOLDMAN DAVID A,GOLDMAN DAVID A,SOFT SIGHT INC (1998-09-09);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/061-465-837-698-336,Patent Application,yes,9,14,2,2,0,D05B19/08;;D05C5/02;;A01G7/045;;Y02P60/14;;D05B19/08;;D05C5/02;;F21V9/00,D05C5/02,700/138,0,0,,,,EXPIRED
75,US,B2,US 8532810 B2,125-847-946-011-007,2013-09-10,2013,US 201213490194 A,2012-06-06,US 201213490194 A;;US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs,"A method and system are disclosed for automatically generating embroidery designs. A described method includes segmenting image data into a plurality of objects including a first object, recursively generating fragments from the first object to generate an order in which the fragments are to be sewn, the order to reduce thread cuts or increase path connectivity between the fragments, and generating an image output file representative of an embroidery design based on the fragments and the order.",GOLDMAN DAVID A;;VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A,SOFT SIGHT INC (1998-09-09);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/125-847-946-011-007,Granted Patent,yes,22,3,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08;;D05C5/02,700/138;;112/470.01,72,64,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709;;044-673-321-337-097;;030-769-874-975-177;;083-199-852-488-811,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507;;10.1109/34.677264;;10.1109/34.574795;;10.1016/0031-3203(96)00039-8,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions on Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions on Pattern Anaysis and Machine Intelligence pp. 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours , 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm for Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions on Image Processing, pp. 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmenation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions on Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions on Image Processing, pp. 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions on Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions on Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p. 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions on Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable,and Reversible Skeletons from the (3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction on Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions on Patern Analysis and Machine Intelligence, pp. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme for Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions on Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions on Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 1140-1153 (1995).;;Singularities and Regularities on Line Pictures via Symmetrical Trapezoids, IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 20, No. 4, Apr. 2008.;;Doermann et al., ""The Interpretation and Reconstruction of Interfering Strokes"", presented in International Workshop on Frontiers in Handwriting Recognition, 2003, pp. 41-50, (10 pages).;;Shigehehiro Fukushima, ""Division-Based Analysis of Symmetry and Its Application"", IEEE Transactions on Pattern Analysis and Machine Intelligence, Feb. 1997, pp. 144-148.;;Lin et al., ""Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique"", 29 Pattern Recognition, Nov. 1996, pp. 1789-1805.;;Toshiyuki Imai, ""A Topology-Oriented Algorithm for Voronoi Diagram of Polygons"", from the Department of Mathematical Engineering and Information Physics, University of Tokyo, 1996 (6 pages).;;Nikolaos G. Bourbakis, ""A Rule-Based Scheme for Synthesis of Texture Images"", IEEE Conference of Systems, Man and Cybernetics, 1987, pp. 999-1003.;;Nishida et al., ""Thin Line Representation From Contour Representation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition"", pp. 29-39 (1992).",EXPIRED
76,US,A,US 2858981 A,113-908-085-342-701,1958-11-04,1958,US 67825457 A,1957-08-14,US 67825457 A;;US 60617356 A,1956-08-24,Vector summer,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/113-908-085-342-701,Granted Patent,no,3,3,2,2,0,G05D3/122;;G05D3/122;;G05D3/121;;G05D3/121;;G06G7/22;;G06G7/22;;G08C19/46;;G08C19/46,G05D3/12;;G06G7/22;;G08C19/46,,0,0,,,,EXPIRED
77,BR,A,BR 0002266 A,125-467-826-077-728,2001-03-13,2001,BR 0002266 A,2000-07-03,US 34652599 A,1999-07-02,"Sensor de eixo para velocidade angular, torque, potência","Patente de Invenção: <B>""SENSOR DE EIXO PARA VELOCIDADE ANGULAR, TORQUE, POTêNCIA""<D>. Em uma modalidade preferida, um sensor de eixo para uma máquina, o sensor de eixo incluindo: primeiro e segundo discos, presos fixamente, de maneira ortogonal, em uma porção de um eixo da máquina, a porção do eixo sendo submetida à torção, e os primeiro e segundo discos sendo operativamente presos na porção do eixo em localizações separadas ao longo da porção do eixo; e uma montagem de sensor, incluindo primeiro e segundo sensores, dipostos em relação de leitura com os primeiro e segundo discos para sentir a posição relativa dos primeiro e segundo discos resultante da torção da porção do eixo e para produzir um sinal representativo de pelo menos um parâmetro relacionado com a torção do eixo.",CURTIS INSTR,GOLDMAN DAVID A,,https://lens.org/125-467-826-077-728,Patent Application,no,0,0,1,5,0,,G01L3/00,,0,0,,,,DISCONTINUED
78,US,A1,US 2012/0245726 A1,033-187-907-591-751,2012-09-27,2012,US 201213490194 A,2012-06-06,US 201213490194 A;;US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,AUTOMATICALLY GENERATING EMBROIDERY DESIGNS,"A method and system are disclosed for automatically generating embroidery designs. A described method includes segmenting image data into a plurality of objects including a first object, recursively generating fragments from the first object to generate an order in which the fragments are to be sewn, the order to reduce thread cuts or increase path connectivity between the fragments, and generating an image output file representative of an embroidery design based on the fragments and the order.",GOLDMAN DAVID A,GOLDMAN DAVID A,SOFT SIGHT INC (1998-09-09);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/033-187-907-591-751,Patent Application,yes,7,0,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08;;G05B19/18,700/131,0,0,,,,EXPIRED
79,US,A1,US 2004/0243273 A1,076-629-328-559-859,2004-12-02,2004,US 80662904 A,2004-03-23,US 80662904 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
   A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/076-629-328-559-859,Patent Application,yes,15,11,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138,0,0,,,,EXPIRED
80,WO,A2,WO 2007/092492 A2,084-298-158-131-986,2007-08-16,2007,US 2007/0003243 W,2007-02-06,US 77140606 P;;US 67123907 A,2006-02-07,SYSTEMS AND METHODS FOR PROCESSING PULMONARY FUNCTION DATA,"The invention provides improved methods for analysis of data obtained from certain pulmonary testing procedures, in particular from whole body plethysmography or from the forced oscillation technique. The improved computer-implemented methods automatically recognize data that has been distorted by patient behaviors during testing. This invention also provides computer systems that interface to devices that perform whole body plethysmography and/or the forced oscillation technique and automatically execute the methods of this invention. This invention also provides for distribution of software that causes computer systems to perform the methods of this invention.",GOLDMAN MICHAEL DAVID,GOLDMAN MICHAEL DAVID,,https://lens.org/084-298-158-131-986,Patent Application,yes,0,1,3,3,0,A61B5/08;;A61B5/0806;;A61B5/411;;A61M2205/7518;;A61M2230/46;;A61M16/0006;;A61M16/1055;;A61M16/106;;A61B5/0806;;A61B5/411;;A61B5/08;;A61M16/0006;;A61M2230/46;;A61M2205/7518;;A61M16/106;;A61M16/1055,,,0,0,,,,PENDING
81,US,A1,US 2010/0191364 A1,133-618-289-672-358,2010-07-29,2010,US 50758809 A,2009-07-22,US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,AUTOMATICALLY GENERATING EMBROIDERY DESIGNS FROM A SCANNED IMAGE,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. A described method of generating embroidery data from image data includes identifying an object from the image data, wherein the object corresponds to a contiguous portion of an image defined by the image data. The described method further includes determining a plurality of possible stitch angles for the object and determining respective numbers of fragments required to stitch the object for each of the possible stitch angles. The method further includes selecting a stitch angle from the plurality of possible stitch angles, wherein the selected stitch angle is to result in a least number of fragments to stitch the object, and generating the embroidery data based on the selected stitch angle.",GOLDMAN DAVID A,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/133-618-289-672-358,Patent Application,yes,17,8,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08;;G06F7/66;;D05C5/00,700/137;;700/138,0,0,,,,EXPIRED
82,US,A1,US 2004/0243275 A1,149-333-511-231-900,2004-12-02,2004,US 80688004 A,2004-03-23,US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
   A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/149-333-511-231-900,Patent Application,yes,20,22,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138,0,0,,,,EXPIRED
83,US,A1,US 2002/0007228 A1,173-723-564-706-475,2002-01-17,2002,US 95052101 A,2001-09-10,US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
   A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/173-723-564-706-475,Patent Application,yes,0,36,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138,0,0,,,,EXPIRED
84,ZA,B,ZA 864397 B,185-405-658-427-348,1987-10-28,1987,ZA 864397 A,1986-06-12,ZA 864397 A;;ZA 855582 A,1985-07-24,TROLLEYS,,GOLDMAN RICHARD DAVID,GOLDMAN RICHARD DAVID,,https://lens.org/185-405-658-427-348,Granted Patent,no,0,0,1,1,0,,B62B/,,0,0,,,,EXPIRED
85,US,B1,US 6836695 B1,092-377-515-807-231,2004-12-28,2004,US 13498198 A,1998-08-17,US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
    A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation. 
",SOFT SIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/092-377-515-807-231,Granted Patent,yes,8,51,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/137;;700/138,2,2,004-714-501-753-60X;;003-861-185-567-859,10.1145/50087.50092;;10.1016/s0734-189x(86)80047-0,"Kwok, Paul C., ""A Thinning Algorithm by Contour Generation"" in Communication of the ACM (Nov. 1988).;;Borgefors, Gunilla, ""Distance Transformations in Digital Images,"" in Computer Vision, Graphics and Image Processing (vol. 34, 1986).",EXPIRED
86,EP,A1,EP 2497616 A1,141-036-446-480-772,2012-09-12,2012,EP 12158765 A,2012-03-09,US 201113044811 A,2011-03-10,Oscillating power tool,"An oscillating power tool comprises a tool body (18) including a motor (22) having an output member (24), and a clamp assembly (30) driven by the output member. The clamp assembly (30) comprises a first clamp member (36) and a second clamp member (38). One of the first (36) and second (38) clamp members moves relative to the other clamp member between an open position and a clamped position to selectively retain a first accessory (14a) between the first (36) and second (38) clamp members. One of the first (36) and second (38) clamp members includes an auxiliary attachment surface (80) configured to selectively connect with a second accessory (14b) while the first accessory (14a) is concurrently retained by the clamp assembly (30).
",BLACK & DECKER INC,GOLDMAN DAVID A,,https://lens.org/141-036-446-480-772,Patent Application,yes,4,4,2,48,0,B24B23/04;;B24B45/006;;B27B5/32;;B27B19/006,B27B5/32;;B24B23/04;;B24B45/00;;B27B19/00,,0,0,,,,DISCONTINUED
87,US,B2,US 6804573 B2,145-386-035-429-046,2004-10-12,2004,US 95052101 A,2001-09-10,US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"
    Apparatus and methods for generating embroidery data from image data automatically identify at least one image characteristic based on at least one of edge contour data and skeletal data. The identified at least one image characteristic includes at least one of a singularity, a discontinuity and a concavity. The methods and apparatus generate the embroidery data based on the at least one image characteristic. 
",SOFT SIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/145-386-035-429-046,Granted Patent,yes,7,47,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138;;700/131;;700/135;;700/136;;700/137,71,64,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709;;044-673-321-337-097,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507;;10.1109/34.677264,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp. 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence 169-176 pp. (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Analysis and Machine Intelligence pp. 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun. S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kowk, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Bases on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;Ji-Rong Lin et al, Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp. 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours, 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm For Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp. 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions On Image Processing, pp. 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmentation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions On Image Processing, pp. 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions On Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions On Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable,and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, pp. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differntial and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G. F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformation, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shpae Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 1140-1153 (1995).;;""Singularities and Regularities on Line Pictures via Symmetrical Trapezoids"", IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 20, No. 4, Apr. 1998.",EXPIRED
88,US,A,US 2862661 A,168-806-476-266-855,1958-12-02,1958,US 60617356 A,1956-08-24,US 60617356 A;;US 67825457 A,1956-08-24,Vector summer,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/168-806-476-266-855,Granted Patent,no,6,5,2,2,0,G05D3/122;;G05D3/122;;G05D3/121;;G05D3/121;;G06G7/22;;G06G7/22;;G08C19/46;;G08C19/46,G05D3/12;;G06G7/22;;G08C19/46,,0,0,,,,EXPIRED
89,US,B2,US 6947808 B2,092-550-371-917-541,2005-09-20,2005,US 80660704 A,2004-03-23,US 80660704 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation.",SOFTSIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/092-550-371-917-541,Granted Patent,yes,14,33,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05B19/08,700/138;;112/102.5;;112/112;;112/475.19,70,63,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp. 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence 169-176 pp. (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Anaysis and Machine Intelligence pp. 411-414, April 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Transactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31 Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhau Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;Ji-Rong Lin et al., Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp. 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours, 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medical Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm For Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp. 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extraction, 9 IEEE Transactions On Image Processing, pp. 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmentation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions On Image Processing, pp. 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions On Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p. 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions On Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Larn et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable, and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, p. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchical Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 1140-1153 (1995).",EXPIRED
90,US,B1,US 8635571 B1,002-901-947-243-699,2014-01-21,2014,US 201213656361 A,2012-10-19,US 201213656361 A,2012-10-19,Integrating multiple FPGA designs by merging configuration settings,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for transmitting and integrating an intellectual property (IP) block with another user's design. The IP developer can design the IP block to include both a secret portion and a public portion. The IP block developer can send or otherwise provide the IP block to another IP user without disclosing the functional description of the secret portion of the IP block. In some implementations, the IP developer provides the public portion to the IP user at the register-transfer-level (RTL) level, as a hardware description language (HDL)-implemented design, or as a synthesizable netlist. In some implementations, the IP developer provides the secret portion of the IP block to the user in the form of programming bits without providing an HDL, RTL, or netlist implementation of the secret portion.",ALTERA CORP,GOLDMAN DAVID SAMUEL,ALTERA CORPORATION (2012-10-22),https://lens.org/002-901-947-243-699,Granted Patent,yes,2,21,2,10,0,G06F30/34;;G06F30/34,G06F17/50,716/117;;716/116,0,0,,,,ACTIVE
91,US,A,US 3313160 A,036-015-522-151-93X,1967-04-11,1967,US 37849964 A,1964-06-29,US 37849964 A,1964-06-29,Remote meter reading system,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/036-015-522-151-93X,Granted Patent,no,5,27,1,1,0,B06B1/04;;B06B1/04;;G08C23/02;;G08C23/02,B06B1/04;;G08C23/02,,0,0,,,,EXPIRED
92,AU,A,AU 1987/080176 A,135-256-755-409-627,1989-04-27,1989,AU 1987/080176 A,1987-10-27,AU 1987/080176 A,1987-10-27,BATTERY TROLLEY,,GOLDMAN RICHARD DAVID,GOLDMAN RICHARD DAVID,,https://lens.org/135-256-755-409-627,Patent Application,no,0,0,1,1,0,Y02E60/10,H01M2/10,,0,0,,,,DISCONTINUED
93,US,A,US 1749216 A,019-921-707-283-793,1930-03-04,1930,US 29401528 A,1928-07-19,US 29401528 A,1928-07-19,Double-acting pump,,GOLDMAN DAVID H,GOLDMAN DAVID H,,https://lens.org/019-921-707-283-793,Granted Patent,no,0,12,1,1,0,F04B9/14;;B05B11/1088;;F04B9/14;;B05B11/1088,B05B11/00;;F04B9/14,,0,0,,,,EXPIRED
94,EP,A1,EP 1076812 A1,042-828-558-257-301,2001-02-21,2001,EP 00905871 A,2000-01-31,US 0002438 W;;US 24553999 A;;US 34652599 A,1999-02-05,"SHAFT SENSOR FOR ANGULAR VELOCITY, TORQUE, POWER",,CURTIS INSTR,GOLDMAN DAVID A,,https://lens.org/042-828-558-257-301,Patent Application,yes,0,1,4,5,0,B62M6/45;;B62M6/50;;G01P3/481;;G01P3/488;;G01L3/109;;G01L3/105;;B62M6/45;;G01P3/488;;B62M6/50;;G01P3/481;;G01L3/109;;G01L3/105,B62M6/45;;B62M6/50;;G01L3/10;;G01P3/481;;G01P3/488,,0,0,,,,DISCONTINUED
95,US,B2,US 7016757 B2,083-375-170-282-920,2006-03-21,2006,US 80686304 A,2004-03-23,US 80686304 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation.",SOFTSIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/083-375-170-282-920,Granted Patent,yes,13,30,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05C5/02;;D05B19/08,700/138,70,63,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Anaysis and Machine Intelligence pp 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaningful Descriptions, 24 Pattern Recognation, pp 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics13 Part B: Cybernetics (2001).;;Hirobumi, Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp 55-67 (2002).;;Ji-Rong Lin et al., Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours , 39 Computer Vision, Graphics, and Image Processing, pp 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm for Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions On Image Processing, pp 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmenation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions On Image Processing, pp 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions On Image Processing, pp 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions On Image Processing, pp 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable,and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp 29-39 (1992).;;Richard G. Casey et al., Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, pp 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp 1481-1485 (1996).;;Paul L. Rosen et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 1140-1153 (1995).",EXPIRED
96,US,A,US 4544953 A,128-759-655-615-184,1985-10-01,1985,US 47945783 A,1983-03-28,US 47945783 A,1983-03-28,Automatic facusing using slope and peak detection,There is disclosed a VIDEO AUTOMATIC FOCUSSING SYSTEM in which a video signal from the television camera is directed to a band pass filter and then detected to produce a DC signal indicative of the video signal as band limited. The detected signal is directed to the inputs of a negative slope detector and peak detector. The detectors monitor the slope of the video signal to form the basis for controlling the motor to achieve automatic focussing on command.,DESIGNS FOR VISION,GOLDMAN DAVID A,DESIGNS FOR VISION INC. A CORP. OF N.Y (1983-03-15),https://lens.org/128-759-655-615-184,Granted Patent,yes,6,13,1,1,0,H04N23/673;;H04N23/673,H04N5/232,358/227,0,0,,,,EXPIRED
97,US,A,US 2919065 A,154-767-288-780-42X,1959-12-29,1959,US 60617456 A,1956-08-24,US 60617456 A,1956-08-24,Integrator,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/154-767-288-780-42X,Granted Patent,no,4,1,1,1,0,G06G7/188;;G06G7/188,G06G7/188,,0,0,,,,EXPIRED
98,US,A,US 2557061 A,180-025-854-268-368,1951-06-19,1951,US 18739350 A,1950-09-29,US 18739350 A,1950-09-29,Music box with selective operation means,,GOLDMAN DAVID A,GOLDMAN DAVID A,,https://lens.org/180-025-854-268-368,Granted Patent,no,3,21,1,1,0,G10F1/06;;G10F1/06,G10F1/06,,0,0,,,,EXPIRED
99,US,B2,US 9200397 B2,181-743-459-524-379,2015-12-01,2015,US 201314011452 A,2013-08-27,US 201314011452 A;;US 201213490194 A;;US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs,"A method and system are disclosed for automatically generating embroidery designs. A described method includes identifying vertices in a set of chain-code points defining an edge of a first object to be embroidered; filtering the vertices by: determining whether a height of a first triangle defined by a first one of the vertices and ones of the vertices that neighbor the first one of the vertices is at least a threshold; and when the height is less than the threshold, eliminating the first one of the vertices from the vertices; and generating embroidery data based on the filtered vertices.",GOLDMAN DAVID A;;CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A,SOFT SIGHT INC (1998-09-09);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/181-743-459-524-379,Granted Patent,yes,38,9,2,2,0,D05B19/08;;D05C5/02;;A01G7/045;;Y02P60/14;;D05B19/08;;D05C5/02;;F21V9/00,D05C5/02;;D05B19/08;;F21V9/00,,71,64,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709;;044-673-321-337-097;;030-769-874-975-177;;083-199-852-488-811;;048-169-901-840-740,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507;;10.1109/34.677264;;10.1109/34.574795;;10.1016/0031-3203(96)00039-8;;10.1109/83.877213;;18262927,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions on Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions on Pattern Anaysis and Machine Intelligence pp. 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba ct al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia ct al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours , 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm for Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmenation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions on Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions on Image Processing, pp. 266-277 (2001).;;Mary L. Corner et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions on Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions on Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p. 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions on Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Ql, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable, and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction on Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;II. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions on Patern Analysis and Machine Intelligence, pp. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G.F. McLean, Geometric Correclionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme for Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions on Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions on Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 1140-1153 (1995).;;Singularities and Regularities on Line Pictures via Symmetrical Trapezoids, IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 20, No. 4, Apr. 2008.;;Doermann et al., ""The Interpretation and Reconstruction of Interfering Strokes,"" pp. 41-51, 1993.;;Fukushima, ""Division-Based Analysis of Symmetry and Its Application,"" 19 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 144-148, Feb. 1, 1997.;;Ji-Rong Lin et al., ""Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique,"" 29 Pattern Recognition, pp. 1789-1805, Nov. 1996.;;Imai, ""A Topology-Oriented Algorithm for Voronoi Diagram of Polygons,"" 6 pages, Aug. 12, 1996.;;Bourbakis, ""A Rule-Based Scheme for Synthesis of Texture Images,"" pp. 999-1003, 1987.;;Ida et al., ""Self-Affine Mapping System and Its Application to Object Contour Extraction,"" 9 IEEE Transactions on Image Processing, pp. 1926-1936, Nov. 2000.",EXPIRED
100,BR,A2,BR 112012028549 A2,089-688-295-676-427,2019-09-24,2019,BR 112012028549 A,2011-05-05,US 2011/0035367 W;;US 33234410 P,2010-05-07,escova de dentes,,GILLETTE CO,PAUL DAVID GOLDMAN,,https://lens.org/089-688-295-676-427,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B7/06;;A46B9/04,,0,0,,,,DISCONTINUED
101,CA,A1,CA 2694208 A1,145-020-888-305-196,2008-12-31,2008,CA 2694208 A,2008-02-21,US 76786707 A;;US 2008/0054550 W,2007-06-25,METHOD AND SYSTEM FOR CREATING AND MANIPULATING EMBROIDERY DESIGNS OVER A WIDE AREA NETWORK,"A method and system are disclosed for creating and manipulating embioideiy designs ovei a wide area net-work. The method includes steps to transmit various embroidery design data ovei a wide area network between a client and a server. The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic rendeiings of possible finished products, and more precisely adjust interpretations through a provided usei interface with minimum latency.",SOFT SIGHT INC,GOLDMAN DAVID A,,https://lens.org/145-020-888-305-196,Patent Application,no,0,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02;;D05C13/00,,0,0,,,,INACTIVE
102,US,S,US D0315619 S,174-561-382-963-865,1991-03-19,1991,US 23816188 F,1988-08-30,US 23816188 F,1988-08-30,Swimmer's mask,,VOIT CORP,GOLDMAN DAVID H,VOIT CORPORATION A NY CORP (1988-08-22),https://lens.org/174-561-382-963-865,Design Right,yes,6,1,1,1,0,,,D29/9,0,0,,,,EXPIRED
103,US,A,US 5881482 A,033-363-308-824-859,1999-03-16,1999,US 83736797 A,1997-04-17,US 83736797 A,1997-04-17,Display having selectable simulated illuminating means,"A display device, including: a front panel having defined therethrough at least two apertures; and an index panel disposed behind the front panel and moveable between at least first and second positions to vary what can be viewed through the at least two apertures by an observer looking at the front panel.",GOLDMAN; DAVID A.,GOLDMAN DAVID A,,https://lens.org/033-363-308-824-859,Granted Patent,yes,4,8,1,3,0,G09F11/23;;G09F11/23,G09F11/23,40/495;;40/113,0,0,,,,EXPIRED
104,US,A1,US 2015/0100004 A1,043-510-838-669-905,2015-04-09,2015,US 201414502090 A,2014-09-30,US 201414502090 A;;US 201361887675 P,2013-10-07,TREMOR REDUCTION SYSTEM AND DEVICE,A tremor reduction device is disclosed. The tremor reduction device has a mechanical flap having a flap portion arranged to apply pressure on part of an inner arm in order to reduce tremor. The pressure can be manually adjusted by moving a rod in a channel in the tremor reduction device. The tremor reduction device has a case for pivotably mounting the mechanical flap and the pressure is at least partly determined by the angle of the mechanical flap relative to the case. The rod has a tapered section and the mechanical flap has a pin in contact the tapered section for changing the angle of the mechanical flap. Optionally a sensor is placed near the pressure applying location to sense the tremor and to provide a sensing signal to a driving mechanism which causes the rod to move in order to adjust the pressure.,GOLDMAN DAVID A,GOLDMAN DAVID A,GOLDMAN JOSEPH (2017-10-19),https://lens.org/043-510-838-669-905,Patent Application,yes,12,17,2,2,0,A61B5/1101;;A61B5/1101;;A61B34/75;;A61B34/75;;A61F5/30;;A61F5/30;;A61H23/006;;A61H2205/06,A61H1/00,601/134,0,0,,,,INACTIVE
105,WO,A3,WO 2007/092492 A3,065-556-335-192-828,2007-11-22,2007,US 2007/0003243 W,2007-02-06,US 77140606 P;;US 67123907 A,2006-02-07,SYSTEMS AND METHODS FOR PROCESSING PULMONARY FUNCTION DATA,"The invention provides improved methods for analysis of data obtained from certain pulmonary testing procedures, in particular from whole body plethysmography or from the forced oscillation technique. The improved computer-implemented methods automatically recognize data that has been distorted by patient behaviors during testing. This invention also provides computer systems that interface to devices that perform whole body plethysmography and/or the forced oscillation technique and automatically execute the methods of this invention. This invention also provides for distribution of software that causes computer systems to perform the methods of this invention.",GOLDMAN MICHAEL DAVID,GOLDMAN MICHAEL DAVID,,https://lens.org/065-556-335-192-828,Search Report,yes,3,0,3,3,0,A61B5/08;;A61B5/0806;;A61B5/411;;A61M2205/7518;;A61M2230/46;;A61M16/0006;;A61M16/1055;;A61M16/106;;A61B5/0806;;A61B5/411;;A61B5/08;;A61M16/0006;;A61M2230/46;;A61M2205/7518;;A61M16/106;;A61M16/1055,A61B5/08,,0,0,,,,PENDING
106,US,B1,US 6650627 B1,080-325-695-925-752,2003-11-18,2003,US 46586399 A,1999-12-16,US 46586399 A,1999-12-16,Tone detection in communication networks,"
    A communication circuitry for providing effective detection of tones in a communication network. The communication circuitry comprises filtration circuitry, summation circuitry, detection circuitry, and interface circuitry. The filtration circuitry is coupled to the summation circuitry and is configured to receive a communication, process the communication to estimate an echo return in the communication, and provide the estimated echo return to the summation circuitry. The summation circuitry is coupled to the detection circuitry and configured to receive the estimated echo return from the filtration circuitry, receive a tone transmission and echo return from the interface circuitry, subtract the estimated echo return from the tone transmission to generate a substantially pure tone, and provide the substantially pure tone to the detection circuitry. The detection circuitry is configured to receive the substantially pure tone and process the substantially pure tone to perform a programmed operation. The interface circuitry is coupled to the filtration circuitry and the summation circuitry and is configured to receive the communication, receive the tone transmission and provide the communication to the filtration circuitry and provide the tone transmission to the summation circuitry. 
",AVAYA TECHNOLOGY CORP,GOLDMAN PETER DAVID,AVAYA TECHNOLOGY CORP (2000-09-29);;LUCENT TECHNOLOGIES INC (1999-12-15),https://lens.org/080-325-695-925-752,Granted Patent,yes,6,5,1,1,0,H04B3/23;;H04M1/505;;H04Q1/444;;H04Q1/444;;H04B3/23;;H04M1/505,H04B3/23;;H04M1/50;;H04Q1/444,370/289;;370/290;;370/292;;375/231;;375/232;;375/233;;379/416;;379/406.05;;379/406.06;;379/406.08;;379/406.1,0,0,,,,EXPIRED
107,US,A,US 3549875 A,115-437-725-532-170,1970-12-22,1970,US 3549875D A,1968-08-28,US 75600268 A,1968-08-28,BILATERAL MOMENT PROBABILITY COMPUTER,,DAVID A GOLDMAN,GOLDMAN DAVID A,,https://lens.org/115-437-725-532-170,Granted Patent,no,0,2,1,1,0,G06G7/20;;G06G7/52;;G06G7/20;;G06G7/52,G06G7/20;;G06G7/52,235/193,0,0,,,,EXPIRED
108,WO,A1,WO 2000/046581 A1,117-962-483-953-447,2000-08-10,2000,US 0002438 W,2000-01-31,US 24553999 A;;US 34652599 A,1999-02-05,"SHAFT SENSOR FOR ANGULAR VELOCITY, TORQUE, POWER","In a preferred embodiment, a shaft sensor for a machine, the shaft sensor including: first and second disks (50 and 52), fixedly orthogonally attached to a portion of a shaft (30) of the machine, the portion of the shaft being subject to torsion, and the first and second disks being operatively attached to the portion of the shaft at spaced apart locations along the portion of the shaft; and a sensor (64, 66) assembly, including relationship with the first and second disks to sense relative position of the first and second disks resulting from torsion of the portion of the shaft and to output a signal representative of at least one parameter related to torsion of the shaft.",CURTIS INSTR,GOLDMAN DAVID A,,https://lens.org/117-962-483-953-447,Patent Application,yes,3,6,4,5,0,B62M6/45;;B62M6/50;;G01P3/481;;G01P3/488;;G01L3/109;;G01L3/105;;B62M6/45;;G01P3/488;;B62M6/50;;G01P3/481;;G01L3/109;;G01L3/105,B62M6/45;;B62M6/50;;G01L3/10;;G01P3/481;;G01P3/488,,0,0,,,,PENDING
109,US,A1,US 2011/0266759 A1,195-414-594-702-503,2011-11-03,2011,US 201113044811 A,2011-03-10,US 201113044811 A;;US 94209810 A;;US 32948010 P,2010-04-29,OSCILLATING TOOL,A clamp arrangement for securing first and second accessories to an oscillating power tool can include a tool body including a motor that drives the first accessory. A clamp assembly can include a first clamp member that moves relative to the accessory between a closed position wherein the clamp assembly retains the first accessory and an open position wherein the first clamp member of the clamp assembly is offset from the first accessory permitting removal of the first accessory while the first clamp member remains coupled to the clamp assembly. The clamp assembly further includes a second clamp member that cooperates with the first clamp member to clamp the first accessory between the first and second clamp members. An auxiliary attachment surface is configured on the second clamp member and selectively connects with the second accessory while the first accessory is concurrently retained by the clamp assembly.,BLACK & DECKER INC,GOLDMAN DAVID A,BLACK & DECKER INC (2011-04-25),https://lens.org/195-414-594-702-503,Patent Application,yes,10,65,1,48,0,B24B23/04;;B24B45/006;;B24B55/10;;B24B57/02;;B27B5/32;;B27B19/006;;B23D61/006;;Y10T279/18;;Y10T279/18;;B27B5/32;;B24B23/04;;B24B57/02;;B24B55/10;;B24B45/006;;B27B19/006;;B23D61/006,B23B31/08;;B23B31/103,279/106,0,0,,,,DISCONTINUED
110,US,B1,US 9032343 B1,040-515-978-105-910,2015-05-12,2015,US 201314106088 A,2013-12-13,US 201314106088 A;;US 201213656361 A,2012-10-19,Integrating multiple FPGA designs by merging configuration settings,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for transmitting and integrating an intellectual property (IP) block with another user's design. The IP developer can design the IP block to include both a secret portion and a public portion. The IP block developer can send or otherwise provide the IP block to another IP user without disclosing the functional description of the secret portion of the IP block. In some implementations, the IP developer provides the public portion to the IP user at the register-transfer-level (RTL) level, as a hardware description language (HDL)-implemented design, or as a synthesizable netlist. In some implementations, the IP developer provides the secret portion of the IP block to the user in the form of programming bits without providing an HDL, RTL, or netlist implementation of the secret portion.",ALTERA CORP,GOLDMAN DAVID SAMUEL,ALTERA CORPORATION (2012-10-22),https://lens.org/040-515-978-105-910,Granted Patent,yes,11,11,2,10,0,G06F30/34;;G06F30/34,G06F17/50,716/103;;716/102,0,0,,,,ACTIVE
111,AU,A1,AU 2008/269041 A1,053-490-857-322-170,2008-12-31,2008,AU 2008/269041 A,2008-02-21,US 76786707 A;;US 2008/0054550 W,2007-06-25,Method and system for creating and manipulating embroidery designs over a wide area network,,SOFT SIGHT INC,GOLDMAN DAVID A,VISTAPRINT SCHWEIZ GMBH (2013-12-12),https://lens.org/053-490-857-322-170,Patent Application,no,0,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02,,0,0,,,,INACTIVE
112,US,B2,US 7016756 B2,168-100-257-072-618,2006-03-21,2006,US 80662904 A,2004-03-23,US 80662904 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. An embroidery data generating mechanism generates accurate embroidery designs. The embroidery data generating mechanism first reads an image data file, which contains bitmapping information generated from a software scanning tool, the information being related to an embroidery pattern that has been scanned. The scanned pattern is broken up into pixels, each pixel in the scanned image having a bitmap associated with the color of the pattern. Each unique color in the scanned pattern has its own unique bitmap. The embroidery generating mechanism also includes a segmentation mechanism and a chain-encoding mechanism which perform operations to enhance the quality of the bitmapped information and to separate regions of the scanned image into objects. A distance transform evaluation mechanism classifies each object as being either a thick object or a thin, predominantly regular object. Additional mechanisms further interpret the objects into entities such as regular and singular regions and compute optimum sewing paths for embroidery data generation.",SOFTSIGHT INC,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/168-100-257-072-618,Granted Patent,yes,15,30,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05C5/02;;D05B19/08,700/138,70,63,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition,pp 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Model, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Anaysis and Machine Intelligence pp 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Transactions on Computers, pp 297-303 (1997).;;Chia-We Liao and Jun S. Huang, Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp 55-67 (2002).;;Ji-Rong Lin et al., Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours, 39 Computer Vision, Graphics, and Image Processing, pp 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental AlgorithmFor Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions On Image Processing, pp 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmentation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions On Image Processing, pp 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmentation and Reconstruction of Signals and Images, 9 IEEE Transactions On Image Processing, pp 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion , p 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based on Pyramidal Segmentation and Fuzzy Clustering, 9 IEEE Transactions On Image Processing, pp 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable, and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, pp 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp 1140-1153 (1995).",EXPIRED
113,US,B2,US 8219238 B2,092-095-791-416-215,2012-07-10,2012,US 50758809 A,2009-07-22,US 50758809 A;;US 80688004 A;;US 95052101 A;;US 13498198 A,1998-08-17,Automatically generating embroidery designs from a scanned image,"A method and system are disclosed for automatically generating embroidery designs from a scanned image. A described method of generating embroidery data from image data includes identifying an object from the image data, wherein the object corresponds to a contiguous portion of an image defined by the image data. The described method further includes determining a plurality of possible stitch angles for the object and determining respective numbers of fragments required to stitch the object for each of the possible stitch angles. The method further includes selecting a stitch angle from the plurality of possible stitch angles, wherein the selected stitch angle is to result in a least number of fragments to stitch the object, and generating the embroidery data based on the selected stitch angle.",GOLDMAN DAVID A;;VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/092-095-791-416-215,Granted Patent,yes,17,3,15,15,0,D05B19/08;;Y02P90/02;;D05B19/08;;Y02P90/02,D05C5/02;;D05B19/08,700/138,71,64,003-861-185-567-859;;081-662-605-343-526;;060-204-690-681-772;;144-101-617-328-706;;109-505-725-992-147;;057-935-596-533-467;;148-317-420-247-02X;;025-296-229-228-20X;;030-769-874-975-177;;057-073-939-157-242;;080-869-186-537-503;;033-589-254-002-041;;028-553-767-760-395;;031-424-811-743-291;;022-488-423-001-399;;059-605-723-790-10X;;141-316-024-045-89X;;004-714-501-753-60X;;046-291-990-350-669;;019-258-075-409-344;;026-631-029-869-434;;002-998-980-753-520;;062-035-692-090-691;;109-303-150-931-654;;083-199-852-488-811;;008-529-736-828-558;;122-830-575-879-631;;089-001-774-690-361;;080-447-989-162-75X;;015-010-869-733-010;;148-587-744-620-628;;053-421-739-618-510;;100-025-931-766-722;;098-033-227-588-424;;108-287-850-830-615;;048-169-901-840-740;;074-828-248-878-840;;044-324-951-155-874;;095-122-617-235-03X;;011-189-595-287-283;;026-738-255-642-967;;017-596-373-751-219;;017-023-219-571-035;;029-230-133-158-060;;045-555-260-936-334;;014-348-998-312-281;;014-506-182-884-886;;110-510-659-560-064;;010-640-479-242-341;;105-074-662-759-569;;050-004-303-386-644;;009-318-193-285-222;;050-396-439-079-032;;002-772-795-917-499;;134-287-771-907-699;;035-329-735-378-201;;120-747-924-975-243;;111-374-554-941-752;;027-698-693-984-812;;014-953-723-969-247;;003-768-463-832-370;;038-023-292-866-210;;060-283-404-587-709;;044-673-321-337-097,10.1016/s0734-189x(86)80047-0;;10.1016/0031-3203(94)90143-0;;10.1016/0031-3203(91)90117-n;;10.1016/0031-3203(95)00118-2;;10.1109/34.574801;;10.1109/34.19037;;10.1109/tc.1977.1674825;;10.1016/0031-3203(90)90068-v;;10.1109/34.574795;;10.1007/bf01427153;;10.1016/0031-3203(95)00142-5;;10.1007/bf00058751;;10.1016/0031-3203(94)00155-3;;10.1016/0031-3203(95)00153-0;;10.1007/bf01451741;;10.1007/bf00144119;;10.1016/0031-3203(96)00007-6;;10.1145/50087.50092;;10.1016/0262-8856(89)90004-8;;10.1006/cviu.1995.1043;;10.1016/0031-3203(91)90031-y;;10.1006/gmip.1997.0450;;10.1109/3477.931528;;18244803;;10.1016/s0031-3203(01)00042-5;;10.1016/0031-3203(96)00039-8;;10.1016/s0734-189x(87)80165-2;;10.1006/cviu.1999.0807;;10.1016/s0146-664x(78)80020-3;;10.1007/bf01428193;;10.1016/0262-8856(95)98756-j;;10.1016/0031-3203(95)00141-7;;10.1109/34.748823;;10.1006/gmip.1997.0444;;10.1016/s0925-7721(01)00003-7;;10.1142/s0218195994000124;;10.1109/83.877213;;18262927;;10.1109/icip.1999.817111;;10.1109/83.855433;;18262975;;10.1109/83.847835;;18262960;;10.1109/83.902291;;18249617;;10.1109/83.869185;;18262912;;10.1109/83.841938;;18255434;;18255416;;10.1109/83.826782;;18255477;;10.1109/83.846249;;18262961;;10.1109/83.847836;;10.1145/73833.73838;;10.1109/34.161346;;10.1006/jvci.1994.1010;;10.1109/34.476016;;10.1007/bf01450853;;10.1006/gmip.1996.0047;;10.1006/gmip.1996.0012;;10.1016/0031-3203(95)00121-2;;10.1109/34.494644;;10.1109/34.368198;;10.1109/34.491619;;10.1006/cviu.1996.0015;;10.1006/gmip.1996.0023;;10.1109/70.563646;;10.1006/gmip.1996.0014;;10.1177/003754979606600303;;18290065;;10.1109/83.536896;;10.1109/34.476507;;10.1109/34.677264,"Gunilla Borgefors, Distance Transformations in Digital Images, 34 Computer Vision Graphics, and Image Processing, pp. 334-371 (1986).;;Gabriella Sanniti Di Bata et al., (3,4) Weighted Skeleton Decomposition for Pattern Representation and Description, 27 Pattern Recognition, pp. 1039-1049 (1994).;;David S. Doermann et al., The Interpretation and Reconstruction of Interfering Strokes, pp. 41-51.;;Robert M. Haralick et al., Glossary of Computer Vision Terms, 24 Pattern Recognition, pp. 69-93 (1991).;;Oivind Due Trier et al., Feature Extraction Methods for Character Recognition-A Survey, 29 Pattern Recognition pp. 641-661 (1996).;;Narenda Ahuja and Jen-Hui, Shape Representation Using a Generalized Potential Field Mode, 19 IEEE Transactions on Pattern Analysis and Machine Intelligence 169-176 pp (1997).;;Carlo Arcelli et al., A One-Pass Two-Operation Process to Detect the Skeletal Pixels on the 4-Distance Transform, 11 IEEE Transactions On Pattern Anaysis and Machine Intelligence pp. 411-414, Apr. 1998.;;Herbert Freeman et al., A Corner-Finding Algorithm for Chain-Coded Curves, IEEE Tranactions on Computers, pp. 297-303 (1997).;;Chia-We Liao and Jun S. Huang,Stroke Segmentation by Bernsterin-Bezier Curve Fitting, 23 Pattern Recognition, pp. 478-484 (1990).;;Shigehehiro Fukushima, Division-Based Analysis of Symmetry and Its Application, 19 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 144-148.;;Remi Ronford, Region-Based Strategies for Active Contour Models, 13 International Journal of Computer Vision, pp. 229-251 (1994).;;I.S.I. Abuhaiba et al., Processing of Binary Images of Handwritten Text Documents, pp. 1161-1177 (1996).;;Stefan Carlsson, Projectively Invariant Decomposition and Recognition of Planar Shapes, 17(2) International Journal of Computer Vision, pp. 193-209 (1996).;;Richard C. Staunton, An Analysis of Hexagonal Thinning Algorithms and Skeletal Shape Representation, 29 Pattern Recognition, pp. 1131-1146 (1996).;;Fernando Rannou et al., Equilateral Polygon Approximation of Closed Contours, 29 Pattern Recognition, pp. 1105-1115 (1996).;;Benjamin B. Kimia et al., Shapes Shocks, and Deformations I: The Components of Two-Dimensional Shape and the Reaction-Diffusion Space, 15 International Journal of Computer Vision, pp. 189-224 (1995).;;Gideon Guy et al., Inferring Global Perceptual Contours From Local Features, 20 International Journal of Computer Vision, pp. 113-133 (1996).;;Roberto Marcondes Cesar Junior et al., Towards Effective Planar Shape Representation With Multiscale Digital Curvature Analysis Based on Signal Processing Techniques, 29 Pattern Recognition, pp. 1559-1569 (1996).;;Paul C. K. Kwok, A Thinning Algorithm by Contour Generation, 31Communications of the ACM, pp. 1314-1324 (1988).;;Paul L. Rosin et al., Segmentation of Edges Into Lines and Arcs, Image and Vision Computing, pp. 109-114 (1989).;;Hirobumi Nishida, Structural Feature Extraction Using Multiple Bases, 62 Computer Vision and Image Understanding, pp. 78-89 (1995).;;G.A.W. West et al., Techniques for Segmenting Image Curves Into Meaninful Descriptions, 24 Pattern Recognition, pp. 643-652 (1991).;;Wenhua Wan et al., Segmentation of Planar Curves into Straight-Line Segments and Elliptical Arcs, 59 Graphical Models and Image Processing, pp. 484-494 (1997).;;Ju Jia Zou et al., Skeletonization of Ribbon-Like Shapes Based on Regularity and Singularity Analyses, 31 IEEE Transactions on Systems, Man, and Cybernetics-Part B: Cybernetics (2001).;;Hirobumi Nishida, Structural Feature Indexing for Retrieval of Partially Visible Shapes, 35 Pattern Recognition, pp. 55-67 (2002).;;Ji-Rong Lin et al., Stroke Extraction for Chinese Characters Using a Trend-Followed Transcribing Technique, 29 Pattern Recognition, pp. 1789-1805.;;M. Pilar Martinez-Perez et al., A Thinning Algorithm Based on Contours , 39 Computer Vision, Graphics, and Image Processing, pp. 186-201 (1987).;;Elyse H. Milun et al., General Ribbon-Based Thinning Algorithms for Stylus-Generated Images, 76 Computer Vision and Image Understanding, pp. 267-277 (1999).;;Irwin Sobel, Neighborhood Coding of Binary Images for Fast Contour Following and General Binary Array Processing, 8 Computer Graphics and Image Processing, pp. 127-135 (1978).;;C.A. Rothwell, et al., Planare Object Recognition Using Projective Shape Representation, 16 International Journal of Computer Vision, pp. 57-99 (1995).;;I.S.I. Abuhaiba et al., Fuzzy State Machines to Recognize Totally Unconstructed Handwritten Strokes, 13 Image and Vision Computing, pp. 755-769 (1995).;;Serban Iliescu et al., Proposed Heuristic Procedures to Preprocess Character Patterns Using Line Adjacency Graphs, 29 Pattern Recognition, pp. 951-969 (1996).;;Fu Chang et al., Feature Analysis Using Line Sweep Thinning Algorithm, 21 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 145-158 (1996).;;Hyeong In Choi et al., New Algorithm for Medial Axis Transform of Plance Domain, 59 Graphical Models and Image Processing, pp. 463-483 (1997).;;Toshiyuki Imai, A Topology-Oriented Algorithm for Voronoi Diagram of Polygons.;;Martin Held, VRONI: An Engineering Approach to the Reliable and Efficient Computation of Voronoi Diagrams of Points and Line Segments, 18 Computational Geometry, pp. 95-123 (2001).;;Kokichi Sugihara, A Robust Topology-Oriented Incremental Algorithm For Voronoi Diagrams, 4 International Journal of Computational Geometry and Applications, pp. 179-228 (1994).;;Nikolaos G. Bourbakis, A Rules Based Scheme for Synthesis of Texture Images, pp. 999-1003.;;Takashi Ida et al., Self-Affine Mapping System and Its Application to Object Contour Extracation, 9 IEEE Transactions On Image Processing, pp. 1926-1936 (2000).;;Takashi Ida et al., Self-Affine Mapping System for Object Contour Extraction, pp. 250-254 (2000).;;Wei-Ying Ma et al., Edge Flow: A Technique for Boundary Detection and Image Segmentation, 9 IEEE Transactions on Image Processing, pp. 1375-1387 (2000).;;Giancarlo Iannizzotto et al., Fast and Accurate Edge-Based Segmenation With No Contour Smoothing in 2-D Real Images, 9 IEEE Transactions On Image Processing, pp. 1232-1237 (2000).;;Tony F. Chan et al., Active Contours Without Edges, 10 IEEE Transactions On Image Processing, pp. 266-277 (2001).;;Mary L. Comer et al., The EM/MPM Algorithm for Segmentation of Textured Images: Analysis and Further Experimental Results, 9 IEEE Transactions on Image Processing, pp. 1731-1744 (2000).;;Gerard J. Genello et al., Graeco-Latin Squares Design for Line Detection in the Presence of Correlated Noise, 9 IEEE Transactions On Image Processing, pp. 609-622 (2000).;;Michael K. Schneider et al., Multiscale Methods for the Segmenation and Reconstruction of Signals and Images, 9 IEEE Transactions on Image Processing, pp. 456-467 (2000).;;Mario A. T. Figueiredo, Unsupervised Contour Representation and Estimation Using B-Splines and a Minimum Description Length Criterion, p. 1075-1087 (2000).;;Mahmoud Ramze Rezaee et al., A Multiresolution Image Segmentation Technique Based On Pyramidal Segementation and Fuzzy Clustering, 9 IEEE Transactions on Image Processing, pp. 1238-1248 (2000).;;Aart Bik et al., Efficient Exploitation of Parallelism on Pentium III and Pentium 4 Processor-Based Systems, Intel Technology Journal Q1, pp. 1-9 (2001).;;Peter W. Shor et al., Detecting and Decomposing Self-Overlapping Curves, ACM, pp. 44-50 (1989).;;Louisa Lam et al., Thinning Methodologies-A Comprehensive Survey, 14 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 869-885 (1992).;;Gabriella Sannti Di Baja, Well-Shaped, Stable,and Reversible Skeletons from the(3,4)-Distance Transform, 5 Journal of Visual Communication and Image Representation, pp. 107-115 (1994).;;S. Di Zeno, Run-Based Algorithms for Binary Image Analysis and Processing, 18 IEEE Transaction On Pattern Analysis and Machine Intelligence, pp. 83-88 (1996).;;H. Nishida et al., Thin Line Representation From Contour Reprsentation of Handprinted Characters, Pixels to Features III: Frontiers in Handwriting Recognition, pp. 29-39 (1992).;;Richard G. Casey et al., A Survey of Methods and Strategies in Character Segmentation, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 691-705 (1996).;;Meir Barozhar et al., Automatice Findind of Main Roads in Aerial Images by Using Geometric Stochastic Models and Estimation, 18 IEEE Transactions On Patern Analysis and Machine Intelligence, pp. 707 (1996).;;David S. Doermann et al., Recovery of Temporal Information From StaticImages of Handwriting, 15 International Journal of Computer Vision, pp. 143-164 (1995).;;Evan C. Sherbrooke et al., Differential and Topological Properties of Medial Axis Transforms, 58 Graphical Models and Image Processing, pp. 574-592 (1996).;;G.F. McLean, Geometric Correctionof Digitized Art, 58 Graphical Models and Image Processing, pp. 142-154 (1996).;;Hsin-Teng Sheu et al., A Rotationally Invariant Two-Phase Scheme For Corner Detection, 29 Pattern Recognition, pp. 819-828 (1996).;;Magdi Mohamed et al., Handwritten Word Recognition Using Segmentation-Free Hidden Markov Modeling and Segmentation-Based Dynamic Programming Techniques, 18 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 548-554 (1996).;;Hirobumi Nishida, Model-Based Shape Matching With Structural Feature Grouping, 17 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 315-320 (1995).;;Steven Gold et al., A Graduated Assignment Algorithm for Graph Matching, 18 IEEE Transactions on Pattern Analysis and Machine Intelligence, pp. 377-388 (1996).;;Jianying Hu, A Hierarchial Approach to Efficient Curvilinear Object Searching, pp. 208-220 (1996).;;Paul L. Rosin, Augmenting Corner Descriptors, 58 Graphical Models and Image Processing, pp. 286-294 (1996).;;Panagiotis G. Tzionas et al., Collision-Free Pathn Planning for Diamond-Shaped Robot Using Two-Dimensional Cellular Automata, 13 IEEE Transactions On Robotics and Automation, pp. 237-250 (1997).;;Hirobumi Nishida, A Structural Model of Curve Deformation by Discontinuous Transformations, 58 Graphical Models and Image Processing, pp. 164-179 (1996).;;Ramanujan S. Kashi et al., 2-D Shape Representation and Averaging Using Normalized Wavelet Descriptors, 66 Simulation, pp. 164-178 (1996).;;Shy-Shyan et al., Skeletonization for Fuzzy Degraded Character Images, 5 IEEE Transactions On Image Processing, pp. 1481-1485 (1996).;;Paul L. Rosin et al., Nonparametric Segmentation of Curves Into Various Representations, 17 IEEE Transactions On Pattern Analysis and Machine Intelligence, pp. 1140-1153 (1995).;;Singularities and Regularities on Line Pictures via Symmetrical Trapezoids, IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 20, No. 4, Apr. 2008.",EXPIRED
114,US,B1,US 6463258 B1,119-361-066-730-858,2002-10-08,2002,US 20386798 A,1998-12-02,US 20386798 A;;US 17089998 A;;US 83736797 A,1997-04-17,Electrical flash card unit and method of use,"
    In a preferred embodiment, a flash card unit, including: a housing; receiving means to receive in the housing a flash card having thereon at least first and second graphics; illuminating apparatus disposed in the housing to selectively illuminate at least one of the first and second graphics; the first graphic including a problem to be solved; and the second graphic including an answer to the problem. 
",GOLDMAN DAVID A.,GOLDMAN DAVID A,,https://lens.org/119-361-066-730-858,Granted Patent,yes,16,0,1,3,0,G09F11/23;;G09F11/23,G09B5/00;;G09F11/23,434/310;;434/311;;40/502,0,0,,,,EXPIRED
115,EP,A2,EP 3861639 A2,015-780-127-131-61X,2021-08-11,2021,EP 19836153 A,2019-11-11,US 201862758854 P;;US 2019/0060799 W,2018-11-12,SENSOR SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,,https://lens.org/015-780-127-131-61X,Patent Application,yes,0,0,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,H04B3/54,,0,0,,,,PENDING
116,EP,A1,EP 1147558 A1,020-517-905-760-790,2001-10-24,2001,EP 99973353 A,1999-11-29,EP 9909268 W;;GB 9826877 A,1998-12-07,ANALOGUE SWITCH,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2004-05-06);;INFINEON TECHNOLOGIES AG (2010-06-02),https://lens.org/020-517-905-760-790,Patent Application,yes,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,EXPIRED
117,KR,A,KR 20160146776 A,043-434-464-580-428,2016-12-21,2016,KR 20167030694 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,- KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,"가이드와이어, 제조 방법, 및 사용 방법이 기술된다. 가이드와이어는 그의 일부분을 따라 하나 이상의 사전형성된 리브를 갖는 코어를 포함할 수 있다. 리브는 가이드와이어의 외측 표면의 일부분을 형성하거나, 가이드와이어의 외측 표면의 텍스처 또는 형상을 형성할 수 있다. 가이드와이어의 리브와 외측 텍스처는 이롭게도 가이드와이어가 신체 내의 원하는 위치에 유지되는 데 도움을 주고 이동을 방지하거나 제한하는 데 도움을 줄 수 있다. 리브를 코어의 외측 표면 상에 형성하는 것은 가이드와이어가 보다 큰 강성과 강직성을 가질 수 있게 할 수 있다. 코어는 리브의 원위에 있는 감소된 직경의 영역을 포함할 수 있다. 가이드와이어는 코어의 감소된 직경의 영역 위에 캡을 포함할 수 있다.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/043-434-464-580-428,Patent Application,no,5,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
118,MX,A,MX 9701731 A,081-429-733-906-150,1997-10-31,1997,MX 9701731 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,METHOD AND APPARATUS FOR DETECTING BARRETT'S METAPLASIA OF THE ESOPHAGUS.,A system for detecting Barrett's metaplasia utilizes an illumination and imaging probe (32) at the end of a catheter (34). The probe (32) illuminates the wall of the esophagus and returns reflected light to be processed to provide a visual indication of the color of the esophageal wall. The position of the probe along the length of the esophagus is also measured to allow a medical practitioner to determine the location of the transition from the pink stomach lining to the white esophageal lining.,BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/081-429-733-906-150,Patent Application,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,PENDING
119,EP,A4,EP 3956916 A4,064-343-693-014-241,2023-01-11,2023,EP 20790963 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,GUIDING PULL RING,,S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/064-343-693-014-241,Search Report,no,8,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/666;;H01H33/00;;H01H75/04,,1,0,,,See also references of WO 2020214591A1,PENDING
120,US,A1,US 2017/0028173 A1,067-073-822-388-015,2017-02-02,2017,US 201515302157 A,2015-04-29,US 201515302157 A;;US 201461985887 P;;US 2015/0028366 W,2014-04-29,Kink-Resistant Guidewire with Improved Rigidity,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,C. R. BARD INC (2016-10-07),https://lens.org/067-073-822-388-015,Patent Application,yes,1,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
121,CA,A1,CA 2199294 A1,122-217-454-654-924,1996-12-12,1996,CA 2199294 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"Non-Irritation, Non-Sensitizing, Non-Ototoxic Otic Antibacterial Compositions","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/122-217-454-654-924,Patent Application,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
122,AU,A,AU 1996/059840 A,181-317-813-936-869,1996-12-24,1996,AU 1996/059840 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"Non-irritation, non-sensitizing, non-ototoxic otic antibacte rial compositions","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER IP GMBH,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/181-317-813-936-869,Patent Application,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
123,US,A1,US 2019/0353613 A1,005-570-750-491-395,2019-11-21,2019,US 201716315616 A,2017-12-08,US 201716315616 A;;US 201662432512 P;;US 2017/0065447 W,2016-12-09,ELECTROPHEROGRAM ANALYSIS,"Methods for analyzing raw electropherogram data are disclosed. Some methods includes extracting color data as a function of time or position from the raw electropherogram darta, selecting from the electropherogram one or more peaks that contain color data for a first dye and substantially no color data from other dyes used in electrophoresis. The method also includes determining the color spectrum of the first dye, and using the color spectrum of the first dye to deconvolve the color data of the raw electropherogram data to separate the contributions of each of the dyes to the raw electropherogram data. Systems and apparatus for producing electropherograms are also disclosed.",INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,INTEGENX INC (2019-04-23),https://lens.org/005-570-750-491-395,Patent Application,yes,0,5,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,G01N27/447;;G16B45/00,,0,0,,,,DISCONTINUED
124,EP,B1,EP 1147558 B1,044-118-850-780-50X,2010-03-31,2010,EP 99973353 A,1999-11-29,EP 9909268 W;;GB 9826877 A,1998-12-07,ANALOGUE SWITCH,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",INFINEON TECHNOLOGIES AG,GOLDMAN RICHARD;;MILES DAVID,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2004-05-06);;INFINEON TECHNOLOGIES AG (2010-06-02),https://lens.org/044-118-850-780-50X,Granted Patent,yes,4,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L27/082;;H01L21/8228;;H01L29/73;;H01L29/732;;H03K17/00;;H03K17/66,,0,0,,,,EXPIRED
125,EP,A1,EP 0782448 A1,079-409-479-786-156,1997-07-09,1997,EP 96917172 A,1996-06-05,US 9608864 W;;US 46504895 A,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (2009-07-20);;BAYER INTELLECTUAL PROPERTY   GMBH, DE (2013-12-18);;BAYER AKTIENGESELLSCHAFT (2007-10-15);;BAYER SCHERING PHARMA AG, DE (2009-03-26);;BAYER INTELLECTUAL PROPERTY GMBH (2013-03-19)",https://lens.org/079-409-479-786-156,Patent Application,yes,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
126,DE,D1,DE 69943351 D1,149-690-508-455-079,2011-05-26,2011,DE 69943351 T,1999-08-02,GB 9819248 A;;EP 9905555 W,1998-09-03,ABSCHIRMUNG GEGEN HOHE SPANNUNG,,INFINEON TECHNOLOGIES AG,MILES DAVID;;GOLDMAN RICHARD,,https://lens.org/149-690-508-455-079,Granted Patent,no,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L23/58;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L27/04,,0,0,,,,EXPIRED
127,AU,A,AU 1999/053730 A,160-907-891-187-224,2000-03-27,2000,AU 1999/053730 A,1999-08-02,EP 9905555 W;;GB 9819248 A,1998-09-03,High voltage shield,,ERICSSON TELEFON AB L M,MILES DAVID;;GOLDMAN RICHARD,,https://lens.org/160-907-891-187-224,Patent Application,no,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,DISCONTINUED
128,EP,A4,EP 3116582 A4,198-452-210-142-33X,2017-04-26,2017,EP 15786448 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,,BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,"C.R. BARD, INC. (2019-11-13)",https://lens.org/198-452-210-142-33X,Search Report,no,5,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,1,0,,,See also references of WO 2015168335A1,ACTIVE
129,WO,A1,WO 2020/214591 A1,014-108-715-952-914,2020-10-22,2020,US 2020/0028113 W,2020-04-14,US 201962835621 P,2019-04-18,GUIDING PULL RING,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/014-108-715-952-914,Patent Application,yes,8,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,PENDING
130,CA,A1,CA 2342904 A1,005-173-048-681-173,2000-03-16,2000,CA 2342904 A,1999-08-02,EP 9905555 W;;GB 9819248 A,1998-09-03,HIGH VOLTAGE SHIELD,"An integrated circuit has a guard ring for shielding a first area (14) (e.g. high voltage area) from a second area (15) (e.g. low voltage). The guard rin g comprises a conductive guard ring (6), (e.g. metal), which is partially exposed through a passivation layer (13) in the integrated circuit (1). A semiconductor guard ring (8), (e.g. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings (16), one located on each side of the semiconductor guard ring (8). A plurality of conductive elements (comprising a metal connection plate (18) and via (19)) connect the conductive guard ring (6) and the semiconductor guard ring (8) at spaced apa rt intervals. The ocnductive guard ring (6), semiconductor guard ring (8) and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attract ed to the exposed metal, and their charge is conducted to ground.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/005-173-048-681-173,Patent Application,no,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,DISCONTINUED
131,NZ,A,NZ 309624 A,023-091-206-623-301,1999-04-29,1999,NZ 30962496 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"NON-IRRITATING, NON-SENSITIZING, NON-OTOTOXIC (HARMFUL TO THE EARS) ANTIBACTERIAL COMPOSITIONS","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER INTELLECTUAL PROPERTY GMBH, DE (2013-08-15);;BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE (2009-08-28)",https://lens.org/023-091-206-623-301,Patent Application,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
132,WO,A2,WO 2020/102115 A2,034-362-331-757-107,2020-05-22,2020,US 2019/0060799 W,2019-11-11,US 201862758854 P,2018-11-12,SENSOR SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,A pool or spa control system includes a sensor system with one or more sensors in contact with a main body of water. The sensor system measures water condition data of the body of water and is mounted on a wall submerged in the main body of water. The pool or spa control system also includes a modem that facilitates data communications between the sensor system and communication equipment positioned at a different location from the main body of water.,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,,https://lens.org/034-362-331-757-107,Patent Application,yes,2,1,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,H04B3/54,,0,0,,,,PENDING
133,WO,A1,WO 1996/039146 A1,057-898-807-817-102,1996-12-12,1996,US 9608864 W,1996-06-05,US 46504895 A,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","Compositions for introduction, preferably by instillation, into human and animal ears, and a method, for the treatment of otitis externa and otitis media, especially otorrhea. The compositions are non-ototoxic, non-irritating and non-sensitizing. The compositions are aqueous based and contain ciprofloxacin and optionally hydrocortisone.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/057-898-807-817-102,Patent Application,yes,2,28,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,PATENTED
134,US,A,US 5843930 A,053-941-968-318-81X,1998-12-01,1998,US 83847397 A,1997-04-07,US 83847397 A;;US 70924596 A;;US 46504895 A,1995-06-06,Method of treating otitis with ciprofloxacin-hydrocortisone suspension,"The invention is directed to a method of treating otitis which comprises introducing an antibacterially-effective amount of a composition comprising a non-ototoxic, topical, otic pharmaceutic composition comprising (a) ciprofloxacin in aqueous solution in an amount effective for antibacterial action; (b) a non-ionic viscosity augmenter unaffected by pH and ionic level, said viscosity augmenter being present in an amount effective for augmenting viscosity of the composition to a viscosity greater than that of water, said viscosity augmenter being at least 85% hydrolyzed polyvinyl alcohol; (c) a non-ototoxic preservative present in an amount effective for antibacterial action, the preservative being benzyl alcohol; (d) water sufficient to produce an aqueous composition; (e) hydrocortisone in aqueous suspension in an amount effective for anti-inflammatory action; (f) lecithin in an amount effective for enhancing suspension of other constituents in the composition; and (g) polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (2008-12-04);;BAYER AKTIENGESELLSCHAFT (1998-08-06);;BAYER INTELLECTUAL PROPERTY GMBH (2012-04-01),https://lens.org/053-941-968-318-81X,Granted Patent,yes,12,54,1,25,0,A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61K9/0046;;A61K9/10;;A61K47/32;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/32,514/171;;514/254;;424/437,8,4,009-885-662-623-425;;018-171-774-252-94X;;073-669-715-578-213;;066-895-354-111-766,3664417;;10.1016/s0738-081x(87)80016-0;;2514697;;10.1055/s-2007-998423;;10.1001/archotol.1990.01870050057006;;2328112;;8486586;;10.1093/jac/31.3.452,"Strauss, M., et al., Otitis External Associated With Aquatic Activities (Swimmer s Ear), Clinics in Dermatology, 1987, pp. 103 111.;;Stange, G., et al., Laryngol Rhino Otol 68 (12) : 653 656 (1989) Abstract .;;Stange, G., et al., Laryngol Rhino Otol 68 (12) : 653 656 (1989), Abstract.;;Esposito, S., et al., Topical and Oral Treatment of Chronic Otitis Media With Ciprofloxacin, Arch Otolaryngol Head Neck Surg vol. 116, 1990, pp. 557 559.;;Garc i a Rodriguez, J.A., et al., Efficacy of 2 Regimens of Local Ciprofloxacin in the Treatment of Ear Infections, Preprint: Drugs 45 (Suppl.), 1993, pp. 40 41.;;Ganz, H., Bacterial Otitis Externa Beyond the Organ Limits Systemic and Topical Combination Treatment with Ciprofloxacin, pp. 2 7 (translation from German) 1992.;;Garc i a Rodriguez, J.A., Efficacy of Topical Ciprofloxacin in the Treatment of Ear Infections in Adults, J Antimicrob Chemother, 1993, pp. 31:452 453.;;Esposito, S., et al., Topical Cirpofloxacin (CP) Versus Parenteral Gentamicin (GM) in Pseudomonas Infections of the Middle Ear, 29. Interscience Conference Antimicrobiotic Agents Chemotherapy * Houston, 545 (1989) Abstract .",EXPIRED
135,EP,A4,EP 3551764 A4,070-627-015-511-910,2020-08-05,2020,EP 17877536 A,2017-12-08,US 201662432512 P;;US 2017/0065447 W,2016-12-09,ELECTROPHEROGRAM ANALYSIS,,INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,,https://lens.org/070-627-015-511-910,Search Report,no,3,0,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,C12Q1/68;;G01N27/447,,1,0,,,See also references of WO 2018107111A1,PENDING
136,AU,A1,AU 2019/380358 A1,084-570-322-551-289,2021-06-10,2021,AU 2019/380358 A,2019-11-11,US 201862758854 P;;US 2019/0060799 W,2018-11-12,Sensor systems principally for swimming pools and spas,A pool or spa control system includes a sensor system with one or more sensors in contact with a main body of water. The sensor system measures water condition data of the body of water and is mounted on a wall submerged in the main body of water. The pool or spa control system also includes a modem that facilitates data communications between the sensor system and communication equipment positioned at a different location from the main body of water.,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,,https://lens.org/084-570-322-551-289,Patent Application,no,0,0,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,H04B3/54,,0,0,,,,PENDING
137,EP,B1,EP 3116582 B1,182-256-806-921-992,2019-11-20,2019,EP 15786448 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,,BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,"C.R. BARD, INC. (2019-11-13)",https://lens.org/182-256-806-921-992,Granted Patent,yes,14,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
138,US,B2,US 8178876 B2,054-088-554-469-125,2012-05-15,2012,US 59538404 A,2004-04-30,US 59538404 A;;US 51153503 P;;US 2004/0013483 W,2003-10-15,Method and configuration for connecting test structures or line arrays for monitoring integrated circuit manufacturing,"A test chip comprises at least one level having an array of regions. Each region is capable of including at least one test structure. At least some of the regions include respective test structures. The level has a plurality of driver lines that provide input signals to the test structures. The level has a plurality of receiver lines that receive output signals from the test structures. The level has a plurality of devices for controlling current flow. Each test structure is connected to at least one of the driver lines with a first one of the devices in between. Each test structure is connected to at least one of the receiver lines with a second one of the devices in between, so that each of the test structures can be individually addressed for testing using the driver lines and receiver lines.",HESS CHRISTOPHER;;GOLDMAN DAVID;;PDF SOLUTIONS INC,HESS CHRISTOPHER;;GOLDMAN DAVID,PDF SOLUTIONS INC (2006-03-27),https://lens.org/054-088-554-469-125,Granted Patent,yes,4,81,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,G06F/;;H01L23/58,257/48;;438/11;;438/14;;438/15;;438/18;;X257E21521;;X257E21525;;716/51;;716/52;;716/56,18,15,024-822-641-021-594;;166-423-305-122-32X;;007-509-467-111-131;;061-374-105-590-174;;013-982-566-833-149;;175-251-535-155-926;;049-364-309-281-265;;099-943-668-368-127;;047-016-299-621-858;;058-443-368-685-499;;019-295-187-457-263;;010-422-136-359-227;;085-437-888-478-31X;;002-572-291-521-750;;002-704-930-635-087,10.1109/66.388016;;10.1016/b978-0-12-234106-9.50014-3;;10.1109/66.484280;;10.1109/66.964320;;10.1007/978-3-642-52314-4_198;;10.1109/icmts.2002.1193190;;10.1109/icmts.1990.67883;;10.1109/icmts.1995.513944;;10.1109/icmts.1998.688058;;10.1109/66.670155;;10.1109/icmts.1994.303485;;10.1109/icmts.1996.585568;;10.1109/66.964321;;10.1109/icmts.1992.185954;;10.1109/icmts.1994.303494,"Stapper, C. H., Rosner, R. J., ""Integrated Circuit Yield Management and Yield Analysis: Development and Implementation,"" IEEE Transactions on Semiconductor Manufacturing, pp. 95-102, vol. 8, No. 2, 1995.;;Ipri, A. C., Sarace, J. C., ""Integrated Circuit Process and Design Rule Evaluation Techniques,"" RCA Review, pp. 323-350, vol. 38, No. 3, Sep. 1977.;;Buehler, M. G., ""Microelectronic Test Chips for VLSI Electronics,"" VLSI Electronics Microstructure Science, pp. 529-576, vol. 6, Chapter 9, Academic Press, 1983.;;Doong, K., Cheng, J., Hsu, C., ""Design and Simulation of Addressable Failure Site Test Structure for IC Process Control Monitor,"" pp. 219-222, International Symposium on Semiconductor Manufacturing, 1999.;;Hess, C., Weiland, L. H., ""Influence of Short Circuits on Data of Contact & Via Open Circuits Determined by a Novel Weave Test Structure,"" IEEE Transactions on Semiconductor Manufacturing, pp. 27-34, vol. 9, No. 1, 1996.;;Hess, C., Stashower, D., Stine, B. E., Weiland, L. H., Verma, G., Miyamoto, K., Inoue, K., ""Fast Extraction of Defect Size Distribution Using a Single Layer Short Flow NEST Structure"", IEEE Transactions on Semiconductor Manufacturing, pp. 330-337, vol. 14, No. 4, 2001.;;Walton, A. J., Ward, D., Robertson, J. M., Holwill R. J., ""A Novel Approach for an Electrical Vernier to Measure Mask Misalignment"", pp. 950-953, 19th European Solid State Device Research Conference ESSDERC '89, Springer Verlag, 1989.;;Hess, C., Stine, B. E., Weiland, L. H., Mitchell, T., Karnett, M., Gardner, K., ""Passive Multiplexer Test Structure for Fast and Accurate Contact and Via Fail Rate Evaluation"", pp. 163-167, Proc. International Conference on Microelectronic Test Structures (ICMTS), vol. 15, Cork (Ireland), 2002.;;Walton, A. J., Gammie, W., Marrow, D., Stevenson, J. T. M., Holwill, R. J., ""A Novel Approach for Reducing the Area Occupied by Contact Pads on Process Control Chips"", International Conference on Microelectronic Test Structures, San Diego, (USA), 1990.;;Hess, C., Weiland, L. H., Bornefeld, R., ""Customized Checkerboard Test Structures to Localize Interconnection Point Defects"", Proc. VLSI Multilevel Interconnection Conference (VMIC), pp. 163-168, Santa Clara (USA), 1997.;;Hess, C., Weiland, L. H., ""Defect Parameter Extraction in Backend Process Steps using a Multilayer Checkerboard Test Structure"", Proc. International Conference on Microelectronic Test Structures (ICMTS), pp. 51-56, Nara (Japan), 1995.;;Hess, C., Weiland, L. H., ""Strategy to Disentangle Multiple Faults to Identify Random Defects within Test Structures"", Proc. International Conference on Microelectronic Test Structures (ICMTS), pp. 141-146, Kanazawa (Japan), 1998.;;Hess, C., Weiland, L. H., ""Harp Test Structure to Electrically Determine Size Distributions of Killer Defects"", IEEE Transactions on Semiconductor Manufacturing, pp. 194-203, vol. 11, No. 2, 1998.;;Hess, C., Weiland, L. H., ""Drop in Process Control Checkerboard Test Structure for Efficient Online Process Characterization and Defect Problem Debugging"", Proc. International Conference on Microelectronic Test Structures (ICMTS), pp. 152-159, San Diego (USA), 1994.;;Hess, C., Weiland, L. H., Lau, G., Simoneit, P., ""Control of Application Specific Interconnection on Gate Arrays Using an Active Checkerboard Test Structure"", Proc. International Conference on Microelectronic Test Structures (ICMTS), pp. 55-60, Trento (Italy), 1996.;;Doong, K., Hsieh, S., Lin, S., Shen, B. Cheng, J., Hess, C., Weiland, L., Hsu, C., ""Addressable Failure Site Test Structures (AFS-TS) for CMOS Processes: Design Guidelines, Fault Simulation, and Implementation"", IEEE Transactions on Semiconductor Manufacturing, pp. 338-355, vol. 14, No. 4, 2001.;;Ward, D., Walton, A. J., Gammie, W. G., Holwill, R. J., ""The Use of a Digital Multiplexer to Reduce Process Control Chip Pad Count"", International Conference on Microelectronic Test Structures, vol. 5, San Diego (USA), 1992.;;Khare, J., Maly, W., Griep, S., Schmitt-Landsiedel, D., ""SRAM-based Extraction of Defect Characteristics"", International Conference on Microelectronic Test Structures, vol. 7, San Diego, USA, 1994.",ACTIVE
139,TW,B,TW 464499 B,075-834-747-665-249,2001-11-21,2001,TW 85106748 A,1996-06-06,US 46504895 A,1995-06-06,"Non-irritation, nonsensitizing, non-ototoxic otic anti-bacterial compositions","Compositions for introduction, preferably by instillation, into human and animal ears, and a method, for the treatment of otitis externa and otitis media, especially otorrhea. The compositions are non-ototoxic, non-irritating and non-sensitizing. The compositions are aqueous based and contain ciprofloxacin and optionally hydrocortisone.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/075-834-747-665-249,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
140,EP,A1,EP 3116582 A1,081-352-534-895-986,2017-01-18,2017,EP 15786448 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,,BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,"C.R. BARD, INC. (2019-11-13)",https://lens.org/081-352-534-895-986,Patent Application,yes,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
141,EP,A1,EP 3551764 A1,030-550-969-663-751,2019-10-16,2019,EP 17877536 A,2017-12-08,US 201662432512 P;;US 2017/0065447 W,2016-12-09,ELECTROPHEROGRAM ANALYSIS,,INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,,https://lens.org/030-550-969-663-751,Patent Application,yes,0,0,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,C12Q1/68,,0,0,,,,PENDING
142,WO,A1,WO 2015/168335 A1,052-669-803-886-45X,2015-11-05,2015,US 2015/0028366 W,2015-04-29,US 201461985887 P,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/052-669-803-886-45X,Patent Application,yes,24,1,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,PENDING
143,AT,T1,AT E505814 T1,048-184-318-601-502,2011-04-15,2011,AT 99939434 T,1999-08-02,GB 9819248 A;;EP 9905555 W,1998-09-03,ABSCHIRMUNG GEGEN HOHE SPANNUNG,,INFINEON TECHNOLOGIES AG,MILES DAVID;;GOLDMAN RICHARD,,https://lens.org/048-184-318-601-502,Granted Patent,no,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,EXPIRED
144,CN,A,CN 101107670 A,104-352-664-500-594,2008-01-16,2008,CN 200480030335 A,2004-04-30,US 51153503 P,2003-10-15,Method and configuration for connecting test structures or line arrays for monitoring integrated circuit manufacturing,"A test chip comprises at least one level having an array of regions. Each region is capable of including at least one test structure. At least some of the regions include respective test structures. The level has a plurality of driver lines that provide input signals to the test structures. The level has a plurality of receiver lines that receive output signals from the test structures. The level has a plurality of devices for controlling current flow. Each test structure is connected to at least one of the driver lines with a first one of the devices in between. Each test structure is connected to at least one of the receiver lines with a second one of the devices in between, so that each of the test structures can be individually addressed for testing using the driver lines and receiver lines.",PDF SOLUTIONS INC,CHRISTOPHER HESS;;DAVID GOLDMAN,,https://lens.org/104-352-664-500-594,Patent Application,no,0,3,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,G11C7/00;;G06F/,,0,0,,,,DISCONTINUED
145,EP,B1,EP 1114459 B1,192-179-283-594-625,2011-04-13,2011,EP 99939434 A,1999-08-02,EP 9905555 W;;GB 9819248 A,1998-09-03,HIGH VOLTAGE SHIELD,,INFINEON TECHNOLOGIES AG,MILES DAVID;;GOLDMAN RICHARD,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2004-05-06);;INFINEON TECHNOLOGIES AG (2010-06-02),https://lens.org/192-179-283-594-625,Granted Patent,yes,6,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L23/58;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L27/04,,0,0,,,,EXPIRED
146,US,A1,US 2020/0150633 A1,110-830-690-627-995,2020-05-14,2020,US 201916680381 A,2019-11-11,US 201916680381 A;;US 201862758854 P,2018-11-12,SENSOR SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,A pool or spa control system includes a sensor system with one or more sensors in contact with a main body of water. The sensor system measures water condition data of the body of water and is mounted on a wall submerged in the main body of water. The pool or spa control system also includes a modem that facilitates data communications between the sensor system and communication equipment positioned at a different location from the main body of water.,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,,https://lens.org/110-830-690-627-995,Patent Application,yes,11,11,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,G05B19/4155;;E04H4/14,,0,0,,,,PENDING
147,CA,C,CA 2199294 C,139-967-764-051-74X,2000-09-19,2000,CA 2199294 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","Compositions of introduction, preferably by instillation, into human and animal ears, and a method, for the treatment of otitis externa and otitis media, especially otorrhea. The compositions are non-ototoxic, non-irritating and non-sensitizing. The compositions are aqueous based and contain ciprofloxacin and optionally hydrocortisone.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/139-967-764-051-74X,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
148,WO,A3,WO 2005/040961 A3,153-471-917-814-065,2007-05-31,2007,US 2004/0013483 W,2004-04-30,US 51153503 P,2003-10-15,METHOD AND CONFIGURATION FOR CONNECTING TEST STRUCTURES OR LINE ARRAYS FOR MONITORING INTEGRATED CIRCUIT MANUFACTURING,"A test chip (200) comprises at least one level having an array of regions (201). Each region (201) is capable of including at least one test structure (202). At least some of the regions (201) include respective test structures (202). The level has a plurality of driver lines (D1-D5) that provide input signals to the test structures (202). The level has a plurality of receiver lines (R1-R8) that receive output signals from the test structures (202). The level has a plurality of devices for controlling current flow. Each test structure (202) is connected to at least one of the driver lines with a first one of the devices in between. East test structure is connected to at least one of the receiver lines (R1-R8) with a second one of the devices in between, so that each of the test structures (202) can be individually addressed for testing using the driver lines (D1-D5) and receiver lines (R1-R8).",PDF SOLUTIONS INC;;HESS CHRISTOPHER;;GOLDMAN DAVID,HESS CHRISTOPHER;;GOLDMAN DAVID,,https://lens.org/153-471-917-814-065,Search Report,yes,2,0,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,G06F/;;G11C7/00,,0,0,,,,PENDING
149,MX,A,MX 2016014146 A,190-988-323-306-243,2017-02-06,2017,MX 2016014146 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY.,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,DAVID GOLDMAN;;MICHAEL DOLGIN,,https://lens.org/190-988-323-306-243,Patent Application,no,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
150,CN,A,CN 109564189 A,002-612-391-630-704,2019-04-02,2019,CN 201780048325 A,2017-12-08,US 201662432512 P;;US 2017/0065447 W,2016-12-09,ELECTROPHEROGRAM ANALYSIS,"Methods for analyzing raw electropherogram data are disclosed. Some methods includes extracting color data as a function of time or position from the raw electropherogram darta, selecting from the electropherogram one or more peaks that contain color data for a first dye and substantially no color data from other dyes used in electrophoresis. The method also includes determining the color spectrumof the first dye, and using the color spectrum of the first dye to deconvolve the color data of the raw electropherogram data to separate the contributions of each of the dyes to the raw electropherogram data. Systems and apparatus for producing electropherograms are also disclosed.",INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,,https://lens.org/002-612-391-630-704,Patent Application,no,7,1,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,G01N27/447;;G01N33/48,,0,0,,,,ACTIVE
151,US,A1,US 2023/0152276 A1,019-005-858-831-116,2023-05-18,2023,US 202217984548 A,2022-11-10,US 202217984548 A;;US 201916315616 A;;US 2017/0065447 W;;US 201662432512 P,2016-12-09,ELECTROPHEROGRAM ANALYSIS,"Methods for analyzing raw electropherogram data are disclosed. Some methods includes extracting color data as a function of time or position from the raw electropherogram data, selecting from the electropherogram one or more peaks that contain color data for a first dye and substantially no color data from other dyes used in electrophoresis. The method also includes determining the color spectrum of the first dye, and using the color spectrum of the first dye to deconvolve the color data of the raw electropherogram data to separate the contributions of each of the dyes to the raw electropherogram data. Systems and apparatus for producing electropherograms are also disclosed.",INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,INTEGENX INC (2019-04-23),https://lens.org/019-005-858-831-116,Patent Application,yes,0,0,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,G01N27/447;;G16B45/00,,0,0,,,,PENDING
152,US,B2,US 9855408 B2,052-514-589-505-09X,2018-01-02,2018,US 201515302157 A,2015-04-29,US 201515302157 A;;US 201461985887 P;;US 2015/0028366 W,2014-04-29,Kink-resistant guidewire with improved rigidity,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,C. R. BARD INC (2016-10-07),https://lens.org/052-514-589-505-09X,Granted Patent,yes,18,2,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61B5/00;;A61M25/09,,2,0,,,"PCT/US2015/028366 filed Apr. 29, 2015 International Search Report dated Aug. 5, 2015.;;EP 15786448.9 filed Oct. 12, 2016 Extended European Search Report dated Mar. 16, 2017.",ACTIVE
153,US,A,US 5664868 A,064-745-717-086-058,1997-09-09,1997,US 65421296 A,1996-05-28,US 65421296 A,1996-05-28,Helmet rigid flashlight bracket,"A helmet rigid flashlight bracket that is replaceably and securingly attachable to a portion of a brim of a helmet that is wearable by a user and replaceably and securingly receives a flashlight of a variety of different flashlights each of which has a handle portion and a light emitting portion that emits a light beam that points substantially at eye level in a forward direction of the user that includes a face plate, flashlight maintaining apparatus, a substantially C-shaped channel, and face plate clamping apparatus. The face plate has a lower portion. The flashlight maintaining apparatus is disposed on the face plate and replaceably and securingly maintains the handle portion of the flashlight of the variety of different flashlights to the face plate. The substantially C-shaped channel is disposed on the lower portion of the face plate in an orientation so as to be parallel to the light beam that emits from the light emitting portion of the flashlight of the variety of different flashlights. And, the face plate clamping apparatus is associated with the substantially C-shaped channel and replaceably and securingly clamps the face plate to the portion of the brim of the helmet, so that the light beam that emits from the light emitting portion of the flashlight of the variety of different flashlights points substantially at eye level in the forward direction of the user.",MONTALBANO; DAVID;;GOLDMAN; MICHAEL,MONTALBANO DAVID;;GOLDMAN MICHAEL,,https://lens.org/064-745-717-086-058,Granted Patent,yes,7,30,1,1,0,A42B3/044;;F21V21/0885;;F21V21/0885;;A42B3/044,A42B3/04;;F21V21/084;;F21V21/088,362/105;;362/106;;362/396;;362/191;;248/229.15,1,0,,,"Advertisement by Wehr Engineering, 8192 W. 700 N. Fairland, IN 46126.",EXPIRED
154,PT,E,PT 782448 E,097-241-617-110-215,2002-07-31,2002,PT 96917172 T,1996-06-05,US 46504895 A,1995-06-06,FORMULACOES OTICAS ANTIBACTERIANAS NAO OTOTOXICAS NAO SENSIBILIZANTES NAO IRRITANTES,"The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,GOLDMAN DAVID;;PURWAR SHIVAJI,,https://lens.org/097-241-617-110-215,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
155,AU,A1,AU 2015/253183 A1,132-529-347-533-321,2016-10-13,2016,AU 2015/253183 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,Kink-resistant guidewire with improved rigidity,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/132-529-347-533-321,Patent Application,no,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
156,US,A,US 2675617 A,136-499-552-624-346,1954-04-20,1954,US 15265850 A,1950-03-29,US 15265850 A,1950-03-29,Ruler,,EVANS & COMPANY,DAVID GOLDMAN;;JOHN GEIGER,,https://lens.org/136-499-552-624-346,Granted Patent,no,13,8,1,1,0,A41H9/02;;A41H9/02,A41H9/02,,0,0,,,,EXPIRED
157,AU,B2,AU 708540 B2,001-831-779-805-199,1999-08-05,1999,AU 1996/059840 A,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/001-831-779-805-199,Granted Patent,no,2,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,1,0,,,REMINGTON'S 19TH EDITION 1995,EXPIRED
158,ES,T3,ES 2173287 T3,010-114-431-607-794,2002-10-16,2002,ES 96917172 T,1996-06-05,US 46504895 A,1995-06-06,"COMPOSICIONES OTICAS ANTIBACTERIANAS NO IRRITANTES, NO SENSIBILIZANTES Y NO OTOTOXICAS.","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/010-114-431-607-794,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
159,DE,B4,DE 112004001975 B4,031-892-474-532-676,2009-11-05,2009,DE 112004001975 T,2004-04-30,US 51153503 P;;US 2004/0013483 W,2003-10-15,Verfahren und Anordnung zur Verbindung von Teststrukturen oder Leitungsarrays zur Überwachung der Herstellung integrierter Schaltungen,,PDF SOLUTIONS INC,HESS CHRISTOPHER;;GOLDMAN DAVID,,https://lens.org/031-892-474-532-676,Granted Patent,no,3,0,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,H01L23/544;;G06F/;;H01L21/66,,16,14,024-822-641-021-594;;166-423-305-122-32X;;007-509-467-111-131;;061-374-105-590-174;;175-251-535-155-926;;049-364-309-281-265;;099-943-668-368-127;;047-016-299-621-858;;058-443-368-685-499;;019-295-187-457-263;;010-422-136-359-227;;085-437-888-478-31X;;002-572-291-521-750;;002-704-930-635-087,10.1109/66.388016;;10.1016/b978-0-12-234106-9.50014-3;;10.1109/66.484280;;10.1109/66.964320;;10.1109/icmts.2002.1193190;;10.1109/icmts.1990.67883;;10.1109/icmts.1995.513944;;10.1109/icmts.1998.688058;;10.1109/66.670155;;10.1109/icmts.1994.303485;;10.1109/icmts.1996.585568;;10.1109/66.964321;;10.1109/icmts.1992.185954;;10.1109/icmts.1994.303494,"Staper,C.H., Rosner,R.J.: ""Integrated Circuit Yield Management and Yield Analysis: Development and Implementation"", IEEE Transaction on Semiconductor Manufacturing, p. 95-102, No. 2, 1995;;Ipri,A.C., Sarace,J.C.: Integrated Circuit Process and Design Rule Evaluation Techniques, RCA Review, p. 323-350, Vol. 38, No. 3, Sept. 1977;;Buehler,M.G. ""Microelectronic Test Chips for VLSI-Electronics"", VLSI-Electronics Microstructure Science, S. 529-576, Bd. 9, Kap. 9, Academic Press, 1983;;Hess,C., Weiland,L.H.: ""Influence of Short Circuit on Data of Contact and Via Open Circuits Determined by a Novel Weave Test Structure"", IEEE Transact. on Semiconductor Manufacturing, p. 27- 34, Vol. 9, No. 1, 1996;;Hess,C., Stashhower,D., Stine,B.E., Weiland,L.H., Verma,G., Miyamoto,K., Inoue,K.: ""Fast Extraction of Defect Size Distribution Using a Single Layer Short Flow NEST Structure"", IEEE Transact. on Semiconductor Manufacturing, p. 330-337, Vol. 14, No. 4, 2001;;Hess,C., Stine,B.E., Weiland,L.H., Mitchell,T., Karnett,M., Gardner,K.: ""Passive Multiplexer Test Structure for Fast and Accurate Contact and Via Fail Rate Evaluation"", Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 15, p. 163-167, Corc (Irland), 2002;;Walton,A.J., Gammie,W., Marrow,D., Stevenson,J.T.M., Holwill,R.J. : ""A Novel Approach For Reducing The Area Occupied By Contacts Pads On Process Control Chips"", Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 3, p. 75-80, San Diego, (USA). 1990;;Hess,C., Weiland,L.H. Bornefeld,R.: ""Customized Checkerboard Test Structures to Localize Interconnection Point Defects"", Proc. 14th Int. VLSI Multilevel Interconnection Conf. (VMIC), p. 163-168, Santa Clara (USA), 1997;;Hess,C., Weiland,L.H.: ""Defect Parameter Extraction in Backend Process Steps Using a Multilayer Checkerboard Test Structure"", Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 8, p. 51-56, Nara (Japan), 1995;;Hess,C., Weiland,L.H.: ""Strategy to Disentangle Multiple Faults to Identify Random Defects within Test Structures"" Proc. IEEE Int . Conf. on Microelectronic Teststructures, p. 141-146, Vol. 11, Kanazawa (Japana9, 1998;;Hess,C., Weiland,L.H.: ""Harp Test Structure to Electrically Determine Size Distributions of Killer Defects"", IEEE Transact. on Semiconductor Manufacturing, p. 194-203, Vol. 11, No. 2, 1998;;Hess,C., Weiland,L.H., ""Drop in Process Checkerboard Test Structure for Efficient Online Process Characterization and Defect Problem Debugging"", Proc. IEEE 1994 Int. Conf. on Microelectronic Test Structures, Vol. 7, p. 152-159, San Diego (USA), 1994;;Hess,C., Weiland,L.H., Lau,G., Simoneit,P.: ""Control of Appl. Specific Interconnection on Gate Arrays Using an Active Checkerboard Test Structure"", Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 9, p. 55-60, Trento (Italien), 1996;;Doong,K., Hsieh,S., Lin,S., Shen,B. Cheng,J., Hess,C., Weiland,L., Hsu,C.: ""Adressable Failure Site Test Stuctures (AFS-TS for CMOS-Processes: Design Guidelines, Fault Simulation and Implementation"", IEEE Transact. on Semiconductor Manufacturing, Vol. 14, No. 4, p. 338-335, 2001;;Ward,D., Walton,A.J., Gammie,W.G., Holwill,R.J.: ""The Use of a Digital Multiplexer to reduce Process Control Chip Pad Account"" Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 5, p. 129-133, San Diego (USA), 1992;;Khare,J., Maly,W., Griep,S., Schmitt-Landsiedel,D.: ""SRAM-based Extraction of Defect Characteristics"", Proc. IEEE Int. Conf. on Microelectronic Test Structures, Vol. 7, p. 98-107, San Diego, (USA), 1999",INACTIVE
160,US,A1,US 2014/0149578 A1,074-001-730-605-378,2014-05-29,2014,US 201313746624 A,2013-01-22,US 201313746624 A;;US 201213685127 A;;US 201213685245 A,2012-11-26,Method For Testing Methods of Accelerating Content Delivery,An exemplary method for testing and communicating a report of a loading of a website capable of having at least some content delivered through a content delivery network. The report provides information about loading of the webpage with geographically-accelerated content delivery relative to loading of the website without accelerated content delivery.,GO DADDY OPERATING CO LLC,GOLDMAN AUGUSTE;;KOOPMAN DAVID,GO DADDY OPERATING COMPANY LLC (2013-01-24),https://lens.org/074-001-730-605-378,Patent Application,yes,18,29,1,15,0,H04L45/02;;H04L45/02,H04L12/26,709/224,0,0,,,,DISCONTINUED
161,MX,A,MX 2021009695 A,146-080-698-850-899,2021-09-10,2021,MX 2021009695 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,GUIDING PULL RING.,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,FANTA THOMAS;;GOLDMAN DAVID,,https://lens.org/146-080-698-850-899,Patent Application,no,0,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,PENDING
162,US,A1,US 2020/0335293 A1,144-776-719-458-398,2020-10-22,2020,US 202016848409 A,2020-04-14,US 202016848409 A;;US 201962835621 P,2019-04-18,GUIDING PULL RING,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,S&C ELECTRIC COMPANY (2019-04-18),https://lens.org/144-776-719-458-398,Patent Application,yes,0,2,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/666;;H01H33/662,,0,0,,,,ACTIVE
163,DE,D1,DE 69942209 D1,175-262-983-064-618,2010-05-12,2010,DE 69942209 T,1999-11-29,GB 9826877 A;;EP 9909268 W,1998-12-07,ANALOGSCHALTER,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",INFINEON TECHNOLOGIES AG,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/175-262-983-064-618,Granted Patent,no,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L27/082;;H01L21/8228;;H01L29/73;;H01L29/732;;H03K17/00;;H03K17/66,,0,0,,,,EXPIRED
164,WO,A2,WO 2005/040961 A2,074-932-732-451-742,2005-05-06,2005,US 2004/0013483 W,2004-04-30,US 51153503 P,2003-10-15,METHOD AND CONFIGURATION FOR CONNECTING TEST STRUCTURES OR LINE ARRAYS FOR MONITORING INTEGRATED CIRCUIT MANUFACTURING,"A test chip (200) comprises at least one level having an array of regions (201). Each region (201) is capable of including at least one test structure (202). At least some of the regions (201) include respective test structures (202). The level has a plurality of driver lines (D1-D5) that provide input signals to the test structures (202). The level has a plurality of receiver lines (R1-R8) that receive output signals from the test structures (202). The level has a plurality of devices for controlling current flow. Each test structure (202) is connected to at least one of the driver lines with a first one of the devices in between. East test structure is connected to at least one of the receiver lines (R1-R8) with a second one of the devices in between, so that each of the test structures (202) can be individually addressed for testing using the driver lines (D1-D5) and receiver lines (R1-R8).",PDF SOLUTIONS INC;;HESS CHRISTOPHER;;GOLDMAN DAVID,HESS CHRISTOPHER;;GOLDMAN DAVID,,https://lens.org/074-932-732-451-742,Patent Application,yes,0,0,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,G06F/,,0,0,,,,PENDING
165,US,A1,US 2019/0220914 A1,088-734-602-115-100,2019-07-18,2019,US 201916245902 A,2019-01-11,US 201916245902 A;;US 201862617501 P,2018-01-15,METHODS AND APPARATUS TO TRANSLATE AND MANAGE PRODUCT DATA,"Methods and apparatus to translate and manage product data are disclosed. A disclosed example system for translating and managing product data pertaining to a plurality of tenants includes a rules executor to verify, based on product attribute rules, that requested product attributes pertaining to a product request from a buyer are valid, an attribute translator to generate platform standard attributes of products corresponding to the tenants, where the attribute translator is to translate tenant-specific product attributes to the platform standard attributes based on the tenant-specific product attributes and the product attribute rules, and an equivalency evaluator to evaluate an equivalency of the products based on the requested product attributes and output the equivalency. The equivalency evaluator is to store the equivalency.",CIMPRESS SCHWEIZ GMBH,FLANNERY KELLEN;;GOLDMAN DAVID,CIMPRESS SCHWEIZ GMBH (2018-03-09),https://lens.org/088-734-602-115-100,Patent Application,yes,0,1,5,5,0,G06Q30/06;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635,G06Q30/06,,0,0,,,,ACTIVE
166,AU,B2,AU 2020/259358 B2,089-292-486-036-069,2023-05-04,2023,AU 2020/259358 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,Guiding pull ring,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/089-292-486-036-069,Granted Patent,no,2,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,ACTIVE
167,DE,T2,DE 69620136 T2,108-240-100-055-498,2002-08-01,2002,DE 69620136 T,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"ANTIBAKTERIELLE PRÄPARATE FÜR DIE OHREN OHNE IRRITIERENDE, SENSIBILISIERENDE UND OTOTOXISCHE WIRKUNGEN","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE (2009-09-10);;BAYER HEALTHCARE AG, 51373 LEVERKUSEN, DE (2004-05-27)",https://lens.org/108-240-100-055-498,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
168,US,B1,US 6426667 B1,126-811-531-261-508,2002-07-30,2002,US 45539899 A,1999-12-06,GB 9826877 A,1998-12-07,Bidirectional analog switch using two bipolar junction transistors which are both reverse connected or operating in the reverse or inverse mode,"
    The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter. 
",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,TELEFONAKTIEBOLAGET LM ERICSSON (2000-02-16);;INFINEON TECHNOLOGIES AG (2004-07-01),https://lens.org/126-811-531-261-508,Granted Patent,yes,25,5,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,327/478;;327/405;;327/419;;327/482;;257/524;;257/525;;257/526,5,0,,,"International Search Report Application No. GB9826877.4.;;International Search Report Application No. PCT/EP99/09268.;;Novelty Search Report, pp. 1-2.;;European Patents Abstracts-p. 65 EP(A)-N.;;European Patents Abstracts-p. 119 EP(A)-N.",EXPIRED
169,WO,A1,WO 2019/140394 A1,111-178-674-659-147,2019-07-18,2019,US 2019/0013507 W,2019-01-14,US 201862617501 P;;US 201916245902 A,2018-01-15,METHODS AND APPARATUS TO TRANSLATE AND MANAGE PRODUCT DATA,"Methods and apparatus to translate and manage product data are disclosed. A disclosed example system for translating and managing product data pertaining to a plurality of tenants includes a rules executor to verify, based on product attribute rules, that requested product attributes pertaining to a product request from a buyer are valid, an attribute translator to generate platform standard attributes of products corresponding to the tenants, where the attribute translator is to translate tenant-specific product attributes to the platform standard attributes based on the tenant-specific product attributes and the product attribute rules, and an equivalency evaluator to evaluate an equivalency of the products based on the requested product attributes and output the equivalency. The equivalency evaluator is to store the equivalency.",CIMPRESS SCHWEIZ GMBH,FLANNERY KELLEN;;GOLDMAN DAVID,,https://lens.org/111-178-674-659-147,Patent Application,yes,3,0,5,5,0,G06Q30/06;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635,G06Q30/06,,0,0,,,,PENDING
170,CN,A,CN 106456942 A,126-931-809-666-240,2017-02-22,2017,CN 201580022202 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,Kink-resistant guidewire with improved rigidity,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/126-931-809-666-240,Patent Application,no,3,5,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
171,DE,T5,DE 112004001975 T5,154-445-490-700-022,2007-01-18,2007,DE 112004001975 T,2004-04-30,US 51153503 P;;US 2004/0013483 W,2003-10-15,Verfahren und Anordnung zur Verbindung von Teststrukturen oder Leitungsarrays zur Überwachung der Herstellung integrierter Schaltungen,,PDF SOLUTIONS INC,HESS CHRISTOPHER;;GOLDMAN DAVID,,https://lens.org/154-445-490-700-022,Patent Application,no,0,0,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,H01L23/544;;G06F/;;H01L21/66,,0,0,,,,INACTIVE
172,ZA,B,ZA 964653 B,004-264-715-515-126,1996-12-12,1996,ZA 964653 A,1996-06-05,US 46504895 A,1995-06-06,Non-irritation non-sensitizing non-ototoxic otic anti-bacterial compositions,"The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,GOLDMAN DAVID;;PURWAR SHIVAJI,,https://lens.org/004-264-715-515-126,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
173,WO,A3,WO 2020/102115 A3,036-058-460-017-507,2020-07-30,2020,US 2019/0060799 W,2019-11-11,US 201862758854 P,2018-11-12,SENSOR SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,A pool or spa control system includes a sensor system with one or more sensors in contact with a main body of water. The sensor system measures water condition data of the body of water and is mounted on a wall submerged in the main body of water. The pool or spa control system also includes a modem that facilitates data communications between the sensor system and communication equipment positioned at a different location from the main body of water.,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,,https://lens.org/036-058-460-017-507,Search Report,yes,2,0,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,H04B3/54,,0,0,,,,PENDING
174,CA,C,CA 3133362 C,041-160-215-893-361,2023-08-22,2023,CA 3133362 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,GUIDING PULL RING,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/041-160-215-893-361,Granted Patent,no,0,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,PENDING
175,US,A1,US 2022/0261872 A1,071-860-789-068-139,2022-08-18,2022,US 202217585137 A,2022-01-26,US 202217585137 A;;US 201916245902 A;;US 201862617501 P,2018-01-15,METHODS AND APPARATUS TO TRANSLATE AND MANAGE PRODUCT DATA,"Methods and apparatus to translate and manage product data are disclosed. A disclosed example apparatus for translating and managing product data pertaining to a plurality of tenants includes at least one memory, instructions, and at least one processor to execute the instructions to verify that a first product request from a buyer is valid based on product attribute rules, the first product request to include a selected value corresponding to a first category of product attributes, reduce, via an iterative process, a set of possible values corresponding to a second category of the product attributes based on the selected value, the second category different from the first category, in response to determining the first product request is invalid, direct the buyer to provide a second product request different from the first product request, generate platform standard attributes of products corresponding to the tenants, the at least one processor to translate tenant-specific product attributes to the platform standard attributes based on the tenant-specific product attributes and the product attribute rules, evaluate an equivalency of the products based on the selected value for the first category of the product attributes and the platform standard attributes, and store the equivalency as a mapping for determining product substitutions.",CIMPRESS SCHWEIZ GMBH,FLANNERY KELLEN;;GOLDMAN DAVID,CIMPRESS SCHWEIZ GMBH (2018-03-09),https://lens.org/071-860-789-068-139,Patent Application,yes,3,0,5,5,0,G06Q30/06;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635,G06Q30/06,,1,1,035-959-340-367-264,10.1016/j.eswa.2009.03.046,"Albadvi, Amir, and Mohammad Shahbazi. ""A hybrid recommendation technique based on product category attributes."" Expert Systems with Applications 36.9 (2009): 11480-11488. (Year: 2009)",PENDING
176,EP,A1,EP 3956916 A1,084-533-713-065-04X,2022-02-23,2022,EP 20790963 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,GUIDING PULL RING,,S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/084-533-713-065-04X,Patent Application,yes,0,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,PENDING
177,AT,T1,AT E214931 T1,188-021-110-144-066,2002-04-15,2002,AT 96917172 T,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"ANTIBAKTERIELLE PRÄPARATE FÜR DIE OHREN OHNE IRRITIERENDE, SENSIBILISIERENDE UND OTOTOXISCHE WIRKUNGEN","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/188-021-110-144-066,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,PENDING
178,EP,B1,EP 0782448 B1,064-572-187-758-546,2002-03-27,2002,EP 96917172 A,1996-06-05,US 9608864 W;;US 46504895 A,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (2009-07-20);;BAYER INTELLECTUAL PROPERTY   GMBH, DE (2013-12-18);;BAYER AKTIENGESELLSCHAFT (2007-10-15);;BAYER SCHERING PHARMA AG, DE (2009-03-26);;BAYER INTELLECTUAL PROPERTY GMBH (2013-03-19)",https://lens.org/064-572-187-758-546,Granted Patent,yes,3,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
179,EP,A4,EP 0782448 A4,050-213-493-357-908,1998-05-20,1998,EP 96917172 A,1996-06-05,US 9608864 W;;US 46504895 A,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (2009-07-20);;BAYER INTELLECTUAL PROPERTY   GMBH, DE (2013-12-18);;BAYER AKTIENGESELLSCHAFT (2007-10-15);;BAYER SCHERING PHARMA AG, DE (2009-03-26);;BAYER INTELLECTUAL PROPERTY GMBH (2013-03-19)",https://lens.org/050-213-493-357-908,Search Report,no,1,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
180,AU,A1,AU 2020/259358 A1,080-552-420-469-073,2021-09-16,2021,AU 2020/259358 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,Guiding pull ring,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/080-552-420-469-073,Patent Application,no,0,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,ACTIVE
181,WO,A1,WO 2000/014801 A1,140-475-984-926-688,2000-03-16,2000,EP 9905555 W,1999-08-02,GB 9819248 A,1998-09-03,HIGH VOLTAGE SHIELD,"An integrated circuit has a guard ring for shielding a first area (14) (e.g. high voltage area) from a second area (15) (e.g. low voltage). The guard ring comprises a conductive guard ring (6), (e.g. metal), which is partially exposed through a passivation layer (13) in the integrated circuit (1). A semiconductor guard ring (8), (e.g. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings (16), one located on each side of the semiconductor guard ring (8). A plurality of conductive elements (comprising a metal connection plate (18) and via (19)) connect the conductive guard ring (6) and the semiconductor guard ring (8) at spaced apart intervals. The ocnductive guard ring (6), semiconductor guard ring (8) and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground.",ERICSSON TELEFON AB L M,MILES DAVID;;GOLDMAN RICHARD,,https://lens.org/140-475-984-926-688,Patent Application,yes,6,7,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L21/3205;;H01L23/52;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,PATENTED
182,AU,B2,AU 2015/253183 B2,154-624-592-697-550,2019-05-09,2019,AU 2015/253183 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,Kink-resistant guidewire with improved rigidity,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/154-624-592-697-550,Granted Patent,no,3,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
183,CA,A1,CA 2354522 A1,148-719-651-830-353,2000-06-15,2000,CA 2354522 A,1999-11-29,EP 9909268 W;;GB 9826877 A,1998-12-07,ANALOGUE SWITCH,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transisto r is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is fr om the collector to emitter.",ERICSSON TELEFON AB L M,MILES DAVID;;GOLDMAN RICHARD,,https://lens.org/148-719-651-830-353,Patent Application,no,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,DISCONTINUED
184,AT,T1,AT E463047 T1,003-998-633-955-300,2010-04-15,2010,AT 99973353 T,1999-11-29,GB 9826877 A;;EP 9909268 W,1998-12-07,ANALOGSCHALTER,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",INFINEON TECHNOLOGIES AG,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/003-998-633-955-300,Granted Patent,no,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,EXPIRED
185,EP,A1,EP 3740926 A1,083-775-507-329-425,2020-11-25,2020,EP 19703477 A,2019-01-14,US 201862617501 P;;US 201916245902 A;;US 2019/0013507 W,2018-01-15,METHODS AND APPARATUS TO TRANSLATE AND MANAGE PRODUCT DATA,,CIMPRESS SCHWEIZ GMBH,FLANNERY KELLEN;;GOLDMAN DAVID,,https://lens.org/083-775-507-329-425,Patent Application,yes,0,0,5,5,0,G06Q30/06;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635,G06Q30/06,,0,0,,,,PENDING
186,US,A1,US 2009/0037131 A1,149-038-986-703-957,2009-02-05,2009,US 59538404 A,2004-04-30,US 59538404 A;;US 51153503 P;;US 2004/0013483 W,2003-10-15,METHOD AND CONFIGURATION FOR CONNECTING TEST STRUCTURES OR LINE ARRAYS FOR MONITORING INTEGRATED CIRCUIT MANUFACTURING,"A test chip comprises at least one level having an array of regions. Each region is capable of including at least one test structure. At least some of the regions include respective test structures. The level has a plurality of driver lines that provide input signals to the test structures. The level has a plurality of receiver lines that receive output signals from the test structures. The level has a plurality of devices for controlling current flow. Each test structure is connected to at least one of the driver lines with a first one of the devices in between. Each test structure is connected to at least one of the receiver lines with a second one of the devices in between, so that each of the test structures can be individually addressed for testing using the driver lines and receiver lines.",HESS CHRISTOPHER;;GOLDMAN DAVID,HESS CHRISTOPHER;;GOLDMAN DAVID,PDF SOLUTIONS INC (2006-03-27),https://lens.org/149-038-986-703-957,Patent Application,yes,4,86,10,10,0,G01R31/2884;;H01L22/34;;H01L2924/3011;;H01L2924/0002;;H01L22/00;;H01L22/34;;H01L2924/3011;;G01R31/2884;;H01L2924/0002,G06F19/00;;G06F/,702/117,0,0,,,,ACTIVE
187,US,B2,US 11631560 B2,005-404-659-101-911,2023-04-18,2023,US 202016848409 A,2020-04-14,US 202016848409 A;;US 201962835621 P,2019-04-18,Guiding pull ring,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,S&C ELECTRIC COMPANY (2019-04-18),https://lens.org/005-404-659-101-911,Granted Patent,yes,16,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/662;;H01H33/666,,2,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2020/028113 dated Jul. 16, 2020. (12 pages).;;European Search Report for European Application No. 20790963.1 dated Dec. 13, 2022. (12 pages).",ACTIVE
188,HK,A1,HK 1002552 A1,010-382-752-274-821,1998-09-04,1998,HK 98101616 A,1998-03-02,US 9608864 W;;US 46504895 A,1995-06-06,"NON-IRRITATION, NON-SENSITIZING, NON-OTOTOXIC OTIC ANTIBACTERIAL COMPOSITIONS","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/010-382-752-274-821,Patent Application,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
189,DE,D1,DE 69620136 D1,037-931-201-809-999,2002-05-02,2002,DE 69620136 T,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"ANTIBAKTERIELLE PRÄPARATE FÜR DIE OHREN OHNE IRRITIERENDE, SENSIBILISIERENDE UND OTOTOXISCHE WIRKUNGEN","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,"BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE (2009-09-10);;BAYER HEALTHCARE AG, 51373 LEVERKUSEN, DE (2004-05-27)",https://lens.org/037-931-201-809-999,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
190,TW,B,TW 418424 B,071-079-831-957-568,2001-01-11,2001,TW 88110860 A,1999-06-28,GB 9819248 A,1998-09-03,High voltage shield,"An integrated circuit has a guard ring for shielding a first area 14 (eg. high voltage area) from a second area 15 (eg. low voltage). The guard ring comprises a conductive guard ring 6, (eg. metal), which is partially exposed through a passivation layer 13 in the integrated circuit 1. A semiconductor guard ring 8, (eg. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings 16, one located on each side of the semiconductor guard ring 8. A plurality of conductive elements (comprising a metal connection plate 18 and via 19) connect the conductive guard ring 6 and the semiconductor guard ring 8 at spaced apart intervals. The conductive guard ring 6, semiconductor guard ring 8 and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/071-079-831-957-568,Granted Patent,no,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,EXPIRED
191,ES,T3,ES 2762648 T3,138-234-466-911-743,2020-05-25,2020,ES 15786448 T,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,Hilo guía resistente al retorcimiento con rigidez mejorada,"Hilo (10) guía, que comprende: un capuchón (30); y un núcleo (18), que comprende: una o más nervaduras (20) formadas a lo largo de una primera parte del núcleo (18), teniendo la primera parte del núcleo (18) un primer diámetro, en el que la una o más nervaduras (20) aumentan la fricción de una superficie exterior del hilo (10) guía, y una región (26) de diámetro reducido distal con respecto a la primera parte que tiene un segundo diámetro menor que el primer diámetro, en el que la región (26) de diámetro reducido del núcleo (18) incluye un canal (22) adyacente a la primera parte del núcleo (18), en el que el canal (22) está conformado para acoplarse con una parte del capuchón (30) en una conexión de ajuste a presión o roscada.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/138-234-466-911-743,Granted Patent,no,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
192,US,A,US 5965549 A,011-272-917-855-958,1999-10-12,1999,US 80189197 A,1997-02-18,US 80189197 A;;US 46504895 A,1995-06-06,Ciprofloxacin-hydrocortisone suspension,"The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (2008-12-04);;BAYER AKTIENGESELLSCHAFT (1998-08-06);;BAYER INTELLECTUAL PROPERTY GMBH (2012-04-01),https://lens.org/011-272-917-855-958,Granted Patent,yes,10,37,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,514/177;;514/255,8,5,009-885-662-623-425;;018-171-774-252-94X;;018-171-774-252-94X;;073-669-715-578-213;;066-895-354-111-766,3664417;;10.1016/s0738-081x(87)80016-0;;2514697;;10.1055/s-2007-998423;;2514697;;10.1055/s-2007-998423;;10.1001/archotol.1990.01870050057006;;2328112;;8486586;;10.1093/jac/31.3.452,"Strauss, M., et al., Otitis Externa Associated With Aquatic Activities (Swimmer s Ear), Clinics in Dermatology, 1987, pp. 103 111.;;Stange, G., et al., Laryngol Rhino Otol 68 (12):653 656 (1989) Abstract .;;Stange, G., et al., Laryngol Rhino Otol 68(12):653 656 (1989).;;Esposito, S., et al., Topical and Oral Treatment of Chronic Otitis Media With Ciprofloxacin, Arch Otolaryngol Head Neck Surg vol. 116, 1990, pp. 557 559.;;Garcia Rodriguez, J.A., et al., Efficacy of 2 Regimens of Local Ciprofloxacin in the Treatment of Ear Infections, Preprint: Drugs 45 (Suppl.), 1993, pp. 40 41.;;Ganz, H., Bacterial Otitis Externa Beyond the Organ Limits Systemic and Topical Combination Treatment with Ciprofloxacin, pp. 2 7 (translation from German).;;Garcia Rodriguez, J.A., Efficacy of Topical Ciprofloxacin in the Treatment of Ear Infections in Adults, J Antimicrob Chemother, 1993, pp. 31:452 453.;;Esposito, S., et al., Topical Cirpofloxacin (CP) Versus Parenteral Gentamicin (GM) in Pseudomonas Infections of the Middle Ear, 29. Interscience Conference An Timicrobiotic Agents Chemotherapy * Houston, 545 (1989) Abstract .",EXPIRED
193,US,A1,US 2023/0236576 A1,050-846-326-326-813,2023-07-27,2023,US 202318128011 A,2023-03-29,US 202318128011 A;;US 201916680381 A;;US 201862758854 P,2018-11-12,SENSOR SYSTEMS PRINCIPALLY FOR SWIMMING POOLS AND SPAS,A pool or spa control system includes a sensor system with one or more sensors in contact with a main body of water. The sensor system measures water condition data of the body of water and is mounted on a wall submerged in the main body of water. The pool or spa control system also includes a modem that facilitates data communications between the sensor system and communication equipment positioned at a different location from the main body of water.,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA,ZODIAC POOL SYSTEMS LLC (2019-02-25),https://lens.org/050-846-326-326-813,Patent Application,yes,0,0,6,6,0,H04B2203/5458;;H04B2203/5483;;H04B3/54;;H05B47/19;;H05B47/185;;E04H4/148;;E04H4/1209;;H05B47/19;;E04H4/148;;G05B19/4155;;G05B2219/49217,G05B19/4155;;E04H4/14;;H05B47/19,,0,0,,,,PENDING
194,US,B2,US 11244371 B2,074-776-435-159-356,2022-02-08,2022,US 201916245902 A,2019-01-11,US 201916245902 A;;US 201862617501 P,2018-01-15,Methods and apparatus to translate and manage product data,"Methods and apparatus to translate and manage product data are disclosed. A disclosed example system for translating and managing product data pertaining to a plurality of tenants includes a rules executor to verify, based on product attribute rules, that requested product attributes pertaining to a product request from a buyer are valid, an attribute translator to generate platform standard attributes of products corresponding to the tenants, where the attribute translator is to translate tenant-specific product attributes to the platform standard attributes based on the tenant-specific product attributes and the product attribute rules, and an equivalency evaluator to evaluate an equivalency of the products based on the requested product attributes and output the equivalency. The equivalency evaluator is to store the equivalency.",CIMPRESS SCHWEIZ GMBH,FLANNERY KELLEN;;GOLDMAN DAVID,CIMPRESS SCHWEIZ GMBH (2018-03-09),https://lens.org/074-776-435-159-356,Granted Patent,yes,16,0,5,5,0,G06Q30/06;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635;;G06Q30/0621;;G06Q30/0629;;G06Q30/0635,G06Q30/00;;G06Q30/06,,2,0,,,"Linder, Markus, Mag Tassilo Pellegrini, and Bakk Martin Schliefnig. “The realization of Semantic Web based E-Commerce and its impacton Business, Consumers and the Economy.” 2006. (Year: 2006).;;International Searching Authority, “International Search Report and Written Opinion,” issued in connection with International Application No. PCT/US2019/013507, dated Apr. 30, 2019, 12 pages.",ACTIVE
195,DK,T3,DK 0782448 T3,125-058-034-854-835,2002-07-08,2002,DK 96917172 T,1996-06-05,US 46504895 A;;US 9608864 W,1995-06-06,"Ikke-irriterende, ikke-sensibiliserende, ikke-ototoksiske antibakterielle ørepræparater","The invention is directed to an aqueous non-ototoxic, topical, otic pharmaceutical composition of matter for treating a mammal consisting essentially of: ciprofloxacin or a pharmaceutically acceptable salt thereof in aqueous solution in an amount effective for antibacterial action; hydrocortisone or a pharmaceutically acceptable salt thereof in an amount effective as an anti-inflammatory agent; polyvinyl alcohol at least about 85% hydrolyzed in an amount effective to suspend the hydrocortisone in solution; water sufficient to produce an aqueous composition; benzyl alcohol in an amount effective for antibacterial action; lecithin in an amount effective for enhancing suspension of other constituents in the composition; and polysorbate ranging from polysorbate 20 to 80 in an amount effective for spreading the preparation on a hydrophobic skin surface to the site of infection or inflammation.",BAYER AG,PURWAR SHIVAJI;;GOLDMAN DAVID,,https://lens.org/125-058-034-854-835,Granted Patent,no,0,0,24,25,0,A61K9/0014;;A61K9/0046;;A61K9/10;;A61K31/57;;A61K47/32;;A61P27/02;;A61P27/16;;A61K9/0046;;A61K47/32;;A61K9/0014;;A61K9/10;;A61K31/57,A61K9/00;;A61K9/10;;A61K31/57;;A61K47/00;;A61K47/32;;A61P27/16,,0,0,,,,EXPIRED
196,AU,A,AU 2000/013875 A,174-133-666-468-363,2000-06-26,2000,AU 2000/013875 A,1999-11-29,EP 9909268 W;;GB 9826877 A,1998-12-07,Analogue switch,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/174-133-666-468-363,Patent Application,no,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,DISCONTINUED
197,CA,C,CA 2943692 C,065-297-127-522-905,2021-12-28,2021,CA 2943692 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/065-297-127-522-905,Granted Patent,no,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
198,EP,A1,EP 1114459 A1,077-036-412-735-58X,2001-07-11,2001,EP 99939434 A,1999-08-02,EP 9905555 W;;GB 9819248 A,1998-09-03,HIGH VOLTAGE SHIELD,,ERICSSON TELEFON AB L M,MILES DAVID;;GOLDMAN RICHARD,TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (2004-05-06);;INFINEON TECHNOLOGIES AG (2010-06-02),https://lens.org/077-036-412-735-58X,Patent Application,yes,0,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,,0,0,,,,EXPIRED
199,CA,A1,CA 2943692 A1,076-327-439-948-810,2015-11-05,2015,CA 2943692 A,2015-04-29,US 201461985887 P;;US 2015/0028366 W,2014-04-29,KINK-RESISTANT GUIDEWIRE WITH IMPROVED RIGIDITY,"A guidewire, methods of manufacture, and methods of use is described. The guidewire may include a core having one or more preformed ribs along a portion thereof. The ribs may form a portion of the outer surface of the guidewire or form a texture or shape of the outer surface of the guidewire. The ribs and outer texture of the guidewire can beneficially help the guidewire remain in a desired location in a body and help prevent or limit migration. Forming the ribs on the outer surface of the core may enable the guidewire to have greater rigidity and stiffness. The core may include a reduced diameter region distal of the ribs. The guidewire may include a cap over the reduced diameter region of the core.",BARD INC C R,GOLDMAN DAVID;;DOLGIN MICHAEL,,https://lens.org/076-327-439-948-810,Patent Application,no,0,0,16,16,0,A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M25/09;;A61M25/09;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M2025/09116;;A61M2025/09191;;A61M2025/09075;;A61M2025/09108;;A61M2025/09175;;A61M2210/1078;;A61M25/09;;A61M2210/1085;;A61M2210/1089,A61M25/09,,0,0,,,,ACTIVE
200,WO,A1,WO 2018/107111 A1,109-287-058-101-116,2018-06-14,2018,US 2017/0065447 W,2017-12-08,US 201662432512 P,2016-12-09,ELECTROPHEROGRAM ANALYSIS,"Methods for analyzing raw electropherogram data are disclosed. Some methods includes extracting color data as a function of time or position from the raw electropherogram darta, selecting from the electropherogram one or more peaks that contain color data for a first dye and substantially no color data from other dyes used in electrophoresis. The method also includes determining the color spectrum of the first dye, and using the color spectrum of the first dye to deconvolve the color data of the raw electropherogram data to separate the contributions of each of the dyes to the raw electropherogram data. Systems and apparatus for producing electropherograms are also disclosed.",INTEGENX INC,KING DAVID;;GOLDMAN BRUCE,,https://lens.org/109-287-058-101-116,Patent Application,yes,5,0,7,7,0,G01N27/44721;;G01N27/44726;;G01N33/48;;G16B45/00;;G01N27/44726,C12Q1/68,,0,0,,,,PENDING
201,WO,A1,WO 2000/035017 A1,085-464-340-029-205,2000-06-15,2000,EP 9909268 W,1999-11-29,GB 9826877 A,1998-12-07,ANALOGUE SWITCH,"The present invention relates to an integrated circuit bidirectional switch formed from bipolar transistor devices, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID,,https://lens.org/085-464-340-029-205,Patent Application,yes,4,1,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/8228;;H01L27/082;;H01L21/331;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,PENDING
202,CA,A1,CA 3133362 A1,189-030-369-576-416,2020-10-22,2020,CA 3133362 A,2020-04-14,US 201962835621 P;;US 2020/0028113 W,2019-04-18,GUIDING PULL RING,"A guiding pull ring member for guiding a unit top contact in a switch assembly into a mounting contact. The guide ring member includes a mounting ring defined in a first plane, a grasping ring coupled to one side of the mounting ring and being defined in a second plane perpendicular to the first plane, and a V-shaped guide piece coupled to the mounting ring at a side opposite from the grasping ring and extending perpendicular to the first plane. The guiding pull ring member has particular application for a solenoid operated vacuum interrupter recloser switch mounted to a utility pole.",S & C ELECTRIC CO,GOLDMAN DAVID;;FANTA THOMAS,,https://lens.org/189-030-369-576-416,Patent Application,no,0,0,10,10,0,H01H33/666;;H01H75/04;;H01H33/008;;H01H33/666;;H01H2033/6665;;H01H33/66207,H01H33/664;;H01H31/12;;H01H33/66;;H01H33/666;;H01H75/04,,0,0,,,,PENDING
203,US,B2,US 10455021 B2,130-415-357-487-922,2019-10-22,2019,US 201414563796 A,2014-12-08,US 201414563796 A,2014-12-08,"Systems, apparatus, and methods for configuring device data streams","Configuring device data streams (DDSs) of a mobile device is described herein. DDSs can include sensor data (captured from one or more sensors of the mobile device) and user-specific data (including application data from applications executed via the mobile device, as well as non-application data). DDS configuration parameters define modifications for the user-specific data and/or the sensor data of the DDS; these modifications can include removing or altering the user-specific data and/or the sensor data. DDSs can be sent to an external storage device via a network, and DDS modifications can be made at the mobile device or at the external storage device. Modified DDSs can be provided to requestors, and thus, the DDS configuration parameters allow a user to control what data is, or is not, included in a DDS for reasons related to privacy, data usage, etc.",EBAY INC,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,EBAY INC (2014-12-05),https://lens.org/130-415-357-487-922,Granted Patent,yes,20,6,5,5,0,G06F21/53;;H04L67/12;;H04W4/70;;H04W4/029;;H04W4/02;;H04W12/065;;H04W12/128;;H04L67/12;;H04W4/70;;H04W4/029;;G06F21/53;;H04W12/065;;H04W12/128,H04L29/08;;H04W4/029;;H04W4/70,,10,1,044-845-367-772-906,10.1007/978-3-540-69170-9_40,"“International Application Serial No. PCT/US2015/042132, International Search Report dated Dec. 10, 2015”, 4 pgs.;;“International Application Serial No. PCT/US2015/042132, Invitation to Pay Additional Fees and Partial Search Report dated Sep. 22, 2015”, 2 pgs.;;“International Application Serial No. PCT/US2015/042132, Written Opinion dated Dec. 10, 2015”, 6 pgs.;;“International Application Serial No. PCT/US2015/064311, International Search Report dated Feb. 12, 2016”, 2 pgs.;;“International Application Serial No. PCT/US2015/064311, Written Opinion dated Feb. 12, 2016”, 8 pgs.;;Llaves, Alejandro, et al., “Towards Efficient Processing of RDF Data Streams”, Ontology Engineering Group, Universidad Politecnica de Madrid, Madrid, Spain, (May 9, 2014), 5 pgs.;;Shipman, Frank, et al., “PerCon: Supporting the Management and Reuse of Wearable Sensor Data”, Center for the Study of Digital Libraries and Department of Computer Science and Engineering, Texas A&M University, College Station, TX., This work was supported in part by grant 10-49217 from the National Science Foundation., (Aug. 25, 2011), 15 pgs.;;Wood, Anthony, et al., “SenQ: An Embedded Query System for Streaming Data in Heterogeneous Interactive Wireless Sensor Networks”, Lecture Notes in Computer Science vol. 5067., Supported by NSF grants CNS-0435060, CNS-0626616, and CNS-0720640., (Apr. 7, 2008), 531-543.;;Xu, Shengliang, et al., “Sensor Data Stream Exploration for Monitoring Applications”, DMSN '11, (Aug. 15, 2011), 6 pgs.;;“International Application Serial No. PCT/US2015/064311, International Preliminary Report on Patentability dated Jun. 22, 2017”, 10 pgs.",ACTIVE
204,US,B2,US 11799964 B2,125-206-259-278-527,2023-10-24,2023,US 201916582460 A,2019-09-25,US 201916582460 A;;US 201414563796 A,2014-12-08,"Systems, apparatus, and methods for configuring device data streams","Configuring device data streams (DDSs) of a mobile device is described herein. DDSs can include sensor data (captured from one or more sensors of the mobile device) and user-specific data (including application data from applications executed via the mobile device, as well as non-application data). DDS configuration parameters define modifications for the user-specific data and/or the sensor data of the DDS; these modifications can include removing or altering the user-specific data and/or the sensor data. DDSs can be sent to an external storage device via a network, and DDS modifications can be made at the mobile device or at the external storage device. Modified DDSs can be provided to requestors, and thus, the DDS configuration parameters allow a user to control what data is, or is not, included in a DDS for reasons related to privacy, data usage, etc.",EBAY INC,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,EBAY INC (2014-12-05),https://lens.org/125-206-259-278-527,Granted Patent,yes,40,0,5,5,0,G06F21/53;;H04L67/12;;H04W4/70;;H04W4/029;;H04W4/02;;H04W12/065;;H04W12/128;;H04L67/12;;H04W4/70;;H04W4/029;;G06F21/53;;H04W12/065;;H04W12/128,H04L67/12;;G06F21/53;;H04W4/029;;H04W4/70;;H04W12/065;;H04W12/128,,19,1,044-845-367-772-906,10.1007/978-3-540-69170-9_40,"Corrected Notice of Allowability received for U.S. Appl. No. 14/563,796, dated Sep. 5, 2019, 9 pages.;;Decision on Pre-Appeal Brief received for U.S. Appl. No. 14/563,796, mailed on Mar. 19, 2019, 2 pages.;;Final Office Action received for U.S. Appl. No. 14/563,796, dated Jun. 15, 2018, 6 pages.;;First Action Interview Office Action received for U.S. Appl. No. 14/563,796, dated Dec. 7, 2017, 7 pages.;;Notice of Allowance received for U.S. Appl. No. 14/563,796, dated Jun. 14, 2019, 7 pages.;;Pre-Interview First Office Action received for U.S. Appl. No. 14/563,796, dated Jun. 16, 2017, 5 pages.;;Request for Pre-Appeal Brief filed on Aug. 15, 2018, for U.S. Appl. No. 14/563,796, 6 pages.;;Response to Office Action Summary Interview filed on Feb. 27, 2018, for U.S. Appl. No. 14/563,796, dated Dec. 7, 2017, 17 pages.;;U.S. Appl. No. 14/563,796, filed Dec. 8, 2014, Issued.;;Llaves, et al., “Towards Efficient Processing of RDF Data Streams”, Ontology Engineering Group, Universidad Politecnica de Madrid, Madrid, Spain, Retrieved from the Internet URL :< https://www.w3.org/2014/02/wot/papers/llaves.pdf>, May 9, 2014, 5 pages.;;International Search Report received for PCT Application No. PCT/US2015/042132, dated Dec. 10, 2015, 4 pages.;;Invitation to Pay Additional Fee and Partial Search Report received for PCT application No. PCT/US2015/042132, dated Sep. 22, 2015, 2 pages.;;Written Opinion received for PCT Patent Application No. PCT/US2015/042132, dated Dec. 10, 2015, 6 pages.;;International Report on Patentability received for PCT Application No. PCT/US2015/064311, dated Jun. 22, 2017, 10 pages.;;International Search Report received for PCT Application No. PCT/US2015/064311, dated Feb. 12, 2016, 2 pages.;;Written Opinion received for PCT Patent Application No. PCT/US2015/064311, dated Feb. 12, 2016, 8 pages.;;Shipman, et al., “PerCon: Supporting the Management and Reuse of Wearable Sensor Data”, Center for the Study of Digital Libraries and Department of Computer Science and Engineering, Texas A&M University, College Station, TX, Retrieved from the Internet URL: < http://psi.cse.tamu.edu/wp-content/uploads/2014/02/shipman-2011-techreport1.pdf>, Aug. 25, 2011, 15 pages.;;Wood, et al., “SenQ: An Embedded Query System for Streaming Data in Heterogeneous Interactive Wireless Sensor Networks”, Lecture Notes in Computer Science vol. 5067, Retrieved from the Internet URL :< https://www.cs.virginia.edu/˜stankovic/psfiles/wood-senq.pdf>, Apr. 7, 2008, pp. 531-543.;;Xu, et al., “Sensor Data Stream Exploration for Monitoring Applications”, Retrieved from the Internet URL :< https://homes.cs.washington.edu/˜magda/papers/xu-dmsn11.pdf>, Aug. 15, 2011, 6 pages.",ACTIVE
205,US,A1,US 2016/0164972 A1,021-969-411-262-488,2016-06-09,2016,US 201414563796 A,2014-12-08,US 201414563796 A,2014-12-08,"SYSTEMS, APPARATUS, AND METHODS FOR CONFIGURING DEVICE DATA STREAMS","Configuring device data streams (DDSs) of a mobile device is described herein. DDSs can include sensor data (captured from one or more sensors of the mobile device) and user-specific data (including application data from applications executed via the mobile device, as well as non-application data). DDS configuration parameters define modifications for the user-specific data and/or the sensor data of the DDS; these modifications can include removing or altering the user-specific data and/or the sensor data. DDSs can be sent to an external storage device via a network, and DDS modifications can be made at the mobile device or at the external storage device. Modified DDSs can be provided to requestors, and thus, the DDS configuration parameters allow a user to control what data is, or is not, included in a DDS for reasons related to privacy, data usage, etc.",EBAY INC,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,EBAY INC (2014-12-05),https://lens.org/021-969-411-262-488,Patent Application,yes,2,7,5,5,0,G06F21/53;;H04L67/12;;H04W4/70;;H04W4/029;;H04W4/02;;H04W12/065;;H04W12/128;;H04L67/12;;H04W4/70;;H04W4/029;;G06F21/53;;H04W12/065;;H04W12/128,H04L29/08,,0,0,,,,ACTIVE
206,US,A1,US 2020/0099747 A1,059-434-725-230-209,2020-03-26,2020,US 201916582460 A,2019-09-25,US 201916582460 A;;US 201414563796 A,2014-12-08,"SYSTEMS, APPARATUS, AND METHODS FOR CONFIGURING DEVICE DATA STREAMS","Configuring device data streams (DDSs) of a mobile device is described herein. DDSs can include sensor data (captured from one or more sensors of the mobile device) and user-specific data (including application data from applications executed via the mobile device, as well as non-application data). DDS configuration parameters define modifications for the user-specific data and/or the sensor data of the DDS; these modifications can include removing or altering the user-specific data and/or the sensor data. DDSs can be sent to an external storage device via a network, and DDS modifications can be made at the mobile device or at the external storage device. Modified DDSs can be provided to requestors, and thus, the DDS configuration parameters allow a user to control what data is, or is not, included in a DDS for reasons related to privacy, data usage, etc.",EBAY INC,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,EBAY INC (2014-12-05),https://lens.org/059-434-725-230-209,Patent Application,yes,6,0,5,5,0,G06F21/53;;H04L67/12;;H04W4/70;;H04W4/029;;H04W4/02;;H04W12/065;;H04W12/128;;H04L67/12;;H04W4/70;;H04W4/029;;G06F21/53;;H04W12/065;;H04W12/128,H04L29/08;;G06F21/53;;H04W4/029;;H04W4/70;;H04W12/12,,0,0,,,,ACTIVE
207,WO,A1,WO 2016/018769 A1,067-199-415-031-258,2016-02-04,2016,US 2015/0042132 W,2015-07-24,US 201414447787 A,2014-07-31,SERVER BASED COMMUNICATION BETWEEN SANDBOXED APPLICATIONS,"A remote server facilitates discovery and communication between multiple applications running in respective sandboxes on the same hardware processing device. The remote server determines that the applications are running on the same processing device based on data received from each of the applications. The determination that the applications are running on the same device may include matching corresponding items of information received in data streams from each the applications. The server then transmits, to one of the applications, the identity of each of the applications that have been determined to be running on the processing device. The server then receives a message from the one of the applications to be delivered to another one of the applications that has been determined to be running on the processing device. The server then transmits the message to said other one of the applications, enabling communication of the message between the applications.",COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,,https://lens.org/067-199-415-031-258,Patent Application,yes,5,2,2,2,0,H04L63/029;;H04L63/0428;;G06F21/53;;H04L67/52;;H04L63/0428;;G06F21/53;;H04L63/029;;H04L67/52,G06F11/34;;G06F7/04;;G06F15/173;;H04L29/08,,0,0,,,,PENDING
208,US,A1,US 2016/0036894 A1,066-087-095-054-73X,2016-02-04,2016,US 201414447787 A,2014-07-31,US 201414447787 A,2014-07-31,SERVER BASED COMMUNICATION BETWEEN SANDBOXED APPLICATIONS,"A remote server facilitates discovery and communication between multiple applications running in respective sandboxes on the same hardware processing device. The remote server determines that the applications are running on the same processing device based on data received from each of the applications. The determination that the applications are running on the same device may include matching corresponding items of information received in data streams from each the applications. The server then transmits, to one of the applications, the identity of each of the applications that have been determined to be running on the processing device. The server then receives a message from the one of the applications to be delivered to another one of the applications that has been determined to be running on the processing device. The server then transmits the message to said other one of the applications, enabling communication of the message between the applications.",COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,EBAY INC (2014-07-30);;PAYPAL INC (2015-07-17),https://lens.org/066-087-095-054-73X,Patent Application,yes,3,17,2,2,0,H04L63/029;;H04L63/0428;;G06F21/53;;H04L67/52;;H04L63/0428;;G06F21/53;;H04L63/029;;H04L67/52,H04L29/08,,0,0,,,,DISCONTINUED
209,WO,A1,WO 2016/094317 A1,081-414-303-469-729,2016-06-16,2016,US 2015/0064311 W,2015-12-07,US 201414563796 A,2014-12-08,CONFIGURING DEVICE DATA STREAMS,"Configuring device data streams (DDSs) of a mobile device is described herein. DDSs can include sensor data (captured from one or more sensors of the mobile device) and user-specific data (including application data from applications executed via the mobile device, as well as non-application data). DDS configuration parameters define modifications for the user-specific data and/or the sensor data of the DDS; these modifications can include removing or altering the user-specific data and/or the sensor data. DDSs can be sent to an external storage device via a network, and DDS modifications can be made at the mobile device or at the external storage device. Modified DDSs can be provided to requestors, and thus, the DDS configuration parameters allow a user to control what data is, or is not, included in a DDS for reasons related to privacy, data usage, etc.",EBAY INC,COLLINS MICHAEL DAVID;;GOLDMAN DAVID W,,https://lens.org/081-414-303-469-729,Patent Application,yes,3,2,5,5,0,G06F21/53;;H04L67/12;;H04W4/70;;H04W4/029;;H04W4/02;;H04W12/065;;H04W12/128;;H04L67/12;;H04W4/70;;H04W4/029;;G06F21/53;;H04W12/065;;H04W12/128,G06F15/16,,0,0,,,,PENDING
210,US,A,US 3332071 A,043-063-053-271-858,1967-07-18,1967,US 42058164 A,1964-12-23,US 42058164 A,1964-12-23,Data retrieval and display system,,GEN PRECISION INC,GOLDMAN DAVID A;;ARNOLD ZISSELMAN,,https://lens.org/043-063-053-271-858,Granted Patent,no,2,25,4,4,0,G06K17/0016;;G08C21/00;;H04N5/262;;G08C21/00;;H04N5/262;;G06K17/0016;;Y10S707/99931,G06K17/00;;G08C21/00;;H04N5/262,,0,0,,,,EXPIRED
211,US,B2,US 8813013 B2,097-913-308-604-464,2014-08-19,2014,US 201313866624 A,2013-04-19,US 201313866624 A;;US 201213656361 A,2012-10-19,Partitioning designs to facilitate certification,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.",ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,ALTERA CORPORATION (2013-04-29),https://lens.org/097-913-308-604-464,Granted Patent,yes,4,10,4,10,0,G06F30/34;;G06F2111/04;;G06F30/34;;G06F30/327;;G06F2111/04;;G06F30/347,G06F17/50,716/117;;716/118,0,0,,,,ACTIVE
212,WO,A3,WO 2012/060907 A3,107-380-091-257-132,2012-09-07,2012,US 2011/0042608 W,2011-06-30,US 91152110 A,2010-10-25,EMBROIDERY IMAGE RENDERING USING TEXTURE DATABASE,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",VISTAPRINT TECHNOLOGIES LTD;;HSU EUGENE;;GOLDMAN DAVID A,HSU EUGENE;;GOLDMAN DAVID A,,https://lens.org/107-380-091-257-132,Search Report,yes,5,0,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T15/04;;G06T11/00,,0,0,,,,PENDING
213,GB,A,GB 2344689 A,150-940-869-684-218,2000-06-14,2000,GB 9826877 A,1998-12-07,GB 9826877 A,1998-12-07,Analogue switch,"An integrated bipolar transistor (2) is isolated from an adjacent complementary transistor (4) and the underlying substrate (20) by oxide material (22,24). The transistor has a low saturation voltage when operated in inverse mode.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID JOHN,,https://lens.org/150-940-869-684-218,Patent Application,no,3,1,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,H1K KAAX          AAX;;H1K KGAH          GAH;;H1K K1AA9         AAX;;H1K K1AA9         GAH;;H1K K11A3         GAH;;H1K K11B4         GAH;;H1K K11D          GAH;;H1K K11D3         GAH;;H3P PCCG          PCCG;;H3T T2F2          -;;H3T T2F4          -;;H3T T2T3B         -;;H3T T3J           -;;H3T T4D           -;;H3T T4S           -,0,0,,,,DISCONTINUED
214,GB,A,GB 2522299 A,018-288-379-466-883,2015-07-22,2015,GB 201418577 A,2014-10-20,US 201361908749 P,2013-11-26,Contextual audio recording,"A contextual audio recording method, performable by a computer system (e.g. smartphone) attached to a network, where during a conversation over the network a microphone attachable to or included in the computer system is used to record 303 audio speech 304 from the user. The audio speech is processed 305 into audio speech data 311. In the audio speech data, the processor monitors 307 for a keyword previously defined 301 by the user. Upon detecting 309 the keyword in the audio speech data, a contextual portion of the audio speech data 315 is extracted 313 including the keyword. The contextual portion of the audio speech data may be converted 317 to text 320 and stored 319. The time interval of the contextual portion may be determined either by a pre-set duration from and including the keyword, or may stop upon detection of another keyword.",SPRINGER DAVID TZVI;;TSEMED PITRONOT LTD,GOLDMAN ANDREW;;SPRINGER DAVID TZVI,,https://lens.org/018-288-379-466-883,Patent Application,no,2,1,4,4,0,G10L15/00;;G10L15/26;;G10L15/26;;G06F3/167;;G10L15/26,G10L15/00;;G06F3/16;;G10L15/26,,1,0,,,"PC World, 6/11/2013, ""Control your PC with these 5 speech recognition programs"", PCWorld.com, [online], Available from: http://www.pcworld.com/article/2055599/control-your-pc-with-these-5-speech-recognition-programs.html [Accessed 15 May 2015]",ACTIVE
215,DE,B1,DE 1499373 B1,077-929-502-340-387,1970-08-20,1970,DE 1499373 A,1965-12-17,US 42058164 A,1964-12-23,Vorrichtung zum Darstellen eines zusammengesetzten Bildes aus feststehenden und veraenderlichen Bilddaten,,SINGER GENERAL PREC INC,ALEXANDER GOLDMAN DAVID;;ZISSELMAN ARNOLD,,https://lens.org/077-929-502-340-387,Patent Application,no,3,0,4,4,0,G06K17/0016;;G08C21/00;;H04N5/262;;G08C21/00;;H04N5/262;;G06K17/0016;;Y10S707/99931,G06K17/00;;G08C21/00;;H04N5/262,,0,0,,,,DISCONTINUED
216,TW,B,TW 334620 B,089-913-983-943-419,1998-06-21,1998,TW 86110573 A,1997-07-25,GB 9714575 A,1997-07-10,Timing circuit,"A timing circuit, for use in an integrated circuit, generates relatively long time periods. The electrical properties (for example the resistance) of a pair of matched components are measured while heat is supplied to one of the component. When the values of the thermally dependent properties of the components differ by a certain amount, the timed period is over. The pair of matched components are located within thermally insulating structures within the IC.",ERICSSON TELEFON AB L M,RICHARD GOLDMAN;;DAVID J MILES,,https://lens.org/089-913-983-943-419,Granted Patent,no,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,0,0,,,,EXPIRED
217,WO,A2,WO 2012/060907 A2,095-233-089-773-978,2012-05-10,2012,US 2011/0042608 W,2011-06-30,US 91152110 A,2010-10-25,EMBROIDERY IMAGE RENDERING USING PARAMETRIC TEXTURE MAPPING,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",VISTAPRINT TECHNOLOGIES LTD;;HSU EUGENE;;GOLDMAN DAVID A,HSU EUGENE;;GOLDMAN DAVID A,,https://lens.org/095-233-089-773-978,Patent Application,yes,12,0,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T15/04,,1,1,075-073-850-027-743,10.1145/360825.360839,"BUI TUONG PHONG: ""Illumination for Computer Generated Pictures"", COMM. ACM, vol. 18, no. 6, June 1975 (1975-06-01), pages 311 - 317, XP058272809, DOI: doi:10.1145/360825.360839",PENDING
218,US,A1,US 2019/0344063 A1,119-933-104-314-128,2019-11-14,2019,US 201916297543 A,2019-03-08,US 201916297543 A;;US 201815978089 A,2018-05-11,GRIP LIGHT,"A grip light for use with a handheld appliance having an exterior grip surface extending from an upper grip portion downward toward an opposite working end, light transmissive material running through the grip from a light receiving surface to a bottom surface of the working end, and a light pipe inlet for receiving light from a light pipe into the light receiving surface and thereby permitting light from the light pipe to be projected out from working end of the grip light to illuminate an area therebelow.",USHIO AMERICA INC,COLLIAS JAMES H;;GOLDMAN DAVID,,https://lens.org/119-933-104-314-128,Patent Application,yes,3,1,2,2,0,A61M37/0076;;A61M37/0076;;F21V21/0885;;F21V21/32;;F21V33/00;;F21W2131/40;;F21W2131/403;;F21Y2115/10;;G02B6/0008,A61M37/00;;F21V21/088,,0,0,,,,DISCONTINUED
219,US,A1,US 2015/0149171 A1,150-938-397-977-06X,2015-05-28,2015,US 201414517967 A,2014-10-20,US 201414517967 A;;US 201361908749 P,2013-11-26,Contextual Audio Recording,"During a conversation over the network, a microphone attachable to or included in a mobile computer system is used to input audio speech from the user of the computer system. The audio speech is processed into audio speech data. In the audio speech data, the processor monitors for a keyword previously defined by the user. Upon detecting the keyword in the audio speech data, a contextual portion of the audio speech data is extracted including the keyword. The contextual portion of the audio speech data may be converted to text and stored in memory of the computer system or on the network.",GOLDMAN ANDREW;;SPRINGER DAVID TZVI,GOLDMAN ANDREW;;SPRINGER DAVID TZVI,,https://lens.org/150-938-397-977-06X,Patent Application,yes,8,10,4,4,0,G10L15/00;;G10L15/26;;G10L15/26;;G06F3/167;;G10L15/26,G10L15/26,704/235,0,0,,,,DISCONTINUED
220,EP,A1,EP 2793149 A1,011-934-893-676-444,2014-10-22,2014,EP 14161865 A,2014-03-27,US 201313866624 A,2013-04-19,Partitioning designs to facilitate certification,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.
",ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,,https://lens.org/011-934-893-676-444,Patent Application,yes,4,0,4,10,0,G06F2115/08;;G06F30/34,G06F17/50,,0,0,,,,ACTIVE
221,CN,A,CN 104112033 A,050-036-968-838-322,2014-10-22,2014,CN 201410155402 A,2014-04-17,US 201313866624 A,2013-04-19,Partitioning Designs To Facilitate Certification,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.",ALTERA CORP,ADAM TITLEY;;DAVID SAMUEL GOLDMAN,,https://lens.org/050-036-968-838-322,Patent Application,no,4,0,4,10,0,G06F30/34;;G06F2115/08,G06F17/50,,0,0,,,,ACTIVE
222,US,A1,US 2014/0189622 A1,146-634-079-973-20X,2014-07-03,2014,US 201313866624 A,2013-04-19,US 201313866624 A;;US 201213656361 A,2012-10-19,PARTITIONING DESIGNS TO FACILITATE CERTIFICATION,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.",ALTERA CORP;;ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,ALTERA CORPORATION (2013-04-29),https://lens.org/146-634-079-973-20X,Patent Application,yes,0,12,4,10,0,G06F30/34;;G06F2111/04;;G06F30/34;;G06F30/327;;G06F2111/04;;G06F30/347,G06F17/50,716/105,0,0,,,,ACTIVE
223,US,A1,US 2012/0101790 A1,178-646-282-848-104,2012-04-26,2012,US 91152110 A,2010-10-25,US 91152110 A,2010-10-25,EMBROIDERY IMAGE RENDERING USING PARAMETRIC TEXTURE MAPPING,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",HSU EUGENE;;GOLDMAN DAVID A;;VISTAPRINT TECHNOLOGIES LTD,HSU EUGENE;;GOLDMAN DAVID A,VISTAPRINT TECHNOLOGIES LIMITED (2010-10-25);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/178-646-282-848-104,Patent Application,yes,7,8,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06G7/48,703/6,0,0,,,,INACTIVE
224,EP,A4,EP 2507717 A4,179-596-113-411-677,2015-06-17,2015,EP 10835180 A,2010-12-03,US 63158809 A;;US 2010/0058873 W,2009-12-04,PREVENTING INFORMATION LEAKAGE BETWEEN COMPONENTS ON A PROGRAMMABLE CHIP IN THE PRESENCE OF FAULTS,,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,,https://lens.org/179-596-113-411-677,Search Report,no,0,0,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F15/16;;G06F17/50,,4,0,,,"MARK MCLEAN ET AL: ""FPGA-BASED SINGLE CHIP CRYPTOGRAPHIC SOLUTION (U)"", 1 March 2007 (2007-03-01), pages 34 - 37, XP055100457, Retrieved from the Internet <URL:http://mil-embedded.com/pdfs/NSA.Mar07.pdf> [retrieved on 20140205];;""AN 567: Quartus II Design Separation Flow"", 1 June 2009 (2009-06-01), pages 1 - 51, XP055187825, Retrieved from the Internet <URL:https://www.altera.com/en_US/pdfs/literature/an/an567.pdf> [retrieved on 20150506];;""White Paper Enabling Design Separation for High-Reliability and Information-Assurance Systems"", 1 June 2009 (2009-06-01), pages 1 - 5, XP055187811, Retrieved from the Internet <URL:https://www.altera.com/en_US/pdfs/literature/wp/wp-01110-design-separation.pdf> [retrieved on 20150506];;See also references of WO 2011069057A1",DISCONTINUED
225,TW,B,TW 457702 B,199-261-994-564-518,2001-10-01,2001,TW 88118043 A,1999-10-19,GB 9826877 A,1998-12-07,Analogue switch,"The present invention relates to an integrated bipolar transistor device, in which the saturation voltage is sought to be reduced. More specifically, an integrated NPN bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the emitter to collector, and an integrated PNP bipolar transistor is formed with oxide insulation, and the normal direction of current flow is from the collector to emitter.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID JOHN,,https://lens.org/199-261-994-564-518,Granted Patent,no,0,0,16,16,0,H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317;;H01L27/0826;;H01L29/7317,H01L21/331;;H01L21/8228;;H01L27/082;;H01L29/73;;H01L29/732;;H03K17/00,,0,0,,,,EXPIRED
226,CN,A,CN 102656576 A,095-710-314-435-959,2012-09-05,2012,CN 201080054798 A,2010-12-03,US 2010/0058873 W;;US 63158809 A,2009-12-04,Preventing information leakage between components on a programmable chip in the presence of faults,"Mechanisms are provided to prevent information leakage between components implemented on a programmable chip such as a Field Programmable Gate Array (FPGA). An automated routing algorithm is effective at enforcing security restrictions with minimal input form the user while providing efficient utilization of the device. Compatible sets of signals are identified and locked, and reservations of routing resources are generated. Remaining signals are rerouted until all signal constraints are met. Specified security constraints with one or more security levels and one or more secure regions may be applied through iterations of the automated routing mechanism.",ALTERA CORP,SAMUEL GOLDMAN DAVID;;MARK BOURGEAULT,,https://lens.org/095-710-314-435-959,Patent Application,no,5,1,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F15/16,,0,0,,,,ACTIVE
227,GB,A,GB 2327161 A,178-231-249-980-045,1999-01-13,1999,GB 9714575 A,1997-07-10,GB 9714575 A,1997-07-10,IC time delay circuit using thermal effects,"Relatively long delays are achieved in an integrated circuit by using thermal effects, thereby avoiding the need for large capacitors or frequency dividers. Thermally dependent electrical properties V2, V4 of a pair of matched components 2,4 are monitored while one of the components is heated 14 or cooled, and when the electrical properties differ by a certain amount the timed period ends. The matched components 2,4, which may be diodes, Zener diodes, resistors or transistors, are located within separate thermally insulating structures 16,18 and 20,22. The delay circuit may be applied to vehicle flashing indicators or as a lamp cadence controller for a telephone terminal display circuit.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/178-231-249-980-045,Patent Application,no,1,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,H2H HSV2          SV2;;H2H H24P          SV2;;H2H H24R          SV2;;H2H H25G          SV2;;H2H H31           SV2;;H3P PCD           PCD;;H3P PCD           PX;;H3P PX            PCD;;H3P PX            PX;;H3T T1P1          -;;H3T T2N1          -;;H3T T2T2X         -;;H3T T2T2Z         -;;H3T T2T3B         -;;H3T T2T3F         -;;H3T T3FX          -;;H3T T3J           -;;H3T T4H2          -;;U1S S1934;;U1S S2215,1,0,,,Basic Integrated Circuit Engineering McGraw-Hill 1975 pages 84 and 413-416,EXPIRED
228,EP,A2,EP 2633497 A2,186-949-464-160-069,2013-09-04,2013,EP 11735727 A,2011-06-30,US 91152110 A;;US 2011/0042608 W,2010-10-25,EMBROIDERY IMAGE RENDERING USING TEXTURE DATABASE,,VISTAPRINT TECHNOLOGIES LTD,HSU EUGENE;;GOLDMAN DAVID A,VISTAPRINT SCHWEIZ GMBH (2013-12-25);;CIMPRESS SCHWEIZ GMBH (2015-11-18),https://lens.org/186-949-464-160-069,Patent Application,yes,0,0,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T11/00;;G06F17/50;;G06T15/04;;G06T15/50,,0,0,,,,DISCONTINUED
229,AU,B2,AU 2016/220264 B2,044-922-432-451-831,2020-03-05,2020,AU 2016/220264 A,2016-02-16,US 201562117795 P;;US 2016/0018049 W,2015-02-18,Lighting assemblies,"Aspects of lighting assemblies principally for pools and spas are addressed. The assemblies may be configured to operate without penetrating housings thereof, thus not adversely impacting waterproof characteristics of the housings. This result is especially beneficial when the housings are installed underwater within pools or spas.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2020-05-21),https://lens.org/044-922-432-451-831,Granted Patent,no,2,0,8,8,0,F21V23/0442;;F21W2131/401;;F21V23/0485;;F21Y2101/00;;F21V23/04;;F21V31/00;;F21V23/04;;F21V31/00;;F21V23/0442;;F21W2131/401;;F21V23/0485;;F21Y2101/00,F21V31/00;;F21V23/04;;F21W131/401,,0,0,,,,ACTIVE
230,CA,A1,CA 2813807 A1,058-073-981-517-762,2012-05-10,2012,CA 2813807 A,2011-06-30,US 91152110 A;;US 2011/0042608 W,2010-10-25,EMBROIDERY IMAGE RENDERING USING PARAMETRIC TEXTURE MAPPING,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",VISTAPRINT TECHNOLOGIES LTD,HSU EUGENE;;GOLDMAN DAVID A,,https://lens.org/058-073-981-517-762,Patent Application,no,0,0,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T15/04,,0,0,,,,DISCONTINUED
231,US,B2,US 7888025 B2,112-619-447-129-768,2011-02-15,2011,US 7437108 A,2008-03-03,US 7437108 A;;US 90495407 P,2007-03-05,Intestinal folate transporter method,"Provided is an isolated and purified DNA molecule comprising the coding region of a PCFT cDNA. Also provided is a segment of the above DNA molecule, capable of serving as a primer for amplifying at least a portion of the DNA molecule. Additionally provided is a pair of the above segments that can be used together as forward and reverse PCR primers for amplifying at least a portion of the above DNA molecule. Further provided is an isolated and purified human PCFT protein. Also provided is a method of evaluating the ability of a human to undergo intestinal folate absorption.",EINSTEIN COLL MED,GOLDMAN I DAVID;;QIU ANDONG,ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (2008-05-09),https://lens.org/112-619-447-129-768,Granted Patent,yes,0,0,2,2,31,C07K14/705;;G01N33/6893;;G01N33/82;;G01N2800/04;;C07K14/705;;G01N33/82;;G01N2800/04;;G01N33/6893,C12Q1/68,435/6,6,6,011-021-420-242-682;;031-895-826-144-778;;016-486-991-438-162;;044-946-282-978-561;;057-470-138-767-998;;037-055-671-170-459,10.1016/j.bbamem.2005.07.003;;16109384;;16143108;;10.1016/j.cell.2005.06.025;;15623659;;10.1158/1078-0432.ccr-04-0932;;10.1158/1078-0432.ccr-1066-03;;14760095;;10.1158/1078-0432.ccr-04-0645;;15448015;;17129779;;10.1016/j.cell.2006.09.041,"Zhao, et al. ""The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells"" Biochim. Biophys. Acta. 1715(1): abstract only (2005).;;Shayeghi, et al. ""Identification of an Intestinal Heme Transporter"" Cell 122:789-801 (2005).;;Zhao, et al. ""Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier"" Clinical Cancer Research 10:8735-8742 (2004).;;Zhao, et al. ""A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors: Contribution to the Preservation of Methotrexate Pharmacologic Activity in HeLa Cells Lacking the Reduced Folate Carrier"" Clinical Cancer Research 10:718-727 (2004).;;Wang, et al. ""Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier"" Clinical Cancer Research 10:6256-6264 (2004).;;Qiu, et al. ""Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary Folate Malabsorption"" Cell 127:917-928 (2006).",INACTIVE
232,WO,A1,WO 1999/003147 A1,030-502-107-130-357,1999-01-21,1999,EP 9804214 W,1998-07-07,GB 9714573 A,1997-07-10,THERMALLY INSULATED INTEGRATED CIRCUITS,"Trench structures are used to surround components of an integrated circuit, in order to provide thermal insulation for those components. The trench structures may include more than one trench.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/030-502-107-130-357,Patent Application,yes,1,0,4,4,0,H01L21/7624;;H01L27/0248,H01L21/762;;H01L27/02,,4,0,,,"PATENT ABSTRACTS OF JAPAN vol. 096, no. 012 26 December 1996 (1996-12-26);;PATENT ABSTRACTS OF JAPAN vol. 006, no. 016 (E - 092) 29 January 1982 (1982-01-29);;PATENT ABSTRACTS OF JAPAN vol. 096, no. 002 29 February 1996 (1996-02-29);;PATENT ABSTRACTS OF JAPAN vol. 009, no. 328 (E - 369) 24 December 1985 (1985-12-24)",PENDING
233,WO,A1,WO 2011/069057 A1,150-318-298-388-748,2011-06-09,2011,US 2010/0058873 W,2010-12-03,US 63158809 A,2009-12-04,PREVENTING INFORMATION LEAKAGE BETWEEN COMPONENTS ON A PROGRAMMABLE CHIP IN THE PRESENCE OF FAULTS,"Mechanisms are provided to prevent information leakage between components implemented on a programmable chip such as a Field Programmable Gate Array (FPGA). An automated routing algorithm is effective at enforcing security restrictions with minimal input form the user while providing efficient utilization of the device. Compatible sets of signals are identified and locked, and reservations of routing resources are generated. Remaining signals are rerouted until all signal constraints are met. Specified security constraints with one or more security levels and one or more secure regions may be applied through iterations of the automated routing mechanism.",ALTERA CORP;;GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,,https://lens.org/150-318-298-388-748,Patent Application,yes,5,0,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F15/16,,1,0,,,See also references of EP 2507717A4,PENDING
234,AU,A1,AU 2016/220264 A1,153-874-420-700-093,2017-09-14,2017,AU 2016/220264 A,2016-02-16,US 201562117795 P;;US 2016/0018049 W,2015-02-18,Lighting assemblies,"Aspects of lighting assemblies principally for pools and spas are addressed. The assemblies may be configured to operate without penetrating housings thereof, thus not adversely impacting waterproof characteristics of the housings. This result is especially beneficial when the housings are installed underwater within pools or spas.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2020-05-21),https://lens.org/153-874-420-700-093,Patent Application,no,0,0,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V31/00;;F21V23/04;;F21W131/401,,0,0,,,,ACTIVE
235,WO,A1,WO 2016/133892 A1,091-955-332-178-570,2016-08-25,2016,US 2016/0018049 W,2016-02-16,US 201562117795 P,2015-02-18,LIGHTING ASSEMBLIES,"Aspects of lighting assemblies principally for pools and spas are addressed. The assemblies may be configured to operate without penetrating housings thereof, thus not adversely impacting waterproof characteristics of the housings. This result is especially beneficial when the housings are installed underwater within pools or spas.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,,https://lens.org/091-955-332-178-570,Patent Application,yes,6,1,8,8,0,F21V23/0442;;F21W2131/401;;F21V23/0485;;F21Y2101/00;;F21V23/04;;F21V31/00;;F21V23/04;;F21V31/00;;F21V23/0442;;F21W2131/401;;F21V23/0485;;F21Y2101/00,F21V23/04;;F21V31/00;;F21W131/401,,0,0,,,,PENDING
236,GB,B,GB 2341272 B,127-286-229-830-742,2003-08-20,2003,GB 9819248 A,1998-09-03,GB 9819248 A,1998-09-03,High voltage shield,,ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID JOHN,,https://lens.org/127-286-229-830-742,Granted Patent,no,1,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,H1K KQC           QC;;H1K K1CA          QC;;H1K K5B1          QC;;H1K K5B2          QC,0,0,,,,EXPIRED
237,US,A1,US 2020/0377213 A1,129-772-996-642-212,2020-12-03,2020,US 202016890857 A,2020-06-02,US 202016890857 A;;US 201962856307 P,2019-06-03,AERIAL DELIVERY OF CHEMICALS FOR SWIMMING POOLS AND SPAS,"Airborne unmanned autonomous vehicles (UAVs) may be used to hover over swimming pools or spas and dispense chemicals (or other materials or devices) directly thereinto. UAVs alternatively or additionally may include sensors designed to identify certain characteristics of pools or spas or of the water therein. The UAVs further may hover over, or land on, pool pads or other areas adjacent or near a pool or spa to deliver or receive parts or other objects.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;MCQUEEN EUGENE KEITH,ZODIAC POOL SYSTEMS LLC (2020-06-11),https://lens.org/129-772-996-642-212,Patent Application,yes,7,0,2,2,0,G05D1/0094;;B64D1/18;;B64D1/02;;B64U2201/00;;B64U2101/32;;B64U2101/45;;B64C39/024;;B64D1/16;;B64D1/02;;G05D1/0038;;B64D1/22;;B64U2101/30;;B64U2101/60;;B64U2201/20,B64C39/02;;B64D1/02;;B64D1/16;;B64D1/22;;G05D1/00,,0,0,,,,ACTIVE
238,EP,B1,EP 0995268 B1,158-230-989-234-515,2003-04-02,2003,EP 98940168 A,1998-07-07,EP 9804213 W;;GB 9714575 A,1997-07-10,TIMING CIRCUIT,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/158-230-989-234-515,Granted Patent,yes,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,1,0,,,"W. VON MÜNCH: ""Einführung in die Halbleitertechnologie"", 1993, TEUBNER, STUTTGART",EXPIRED
239,US,B2,US 8356358 B2,164-746-131-743-081,2013-01-15,2013,US 63158809 A,2009-12-04,US 63158809 A,2009-12-04,Preventing information leakage between components on a programmable chip in the presence of faults,"Mechanisms are provided to prevent information leakage between components implemented on a programmable chip such as a Field Programmable Gate Array (FPGA). An automated routing algorithm is effective at enforcing security restrictions with minimal input form the user while providing efficient utilization of the device. Compatible sets of signals are identified and locked, and reservations of routing resources are generated. Remaining signals are rerouted until all signal constraints are met. Specified security constraints with one or more security levels and one or more secure regions may be applied through iterations of the automated routing mechanism.",ALTERA CORP;;GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,ALTERA CORPORATION (2009-11-20),https://lens.org/164-746-131-743-081,Granted Patent,yes,6,3,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F21/00;;G06F17/50,726/26;;726/32;;716/126,2,0,,,"M. McLean and J. Moore, ""FPGA-Based Single Chip Cryptographic Solution,"" Military Embedded Systems, Mar. 2007, http://www.mil-embedded.com/articles/id?2069.;;International Search Report and Written Opinion dated Feb. 15, 2011, from Application No. PCT/US2010/058873.",INACTIVE
240,WO,A1,WO 1999/003203 A1,185-586-746-305-805,1999-01-21,1999,EP 9804213 W,1998-07-07,GB 9714575 A,1997-07-10,TIMING CIRCUIT,"A timing circuit, for use in an integrated circuit, generates relatively long time periods. The electrical properties (for example the resistance) of a pair of matched components are measured while heat is supplied to one of the components. When the values of the thermally dependent properties of the components differ by a certain amount, the timed period is over. The pair of matched components are located within thermally insulating structures within the IC.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/185-586-746-305-805,Patent Application,yes,3,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,0,0,,,,PATENTED
241,US,B1,US 10226611 B1,199-099-787-936-056,2019-03-12,2019,US 201815978089 A,2018-05-11,US 201815978089 A,2018-05-11,Grip light,"A grip light for use with a tattoo machine having an exterior grip surface extending from an upper grip portion downward toward an opposite working end and surrounding a channel extending through the upper portion to the working end, light transmissive material running through the grip from a light receiving surface to a bottom surface of the working end, and a light pipe inlet for receiving light from a light pipe into the light receiving surface and thereby permitting light from the light pipe to be projected out from working end of the grip light to illuminate an area therebelow.",USHIO AMERICA INC,COLLIAS JAMES H;;GOLDMAN DAVID,USHIO AMERICA INC (2018-02-20),https://lens.org/199-099-787-936-056,Granted Patent,yes,8,6,2,2,0,A61M37/0076;;A61M37/0076;;F21V21/0885;;F21V21/32;;F21V33/00;;F21W2131/40;;F21W2131/403;;F21Y2115/10;;G02B6/0008,A61M37/00;;F21V21/088;;F21V21/32;;F21W131/403,,1,0,,,"KR200470739Y1, Tattooing machine with lighting means, English translation of Korean patent KR200470739Y1 granted on Jan. 8, 2014, from Google Patents, visited https://patents.google.com/patent/KR200470739Y1 on Feb. 21, 2018.",INACTIVE
242,US,A,US 4508820 A,025-409-573-003-219,1985-04-02,1985,US 58286284 A,1984-02-27,US 58286284 A;;US 40776282 A,1982-08-13,Method for simultaneously monitoring turnover rate in multiple proteins,"The invention provides an assay method for cellular and extracellular protein biodynamics comprising the use of radiochemical techniques in combination with high resolution protein separation procedures and recently developed silver stain techniques, to assess turnover of polypeptides over time. Quenching of polypeptide radiolables in silver stained gels is obviated by the use of .sup.14 C-labelled amino acids as precursors.",US HEALTH,MERRIL CARL R;;GOLDMAN DAVID,UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (1984-05-03),https://lens.org/025-409-573-003-219,Granted Patent,yes,0,14,1,1,0,G01N33/60;;G01N33/6836;;G01N33/60;;G01N33/6836,G01N33/60;;G01N33/68,435/29;;424/1.1;;435/35,9,6,002-964-706-358-151;;053-871-206-002-56X;;018-760-447-689-330;;022-942-165-887-146;;058-030-925-504-502;;088-892-099-876-917,10.1016/0003-2697(79)90732-2;;94518;;6163373;;10.1016/0003-2697(81)90136-6;;92027;;10.1073/pnas.76.9.4335;;pmc411569;;6162199;;10.1126/science.6162199;;10.1016/0003-2697(81)90352-3;;6172051;;7199389;;10.1016/0092-8674(82)90344-0,"Switzer III, et al., Analytical Biochem., 98, (1), 231 237, (1979).;;Merril et al., Analytical Biochem., 110, (1), 201 207, (1981).;;Merril et al., Proc. Natl. Acad. Sci., U.S.A., 76, (9), 4335 4339, (1979).;;Merril et al., Science, 211, (4489), 1437 8, (1981).;;Van Keuren et al., Analyt. Biochem., vol. 116, (1981), 248 255.;;Mafart et al., Chem. Abstracts, vol. 94, (1981), 135432d.;;Kucukalic et al., Chem. Abstracts, vol. 89, (1978), 176958v.;;Milenkovic, Chem. Abstracts, vol. 90, (1979), 85652v.;;Variations in Expression of Mutant Actin Accompanying Incremental Increases in Human Fibroblast Tumorigenicity , Cell, 28: 259 268, (1982).",EXPIRED
243,GB,B,GB 2327161 B,048-206-110-954-653,2001-05-16,2001,GB 9714575 A,1997-07-10,GB 9714575 A,1997-07-10,Timing circuit,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/048-206-110-954-653,Granted Patent,no,2,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,H2H HSV2          SV2;;H2H H24P          SV2;;H2H H24R          SV2;;H2H H25G          SV2;;H2H H31           SV2;;H3P PCD           PCD;;H3P PCD           PX;;H3P PX            PCD;;H3P PX            PX;;H3T T1P1          -;;H3T T2N1          -;;H3T T2T2X         -;;H3T T2T2Z         -;;H3T T2T3B         -;;H3T T2T3F         -;;H3T T3FX          -;;H3T T3J           -;;H3T T4H2          -;;U1S S1934;;U1S S2215,1,0,,,Basic Integrated Circuit Engineering McGraw-Hill 1975 pages 84 and 413-416,EXPIRED
244,GB,B,GB 2522299 B,137-395-338-229-070,2018-04-11,2018,GB 201418577 A,2014-10-20,US 201361908749 P,2013-11-26,Contextual audio recording,,DAVID TZVI SPRINGER;;TSEMED PITRONOT LTD,ANDREW GOLDMAN;;DAVID TZVI SPRINGER,,https://lens.org/137-395-338-229-070,Granted Patent,no,2,0,4,4,0,G10L15/00;;G10L15/26;;G10L15/26;;G06F3/167;;G10L15/26,G10L15/00;;G06F3/16;;G10L15/26,,1,0,,,"PC World, 6/11/2013, ""Control your PC with these 5 speech recognition programs"", PCWorld.com, [online], Available from: http://www.pcworld.com/article/2055599/control-your-pc-with-these-5-speech-recognition-programs.html [Accessed 15 May 2015]",ACTIVE
245,CN,A,CN 103180880 A,166-620-354-306-195,2013-06-26,2013,CN 201180051406 A,2011-06-30,US 2011/0042608 W;;US 91152110 A,2010-10-25,Embroidery image rendering using parametric texture mapping,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",VISTAPRINT TECHNOLOGIES LTD,HSU EUGENE;;GOLDMAN DAVID A,,https://lens.org/166-620-354-306-195,Patent Application,no,3,1,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T11/00;;G06T15/04,,0,0,,,,DISCONTINUED
246,US,A1,US 2011/0138223 A1,030-465-378-042-156,2011-06-09,2011,US 63158809 A,2009-12-04,US 63158809 A,2009-12-04,PREVENTING INFORMATION LEAKAGE BETWEEN COMPONENTS ON A PROGRAMMABLE CHIP IN THE PRESENCE OF FAULTS,"Mechanisms are provided to prevent information leakage between components implemented on a programmable chip such as a Field Programmable Gate Array (FPGA). An automated routing algorithm is effective at enforcing security restrictions with minimal input form the user while providing efficient utilization of the device. Compatible sets of signals are identified and locked, and reservations of routing resources are generated. Remaining signals are rerouted until all signal constraints are met. Specified security constraints with one or more security levels and one or more secure regions may be applied through iterations of the automated routing mechanism.",ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,ALTERA CORPORATION (2009-11-20),https://lens.org/030-465-378-042-156,Patent Application,yes,5,4,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F11/07,714/10;;X714E11023,0,0,,,,INACTIVE
247,US,A,US 6054892 A,092-938-954-383-802,2000-04-25,2000,US 11210398 A,1998-07-08,GB 9714575 A,1997-07-10,Timing circuit,"A timing circuit, for use in an integrated circuit, generates relatively long time periods. The electrical properties (for example the resistance) of a pair of matched components are measured while heat is supplied to one of the components. When the values of the thermally dependent properties of the components differ by a certain amount, the timed period is over. The pair of matched components are located within thermally insulating structures within the IC.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,TELEFONAKTIEBOLAGET LM ERICSSON (1998-12-02);;INFINEON TECHNOLOGIES AG (2004-07-01),https://lens.org/092-938-954-383-802,Granted Patent,yes,15,13,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,327/512;;327/77;;327/83,1,0,,,"Basic Integrated Circuit Engineering , McGraw Hill 1975, pp. 84, 413 416.",EXPIRED
248,US,A2,US 2019/0153738 A2,095-697-249-950-407,2019-05-23,2019,US 201615749753 A,2016-08-05,US 201615749753 A;;US 201562201265 P;;US 2016/0045697 W,2015-08-05,CHEMICAL INJECTOR FOR USE WITH A POOL OR SPA SYSTEM AND RELATED METHODS,"A chemical injector for use with a pool system can include an assembly having a disposable chemical container (214) and a pump (106,216). The disposable chemical container can fluidly seal a chemical in an inner volume of the disposable chemical container. The pump can be coupled to the disposable chemical container for injecting the chemical into the fluid flow of the pool system.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2016-11-07),https://lens.org/095-697-249-950-407,Amended Application,no,0,0,4,4,0,E04H4/1281;;B01F25/316;;E04H4/1281;;C02F1/686;;C02F2103/42;;C02F2201/006;;E04H4/1245,E04H4/12;;B01F5/04;;C02F1/68,,0,0,,,,ACTIVE
249,US,B2,US 10480204 B2,183-912-700-589-820,2019-11-19,2019,US 201615749753 A,2016-08-05,US 201615749753 A;;US 201562201265 P;;US 2016/0045697 W,2015-08-05,Chemical injector for use with a pool or spa system and related methods,"A chemical injector for use with a pool system can include an assembly having a disposable chemical container ( 214 ) and a pump ( 106,216 ). The disposable chemical container can fluidly seal a chemical in an inner volume of the disposable chemical container. The pump can be coupled to the disposable chemical container for injecting the chemical into the fluid flow of the pool system.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2016-11-07),https://lens.org/183-912-700-589-820,Granted Patent,yes,7,0,4,4,0,E04H4/1281;;B01F25/316;;E04H4/1281;;C02F1/686;;C02F2103/42;;C02F2201/006;;E04H4/1245,E04H4/12;;B01F5/04;;C02F1/68;;C02F103/42,,2,0,,,"International Application No. PCT/US2016/045697, “International Preliminary Report on Patentability”, dated Feb. 15, 2018, 10 pages.;;International Application No. PCT/US2016/045697, “International Search Report and Written Opinion”, dated Oct. 31, 2016, 15 pages.",ACTIVE
250,EP,A1,EP 0995268 A1,009-259-370-880-456,2000-04-26,2000,EP 98940168 A,1998-07-07,EP 9804213 W;;GB 9714575 A,1997-07-10,TIMING CIRCUIT,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/009-259-370-880-456,Patent Application,yes,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,1,0,,,See references of WO 9903203A1,EXPIRED
251,EP,B1,EP 3268666 B1,012-794-053-177-276,2020-04-08,2020,EP 16708289 A,2016-02-16,US 201562117795 P;;US 2016/0018049 W,2015-02-18,LIGHTING ASSEMBLIES,,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2020-02-19),https://lens.org/012-794-053-177-276,Granted Patent,yes,2,0,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V31/00;;F21V23/04;;F21W131/401,,0,0,,,,ACTIVE
252,GB,A,GB 2327146 A,075-864-221-935-598,1999-01-13,1999,GB 9714573 A,1997-07-10,GB 9714573 A,1997-07-10,Thermal insulation of integrated circuit components,"Trench structures 24, 26 are used to surround, or partially surround, component(s) of an integrated circuit to provide thermal insulation for the component(s). The isolated component(s) may be a transistor or more than one matched components, i.e. bipolar transistors 20, 22. The thermally isolated region may include heating resistors 30-36 and a temperature sensor 28. The trenches 24, 26 may be filled with silicon dioxide, silicon nitride or a mixture of polysilicon and silicon dioxide, and may also include voids.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/075-864-221-935-598,Patent Application,no,5,2,4,4,0,H01L21/7624;;H01L27/0248,H01L21/762;;H01L27/02,H1K KGX           GX;;H1K K1AA9         GX;;H1K K1ET          GX;;H1K K11B4         GX;;H1K K11D          GX;;H1K K11D1         GX;;H1K K11D3         GX;;H1K K9N3          GX,0,0,,,,DISCONTINUED
253,CA,A,CA 757761 A,147-394-637-089-74X,1967-04-25,1967,CA 757761D A,,CA 757761T A,,INFORMATION DISPLAY SYSTEM,,GEN PRECISION INC,ZISSELMAN ARNOLD;;GOLDMAN DAVID A,,https://lens.org/147-394-637-089-74X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
254,AU,A,AU 1998/088581 A,006-027-224-785-109,1999-02-08,1999,AU 1998/088581 A,1998-07-07,EP 9804213 W;;GB 9714575 A,1997-07-10,Timing circuit,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/006-027-224-785-109,Patent Application,no,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,0,0,,,,DISCONTINUED
255,ES,T3,ES 2798577 T3,038-826-598-451-084,2020-12-11,2020,ES 16708289 T,2016-02-16,US 201562117795 P;;US 2016/0018049 W,2015-02-18,Ensamblajes de iluminación,"Un método para cambiar una pantalla de iluminación asociada con una piscina, que comprende: a. proporcionar un ensamblaje de iluminación que comprende: (i) una carcasa (14) de iluminación: - que tiene una superficie (18) exterior y - que contiene cuatro interruptores o sensores (10) en la misma; (ii) un collar (30), externo a la carcasa (14) de iluminación y configurado para deslizarse generalmente en línea recta a lo largo de la superficie (18) exterior, para cambiar los estados conductores de los cuatro interruptores (10) o sensores y b instalar el ensamblaje de iluminación dentro de la piscina; y c. deslizar el collar (30) generalmente en línea recta a lo largo de la superficie (18) exterior para hacer que un interruptor (10) o sensor cambie su estado conductivo, haciendo que el ensamblaje de iluminación cambie la pantalla de iluminación.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,,https://lens.org/038-826-598-451-084,Granted Patent,no,0,0,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V31/00;;F21V23/04;;F21W131/401,,0,0,,,,ACTIVE
256,CA,A,CA 120789 A,039-518-699-000-620,1909-09-28,1909,CA 120789D A,1909-05-31,CA 120789T A,1909-05-31,DISINFECTING MONEY DRAWER,,GOOLDMAN HIRSCH H;;GOLDMAN DAVID,GOOLDMAN HIRSCH H;;GOLDMAN DAVID,,https://lens.org/039-518-699-000-620,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
257,US,A1,US 2008/0241947 A1,142-469-691-451-756,2008-10-02,2008,US 7437108 A,2008-03-03,US 7437108 A;;US 90495407 P,2007-03-05,Intestinal folate transporter,"Provided is an isolated and purified DNA molecule comprising the coding region of a PCFT cDNA. Also provided is a segment of the above DNA molecule, capable of serving as a primer for amplifying at least a portion of the DNA molecule. Additionally provided is a pair of the above segments that can be used together as forward and reverse PCR primers for amplifying at least a portion of the above DNA molecule. Further provided is an isolated and purified human PCFT protein. Also provided is a method of evaluating the ability of a human to undergo intestinal folate absorption.",GOLDMAN I DAVID;;QUI ANDONG,GOLDMAN I DAVID;;QUI ANDONG,ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (2008-05-09),https://lens.org/142-469-691-451-756,Patent Application,yes,0,0,2,2,31,C07K14/705;;G01N33/6893;;G01N33/82;;G01N2800/04;;C07K14/705;;G01N33/82;;G01N2800/04;;G01N33/6893,G01N33/68;;C07H21/00;;C07K14/00,436/86;;536/23.1;;536/24.33;;530/350,0,0,,,,INACTIVE
258,US,B2,US 9111060 B2,149-441-449-329-058,2015-08-18,2015,US 201414329312 A,2014-07-11,US 201414329312 A;;US 201313866624 A;;US 201213656361 A,2012-10-19,Partitioning designs to facilitate certification,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.",ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,,https://lens.org/149-441-449-329-058,Granted Patent,yes,11,3,4,10,0,G06F30/34;;G06F2111/04;;G06F30/34;;G06F30/327;;G06F2111/04;;G06F30/347,G06F17/50,,0,0,,,,ACTIVE
259,AU,A1,AU 2011/324027 A1,163-161-892-191-672,2013-05-02,2013,AU 2011/324027 A,2011-06-30,US 91152110 A;;US 2011/0042608 W,2010-10-25,Embroidery image rendering using texture database,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",VISTAPRINT SCHWEIZ GMBH,HSU EUGENE;;GOLDMAN DAVID A,VISTAPRINT SCHWEIZ GMBH (2013-12-12),https://lens.org/163-161-892-191-672,Patent Application,no,0,0,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06T11/00;;G06T15/04,,0,0,,,,DISCONTINUED
260,US,A1,US 2016/0238223 A1,191-160-580-895-866,2016-08-18,2016,US 201615044640 A,2016-02-16,US 201615044640 A;;US 201562117795 P,2015-02-18,LIGHTING ASSEMBLIES,"Aspects of lighting assemblies principally for pools and spas are addressed. The assemblies may be configured to operate without penetrating housings thereof, thus not adversely impacting waterproof characteristics of the housings. This result is especially beneficial when the housings are installed underwater within pools or spas.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2016-03-14),https://lens.org/191-160-580-895-866,Patent Application,yes,2,0,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V23/04;;F21V31/00,,0,0,,,,ACTIVE
261,US,A1,US 2018/0223552 A1,056-213-303-827-998,2018-08-09,2018,US 201615749753 A,2016-08-05,US 201615749753 A;;US 201562201265 P;;US 2016/0045697 W,2015-08-05,CHEMCIAL INJECTOR FOR USE WITH A POOL OR SPA SYSTEM AND RELATED METHODS,"A chemical injector for use with a pool system can include an assembly having a disposable chemical container ( 214 ) and a pump ( 106,216 ). The disposable chemical container can fluidly seal a chemical in an inner volume of the disposable chemical container. The pump can be coupled to the disposable chemical container for injecting the chemical into the fluid flow of the pool system.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,,https://lens.org/056-213-303-827-998,Patent Application,yes,5,0,4,4,0,E04H4/1281;;B01F25/316;;E04H4/1281;;C02F1/686;;C02F2103/42;;C02F2201/006;;E04H4/1245,E04H4/12;;B01F5/04;;C02F1/68,,0,0,,,,ACTIVE
262,GB,A9,GB 2327161 A9,063-337-999-665-154,,,GB 9714575 A,1997-07-10,GB 9714575 A,1997-07-10,IC time delay circuit using thermal effects,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/063-337-999-665-154,Patent Application,no,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,H2H HSV2          SV2;;H2H H24P          SV2;;H2H H24R          SV2;;H2H H25G          SV2;;H2H H31           SV2;;H3P PCD           PCD;;H3P PCD           PX;;H3P PX            PCD;;H3P PX            PX;;H3T T1P1          -;;H3T T2N1          -;;H3T T2T2X         -;;H3T T2T2Z         -;;H3T T2T3B         -;;H3T T2T3F         -;;H3T T3FX          -;;H3T T3J           -;;H3T T4H2          -;;U1S S1934;;U1S S2215,0,0,,,,EXPIRED
263,US,A,US 4656473 A,082-758-418-887-731,1987-04-07,1987,US 65784984 A,1984-10-04,US 65784984 A,1984-10-04,Secure card and sensing system,"An identification card is disclosed as for supporting commercial or other significant transactions involving a designated subject. The card incorporates a machine-readable record and is produced with an individual birefringent characteristic to modulate a light beam for card identification. In one embodiment, the card incorporates apparent stress waves to modulate an orientation-frequency characteristic (e.g. polarization angle) of a light beam. The machine-readable record on the card indicates the characteristic birefringence for confirming the card to be authentic. Methods are disclosed for producing and testing the cards. A system is disclosed for sensing card characteristics by modulated light including polarized light techniques to record and verify the cards with allowance for changes, as by card aging.",LIGHT SIGNATURES INC,GOLDMAN ROBERT N;;GOLD DAVID,LIGHT SIGNATURES INC. A CA CORP (1984-09-11),https://lens.org/082-758-418-887-731,Granted Patent,yes,4,19,1,2,0,G07F7/08;;G07F7/08;;G06K19/14;;G06K19/14;;G07F7/0813;;G07F7/0813;;G07F7/086;;G07F7/086;;G07F7/12;;G07F7/12,G06K19/14;;G07F7/08;;G07F7/12,340/825.34;;235/380;;356/71,0,0,,,,EXPIRED
264,US,B2,US 11634224 B2,099-124-691-678-386,2023-04-25,2023,US 202016890857 A,2020-06-02,US 202016890857 A;;US 201962856307 P,2019-06-03,Aerial delivery of chemicals for swimming pools and spas,"Airborne unmanned autonomous vehicles (UAVs) may be used to hover over swimming pools or spas and dispense chemicals (or other materials or devices) directly thereinto. UAVs alternatively or additionally may include sensors designed to identify certain characteristics of pools or spas or of the water therein. The UAVs further may hover over, or land on, pool pads or other areas adjacent or near a pool or spa to deliver or receive parts or other objects.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;MCQUEEN EUGENE KEITH,ZODIAC POOL SYSTEMS LLC (2020-06-11),https://lens.org/099-124-691-678-386,Granted Patent,yes,10,0,2,2,0,G05D1/0094;;B64D1/18;;B64D1/02;;B64U2201/00;;B64U2101/32;;B64U2101/45;;B64C39/024;;B64D1/16;;B64D1/02;;G05D1/0038;;B64D1/22;;B64U2101/30;;B64U2101/60;;B64U2201/20,B64C39/02;;B64D1/00;;B64D1/02;;B64D1/16;;B64D1/22;;C02F1/00;;G05D1/00,,0,0,,,,ACTIVE
265,US,A1,US 2014/0325462 A1,129-243-873-145-36X,2014-10-30,2014,US 201414329312 A,2014-07-11,US 201414329312 A;;US 201313866624 A;;US 201213656361 A,2012-10-19,PARTITIONING DESIGNS TO FACILITATE CERTIFICATION,"This disclosure relates generally to field-programmable gate arrays (FPGAs). Some implementations relate to methods and systems for partitioning FPGA circuit designs to facilitate certification. In one aspect, a method includes generating a hardware description language (HDL) implementation of a circuit design. The method additionally includes partitioning the design into a first portion and a second portion. In some implementations, the second portion corresponds to a safety-critical portion of the design while the first portion corresponds to a non-safety-critical portion. The method additionally includes generating first configuration settings for the first portion and generating second configuration settings for the second portion. The method additionally includes verifying, or providing to a third-party certification body for verification, the first configuration settings for the first portion and the second configuration settings for the second portion. The method further includes providing the configuration settings for the second portion for programming into a PLD.",ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,,https://lens.org/129-243-873-145-36X,Patent Application,yes,2,3,4,10,0,G06F30/34;;G06F2111/04;;G06F30/34;;G06F30/327;;G06F2111/04;;G06F30/347,G06F17/50,716/105,0,0,,,,ACTIVE
266,CA,A1,CA 2295814 A1,149-525-168-819-980,1999-01-21,1999,CA 2295814 A,1998-07-07,EP 9804213 W;;GB 9714575 A,1997-07-10,TIMING CIRCUIT,"A timing circuit, for use in an integrated circuit, generates relatively long time periods. The electrical properties (for example the resistance) of a pair of matched components are measured while heat is supplied to one of the components. When the values of the thermally dependent properties of the components differ by a certain amount, the timed period is over. The pair of matched components are located within thermally insulating structures within the IC.",ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/149-525-168-819-980,Patent Application,no,0,0,16,16,0,H03K3/023;;H03K3/0231;;H03K3/0231;;H03K17/28;;H03K17/28,H03K3/02;;H03K3/0231;;H03K17/28,,0,0,,,,DISCONTINUED
267,GB,A,GB 2341272 A,158-962-175-409-009,2000-03-08,2000,GB 9819248 A,1998-09-03,GB 9819248 A,1998-09-03,Shielding integrated circuits from particle radiation,"An integrated circuit has a guard ring for shielding a first, eg. high voltage area 14, from a second, eg.low voltage area 15. The guard ring comprises a conductive guard ring 6, (eg. metal), which is partially exposed through a passivation layer 13 in the integrated circuit 1. A semiconductor guard ring 8, (eg. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings 16, one located on each side of the semiconductor guard ring 8. A plurality of conductive elements (comprising a metal connection plate 18 and via 19) connect the conductive guard ring 6 and the semiconductor guard ring 8 at spaced apart intervals. The conductive guard ring 6, semiconductor guard ring 8 and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground.",ERICSSON TELEFON AB L M,GOLDMAN RICHARD;;MILES DAVID JOHN,,https://lens.org/158-962-175-409-009,Patent Application,no,1,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L23/52;;H01L21/3205;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,H1K KQC           QC;;H1K K1CA          QC;;H1K K5B1          QC;;H1K K5B2          QC,0,0,,,,EXPIRED
268,EP,A1,EP 3268666 A1,187-815-368-704-348,2018-01-17,2018,EP 16708289 A,2016-02-16,US 201562117795 P;;US 2016/0018049 W,2015-02-18,LIGHTING ASSEMBLIES,,ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2020-02-19),https://lens.org/187-815-368-704-348,Patent Application,yes,0,1,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V31/00;;F21V23/04;;F21W131/401,,1,0,,,See references of WO 2016133892A1,ACTIVE
269,EP,A1,EP 2507717 A1,037-951-799-597-457,2012-10-10,2012,EP 10835180 A,2010-12-03,US 63158809 A;;US 2010/0058873 W,2009-12-04,PREVENTING INFORMATION LEAKAGE BETWEEN COMPONENTS ON A PROGRAMMABLE CHIP IN THE PRESENCE OF FAULTS,,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK,,https://lens.org/037-951-799-597-457,Patent Application,yes,0,0,7,7,0,G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F21/76;;G09C1/00;;G06F30/34;;G06F30/394;;G06F2117/02;;G06F30/347,G06F15/16;;G06F17/50,,0,0,,,,DISCONTINUED
270,AU,A,AU 1998/088582 A,166-221-319-996-727,1999-02-08,1999,AU 1998/088582 A,1998-07-07,EP 9804214 W;;GB 9714573 A,1997-07-10,Thermally insulated integrated circuits,,ERICSSON TELEFON AB L M,MILES DAVID JOHN;;GOLDMAN RICHARD,,https://lens.org/166-221-319-996-727,Patent Application,no,0,0,4,4,0,H01L21/7624;;H01L27/0248,H01L21/762;;H01L27/02,,0,0,,,,DISCONTINUED
271,WO,A1,WO 2017/024199 A1,015-864-688-404-68X,2017-02-09,2017,US 2016/0045697 W,2016-08-05,US 201562201265 P,2015-08-05,CHEMICAL INJECTOR FOR USE WITH A POOL OR SPA SYSTEM AND RELATED METHODS,"A chemical injector for use with a pool system can include an assembly having a disposable chemical container (214) and a pump (106,216). The disposable chemical container can fluidly seal a chemical in an inner volume of the disposable chemical container. The pump can be coupled to the disposable chemical container for injecting the chemical into the fluid flow of the pool system.",ZODIAC POOL SYSTEMS INC,GOLDMAN DAVID;;HENG HWA LEUNG,,https://lens.org/015-864-688-404-68X,Patent Application,yes,3,5,4,4,0,E04H4/1281;;B01F25/316;;E04H4/1281;;C02F1/686;;C02F2103/42;;C02F2201/006;;E04H4/1245,E04H4/12,,0,0,,,,PENDING
272,US,B2,US 10072832 B2,105-111-906-899-147,2018-09-11,2018,US 201615044640 A,2016-02-16,US 201615044640 A;;US 201562117795 P,2015-02-18,Lighting assemblies,"Aspects of lighting assemblies principally for pools and spas are addressed. The assemblies may be configured to operate without penetrating housings thereof, thus not adversely impacting waterproof characteristics of the housings. This result is especially beneficial when the housings are installed underwater within pools or spas.",ZODIAC POOL SYSTEMS INC;;ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HENG HWA LEUNG,ZODIAC POOL SYSTEMS LLC (2016-03-14),https://lens.org/105-111-906-899-147,Granted Patent,yes,10,0,8,8,0,F21V23/04;;F21V23/04;;F21V23/0442;;F21V23/0442;;F21V23/0485;;F21V23/0485;;F21V31/00;;F21V31/00;;F21W2131/401;;F21W2131/401;;F21Y2101/00;;F21Y2101/00,F21V33/00;;F21V23/04;;F21V31/00;;F21W131/401,,2,0,,,"International Patent Application No. PCT/US2016/018049 , International Search Report and Written Opinion, dated Apr. 14, 2016, 12 pages.;;International Patent Application No. PCT/US2016/018049, “International Preliminary Report on Patentability”, dated Aug. 31, 2017, 8 pages.",ACTIVE
273,US,B2,US 8818773 B2,136-249-429-959-253,2014-08-26,2014,US 91152110 A,2010-10-25,US 91152110 A,2010-10-25,Embroidery image rendering using parametric texture mapping,"Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction.",EUGENE HSU;;DAVID GOLDMAN A;;VISTAPRINT SCHWEIZ GMBH,EUGENE HSU;;DAVID GOLDMAN A,VISTAPRINT TECHNOLOGIES LIMITED (2010-10-25);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/136-249-429-959-253,Granted Patent,yes,19,4,8,8,0,G06T15/04;;G06T15/506;;G06T2210/16;;G06T11/001;;G06T11/60;;G06T15/04;;G06T2210/16;;G06T15/506;;G06F30/00;;G06T11/001,G06F17/50;;G06T11/00,703/6;;345/582,10,2,027-607-026-511-257;;152-775-844-902-30X,10.1007/11744085_6;;10.1109/hicss.2000.926858,"Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, mailed on Jul. 25, 2012 for International Application No. PCT/US2011/042608.;;""Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration,"" mailed Aug. 3, 2012 for International Application No. PCT/US2012/033104.;;""Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration,"" mailed Jul. 25, 2012 for International Application No. PCT/US2012/033096.;;Ding, et al., ""Semi-Automatic Image Personalization Tool for Variable Text Insertion and Replacement,"" Proceedings of the International Society for Optical Engineering SPIE, vol. 7540, pp. 1-11, XP-002678817, 2010.;;Final Office Action dated Oct. 29, 2013 for U.S. Appl. No. 13/084,550.;;Gilmours Wholesale Food & Beverage, ""Webshot Help and Frequently Asked Questions,"" Retrieved from the Internet: URL: https://www.gilmours.co.nz/content/frequently-asked-questions.pdf, 5 pages, updated Mar. 22, 2011.;;Office Action dated Jan. 17, 2013 for U.S. Appl. No. 13/084,550.;;Wauters, ""DAZZ Offers a Way to Preview PhotoGifts Prior to Purchase,"" http://techcrunch.com; Feb. 28, 2009, Retrieved from the Internet: URL: http://techcrunch.com/2009/02/28/dazz-offers-a-way-to-preview-photo-gifts-prior-to-purchase/.;;White et al., ""Retexturing Single Views Using Texture and Shading,"" Computer Vision-ECCV 2006, Part IV, Lecture Notes in Computer Science 3954, pp. 70-81, Jan. 1, 2006.;;Yen, et al., ""Web-Based Virtual Reality Catalog in Electronic Commerce,"" Proceedings of the 33rd Hawaii International Conference on System Sciences, pp. 1-10, Jan. 4-7, 2000.",INACTIVE
274,EP,B1,EP 2793149 B1,175-833-505-362-043,2018-11-14,2018,EP 14161865 A,2014-03-27,US 201313866624 A,2013-04-19,Partitioning designs to facilitate certification,,ALTERA CORP,TITLEY ADAM;;GOLDMAN DAVID SAMUEL,,https://lens.org/175-833-505-362-043,Granted Patent,yes,4,0,4,10,0,G06F2115/08;;G06F30/34,G06F17/50,,0,0,,,,ACTIVE
275,WO,A2,WO 2008/109496 A2,019-579-318-112-332,2008-09-12,2008,US 2008/0055610 W,2008-03-03,US 71444007 A,2007-03-06,PRESSURE CONTROL FOR VACUUM PROCESSING SYSTEM,"A pressure control system includes a digital communication network between a pressure sensor and a pressure controller. The digital communication network is configured to communicate signals between the pressure sensor and the pressure controller. The pressure sensor is configured to measure pressure within a vacuum chamber in a processing tool. The pressure controller is responsive to pressure measurements made by the pressure sensor and communicated to the pressure controller through the digital communication network, to control the pressure within the vacuum chamber so as to maintain the pressure in the vacuum chamber at a pressure set point received from the tool.",MKS INSTR INC;;CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/019-579-318-112-332,Patent Application,yes,0,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,,,0,0,,,,PENDING
276,CN,B,CN 101681175 B,089-495-672-221-890,2014-08-27,2014,CN 200880007490 A,2008-03-03,US 2008/0055610 W;;US 71444007 A,2007-03-06,Pressure control for vacuum processing system,,MKS INSTR INC,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/089-495-672-221-890,Granted Patent,no,0,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20,,0,0,,,,ACTIVE
277,WO,A3,WO 2008/109496 A3,068-285-057-482-012,2009-10-29,2009,US 2008/0055610 W,2008-03-03,US 71444007 A,2007-03-06,PRESSURE CONTROL FOR VACUUM PROCESSING SYSTEM,"A pressure control system includes a digital communication network between a pressure sensor and a pressure controller. The digital communication network is configured to communicate signals between the pressure sensor and the pressure controller. The pressure sensor is configured to measure pressure within a vacuum chamber in a processing tool. The pressure controller is responsive to pressure measurements made by the pressure sensor and communicated to the pressure controller through the digital communication network, to control the pressure within the vacuum chamber so as to maintain the pressure in the vacuum chamber at a pressure set point received from the tool.",MKS INSTR INC;;CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/068-285-057-482-012,Search Report,yes,3,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20,,0,0,,,,PENDING
278,EP,B1,EP 2137586 B1,111-878-301-995-292,2013-05-08,2013,EP 08731208 A,2008-03-03,US 2008/0055610 W;;US 71444007 A,2007-03-06,PRESSURE CONTROL FOR VACUUM PROCESSING SYSTEM,,MKS INSTR INC,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/111-878-301-995-292,Granted Patent,yes,3,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20,,0,0,,,,ACTIVE
279,CN,A,CN 101681175 A,054-363-693-507-260,2010-03-24,2010,CN 200880007490 A,2008-03-03,US 2008/0055610 W;;US 71444007 A,2007-03-06,Pressure control for vacuum processing system,"A pressure control system includes a digital communication network between a pressure sensor and a pressure controller. The digital communication network is configured to communicate signals between the pressure sensor and the pressure controller. The pressure sensor is configured to measure pressure within a vacuum chamber in a processing tool. The pressure controller is responsive to pressure measurements made by the pressure sensor and communicated to the pressure controller through the digital communication network, to control the pressure within the vacuum chamber so as to maintain the pressure in the vacuum chamber at a pressure set point received from the tool.",MKS INSTR INC,DAVID CHAMBERLAIN;;GOLDMAN DAVID J;;GORDON HILL,,https://lens.org/054-363-693-507-260,Patent Application,no,0,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20,,0,0,,,,ACTIVE
280,EP,A2,EP 2137586 A2,012-197-867-644-94X,2009-12-30,2009,EP 08731208 A,2008-03-03,US 2008/0055610 W;;US 71444007 A,2007-03-06,PRESSURE CONTROL FOR VACUUM PROCESSING SYSTEM,,MKS INSTR INC,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/012-197-867-644-94X,Patent Application,yes,0,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20,,0,0,,,,ACTIVE
281,KR,A,KR 20100014904 A,153-251-331-049-963,2010-02-11,2010,KR 20097018456 A,2008-03-03,US 71444007 A,2007-03-06,PRESSURE CONTROL FOR VACUUM PROCESSING SYSTEM,"A pressure control system includes a digital communication network between a pressure sensor and a pressure controller. The digital communication network is configured to communicate signals between the pressure sensor and the pressure controller. The pressure sensor is configured to measure pressure within a vacuum chamber in a processing tool. The pressure controller is responsive to pressure measurements made by the pressure sensor and communicated to the pressure controller through the digital communication network, to control the pressure within the vacuum chamber so as to maintain the pressure in the vacuum chamber at a pressure set point received from the tool.",MKS INSTR INC,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,,https://lens.org/153-251-331-049-963,Patent Application,no,0,0,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,G05D16/20;;H04L12/28,,0,0,,,,DISCONTINUED
282,US,A1,US 2008/0216901 A1,156-985-024-157-050,2008-09-11,2008,US 71444007 A,2007-03-06,US 71444007 A,2007-03-06,Pressure control for vacuum processing system,"A pressure control system includes a digital communication network between a pressure sensor and a pressure controller. The digital communication network is configured to communicate signals between the pressure sensor and the pressure controller. The pressure sensor is configured to measure pressure within a vacuum chamber in a processing tool. The pressure controller is responsive to pressure measurements made by the pressure sensor and communicated to the pressure controller through the digital communication network, to control the pressure within the vacuum chamber so as to maintain the pressure in the vacuum chamber at a pressure set point received from the tool.",MKS INSTR INC,CHAMBERLAIN DAVID;;GOLDMAN DAVID J;;HILL GORDON,MKS INSTRUMENTS INC (2007-05-03),https://lens.org/156-985-024-157-050,Patent Application,yes,7,106,10,10,0,G05D16/2013;;H01L21/67253;;Y10T137/7759;;G05D16/20;;H04L12/28;;Y10T137/7759;;G05D16/2013;;H01L21/67253,F16K31/12,137/486,0,0,,,,DISCONTINUED
283,US,B1,US 6493442 B1,066-053-354-734-102,2002-12-10,2002,US 58952800 A,2000-06-07,US 58952800 A,2000-06-07,AIN triggers to invoke non-AIN features,"
    An addition to AIN that allows SSP triggers to jump to internal SSP addresses for feature processing without a return. There is no query sent to an SCP nor the associated response message, call processing is not suspended, and there is no need for fault handling associated with the trigger. 
",AG COMMUNICATION SYSTEMS CORP,GOLDMAN STUART O;;ZWICK DAVID J,AG COMMUNICATION SYSTEMS CORPORATION (2000-06-07);;WSOU INVESTMENTS LLC (2017-07-22),https://lens.org/066-053-354-734-102,Granted Patent,yes,3,9,3,3,0,H04Q3/0037;;H04Q3/0037,H04Q3/00,379/207.02;;379/220.01;;370/261;;707/10,0,0,,,,EXPIRED
284,US,B2,US 7217265 B2,074-626-423-737-661,2007-05-15,2007,US 13157705 A,2005-05-18,US 13157705 A,2005-05-18,Treatment of cellulite with mid-infrared radiation,A method and apparatus that will alter the fibrous strands in the fatty layers of the skin to reduce the appearance of cellulite. Electromagnetic energy is used to selectively shrink or alternatively loosen the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite while avoiding damage to the surrounding fatty cells.,COOLTOUCH INC,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2005-04-28),https://lens.org/074-626-423-737-661,Granted Patent,yes,25,158,2,21,0,A61B18/203;;A61B2017/00084;;A61B2018/00005;;A61B2018/00452;;A61B18/203;;A61B2018/00005;;A61B2018/00452;;A61B2017/00084,A61B18/20,606/9;;128/898;;607/89,1,0,,,"U.S. Appl. No. 10/391,221, filed Mar. 17, 2003, by Anderson et al.",INACTIVE
285,US,A1,US 2018/0263946 A1,112-459-206-446-658,2018-09-20,2018,US 201815988568 A,2018-05-24,US 201815988568 A;;US 201514679716 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/112-459-206-446-658,Patent Application,yes,5,2,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K9/16;;A61K31/225;;A61K9/20;;A61K9/28;;A61K9/48;;A61K31/60;;A61K31/616;;A61K45/06,,0,0,,,,DISCONTINUED
286,US,A,US 5864674 A,132-314-135-055-120,1999-01-26,1999,US 77848197 A,1997-01-03,US 77848197 A,1997-01-03,Reconfigurable lan and method of adding clients thereto,"A reconfigurable Local Area Network (LAN) and method of controlling the reconfigurable LAN. Clients connected to the LAN are connected according to priority, e.g., based on speed. New client requesting access to the LAN are inserted according to priority. First, a determination is made of where to place the new client so as to maintain the connection order. The new client is inserted between higher priority clients (faster clients) and lower priority clients (slower clients) than the new client.",AT & T CORP,GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,AT&T CORP (1997-02-20),https://lens.org/132-314-135-055-120,Granted Patent,yes,2,6,1,1,0,H04L12/42;;H04L12/44;;H04L12/42;;H04L12/44,H04L12/42;;H04L12/44,395/200.51,0,0,,,,EXPIRED
287,ZA,B,ZA 201405511 B,132-176-425-219-776,2022-12-21,2022,ZA 201405511 A,2014-07-25,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN IDEC MA INC A CORP ORGANISED AND EXISTING UNDER THE LAWS OF THE STATE OF MASSACHUSETTS U S A,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,,https://lens.org/132-176-425-219-776,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,0,0,,,,ACTIVE
288,CA,A1,CA 2711917 A1,151-191-249-134-97X,2009-07-23,2009,CA 2711917 A,2009-01-14,US 2094108 P;;US 2009/0031017 W,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/151-191-249-134-97X,Patent Application,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05C11/16;;D05C13/02,,0,0,,,,INACTIVE
289,US,A1,US 2012/0203372 A1,161-500-946-183-936,2012-08-09,2012,US 201213446739 A,2012-04-13,US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"Systems, Methods and Apparatus for Embroidery Thread Color Management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first number of thread colors to be used by first designs assigned to a first embroidery machine, determining a second number of thread colors to be used by second designs assigned to a second embroidery machine, determining a difference between a first production time for the first embroidery machine and a second production time for the second embroidery machine, identifying which one of the first designs would increase the second number of thread colors by the smallest number when that one of the first designs is added to the second designs, and moving the identified one of the first designs to the second designs.",GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/161-500-946-183-936,Patent Application,yes,5,5,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/02;;D05C5/02,700/138;;112/102.5,0,0,,,,ACTIVE
290,SU,A1,SU 1059301 A1,186-398-241-177-009,1983-12-07,1983,SU 3398593 A,1982-02-25,SU 3398593 A,1982-02-25,SLIDING BEARING,,SKTB GERMETICHNYKH SKVAZHINNYK,VERBITSKIJ DAVID I;;GOLDMAN ISAAK M,,https://lens.org/186-398-241-177-009,Limited Patent,no,0,0,1,1,0,,F16C27/00,,0,0,,,,EXPIRED
291,CA,A1,CA 2199470 A1,002-965-576-425-145,1996-03-28,1996,CA 2199470 A,1995-09-21,US 31027194 A,1994-09-21,ALLELIC VARIATION OF THE SEROTONIN 5HT2C RECEPTOR,"Isolated DNA encoding the serotonin 5HT2C receptor with serine at amino acid position 23, antibody specific to such a variant receptor and the variant receptor protein itself are used in methods for detecting the presence of an allelic variant of the serotonin 5HT2C gene or receptor.",US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/002-965-576-425-145,Patent Application,no,0,0,8,8,0,C07K14/70571;;C07K14/70571,G01N33/53;;C07K14/705;;C07K16/28;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,0,0,,,,DISCONTINUED
292,US,A1,US 2015/0209318 A1,052-029-988-024-083,2015-07-30,2015,US 201514679716 A,2015-04-06,US 201514679716 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC (2015-03-23),https://lens.org/052-029-988-024-083,Patent Application,yes,2,27,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/16;;A61K9/20;;A61K9/28;;A61K9/48;;A61K31/616,,0,0,,,,DISCONTINUED
293,US,B2,US 7920939 B2,059-177-978-757-039,2011-04-05,2011,US 76786707 A,2007-06-25,US 76786707 A;;US 84808006 P,2006-09-30,Method and system for creating and manipulating embroidery designs over a wide area network,"A method and system are disclosed for creating and manipulating embroidery designs over a wide area network. The method includes steps to transmit various embroidery design data over a wide area network between a client and a server The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic renderings of possible finished products, and more precisely adjust interpretations through a provided user interface with minimum latency.",VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/059-177-978-757-039,Granted Patent,yes,23,9,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02,700/138,2,0,,,"International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with counterpart international application serial No. PCT/US2008/054550, issued Jan. 5, 2010, 7 pages.;;International Search Report and Written Opinion for corresponding international patent application No. PCT/US08/54550, Mailed May 21, 2008, 8 pages.",ACTIVE
294,AU,A1,AU 2017/208367 A1,073-273-038-229-76X,2017-08-17,2017,AU 2017/208367 A,2017-07-28,AU 2017/208367 A;;AU 2013/204286 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;AU 2013/203445 A;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,DAWSON KATHERINE;;GOLDMAN DAVID;;NIRULA AJAY,,https://lens.org/073-273-038-229-76X,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,C07C69/74;;A61K31/225;;A61P25/00,,0,0,,,,DISCONTINUED
295,EP,A2,EP 2185678 A2,094-655-796-966-780,2010-05-19,2010,EP 08807420 A,2008-08-25,IB 2008053407 W;;US 96695307 P,2007-08-31,COMPOSITIONS AND VISUAL PERCEPTION CHANGING METHODS,,PROCTER & GAMBLE,GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,,https://lens.org/094-655-796-966-780,Patent Application,yes,0,0,6,6,0,C11D3/40;;C11D17/0039;;C11D3/40;;C11D17/0039,C11D3/40,,0,0,,,,DISCONTINUED
296,US,A1,US 2013/0166193 A1,129-842-714-696-951,2013-06-27,2013,US 201113335124 A,2011-12-22,US 201113335124 A,2011-12-22,"SYSTEMS, METHODS, AND APPARATUS FOR PROVIDING INDOOR NAVIGATION","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2016-02-26),https://lens.org/129-842-714-696-951,Patent Application,yes,5,94,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/12,701/410;;701/445,1,0,,,"Machine Translation of KR 10-2006-123799; Title Advertisement, POS, and Navigation Integrated Cart; Inventor: Gyeong-Hwan Cha; Publication Date: 12 May 2006.",INACTIVE
297,US,B2,US 9513127 B2,141-822-717-813-793,2016-12-06,2016,US 201113335124 A,2011-12-22,US 201113335124 A,2011-12-22,"Systems, methods, and apparatus for providing indoor navigation","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA;;APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2016-02-26),https://lens.org/141-822-717-813-793,Granted Patent,yes,60,8,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/10;;G01C21/00;;G01C21/12;;G01C21/16;;G01C21/20;;G01C21/26;;G01C21/28;;G05D1/02,,14,2,131-257-871-619-401;;079-067-912-209-783,10.1145/1410012.1410020;;10.1002/(sici)1097-4563(199704)14:4<231::aid-rob2>3.3.co;2-1,"Machine Translation of KR 10-2006-123799; Title Advertisement, POS, and Navigation Integrated Cart; Inventor: Gyeong-Hwan Cha; Publication Date: May 12, 2006.;;International Search Report and Written Opinion issued Feb. 20, 2013 for corresponding International Appln. No. PCT/US2012/070148.;;Nguyen, ""Nokia Indoor Navigation: Next Level of Location-Based Apps"", published Apr. 20, 2011 (2 pages).;;Fischer et al., ""Ultrasound-aided pedestrian dead reckoning for indoor navigation"", Proc. of the first ACM International workshop on Mobile entity localization and tracking in GPS-less environments, published in 2008 (1 page).;;""Locate and Engage the In-Store Shopper"", pages from www.zulutimecorp.com (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Empson, ""Zulu Time Issued Patent for Location Aware Wireless Networks"", published Apr. 11, 2011 (4 pages).;;""Zulu-Time LiveFind is a software solution leveraging in-store Wi-Fi for smartphone geolocation"", pages from www.zulutimecorp.com/livefind (2 pages)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;""News"" from www.polestar.eu/en (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Sayerse et al., ""NAO Campus on ANDROID: The First Indoor Location Solution that the Market Expected"", published Jul. 29, 2010 (2 pages).;;""Shop, Scan, Save, Share, Splurge. Pay"", pages from www.modivmedia.com/index.html (2 pages)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;""Introducing . . . Scan It Mobile"", pages from www.stopandshop.com/our-stores/tools/scan-it-mobile.htm (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;First Offie Action issued Jan. 31, 2014 for related U.S. Appl. No. 13/839,512.;;Borenstein et al.;, Mobile Robot Positioning-Sensors and Techniques; 1997; Journal of Robotic Systems, Special Issue on Mobile Robots; vol. 14, No. 4, pp. 231-244.;;International Preliminary Report on Patentability issued Dec. 12. 2013 for Intl. Appln. PCT/US12/70148.",INACTIVE
298,US,A1,US 2007/0184100 A1,187-883-094-644-652,2007-08-09,2007,US 34697506 A,2006-02-03,US 34697506 A,2006-02-03,Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates,"The invention provides a composition comprising a solid ibuprofen concentrate, wherein the solid ibuprofen concentrate comprises (a) a solid ibuprofen free acid and (b) a solid ibuprofen alkali salt, and wherein at least 90% of the weight of the solid ibuprofen concentrate is ibuprofen free acid and ibuprofen alkali salt, as well as methods of producing such a composition.",PHARMACEUTICS INTERNAT INC,HASSAN EMADELDIN;;GUMUDAVELLI SRIDHAR;;GOLDMAN DAVID,PHARMACEUTICS INTERNATIONAL INCORPORATED (2006-03-17),https://lens.org/187-883-094-644-652,Patent Application,yes,12,5,4,4,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K31/192;;A61K31/192,A61K9/48;;A61K9/20;;A61K9/64;;A61K31/192,424/451;;424/456;;424/464;;514/569,0,0,,,,INACTIVE
299,AU,A1,AU 2017/200394 A1,186-173-317-539-348,2017-02-09,2017,AU 2017/200394 A,2017-01-20,AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/186-173-317-539-348,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
300,CA,C,CA 2711917 C,003-301-177-471-341,2016-06-28,2016,CA 2711917 A,2009-01-14,US 2094108 P;;US 2009/0031017 W,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",VISTAPRINT TECH LTD,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/003-301-177-471-341,Granted Patent,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05C11/16;;D05C13/02,,0,0,,,,INACTIVE
301,HK,A1,HK 1202261 A1,018-448-873-390-992,2015-09-25,2015,HK 15102805 A,2015-03-18,US 2013/0024946 W;;US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/018-448-873-390-992,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K/,,0,0,,,,PENDING
302,IL,A0,IL 241403 A0,046-907-970-100-577,2016-05-31,2016,IL 24140315 A,2015-09-09,IL 24140315 A,2015-09-09,Open terrain navigation system and methods,,ELBIT SYSTEMS LAND & C4I LTD;;GOLDMAN BENNY;;ZAPHIR DAVID;;ARIAV IDO,GOLDMAN BENNY;;ZAPHIR DAVID;;ARIAV IDO,,https://lens.org/046-907-970-100-577,Patent Application,no,0,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,,,0,0,,,,ACTIVE
303,US,A,US 5917424 A,046-244-826-412-344,1999-06-29,1999,US 77837496 A,1996-12-31,US 77837496 A,1996-12-31,Duplicate page sensor system and method,"A system and method of using one-way or two-way paging to establish communications with a mobile party and sensing duplicate pages. A one-way or two-way paging device operates to compare an incoming page with pages that have been received within a predetermined, and preferably subscriber adjustable, time interval. If the incoming page is determined as being identical to a page received and stored by the pager within the preceding predetermined time interval, then the incoming page is deemed a duplicate page, and is therefore disregarded. If the incoming page is determined as not being identical to any pages received within the predetermined time interval, then the page is deemed a new page, which is stored by the pager for comparison to any pages subsequently received within the predetermined time interval, and the paging device notifies the subscriber of the new page. In another embodiment, when a page is sent out to a two-way paging device by the paging system, the paging system updates a database which contains paging information for pages sent out to each subscriber. A two-way paging device that identifies an apparent duplicate page sends a reverse page query to the paging system, requesting confirmation as to the invalidity of the apparent duplicate page. The reverse page includes information that identifies the apparent duplicate page, and the paging system compares this information with that stored in the database to determine whether two separate pages matching the apparent duplicate page were transmitted by the paging system.",AT & T CORP,GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP,AT&T CORPORATION (1996-11-01),https://lens.org/046-244-826-412-344,Granted Patent,yes,5,51,1,1,0,H04W88/023;;H04W88/023,H04W88/02,340/825.44;;455/38.2;;455/38.1,0,0,,,,EXPIRED
304,AU,B2,AU 2013/203445 B2,045-503-365-004-045,2016-10-20,2016,AU 2013/203445 A,2013-02-06,US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/045-503-365-004-045,Granted Patent,no,7,2,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
305,CA,C,CA 2901565 C,045-162-898-747-797,2016-06-14,2016,CA 2901565 A,2009-01-14,US 2094108 P;;CA 2711917 A,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/045-162-898-747-797,Granted Patent,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/02,,0,0,,,,INACTIVE
306,SU,A1,SU 1086284 A1,070-838-805-235-64X,1984-04-15,1984,SU 3425024 A,1982-04-19,SU 3425024 A,1982-04-19,DEVICE FOR PROTECTING PIPE-LINE JOINTS AGAINST AGGRESSION MEDIUM,,SP KT B GERMETICHNYKH SKVAZHIN,GOLDMAN ISAAK M;;VERBITSKIJ DAVID I,,https://lens.org/070-838-805-235-64X,Limited Patent,no,0,0,1,1,0,,F16L35/00,,0,0,,,,EXPIRED
307,US,A1,US 2009/0057619 A1,068-224-347-791-826,2009-03-05,2009,US 19815608 A,2008-08-26,US 19815608 A;;US 96695307 P,2007-08-31,Compositions and Visual Perception Changing Methods,"A composition includes at least one visual indicator dye and a surfactant. Upon dilution of the composition with a volume of water a diluted product is formed, and wherein: i) the extinction coefficient of the composition is less than the extinction coefficient of the diluted product measured at a wavelength from about 400 nm to about 700 nm; ii) a ratio of an absorbance measured between about 550-650 nm and an absorbance measured between about 395-440 nm increases upon increasing dilution of the composition; and/or iii) the pK a of the composition is greater than the pK a of the diluted product. Additionally, methods for changing the visual perception of a composition comprise diluting a composition.",GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,THE PROCTER & GAMBLE COMPANY (2008-09-24),https://lens.org/068-224-347-791-826,Patent Application,yes,37,0,6,6,0,C11D3/40;;C11D17/0039;;C11D3/40;;C11D17/0039,C09K3/00,252/408.1,0,0,,,,DISCONTINUED
308,CN,A,CN 104220061 A,083-022-188-851-016,2014-12-17,2014,CN 201380018792 A,2013-02-06,US 2013/0024946 W;;US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/083-022-188-851-016,Patent Application,no,3,3,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,1,1,044-493-744-726-635,10.1080/03639040601050197;;17654026,"JITKA MUZIKOVA ET AL: ""A Study of the Properties of Compacts from Silicified Microcrystalline Celluloses"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》",DISCONTINUED
309,EP,A1,EP 3927917 A1,094-048-333-646-348,2021-12-29,2021,EP 20716664 A,2020-03-12,US 201962835938 P;;US 2020/0022287 W,2019-04-18,METHOD OF CREATING A DESIRED TEMPERATURE IN SWIMMING POOLS OR SPAS,,ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,,https://lens.org/094-048-333-646-348,Patent Application,yes,0,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,E04H4/12,,0,0,,,,PENDING
310,US,A1,US 2010/0017011 A1,158-902-857-436-923,2010-01-21,2010,US 35392809 A,2009-01-14,US 35392809 A;;US 2094108 P,2008-01-14,"Systems, Methods and Apparatus for Embroidery Thread Management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/158-902-857-436-923,Patent Application,yes,9,9,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,700/138;;112/475.19,0,0,,,,ACTIVE
311,US,B2,US 6788777 B2,189-297-176-646-564,2004-09-07,2004,US 90821001 A,2001-07-20,US 90821001 A,2001-07-20,Alternative treatment for AIN fault handling,"
    An enhancement to AIN fault handling that allows SSP triggers to access an alternative treatment application when fault handling is invoked. If an alternative treatment application is referenced in the BCM fault handling attribute, then the application is called when AIN fault handling is invoked. If the alternative treatment application is not successful in completing the service function, then one of the traditional fault handling options is applied, (i.e., routing to a specific directory number, voice announcement then terminate call, continue, or final treatment). The present invention allows a last attempt at completing the service function by the alternative treatment application after fault handling is called, but before default handling or final treatment is invoked. 
",LUCENT TECHNOLOGIES INC,GOLDMAN STUART O;;ZWICK DAVID J,AG COMMUNICATION SYSTEMS CORP (2001-07-17),https://lens.org/189-297-176-646-564,Granted Patent,yes,2,12,2,2,0,H04M3/2254;;H04M3/2254;;H04M2207/12;;H04M2207/12;;H04Q3/0037;;H04Q3/0037,H04M3/22;;H04Q3/00,379/221.08;;379/207.02;;379/221.09;;379/221.12,0,0,,,,EXPIRED
312,US,S,US D0357046 S,197-453-262-378-975,1995-04-04,1995,US 720593 F,1993-03-01,US 720593 F,1993-03-01,Hand grip for an in-line roller skate brake actuator,,GOLDMAN DAVID A;;DALTON ROBERT J,GOLDMAN DAVID A;;DALTON ROBERT J,,https://lens.org/197-453-262-378-975,Design Right,yes,8,0,1,1,0,,,D21/226,0,0,,,,EXPIRED
313,US,B2,US 8692541 B2,187-593-422-129-620,2014-04-08,2014,US 201113253192 A,2011-10-05,US 201113253192 A,2011-10-05,Position sensing head with redundancy,"A position sensing head combines a sensing element and a simplified electronic module to enable operation with one wire, in addition to a circuit common, for providing power and transmitting a signal, while separating the sensing head from signal conditioning circuits by over 10 meters. The simplicity of the electronic module allows the use of basic electronic components that operate at more than 225° C. The signal is a variable frequency impressed onto the one wire, which can be read by a frequency meter. Another signal, such as a position or temperature, can be impressed onto the one wire at the same time as the first signal. The second signal is of a different frequency range so that it will not interfere with the first. A demodulator circuit can separate the two signals. The sensing element construction allows for locating up to three active elements measuring the same target.",NYCE DAVID SCOTT;;GOLDMAN LEONARD HILLEL,NYCE DAVID SCOTT;;GOLDMAN LEONARD HILLEL,,https://lens.org/187-593-422-129-620,Granted Patent,yes,12,4,2,2,0,G01D5/2291;;G01D5/2291,G01B7/14,324/207.16;;324/207.13;;324/207.15;;324/207.11,0,0,,,,ACTIVE
314,EP,A1,EP 2363522 A1,007-168-506-671-690,2011-09-07,2011,EP 11156950 A,2009-01-14,EP 09703028 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.
",VISTAPRINT TECHNOLOGIES LTD;;GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,"PATEL, NIRAV B. (2011-09-14);;VISTAPRINT SCHWEIZ GMBH (2014-02-12);;CIMPRESS SCHWEIZ GMBH; CH (2015-09-11);;CIMPRESS SCHWEIZ GMBH, CH (2015-12-15);;VISTAPRINT TECHNOLOGIES LIMITED (2013-01-02);;GOLDMAN, DAVID A. (2011-09-14);;VISTAPRINT LIMITED, BM (2014-01-29);;VISTAPRINT SCHWEIZ GMBH, CH (2013-11-14);;CIMPRESS GMBH, CH (2015-09-02)",https://lens.org/007-168-506-671-690,Patent Application,yes,7,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/12;;D05C5/02,,0,0,,,,ACTIVE
315,IL,A,IL 290378 A,031-153-633-415-241,2022-04-01,2022,IL 29037822 A,2022-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,,BIOGEN MA INC;;GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/031-153-633-415-241,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,0,0,,,,PENDING
316,US,B1,US 6314427 B1,024-936-483-329-694,2001-11-06,2001,US 25898499 A,1999-02-26,US 25898499 A,1999-02-26,Method and apparatus for using an information model to organize an information repository into an extensible hierarchy of organizational information,"An apparatus and method for accessing an information repository, including computer readable program code stored on computer readable media, where the computer readable program code includes code for organizing information stored in the information repository into a hierarchy of organizational information, and the code creates a hierarchy of a number of derived containers that have contents and are generated in conformance with an information model which has a hierarchy of type-defined container definition nodes, where some of the derived containers correspond to type-defined container definition nodes that are organization-based container definition nodes that represent a category of information in the information repository.",HEWLETT PACKARD CO,GOLDMAN JASON D;;LACHELT DAVID J,HEWLETT-PACKARD COMPANY (1999-04-01);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-01-31),https://lens.org/024-936-483-329-694,Granted Patent,yes,4,20,1,1,0,G06F16/958;;G06F16/954;;G06F16/954;;Y10S707/99944;;Y10S707/99943;;G06F16/958,G06F17/30,707/100;;707/102;;707/103,0,0,,,,EXPIRED
317,US,A1,US 2007/0219828 A1,070-630-929-825-630,2007-09-20,2007,US 71281807 A,2007-03-01,US 71281807 A;;US 78304906 P,2006-03-16,System and method for providing information with respect to the use of healthcare spending accounts,"A system and method which considers information such as amounts in one or more healthcare accounts of a consumer, limitations of a healthcare plan under which the consumer is covered, relevant tax rates for the consumer, rate(s) of return on investment for out-of-pocket fund(s) of the consumer, and rate(s) of return on investment for healthcare spending account(s) of the consumer to evaluate and inform the consumer how the consumer should spend the amounts in their healthcare accounts and/or out-of-pockets accounts to meet to-be-paid costs associated with a healthcare bill.",SIMPLEHX LLC,SCHLICHER JAMES COE;;GOLDMAN DAVID JASON,SIMPLEHX LLC (2007-03-15),https://lens.org/070-630-929-825-630,Patent Application,yes,7,8,1,1,0,G06Q10/00;;G06Q40/00;;G06Q40/08;;G06Q10/10;;G06Q10/00;;G06Q40/08;;G06Q40/00;;G06Q10/10,G06Q10/00,705/2;;705/35;;705/4,0,0,,,,DISCONTINUED
318,US,A1,US 2013/0261964 A1,082-244-390-359-241,2013-10-03,2013,US 201313839512 A,2013-03-15,US 201313839512 A;;US 201113335124 A,2011-12-22,"SYSTEMS, METHODS, AND APPARATUS FOR PROVIDING INDOOR NAVIGATION USING MAGNETIC SENSORS","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes an absolute position sensor coupled to a case attached to a moveable object including a motion sensor coupled to a case including a first magnetic field sensor configured to detect a polarity of a magnet as the magnet passes in proximity to the first magnetic field sensor, a code wheel having two or more magnets alternately oriented with north and south polarities facing toward the first magnetic sensor, the code wheel positioned to rotate in unison with a wheel of the moveable object, and encoder circuitry configured to determine an amount of rotation of the wheel of the moveable object based on an output of the first magnetic field sensor.",GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2016-02-23),https://lens.org/082-244-390-359-241,Patent Application,yes,22,81,2,11,0,G01C21/12;;G01C21/206;;G01C21/1656;;G01C21/1654;;G05D1/0272;;G05D1/0259;;G05D1/0268;;G05D1/0276;;G01C21/206;;G01C21/265;;G01C21/005;;G01C21/12;;G01C21/1654;;G01C21/1656,G01B7/14;;G01C21/20,701/500;;701/408;;324/207.13;;324/207.12;;324/207.2,2,1,079-067-912-209-783,10.1002/(sici)1097-4563(199704)14:4<231::aid-rob2>3.3.co;2-1,"Machine Translation of KR 10-2006-123799; Title: Advertisement, POS, and Navigation Integrated Cart; Inventor: Gyeong-Hwan Cha; Publication Date: 12 May 2006.;;J. Borenstein et al; Mobile Robot Positioning-Sensors and Techniques; 1997; Journal of Robotic Systems, Special Issue on Mobile Robots; Vol 14, No. 4, pp 231-244.",INACTIVE
319,AU,B2,AU 2020/244395 B2,081-177-721-526-179,2022-11-24,2022,AU 2020/244395 A,2020-09-28,AU 2020/244395 A;;AU 2018/260937 A;;AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic 5 parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/081-177-721-526-179,Granted Patent,no,7,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
320,AU,A,AU 1994/070922 A,095-656-152-289-236,1994-11-21,1994,AU 1994/070922 A,1994-04-29,IL 10556393 A;;US 9404630 W,1993-04-30,"Personalized method and system for storage, communication, analysis and processing of health-related data",,HEVER FOR LIFE FOR HEALTH FOR;;GOLDMAN ARNOLD J;;GREENBERG DAVID L,GOLDMAN ARNOLD J;;GREENBERG DAVID L,,https://lens.org/095-656-152-289-236,Patent Application,no,0,0,5,5,0,G16H80/00;;G16H10/60;;G16H40/67;;G16H20/13;;G16H80/00;;G16H10/60;;G16H20/13;;G16H40/67,G06F19/00,,0,0,,,,PENDING
321,US,A,US 5101646 A,097-724-304-645-733,1992-04-07,1992,US 66685691 A,1991-03-07,US 66685691 A,1991-03-07,Tamper-resistant lock,"The invention provides a lock having a thick U-shaped shackle, a transverse housing for receivably locking extending ends of the shackle, a pair of longitudinal members which lockably intersect the shackle ends and which are actuated by a lock protected within the intermediate portion of the housing. In an exemplary embodiment of the invention, the shackle and housing are constructed of substantially thick tubular metal, and the shackle ends may be conformed to openings in the housing. The longitudinal members may be extended post members which intersect inserted shackle ends or may be forked members which slidably engage flat portions on inserted shackle ends. The locking mechanism may be activated through a rack-and-pinion, cam-and-pin, or similar assembly, and may further comprise shackle ends having flat sections conformed to the housing openings to prevent rotation. The compact and integral design affords improved resistance to tampering such as by shattering or cutting/twisting methods.",GOLDMAN DAVID S;;KRIGSMAN CRAIG L,GOLDMAN DAVID S;;KRIGSMAN CRAIG L,,https://lens.org/097-724-304-645-733,Granted Patent,yes,3,8,1,2,0,E05B67/22;;E05B67/22;;E05B67/063;;E05B67/063;;Y10T70/454;;Y10T70/454;;Y10T70/459;;Y10T70/459;;Y10T70/491;;Y10T70/491,E05B67/06;;E05B67/22,70 38A;;70/39;;70/53,0,0,,,,EXPIRED
322,DE,T2,DE 60024231 T2,126-053-729-867-919,2006-08-03,2006,DE 60024231 T,2000-02-18,US 12081299 P;;US 0004189 W,1999-02-19,POLYMORPHISMUS IM GEN FÜR DIE MENSCHLICHE GABA A REZEPTOR ALPHA 6 UNTEREINHEIT,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/126-053-729-867-919,Granted Patent,no,0,0,9,11,0,C07K14/70571,C12N15/12;;C07K14/705;;C07K16/28;;C12Q1/68;;G01N33/50;;G01N33/68,,0,0,,,,EXPIRED
323,CA,A,CA 905524 A,130-895-853-000-074,1972-07-18,1972,CA 905524D A,,CA 905524T A,,VIDEO DISPLAY SYSTEM,,COLUMBIA BROADCASTING SYST INC,GOLDMAN DAVID A;;OPPENHEIMER HENRY N,,https://lens.org/130-895-853-000-074,Granted Patent,no,0,0,1,1,0,,G08B23/00;;G09G5/34,,0,0,,,,EXPIRED
324,US,A1,US 2013/0319308 A1,191-469-637-592-993,2013-12-05,2013,US 201313961633 A,2013-08-07,US 201313961633 A;;US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/191-469-637-592-993,Patent Application,yes,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,112/102.5,0,0,,,,ACTIVE
325,WO,A1,WO 2023/219971 A1,028-145-598-911-195,2023-11-16,2023,US 2023/0021405 W,2023-05-08,US 202217740340 A,2022-05-09,HEADLAMP WITH BATTERY UNIT AND BOOSTER,"Various embodiments herein provide a headlamp with a light unit, a battery unit, and a booster unit. The booster unit includes an engagement mechanism (e.g., a bar, such as a U-shaped bar) that mechanically couples the booster unit to the battery unit to provide additional power. The engagement mechanism may further form a clip to couple the booster unit to another item when the booster unit is not coupled to the battery unit. The booster unit may include one or more lights, one or more controls for the one or more lights, and/or an outgoing power port to provide power to another device (other than the battery unit and light unit). Other embodiments may be described and claimed.",COAST CUTLERY CO,ERNST TODD;;SHEEHY BRIAN;;GOLDMAN DAVID;;LEWIN DAVID,,https://lens.org/028-145-598-911-195,Patent Application,yes,5,0,2,2,0,F21Y2115/10;;F21L4/08;;F21L4/02;;F21V21/084;;F21V23/0421;;F21V23/0428;;F21V17/105;;F21V17/104;;F21V21/084;;F21V23/06;;F21V17/105;;F21S9/02,F21V17/10;;F21L4/08;;F21V23/00;;F21W131/40;;H05B47/155,,0,0,,,,PENDING
326,CA,A1,CA 2859546 A1,018-526-337-750-676,2013-06-27,2013,CA 2859546 A,2012-12-17,US 201113335124 A;;US 2012/0070148 W,2011-12-22,"SYSTEMS, METHODS, AND APPARATUS FOR PROVIDING INDOOR NAVIGATION","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,,https://lens.org/018-526-337-750-676,Patent Application,no,0,0,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/00;;G01C21/12;;H04W4/04,,0,0,,,,DISCONTINUED
327,ES,T3,ES 2254157 T3,019-259-214-207-318,2006-06-16,2006,ES 00913524 T,2000-02-18,US 12081299 P,1999-02-19,SUBUNIDAD ALFA-6 DEL RECEPTOR POLIFORMICO HUMANO GABAA.,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/019-259-214-207-318,Granted Patent,no,0,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,EXPIRED
328,WO,A1,WO 2017/042821 A1,031-822-482-698-971,2017-03-16,2017,IL 2016051008 W,2016-09-11,IL 24140315 A,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/031-822-482-698-971,Patent Application,yes,5,2,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,1,0,,,See also references of EP 3347678A4,PENDING
329,US,B2,US 8578621 B2,014-324-672-229-123,2013-11-12,2013,US 82298910 A,2010-06-24,US 82298910 A,2010-06-24,Drill presses having laser alignment systems and methods therefor,"A laser alignment system for a drill press includes first and second adjustable laser assemblies mountable on the drill press. Each adjustable laser assembly includes a base firmly affixed to the drill press, a rotatable element mounted on the base and being adapted to selectively rotate relative to the base, a pivotable element mounted on the rotatable element and being adapted to selectively pivot relative to the rotatable element, and a laser mounted on the pivotable element and being adapted to move simultaneously with the pivotable element. The laser alignment system includes a pivot adjusting mechanism coupled with the pivotable element for selectively pivoting the pivotable element relative to the rotatable element, and a rotation adjusting mechanism coupled with the rotatable element for selectively rotating the rotatable element relative to the base.",MONTPLAISIR SARAH JANE;;GOLDMAN DAVID ANDREW;;CHANG TYPE IND COMPANY LTD,MONTPLAISIR SARAH JANE;;GOLDMAN DAVID ANDREW,BLACK & DECKER INC (2010-07-22);;CHANG TYPE INDUSTRIAL COMPANY LTD (2011-09-29),https://lens.org/014-324-672-229-123,Granted Patent,yes,8,4,2,2,0,B23Q17/2423;;B25H1/0092;;Y10T408/21;;B23Q17/2423;;B25H1/0092,G01B11/27,33/638;;33/286;;X 33DIG 21,0,0,,,,ACTIVE
330,CA,A1,CA 2901565 A1,039-878-983-953-858,2009-07-23,2009,CA 2901565 A,2009-01-14,US 2094108 P;;CA 2711917 A,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/039-878-983-953-858,Patent Application,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/02,,0,0,,,,INACTIVE
331,AU,B2,AU 2017/200394 B2,030-556-242-135-349,2018-12-06,2018,AU 2017/200394 A,2017-01-20,AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/030-556-242-135-349,Granted Patent,no,8,2,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
332,EP,A1,EP 2297391 A1,099-896-594-393-856,2011-03-23,2011,EP 09703028 A,2009-01-14,US 2009/0031017 W;;US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT",,VISTAPRINT TECHNOLOGIES LTD;;GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,VISTAPRINT SCHWEIZ GMBH (2013-12-25);;VISTAPRINT TECHNOLOGIES LIMITED (2011-10-05);;CIMPRESS SCHWEIZ GMBH (2015-11-18),https://lens.org/099-896-594-393-856,Patent Application,yes,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/08,,0,0,,,,ACTIVE
333,BR,A8,BR 112014019462 A8,141-660-011-024-515,2017-07-11,2017,BR 112014019462 A,2013-02-06,US 2013/0024946 W;;US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,COMPOSIÇÕES FARMACÊUTICAS CONTENDO FUMARATO DE DIMETILA,"COMPOSIÇÕES FARMACÊUTICAS CONTENDO FUMARATO DE DIMETILA. São fornecidas aqui composições contendo compostos ou sais farmaceuticamente aceitáveis, que metabolizam ao fumarato de monometila com certos parâmetros farmacocinéticos e métodos para tratamento, profilaxia ou melhora de doenças neurodegenerativas incluindo esclerose múltipla usando-se tais composições em um indivíduo, em que se as composições contiverem fumarato de dimetila, a quantidade total de fumarato de dimetila na composição varia de cerca de 43 % p/p a cerca de 95 % p/p.",BIOGEN IDEC INC;;BIOGEN MA INC,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,BIOGEN MA INC. (US) (2019-04-24),https://lens.org/141-660-011-024-515,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
334,US,B1,US 6977946 B1,141-286-384-024-430,2005-12-20,2005,US 74908901 A,2001-03-12,US 74908901 A,2001-03-12,Virtual connection service cache for filling available bandwidth,"A method to utilize unscheduled bandwidth in a calendar-based VC scheduling scheme by caching a plurality of virtual connections for processing. A plurality of virtual connection addresses are stored in a cache memory. A virtual connection corresponding to one of these addresses is processed if one of the time periods for transmitting on the trunk is liable to be wasted because no cell is available through the normal calendaring algorithm. A VC cache is added to the VC scheduler in “parallel” with the calendar-based scheduler. When the calendar-based scheduler has a time period in which no VC is scheduled for transmission on the trunk, a VC address is obtained from the cache and that VC is processed. What makes this scheme work is the observation that the VCs that have been active will have more cells to transmit.",CISCO TECH IND,GOLDMAN GARY;;HUGHES DAVID;;MARATHE MADHAV,CISCO TECHNOLOGY INC (2001-02-22),https://lens.org/141-286-384-024-430,Granted Patent,yes,2,0,1,1,0,H04L47/263;;H04L47/525;;H04L47/568;;H04L2012/5679;;H04L47/50;;H04L47/10;;H04L47/568;;H04L2012/5679;;H04L47/263;;H04L47/525;;H04L47/50,H04J3/16;;H04L12/56,370/468;;370/395.41;;370/412,0,0,,,,EXPIRED
335,AU,B2,AU 2018/260937 B2,191-045-461-941-539,2020-07-02,2020,AU 2018/260937 A,2018-11-09,AU 2018/260937 A;;AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Abstract: Compositions comprising compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate (MMF), such as dimethyl fumarate (DMF), and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/191-045-461-941-539,Granted Patent,no,7,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
336,US,A1,US 2013/0088243 A1,079-404-572-786-713,2013-04-11,2013,US 201113253192 A,2011-10-05,US 201113253192 A,2011-10-05,POSITION SENSING HEAD WITH REDUNDANCY,"A position sensing head combines a sensing element and a simplified electronic module to enable operation with one wire, in addition to a circuit common, for providing power and transmitting a signal, while separating the sensing head from signal conditioning circuits by over 10 meters. The simplicity of the electronic module allows the use of basic electronic components that operate at more than 225° C. The signal is a variable frequency impressed onto the one wire, which can be read by a frequency meter. Another signal, such as a position or temperature, can be impressed onto the one wire at the same time as the first signal. The second signal is of a different frequency range so that it will not interfere with the first. A demodulator circuit can separate the two signals. The sensing element construction allows for locating up to three active elements measuring the same target.",NYCE DAVID SCOTT;;GOLDMAN LEONARD HILLEL,NYCE DAVID SCOTT;;GOLDMAN LEONARD HILLEL,,https://lens.org/079-404-572-786-713,Patent Application,yes,12,3,2,2,0,G01D5/2291;;G01D5/2291,G01R27/28,324/655,0,0,,,,ACTIVE
337,US,A1,US 2020/0222354 A1,076-071-907-460-60X,2020-07-16,2020,US 202016826938 A,2020-03-23,US 202016826938 A;;US 201514679716 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC (2013-03-28),https://lens.org/076-071-907-460-60X,Patent Application,yes,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/16;;A61K9/20;;A61K9/28;;A61K9/48;;A61K31/60;;A61K31/616;;A61K45/06,,0,0,,,,DISCONTINUED
338,US,B1,US 6384463 B1,129-842-592-479-19X,2002-05-07,2002,US 37910799 A,1999-08-23,GB 9819248 A,1998-09-03,High voltage shield,"
    An integrated circuit has a guard ring for shielding a first area  14  (eg. high voltage area) from a second area  15  (eg. low voltage). The guard ring comprises a conductive guard ring  6,  (eg. metal), which is partially exposed through a passivation layer  13  in the integrated circuit  1.  A semiconductor guard ring  8,  (eg. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings  16,  one located on each side of the semiconductor guard ring  8.  A plurality of conductive elements (comprising a metal connection plate  18  and via  19  ) connect the conductive guard ring  6  and the semiconductor guard ring  8  at spaced apart intervals. The conductive guard ring  6,  semiconductor guard ring  8  and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground. 
",ERICSSON TELEFON AB L M,MILES DAVID J;;GOLDMAN RICHARD J,TELEFONAKTIEBOLAGET LM ERICSSON (1999-10-08);;INFINEON TECHNOLOGIES AG (2004-07-01),https://lens.org/129-842-592-479-19X,Granted Patent,yes,15,28,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L21/3205;;H01L23/52;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,257/499;;257/646;;257/622,0,0,,,,EXPIRED
339,AU,A1,AU 2016/320857 A1,138-026-042-742-951,2018-04-26,2018,AU 2016/320857 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,Open terrain navigation systems and methods,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/138-026-042-742-951,Patent Application,no,0,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,0,0,,,,ACTIVE
340,CA,A1,CA 2161627 A1,182-228-369-513-000,1994-11-10,1994,CA 2161627 A,1994-04-29,IL 10556393 A,1993-04-30,"PERSONALIZED METHOD AND SYSTEM FOR STORAGE, COMMUNICATION, ANALYSIS AND PROCESSING OF HEALTH-RELATED DATA","A health care system for specifying edibles to individual subjects is disclosed herein. The personalized method and system for storage, communication, analysis and processing of health-related data comprises storage means containing data relating to health and edibles and is adapted to receive data on the conditions and characteristics of the individual subjects. The health care system further comprises input terminals adapted to be coupled to the storage means for providing data on the conditions and characteristics of the individual subjects, and a health computer for correlating the data relating to health and edibles with the data on the condition and characteristics of an individual subject to provide a personalize prescription of edibles.",HEVER FOR LIFE FOR HEALTH FOR,GOLDMAN ARNOLD J;;GREENBERG DAVID L,,https://lens.org/182-228-369-513-000,Patent Application,no,0,0,5,5,0,G16H80/00;;G16H10/60;;G16H40/67;;G16H20/13;;G16H80/00;;G16H10/60;;G16H20/13;;G16H40/67,G06F19/00,,0,0,,,,DISCONTINUED
341,IL,B2,IL 290378 B2,181-487-373-334-03X,2023-05-01,2023,IL 29037822 A,2022-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,,BIOGEN MA INC;;BIOGEN MA INC;;GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/181-487-373-334-03X,Unknown,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/60;;A61K31/225;;A61K31/616;;A61K45/06;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00,,0,0,,,,PENDING
342,WO,A3,WO 1996/009386 A3,197-369-433-910-531,1996-05-02,1996,US 9512002 W,1995-09-21,US 31027194 A,1994-09-21,ALLELIC VARIATION OF THE SEROTONIN 5HT2C RECEPTOR,"Isolated DNA encoding the serotonin 5HT2C receptor with serine at amino acid position 23, antibody specific to such a variant receptor and the variant receptor protein itself are used in methods for detecting the presence of an allelic variant of the serotonin 5HT2C gene or receptor.",US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/197-369-433-910-531,Search Report,yes,1,0,8,8,0,C07K14/70571;;C07K14/70571,C07K14/705;;C07K16/28;;C12N5/10;;G01N33/53;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,5,4,044-700-164-648-094;;010-950-964-836-85X;;048-850-068-921-774;;058-540-444-410-337,7557992;;10.1006/geno.1995.1042;;1463016;;pmc1682899;;1722404;;10.1016/0006-291x(91)92105-s;;8257994;;10.1002/humu.1380020513,"LAPPALAINEN J ET AL: ""Identification of cys-ser substitution in the 5-HT-2C (HTR2C) receptor gene and allelic association to violent behavior and alcoholism"", AMERICAN JOURNAL OF HUMAN GENETICS, 55 (3 SUPPL.). 09-1994. A156.;;LAPPALAINEN J ET AL: ""Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C)."", GENOMICS, MAY 20 1995, 27 (2) P274-9, UNITED STATES;;NIELSEN D A ET AL: ""Genetic mapping of the human tryptophan hydroxylase gene on chromosome II, using an intronic conformational polymorphism"", AMERICAN JOURNAL OF HUMAN GENETICS, 1992, 6, 1366-1371;;SALTZMAN, A.G. ET AL.;: ""Cloning of the human serotonin 5-HT2 and 5HT1C receptor subtypes"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 181, no. 3, 31 December 1991 (1991-12-31), ORLANDO, FL US, pages 1469 - 1478;;GLAVAC D ET AL: ""Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations."", HUM MUTAT, 1993, 2 (5) P404-14, UNITED STATES",PENDING
343,GB,A,GB 1208921 A,010-200-453-134-124,1970-10-14,1970,GB 1563368 A,1968-04-01,US 63941767 A,1967-05-18,APPARATUS FOR SELECTIVELY COMPOSING VOICE MESSAGES IN A PLURALITY OF CHANNELS,"1,208,921. Automatic exchange systems. COGNITRONICS CORP. 1 April, 1968 [18 May, 1967], No. 15633/68. Headings H4K and H4R. A speaking machine is adapted to simultaneously supply a plurality of different spoken messages to a corresponding plurality of output lines in accordance with coded representations of the message. The apparatus shown is adapted to convert coded signals (which may represent answers from a computer) into their verbal equivalents and transmit them to appropriate telephone subscribers. The subscribers are equipped with touch-tone dialling facilities by means of which they can send coded enquiries relating to metering rates, account or other inventory information. The answers are stored in verbal form on a storage drum 30 which is of the photo-electric type, but may be of the magnetic type, each possible phrase or word is stored on a different track associated with a different read amplifier MA0 to MA31. A phrase fills a complete track, while a word is repeated at three equally spaced intervals around a track. The commencement of each word and the start of a phrase are marked by pulses on a flag track associated with a further read amplifier 36. The output of this amplifier passes to a circuit 37 which distinguishes between a word start pulse and a phrase start pulse by detecting its duration and energizes one of a pair of lines 38 and 39 leading to the computer. The module shown to the right of the Figure can deal with ten simultaneous calls and has ten outputs, one each from output amplifiers SAFi-1 to SAF-10. Each output amplifier has associated with it a five bit flip-flop register 51-60 and a comparator 71-80. When the computer receives a signal on line 38 or 39 as previously described, it clears some or all of the registers 51-60 and enters into them the binary code designations of the next words or phrases to be transmitted one to each line. All tracks on the drum are read out simultaneously and scanned rapidly by a counter 42 and a diode AND gate matrix 43 feeding an OR gate 45 to provide a multiplex verbal message on a line 46. This message is applied simultaneously to the amplifiers SAF-1 to SAF-10, but each amplifier is only opened during the time slot associated with the message track specified in the register 51 to 60 associated with that amplifier. The gating signal for the amplifier SAF-1 for example is provided by coincidence circuit 71 when the count of the counter 42 coincides with the code set in the register 51. A maintenance and check unit enables a coded representation to be inserted into a register under manual control.",COGNITRONICS CORP,SHEPARD DAVID HAMMOND;;GOLDMAN ALAN LEE,,https://lens.org/010-200-453-134-124,Granted Patent,no,0,1,3,3,0,G11B20/00;;G11B20/00,G11B20/00,H4K KFD           KFD;;H4K K1A10         KOD;;H4K K1A6          KOD;;H4K K1A8          KOD;;H4K K1H3B3A       K1Z;;H4K K1K1          K1Z;;H4K K1K3          K1Z;;H4K K1K5B         K1Z;;H4K K1L           KOD;;H4K K1L10         -;;H4R RPMB          RPMB;;H4R R22X          -,0,0,,,,EXPIRED
344,EP,B1,EP 2363522 B1,049-361-027-111-07X,2013-08-28,2013,EP 11156950 A,2009-01-14,EP 09703028 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management",,VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,"PATEL, NIRAV B. (2011-09-14);;VISTAPRINT SCHWEIZ GMBH (2014-02-12);;CIMPRESS SCHWEIZ GMBH; CH (2015-09-11);;CIMPRESS SCHWEIZ GMBH, CH (2015-12-15);;GOLDMAN, DAVID A. (2011-09-14);;VISTAPRINT TECHNOLOGIES LIMITED (2013-01-02);;VISTAPRINT LIMITED, BM (2014-01-29);;VISTAPRINT SCHWEIZ GMBH, CH (2013-11-14);;CIMPRESS GMBH, CH (2015-09-02)",https://lens.org/049-361-027-111-07X,Granted Patent,yes,7,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/12;;D05C5/02,,0,0,,,,ACTIVE
345,US,B2,US 9243918 B2,083-902-836-664-32X,2016-01-26,2016,US 201313839512 A,2013-03-15,US 201313839512 A;;US 201113335124 A,2011-12-22,"Systems, methods, and apparatus for providing indoor navigation using magnetic sensors","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes an absolute position sensor coupled to a case attached to a moveable object including a motion sensor coupled to a case including a first magnetic field sensor configured to detect a polarity of a magnet as the magnet passes in proximity to the first magnetic field sensor, a code wheel having two or more magnets alternately oriented with north and south polarities facing toward the first magnetic sensor, the code wheel positioned to rotate in unison with a wheel of the moveable object, and encoder circuitry configured to determine an amount of rotation of the wheel of the moveable object based on an output of the first magnetic field sensor.",GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA;;APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2016-02-23),https://lens.org/083-902-836-664-32X,Granted Patent,yes,62,7,2,11,0,G01C21/12;;G01C21/206;;G01C21/1656;;G01C21/1654;;G05D1/0272;;G05D1/0259;;G05D1/0268;;G05D1/0276;;G01C21/206;;G01C21/265;;G01C21/005;;G01C21/12;;G01C21/1654;;G01C21/1656,G01C21/16;;G01C21/00;;G01C21/12;;G01C21/20;;G01C21/26;;G01D5/12;;G05D1/02,,14,2,079-067-912-209-783;;131-257-871-619-401,10.1002/(sici)1097-4563(199704)14:4<231::aid-rob2>3.3.co;2-1;;10.1145/1410012.1410020,"Machine Translation of KR 10-2006-123799; Title: Advertisement, POS, and Navigation Integrated Cart; Inventor: Gyeong-Hwan Cha; Publication Date: May 12, 2006.;;J. Borenstein et al; Mobile Robot Positioning-Sensors and Techniques; 1997; Journal of Robotic Systems, Special Issue on Mobile Robots; vol. 14, No. 4, pp. 231-244.;;Nguyen, ""Nokia Indoor Navigation: Next Level of Location-Based Apps"", published Apr. 20, 2011 (2 pages).;;Fischer et al., ""Ultrasound-aided pedestrian dead reckoning for indoor navigation"", Proc. of the first ACM International workshop on Mobile entity localization and tracking in GPS-less environments, published in 2008 (1 page).;;""Locate and Engage the In-Store Shopper"", pages from www.zulutimecorp.com (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Empson, ""Zulu Time Issued Patent for Location Aware Wireless Networks"", published Apr. 11, 2011 (4 pages).;;""Zulu-Time LiveFind is a software solution leveraging in-store Wi-Fi for smartphone geolocation"", pages from www.zulutimecorp.com/livefind (2 pages)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;""News"" from www.polestar.eu/en (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Sayerse et al., ""NAO Campus on ANDROID: The First Indoor Location Solution that the Market Expected"", published Jul. 29, 2010 (2 pages).;;""Shop, Scan, Save, Share, Splurge. Pay"", pages from www.modivmedia.com/index.html (2 pages)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;""Introducing . . . Scan It Mobile"", pages from www.stopandshop.com/our-stores/tools/scan-it-mobile.htm (1 page)-accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;International Search Report and Written Opinion issued Feb. 20, 2013 for related International Appln. No. PCT/US2012/070148.;;Office Action issued May 13, 2013 for related U.S. Appl. No. 13/335,124.;;International Preliminary Report on Patentability issued Dec. 12, 2013 for Intl. Appln. PCT/US12/70148.",INACTIVE
346,EP,A4,EP 2297391 A4,092-601-530-763-074,2014-06-25,2014,EP 09703028 A,2009-01-14,US 2009/0031017 W;;US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT",,VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,VISTAPRINT SCHWEIZ GMBH (2013-12-25);;VISTAPRINT TECHNOLOGIES LIMITED (2011-10-05);;CIMPRESS SCHWEIZ GMBH (2015-11-18),https://lens.org/092-601-530-763-074,Search Report,no,4,1,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05B19/12,,1,0,,,See also references of WO 2009091838A1,ACTIVE
347,US,B2,US 8515572 B2,112-324-841-946-549,2013-08-20,2013,US 201213446739 A,2012-04-13,US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first number of thread colors to be used by first designs assigned to a first embroidery machine, determining a second number of thread colors to be used by second designs assigned to a second embroidery machine, determining a difference between a first production time for the first embroidery machine and a second production time for the second embroidery machine, identifying which one of the first designs would increase the second number of thread colors by the smallest number when that one of the first designs is added to the second designs, and moving the identified one of the first designs to the second designs.",GOLDMAN DAVID A;;PATEL NIRAV B;;VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/112-324-841-946-549,Granted Patent,yes,14,3,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,700/138;;112/470.01,3,0,,,"International Searching Authority, ""International Search Report,"" issued in connection with counterpart international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 2 pages.;;International Searching Authority, ""Written Opinion of the International Searching Authority,"" issued in connection with international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 6 pages.;;International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with international application serial No. PCT/US2009/031017, issued Jul. 20, 2010, 8 pages.",ACTIVE
348,CN,B,CN 101952500 B,133-788-116-460-439,2013-11-20,2013,CN 200980104648 A,2009-01-14,US 2009/0031017 W;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management",,SOFT SIGHT INC,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/133-788-116-460-439,Granted Patent,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,,0,0,,,,INACTIVE
349,US,A1,US 2003/0165228 A1,142-088-474-410-342,2003-09-04,2003,US 90821001 A,2001-07-20,US 90821001 A,2001-07-20,Alternative treatment for AIN fault handling,"
   An enhancement to AIN fault handling that allows SSP triggers to access an alternative treatment application when fault handling is invoked. If an alternative treatment application is referenced in the BCM fault handling attribute, then the application is called when AIN fault handling is invoked. If the alternative treatment application is not successful in completing the service function, then one of the traditional fault handling options is applied, (i.e., routing to a specific directory number, voice announcement then terminate call, continue, or final treatment). The present invention allows a last attempt at completing the service function by the alternative treatment application after fault handling is called, but before default handling or final treatment is invoked. 
",GOLDMAN STUART O.;;ZWICK DAVID J.,GOLDMAN STUART O;;ZWICK DAVID J,AG COMMUNICATION SYSTEMS CORP (2001-07-17),https://lens.org/142-088-474-410-342,Patent Application,yes,2,6,2,2,0,H04M3/2254;;H04M3/2254;;H04M2207/12;;H04M2207/12;;H04Q3/0037;;H04Q3/0037,H04M3/22;;H04Q3/00,379/221.08;;379/207.02,0,0,,,,EXPIRED
350,AU,B2,AU 2016/320857 B2,156-683-364-259-658,2021-09-23,2021,AU 2016/320857 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,Open terrain navigation systems and methods,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/156-683-364-259-658,Granted Patent,no,1,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,0,0,,,,ACTIVE
351,WO,A1,WO 2007/092784 A1,177-991-213-552-765,2007-08-16,2007,US 2007/0061559 W,2007-02-02,US 34697506 A,2006-02-03,COMPOSITIONS CONTAINING SOLID IBUPROFEN CONCENTRATES AND METHODS OF MAKING SOLID IBUPROFEN CONCENTRATES,"The invention provides a composition comprising a solid ibuprofen concentrate, wherein the solid ibuprofen concentrate comprises (a) a solid ibuprofen free acid and (b) a solid ibuprofen alkali salt, and wherein at least 90% of the weight of the solid ibuprofen concentrate is ibuprofen free acid and ibuprofen alkali salt, as well as methods of producing such a composition.",PHARMACEUTICS INTERNATIONAL IN;;HASSAN EMADELDIN;;GUMUDAVELLI SRIDHAR;;GOLDMAN DAVID,HASSAN EMADELDIN;;GUMUDAVELLI SRIDHAR;;GOLDMAN DAVID,,https://lens.org/177-991-213-552-765,Patent Application,yes,4,5,4,4,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K31/192;;A61K31/192,A61K9/20;;A61K9/48;;A61K31/192,,3,3,103-951-545-907-39X;;160-969-827-542-440;;034-172-030-275-334,10.1080/03639040500215784;;16109624;;1820883;;7955775;;10.2165/00003088-199427020-00004,"SHAW LANCE R ET AL: ""The effect of selected water-soluble excipients on the dissolution of paracetamol and Ibuprofen."", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY JUL 2005, vol. 31, no. 6, July 2005 (2005-07-01), pages 515 - 525, XP009085125, ISSN: 0363-9045;;HANNULA A M ET AL: ""Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules."", EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 1991, vol. Spec No 3, 1991, pages 221 - 227, XP009085124, ISSN: 0398-7639;;NEUVONEN PERTTI J ET AL: ""Enhancement of drug absorption by antacids: An unrecognised drug interaction"", CLINICAL PHARMACOKINETICS, vol. 27, no. 2, 1994, pages 120 - 128, XP009085128, ISSN: 0312-5963",PENDING
352,US,S,US D0277669 S,185-218-628-317-785,1985-02-19,1985,US 43625982 F,1982-10-25,US 43625982 F,1982-10-25,Wall projection CTV unit,,ZENITH ELECTRONICS CORP,CHUBOFF DAVID P;;GOLDMAN ARNOLD S,ZENITH ELECTRONICS CORPORATION A DE CORP (1984-10-02),https://lens.org/185-218-628-317-785,Design Right,yes,6,1,1,1,0,,,D14/84,0,0,,,,EXPIRED
353,KR,A,KR 20150001726 A,017-745-220-677-405,2015-01-06,2015,KR 20147024886 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/017-745-220-677-405,Patent Application,no,3,1,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/255;;A61K9/14;;A61K9/30;;A61P25/00;;A61P29/00,,0,0,,,,ACTIVE
354,US,B2,US 8170708 B2,022-054-509-694-036,2012-05-01,2012,US 35392809 A,2009-01-14,US 35392809 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",GOLDMAN DAVID A;;PATEL NIRAV B;;VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/022-054-509-694-036,Granted Patent,yes,9,16,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,700/138;;112/278,3,0,,,"International Searching Authority, ""International Search Report,"" issued in connection with counterpart international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 2 pages.;;International Searching Authority, ""Written Opinion of the International Searching Authority,"" issued in connection with international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 6 pages.;;International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with international application serial No. PCT/US2009/031017, issued Jul. 20, 2010, 8 pages.",ACTIVE
355,US,A,US 5654139 A,044-056-863-791-856,1997-08-05,1997,US 31027194 A,1994-09-21,US 31027194 A,1994-09-21,Allelic variation of the serotonin 5HT2c receptor,"We describe identification of a non-conservative amino acid substitution in the 5-HT.sub.2C receptor gene. The variant was found using single strand conformational polymorphism (SSCP) analysis. By typing this polymorphism in CEPH families, the gene was genetically mapped on the long arm of the X chromosome. Since this polymorphism was not detectable as a conventional RFLP, we also developed a PCR-RFLP based method which allows rapid genotyping in populations and families.",US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (1994-12-07),https://lens.org/044-056-863-791-856,Granted Patent,yes,3,21,8,8,6,C07K14/70571;;C07K14/70571,G01N33/53;;C07K14/705;;C07K16/28;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,435/6;;536/23.5;;536/24.3;;536/24.31;;536/24.33;;435/320.1;;435/334,10,8,101-438-917-445-975;;048-850-068-921-774;;046-395-669-751-93X;;003-401-992-803-806;;002-913-028-340-998;;118-481-279-351-827;;010-950-964-836-85X;;058-540-444-410-337,10.1016/0165-6147(93)90016-d;;8372403;;1722404;;10.1016/0006-291x(91)92105-s;;10.1016/0955-0674(94)90134-1;;8024808;;8474430;;8388989;;1381232;;10.1097/00001756-199204000-00014;;1463016;;pmc1682899;;8257994;;10.1002/humu.1380020513,"Humphrey et al., Trends Pharmacol. Sci. 14:233, 1993.;;Saltzman et al., Biochem. Biophys. Res. Commun. 181:1469, 1991.;;Baldwin, Curr. Opin. Cell Biol. 6:180, 1994.;;Chanda et al., Mol. Pharmacol. 43:516, 1993.;;Choudhary et al., Mol. Pharmacol. 43:755, 1993.;;Foguet, M. et al., Neuroreport 3(4):345 48, 1992.;;Lappalainen, J. et al., American Journal of Human Genetics, 55 (3 Suppl.), p. A156, Abstract 899, Oct. 1994.;;Lappalainen et al., Genamics, 27(2):274 79, 1995.;;Nielsen, D., et al., Genetic Mapping of the Human Tryptophan Hydroxylase Gene on Chromosome II, Using an Intronic Conformational Polymorphism , Am. J. Hum. Genet., 51:1366 1371, 1992.;;Glavac, D, et al., Optimization of the Single Strand Conformation Polymorphism (SSCP) Technique for Detection of Point Mutations , Human Mutation, 2:404 414, 1993.",EXPIRED
356,IL,B1,IL 290378 B1,033-398-692-677-549,2023-01-01,2023,IL 29037822 A,2022-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,,BIOGEN MA INC;;BIOGEN MA INC;;GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/033-398-692-677-549,Unknown,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,0,0,,,,PENDING
357,SU,A1,SU 1078538 A1,088-588-527-111-472,1984-03-07,1984,SU 3422219 A,1982-04-14,SU 3422219 A,1982-04-14,STATOR FOR ELECTRIC MACHINE,,SP KT B GERMETICHNYKH SKVAZHIN,GOLDMAN ISAAK M;;VERBITSKIJ DAVID I,,https://lens.org/088-588-527-111-472,Limited Patent,no,0,0,1,1,0,,H02K5/12,,0,0,,,,EXPIRED
358,US,B2,US 11493942 B2,108-057-857-994-985,2022-11-08,2022,US 202016816703 A,2020-03-12,US 202016816703 A;;US 201962835938 P,2019-04-18,Systems and methods of creating certain water conditions in swimming pools or spas,"“Just in time” operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,ZODIAC POOL SYSTEMS LLC (2019-07-22),https://lens.org/108-057-857-994-985,Granted Patent,yes,10,1,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,G05B13/04;;E04H4/12;;G05D23/19,,2,0,,,"International Application No. PCT/US2020/022287, International Search Report and Written Opinion dated Jul. 1, 2020, 10 pages.;;International Application No. PCT/US2020/022287, International Preliminary Report on Patentability dated Oct. 28, 2021, 7 pages.",ACTIVE
359,WO,A2,WO 2000/049151 A2,141-096-518-137-151,2000-08-24,2000,US 0004189 W,2000-02-18,US 12081299 P,1999-02-19,POLYMORPHIC HUMAN GABAA RECEPTOR alpha -6 SUBUNIT,"Compositions and methods based on a polymorphism in the gene encoding the α6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the α6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV;;GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/141-096-518-137-151,Patent Application,yes,0,0,9,11,14,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,PATENTED
360,WO,A2,WO 1996/009386 A2,160-950-127-235-140,1996-03-28,1996,US 9512002 W,1995-09-21,US 31027194 A,1994-09-21,ALLELIC VARIATION OF THE SEROTONIN 5HT2C RECEPTOR,"Isolated DNA encoding the serotonin 5HT2C receptor with serine at amino acid position 23, antibody specific to such a variant receptor and the variant receptor protein itself are used in methods for detecting the presence of an allelic variant of the serotonin 5HT2C gene or receptor.",US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/160-950-127-235-140,Patent Application,no,0,19,8,8,6,C07K14/70571;;C07K14/70571,C07K14/705;;C07K16/28;;C12N5/10;;G01N33/53;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,0,0,,,,PENDING
361,WO,A2,WO 1994/025927 A2,168-503-537-390-924,1994-11-10,1994,US 9404630 W,1994-04-29,IL 10556393 A,1993-04-30,"PERSONALIZED METHOD AND SYSTEM FOR STORAGE, COMMUNICATION, ANALYSIS AND PROCESSING OF HEALTH-RELATED DATA","A health care system for specifying edibles to individual subjects is disclosed herein. The personalized method and system for storage, communication, analysis and processing of health-related data comprises storage means containing data relating to health and edibles and is adapted to receive data on the conditions and characteristics of the individual subjects. The health care system further comprises input terminals adapted to be coupled to the storage means for providing data on the conditions and characteristics of the individual subjects, and a health computer for correlating the data relating to health and edibles with the data on the condition and characteristics of an individual subject to provide a personalized prescription of edibles.",HEVER FOR LIFE FOR HEALTH FOR;;GOLDMAN ARNOLD J;;GREENBERG DAVID L,GOLDMAN ARNOLD J;;GREENBERG DAVID L,,https://lens.org/168-503-537-390-924,Patent Application,no,0,5,5,5,0,G16H80/00;;G16H10/60;;G16H40/67;;G16H20/13;;G16H80/00;;G16H10/60;;G16H20/13;;G16H40/67,G06F19/00,,0,0,,,,PENDING
362,US,B2,US 9144463 B2,180-354-518-177-261,2015-09-29,2015,US 201313743068 A,2013-01-16,US 201313743068 A;;US 10109508 A;;US 84715307 A;;US 67502807 A;;US 13157705 A,2005-05-18,Treatment of cellulite and adipose tissue with mid-infrared radiation,"A handpiece and method of use for laser-assisted liposuction for melting, disrupting, and removing cellulite and adipose tissue. Electromagnetic energy is used to selectively melt or disrupt cellulite and adipose tissue and ablate the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite and adipose tissue, while avoiding damage to the surrounding fatty cells.",HENNINGS DAVID R;;GOLDMAN MITCHEL P;;COOL TOUCH INC,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2008-04-14),https://lens.org/180-354-518-177-261,Granted Patent,yes,4,1,4,21,0,A61B18/22;;A61B2018/2005;;A61N2005/0659;;A61B2017/00747;;A61B18/203;;A61B2018/00464;;A61B2018/00452;;A61B2018/2005;;A61N2005/0659;;A61B18/28,A61B19/00;;A61B18/20;;A61B18/22;;A61B18/28;;A61N5/06,,0,0,,,,INACTIVE
363,US,A1,US 2008/0188835 A1,199-421-868-818-943,2008-08-07,2008,US 10109508 A,2008-04-10,US 10109508 A;;US 84715307 A;;US 67502807 A;;US 13157705 A,2005-05-18,TREATMENT OF CELLULITE AND ADIPOSE TISSUE WITH MID-INFRARED RADIATION,"A handpiece and method of use for laser-assisted liposuction for melting, disrupting, and removing cellulite and adipose tissue. Electromagnetic energy is used to selectively melt or disrupt cellulite and adipose tissue and ablate the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite and adipose tissue, while avoiding damage to the surrounding fatty cells.",COOLTOUCH INC,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2008-04-14),https://lens.org/199-421-868-818-943,Patent Application,yes,30,47,4,21,0,A61B18/22;;A61B2018/2005;;A61N2005/0659;;A61B2017/00747;;A61B18/203;;A61B2018/00464;;A61B2018/00452;;A61B2018/2005;;A61N2005/0659;;A61B18/28,A61B18/22;;A61M1/00,604/542;;606/15,0,0,,,,INACTIVE
364,US,B2,US 6492219 B2,015-941-143-776-578,2002-12-10,2002,US 90975701 A,2001-07-23,US 90975701 A;;GB 9819248 A;;US 37910799 A,1998-09-03,High voltage shield,"
    An integrated circuit has a guard ring for shielding a first area  14  (eg. high voltage area) from a second area  15  (eg.low voltage). The guard ring comprises a conductive guard ring  6  , (eg. metal), which is partially exposed through a passivation layer  13  in the integrated circuit  1.  A semiconductor guard ring  8  , (eg. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings  16  , one located on each side of the semiconductor guard ring  8.  A plurality of conductive elements (comprising a metal connection plate  18  and via  19  ) connect the conductive guard ring  6  and the semiconductor guard ring  8  at spaced apart intervals. The conductive guard ring  6  , semiconductor guard ring  8  and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground. 
",ERICSSON TELEFON AB L M,MILES DAVID J;;GOLDMAN RICHARD J,INFINEON TECHNOLOGIES AG (2004-07-01),https://lens.org/015-941-143-776-578,Granted Patent,yes,13,0,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L21/3205;;H01L23/52;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,438/218;;438/348,0,0,,,,EXPIRED
365,DE,D1,DE 60024231 D1,031-888-198-156-704,2005-12-29,2005,DE 60024231 T,2000-02-18,US 12081299 P;;US 0004189 W,1999-02-19,POLYMORPHISMUS IM GEN FÜR DIE MENSCHLICHE GABA A REZEPTOR ALPHA 6 UNTEREINHEIT,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/031-888-198-156-704,Granted Patent,no,0,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,EXPIRED
366,US,A1,US 2018/0185319 A1,020-190-306-624-293,2018-07-05,2018,US 201815910745 A,2018-03-02,US 201815910745 A;;US 201313827228 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/020-190-306-624-293,Patent Application,yes,0,3,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/16;;A61K9/20;;A61K9/28;;A61K9/48;;A61K31/60;;A61K31/616;;A61K45/06,,0,0,,,,DISCONTINUED
367,TN,A1,TN 2014000321 A1,032-447-841-666-512,2015-12-21,2015,TN 2014000321 A,2014-07-24,US 201261723048 P;;US 2013/0024946 W,2012-11-06,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/032-447-841-666-512,Patent Application,no,0,0,1,68,0,,A61K31/225,,0,0,,,,PENDING
368,EP,A1,EP 3347678 A1,060-032-073-775-230,2018-07-18,2018,EP 16843850 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,,ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/060-032-073-775-230,Patent Application,yes,0,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,0,0,,,,PENDING
369,WO,A1,WO 2020/214289 A1,065-793-723-798-206,2020-10-22,2020,US 2020/0022287 W,2020-03-12,US 201962835938 P,2019-04-18,METHOD OF CREATING A DESIRED TEMPERATURE IN SWIMMING POOLS OR SPAS,"""Just in time"" operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature ( i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,,https://lens.org/065-793-723-798-206,Patent Application,yes,4,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,E04H4/12,,0,0,,,,PENDING
370,US,B1,US 7440474 B1,103-874-524-897-579,2008-10-21,2008,US 94260304 A,2004-09-15,US 94260304 A,2004-09-15,Method and apparatus for synchronizing clocks on packet-switched networks,"The present invention is directed to the synchronization of clock frequencies across packet data networks. In particular, one or more communication endpoints may produce a clock signal that is synchronized to a master clock source. Synchronization is performed by providing timing packets containing information regarding a number of clock cycles counted on the master clock source to a controlled clock source. The controlled clock source uses the provided count to increment a counter value. At the same time, the counter value on the controlled clock source is decremented by the controlled clock source clock. The resulting counter value is used to address a correction table. A correction value from the correction table is applied to the frequency control input of the controlled clock source clock.",AVAYA INC,GOLDMAN PETER DAVID;;MCSHEA MATTHEW DUANE,AVAYA TECHNOLOGY CORP (2004-09-13),https://lens.org/103-874-524-897-579,Granted Patent,yes,8,23,1,1,0,H04J3/0664;;H04J3/0664,H04J3/06,370/503;;370/516,1,0,,,"Mills, David L., ""RFC 1305 Network Time Protocol (Version 3) Specification, Implementation,"" Univ. of Delaware, Mar. 1992, pp. 1-108.",ACTIVE
371,AU,A1,AU 2013/204286 A1,111-510-323-015-827,2013-08-22,2013,AU 2013/204286 A,2013-04-12,US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;AU 2013/203445 A;;US 2013/0024946 W,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. Figure 1 Compaction Profiles- Pressure Plot --*-Blend A a 3.0 -- Blend B =2.5 U) 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 Compaction Pressure (MPa)",BIOGEN IDEC INC,DAWSON KATHERINE;;GOLDMAN DAVID;;NIRULA AJAY,,https://lens.org/111-510-323-015-827,Patent Application,no,0,1,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,C07C69/74;;A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
372,AU,A1,AU 2012/355436 A1,111-694-824-512-847,2014-07-10,2014,AU 2012/355436 A,2012-12-17,US 201113335124 A;;US 2012/0070148 W,2011-12-22,"Systems, methods, and apparatus for providing indoor navigation","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,,https://lens.org/111-694-824-512-847,Patent Application,no,0,0,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/00;;G01C21/12,,0,0,,,,DISCONTINUED
373,WO,A1,WO 2013/119677 A1,126-504-840-324-728,2013-08-15,2013,US 2013/0024946 W,2013-02-06,US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/126-504-840-324-728,Patent Application,yes,19,95,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,6,2,001-746-288-965-466;;089-633-159-085-704,4151086;;10.1111/j.2042-7158.1974.tb09261.x;;10.1016/j.ijpharm.2012.06.059;;22776803,"ALASTAIR COMPSTON ET AL.: ""McAlpine's Multiple Sclerosis"", 2006, CHURCHILL LIVINGSTONE ELSEVIER;;NEWTON, J. M, JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 26, 1974, pages 215 - 216;;NORQUIST JM ET AL., CURR MED RES OPIN, vol. 23, 2007, pages 1547 - 1560;;ANONYMOUS: ""PROSOLV® SMCC. Silicified Microcrystalline Cellulose"", JRS PHARMA, 1 January 2022 (2022-01-01), XP055933401, Retrieved from the Internet <URL:https://www.jrspharma.com/pharma_en/products-services/excipients/hfe/prosolv-smcc.php> [retrieved on 20220621];;PODCZECK FRIDRUN: ""Methods for the practical determination of the mechanical strength of tablets—From empiricism to science"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 436, no. 1-2, 1 October 2012 (2012-10-01), NL , pages 214 - 232, XP055933400, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2012.06.059;;SOFIA MATTSSON: ""Pharmaceutical binders and their function in directly compressed tables. Mechanistic Studies on the Effect of Dry Binders on Mechanical Strength, Pore Structure and Disintegration of Tablets"", DISSERTATION, 2000, Uppsala, XP055933404, Retrieved from the Internet <URL:https://uu.diva-portal.org/smash/get/diva2:166025/FULLTEXT01.pdf>",PENDING
374,EP,A2,EP 0782618 A2,160-749-524-838-258,1997-07-09,1997,EP 95935029 A,1995-09-21,US 9512002 W;;US 31027194 A,1994-09-21,ALLELIC VARIATION OF THE SEROTONIN 5HT 2C? RECEPTOR,,US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/160-749-524-838-258,Patent Application,yes,0,0,8,8,0,C07K14/70571;;C07K14/70571,G01N33/53;;C07K14/705;;C07K16/28;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,0,0,,,,DISCONTINUED
375,AU,A,AU 2000/034959 A,180-811-817-942-235,2000-09-04,2000,AU 2000/034959 A,2000-02-18,US 12081299 P;;US 0004189 W,1999-02-19,Polymorphic human gabaa receptor alpha-6 subunit,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/180-811-817-942-235,Patent Application,no,0,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,DISCONTINUED
376,BR,B1,BR 112014019462 B1,002-016-199-005-043,2022-03-22,2022,BR 112014019462 A,2013-02-06,US 2013/0024946 W;;US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Composições farmacêuticas contendo fumarato de dimetila,"composições farmacêuticas contendo fumarato de dimetila. são fornecidas aqui composições contendo compostos ou sais farmaceuticamente aceitáveis, que metabolizam ao fumarato de monometila com certos parâmetros farmacocinéticos e métodos para tratamento, profilaxia ou melhora de doenças neurodegenerativas incluindo esclerose múltipla usando-se tais composições em um indivíduo, em que se as composições contiverem fumarato de dimetila, a quantidade total de fumarato de dimetila na composição varia de cerca de 43 % p/p a cerca de 95 % p/p.",BIOGEN IDEC INC;;BIOGEN MA INC,NIRULA AJAY;;GOLDMAN DAVID;;DAWSON KATHERINE,BIOGEN MA INC. (US) (2019-04-24),https://lens.org/002-016-199-005-043,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
377,US,A1,US 2013/0131658 A1,007-697-561-409-453,2013-05-23,2013,US 201313743068 A,2013-01-16,US 201313743068 A;;US 10109508 A;;US 84715307 A;;US 67502807 A;;US 13157705 A,2005-05-18,Treatment of Cellulite and Adipose Tissue with Mid-Infrared Radiation,"A handpiece and method of use for laser-assisted liposuction for melting, disrupting, and removing cellulite and adipose tissue. Electromagnetic energy is used to selectively melt or disrupt cellulite and adipose tissue and ablate the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite and adipose tissue, while avoiding damage to the surrounding fatty cells.",HENNINGS DAVID R;;GOLDMAN MITCHEL P,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2008-04-14),https://lens.org/007-697-561-409-453,Patent Application,yes,4,0,4,21,0,A61B18/22;;A61B2018/2005;;A61N2005/0659;;A61B2017/00747;;A61B18/203;;A61B2018/00464;;A61B2018/00452;;A61B2018/2005;;A61N2005/0659;;A61B18/28,A61B18/28,606/15,0,0,,,,INACTIVE
378,US,A,US 3534171 A,005-521-756-060-544,1970-10-13,1970,US 3534171D A,1967-05-18,US 63941767 A,1967-05-18,MULTIPLEXING VOICE STORAGE READOUT SYSTEM,,COGNITRONICS CORP,SHEPARD DAVID H;;GOLDMAN ALAN L,,https://lens.org/005-521-756-060-544,Granted Patent,no,2,6,3,3,0,G11B20/00;;G11B20/00,G11B20/00,179/1,0,0,,,,EXPIRED
379,US,A,US 3300591 A,011-566-957-016-343,1967-01-24,1967,US 32011763 A,1963-10-30,US 32011763 A,1963-10-30,Audio playback unit,,COGNITRONICS CORP,GUSHUE EDWARD J;;GOLDMAN DAVID A,,https://lens.org/011-566-957-016-343,Granted Patent,no,9,9,1,1,0,G11B7/003;;G11B7/003,G11B7/003,,0,0,,,,EXPIRED
380,CA,C,CA 2349766 C,032-032-088-364-527,2006-10-10,2006,CA 2349766 A,2001-06-06,US 58952800 A,2000-06-07,AIN TRIGGERS TO INVOKE NON-AIN FEATURES,"An addition to AIN that allows SSP triggers to jump to internal SSP addresses for feature processing without a return. The invention takes advantage of the existing AIN trigger mechanism and definitions, and adds the capability of a jump to an internal SSP address for continued call processing. There is no query sent to an SCP nor the associated response message, call processing is not suspended, and there is no need for fault handling associated with the trigger.",AG COMMUNICATION SYSTEMS CORP,ZWICK DAVID J;;GOLDMAN STUART O,,https://lens.org/032-032-088-364-527,Granted Patent,no,0,0,3,3,0,H04Q3/0037;;H04Q3/0037,H04Q1/30;;H04Q3/00,,0,0,,,,EXPIRED
381,US,A1,US 2007/0205135 A1,064-459-526-113-650,2007-09-06,2007,US 67667007 A,2007-02-20,US 67667007 A;;US 77789706 P,2006-03-01,Construction Jobsite Product Packaging Arrangement,"A packaging arrangement for a construction jobsite product including a construction jobsite product, a carrying case for carrying the construction jobsite product, a sleeve disposed around the carrying case, wherein the carrying case has a bar code disposed on an outer surface of the carrying case. The sleeve may have a window or opening.",GOLDMAN DAVID A;;CAMPBELL HARRY J,GOLDMAN DAVID A;;CAMPBELL HARRY J,,https://lens.org/064-459-526-113-650,Patent Application,yes,14,6,1,1,0,A45C3/02;;B65D5/38;;B65D5/4204;;B65D2203/06;;B65D5/38;;B65D2203/06;;A45C3/02;;B65D5/4204,B65D65/16;;B65D25/54;;B65D85/00;;B65D85/28,206/776;;206/459.5;;206/372;;229/87.06,0,0,,,,DISCONTINUED
382,EC,A,EC SP14014870 A,059-914-494-330-116,2015-09-30,2015,EC PI201414870 A,2014-08-20,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN FUMARATO DE DIMETILO,"Se proporcionan en la presente composiciones que contienen compuestos, o sales farmacéuticamente aceptables, que se metabolizan en fumarato de monometilo con ciertos parámetros farmacocinéticos y métodos para tratar, profilaxis, o mejora de enfermedades neurodegenerativas que incluyen esclerosis múltiple utilizando tales composiciones en un sujeto, en donde si las composiciones contienen fumarato de dimetilo, la cantidad total de fumarato de dimetilo en las composiciones oscila de alrededor de 43% p/p a alrededor de 95% p/p.",BIOGEN IDEC INC,GOLDMAN DAVID;;NIRULA AJAY;;DAWSON KATHERINE,,https://lens.org/059-914-494-330-116,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,PENDING
383,US,B2,US 9103059 B2,105-455-872-961-780,2015-08-11,2015,US 201314083238 A,2013-11-18,US 201314083238 A;;US 96935910 A;;US 76786707 A;;US 84808006 P,2006-09-30,Methods and apparatus to manipulate embroidery designs via a communication network,"Methods and apparatus to manipulate embroidery designs via a communication network are disclosed. An example apparatus includes An apparatus for manipulating an embroidery design via a communication network, comprising a client computer to: receive a communication from a server, the communication including embroidery data; display, via a user interface of the client computer, a first image based on the embroidery data; edit the embroidery data stored in a memory of the client computer to create modified embroidery data in response to receiving a command via the user interface of the client computer; and display, via the user interface of the client computer, a second image based on the modified embroidery data in the memory of the client computer.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2007-06-25);;SOFT SIGHT INC (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/105-455-872-961-780,Granted Patent,yes,31,4,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02;;G06T11/60,,7,0,,,"International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with counterpart international application serial No. PCT/US2008/054550, issued Jan. 5, 2010 (7 pages).;;International Bureau, ""International Search Report and Written Opinion"" issued in connection with counterpart international patent application No. PCT/ US08/54550, mailed May 21, 2008 (8 pages).;;United States Patent and Trademark Office, ""Office Action"" issued in connection with U.S. Appl. No. 11/767,867, notified Jul. 9, 2010 (13 pages).;;United States Patent and Trademark Office, ""Notice of Allowance"" issued in connection with U.S. Appl. No. 11/767,867, mailed Dec. 1, 2010 (4 pages).;;United States Patent and Trademark Office, ""Office Action"" issued in connection with U.S. Appl. No. 12/969,359, mailed Apr. 8, 2013 (10 pages).;;United States Patent and Trademark Office, ""Office Action"" issued in connection with U.S. Appl. No. 12/969,359, mailed Apr. 20, 2012 (15 pages).;;United States Patent and Trademark Office, ""Notice of Allowance"" issued in connection with U.S. Appl. No. 12/969,359, mailed Jul. 17, 2013 (4 pages).",ACTIVE
384,EP,A1,EP 2811994 A1,130-285-277-817-984,2014-12-17,2014,EP 13746306 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC. (2019-04-10),https://lens.org/130-285-277-817-984,Patent Application,yes,16,1,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20,,0,0,,,,PENDING
385,MX,A,MX 2014009469 A,129-724-360-985-23X,2014-09-22,2014,MX 2014009469 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE.,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,DAWSON KATHERINE;;GOLDMAN DAVID;;NIRULA AJAY,"SHIRE HUMAN GENETIC THERAPIES, INC. (2016-06-13);;W. R. GRACE & CO.-CONN (2016-06-13)",https://lens.org/129-724-360-985-23X,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
386,US,B2,US 9150990 B2,178-614-262-691-641,2015-10-06,2015,US 201414466521 A,2014-08-22,US 201414466521 A;;US 201313961633 A;;US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a set of thread colors needed for a set of embroidery designs including a first embroidery design and a second embroidery design, annotating the second embroidery design, the annotating comprising appending a reference to the second embroidery design in a first queue of designs to be embroidered by a first embroidery machine, and rolling back the annotation of the second embroidery design. The rolling back comprises removing the annotation, removing the reference, and removing a thread color from the set of thread colors, the thread color resulting from the second embroidery design.",VISTAPRINT SCHWEIZ GMBH;;CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/178-614-262-691-641,Granted Patent,yes,33,2,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05B19/08;;D05B19/12,,10,0,,,"International Searching Authority, ""International Search Report,"" issued in connection with counterpart international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 2 pages.;;International Searching Authority, ""Written Opinion of the International Searching Authority,"" issued in connection with international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 6 pages.;;International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with international application serial No. PCT/US2009/031017, issued Jul. 20, 2010, 8 pages.;;United States Patent and Trademark Office, ""Notice of Allowance and Fee(s) Due"", issued in connection with U.S. Appl. No. 13/446,739, mailed Apr. 18, 2013, 6 pages.;;United States Patent and Trademark Office, ""Non-Final Office Action"", issued in connection with U.S. Appl. No. 13/446,739, mailed Dec. 28, 2012, 6 pages.;;United States Patent and Trademark Office, ""Notice of Allowance and Fee(s) Due"", issued in connection with U.S. Appl. No. 12/353,928, mailed Dec. 16, 2011, 5 pages.;;United States Patent and Trademark Office, ""Non-Final Office Action"", issued in connection with U.S. Appl. No. 12/353,928, mailed May 27, 2011, 17 pages.;;European Patent Office, ""Extended European Search Report,"" issued in connection with Application No. 09703028.2, May 28, 2014, 4 pages.;;United States Patent and Trademark Office, ""Non-Final Office Action"", issued in connection with U.S. Appl. No. 13/961,633, mailed Oct. 10, 2013, 19 pages.;;United States Patent and Trademark Office, ""Notice of Allowance and Fee(s) Due"", issued in connection with U.S. Appl. No. 13/961,633, mailed Mar. 7, 2014, 13 pages.",ACTIVE
387,US,A,US 3676850 A,193-292-564-906-518,1972-07-11,1972,US 3676850D A,1971-02-11,US 11466971 A,1971-02-11,VIDEO DISPLAY SYSTEM,"Teletype information signals from two different stock exchanges are stored in respective recirculating registers. Under the control of timing signals, the contents of the two registers are periodically advanced and alternately supplied to a character generator which converts the coded teletype information into an electronic array of corresponding letters or figures. Each array is sequentially scanned by a controlled electrical commutator and the scanned signals are supplied to a cathode ray tube for reproduction. The horizontal and vertical scanning coils for the tube are rotated 90 DEG from their usual positions such that information signals are displayed as advancing transversely across the face of the device.",COLUMBIA BROADCASTING SYST INC,GOLDMAN DAVID A;;OPPENHEIMER HENRY N,,https://lens.org/193-292-564-906-518,Granted Patent,no,4,14,1,1,0,G09G5/343;;G09G5/343,G09G5/34,340/154;;340324   A,0,0,,,,EXPIRED
388,NZ,A,NZ 627980 A,013-031-128-518-874,2016-12-23,2016,NZ 62798013 A,2013-02-06,US 2013/0024946 W;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Disclosed herein are compositions comprising dimethyl fumarate in the ranges from about 43% w/w to about 95% w/w. Also disclosed are methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject.",BIOGEN MA INC,DAWSON KATHERINE;;GOLDMAN DAVID;;NIRULA AJAY,,https://lens.org/013-031-128-518-874,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,PENDING
389,WO,A3,WO 2009/027925 A3,021-133-769-217-948,2009-06-04,2009,IB 2008053407 W,2008-08-25,US 96695307 P,2007-08-31,COMPOSITIONS AND VISUAL PERCEPTION CHANGING METHODS,"A composition includes at least one visual indicator dye and a surfactant. Upon dilution of the composition with a volume of water a diluted product is formed, and wherein: i) the extinction coefficient of the composition is less than the extinction coefficient of the diluted product measured at a wavelength from about 400 nm to about 700 nm; ii) a ratio of an absorbance measured between about 550-650 nm and an absorbance measured between about 395-440 nm increases upon increasing dilution of the composition; and/or iii) the pKa of the composition is greater than the pKa of the diluted product. Additionally, methods for changing the visual perception of a composition comprise diluting a composition.",PROCTER & GAMBLE;;GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,,https://lens.org/021-133-769-217-948,Search Report,yes,0,0,6,6,0,C11D3/40;;C11D17/0039;;C11D3/40;;C11D17/0039,C11D3/40,,1,1,042-678-697-080-568,10.1016/s0167-7322(00)00131-8,"MCHEDLOV-PETROSSIYAN N.O., TIMIY A.V., VODOLAZKAYA N.A.: ""Binding of sulfonephthalein anions to the micelles of an anionic surfactant"", JOURNAL OF MOLECULAR LIQUIDS, 2000, pages 75 - 84, XP002515769",PENDING
390,CA,C,CA 2862885 C,032-236-520-952-059,2020-06-02,2020,CA 2862885 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/032-236-520-952-059,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
391,US,A1,US 2008/0079727 A1,032-500-130-684-669,2008-04-03,2008,US 76786707 A,2007-06-25,US 76786707 A;;US 84808006 P,2006-09-30,Method and System for Creating and Manipulating Embroidery Designs Over a Wide Area Network,"A method and system are disclosed for creating and manipulating embroidery designs over a wide area network. The method includes steps to transmit various embroidery design data over a wide area network between a client and a server The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic renderings of possible finished products, and more precisely adjust interpretations through a provided user interface with minimum latency.",SOFT SIGHT INC,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/032-500-130-684-669,Patent Application,yes,20,30,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,G06T11/20,345/441;;345/418,0,0,,,,ACTIVE
392,CA,A1,CA 2862885 A1,039-791-602-906-264,2013-08-15,2013,CA 2862885 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/039-791-602-906-264,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
393,US,A,US 5398529 A,040-731-562-863-589,1995-03-21,1995,US 86385892 A,1992-04-06,US 86385892 A;;US 66685691 A,1991-03-07,Tamper-resistant lock,"A lock is provided having a thick U-shaped shackle, a transverse housing for receivably locking extending ends of the shackle, a pair of longitudinal members which lockably intersect the shackle ends and which are actuated by a lock protected within the intermediate portion of the housing. In an exemplary embodiment of the lock, the shackle and housing are constructed of substantially thick tubular metal, and the shackle ends may be conformed to openings in the housing. The longitudinal members may be extended post members which intersect inserted shackle ends or may be forked members which slidably engage flat portions on inserted shackle ends. The locking mechanism may be activated through a rack-and-pinion, cam-and-pin, or hook-and-pin assembly, and may further comprise shackle ends having flat sections conformed to the housing openings to prevent rotation. In another exemplary embodiment of the lock, the lock incorporates a second U-shaped shackle on the opposite side of the housing from the first shackle. The compact and integral design affords improved resistance to tampering such as by shattering or cutting/twisting methods.",GOLDMAN; DAVID S.;;KRIGSMAN; CRAIG L.,GOLDMAN DAVID S;;KRIGSMAN CRAIG L,,https://lens.org/040-731-562-863-589,Granted Patent,yes,22,33,1,2,0,E05B67/063;;E05B67/22;;Y10T70/454;;Y10T70/491;;Y10T70/459;;Y10T70/454;;Y10T70/491;;Y10T70/459;;E05B67/22;;E05B67/063,E05B67/06;;E05B67/22,70 38A;;70/39;;70/53,0,0,,,,EXPIRED
394,MX,B,MX 370785 B,053-339-215-649-145,2020-01-06,2020,MX 2014009469 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE.,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,KATHERINE DAWSON;;DAVID GOLDMAN;;AJAY NIRULA,"SHIRE HUMAN GENETIC THERAPIES, INC. (2016-06-13);;W. R. GRACE & CO.-CONN (2016-06-13)",https://lens.org/053-339-215-649-145,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20,,0,0,,,,ACTIVE
395,DE,A1,DE 1774254 A1,060-083-653-075-986,1971-07-22,1971,DE 1774254 A,1968-05-13,US 63941767 A,1967-05-18,Vorrichtung zur selektiven Zusammenstellung von Sprachmitteilungen in mehreren Kanaelen,,COGNITRONICS CORP,HAMMOND SHEPARD DAVID;;LEE GOLDMAN ALAN,,https://lens.org/060-083-653-075-986,Patent Application,no,0,0,3,3,0,G11B20/00;;G11B20/00,G11B20/00,,0,0,,,,DISCONTINUED
396,US,A1,US 2011/0087728 A1,098-408-218-757-896,2011-04-14,2011,US 96935910 A,2010-12-15,US 96935910 A;;US 76786707 A;;US 84808006 P,2006-09-30,METHOD AND SYSTEM FOR CREATING AND MANIPULATING EMBROIDERY DESIGNS OVER A WIDE AREA NETWORK,"Methods and apparatus to manipulate embroidery designs via a communication network are disclosed. The method includes receiving at a server, via the communication network, a request from a client computer, the request including first data associated with the embroidery design, processing at least some of the first data at the server to generate at least one of image data or embroidery data, and transmitting, via the communication network, a response to the client computer, the response to be received by a user interface for manipulating embroidery design information at the client computer and including at least one of the image data or the embroidery data.",GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2007-06-25);;SOFT SIGHT INC (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/098-408-218-757-896,Patent Application,yes,25,5,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,G06F15/16,709/203,0,0,,,,ACTIVE
397,EP,A4,EP 2811994 A4,124-366-616-020-660,2016-01-13,2016,EP 13746306 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC. (2019-04-10),https://lens.org/124-366-616-020-660,Search Report,no,3,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20,,0,0,,,,PENDING
398,CA,C,CA 2998111 C,138-458-961-367-514,2020-01-28,2020,CA 2998111 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/138-458-961-367-514,Granted Patent,no,0,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,0,0,,,,ACTIVE
399,US,A1,US 2019/0358190 A1,187-816-880-958-464,2019-11-28,2019,US 201916532155 A,2019-08-05,US 201916532155 A;;US 201815988568 A;;US 201514679716 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC (2013-03-28),https://lens.org/187-816-880-958-464,Patent Application,yes,0,2,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/16;;A61K9/20;;A61K9/28;;A61K9/48;;A61K31/60;;A61K31/616;;A61K45/06,,0,0,,,,DISCONTINUED
400,EA,B1,EA 038152 B1,188-732-283-392-421,2021-07-14,2021,EA 201491484 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds or pharmaceutically acceptable salts thereof, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters, and methods for treating, prophylaxis or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43 to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/188-732-283-392-421,Granted Patent,no,5,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
401,US,B2,US 11789475 B2,197-357-217-199-45X,2023-10-17,2023,US 202217950082 A,2022-09-21,US 202217950082 A;;US 202016816703 A;;US 201962835938 P,2019-04-18,Systems and methods of creating certain water conditions in swimming pools or spas,"“Just in time” operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,ZODIAC POOL SYSTEMS LLC (2019-07-22),https://lens.org/197-357-217-199-45X,Granted Patent,yes,13,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,E04H4/12;;G05D23/19;;G05B13/04,,7,0,,,"International Application No. PCT/US2020/022287, International Preliminary Report on Patentability dated Oct. 28, 2021, 7 pages, printed copy with parent case: U.S. Appl. No. 16/816,703.;;International Application No. PCT/US2020/022287, International Search Report and Written Opinion dated Jul. 1, 2020, 10 pages, printed copy with parent case: U.S. Appl. No. 16/816,703.;;U.S. Appl. No. 16/816,703, Advisory Action dated Apr. 26, 2022, 2 pages.;;U.S. Appl. No. 16/816,703, Final Office Action dated Feb. 17, 2022, 13 pages.;;U.S. Appl. No. 16/816,703, Non-Final Office Action dated Sep. 2, 2021, 11 pages.;;U.S. Appl. No. 16/816,703, Notice of Allowance dated Jul. 11, 2022, 11 pages.;;European Application No. 20716664.6, Office Action dated Jun. 1, 2023, 4 pages.",ACTIVE
402,CN,A,CN 102978842 A,013-996-232-908-304,2013-03-20,2013,CN 201210549944 A,2009-01-14,US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/013-996-232-908-304,Patent Application,no,0,2,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05B19/12,,0,0,,,,INACTIVE
403,CN,A,CN 114146079 A,015-231-797-011-877,2022-03-08,2022,CN 202111171982 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;CN 201380018792 A,2012-02-07,Pharmaceutical composition containing dimethyl fumarate,"Provided herein are compositions containing compounds or pharmaceutically acceptable salts that metabolize to monomethyl fumarate having certain pharmacokinetic parameters and methods of using the compositions in subjects to treat, prevent, or ameliorate neurodegenerative diseases, including multiple sclerosis, the total amount of dimethyl fumarate in the composition ranges from about 43% w/w to about 95% w/w.",BIAOGONLEMA COMPANY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/015-231-797-011-877,Patent Application,no,2,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K47/02;;A61K47/04;;A61K47/38;;A61P25/00,,3,1,044-493-744-726-635,10.1080/03639040601050197;;17654026,"崔福德主编: ""《药用辅料应用指南》"", 31 December 2011, 中国医药科技出版社;;梅兴国主编: ""《微载体药物递送系统》"", 31 December 2009, 华中科技大学出版社;;JITKA MUZIKOVA ET AL: ""A Study of the Properties of Compacts from Silicified Microcrystalline Celluloses"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》",DISCONTINUED
404,US,B2,US 8357146 B2,027-243-481-730-051,2013-01-22,2013,US 10109508 A,2008-04-10,US 10109508 A;;US 84715307 A;;US 67502807 A;;US 13157705 A,2005-05-18,Treatment of cellulite and adipose tissue with mid-infrared radiation,"A handpiece and method of use for laser-assisted liposuction for melting, disrupting, and removing cellulite and adipose tissue. Electromagnetic energy is used to selectively melt or disrupt cellulite and adipose tissue and ablate the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite and adipose tissue, while avoiding damage to the surrounding fatty cells.",COOLTOUCH INC;;HENNINGS DAVID R;;GOLDMAN MITCHEL P,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2008-04-14),https://lens.org/027-243-481-730-051,Granted Patent,yes,30,26,4,21,0,A61B18/22;;A61B2018/2005;;A61N2005/0659;;A61B2017/00747;;A61B18/203;;A61B2018/00464;;A61B2018/00452;;A61B2018/2005;;A61N2005/0659;;A61B18/28,A61M1/00;;A61B18/18,606/15;;606/13;;607/88;;607/92;;604/542,25,3,030-084-199-131-533;;080-578-796-462-828;;043-316-481-698-412,10.1002/lsm.1900170402;;8684236;;10.1002/(sici)1096-9101(1996)18:4<335::aid-lsm2>3.0.co;2-t;;8732572;;10.1002/(sici)1096-9101(1996)18:4<325::aid-lsm1>3.0.co;2-u;;8732571,"U.S. Appl. No. 10/391,221, filed Mar. 17, 2003, by Anderson et al.;;U.S. Appl. No. 10/697,212, filed Oct. 30, 2003, by Hennings et al.;;U.S. Appl. No. 10/351,273, filed Jan. 24, 2003, by Baumgardner et al.;;U.S. Appl. No. 09/934,356, filed Aug. 21, 2001, by Koop.;;U.S. Appl. No. 09/134,776, filed Aug. 1998 by Koop et al.;;U.S. Appl. No. 10/738,384, filed Dec. 2003 by Hennings et al.;;U.S. Appl. No. 11/131,577, filed May 2005 by Hennings et al.;;U.S. Appl. No. 09/185,490, filed Jul. 2000 by Koop et al.;;U.S. Appl. No. 09/135,330, filed Jul. 1998 by Koop et al.;;U.S. Appl. No. 10/160,579, filed May 2002 by Koop et al.;;U.S. Appl. No. 10/031,154, filed Jan. 2005 by Koop et al.;;U.S. Appl. No. 08/482,208, filed Jun. 1995 by Hennings et al.;;U.S. Appl. No. 08/631,800, filed Apr. 1996 by Hennings et al.;;U.S. Appl. No. 10/699,212, filed Oct. 2003 by Hennings et al.;;U.S. Appl. No. 351,273, filed Jan. 2003 by Hennings et al.;;U.S. Appl. No. 10/335,176, filed Dec. 2002 by Baumgardner et al.;;Dr. Michael Olding, ""Does Lipo-dissove Work?"" published Jun. 28, 2007, www.washingtonpost.com, 7 pages.;;Elisa M. Chavez, ""In Vitro Study of Photothermal Laser Effects on Bovine Oral Soft Tissue"", ISLD 1992, 4 pages.;;T. Milner, D. Dave, L. Liew, K. Keikhanzade & J. Nelson, ""Evaluation of the Bare Fiber Tip Technique for Cutting Ex-Vivo Human Skin at Two Laser Wavelengths"", 3 pages.;;U.S. Appl. No. 11/612,324, filed Dec. 2006 by Hennings at al.;;Wong et al; ""Thermo-Optical response of cartilage during feedback controlled laser-assisted reshaping."" SPIE vol. 2975 , pp. 310-315. (1997).;;Chao et al;""Viability of Porcine Nasal Septal Grafts Following Nd:YAG (?=1.32um) Laser Radiation"", SPIE vol. 3914 , 543-552 (2000).;;Bass et al; ""Laser Tissue Welding: A comprehensive reveiw of current and future clinical applications."" Lasers in Surgery and Medicine 17:315-349 (1995).;;Poppas et al, ""Temperature controlled laser photocoagulation of soft tissue: In vivo evaluation using a tissue welding model"" Lasers in Surgery and Medicine 18:335-344 (1996).;;Cilesiz et al:""Controlled temperature tissue fusion: Argon laser welding of canine intestine in vitro."" Lasers in Surgery and Medicine 18: 325-344 (1996).",INACTIVE
405,US,B2,US 10712158 B2,031-364-452-394-648,2020-07-14,2020,US 201615758039 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,Open terrain navigation systems and methods,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,ELBIT SYSTEMS LAND AND C4I LTD (2018-08-01),https://lens.org/031-364-452-394-648,Granted Patent,yes,8,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/04;;G01C21/00;;G01C21/20;;G01C21/34;;G01C21/36;;G06K9/00;;G06K9/62;;G06T17/05,,2,0,,,"International Search Report of PCT Application No. PCT/IL2016/051008, dated Dec. 18, 2016.;;Extended European Search Report for EP Application No. EP16843850.5, dated Apr. 18, 2019.",ACTIVE
406,AU,B2,AU 2013/204286 B2,073-452-958-561-988,2017-05-11,2017,AU 2013/204286 A,2013-04-12,US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;AU 2013/203445 A;;US 2013/0024946 W,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. Figure 1 Compaction Profiles- Pressure Plot --*-Blend A a 3.0 -- Blend B =2.5 U) 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 Compaction Pressure (MPa)",BIOGEN MA INC,DAWSON KATHERINE;;GOLDMAN DAVID;;NIRULA AJAY,,https://lens.org/073-452-958-561-988,Granted Patent,no,1,2,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,C07C69/74;;A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
407,CN,B,CN 102978842 B,091-405-366-174-862,2014-12-24,2014,CN 201210549944 A,2009-01-14,US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management",,VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/091-405-366-174-862,Granted Patent,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02;;D05B19/12,,0,0,,,,INACTIVE
408,EP,A1,EP 1978942 A1,093-262-438-876-597,2008-10-15,2008,EP 07763144 A,2007-02-02,US 2007/0061559 W;;US 34697506 A,2006-02-03,COMPOSITIONS CONTAINING SOLID IBUPROFEN CONCENTRATES AND METHODS OF MAKING SOLID IBUPROFEN CONCENTRATES,,PHARMACEUTICS INTERNATIONAL IN,HASSAN EMADELDIN;;GUMUDAVELLI SRIDHAR;;GOLDMAN DAVID,,https://lens.org/093-262-438-876-597,Patent Application,yes,0,0,4,4,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K31/192;;A61K31/192,A61K9/20;;A61K9/48;;A61K31/192,,1,0,,,See references of WO 2007092784A1,DISCONTINUED
409,CN,A,CN 113244185 A,106-204-216-768-78X,2021-08-13,2021,CN 202110490355 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;CN 201380018792 A,2012-02-07,Pharmaceutical composition containing dimethyl fumarate,"The invention relates to a pharmaceutical composition containing dimethyl fumarate. Provided are compositions containing compounds or pharmaceutically acceptable salts that metabolize to monomethyl fumarate having certain pharmacokinetic parameters and methods of using the compositions in subjects to treat, prevent, or ameliorate neurodegenerative diseases, including multiple sclerosis. The total amount of dimethyl fumarate in the composition ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/106-204-216-768-78X,Patent Application,no,2,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K9/48;;A61K9/32;;A61K9/36;;A61K31/225;;A61K47/04;;A61K47/32;;A61K47/38;;A61P25/00,,1,1,044-493-744-726-635,10.1080/03639040601050197;;17654026,"JITKA MUZIKOVA ET AL.: ""A Study of the Properties of Compacts from Silicified Microcrystalline Celluloses"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》",PENDING
410,EP,A4,EP 3347678 A4,129-610-854-727-534,2019-05-22,2019,EP 16843850 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,,ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/129-610-854-727-534,Search Report,no,2,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34;;G01C21/00;;G01C21/04;;G01C21/20;;G01C21/36,,1,0,,,See also references of WO 2017042821A1,PENDING
411,US,A1,US 2023/0418316 A1,138-955-651-797-962,2023-12-28,2023,US 202318242383 A,2023-09-05,US 202318242383 A;;US 202217950082 A;;US 202016816703 A;;US 201962835938 P,2019-04-18,SYSTEMS AND METHODS OF CREATING CERTAIN WATER CONDITIONS IN SWIMMING POOLS OR SPAS,"“Just in time” operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,,https://lens.org/138-955-651-797-962,Patent Application,yes,0,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,E04H4/12;;G05D23/19;;G05B13/04,,0,0,,,,PENDING
412,WO,A3,WO 1994/025927 A3,138-151-060-542-18X,1995-01-12,1995,US 9404630 W,1994-04-29,IL 10556393 A,1993-04-30,"PERSONALIZED METHOD AND SYSTEM FOR STORAGE, COMMUNICATION, ANALYSIS AND PROCESSING OF HEALTH-RELATED DATA","A health care system for specifying edibles to individual subjects is disclosed herein. The personalized method and system for storage, communication, analysis and processing of health-related data comprises storage means containing data relating to health and edibles and is adapted to receive data on the conditions and characteristics of the individual subjects. The health care system further comprises input terminals adapted to be coupled to the storage means for providing data on the conditions and characteristics of the individual subjects, and a health computer for correlating the data relating to health and edibles with the data on the condition and characteristics of an individual subject to provide a personalized prescription of edibles.",HEVER FOR LIFE FOR HEALTH FOR;;GOLDMAN ARNOLD J;;GREENBERG DAVID L,GOLDMAN ARNOLD J;;GREENBERG DAVID L,,https://lens.org/138-151-060-542-18X,Search Report,yes,4,0,5,5,0,G16H80/00;;G16H10/60;;G16H40/67;;G16H20/13;;G16H80/00;;G16H10/60;;G16H20/13;;G16H40/67,G06F19/00,,3,2,044-044-857-367-452;;033-130-067-438-991,10.1109/iembs.1990.691720;;10.1111/j.1464-5491.1989.tb01192.x;;2527674,"E.GOMEZ ET AL: ""THE USE OF THE DIACRONO AS AN AID IN AMBULATORY DECISION MAKING OF DIABETIC PATIENTS"", PROCEEDINGS OF THE TWELFTH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, IEEE PRESS NEW YORK US, vol. 3/5, 1 November 1990 (1990-11-01), PHILADELPHIA US, pages 1226 - 1227, XP000244746;;E.J.GOMEZ-AGUILERA ET AL: ""DIACRONO: A NEW PORTABLE MICROCOMPUTER SYSTEM FOR DIABETES MANAGEMENT"", PROCEEDINGS OF THE NINTH ANNUAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, IEEE PRESS NEW YORK US, vol. 3/4, 13 November 1987 (1987-11-13), BOSTON US, pages 1231 - 1232, XP000040726;;C.D.SAUDEK: ""DATA SOURCE AUTOMATION: NEW TECHNOLOGY FOR THE MANAGEMENT OF PATIENT-GENERATED TEST RESULTS"", DIABETIC MEDICINE, JOURNAL OF THE BRITISH DIABETIC ASSOCIATION, vol. 6, no. 5, July 1989 (1989-07-01), JOHN WILEY & SON, UK, pages 394 - 399",PENDING
413,AU,B2,AU 693944 B2,156-386-037-379-635,1998-07-09,1998,AU 1995/037203 A,1995-09-21,US 31027194 A;;US 9512002 W,1994-09-21,Allelic variation of the serotonin 5ht<sub>2c</sub> receptor,,US HEALTH,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/156-386-037-379-635,Granted Patent,no,1,0,8,8,0,C07K14/70571;;C07K14/70571,G01N33/53;;C07K14/705;;C07K16/28;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,0,0,,,,EXPIRED
414,AU,A1,AU 2018/260937 A1,160-938-372-048-179,2018-12-06,2018,AU 2018/260937 A,2018-11-09,AU 2018/260937 A;;AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Abstract: Compositions comprising compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate (MMF), such as dimethyl fumarate (DMF), and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/160-938-372-048-179,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
415,WO,A2,WO 2009/027925 A2,167-785-545-627-188,2009-03-05,2009,IB 2008053407 W,2008-08-25,US 96695307 P,2007-08-31,COMPOSITIONS AND VISUAL PERCEPTION CHANGING METHODS,"A composition includes at least one visual indicator dye and a surfactant. Upon dilution of the composition with a volume of water a diluted product is formed, and wherein: i) the extinction coefficient of the composition is less than the extinction coefficient of the diluted product measured at a wavelength from about 400 nm to about 700 nm; ii) a ratio of an absorbance measured between about 550-650 nm and an absorbance measured between about 395-440 nm increases upon increasing dilution of the composition; and/or iii) the pKa of the composition is greater than the pKa of the diluted product. Additionally, methods for changing the visual perception of a composition comprise diluting a composition.",PROCTER & GAMBLE;;GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,,https://lens.org/167-785-545-627-188,Patent Application,yes,0,1,6,6,0,C11D3/40;;C11D17/0039;;C11D3/40;;C11D17/0039,,,0,0,,,,PENDING
416,US,A1,US 2014/0364988 A1,167-099-595-835-524,2014-12-11,2014,US 201414466521 A,2014-08-22,US 201414466521 A;;US 201313961633 A;;US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a set of thread colors needed for a set of embroidery designs including a first embroidery design and a second embroidery design, annotating the second embroidery design, the annotating comprising appending a reference to the second embroidery design in a first queue of designs to be embroidered by a first embroidery machine, and rolling back the annotation of the second embroidery design. The rolling back comprises removing the annotation, removing the reference, and removing a thread color from the set of thread colors, the thread color resulting from the second embroidery design.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/167-099-595-835-524,Patent Application,yes,13,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/08;;D05C5/02,700/138;;112/470.04,0,0,,,,ACTIVE
417,AU,B2,AU 2009/205456 B2,164-970-119-436-843,2014-07-17,2014,AU 2009/205456 A,2009-01-14,US 2094108 P;;US 2009/0031017 W,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,VISTAPRINT SCHWEIZ GMBH (2013-12-12);;VISTAPRINT TECHNOLOGIES LIMITED (2010-08-26),https://lens.org/164-970-119-436-843,Granted Patent,no,3,0,24,24,0,D05B19/12;;D05C5/02;;D05B19/08;;D05B19/12;;D05C5/02;;D05B19/08,D05C5/02,,0,0,,,,INACTIVE
418,US,A1,US 2023/0018961 A1,173-827-215-804-786,2023-01-19,2023,US 202217950082 A,2022-09-21,US 202217950082 A;;US 202016816703 A;;US 201962835938 P,2019-04-18,SYSTEMS AND METHODS OF CREATING CERTAIN WATER CONDITIONS IN SWIMMING POOLS OR SPAS,"“Just in time” operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,ZODIAC POOL SYSTEMS LLC (2019-07-22),https://lens.org/173-827-215-804-786,Patent Application,yes,0,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,G05D23/19;;E04H4/12;;G05B13/04,,0,0,,,,ACTIVE
419,AU,A1,AU 2013/203445 A1,190-736-042-323-804,2013-08-22,2013,AU 2013/203445 A,2013-02-06,US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/190-736-042-323-804,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
420,NI,A,NI 201400086 A,005-450-160-712-550,2015-01-08,2015,NI 201400086 A,2014-08-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN FUMARATO DE DIMETILO,"Se proporcionan en la presente composiciones que contienen compuestos, o sales farmacéuticamente aceptables, que se metabolizan en fumarato de monometilo con ciertos parámetros farmacocinéticos y métodos para tratar, profilaxis, o mejora de enfermedades neurodegenerativas que incluyen esclerosis múltiple utilizando tales composiciones en un sujeto, en donde si las composiciones contienen fumarato de dimetilo, la cantidad total de fumarato de dimetilo en las composiciones oscila de alrededor de 43% p/p a alrededor de 95% p/p.",BIOGEN IDEC INC,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,,https://lens.org/005-450-160-712-550,Granted Patent,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,ACTIVE
421,US,B2,US 8588954 B2,033-556-811-211-428,2013-11-19,2013,US 96935910 A,2010-12-15,US 96935910 A;;US 76786707 A;;US 84808006 P,2006-09-30,Method and system for creating and manipulating embroidery designs over a wide area network,"Methods and apparatus to manipulate embroidery designs via a communication network are disclosed. The method includes receiving at a server, via the communication network, a request from a client computer, the request including first data associated with the embroidery design, processing at least some of the first data at the server to generate at least one of image data or embroidery data, and transmitting, via the communication network, a response to the client computer, the response to be received by a user interface for manipulating embroidery design information at the client computer and including at least one of the image data or the embroidery data.",GOLDMAN DAVID A;;PATEL NIRAV B;;VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2007-06-25);;SOFT SIGHT INC (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/033-556-811-211-428,Granted Patent,yes,26,5,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02,700/138,4,0,,,"International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with counterpart international application serial No. PCT/US2008/054550, issued Jan. 5, 2010 (7 pages).;;International Search Report and Written Opinion for corresponding international patent application No. PCT/ US08/54550, mailed May 21, 2008 (8 pages).;;United States Patent and Trademark Office, Office Action issued in connection with U.S. Appl. No. 11/767,867, notified Jul. 9, 2010 (13 pages).;;United States Patent and Trademark Office, ""Notice of Allowance"" issued in connection with U.S. Appl. No. 11/767,867, mailed Dec. 1, 2010 (4 pages).",ACTIVE
422,US,A1,US 2011/0318122 A1,066-775-273-011-53X,2011-12-29,2011,US 82298910 A,2010-06-24,US 82298910 A,2010-06-24,DRILL PRESSES HAVING LASER ALIGNMENT SYSTEMS AND METHODS THEREFOR,"A laser alignment system for a drill press includes first and second adjustable laser assemblies mountable on the drill press. Each adjustable laser assembly includes a base firmly affixed to the drill press, a rotatable element mounted on the base and being adapted to selectively rotate relative to the base, a pivotable element mounted on the rotatable element and being adapted to selectively pivot relative to the rotatable element, and a laser mounted on the pivotable element and being adapted to move simultaneously with the pivotable element. The laser alignment system includes a pivot adjusting mechanism coupled with the pivotable element for selectively pivoting the pivotable element relative to the rotatable element, and a rotation adjusting mechanism coupled with the rotatable element for selectively rotating the rotatable element relative to the base.",MONTPLAISIR SARAH JANE;;GOLDMAN DAVID ANDREW;;BLACK & DECKER INC,MONTPLAISIR SARAH JANE;;GOLDMAN DAVID ANDREW,BLACK & DECKER INC (2010-07-22);;CHANG TYPE INDUSTRIAL COMPANY LTD (2011-09-29),https://lens.org/066-775-273-011-53X,Patent Application,yes,8,13,2,2,0,B23Q17/2423;;B25H1/0092;;Y10T408/21;;B23Q17/2423;;B25H1/0092,B23B49/00;;G01B11/27,408/16;;356/400,0,0,,,,ACTIVE
423,EP,A2,EP 1153130 A2,067-990-770-171-436,2001-11-14,2001,EP 00913524 A,2000-02-18,US 0004189 W;;US 12081299 P,1999-02-19,POLYMORPHIC HUMAN GABA A RECEPTOR ALPHA-6 SUBUNIT,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/067-990-770-171-436,Patent Application,yes,0,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,EXPIRED
424,AU,A1,AU 2009/205456 A1,097-154-073-648-600,2009-07-23,2009,AU 2009/205456 A,2009-01-14,US 2094108 P;;US 2009/0031017 W,2008-01-14,"Systems, methods and apparatus for embroidery thread color management",,SOFT SIGHT INC;;DAVID GOLDMAN;;NIRAV PATEL,PATEL NIRAV B;;GOLDMAN DAVID A,VISTAPRINT SCHWEIZ GMBH (2013-12-12);;VISTAPRINT TECHNOLOGIES LIMITED (2010-08-26),https://lens.org/097-154-073-648-600,Patent Application,no,0,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,,0,0,,,,INACTIVE
425,CA,A1,CA 2349766 A1,114-996-128-593-981,2001-12-07,2001,CA 2349766 A,2001-06-06,US 58952800 A,2000-06-07,AIN TRIGGERS TO INVOKE NON-AIN FEATURES,"An addition to AIN that allows SSP triggers to jump to internal SSP addresses for feature processing without a return. The invention takes advantage of the existing AIN trigger mechanism and definitions, and adds the capability of a jump to an internal SSP ad- dress for continued call processing. There is no query sent to an SCP nor the associated response message, call processing is not suspended, and there is no need for fault handling associated with the trigger.",AG COMMUNICATION SYSTEMS CORP,ZWICK DAVID J;;GOLDMAN STUART O,,https://lens.org/114-996-128-593-981,Patent Application,no,0,0,3,3,0,H04Q3/0037;;H04Q3/0037,H04Q3/00,,0,0,,,,EXPIRED
426,WO,A3,WO 1996/009386 A3,106-915-671-724-069,1996-03-28,1996,US US9512002,1995-09-21,"US 8/310,271",1994-09-21,ALLELIC VARIATION OF THE SEROTONIN 5HT2C RECEPTOR,"Isolated DNA encoding the serotonin 5HT2C receptor with serine at amino acid position 23, antibody specific to such a variant receptor and the variant receptor protein itself are used in methods for detecting the presence of an allelic variant of the serotonin 5HT2C gene or receptor.","THE GOVERNMENT OF THE UNITED STATES OF AMERICA, re","LAPPALAINEN, Jaakko;;LINNOILA, Markku;;GOLDMAN, David",,https://lens.org/106-915-671-724-069,Search Report,yes,0,0,1,1,0,,C07K14/705,,0,0,,,,UNKNOWN
427,AT,T1,AT E310820 T1,120-375-462-086-120,2005-12-15,2005,AT 00913524 T,2000-02-18,US 12081299 P;;US 0004189 W,1999-02-19,POLYMORPHISMUS IM GEN FÜR DIE MENSCHLICHE GABA A REZEPTOR ALPHA 6 UNTEREINHEIT,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/120-375-462-086-120,Granted Patent,no,0,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,0,0,,,,EXPIRED
428,CL,A1,CL 2014002077 A1,124-385-958-345-418,2014-12-05,2014,CL 2014002077 A,2014-08-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,"Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.",,BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/124-385-958-345-418,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P43/00,,0,0,,,,PENDING
429,DE,A1,DE 1928195 A1,124-514-577-071-036,1970-08-20,1970,DE 1928195 A,1969-06-03,US 73408268 A,1968-06-03,Einrichtung zur visuellen Darstellung von durch Telegraphiesignale repraesentierten Zeichen,,COLUMBIA BROADCASTING SYST INC,A GOLDMAN DAVID;;N OPENHEIMER HENRY,,https://lens.org/124-514-577-071-036,Patent Application,no,0,0,2,2,0,G09G5/222;;H04L13/188,G09G5/22;;H04L13/18,,0,0,,,,PENDING
430,CN,A,CN 114146081 A,137-269-149-579-576,2022-03-08,2022,CN 202111173089 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;CN 201380018792 A,2012-02-07,Pharmaceutical composition containing dimethyl fumarate,"Provided herein are compositions containing compounds or pharmaceutically acceptable salts that metabolize to monomethyl fumarate having certain pharmacokinetic parameters and methods of using the compositions in subjects to treat, prevent, or ameliorate neurodegenerative diseases, including multiple sclerosis, the total amount of dimethyl fumarate in the composition ranges from about 43% w/w to about 95% w/w.",BIAOGONLEMA COMPANY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/137-269-149-579-576,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K47/02;;A61K47/04;;A61K47/12;;A61K47/38;;A61P25/28;;A61P29/00;;A61P37/02,,0,0,,,,PENDING
431,US,A1,US 2014/0343846 A1,145-756-569-749-461,2014-11-20,2014,US 201414454511 A,2014-08-07,US 201414454511 A;;US 201113335124 A;;US 201361863234 P,2011-12-22,"SYSTEMS, METHODS, AND APPARATUS FOR PROVIDING INDOOR NAVIGATION USING OPTICAL FLOOR SENSORS","An apparatus includes (i) an absolute position sensor coupled to a case, the position sensor including a light sensor, and circuitry configured to determine an identifier within a barcode, the individual bars of the barcode being sensed by the light sensor, and (ii) a motion sensor coupled to the case, the motion sensor including a first magnetic field sensor, a code wheel having two or more magnets positioned to rotate in unison with a wheel of the moveable object, and encoder circuitry configured to determine an amount of rotation of the wheel of the moveable object based on an output of the first magnetic field sensor.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2015-02-11),https://lens.org/145-756-569-749-461,Patent Application,yes,8,76,2,11,0,G01C21/12;;G01C21/206;;Y10S901/46;;Y10S901/47;;G01C21/1656;;G01C21/1654;;G01C21/206;;G05D1/0272;;G01C22/00;;G05D1/0231;;G01C21/20;;Y10S901/46;;G05D1/0234;;Y10S901/47;;G05D1/0242;;G05D1/0244;;G01C21/12;;G01C21/1654;;G01C21/1656,G01C21/20,701/525,1,0,,,"Opticon, Bar Code Configuration and Command Manual, ver. 12, December 2009, U1-U30,",INACTIVE
432,AU,A,AU 1995/037203 A,000-733-933-889-250,1996-04-09,1996,AU 1995/037203 A,1995-09-21,US 31027194 A;;US 9512002 W,1994-09-21,Allelic variation of the serotonin 5htÕ2c? receptor,,US GOV HEALTH & HUMAN SERV,LAPPALAINEN JAAKKO;;LINNOILA MARKKU;;GOLDMAN DAVID,,https://lens.org/000-733-933-889-250,Patent Application,no,0,0,8,8,0,C07K14/70571;;C07K14/70571,G01N33/53;;C07K14/705;;C07K16/28;;C12N5/10;;C12N15/09;;C12N15/12;;C12P21/02;;C12P21/08;;C12Q1/68;;C12R1/91;;G01N33/577,,0,0,,,,EXPIRED
433,EP,B1,EP 1153130 B1,005-400-319-765-06X,2005-11-23,2005,EP 00913524 A,2000-02-18,US 0004189 W;;US 12081299 P,1999-02-19,POLYMORPHIC HUMAN GABA A RECEPTOR ALPHA-6 SUBUNIT,"Compositions and methods based on a polymorphism in the gene encoding the alpha 6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the alpha 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/005-400-319-765-06X,Granted Patent,yes,2,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,4,0,,,"HADINGHAM K ET AL: ""Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors"" MOL PHARMACOL., vol. 49, no. 2, February 1996 (1996-02), pages 253-259, XP000929988 cited in the application;;IWATA N ET AL: ""Relationship between a GABAA alpha 6 Pro385Ser substitution and benzodiazepine sensitivity"" AM J PSYCHIATRY, vol. 156, no. 9, September 1999 (1999-09), pages 1447-1449, XP000929991;;RADEL M ET AL: ""Detection of sequence variants in GABAA receptor subunit genes by DHPLC analysis"" ALCOHOLISM CLINICAL AND EXPERIMENTAL RESEARCH , vol. 22, no. 3 Abstr. Suppl., May 1998 (1998-05), page 98A XP000929992;;KORPI E ET AL: ""Benzodiazepine-induced motor impairment linked to point mutation in cerebellar GABAA receptor"" NATURE., vol. 361, no. 6410, 28 January 1993 (1993-01-28), pages 356-359, XP002145018 cited in the application",EXPIRED
434,JP,A,JP 2017222705 A,038-115-900-998-152,2017-12-21,2017,JP 2017149548 A,2017-08-02,US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITION COMPRISING DIMETHYL FUMARATE,"PROBLEM TO BE SOLVED: To provide a method for treating, preventing or ameliorating neurodegenerative diseases including multiple sclerosis.SOLUTION: There is provided a composition comprising dimethyl fumarate and one or more excipients, wherein the total amount of dimethyl fumarate in the composition is approximately 43 to approximately 95%w/w, preferably approximately 50 to approximately 80%w/w, particularly preferably approximately 65%w/w. There is provided a composition in which one or more excipients are one or more extenders, one or more disintegrators, one or more glidants, one or more lubricants and a combination thereof. There is provided a pharmaceutical composition in a microtablet form which is coated with one or more of a methacrylic acid-methyl acrylate copolymer, a methacrylic acid-ethyl acrylate copolymer, a methacrylic acid-methacrylate copolymer, ethylcellulose, hydroxypropylcellulose and a methyl acrylate-methyl methacrylate-methacrylic acid copolymer.SELECTED DRAWING: None",BIOGEN MA INC,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,,https://lens.org/038-115-900-998-152,Patent Application,no,11,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20;;A61K9/32;;A61K31/616;;A61K31/695;;A61K45/00;;A61K47/02;;A61K47/04;;A61K47/12;;A61K47/32;;A61K47/38;;A61P17/00;;A61P25/00;;A61P43/00,,2,0,,,"改訂 医薬品添加物ハンドブック, vol. 第５版, JPN6016042727, 2007, pages 276 - 309, ISSN: 0003887202;;INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 416, JPN6017024496, 17 June 2011 (2011-06-17), pages 120 - 128, ISSN: 0003887203",ACTIVE
435,SG,A,SG 11201404705Y A,052-921-710-234-657,2014-10-30,2014,SG 11201404705Y A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,,BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/052-921-710-234-657,Unknown,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,,,0,0,,,,PENDING
436,US,A,US 5464235 A,050-985-018-113-98X,1995-11-07,1995,US 2270293 A,1993-03-01,US 2270293 A,1993-03-01,Brake lock for in-line roller skate braking system,The braking system for an in-line roller skate is operated by a cable attached to a trigger type of lever in a hand grip. This braking system is improved by incorporating an arrangement for allowing the skater to quickly attach or detach the end of the brake cable at the skate. Locking of the brakes to permit walking without rolling is obtained by incorporating a latch mechanism in the gripper handle. The gripper handle is storable by a snap-on type retainer for the belt or pocket of the user which permits the brake cable to move without unintentionally releasing the retainer from the person of the skater while avoiding kinking and twisting of the cable in response to the normal skating motions of the skater. Retention of the cable relative to the thigh of the user is realized by a belt or other attachment arrangement including a Velcro type of clip.,GOLDMAN; DAVID A.;;DALTON; ROBERT J.,GOLDMAN DAVID A;;DALTON ROBERT J,ABB ALSTOM POWER INC (2000-05-06),https://lens.org/050-985-018-113-98X,Granted Patent,yes,14,44,1,1,0,A63C17/1409;;A63C17/1409;;A63C2017/1472;;A63C2017/1472;;Y10T74/20438;;Y10T74/20438,A63C17/14,280/11.2;;X188  2D;;74/502.2,0,0,,,,EXPIRED
437,US,A1,US 2013/0295169 A1,059-514-549-277-509,2013-11-07,2013,US 201313827228 A,2013-03-14,US 201313827228 A;;US 201313760916 A;;US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,Pharmaceutical Compositions Containing Dimethyl Fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,BIOGEN MA INC (2013-03-28),https://lens.org/059-514-549-277-509,Patent Application,yes,3,43,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20;;A61K9/48;;A61K31/616,424/451;;514/547;;424/465;;424/489;;514/163,1,1,021-649-435-414-199,10.1016/j.ejpb.2007.01.014;;17329086,"Davies, Peter N., et al. ""The determination of the mechanical strength of tablets of different shapes."" European journal of pharmaceutics and biopharmaceutics 67.1 (2007): 268-276.",DISCONTINUED
438,EP,B1,EP 2297391 B1,062-267-332-474-846,2016-06-29,2016,EP 09703028 A,2009-01-14,US 2009/0031017 W;;US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT",,CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,VISTAPRINT SCHWEIZ GMBH (2013-12-25);;VISTAPRINT TECHNOLOGIES LIMITED (2011-10-05);;CIMPRESS SCHWEIZ GMBH (2015-11-18),https://lens.org/062-267-332-474-846,Granted Patent,yes,8,0,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05B19/08,,0,0,,,,ACTIVE
439,US,A,US 5542420 A,082-879-606-876-862,1996-08-06,1996,US 23701294 A,1994-04-29,IL 10556393 A,1993-04-30,"Personalized method and system for storage, communication, analysis, and processing of health-related data","The present invention relates to a health care system for specifying edibles to individual subjects. The personalized method and system for storage, communication, analysis and processing of health-related data comprises a storage containing data relating to health and edibles and is adapted to receive data on the conditions and characteristics of the individual subjects. The health care system further comprises input terminals adapted to be coupled to the storage means for providing data on the conditions and characteristics of the individual subjects, and a health computer for correlating the data relating to health and edibles with the data on the condition and characteristics of an individual subject to provide a personalized prescription of edibles.",GOLDMAN; ARNOLD J.;;GREENBERG; DAVID L.,GOLDMAN ARNOLD J;;GREENBERG DAVID L,HEVER FOR LIFE FOR HEALTH FOR SPIRIT LTD (1994-06-20);;FOR LIFE FOR HEALTH FOR SPIRIT LTD (1994-06-20),https://lens.org/082-879-606-876-862,Granted Patent,yes,9,305,5,5,0,G16H80/00;;G16H10/60;;G16H40/67;;G16H20/13;;G16H80/00;;G16H10/60;;G16H20/13;;G16H40/67,G06F19/00,128/630;;364/413.29,3,1,033-130-067-438-991,10.1111/j.1464-5491.1989.tb01192.x;;2527674,"Gomez E., et al., The Use of the Diacrono as an Aid in Ambulatory Decision Making of Diabetic Patients, Proceedings of the Twelfth Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Nov. 1 4, 1990, vol. 12, No. 3 (Part 3/5), pp. 1226 1227 (XP 000244746).;;Gomez Aquilera, E.J., et al., Diacrono: A New Portable Microcomputer System for Diabetes Management, Proceedings of the Ninth Annual Conference of the IEEE Engineering in Medicine and Biology Society, Nov. 13 16, 1987, vol. 3 of 4, pp. 1231 1232 (XP 000040726).;;Saudek, C.D., Data Source Automation: New Technology for the Management of Patient Generated Test Results , Diabetic Medicine, Journal of the British Diabetic Association, Jul. 1989, vol. 6, No. 5, pp. 394 399.",EXPIRED
440,JP,A,JP 2019059732 A,090-329-800-586-176,2019-04-18,2019,JP 2018204599 A,2018-10-31,US 201261723048 P;;US 201261625621 P;;US 201261596202 P,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"To provide methods for treating, preventing or ameliorating neurodegenerative diseases including multiple sclerosis.SOLUTION: Disclosed herein is a composition comprising dimethyl fumarate and one or more excipients, where the total amount of dimethyl fumarate in the composition ranges about 43-95% w/w, preferably about 50-80% w/w, specifically preferably about 65% w/w. In an embodiment, the one or more excipient is selected from one or more fillers, one or more disintegrants, one or more glidants, one or more lubricants and combinations thereof. The pharmaceutical composition may be in a form of microtablets coated with one or more of methacrylic acid-methyl acrylate copolymer, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl acrylate copolymer, ethyl cellulose, hydroxyl propyl cellulose, and methyl acrylate-methyl methacrylate-methacrylic acid copolymer.SELECTED DRAWING: None",BIOGEN MA INC,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,,https://lens.org/090-329-800-586-176,Patent Application,no,7,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/22;;A61K9/16;;A61K9/32;;A61K9/36;;A61K9/48;;A61K31/616;;A61K31/695;;A61K47/04;;A61K47/12;;A61K47/32;;A61K47/38;;A61P25/00;;A61P43/00,,1,0,,,"改訂 医薬品添加物ハンドブック, vol. 第５版, JPN6016042727, 2007, pages 276 - 309, ISSN: 0004504777",PENDING
441,US,A1,US 2001/0038138 A1,109-102-465-125-605,2001-11-08,2001,US 90975701 A,2001-07-23,US 90975701 A;;GB 9819248 A;;US 37910799 A,1998-09-03,High voltage shield,"
    An integrated circuit has a guard ring for shielding a first area 14  (eg. high voltage area) from a second area 15  (eg. low voltage). The guard ring comprises a conductive guard ring 6 , (eg. metal), which is partially exposed through a passivation layer 13  in the integrated circuit 1 . A semiconductor guard ring 8 , (eg. silicon), is isolated from the first and second areas of semiconductor by at least two trench rings 16 , one located on each side of the semiconductor guard ring 8 . A plurality of conductive elements (comprising a metal connection plate 18  and via 19 ) connect the conductive guard ring 6  and the semiconductor guard ring 8  at spaced apart intervals. The conductive guard ring 6 , semiconductor guard ring 8  and conductive elements are all connected to a ground source. If high energy particles move from the first area towards the second area, they are attracted to the exposed metal, and their charge is conducted to ground. 
",ERICSSON TELEFON AB L M,MILES DAVID J;;GOLDMAN RICHARD J,INFINEON TECHNOLOGIES AG (2004-07-01),https://lens.org/109-102-465-125-605,Patent Application,yes,0,8,20,20,0,H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002;;H01L21/76;;H01L23/552;;H01L23/585;;H01L2924/3011;;H01L2924/0002,H01L21/3205;;H01L23/52;;H01L21/822;;H01L23/552;;H01L23/58;;H01L27/04,257/544,0,0,,,,EXPIRED
442,WO,A3,WO 2000/049151 A3,101-394-152-705-306,2000-12-07,2000,US 0004189 W,2000-02-18,US 12081299 P,1999-02-19,POLYMORPHIC HUMAN GABAA RECEPTOR alpha -6 SUBUNIT,"Compositions and methods based on a polymorphism in the gene encoding the α6 subunit of the human GABAA neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the α6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs.",US GOV HEALTH & HUMAN SERV;;GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,GOLDMAN DAVID;;IWATA NAKAO;;SHUCKIT MARK,,https://lens.org/101-394-152-705-306,Search Report,yes,2,0,9,11,0,C07K14/70571,C07K14/705;;C12N15/12,,4,3,060-552-071-696-052;;128-530-640-017-194;;028-351-149-591-744,8632757;;10.1176/ajp.156.9.1447;;10484961;;7678923;;10.1038/361356a0,"HADINGHAM K ET AL: ""Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors"", MOL PHARMACOL., vol. 49, no. 2, February 1996 (1996-02-01), pages 253 - 259, XP000929988;;IWATA N ET AL: ""Relationship between a GABAA alpha 6 Pro385Ser substitution and benzodiazepine sensitivity"", AM J PSYCHIATRY, vol. 156, no. 9, September 1999 (1999-09-01), pages 1447 - 1449, XP000929991;;RADEL M ET AL: ""Detection of sequence variants in GABAA receptor subunit genes by DHPLC analysis"", ALCOHOLISM CLINICAL AND EXPERIMENTAL RESEARCH, vol. 22, no. 3 Abstr. Suppl., May 1998 (1998-05-01), pages 98A, XP000929992;;KORPI E ET AL: ""Benzodiazepine-induced motor impairment linked to point mutation in cerebellar GABAA receptor"", NATURE., vol. 361, no. 6410, 28 January 1993 (1993-01-28), pages 356 - 359, XP002145018",PATENTED
443,SU,A1,SU 744686 A1,144-858-919-460-379,1980-06-30,1980,SU 2594837 A,1978-03-27,SU 2594837 A,1978-03-27,AUTOMATIC DISPENSER,,K PT I BYTOVOGO OBSLUZHIVANIYA,GOLDMAN SHMIL O;;LEJBELMAN DAVID L,,https://lens.org/144-858-919-460-379,Limited Patent,no,0,0,1,1,0,,G07F5/26,,0,0,,,,EXPIRED
444,PH,A1,PH 12014501750 A1,005-958-205-922-621,2014-11-10,2014,PH 12014501750 A,2014-08-04,US 201261596202 P;;US 201261723048 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43 pcnt w/w to about 95 pcnt w/w.",BIOGEN IDEC INC,DAVID GOLDMAN;;KATHERINE DAWSON;;AJAY NIRULA,,https://lens.org/005-958-205-922-621,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,PENDING
445,SU,A1,SU 1078265 A1,021-548-010-133-305,1984-03-07,1984,SU 3463995 A,1982-07-05,SU 3463995 A,1982-07-05,METHOD OF REGISTERING PRESSURE AND DATA DECODING,,SP KT B GERMETICHESKIKH SKVAZH,VERBITSKIJ DAVID I;;GOLDMAN ISAAK M,,https://lens.org/021-548-010-133-305,Limited Patent,no,0,0,1,1,0,,G01L19/10,,0,0,,,,EXPIRED
446,AU,A1,AU 2020/257838 A1,027-773-495-557-710,2021-10-14,2021,AU 2020/257838 A,2020-03-12,US 201962835938 P;;US 2020/0022287 W,2019-04-18,Method of creating a desired temperature in swimming pools or spas,"""Just in time"" operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,,https://lens.org/027-773-495-557-710,Patent Application,no,0,0,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,E04H4/12,,0,0,,,,PENDING
447,US,B2,US 9702707 B2,082-446-907-081-840,2017-07-11,2017,US 201414454511 A,2014-08-07,US 201414454511 A;;US 201113335124 A;;US 201361863234 P,2011-12-22,"Systems, methods, and apparatus for providing indoor navigation using optical floor sensors","An apparatus includes (i) an absolute position sensor coupled to a case, the position sensor including a light sensor, and circuitry configured to determine an identifier within a barcode, the individual bars of the barcode being sensed by the light sensor, and (ii) a motion sensor coupled to the case, the motion sensor including a first magnetic field sensor, a code wheel having two or more magnets positioned to rotate in unison with a wheel of the moveable object, and encoder circuitry configured to determine an amount of rotation of the wheel of the moveable object based on an output of the first magnetic field sensor.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,APPLABZ LLC (2015-02-11),https://lens.org/082-446-907-081-840,Granted Patent,yes,68,9,2,11,0,G01C21/12;;G01C21/206;;Y10S901/46;;Y10S901/47;;G01C21/1656;;G01C21/1654;;G01C21/206;;G05D1/0272;;G01C22/00;;G05D1/0231;;G01C21/20;;Y10S901/46;;G05D1/0234;;Y10S901/47;;G05D1/0242;;G05D1/0244;;G01C21/12;;G01C21/1654;;G01C21/1656,G01C21/12;;G01C21/16;;G01C21/20;;G01C22/00;;G05D1/02,,13,2,079-067-912-209-783;;131-257-871-619-401,10.1002/(sici)1097-4563(199704)14:4<231::aid-rob2>3.3.co;2-1;;10.1145/1410012.1410020,"Opticon, Bar Code Configuration and Command Manual, ver. 12, Dec. 2009, U1-U30.;;Borenstein et al.; Mobile Robot Positioning-Sensors and Techniques; 1997; Journal of Robotic Systems, Special Issue on Mobile Robots; vol. 14, No. 4, pp. 231-244.;;International Search Report and Written Opinion issued Feb. 20, 2013 for corresponding International Appln. No. PCT/US2012/070148.;;Nguyen, “Nokia Indoor Navigation: Next Level of Location-Based Apps”, published Apr. 20, 2011 (2 pages).;;Fischer et al., “Ultrasound-aided pedestrian dead reckoning for indoor navigation”, Proc. of the first ACM International workshop on Mobile entity location and tracking in GPS-less environments, published in 2008 (1 page).;;“Locate and Engage the In-Store Shopper”, pages from www.zulutimecorp.com (1 page)—accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Empson, “Zulu Time Issued Patent for Location Aware Wireless Networks”, published Apr. 11, 2011 (4 pages).;;“Zulu-Time LiveFind is a software solution leveraging in-store Wi-Fi for smartphone geolocation”, pages from www.zulutimecorp.com/livefind (2 pages)—accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;“News” from www.polestar.eu/en (1 page)—accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;Sayerse et al., “NAO Campus on ANDROID: The First Indoor Location Solution that the Market Expected”, published Jul. 29, 2010 (2 pages).;;“Shop, Scan, Save, Share, Splurge. Pay”, pages from www.modivmedia.com/index.html (2 pages)—accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;“Introducing . . . Scan It Mobile”, pages from www.stopandshop.com/our—stores/tools/scan—it—mobile.htm (1 page)—accessed from the Internet on Dec. 29, 2011, available before Dec. 22, 2011.;;International Preliminary Report on Patentability issued Dec. 12, 2013 for Intl. Appln. PCT/US212/70148.",INACTIVE
448,CA,A1,CA 2998111 A1,087-211-318-208-976,2017-03-16,2017,CA 2998111 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,,https://lens.org/087-211-318-208-976,Patent Application,no,0,0,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/34,,0,0,,,,ACTIVE
449,AU,A1,AU 2020/244395 A1,090-043-685-665-472,2020-10-29,2020,AU 2020/244395 A,2020-09-28,AU 2020/244395 A;;AU 2018/260937 A;;AU 2017/200394 A;;AU 2013/203445 A;;US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic 5 parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/090-043-685-665-472,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
450,US,A1,US 2014/0074278 A1,111-355-456-828-605,2014-03-13,2014,US 201314083238 A,2013-11-18,US 201314083238 A;;US 96935910 A;;US 76786707 A;;US 84808006 P,2006-09-30,METHODS AND APPARATUS TO MANIPULATE EMBROIDERY DESIGNS VIA A COMMUNICATION NETWORK,"Methods and apparatus to manipulate embroidery designs via a communication network are disclosed. An example apparatus includes An apparatus for manipulating an embroidery design via a communication network, comprising a client computer to: receive a communication from a server, the communication including embroidery data; display, via a user interface of the client computer, a first image based on the embroidery data; edit the embroidery data stored in a memory of the client computer to create modified embroidery data in response to receiving a command via the user interface of the client computer; and display, via the user interface of the client computer, a second image based on the modified embroidery data in the memory of the client computer.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC (2007-06-25);;SOFT SIGHT INC (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/111-355-456-828-605,Patent Application,yes,2,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02;;G06T11/60,700/138,0,0,,,,ACTIVE
451,US,A1,US 2006/0265032 A1,143-107-530-937-999,2006-11-23,2006,US 13157705 A,2005-05-18,US 13157705 A,2005-05-18,Treatment of cellulite with mid-infrared radiation,A method and apparatus that will alter the fibrous strands in the fatty layers of the skin to reduce the appearance of cellulite. Electromagnetic energy is used to selectively shrink or alternatively loosen the collagen in the constricting bands of connective tissue that causes the dimpled appearance of cellulite while avoiding damage to the surrounding fatty cells.,HENNINGS DAVID R;;GOLDMAN MITCHEL P,HENNINGS DAVID R;;GOLDMAN MITCHEL P,NEW STAR LASERS INC (2005-04-28),https://lens.org/143-107-530-937-999,Patent Application,yes,25,65,2,21,0,A61B18/203;;A61B2017/00084;;A61B2018/00005;;A61B2018/00452;;A61B18/203;;A61B2018/00005;;A61B2018/00452;;A61B2017/00084,A61N5/06,607/89,0,0,,,,INACTIVE
452,US,A1,US 2018/0245922 A1,144-259-393-416-191,2018-08-30,2018,US 201615758039 A,2016-09-11,IL 24140315 A;;IL 2016051008 W,2015-09-09,OPEN TERRAIN NAVIGATION SYSTEMS AND METHODS,"Navigation systems and methods are provided. A classifier is configured to transform a received image of a terrain into a classified image in which patches of pixels from the received image are represented as being in one of a specified number of material classes, each associated with respective terrain parameters. A physical traversability module is configured to determine, for the material parameters, a terrain topography and given vehicle parameters, a degree of traversability of the vehicle through the terrain as represented by the received image, to yield a traversability map. A routing module is configured to derive traversability measure(s) for route(s) through the classified image and with respect to the traversability map, between a given origin and a given destination or within a region with respect to a user-defined mission. A graphical user interface is configured to display the route(s) according to the traversability measure(s).",ELBIT SYSTEMS LAND & C4I LTD,ZAPHIR DAVID;;ARIAV IDO;;GOLDMAN BENNY,ELBIT SYSTEMS LAND AND C4I LTD (2018-08-01),https://lens.org/144-259-393-416-191,Patent Application,yes,0,10,10,10,0,G01C21/005;;G01C21/3461;;G01C21/367;;G01C21/20;;G01C21/367;;G01C21/3461;;G01C21/005;;G06F18/24;;G01C21/04;;G01C21/20;;G06T17/05;;G06T2207/30181,G01C21/04;;G01C21/20,,0,0,,,,ACTIVE
453,US,A1,US 2020/0333813 A1,155-902-965-210-658,2020-10-22,2020,US 202016816703 A,2020-03-12,US 202016816703 A;;US 201962835938 P,2019-04-18,SYSTEMS AND METHODS OF CREATING CERTAIN WATER CONDITIONS IN SWIMMING POOLS OR SPAS,"“Just in time” operational techniques allow equipment of swimming pools or spas to achieve identified water temperatures at specified times. A user may supply information such as a desired water temperature (i.e. a temperature set point) and a time at which the water is desired to be at the desired temperature. After receiving the user-supplied information, software may account as well for certain environmental conditions to devise a suitable schedule for controlling heating of the water of the swimming pool or spa. Adjustments may be made to the schedule based on then-current water temperatures or other changed conditions.",ZODIAC POOL SYSTEMS LLC,GOLDMAN DAVID;;HANSON TRACY;;HOLMQUIST JEFF,ZODIAC POOL SYSTEMS LLC (2019-07-22),https://lens.org/155-902-965-210-658,Patent Application,yes,2,3,8,8,0,E04H4/129;;E04H4/129;;G05B13/048;;G05D23/1917;;G05D23/1951,G05D23/19;;E04H4/12;;G05B13/04,,0,0,,,,ACTIVE
454,PE,A1,PE 20150092 A1,167-201-006-869-127,2015-02-06,2015,PE 2014001232 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,COMPOSICIONES FARMACEUTICAS QUE CONTIENEN FUMARATO DE DIMETILO,"SE REFIERE A UNA COMPOSICION QUE COMPRENDE FUMARATO DE DIMETILO Y MAS EXCIPIENTES, CARACTERIZADA PORQUE LA CANTIDAD TOTAL DE FUMARATO DE DIMETILO EN LA COMPOSICION OSCILA DE 43% P/P A 95% P/P, DICHA COMPOSICION SE ENCUENTRA EN FORMA DE UN COMPRIMIDO. UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/167-201-006-869-127,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,DISCONTINUED
455,AU,A4,AU 2015/100298 A4,131-861-124-102-506,2015-04-09,2015,AU 2015/100298 A,2015-03-10,US 2013/0054261 W,2013-08-09,Remotely controlling aspects of pools and spas,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or 5 utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various 10 information. 6> 4 / *1 1%J S a. 'C AN ii t 4 U 6z r~N ft ______I",ZODIAC POOL SYSTEMS INC,MC QUEEN E KEITH;;NIBLER DAVID;;GOLDMAN DAVID,,https://lens.org/131-861-124-102-506,Limited Patent,no,0,19,1,1,0,,H04W4/00;;H04W4/20,,0,0,,,,INACTIVE
456,US,B2,US 8831766 B2,009-869-857-146-77X,2014-09-09,2014,US 201313961633 A,2013-08-07,US 201313961633 A;;US 201213446739 A;;US 35392809 A;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",GOLDMAN DAVID A;;PATEL NIRAV B;;VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2009-04-01);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/009-869-857-146-77X,Granted Patent,yes,20,2,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,700/138;;112/470.01;;112/278,8,0,,,"International Searching Authority, ""International Search Report,"" issued in connection with counterpart international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 2 pages;;International Searching Authority, ""Written Opinion of the International Searching Authority,"" issued in connection with international application No. PCT/US2009/031017, mailed Apr. 7, 2009, 6 pages.;;International Bureau, ""International Preliminary Report on Patentability,"" issued in connection with international application serial No. PCT/US2009/031017, issued Jul. 20, 2010, 8 pages.;;United States Patent and Trademark Office, ""Notice of Allowance and Fee(s) Due"", issued in connection with U.S. Appl. No. 13/446,739, mailed Apr. 18, 2013, 6 pages.;;United States Patent and Trademark Office, ""Non-Final Office Action"", issued in connection with U.S. Appl. No. 13/446,739, mailed Dec. 28, 2012, 6 pages.;;United States Patent and Trademark Office, ""Notice of Allowance and Fee(s) Due"", issued in connection with U.S. Appl. No. 12/353,928, mailed Dec. 16, 2011, 5 pages.;;United States Patent and Trademark Office, ""Non-Final Office Action"", issued in connection with U.S. Appl. No. 12/353,928, mailed May 27, 2011, 17 pages.;;European Patent Office, ""Extended European Search Report,"" issued in connection with Application No. 09703028.2, May 28, 2014, 4 pages.",ACTIVE
457,MX,A,MX 2010002308 A,003-556-069-310-836,2010-03-18,2010,MX 2010002308 A,2008-08-25,US 96695307 P;;IB 2008053407 W,2007-08-31,COMPOSITIONS AND VISUAL PERCEPTION CHANGING METHODS.,"A composition includes at least one visual indicator dye and a surfactant. Upon dilution of the composition with a volume of water a diluted product is formed, and wherein: i) the extinction coefficient of the composition is less than the extinction coefficient of the diluted product measured at a wavelength from about 400 nm to about 700 nm; ii) a ratio of an absorbance measured between about 550-650 nm and an absorbance measured between about 395-440 nm increases upon increasing dilution of the composition; and/or iii) the pKa of the composition is greater than the pKa of the diluted product. Additionally, methods for changing the visual perception of a composition comprise diluting a composition.",PROCTER & GAMBLE,GOLDMAN STEPHEN ALLEN;;CARTER JOHN DAVID,,https://lens.org/003-556-069-310-836,Patent Application,no,0,0,6,6,0,C11D3/40;;C11D17/0039;;C11D3/40;;C11D17/0039,C11D3/40,,0,0,,,,PENDING
458,AU,B2,AU 2008/269041 B2,073-642-404-089-308,2014-04-24,2014,AU 2008/269041 A,2008-02-21,US 76786707 A;;US 2008/0054550 W,2007-06-25,Method and system for creating and manipulating embroidery designs over a wide area network,"[0038] A method and system are disclosed for creating and manipulating embioideiy designs ovei a wide area network. The method includes steps to transmit various embroidery design data ovei a wide area network between a client and a server. The manner in which the embroidery design data is created, manipulated, and transmitted allows a user to preview photo realistic rendeiings of possible finished products, and more precisely adjust interpretations through a provided usei interface with minimum latency.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV B,VISTAPRINT SCHWEIZ GMBH (2013-12-12),https://lens.org/073-642-404-089-308,Granted Patent,no,4,0,11,11,0,G06T11/60;;G06T2200/16;;G06T11/60;;G06T2200/16;;D05C5/02,D05C5/02,,0,0,,,,INACTIVE
459,CN,A,CN 114146080 A,093-275-255-488-121,2022-03-08,2022,CN 202111172018 A,2013-02-06,US 201261596202 P;;US 201261625621 P;;US 201261723048 P;;CN 201380018792 A,2012-02-07,Pharmaceutical composition containing dimethyl fumarate,"Provided herein are compositions containing compounds or pharmaceutically acceptable salts that metabolize to monomethyl fumarate having certain pharmacokinetic parameters and methods of using the compositions in subjects to treat, prevent, or ameliorate neurodegenerative diseases, including multiple sclerosis, the total amount of dimethyl fumarate in the composition ranges from about 43% w/w to about 95% w/w.",BIAOGONLEMA COMPANY,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/093-275-255-488-121,Patent Application,no,2,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61K9/20;;A61K47/02;;A61K47/04;;A61K47/12;;A61K47/38;;A61P25/28;;A61P29/00;;A61P37/02,,4,1,044-493-744-726-635,10.1080/03639040601050197;;17654026,"崔福德主编: ""《药剂学（第2版》"", 31 December 2011, 中国医药科技出版社;;梅兴国主编: ""《微载体药物递送系统》"", 31 December 2009, 华中科技大学出版社;;姚静编: ""《药用辅料应用指南》"", 31 August 2011, 中国医药科技出版社;;JITKA MUZIKOVA ET AL: ""A Study of the Properties of Compacts from Silicified Microcrystalline Celluloses"", 《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》",DISCONTINUED
460,CN,A,CN 101952500 A,103-410-101-445-09X,2011-01-19,2011,CN 200980104648 A,2009-01-14,US 2009/0031017 W;;US 2094108 P,2008-01-14,"Systems, methods and apparatus for embroidery thread color management","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",SOFT SIGHT INC,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/103-410-101-445-09X,Patent Application,no,8,1,24,24,0,D05B19/08;;D05B19/08;;D05B19/12;;D05B19/12;;D05C5/02;;D05C5/02,D05C5/02,,0,0,,,,INACTIVE
461,AU,C1,AU 2013/203445 C1,102-335-099-955-600,2017-04-20,2017,AU 2013/203445 A,2013-02-06,US 201261723048 P;;US 201261596202 P;;US 201261625621 P;;US 2013/0024946 W,2012-02-07,Pharmaceutical compositions containing dimethyl fumarate,"Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.",BIOGEN MA INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJAY,,https://lens.org/102-335-099-955-600,Amended Patent,no,7,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225;;A61P25/00,,0,0,,,,ACTIVE
462,WO,A1,WO 2009/091838 A1,112-821-547-198-030,2009-07-23,2009,US 2009/0031017 W,2009-01-14,US 2094108 P,2008-01-14,"SYSTEMS, METHODS AND APPARATUS FOR EMBROIDERY THREAD COLOR MANAGEMENT","Systems, methods, and apparatus for embroidery thread color management are disclosed. An example method comprises determining a first set of thread colors to be used in an embroidery design, determining a second set of thread colors assigned to a first embroidery machine, determining a third set of thread colors assigned to a second embroidery machine, determining a first difference of the number of thread colors in the first set of thread colors that are not in the second set of thread colors, determining a second difference of the number of thread colors in the first set of thread colors that are not in the third set of thread colors, and assigning the embroidery design to a queue for the first embroidery machine when the first difference is smaller than the second difference.",SOFT SIGHT INC;;GOLDMAN DAVID A;;PATEL NIRAV B,GOLDMAN DAVID A;;PATEL NIRAV B,,https://lens.org/112-821-547-198-030,Patent Application,yes,4,3,24,24,0,D05B19/12;;D05C5/02;;D05B19/08;;D05B19/12;;D05C5/02;;D05B19/08,D05C5/02,,0,0,,,,PENDING
463,US,B1,US 6321229 B1,106-732-308-615-421,2001-11-20,2001,US 25857699 A,1999-02-26,US 25857699 A,1999-02-26,Method and apparatus for using an information model to organize an information repository into a hierarchy of information,"The invention described herein is an apparatus for accessing an information repository, including computer readable program code stored on computer readable media, where the computer readable program code includes code for organizing information stored in the information repository into a hierarchy. The hierarchy is a hierarchy of a number of derived containers that are generated in conformance with an information model which is a hierarchy of container definition nodes. Each of the derived containers corresponds to a different one of the container definition nodes, represents a category of information in the information repository, and has contents which can be other derived containers and/or information extracted from the information repository.",HEWLETT PACKARD CO,GOLDMAN JASON DAVID;;O'KEEFE BRIAN JOHN,HEWLETT-PACKARD COMPANY (1999-04-01);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-01-31);;HEWLETT PACKARD ENTERPRISE COMPANY (2015-10-02),https://lens.org/106-732-308-615-421,Granted Patent,yes,3,360,1,1,0,G06F16/9027;;G06F16/9027;;Y10S707/99931,G06F17/30,707/100;;707/103;;707/1,0,0,,,,EXPIRED
464,SU,A1,SU 1101590 A1,156-856-664-006-540,1984-07-07,1984,SU 3574863 A,1983-02-17,SU 3574863 A,1983-02-17,CENTRIFUGAL PUMP IMPELLER,,SP KT B GERMETICHNYKH SKVAZHIN,GOLDMAN ISAAK M;;VERBITSKIJ DAVID I,,https://lens.org/156-856-664-006-540,Limited Patent,no,0,0,1,1,0,,F04D29/24,,0,0,,,,EXPIRED
465,WO,A1,WO 2013/096222 A1,168-527-850-496-924,2013-06-27,2013,US 2012/0070148 W,2012-12-17,US 201113335124 A,2011-12-22,"SYSTEMS, METHODS, AND APPARATUS FOR PROVIDING INDOOR NAVIGATION","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,,https://lens.org/168-527-850-496-924,Patent Application,no,7,3,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/00;;G01C21/12,,0,0,,,,PENDING
466,GB,A,GB 2512519 A,190-818-005-408-04X,2014-10-01,2014,GB 201410855 A,2012-12-17,US 201113335124 A;;US 2012/0070148 W,2011-12-22,"Systems, methods, and apparatus for providing indoor navigation","An indoor navigational system determines a location of a moveable object in an indoor area and displays this location to a user. The system includes one or more dead-reckoning sensors, one or more absolute position sensors, and a processor. The processor determines the location of the moveable object based on signals received from the sensors. The system also includes a display device to display the location of the moveable object in a graphical representation of the indoor area based on messages from the processor indicating the location of the moveable object.",APPLABZ LLC,GOLDMAN DAVID ALLAN;;PATEL NIRAV BALKRISHNA,,https://lens.org/190-818-005-408-04X,Patent Application,no,7,0,7,11,0,G01C21/206;;G01C21/12;;G01C21/1656;;G01C21/12;;G01C21/206;;G01C21/1656;;G05D1/0231;;G05D1/0242;;G05D1/0272;;G05D1/0259;;G05D1/0276;;G05D1/0268;;G01C21/265;;G01C21/005;;G01C21/28;;G01C21/206;;G01C21/1656;;G01C21/12,G01C21/20;;G01C21/12,,0,0,,,,DISCONTINUED
467,US,B2,US 7582679 B2,194-895-331-030-980,2009-09-01,2009,US 34697506 A,2006-02-03,US 34697506 A,2006-02-03,Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates,"The present invention is directed to a solid ibuprofen concentrate composition and method of producing the composition. The solid ibuprofen concentrate contains (a) a solid ibuprofen free acid and (b) a solid ibuprofen alkali salt, and is characterized in that at least 90% of the weight of the solid ibuprofen concentrate is ibuprofen free acid and ibuprofen alkali salt.",PHARMACEUTICS INTERNAT INC,HASSAN EMADELDIN;;GUMUDAVELLI SRIDHAR;;GOLDMAN DAVID,PHARMACEUTICS INTERNATIONAL INCORPORATED (2006-03-17),https://lens.org/194-895-331-030-980,Granted Patent,yes,14,0,4,4,0,A61K9/1611;;A61K9/1611;;A61K9/1635;;A61K9/1635;;A61K31/192;;A61K31/192,A61K31/19,514/570,6,4,160-969-827-542-440;;034-172-030-275-334;;103-951-545-907-39X;;009-090-452-872-918,1820883;;7955775;;10.2165/00003088-199427020-00004;;10.1080/03639040500215784;;16109624;;10.1016/0378-5173(92)90232-q,"European Patent Office, International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2007/061559 (Feb. 2, 2007).;;Hannula, et al., ""Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules,"" European Journal of Drug Metabolism and Pharmacokinetics, 3: 221-227 (1991).;;Neuvonen et al., ""Enhancement of Drug Adsorption by Antacids: An Unrecognised Drug Interaction,"" Clinical Pharmacokinetics, 27(2): 120-128 (1994).;;Shaw et al., ""The Effect of Selected Water-Soluble Excipients on the Dissolution of Paracetamol and Ibuprofen,"" Drug Development and Industrial Pharmacy, 31 (6): 515-525 (Jul. 2005).;;International Preliminary Report on Patentability in International Application No. PCT/US2007/061559, dated Aug. 5, 2008.;;S. K. Dwivedi et al., Int. J. Pharm. 87:95-104 (1992).",INACTIVE
468,ES,T3,ES 2862452 T3,004-830-516-999-627,2021-10-07,2021,ES 13779945 T,2013-08-09,US 201213600567 A;;US 2013/0054261 W,2012-08-31,Método para controlar piscinas y spas de forma remota,"Un método para controlar los equipos de piscina o spa a través de un dispositivo de red (18) conectado a un controlador (14) diseñado para controlar el funcionamiento de dichos equipos de piscina o spa, dicho método comprende las siguientes etapas: a. transmitir, desde el dispositivo de red (18), una señal que imita un punto de acceso para una primera red Wi-Fi; b. recibir, en un dispositivo receptor (50), la señal transmitida por el dispositivo de red (18); c. conectar el dispositivo receptor (50) para la comunicación inalámbrica con el dispositivo de red (18); d. a continuación, el dispositivo de red (18) identifica para el dispositivo receptor (50) varias señales de red que se reciben, transmitiendo de forma inalámbrica, desde el dispositivo de red (18) al dispositivo receptor (50), un identificador de conjunto de servicios, SSID, de al menos una segunda red Wi-Fi con la que el dispositivo de red (18) se puede comunicar de forma inalámbrica; e. reconfigurar el dispositivo de red (18) por un usuario del dispositivo receptor (50) designando el SSID de la al menos una segunda red Wi-Fi o proporcionando manualmente al dispositivo receptor (50) el SSID de una segunda red Wi-Fi diferente, para la comunicación inalámbrica con el dispositivo de red (18); y f. controlar los equipos de piscina o spa mediante el dispositivo de red (18), a través de la segunda red Wi-Fi designada.",ZODIAC POOL SYSTEMS LLC,MC QUEEN E;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,,https://lens.org/004-830-516-999-627,Granted Patent,no,0,0,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20;;H04W48/20,,0,0,,,,ACTIVE
469,US,A9,US 2017/0364100 A9,096-922-606-508-559,2017-12-21,2017,US 201514728678 A,2015-06-02,US 201514728678 A;;US 201213600567 A;;US 201514711443 A;;US 201213346752 A;;US 201462011913 P;;US 201161433636 P,2011-01-18,CONTROLLING ASPECTS OF POOLS AND SPAS,"Described are systems and methods for controlling pool and spa equipment. A device may communicate wirelessly with pool and spa controls directly (point-to-point) as well as indirectly, either via the Internet or as part of a local area network (LAN). The device may be a smart phone, tablet, or other appropriate apparatus.",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,ZODIAC POOL SYSTEMS LLC (2015-06-03),https://lens.org/096-922-606-508-559,Amended Application,yes,2,3,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,G05D7/06;;C02F103/42;;G05B15/02;;H04L12/28;;H04L29/08;;H04W4/00;;H04W8/24,,0,0,,,,DISCONTINUED
470,US,B1,US 11746999 B1,157-082-472-598-780,2023-09-05,2023,US 202217740340 A,2022-05-09,US 202217740340 A,2022-05-09,Headlamp with battery unit and booster unit,"Various embodiments herein provide a headlamp with a light unit, a battery unit, and a booster unit. The booster unit includes an engagement mechanism (e.g., a bar, such as a U-shaped bar) that mechanically couples the booster unit to the battery unit to provide additional power. The engagement mechanism may further form a clip to couple the booster unit to another item when the booster unit is not coupled to the battery unit. The booster unit may include one or more lights, one or more controls for the one or more lights, and/or an outgoing power port to provide power to another device (other than the battery unit and light unit). Other embodiments may be described and claimed.",COAST CUTLERY CO,ERNST TODD;;SHEEHY BRIAN;;GOLDMAN DAVID;;LEWIN DAVID D,COAST CUTLERY CO (2022-05-05),https://lens.org/157-082-472-598-780,Granted Patent,yes,3,0,2,2,0,F21Y2115/10;;F21L4/08;;F21L4/02;;F21V21/084;;F21V23/0421;;F21V23/0428;;F21V17/105;;F21V17/104;;F21V21/084;;F21V23/06;;F21V17/105;;F21S9/02,F21V21/084;;F21S9/02;;F21V17/10;;F21V23/06,,0,0,,,,ACTIVE
471,US,A1,US 2019/0268738 A1,153-519-472-550-73X,2019-08-29,2019,US 201916410544 A,2019-05-13,US 201916410544 A;;US 201815876560 A;;US 201213600567 A,2012-08-31,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS LLC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS INC (2012-11-07),https://lens.org/153-519-472-550-73X,Patent Application,yes,0,0,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20,,0,0,,,,ACTIVE
472,US,A1,US 2014/0064139 A1,158-714-206-058-369,2014-03-06,2014,US 201213600567 A,2012-08-31,US 201213600567 A,2012-08-31,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS INC (2012-11-07),https://lens.org/158-714-206-058-369,Patent Application,yes,5,42,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W84/12;;H04W4/20,370/254,0,0,,,,DISCONTINUED
473,US,B2,US 11096024 B2,102-034-101-898-977,2021-08-17,2021,US 202016732474 A,2020-01-02,US 202016732474 A;;US 201916410544 A;;US 201815876560 A;;US 201213600567 A,2012-08-31,Remotely controlling aspects of pools and spas,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS LLC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2012-11-07),https://lens.org/102-034-101-898-977,Granted Patent,yes,31,4,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20;;H04W84/12,,40,1,099-203-585-967-796,10.1109/auswireless.2007.27,"Aqua Connect(tm) Home Network, Hayward, Available Online at: https://www.hayward-Qool.com/ pdf/manuals/AguaConnectOperationsManual.pdf, 2011, 16 pages.;;U.S. Appl. No. 13/346,752, Advisory Action dated Mar. 13, 2015, 3 pages.;;U.S. Appl. No. 13/346,752, Final Office Action dated Jan. 21, 2014, 11 pages.;;U.S. Appl. No. 13/346,752, Final Office Action dated Nov. 13, 2014, 11 pages.;;U.S. Appl. No. 13/346,752, Non-Final Office Action dated Jul. 9, 2014, 10 pages.;;U.S. Appl. No. 13/346,752, Non-Final Office Action dated Jun. 27, 2013, 9 pages.;;U.S. Appl. No. 13/600,567, Advisory Action dated Feb. 23, 2015, 3 pages.;;U.S. Appl. No. 13/600,567, Final Office Action dated Dec. 9, 2015, 21 pages.;;U.S. Appl. No. 13/600,567, Final Office Action dated Feb. 2, 2015, 23 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Mar. 25, 2015, 12 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Sep. 5, 2014, 16 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Mar. 28, 2014, 17 pages.;;U.S. Appl. No. 14/711,443, Non-Final Office Action dated Nov. 2, 2017, 7 pages.;;U.S. Appl. No. 14/711,443, Notice of Allowance dated May 18, 2018, 8 Pages.;;U.S. Appl. No. 14/728,678, Advisory Action mailed on Jul. 5, 2018, 3 pages.;;U.S. Appl. No. 14/728,678, Final Office Action dated Mar. 12, 2018, 11 pages.;;U.S. Appl. No. 14/728,678, Non-Final Office Action dated Sep. 11, 2017, 16 pages.;;U.S. Appl. No. 15/712,589, Final Office Action dated Nov. 20, 2018, 11 pages.;;U.S. Appl. No. 15/712,589, Non-Final Office Action dated Jun. 14, 2018, 12 pages.;;U.S. Appl. No. 15/712,589, Notice of Allowance dated Feb. 7, 2019, 8 pages.;;U.S. Appl. No. 15/876,560, Corrected Notice of Allowability dated May 15, 2019, 9 pages.;;U.S. Appl. No. 15/876,560, Notice of Allowance dated Mar. 19, 2019, 13 pages.;;U.S. Appl. No. 16/410,544, Corrected Notice of Allowability dated Oct. 30, 2019, 9 pages.;;U.S. Appl. No. 16/410,544, Notice of Allowance dated Oct. 18, 2019, 18 pages.;;Australian Application No. AU2015275057, First Examination Report dated Sep. 25, 2018, 3 pages.;;Australian Application No. AU2015275057, Notice of Acceptance dated May 28, 2019, 3 pages.;;Australian Application No. AU2015275057, Second Examination Report dated Sep. 25, 2018, 3 pages.;;Australian Application No. AU2015275057, Fourth Examination Report dated Feb. 6, 2019, 4 pages.;;Australian Application No. AU2015275057, Third Examination Report dated Dec. 13, 2018, 3 pages.;;Dhawan, Analogy of Promising Wireless Technologies on Different Frequencies: Bluetooth, Wi Fi, and WiMAX, The 2nd International Conference on Wireless, Wireless Broadband and Ultra Wideband Communications, 2007, 9 pages.;;European Application No. EP12700763.1, Office Action dated Nov. 6, 2018, 10 pages.;;European Application No. EP13779945.8, Office Action dated Apr. 17, 2018, 4 pages.;;European Application No. EP13779945.8, Office Action dated Oct. 23, 2019, 4 pages.;;International Application No. PCT/US2012/020694, International Preliminary Report on Patentability dated Aug. 1, 2013, 7 pages.;;International Application No. PCT/US2012/020694, International Search Report and Written Opinion dated Jun. 27, 2012, 9 pages.;;International Application No. PCT/US2013/054261, International Preliminary Report on Patentability dated Mar. 3, 2015, 7 pages.;;International Application No. PCT/US2013/054261, International Search Report and Written Opinion dated Mar. 27, 2014, 10 pages.;;International Application No. PCT/US2015/033793, International Preliminary Report on Patentability dated Dec. 22, 2016, 11 pages.;;International Application No. PCT/US2015/033793, International Search Report and Written Opinion dated Sep. 28, 2015, 13 pages.;;European Application No. EP13779945.8, Notice of Decision to Grant, dated Jan. 11, 2021, 2 pages.",ACTIVE
474,EP,A1,EP 0637341 A1,095-882-925-142-726,1995-02-08,1995,EP 93909614 A,1993-04-22,US 9303811 W;;US 87391392 A,1992-04-24,A PREDICTIVE ASSAY FOR SUICIDAL BEHAVIOR.,,US HEALTH,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,,https://lens.org/095-882-925-142-726,Patent Application,yes,0,1,7,7,0,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C12N15/09;;C07H21/04;;C12N9/02;;C12P19/34;;C12Q1/68,,0,0,,,,DISCONTINUED
475,AU,A,AU 1993/040337 A,037-100-286-171-359,1993-11-29,1993,AU 1993/040337 A,1993-04-22,US 87391392 A;;US 9303811 W,1992-04-24,A predictive assay for suicidal behavior,,UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,,https://lens.org/037-100-286-171-359,Patent Application,no,0,0,7,7,0,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C12N15/09;;C07H21/04;;C12N9/02;;C12P19/34;;C12Q1/68,,0,0,,,,EXPIRED
476,US,A1,US 2018/0206088 A1,007-879-590-181-985,2018-07-19,2018,US 201815876560 A,2018-01-22,US 201815876560 A;;US 201213600567 A,2012-08-31,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS INC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS INC (2012-11-07),https://lens.org/007-879-590-181-985,Patent Application,yes,0,0,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20,,0,0,,,,ACTIVE
477,US,A1,US 2015/0362925 A1,076-057-881-091-517,2015-12-17,2015,US 201514728678 A,2015-06-02,US 201514728678 A;;US 201213600567 A;;US 201514711443 A;;US 201213346752 A;;US 201462011913 P;;US 201161433636 P,2011-01-18,CONTROLLING ASPECTS OF POOLS AND SPAS,"Described are systems and methods for controlling pool and spa equipment. A device may communicate wirelessly with pool and spa controls directly (point-to-point) as well as indirectly, either via the Internet or as part of a local area network (LAN). The device may be a smart phone, tablet, or other appropriate apparatus.",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,,https://lens.org/076-057-881-091-517,Patent Application,yes,0,37,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,G05D7/06;;G05B15/02;;H04W4/00;;H04W8/24,,0,0,,,,DISCONTINUED
478,US,A,US 5589331 A,032-919-432-085-445,1996-12-31,1996,US 12562893 A,1993-09-22,US 12562893 A;;US 87391392 A,1992-04-24,Method for detecting abnormal serotonergic function,"A method of detecting abnormal serotonergic function in an impulsive human subject is disclosed. The method comprises detecting an L allele of a gene encoding tryptophan hydroxylase. The invention also includes an isolated nucleic acid having a sequence specific to an L allele of a gene encoding tryptophan hydroxylase. The nucleic acid may migrate in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele of a gene encoding tryptophan hydroxylase, and migrate in a nondenaturing gel at a rate about 1.02 times the migration rate of the second nucleic acid.",US ARMY,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (1993-11-18),https://lens.org/032-919-432-085-445,Granted Patent,yes,1,7,7,7,8,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C07H21/04;;C12N9/02;;C12P19/34;;C12N15/09;;C12Q1/68,435/6;;536/24.33;;536/23.2;;435/91.2,23,20,010-950-964-836-85X;;006-488-487-104-020;;106-191-665-709-101;;056-544-214-550-84X;;024-539-849-287-38X;;017-723-321-590-248;;001-259-003-435-27X;;012-308-671-684-498;;075-128-953-039-451;;134-959-746-582-967;;105-394-436-122-95X;;024-458-546-723-709;;010-073-612-474-419;;053-274-212-789-690;;119-349-254-731-426;;014-693-284-605-768;;032-154-622-226-825;;004-516-100-691-228;;141-957-404-959-984;;127-568-791-283-577,1463016;;pmc1682899;;10.1093/nar/19.2.405;;pmc333615;;2014179;;10.1001/archpsyc.1976.01770100055005;;971028;;420544;;10.1001/archpsyc.1979.01780020114013;;10.1093/nar/18.14.4257;;pmc331198;;2377472;;10.1159/000133075;;2055111;;3475690;;10.1073/pnas.84.16.5530;;pmc298896;;1645430;;10.1016/0169-328x(91)90073-7;;pmc328372;;1649449;;10.1093/nar/19.13.3507;;1691893;;10.1111/j.1600-0447.1990.tb06449.x;;10.2466/pr0.1989.64.1.258;;2467320;;6198573;;10.1016/0024-3205(83)90344-2;;3019268;;10.1001/archpsyc.1986.01800100048007;;6164071;;10.1016/0165-1781(81)90004-4;;2687159;;10.1016/0888-7543(89)90129-8;;10.1016/s0193-953x(18)30626-9;;3088550;;10.1017/s0140525x00022871;;1714508;;10.1002/jnr.490280402;;10.1001/archpsyc.1981.01780310031002;;6166274;;2435256;;10.1001/archpsyc.1987.01800150053007,"Nielsen et al., Am J. Hum. Genet. 51(6): 1366 1371 (Dec. 1992).;;Ainsworth et al., Diagnostic single strand conformational polymorphism, (SSCP): a simplified non radioisotopic method as applied to a Tay Sachs B1 variant, Nucleic Acids Research, 19(2): 405 406 (1991).;;Arato et al., Serotonin dysregulation in suicide, Royal Society of Medicine Services International Congress and Symposium, Series No. 165, pp. 41 46 (1991).;;Asberg et al., 5 HIAA in the Cerebrospinal Fluid, Arch Gen Psychiatry, 33: 1193 1197 (1976).;;Ballenger et al., Alcohol and Central Serotonin Metabolism in Man, Arch Gen Psychiatry, 36:224 227 (1979).;;Boularand et al., Complete coding sequence of human tryptophan hydroxylase, Nucleic Acids Research, 18 (14): 4257 (1990).;;Craig et al., Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.5 p14 by in situ hybridization, Cytoenetics and Cell Genetics, 56 (3 4):157 159 (1991).;;Grenett et al., Full length cDNA for rabbit tryptophan hydroxylase: Functional domains and evoluation of Aromatic Amino acid hydroxylases, Proc. natl. Acad. Sci. USA, 84:5530 5534 (1987).;;Kim et al., Molecular cloning and characterization of cDNA encoding tryptophan hydroxylase from rat central serotonergic neurons, Molecular Brain Research, 9:277 283 (1991).;;Kovar et al., Two dimensional single strand conformation polymorphism analysis: a useful tool for the detection of mutations in long DNA fragments, Nucleic Acids Research, 19 (13): 3507 3510 (1991).;;Roy et al., Cerebrospinal fluid monoamine metabolites in alcoholic patients who attempt suicide, Acta Psychiatr Scand, 81:58 61 (1989).;;Lester, Biochemical correlates of suicidal behavior in arsonists, Psychological Reports, 64:258 (1989).;;Linnoila et al., Low cerebrospinal fluid 5 hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior, Life Sciences, 33:2609 2614 (1983).;;Lopez Ibor Jr., et al., Serotonin, impulsiveness and aggression in humans, Royal Society of Medicine Services International Congress and Symposium, Series No. 165, pp. 35 40 (1991).;;Mann et al., Increased Serotonin 2 and Adrenergic Receptor Binding in the Frontal Cortices of Suicide Victims, Arch Gen Psychiatry, 43:954 959 (1986).;;Oreland et al., Platelet MAO Activity and Monoamine Metabolites in Cerebrospinal Fluid in Depressed and Suicidal Patients and in Healthy Controls, Psychiatry Research, 4: 21 29 (1981).;;Orita et al., Rapid and Sensitive Detection of Point Mutations and DNA Polymorphisms Using the Polymerase Chain Reaction, Genomics , 5:874 879 (1989).;;Woodcock in Restak, ed. A Neuropsychiatric Approach to Impulse Disorders, Psychiatric Clinics of North America, 9 (2): 341 352 (1986).;;Roy et al., Serotonin in Suicide, Violence, and Alcoholism, Serotonin in Major Psychiatric Disorders, pp. 187 208 (1990) Cocaro et al. ed.;;Soubrie et al., Reconciling the role of central serotonin neurons in human and animal behavior, The Behavioral and Brain Sciences, 9 (2):319 364 (1986).;;Stoll et al., Isolation and Structural Characterization of the Murine Tryptophan Hydroxylase Gene, Journal of Neuroscience Research, 28:457 465 (1991).;;Traskman et al., Monoamine Metabolites in CSF and Suicidal Behavior, Arch Gen Psychiatry, 38:631 636 (1981).;;Virkkunen et al., Cerebrospinal Fluid Monoamine Metabolite Levels in Male Arsonists, Arch Gen Psychiatry, 44:241 247 (1987).",EXPIRED
479,AU,A1,AU 2015/275057 A1,072-646-707-068-178,2017-02-02,2017,AU 2015/275057 A,2015-06-02,US 201462011913 P;;US 2015/0033793 W,2014-06-13,Controlling aspects of pools and spas,"Described are systems and methods for controlling pool and spa equipment. A device may communicate wirelessly with pool and spa controls directly (point-to-point) as well as indirectly, either via the Internet or as part of a local area network (LAN). The device may be a smart phone, tablet, or other appropriate apparatus.",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,,https://lens.org/072-646-707-068-178,Patent Application,no,0,20,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,H04L29/08;;A63B69/12;;E04H4/00;;E04H4/12;;F04D27/00;;G08C17/02;;H04L12/28;;H04W4/00;;H04W84/12;;H04W88/02,,0,0,,,,ACTIVE
480,EP,A1,EP 3155790 A1,103-252-033-523-787,2017-04-19,2017,EP 15731766 A,2015-06-02,US 201462011913 P;;US 2015/0033793 W,2014-06-13,CONTROLLING ASPECTS OF POOLS AND SPAS,,ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,,https://lens.org/103-252-033-523-787,Patent Application,yes,0,8,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,H04L29/08;;A63B69/12;;E04H4/00;;E04H4/12;;F04D27/00;;G08C17/02;;H04L12/28;;H04W4/00;;H04W84/12;;H04W88/02,,0,0,,,,DISCONTINUED
481,US,B2,US 10375543 B2,032-222-605-698-275,2019-08-06,2019,US 201815876560 A,2018-01-22,US 201815876560 A;;US 201213600567 A,2012-08-31,Remotely controlling aspects of pools and spas,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS LLC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS INC (2012-11-07),https://lens.org/032-222-605-698-275,Granted Patent,yes,16,19,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20;;H04W84/12,,3,1,099-203-585-967-796,10.1109/auswireless.2007.27,"Dhawan, “Analogy of Promising Wireless Technologies on Different Frequencies: Bluetooth, Wi Fi, and WiMAX”, Wireless Broadband and Ultra Wideband Communications, The 2nd International Conference on, IEEE, Aug. 1, 2007, 14 pages.;;International Patent Application No. PCT/US2013/054261, “International Search Report and Written Opinion”, dated Mar. 27, 2014, 10 pages.;;European Application No. 13779945.8, Office Action dated Apr. 17, 2018, 4 pages.",ACTIVE
482,WO,A1,WO 2015/191336 A1,140-953-266-317-523,2015-12-17,2015,US 2015/0033793 W,2015-06-02,US 201462011913 P,2014-06-13,CONTROLLING ASPECTS OF POOLS AND SPAS,"Described are systems and methods for controlling pool and spa equipment. A device may communicate wirelessly with pool and spa controls directly (point-to-point) as well as indirectly, either via the Internet or as part of a local area network (LAN). The device may be a smart phone, tablet, or other appropriate apparatus.",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,,https://lens.org/140-953-266-317-523,Patent Application,yes,3,10,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,H04L29/08;;A63B69/12;;E04H4/00;;E04H4/12;;F04D27/00;;G08C17/02;;H04L12/28;;H04W4/00;;H04W84/12;;H04W88/02,,0,0,,,,PENDING
483,CA,A1,CA 2130904 A1,053-915-543-223-023,1993-11-11,1993,CA 2130904 A,1993-04-22,US 87391392 A,1992-04-24,A PREDICTIVE ASSAY FOR SUICIDAL BEHAVIOR,"2130904 9322458 PCTABS00027 A method of predicting abnormal serotonergic function in an impulsive human subject is disclosed. The method comprises detecting an L allele of a gene encoding tryptophan hydroxylase. The invention also includes an isolated nucleic acid having a sequence specific to an L allele of a gene encoding tryptophan hydroxylase. The nucleic acid may migrate in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele of a gene encoding tryptophan hydroxylase, and migrate in a nondenaturing gel at a rate about 1.02 times the migration rate of the second nucleic acid.",US ARMY,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,,https://lens.org/053-915-543-223-023,Patent Application,no,0,0,7,7,0,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C12N15/09;;C07H21/04;;C12N9/02;;C12P19/34;;C12Q1/68,,0,0,,,,DISCONTINUED
484,WO,A1,WO 1993/022458 A1,184-022-352-189-784,1993-11-11,1993,US 9303811 W,1993-04-22,US 87391392 A,1992-04-24,METHOD FOR DETECTING ABNORMAL SEROTONERGIC FUNCTION,"A method of predicting abnormal serotonergic function in an impulsive human subject is disclosed. The method comprises detecting an L allele of a gene encoding tryptophan hydroxylase. The invention also includes an isolated nucleic acid having a sequence specific to an L allele of a gene encoding tryptophan hydroxylase. The nucleic acid may migrate in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele of a gene encoding tryptophan hydroxylase, and migrate in a nondenaturing gel at a rate about 1.02 times the migration rate of the second nucleic acid.",US ARMY,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,,https://lens.org/184-022-352-189-784,Patent Application,yes,0,5,7,7,4,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C07H21/04;;C12N9/02;;C12P19/34;;C12Q1/68;;C12N15/09,,3,3,010-950-964-836-85X;;012-308-671-684-498;;017-723-321-590-248,1463016;;pmc1682899;;1645430;;10.1016/0169-328x(91)90073-7;;10.1159/000133075;;2055111,"THE AMERICAN JOURNAL OF HUMAN GENETICS vol. 51, no. 6, December 1992, CHICAGO, USA pages 1366 - 1371 NIESSEN, D.A. ET AL 'genetic mapping of human tryptophan hydroxylase gene on chromosome 11, using an intronic conformational polymorphism';;MOLECULAR BRAIN RESEARCH vol. 9, 1991, AMSTERDAM. THE NETHERLANDS pages 277 - 283 KIM, K.S. ET AL 'molecular cloning and characterization of cDNA encoding tryptophan hydroxylase from rat central sertonergic neurons';;CYTOGENETICS AND CELL GENETICS vol. 56, no. 3-4, 1991, BASEL, SWITZERLAND pages 157 - 159 CRAIG, S.P. ET AL 'localization of human tryptophan hydroxylase (TPH) to chromosome 11p15-p14 by in situ hybridization' cited in the application",PENDING
485,US,A1,US 2020/0137534 A1,006-769-098-427-011,2020-04-30,2020,US 202016732474 A,2020-01-02,US 202016732474 A;;US 201916410544 A;;US 201815876560 A;;US 201213600567 A,2012-08-31,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS LLC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2012-11-07),https://lens.org/006-769-098-427-011,Patent Application,yes,0,11,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20,,0,0,,,,ACTIVE
486,AU,B2,AU 2015/275057 B2,075-750-488-897-88X,2019-06-06,2019,AU 2015/275057 A,2015-06-02,US 201462011913 P;;US 2015/0033793 W,2014-06-13,Controlling aspects of pools and spas,"Described are systems and methods for controlling pool and spa equipment. A device may communicate wirelessly with pool and spa controls directly (point-to-point) as well as indirectly, either via the Internet or as part of a local area network (LAN). The device may be a smart phone, tablet, or other appropriate apparatus.",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID;;NIBLER DAVID;;MCQUEEN E KEITH,,https://lens.org/075-750-488-897-88X,Granted Patent,no,1,0,6,6,0,H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;H04L67/025;;H04L67/125;;H04W4/00;;C02F2103/42;;C02F2209/008;;G08C2201/93;;H04L12/282;;G05B15/02;;G05D7/0676;;H04W8/24,H04L29/08;;A63B69/12;;E04H4/00;;E04H4/12;;F04D27/00;;G08C17/02;;H04L12/28;;H04W4/00;;H04W84/12;;H04W88/02,,0,0,,,,ACTIVE
487,US,B2,US 10560820 B2,189-536-024-227-77X,2020-02-11,2020,US 201916410544 A,2019-05-13,US 201916410544 A;;US 201815876560 A;;US 201213600567 A,2012-08-31,Remotely controlling aspects of pools and spas,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time-varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS LLC,MCQUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS INC (2012-11-07),https://lens.org/189-536-024-227-77X,Granted Patent,yes,18,15,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20;;H04W84/12,,19,1,099-203-585-967-796,10.1109/auswireless.2007.27,"U.S. Appl. No. 13/600,567, Advisory Action dated Feb. 23, 2015, 3 pages.;;U.S. Appl. No. 13/600,567, Final Office Action dated Dec. 9, 2015, 21 pages.;;U.S. Appl. No. 13/600,567, Final Office Action dated Feb. 2, 2015, 23 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Mar. 28, 2014, 17 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Mar. 25, 2015, 12 pages.;;U.S. Appl. No. 13/600,567, Non-Final Office Action dated Sep. 5, 2014, 16 pages.;;U.S. Appl. No. 14/728,678, Advisory Action dated Jul. 5, 2018, 3 pages.;;U.S. Appl. No. 14/728,678, Final Office Action dated Mar. 12, 2018, 11 pages.;;U.S. Appl. No. 14/728,678, Non-Final Office Action dated Sep. 11, 2017, 16 pages.;;U.S. Appl. No. 15/876,560, Corrected Notice of Allowability dated May 15, 2019, 9 pages.;;U.S. Appl. No. 15/876,560, Notice of Allowance dated Mar. 19, 2019, 13 pages.;;Dhawan, Analogy of Promising Wireless Technologies on Different Frequencies: Bluetooth, Wi Fi, and WiMAX, Wireless Broadband and Ultra Wideband Communications, The 2nd International Conference on Wireless, Aug. 1, 2007, 14 pages.;;European Patent Application No. 13779945.8, Office Action dated Apr. 17, 2018, 4 pages.;;International Application No. PCT/US2013/054261, International Preliminary Report on Patentability dated Mar. 27, 2014, 10 pages.;;International Application No. PCT/US2012/020694, International Preliminary Report on Patentability dated Aug. 1, 2013, 7 pages.;;International Application No. PCT/US2012/020694, International Search Report and Written Opinion dated Jun. 27, 2012, 9 pages.;;International Application No. PCT/US2013/054261, International Search Report and Written Opinion dated Mar. 27, 2014, 10 pages.;;International Application No. PCT/US2015/033793, International Preliminary Report on Patentability dated Dec. 22, 2016, 11 pages.;;International Application No. PCT/US2015/033793, International Search Report and Written Opinion dated Sep. 28, 2015, 13 pages.",ACTIVE
488,AU,B2,AU 682002 B2,110-842-512-476-58X,1997-09-18,1997,AU 1993/040337 A,1993-04-22,US 87391392 A;;US 9303811 W,1992-04-24,A predictive assay for suicidal behavior,,US ARMY,NIELSEN DAVID A;;GOLDMAN DAVID;;LINNOILA MARKKU;;VIRKKUNEN MATTI,,https://lens.org/110-842-512-476-58X,Granted Patent,no,0,0,7,7,0,C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C12Q2600/156,C12N15/09;;C07H21/04;;C12N9/02;;C12P19/34;;C12Q1/68,,0,0,,,,EXPIRED
489,WO,A2,WO 2021/048838 A2,116-512-491-903-875,2021-03-18,2021,IL 2020050973 W,2020-09-07,IL 26922319 A;;US 201962897453 P,2019-09-09,AUTOMATED ANALYSIS OF IMAGE DATA TO DETERMINE FRACTIONAL FLOW RESERVE,"A system and method for analysis of a vessel automatically detects a pathology in a first image of the vessel and attaches a virtual mark to the pathology in the first image. The system may detect the same pathology in a second image of the vessel, based on the virtual mark, and may then provide analysis (e.g., determine an FFR value) of the pathology based on the pathology detected in the first and second images.",MEDHUB LTD,BARUCH EL OR;;GOLDMAN DAVID;;KASSEL ALEXANDRE,,https://lens.org/116-512-491-903-875,Patent Application,yes,0,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,,,0,0,,,,PENDING
490,WO,A3,WO 2021/048838 A3,065-265-202-070-157,2021-05-06,2021,IL 2020050973 W,2020-09-07,IL 26922319 A;;US 201962897453 P,2019-09-09,AUTOMATED ANALYSIS OF IMAGE DATA TO DETERMINE FRACTIONAL FLOW RESERVE,"A system and method for analysis of a vessel automatically detects a pathology in a first image of the vessel and attaches a virtual mark to the pathology in the first image. The system may detect the same pathology in a second image of the vessel, based on the virtual mark, and may then provide analysis (e.g., determine an FFR value) of the pathology based on the pathology detected in the first and second images.",MEDHUB LTD,BARUCH EL OR;;GOLDMAN DAVID;;KASSEL ALEXANDRE,,https://lens.org/065-265-202-070-157,Search Report,yes,4,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,A61B5/02;;A61B5/00;;A61B5/026;;A61B6/03;;G06T7/00;;G16H30/00;;G16H30/20,,0,0,,,,PENDING
491,AU,A,AU 2000/023679 A,141-822-401-079-932,2000-07-03,2000,AU 2000/023679 A,1999-12-16,US 21570798 A;;US 9930119 W,1998-12-18,Chewable drug delivery system,,BAYER AG,NACHED HASSAN;;GOLDMAN DAVID;;AMATRUDA JOHN M,,https://lens.org/141-822-401-079-932,Patent Application,no,0,0,3,3,0,A61K9/006;;A61K9/0007;;A61K9/0056,A61K9/00;;A61K9/46,,0,0,,,,DISCONTINUED
492,US,A1,US 2019/0095567 A1,182-193-645-339-946,2019-03-28,2019,US 201715719413 A,2017-09-28,US 201715719413 A,2017-09-28,INTEGRATED CIRCUIT WITH PEEK AND POKE PROTECTION CIRCUITRY FOR A MULTI-TENANT USAGE MODEL,Methods and apparatus for extracting a setting of configuration bits to create an exclusion configuration for providing protection against peek and poke attacks in a multi-tenant usage model of a configurable device is provided. The device may host multiple parties that do not trust each other. Peek and poke attacks are orchestrated by tapping (peeking) and driving (poking) wires associated with other parties. Such attacks may be disabled by excluding the settings of configuration bits that would allow these attacks by other parties. This set of configuration bits that should be excluded for preventing all peek and poke attacks creates the exclusion configuration. Methods are described that disable a particular class of peek and/or poke attacks through the use of partial reconfiguration. Methods and apparatus are described to dynamically detect peek and/or poke attacks.,INTEL CORP,WEBER SCOTT;;ATSATT SEAN R;;GOLDMAN DAVID,ALTERA CORPORATION (2023-12-19);;INTEL CORPORATION (2017-09-27),https://lens.org/182-193-645-339-946,Patent Application,yes,0,2,3,3,0,G06F30/34;;G06F30/34;;G06F2111/04,G06F17/50,,0,0,,,,ACTIVE
493,WO,A1,WO 2021/117043 A1,151-243-785-968-670,2021-06-17,2021,IL 2020051276 W,2020-12-10,IL 27129419 A;;US 201962945896 P,2019-12-10,AUTOMATIC STENOSIS DETECTION,"Embodiments of the invention provide a fully automated solution to vessel analysis based on image data. A system for analysis of a vessel receives a 2D lengthwise image of a patient's vessels, the image obtained during X-ray angiography and applies a pre-trained classifier on the image to output an indication of a presence of a stenosis in the vessels and an x,y location of the stenosis. The indication of the stenosis is then displayed via a user interface device, on an image of the patient's vessels, at the x,y location of the stenosis.",MEDHUB LTD,BARUCH EL OR;;GOLDMAN DAVID;;LOEVSKY IGAL,,https://lens.org/151-243-785-968-670,Patent Application,yes,3,2,2,3,0,A61B6/504;;A61B8/0891;;A61B6/507;;A61B6/5217;;G06T7/0016;;G06T2207/10116;;G06T2207/20081;;G06T2207/30104;;G06T2207/30172;;G06T2207/10024;;G06T2207/20084;;G16H30/40;;A61B6/12;;A61B6/504;;A61B6/507;;A61B6/5217;;G06T7/0012;;G06T7/20;;G06T2207/10024;;G06T2207/10116;;G06T2207/20081;;G06T2207/30104;;G06T2207/30172,A61B5/02;;A61B5/026;;G06T11/00,,1,1,000-661-589-195-662,10.1109/bibm47256.2019.8983033,"CONG CHAO, LIMA JOAO, VENKATESH BHARATH, RD 3, VASCONCELLOS HENRIQUE DORIA: ""Automated Stenosis Detection and Classification in X-ray Angiography Using Deep Neural Network"", IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM), 18 November 2019 (2019-11-18), pages 1301 - 1308, XP033703872",PENDING
494,US,A1,US 2017/0284002 A1,148-365-849-355-054,2017-10-05,2017,US 201715621769 A,2017-06-13,US 201715621769 A;;US 201514886383 A;;US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,PRINTER DRIVER SYSTEMS AND METHODS FOR AUTOMATIC GENERATION OF EMBROIDERY DESIGNS,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method to convert image data to embroidery data, includes converting image data representing an image to first vector data, converting the first vector data into component data structures that specify regions within the image, converting a first one of the component data structures into a fill shape including second vector data, converting a second one of the component data structures into a stroke shape including third vector data, and generating embroidery data structures using the fill shape and the stroke shape.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2006-08-22);;SOFT SIGHT INC. (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2013-10-08);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/148-365-849-355-054,Patent Application,yes,0,4,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05B19/08;;D05B19/02;;D05B19/12,,0,0,,,,ACTIVE
495,EP,A2,EP 4027873 A2,069-980-490-050-81X,2022-07-20,2022,EP 20863367 A,2020-09-07,IL 26922319 A;;US 201962897453 P;;IL 2020050973 W,2019-09-09,AUTOMATED ANALYSIS OF IMAGE DATA TO DETERMINE FRACTIONAL FLOW RESERVE,,MEDHUB LTD,BRUCH-EL OR;;GOLDMAN DAVID;;KASSEL ALEXANDRE,,https://lens.org/069-980-490-050-81X,Patent Application,yes,0,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,A61B5/00;;A61B5/02;;A61B5/026;;A61B6/03;;G06T7/00;;G16H30/00;;G16H30/20,,0,0,,,,PENDING
496,IL,B,IL 271294 B,095-855-986-798-354,2021-06-30,2021,IL 27129419 A,2019-12-10,IL 27129419 A,2019-12-10,Automatic stenosis detection,,MEDHUB LTD;;OR BARUCH EL;;DAVID GOLDMAN;;IGAL LOEVSKY,OR BARUCH EL;;DAVID GOLDMAN;;IGAL LOEVSKY,,https://lens.org/095-855-986-798-354,Unknown,no,0,0,1,3,0,,,,0,0,,,,ACTIVE
497,WO,A2,WO 2000/035418 A2,138-978-097-418-25X,2000-06-22,2000,US 9930119 W,1999-12-16,US 21570798 A,1998-12-18,CHEWABLE DRUG DELIVERY SYSTEM,The present invention relates to an organoleptic chewable drug delivery system for a pharmaceutically active composition targeting the oral cavity. This chewable drug delivery system is capable of rapidly releasing the active pharmaceutical agent and extending its retention in the oral cavity to improve the therapeutic activity. The drug delivery system comprises a bioadhesive component and an effervescent disintegrating component. The invention also comprises a method for preparing the pharmaceutically active chewable drug delivery system and a method for prolonging the contact of the pharmaceutical composition in the oral cavity.,BAYER AG;;NACHED HASSAN;;GOLDMAN DAVID;;AMATRUDA JOHN M,NACHED HASSAN;;GOLDMAN DAVID;;AMATRUDA JOHN M,,https://lens.org/138-978-097-418-25X,Patent Application,yes,0,21,3,3,0,A61K9/006;;A61K9/0007;;A61K9/0056,A61K9/00;;A61K9/46,,0,0,,,,PENDING
498,IL,B2,IL 269223 B2,116-009-629-837-965,2023-06-01,2023,IL 26922319 A,2019-09-09,IL 26922319 A,2019-09-09,Automated analysis of image data to determine fractional flow reserve,,MEDHUB LTD;;OR BARUCH EL;;DAVID GOLDMAN;;ALEXANDRE KASSEL,OR BARUCH EL;;DAVID GOLDMAN;;ALEXANDRE KASSEL,,https://lens.org/116-009-629-837-965,Unknown,no,1,0,2,9,0,H01Q1/2291;;H01Q1/525;;H04B7/15571;;Y02D30/00;;H01Q19/26;;H04B7/15578;;Y02D30/50;;H02J50/50;;H04W16/26;;H01Q1/245;;H04B1/3838;;Y02D30/70,H01Q19/26;;H02J50/50;;H04W16/26,,0,0,,,,PENDING
499,US,B2,US 8095232 B2,072-730-203-816-680,2012-01-10,2012,US 55600806 A,2006-11-02,US 55600806 A;;US 73283105 P,2005-11-02,Printer driver systems and methods for automatic generation of embroidery designs,"An example printer driver system and method disclosed herein includes determining a set of line segments corresponding to received image information, determining a first polygon from a first subset of the set of line segments, determining a second polygon from a second subset of the set of line segments, determining that a first line segment in the first subset and a second line segment in the second subset are collinear, removing the first line segment from the set of line segments, subtracting the first line segment from the second line segment to form a third line segment, replacing the second line segment in the set of line segments with the third line segment, determining a path corresponding to the set of line segments, determining a set of coordinates corresponding to the path, and instructing an embroidery machine to stitch the path in a substrate using the set of coordinates.",GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI;;VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/072-730-203-816-680,Granted Patent,yes,16,5,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02,700/138;;700/136;;112/475.18;;112/475.19,1,0,,,"Song et al., ""Algorithms for Vector Graphic Optimization and Compression,"" Advances of Computer Graphics, 2006, pp. 665-672, Springer-Verlag, Berlin/Heidelberg.",ACTIVE
500,US,B2,US 6762294 B2,146-713-760-439-425,2004-07-13,2004,US 93058901 A,2001-08-15,US 93058901 A;;US 0004189 W;;US 12081299 P,1999-02-19,Polynucleotides encoding polymorphic human GABAA receptor alpha-6 subunit,"
    Compositions and methods based on a polymorphism in the gene encoding the 6 subunit of the human GABA _{ A } neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs. 
",US HEALTH,GOLDMAN DAVID;;IWATA NAKAO;;SCHUCKIT MARC A,GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (2002-12-11),https://lens.org/146-713-760-439-425,Granted Patent,yes,2,0,2,11,14,C07K14/70571;;C07K14/70571,C07K14/705,536/23.5;;435/6,18,16,057-234-111-317-87X;;040-537-330-786-394;;016-318-439-871-648;;053-113-519-691-084;;000-470-206-645-354;;120-894-864-784-698;;060-552-071-696-052;;128-530-640-017-194;;084-196-452-810-050;;028-351-149-591-744;;077-750-740-364-43X;;039-679-414-845-847;;057-051-145-273-412;;035-546-031-867-77X;;032-313-209-584-827;;125-734-099-576-267,10.1096/fasebj.5.14.1661244;;1661244;;2782481;;10.1176/ajp.146.10.1333;;7259422;;10.1001/archpsyc.1981.01780330019001;;1335221;;10.1111/j.1530-0277.1992.tb00699.x;;8048734;;10.1111/j.1530-0277.1994.tb00021.x;;2700603;;8632757;;10.1176/ajp.156.9.1447;;10484961;;10.1038/sj.mp.4000706;;10889535;;7678923;;10.1038/361356a0;;10.1038/346648a0;;2166916;;10.1176/ajp.149.11.1534;;1415821;;10.1016/s0006-3223(98)00248-0;;10088053;;10.1111/j.1530-0277.1988.tb00228.x;;3056066;;1758188;;10.15288/jsa.1991.52.601;;10.1016/s0165-6147(97)90675-1,"Burt, D. R. and Kamatchi, G. L. (1991) GABAA receptor subtypes: from pharmacology to molecular biology. FASEB J. 5:2916-2923.;;Ciraulo, D. A., et al. (1989) Parental Alcoholism as a Risk Factor in Benzodiazepine Abuse: A Pilot Study. Am. J. Psychiatry 146:1333-1335.;;Cloninger, C. R., et al. (1981) Inheritance of Alcohol Abuse. Arch. Gen. Psychiatry 38:861-868.;;Cowley, D. S., et al. (1992) Response to Diazepam in Sons of Alcoholics. Alcohol. Clin. Exp. Res. 16(6):1057-1063.;;Cowley, D. S., et al. (1994) Eye Movement Effects of Diazepam in Sons of Alcoholic Fathers and Male Control Subjects. Alcohol. Clin. Exp. Res 18(2):324-332.;;Deitrich, R. A., et al. (1989) Mechanism of Action of Ethanol: Initial Central Nervous System Actions. Pharmacol. Rev. 41(4):489-537.;;Hadingham, K. L., et al. (1996) Cloning of cDNAs Encoding the Human gamma-Aminobutyric acid Type A Receptor alpha6 Subunit and Characterization of the Pharmacology of alpha6-Containing receptors. Mol. Pharmacol. 49:253-259.;;Iwata, N., et al. (1999) Relationship Between a GABAA alpha6 Pro385Ser Substitution and Benzodiazepine Sensitivity. Am. J. Psychiatry 156(9):1447-1449.;;Iwata, N., et al. (1999) GABAA alpha6 polymorphisms and relationship to benzodiazepine sensitivity. (Abstract) Biol. Psychiatry Suppl. 45:82S;;Iwata, N., et al. (2000) Identification of a naturally occuring Pro385-Ser385 substitution in the GABAA receptor alpha6 subunit gene in alcoholics and healthy volunteers. Mol. Psychiatry 5:316-319.;;Korpi, E. R., et al. (1993) Benzodiazepine-induced motor impairment linked to point mutation in cerebellar GABAA receptor. Nature 361:356-359.;;Luddens, H., et al. (1990) Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature 346:648-651.;;Pollock, V. E. (1992) Meta-Analysis of Subjective Sensitivity to Alcohol in Sons of Alcoholics. Am. J. Psychiatry 149:1534-1538.;;Radel, M., et al. (1998) Detection of Sequence Variants in GABAA Receptor Subunit Genes by DHPLC Analysis. (Abstract) (Alcohol Clin. Exp. Res. 22(3):98A.;;Schuckit, M. A., et al. (1999) Selective Genotyping for the Role of 5-HT2A, 5-HT2C, and GABAalpha6 Receptors and the Serotonin Transporter in the Level of Response to Alcohol: A Pilot Study, Biol. Psychiatry 45:647-651.;;Schuckit, M. A. (1988) Reactions to Alcohol in Sons of Alcoholics and Controls. Alcohol Clin. Exp. Res. 12(4): 465-470.;;Schuckit, M. A., et al. (1991) Subjective Feelings and Changes in Body Sway Following Diazepam in Sons of Alcoholics and Control Subjects. J. Stud. Alcohol 52(6):601-608.;;Sigel, E. and Buhr, A. (1997) The benzodiazepine binding site of GABAA receptors. TiPS 18:425-429.",EXPIRED
501,US,B2,US 9683322 B2,000-792-155-625-864,2017-06-20,2017,US 201514886383 A,2015-10-19,US 201514886383 A;;US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,Printer driver systems and methods for automatic generation of embroidery designs,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method to convert image data to embroidery data, includes converting image data representing an image to first vector data, converting the first vector data into component data structures that specify regions within the image, converting a first one of the component data structures into a fill shape including second vector data, converting a second one of the component data structures into a stroke shape including third vector data, and generating embroidery data structures using the fill shape and the stroke shape.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,VISTPRINT SCHWEIZ GMBH (2013-10-08);;SOFT SIGHT INC. (A DELWARE CORPORATION) (2008-06-10);;SOFT SIGHT INC (2006-08-22);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/000-792-155-625-864,Granted Patent,yes,30,0,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02;;D05B19/02;;D05B19/08;;D05B19/12,,11,0,,,"Song et al., “Algorithms for Vector Graphic Optimization and Compression,” Advances of Computer Graphics, 2006, pp. 665-672, Springer-Verlag, Berlin/Heidelberg. (8 pages).;;“Definition of: printer driver,” http://www.pcmag.com/encyclopedia/term/49695/printer-driver, retrieved from the internet on Jun. 12, 2015, 2 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 14/174,540, Dec. 2, 2014, 20 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 14/174,540, Jun. 15, 2015, 16 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 11/556,008, Jul. 24, 2009, 16 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 11/556,008, Nov. 3, 2009, 20 pages.;;United States Patent and Trademark Office, “Final Office Action,” issued in connection with U.S. Appl. No. 11/556,008, Jun. 9, 2010, 14 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 11/556,008, Sep. 7, 2011, 13 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 13/346,338, Aug. 1, 2012, 19 pages.;;United States Patent and Trademark Office, “Final Office Action,” issued in connection with U.S. Appl. No. 13/346,338, Apr. 22, 2013, 15 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 13/346,338, Oct. 8, 2013, 18 pages.",ACTIVE
502,GB,A,GB 2481419 A,064-638-662-385-590,2011-12-28,2011,GB 201010517 A,2010-06-22,GB 201010517 A,2010-06-22,A Sandwich container and blank,"The present invention relates to a food product container (101), a blank (100) for a container (101) and a method for manufacturing said container (101) and blank (100). The blank (100) comprising sealing means (116) and at least one panel, wherein the sealing means (116) is provided on said at least one panel and positioned on said panel so as to be coincident with at least one vertex (117) of the container (101) when the blank (100) is assembled. The sealing means may be a heat activated resin, the blank may include a window, and the container may be for a sandwich. Further sealing may be provided to hermetically seal the container and wherein the atmosphere of the container may be modified with nitrogen and carbon dioxide.",COLPAC LTD,GOLDMAN NEIL VERNON HAROLD;;MILLS FRANK DAVID,,https://lens.org/064-638-662-385-590,Patent Application,no,8,3,2,2,0,B65D5/2028;;B65D5/2042;;B65D5/2061;;B65D5/2071;;B65D5/4204;;B65D81/2069;;B65D81/2076;;B65D5/2042;;B65D5/242;;B65D5/243;;B65D5/4204;;B65D85/36;;B65D2585/363,B65D5/20;;B65D5/42;;B65D81/20,,0,0,,,,DISCONTINUED
503,US,A1,US 2022/0327271 A1,096-703-871-272-014,2022-10-13,2022,US 202217850560 A,2022-06-27,US 202217850560 A;;US 201715719413 A,2017-09-28,INTEGRATED CIRCUIT WITH PEEK AND POKE PROTECTION CIRCUITRY FOR MULTI-TENANT USAGE MODEL,Methods and apparatus for extracting a setting of configuration bits to create an exclusion configuration for providing protection against peek and poke attacks in a multi-tenant usage model of a configurable device is provided. The device may host multiple parties that do not trust each other. Peek and poke attacks are orchestrated by tapping (peeking) and driving (poking) wires associated with other parties. Such attacks may be disabled by excluding the settings of configuration bits that would allow these attacks by other parties. This set of configuration bits that should be excluded for preventing all peek and poke attacks creates the exclusion configuration. Methods are described that disable a particular class of peek and/or poke attacks through the use of partial reconfiguration. Methods and apparatus are described to dynamically detect peek and/or poke attacks.,INTEL CORP,WEBER SCOTT;;ATSATT SEAN R;;GOLDMAN DAVID,ALTERA CORPORATION (2023-12-19),https://lens.org/096-703-871-272-014,Patent Application,yes,0,0,3,3,0,G06F30/34;;G06F30/34;;G06F2111/04,G06F30/34,,0,0,,,,PENDING
504,CN,A,CN 114340481 A,138-314-407-775-286,2022-04-12,2022,CN 202080062699 A,2020-09-07,IL 26922319 A;;US 201962897453 P;;IL 2020050973 W,2019-09-09,Automatic analysis of image data for determining traffic reserve scores,"A system and method for analyzing a pipe that automatically detects a condition in a first image of the pipe and appends a virtual marker to the condition in the first image. The system may detect the same condition in a second image of the conduit based on the virtual marker, and then may provide an analysis of the condition (e.g., determine an FFR value) based on the condition detected in the first image and the second image.",MEID HOU CO LTD,BARUCH EL OMAR;;GOLDMAN DAVID;;KASSEL ADOLF,,https://lens.org/138-314-407-775-286,Patent Application,no,0,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,A61B5/02;;A61B5/00;;A61B5/026;;A61B6/03;;G06T7/00;;G16H30/00;;G16H30/20,,0,0,,,,PENDING
505,US,A1,US 2003/0138776 A1,027-953-766-421-654,2003-07-24,2003,US 93058901 A,2001-08-15,US 93058901 A;;US 0004189 W;;US 12081299 P,1999-02-19,Polymorphic human GABAA receptor alpha-6 subunit,"
    Compositions and methods based on a polymorphism in the gene encoding the 6 subunit of the human GABA _{A } neurotransmitter receptor are disclosed. This polymorphism results in the substitution of a serine residue for a proline residue ordinarily present at amino acid position 385 of the 6 polypeptide sequence. Significantly, the polymorphism was associated with decreased sensitivity to ethanol and benzodiazepine drugs. 
",GOLDMAN DAVID;;IWATA NAKAO;;SCHUCKIT MARC A.,GOLDMAN DAVID;;IWATA NAKAO;;SCHUCKIT MARC A,GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (2002-12-11),https://lens.org/027-953-766-421-654,Patent Application,yes,0,5,2,11,13,C07K14/70571;;C07K14/70571,C07K14/705,435/6;;435/69.1;;435/320.1;;435/325;;X53035;;536/23.5,0,0,,,,EXPIRED
506,US,A1,US 2023/0108800 A1,039-287-404-222-600,2023-04-06,2023,US 202217955174 A,2022-09-28,US 202217955174 A;;US 202163249802 P,2021-09-29,INFUSION PUMP WITH MULTIPLE RESERVOIRS,Rotary microfluidic medical pump and pumping method embodiments are discussed herein that may be used for controlled delivery of small and precise volumes of therapeutic or non-therapeutic fluids in a variety of environmental conditions. Certain medical pump and pumping method embodiments discussed herein may also include pump systems having a plurality of reservoirs and which are configured for pumping a plurality of fluids such as medicaments via a common pump mechanism and outlet tubing.,QUASURAS INC,NEESE DAVID;;GOLDMAN MARC;;DIPERNA PAUL M,QUASURAS INC (2022-11-04),https://lens.org/039-287-404-222-600,Patent Application,yes,0,0,2,2,0,A61M5/14248;;A61M5/1452;;A61M2005/14533;;A61M2205/3331;;A61M5/172;;A61M5/16827;;A61M2205/3523;;A61M5/14248;;A61M5/1452;;A61M2205/3327;;A61M2205/8206;;A61M2205/3331;;A61M2005/14533;;A61M2205/128,A61M5/142;;A61M5/145,,0,0,,,,PENDING
507,EP,A4,EP 4027873 A4,052-547-067-599-894,2023-09-20,2023,EP 20863367 A,2020-09-07,IL 26922319 A;;US 201962897453 P;;IL 2020050973 W,2019-09-09,AUTOMATED ANALYSIS OF IMAGE DATA TO DETERMINE FRACTIONAL FLOW RESERVE,,MEDHUB LTD,BRUCH-EL OR;;GOLDMAN DAVID;;KASSEL ALEXANDRE,,https://lens.org/052-547-067-599-894,Search Report,no,2,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,A61B5/02;;A61B5/00;;A61B5/026;;A61B6/03;;G06T7/00;;G16H30/00;;G16H30/20;;G16H30/40;;G16H50/20;;G16H50/30;;G16H50/50,,0,0,,,,PENDING
508,US,B2,US 11379645 B2,163-334-241-864-741,2022-07-05,2022,US 201715719413 A,2017-09-28,US 201715719413 A,2017-09-28,Integrated circuit with peek and poke protection circuitry for a multi-tenant usage model,Methods and apparatus for extracting a setting of configuration bits to create an exclusion configuration for providing protection against peek and poke attacks in a multi-tenant usage model of a configurable device is provided. The device may host multiple parties that do not trust each other. Peek and poke attacks are orchestrated by tapping (peeking) and driving (poking) wires associated with other parties. Such attacks may be disabled by excluding the settings of configuration bits that would allow these attacks by other parties. This set of configuration bits that should be excluded for preventing all peek and poke attacks creates the exclusion configuration. Methods are described that disable a particular class of peek and/or poke attacks through the use of partial reconfiguration. Methods and apparatus are described to dynamically detect peek and/or poke attacks.,INTEL CORP,WEBER SCOTT;;ATSATT SEAN R;;GOLDMAN DAVID,ALTERA CORPORATION (2023-12-19);;INTEL CORPORATION (2017-09-27),https://lens.org/163-334-241-864-741,Granted Patent,yes,9,0,3,3,0,G06F30/34;;G06F30/34;;G06F2111/04,G06F30/34;;G06F111/04,,0,0,,,,ACTIVE
509,WO,A1,WO 2023/055819 A1,015-099-252-705-822,2023-04-06,2023,US 2022/0045065 W,2022-09-28,US 202163249802 P,2021-09-29,INFUSION PUMP WITH MULTIPLE RESERVOIRS,Rotary microfluidic medical pump and pumping method embodiments are discussed herein that may be used for controlled delivery of small and precise volumes of therapeutic or non-therapeutic fluids in a variety of environmental conditions. Certain medical pump and pumping method embodiments discussed herein may also include pump systems having a plurality of reservoirs and which are configured for pumping a plurality of fluids such as medicaments via a common pump mechanism and outlet tubing.,QUASURAS INC,NEESE DAVID;;GOLDMAN MARC;;DIPERNA PAUL M,,https://lens.org/015-099-252-705-822,Patent Application,yes,7,0,2,2,0,A61M5/14248;;A61M5/1452;;A61M2005/14533;;A61M2205/3331;;A61M5/172;;A61M5/16827;;A61M2205/3523;;A61M5/14248;;A61M5/1452;;A61M2205/3327;;A61M2205/8206;;A61M2205/3331;;A61M2005/14533;;A61M2205/128,A61M5/142;;A61M5/172;;G16H20/17,,0,0,,,,PENDING
510,US,A1,US 2007/0118245 A1,045-075-745-666-341,2007-05-24,2007,US 55600806 A,2006-11-02,US 55600806 A;;US 73283105 P,2005-11-02,PRINTER DRIVER SYSTEMS AND METHODS FOR AUTOMATIC GENERATION OF EMBROIDERY DESIGNS,"An example printer driver system and method disclosed herein includes determining a set of line segments corresponding to received image information, determining a first polygon from a first subset of the set of line segments, determining a second polygon from a second subset of the set of line segments, determining that a first line segment in the first subset and a second line segment in the second subset are collinear, removing the first line segment from the set of line segments, subtracting the first line segment from the second line segment to form a third line segment, replacing the second line segment in the set of line segments with the third line segment, determining a path corresponding to the set of line segments, determining a set of coordinates corresponding to the path, and instructing an embroidery machine to stitch the path in a substrate using the set of coordinates.",GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2008-06-11);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/045-075-745-666-341,Patent Application,yes,16,24,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02,700/138,0,0,,,,ACTIVE
511,US,A1,US 2016/0040340 A1,138-000-209-507-625,2016-02-11,2016,US 201514886383 A,2015-10-19,US 201514886383 A;;US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,PRINTER DRIVER SYSTEMS AND METHODS FOR AUTOMATIC GENERATION OF EMBROIDERY DESIGNS,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method to convert image data to embroidery data, includes converting image data representing an image to first vector data, converting the first vector data into component data structures that specify regions within the image, converting a first one of the component data structures into a fill shape including second vector data, converting a second one of the component data structures into a stroke shape including third vector data, and generating embroidery data structures using the fill shape and the stroke shape.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,VISTPRINT SCHWEIZ GMBH (2013-10-08);;SOFT SIGHT INC. (A DELWARE CORPORATION) (2008-06-10);;SOFT SIGHT INC (2006-08-22);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/138-000-209-507-625,Patent Application,yes,3,3,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05B19/08;;D05B19/12,,0,0,,,,ACTIVE
512,US,B2,US 9163343 B2,000-056-892-278-043,2015-10-20,2015,US 201414174540 A,2014-02-06,US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,Printer driver systems and methods for automatic generation of embroidery designs,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method includes receiving a print command associated with print data representative of a design to be embroidered, and generating embroidery data using a printer driver and based on the print data.",VISTAPRINT SCHWEIZ GMBH;;CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2006-08-22);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/000-056-892-278-043,Granted Patent,yes,24,2,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02;;D05B19/02;;D05B19/08;;D05B19/12,,2,0,,,"Printer Driver Definitions.;;Song et al., ""Algorithms for Vector Graphic Optimization and Compression,"" Advances of Computer Graphics, 2006, pp. 665-672, Springer-Verlag, Berlin/Heidelberg. (8 pages).",ACTIVE
513,US,B2,US 8660683 B2,026-822-399-777-977,2014-02-25,2014,US 201213346338 A,2012-01-09,US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,Printer driver systems and methods for automatic generation of embroidery designs,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method includes identifying intersections of line segments from different ones of first polygonal objects, determining relationships between the line segments based on the intersections, removing a redundancy between at least two of the line segments, generating, using a computer, second polygonal objects based on the intersections and the line segments, and outputting, from the computer, embroidery data representative of the second polygonal objects.",GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI;;VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC. A NEW YORK CORPORATION (2006-08-22);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/026-822-399-777-977,Granted Patent,yes,20,4,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02,700/138;;112/470.01,1,0,,,"Song et al., ""Algorithms for Vector Graphic Optimization and Compression,"" Advances of Computer Graphics, 2006, pp. 665-672, Springer-Verlag, Berlin/Heidelberg. (8 pages).",ACTIVE
514,WO,A3,WO 2000/035418 A3,046-455-122-210-381,2000-12-21,2000,US 9930119 W,1999-12-16,US 21570798 A,1998-12-18,CHEWABLE DRUG DELIVERY SYSTEM,The present invention relates to an organoleptic chewable drug delivery system for a pharmaceutically active composition targeting the oral cavity. This chewable drug delivery system is capable of rapidly releasing the active pharmaceutical agent and extending its retention in the oral cavity to improve the therapeutic activity. The drug delivery system comprises a bioadhesive component and an effervescent disintegrating component. The invention also comprises a method for preparing the pharmaceutically active chewable drug delivery system and a method for prolonging the contact of the pharmaceutical composition in the oral cavity.,BAYER AG;;NACHED HASSAN;;GOLDMAN DAVID;;AMATRUDA JOHN M,NACHED HASSAN;;GOLDMAN DAVID;;AMATRUDA JOHN M,,https://lens.org/046-455-122-210-381,Search Report,yes,2,0,3,3,0,A61K9/006;;A61K9/0007;;A61K9/0056,A61K9/00;;A61K9/46,,0,0,,,,PENDING
515,US,B2,US 7273699 B2,138-181-144-698-832,2007-09-25,2007,US 20656102 A,2002-07-25,US 20656102 A;;US 35394102 P,2002-01-31,Methods for detecting nucleic acid sequence variation,"Sequence variations, such as polymorphisms, are detected by detecting differences between or among melting profiles of plural nucleic acids. Melting profiles are produced by observing the nucleic acids during a temperature change over a period of time. If the nucleic acids are diluted into solutions for analysis, the nucleic acid concentrations between or among the solutions can be substantially the same. The melting profiles and sequence variation can be used to identify changes in a wild-type nucleic acid sequence, such as a single-nucleotide polymorphism (SNP), a small insertion or deletion, or a small inversion.",US HEALTH,LIPSKY ROBERT H;;MAZZANTI CHIARA;;GOLDMAN DAVID,GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES THE (2003-08-28),https://lens.org/138-181-144-698-832,Granted Patent,yes,2,1,2,2,29,C12Q1/6827;;C12Q1/6827,C12Q1/68;;C12P19/34,435/6;;435/91.2,9,7,017-172-801-367-573;;017-449-418-614-585;;010-055-385-889-761;;050-667-679-837-367;;085-146-006-152-626;;105-796-711-217-737;;069-908-050-822-402,10.1093/clinchem/46.3.425;;10702535;;10.2144/01302tt05;;11233605;;10.1093/clinchem/46.1.119;;10620581;;11549577;;pmc1850450;;10.1016/s0002-9440(10)61760-9;;10.1093/clinchem/47.4.635;;11274012;;10702534;;10.1093/clinchem/46.3.423;;10.1006/abio.1996.9916;;9056205,"Taparowsk et al. GenBank Accession No. L00041. National Center for Biotechnology Information, NIH, NLM (Bethesda, MD, USA) Jan. 8, 1995.;;McKie et al. GenBank Accession No. AF352795. National Center for Biotechnology Information, NIH, NLM (Bethesda, MD, USA) Apr. 10, 2001.;;Hermann (Clinical Chemistry. 2000. 46: 425-428.;;Akey et al., ""Melting Curve Analysis of SNPs (McSNP(R)): a Gel-Free and Inexpensive Approach for SNP Genotyping,"" BioTechniques 30:358-367 (2001).;;Aoshima et al., ""Rapid Detection of Deletion Mutations in Inherited Metobolic Diseases by Melting Curve Analysis with LightCycler,"" Clin. Chem. 46:119-131 (2000).;;Elenitoba-Johnson et al., ""Solution-Based Scanning for Single-Base Alterations Using a Double-Stranded DNA Binding Dye and Fluorescence-Melting Profiles,"" Am. J. Pathol. 159:845-853 (2001).;;Lipsky et al., ""DNA Melting Analysis for Detection of Single Nucleotide Polymorphisms,"" Clin. Chem. 47:635-644 (2001).;;Marziliano et al., ""Melting Temperature Assay for a UGTIA Gene Variant in Gilbert Syndrome,"" Clin. Chem. 46:423-425 (2000).;;Ririe et al., ""Product Differentiation by Analysis of DNA Melting Curves during the Polymerase Chain Reaction,"" Analy. Biochem. 245:154-160 (1997).",EXPIRED
516,US,A1,US 2012/0109358 A1,028-715-011-863-959,2012-05-03,2012,US 201213346338 A,2012-01-09,US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,PRINTER DRIVER SYSTEMS AND METHODS FOR AUTOMATIC GENERATION OF EMBROIDERY DESIGNS,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method includes identifying intersections of line segments from different ones of first polygonal objects, determining relationships between the line segments based on the intersections, removing a redundancy between at least two of the line segments, generating, using a computer, second polygonal objects based on the intersections and the line segments, and outputting, from the computer, embroidery data representative of the second polygonal objects.",GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC. A NEW YORK CORPORATION (2006-08-22);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/028-715-011-863-959,Patent Application,yes,4,5,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02,700/138,0,0,,,,ACTIVE
517,CO,A2,CO 7141407 A2,156-509-611-672-447,2014-12-12,2014,CO 14196527 A,2014-09-05,US 201261596202 P;;US 201261625621 P;;US 201261723048 P,2012-02-07,Composiciones farmacéuticas que contienen fumarato de dimetilo,"Se proporcionan en la presente composiciones que contienen compuestos,o sales farmacéuticamente aceptables, que se metabolizan en fumarato de monometilocon ciertos parámetros farmacocinéticos y métodos para tratar, profilaxis, o mejora deenfermedades neurodegenerativas que incluyen esclerosis múltiple utilizando talescomposiciones en un sujeto, en donde si las composiciones contienen fumarato dedimetilo, la cantidad total de fumarato de dimetilo en las composiciones oscila dealrededor de 43% p/p a alrededor de 95% p/p",BIOGEN IDEC INC,GOLDMAN DAVID;;DAWSON KATHERINE;;NIRULA AJA Y,,https://lens.org/156-509-611-672-447,Patent Application,no,0,0,66,68,0,A61K31/616;;A61K9/2054;;A61K9/2846;;A61K31/225;;A61K45/06;;A61K9/2072;;A61K9/4808;;A61P17/00;;A61P25/00;;A61P25/28;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P9/00;;A61K31/225;;A61P25/00;;A61P37/00;;A61K31/616;;A61P37/02;;A61K45/06;;A61P25/28;;A61P43/00;;A61K9/2054;;A61P9/00;;A61K9/2072;;A61K9/2833;;A61P37/06;;A61K9/16;;A61K9/4808;;A61P29/00;;A61K31/60;;A61P17/00;;A61K9/2846;;A61K2300/00;;A61K31/225;;A61K31/60;;A61K45/06;;A61K9/2054;;A61K9/2846;;A61K31/616;;A61K9/2072;;A61K9/4808;;A61K9/16;;A61K9/2833,A61K31/225,,0,0,,,,PENDING
518,US,B2,US 10047463 B2,194-707-287-593-696,2018-08-14,2018,US 201715621769 A,2017-06-13,US 201715621769 A;;US 201514886383 A;;US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,Printer driver systems and methods for automatic generation of embroidery designs,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method to convert image data to embroidery data, includes converting image data representing an image to first vector data, converting the first vector data into component data structures that specify regions within the image, converting a first one of the component data structures into a fill shape including second vector data, converting a second one of the component data structures into a stroke shape including third vector data, and generating embroidery data structures using the fill shape and the stroke shape.",CIMPRESS SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2006-08-22);;SOFT SIGHT INC. (A DELAWARE CORPORATION) (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2013-10-08);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/194-707-287-593-696,Granted Patent,yes,30,0,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05C5/02;;D05B19/02;;D05B19/08;;D05B19/12,,11,0,,,"Song et al., “Algorithms for Vector Graphic Optimization and Compression,” Advances of Computer Graphics, 2006, pp. 665-672, Springer-Verlag, Berlin/Heidelberg, 8 pages.;;“Definition of printer driver,” http://www.pcmag.com/encyclopedia/term/49695/printer-driver, retrieved from the internet on Jun. 12, 2015, 2 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 14/174,540, dated Dec. 2, 2014, 20 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 14/174,540, dated Jun. 15, 2015, 16 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 11/556,008, dated Jul. 24, 2009, 16 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 11/556,008, dated Nov. 3, 2009, 20 pages.;;United States Patent and Trademark Office, “Final Office Action,” issued in connection with U.S. Appl. No. 11/556,008, dated Jun. 9, 2010, 14 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 11/556,008, dated Sep. 7, 2011, 13 pages.;;United States Patent and Trademark Office, “Non-Final Office Action,” issued in connection with U.S. Appl. No. 13/346,338, dated Aug. 1, 2012, 19 pages.;;United States Patent and Trademark Office, “Final Office Action,” issued in connection with U.S. Appl. No. 13/346,338, dated Apr. 22, 2013, 15 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” issued in connection with U.S. Appl. No. 13/346,338, dated Oct. 8, 2013, 18 pages.",ACTIVE
519,US,A1,US 2022/0335612 A1,069-175-974-813-666,2022-10-20,2022,US 202017641126 A,2020-09-07,US 202017641126 A;;IL 26922319 A;;US 201962897453 P;;IL 2020050973 W,2019-09-09,AUTOMATED ANALYSIS OF IMAGE DATA TO DETERMINE FRACTIONAL FLOW RESERVE,"A system and method for analysis of a vessel automatically detects a pathology in a first image of the vessel and attaches a virtual mark to the pathology in the first image. The system may detect the same pathology in a second image of the vessel, based on the virtual mark, and may then provide analysis (e.g., determine an FFR value) of the pathology based on the pathology detected in the first and second images.",MEDHUB LTD,BRUCH-EL OR;;GOLDMAN DAVID;;KASSEL ALEXANDRE,MEDHUB LTD (2022-02-21),https://lens.org/069-175-974-813-666,Patent Application,yes,0,0,7,9,0,G16H50/30;;G06T7/0012;;A61B5/02007;;G16H30/40;;G16H50/50;;A61B2576/00;;A61B5/7264;;A61B5/7221;;A61B5/743;;A61B5/02028;;G06T2207/30048;;G06T2207/30104;;G16H50/20;;A61B5/02007;;A61B5/02028;;A61B5/743;;G06T7/0014;;G06T2200/24;;G06T2207/30048;;G06T2207/30104;;G06T2207/30204,A61B5/00;;G06T7/00;;A61B5/02,,0,0,,,,PENDING
520,US,A1,US 2014/0156054 A1,079-327-032-591-142,2014-06-05,2014,US 201414174540 A,2014-02-06,US 201414174540 A;;US 201213346338 A;;US 55600806 A;;US 73283105 P,2005-11-02,PRINTER DRIVER SYSTEMS AND METHODS FOR AUTOMATIC GENERATION OF EMBROIDERY DESIGNS,"Printer driver systems and methods for automatic generation of embroidery designs are disclosed. An example method includes receiving a print command associated with print data representative of a design to be embroidered, and generating embroidery data using a printer driver and based on the print data.",VISTAPRINT SCHWEIZ GMBH,GOLDMAN DAVID A;;PATEL NIRAV;;SONG MINGKUI,SOFT SIGHT INC (2008-06-10);;SOFT SIGHT INC. A NEW YORK CORPORATION (2006-08-22);;SOFT SIGHT INC. A DELAWARE CORPORATION (2008-06-10);;VISTAPRINT TECHNOLOGIES LIMITED (2010-06-30);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/079-327-032-591-142,Patent Application,yes,4,4,10,10,0,D05B19/08;;D05B19/08;;D05B19/02;;D05B19/12,D05B19/12;;D05B19/02,700/138,1,0,,,Printer Driver Definitions,ACTIVE
521,IL,A,IL 269223 A,162-525-239-053-187,2021-03-25,2021,IL 26922319 A,2019-09-09,IL 26922319 A,2019-09-09,Automated analysis of image data to determine fractional flow reserve,,MEDHUB LTD;;OR BARUCH EL;;DAVID GOLDMAN;;ALEXANDRE KASSEL,OR BARUCH EL;;DAVID GOLDMAN;;ALEXANDRE KASSEL,,https://lens.org/162-525-239-053-187,Patent Application,no,0,0,2,9,0,H01Q1/2291;;H01Q1/525;;H04B7/15571;;Y02D30/00;;H01Q19/26;;H04B7/15578;;Y02D30/50;;H02J50/50;;H04W16/26;;H01Q1/245;;H04B1/3838;;Y02D30/70,,,0,0,,,,PENDING
522,WO,A3,WO 2014/035637 A3,062-650-508-093-548,2014-05-15,2014,US 2013/0054261 W,2013-08-09,US 201213600567 A,2012-08-31,METHODS FOR REMOTELY CONTROLLING POOLS AND SPAS AND MODIFYING WATER CONTAINED THEREIN,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time -varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS INC,MC QUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,,https://lens.org/062-650-508-093-548,Search Report,yes,2,0,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20,,1,1,099-203-585-967-796,10.1109/auswireless.2007.27,"SANJEEV DHAWAN ED - ANONYMOUS: ""Analogy of Promising Wireless Technologies on Different Frequencies: Bluetooth, WiFi, and WiMAX"", WIRELESS BROADBAND AND ULTRA WIDEBAND COMMUNICATIONS, 2007. AUSWIRELESS 2007. THE 2ND INTERNATIONAL CONFERENCE ON, IEEE, PI, 1 August 2007 (2007-08-01), pages 14 - 14, XP031132756, ISBN: 978-0-7695-2842-7",PENDING
523,EP,B1,EP 2891342 B1,164-889-135-670-279,2021-01-20,2021,EP 13779945 A,2013-08-09,US 201213600567 A;;US 2013/0054261 W,2012-08-31,METHOD FOR REMOTELY CONTROLLING POOLS AND SPAS,,ZODIAC POOL SYSTEMS LLC,MC QUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2021-01-20),https://lens.org/164-889-135-670-279,Granted Patent,yes,2,0,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20;;H04W48/20,,1,0,,,"SANJEEV DHAWAN ED - ANONYMOUS: ""Analogy of Promising Wireless Technologies on Different Frequencies: Bluetooth, WiFi, and WiMAX"", WIRELESS BROADBAND AND ULTRA WIDEBAND COMMUNICATIONS, 2007. AUSWIRELESS 2007. THE 2ND INTERNATIONAL CONFERENCE ON, IEEE, PI, 1 August 2007 (2007-08-01), pages 14-14, XP031132756, ISBN: 978-0-7695-2842-7",ACTIVE
524,US,A1,US 2015/0049750 A1,197-625-952-978-95X,2015-02-19,2015,US 201414457206 A,2014-08-12,US 201414457206 A;;US 201361866587 P,2013-08-16,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. The Wi-Fi Protected Setup (WPS) standard may be employed to facilitate formation of networks including networking devices associated with controllers of pool and spa equipment.,ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID ANDREW;;NIBLER DAVID;;MCQUEEN E KEITH,ZODIAC POOL SYSTEMS INC (2013-10-07),https://lens.org/197-625-952-978-95X,Patent Application,yes,3,31,2,2,0,G05B15/02;;G05B19/048;;G05B23/0216;;G05B2219/163;;G05B2219/25011;;G05B2219/25168;;G05B2219/2642;;H04W4/38;;G08C17/02;;H04W4/38;;G05B2219/163;;G05B23/0216;;G05B15/02;;G05B2219/25011;;G05B19/048;;G05B2219/25168;;G05B2219/2642;;G08C17/02;;H04L12/282;;H04L67/125;;H04L2012/2841,G08C17/02;;H04L12/28;;H04L29/08;;H04W4/38,370/338,1,0,,,"Wi-Fi Alliance, FAQ How does Wi-Fi Protected Setup work?, http://www.wi-fi.org/knowledge-center/faq/how-does-wi-fi-protected-setup-work",DISCONTINUED
525,WO,A2,WO 2014/035637 A2,187-544-087-889-401,2014-03-06,2014,US 2013/0054261 W,2013-08-09,US 201213600567 A,2012-08-31,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. Internet-enabled access to pool and spa controllers may happen without any need for users to create firewall ports or utilize static internet protocol addresses. Certain networking devices may be configured using a USB connection or SD card, avoiding any requirement for an Ethernet cable or supplying separate power to the devices during configuration. Other devices may be configured wirelessly, without need of any USB connection or SD card. Time -varying data may be obtained in respect of one or more installations and analyzed for various information.",ZODIAC POOL SYSTEMS INC,MC QUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,,https://lens.org/187-544-087-889-401,Patent Application,yes,0,6,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W84/12;;H04W4/20,,0,0,,,,PENDING
526,EP,A2,EP 2891342 A2,008-504-334-517-780,2015-07-08,2015,EP 13779945 A,2013-08-09,US 201213600567 A;;US 2013/0054261 W,2012-08-31,METHODS FOR REMOTELY CONTROLLING POOLS AND SPAS AND MODIFYING WATER CONTAINED THEREIN,,ZODIAC POOL SYSTEMS INC,MC QUEEN E KEITH;;NIBLER DAVID;;UY DINDO;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2021-01-20),https://lens.org/008-504-334-517-780,Patent Application,yes,0,9,12,12,0,H04W84/12;;H04W4/38;;H04W48/20;;H04W84/12;;H04W4/20;;H04W4/38,H04W4/38;;H04W4/20,,0,0,,,,ACTIVE
527,WO,A1,WO 2022/046370 A1,078-450-258-094-162,2022-03-03,2022,US 2021/0044301 W,2021-08-03,US 202017001330 A,2020-08-24,PORTABLE INFUSION PUMP WITH PINCH/SQUEEZE PUMPING ACTION,"A device for infusing a medicament into a patient includes a disposable component having a collapsible reservoir for holding the medicament, a cannula, and an elastomeric tube connected in fluid communication between the reservoir and the cannula. A manipulator is mounted on a chassis for engagement with the elastomeric tube. The manipulator includes a piston and respective pinchers upstream and downstream from the piston for a close/open open/close changeover operation. In concert therewith, the piston cyclically advances and withdraws relative to a platen to thereby alternatingly dilate/constrict the tube section. When the upstream pincher is open, the piston withdraws to create a low fluid pressure, P Lo , in the tube section to draw medicament into the tube. Alternately, when the downstream pincher is open, the piston is advanced to create a high fluid pressure, P Hi , on the tube to infuse medicament into the patient.",MODULAR MEDICAL INC,NEESE DAVID;;DIPERNA PAUL M;;GOLDMAN MARC D,,https://lens.org/078-450-258-094-162,Patent Application,yes,6,0,3,3,0,A61M5/14244;;A61M5/14216;;A61M2205/10;;A61M2205/106;;A61M5/14216;;A61M2205/8275;;A61M5/14244;;A61M5/1452,A61M5/142,,0,0,,,,PENDING
528,US,B1,US 11746998 B1,108-436-718-050-810,2023-09-05,2023,US 202217871832 A,2022-07-22,US 202217871832 A,2022-07-22,Light device and support device,"Various embodiments herein provide a light device that is selectively attachable to another device. For example, in some embodiments, the light device may be selectively attachable to a glove wrap that may be worn on a hand of a user. The light device may include a housing and a light unit coupled to the housing. The light unit may be selectively extendable from the housing, e.g., via a flexible neck. The light device may include an engagement mechanism to selectively attach the light device to the other device in any of multiple configurations. Other embodiments may be described and claimed.",COAST CUTLERY CO,ERNST TODD;;SHEEHY BRIAN;;GOLDMAN DAVID;;WOOD PAUL,COAST CUTLERY CO (2022-07-19),https://lens.org/108-436-718-050-810,Granted Patent,yes,7,0,1,1,0,F21Y2115/10;;F21L4/04;;F21V21/0816;;F21V21/0885;;F21V21/145;;F21V21/0816;;F21L4/045;;F21V21/0832;;F21V21/145;;F21V21/0885,F21V21/08;;F21L4/04;;F21V21/088;;F21V21/14,,0,0,,,,ACTIVE
529,WO,A1,WO 2021/113537 A1,196-532-885-002-121,2021-06-10,2021,US 2020/0063151 W,2020-12-03,US 201962945033 P;;US 201962944999 P,2019-12-06,ROTARY MICROFLUIDIC MEDICAL PUMP,"Rotary microfluidic medical pump and pumping method embodiments are discussed herein that may be used for controlled delivery of small and precise volumes of therapeutic or non-therapeutic fluids in a variety of environmental conditions. Certain medical pump and pumping method embodiments discussed herein may also be useful for the controlled delivery of certain therapeutic fluids that may be susceptible to degradation when exposed to high levels of pressure, flow velocity, shear stress or the like.",QUASURAS INC,DIPERNA PAUL;;GOLDMAN MARC;;NEESE DAVID;;HEARTY PATRICK,,https://lens.org/196-532-885-002-121,Patent Application,yes,8,2,8,8,0,A61M2005/14288;;A61M5/14248;;A61M2205/273;;A61M2205/3327;;A61M2205/3331;;A61M2205/3553;;A61M2205/6072;;A61M2205/8206;;A61M2205/50;;A61M2205/52;;A61M2005/14268;;A61M5/14586;;A61M5/16809;;A61M2205/581;;A61M2205/584;;A61M2205/3368;;A61M2005/16868;;A61M2205/18;;A61M2205/6018;;A61M2205/6027;;A61M2205/6036;;A61M2205/6045;;A61M2205/6054;;A61M5/142;;A61M2005/14288;;A61M2205/273;;A61M2205/3327;;A61M2205/3553;;A61M2205/6072;;A61M5/145;;A61M2205/3331;;A61M2205/8206;;A61M5/14248;;A61M2205/50;;A61M2205/52;;G09B23/285;;A61M5/1413,A61M5/142;;A61M5/172,,1,0,,,See also references of EP 4069333A4,PENDING
530,US,A1,US 2013/0120454 A1,002-887-267-315-670,2013-05-16,2013,US 86854010 A,2010-08-25,US 86854010 A;;US 24393109 P,2009-09-18,Methods and Apparatuses for Generating Thumbnail Summaries for Image Collections,"Methods and apparatuses for generating thumbnail summaries for image collections are described. Thumbnails summaries may be representative of the image collection while being disjoint from each other. In some embodiments, a method may sample crops from some or all images in an image collection. From these candidate crops, the method may select representative but disjoint crops. In some embodiments, a desired representativeness and/or disjointedness of the candidate crops may be defined by a user. The method may then generate and/or select thumbnail summaries for the collection of images based at least in part on the selected candidate crops.",SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,ADOBE INC (2010-08-19),https://lens.org/002-887-267-315-670,Patent Application,yes,14,23,2,2,0,G06F16/54;;G06T11/00;;G06T15/503;;G06T3/04;;G06F16/54;;G06T3/04;;G06T3/4038;;G06T11/00;;G06T15/503,G09G5/00,345/635,1,1,045-981-655-378-439,10.1145/964696.964707,"Automatic thumbnail cropping and its effectiveness Bongwon Suh, Haibin Ling, Benjamin B. Bederson, David W. Jacobs November 2003; Proceedings of the 16th annual ACM symposium on User interface software and technology Publisher: ACM Request Permissions",ACTIVE
531,WO,A3,WO 2003/009965 A3,191-732-892-615-852,2004-03-18,2004,IL 0200611 W,2002-07-23,IL 14449501 A,2001-07-23,CUTLERY POLISHING APPARATUS,"An apparatus (10) for automatically polishing kitchen utensils. The apparatus (10) comprise one or more entry ports (12), through which the ustensils are loaded onto said tracks, to a collection point, from which ustensils are retrieved in a dry, polished state, wherein each of the one or more conveyor tracks (16) comprises a plurality of rotatable drive wheels (18) for moving said ustensils along the tracks together with means (38) for causing the drive wheels to rotate, and a plurality of rotatable brushes (20) together with means (34) for rotating said brushes, such that the rotating brushes dry and polish said utensils, and means (14) for spaying polishing medium onto said utensils.",MAOF INNOVATION AND TECHNOLOGI;;ENGEL RAMI;;DAN YARIV;;GELES DAVID;;GOLDMAN NITAI,ENGEL RAMI;;DAN YARIV;;GELES DAVID;;GOLDMAN NITAI,,https://lens.org/191-732-892-615-852,Search Report,yes,3,0,4,4,0,A46B13/001;;B24B19/001;;B24B29/005;;B24B29/10;;B24D13/10,A46B13/00;;B24B19/00;;B24B29/10;;B24D13/10,,0,0,,,,PENDING
532,AT,T1,AT E437236 T1,151-476-166-280-348,2009-08-15,2009,AT 04759878 T,2004-04-16,US 41776303 A;;US 2004/0011608 W,2003-04-17,VORRICHTUNG UND VERFAHREN ZUR PRÜFUNG VON FLÜSSIGEN PROBEN,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,GOLDMAN ROSS;;TOWNSEND DAVID;;SMITH KENNETH;;MCCARTHY KATHLEEN,,https://lens.org/151-476-166-280-348,Granted Patent,no,0,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,B01L3/00;;C12M1/22;;C12Q1/06,,0,0,,,,ACTIVE
533,NZ,A,NZ 737725 A,023-296-063-117-813,2019-06-28,2019,NZ 73772513 A,2013-06-03,US 201261655381 P;;NZ 73193213 A,2012-06-04,Crystalline forms of a bruton’s tyrosine kinase inhibitor,"Disclosed herein is a crystalline Form C of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising 2-Theta peaks at about 7.0°, about 14.0°, about 15.7°, about 18.2°, about 19.1°, about 19.5°, about 20.3°, about 22.1°, and about 22.9°. Also disclosed is a crystalline Form C of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, wherein the crystalline form has a differential scanning calorimetry (DSC) thermogram having an endotherm having an onset at about 134 °C to about 135 °C with a peak at about 137 °C to about 139 °C. Further disclosed are pharmaceutical formulations and medical uses of crystalline Form C.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID,,https://lens.org/023-296-063-117-813,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K47/38;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
534,US,A1,US 2003/0157507 A1,165-733-092-370-828,2003-08-21,2003,US 20656102 A,2002-07-25,US 20656102 A;;US 35394102 P,2002-01-31,Methods for detecting nucleic acid sequence variation,"
   Sequence variations, such as polymorphisms, are detected by detecting differences between or among melting profiles of plural nucleic acids. Melting profiles are produced by observing the nucleic acids during a temperature change over a period of time. If the nucleic acids are diluted into solutions for analysis, the nucleic acid concentrations between or among the solutions can be substantially the same. The melting profiles and sequence variation can be used to identify changes in a wild-type nucleic acid sequence, such as a single-nucleotide polymorphism (SNP), a small insertion or deletion, or a small inversion. 
",US HEALTH,LIPSKY ROBERT H;;MAZZANTI CHIARA M;;GOLDMAN DAVID,GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES THE (2003-08-28),https://lens.org/165-733-092-370-828,Patent Application,yes,2,20,2,2,24,C12Q1/6827;;C12Q1/6827,C12Q1/68,435/6,0,0,,,,EXPIRED
535,US,B2,US 8599219 B2,179-259-757-702-253,2013-12-03,2013,US 86854010 A,2010-08-25,US 86854010 A;;US 24393109 P,2009-09-18,Methods and apparatuses for generating thumbnail summaries for image collections,"Methods and apparatuses for generating thumbnail summaries for image collections are described. Thumbnails summaries may be representative of the image collection while being disjoint from each other. In some embodiments, a method may sample crops from some or all images in an image collection. From these candidate crops, the method may select representative but disjoint crops. In some embodiments, a desired representativeness and/or disjointedness of the candidate crops may be defined by a user. The method may then generate and/or select thumbnail summaries for the collection of images based at least in part on the selected candidate crops.",SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E;;ADOBE SYSTEMS INC,SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,ADOBE INC (2010-08-19),https://lens.org/179-259-757-702-253,Granted Patent,yes,73,11,2,2,0,G06F16/54;;G06T11/00;;G06T15/503;;G06T3/04;;G06F16/54;;G06T3/04;;G06T3/4038;;G06T11/00;;G06T15/503,G09G5/02;;G06T3/40;;G06T11/00;;G06T15/50,345/635,98,47,045-981-655-378-439;;100-174-955-372-516;;164-611-077-215-676;;010-584-229-002-827;;064-348-768-458-019;;171-563-516-927-107;;047-321-294-726-555;;042-689-645-533-661;;036-712-812-707-784;;006-569-037-594-733;;138-886-667-508-17X;;197-763-750-194-941;;075-286-905-404-93X;;002-904-180-765-355;;086-164-816-979-110;;013-759-719-034-849;;091-368-519-826-690;;042-579-334-928-167;;192-540-347-759-682;;007-057-842-134-091;;030-777-962-603-795;;046-559-636-039-311;;090-847-908-435-564;;123-534-977-219-353;;082-859-022-686-637;;051-388-541-746-459;;008-386-133-216-987;;036-158-814-512-635;;053-138-689-081-378;;060-048-731-801-602;;080-004-418-421-532;;029-656-348-079-894;;033-815-104-020-861;;023-498-194-066-134;;079-200-603-418-338;;125-285-578-163-901;;091-929-151-553-061;;043-814-218-233-994;;134-183-246-339-631;;045-689-670-465-33X;;176-820-572-106-65X;;081-749-474-301-124;;173-061-018-421-050;;127-871-225-096-269;;142-532-092-334-004;;014-842-060-437-773;;091-660-617-416-933,10.1145/964696.964707;;10.1145/1576246.1531330;;10.5244/c.23.116;;10.1007/978-3-540-88688-4_9;;17224616;;10.1109/tpami.2007.60;;10.1145/1186562.1015718;;10.21236/ada540639;;10.1145/245.247;;10.1145/1275808.1276392;;10.1145/1275808.1276382;;10.1145/1186822.1073263;;10.1145/882262.882264;;10.1145/1201775.882269;;10.1145/1179352.1141965;;10.1109/cvpr.2008.4587842;;10.1145/258734.258861;;16173188;;10.1109/tpami.2005.185;;10.1145/344779.345009;;10.1145/74334.74361;;10.1145/1201775.882345;;16792093;;10.1109/tpami.2006.131;;10.1109/cvpr.2005.31;;10.1145/218380.218446;;10.1145/1809939.1809954;;10.1016/j.cag.2010.11.002;;10.1145/364338.364405;;10.1145/1731047.1731048;;10.1109/tip.2010.2049240;;20435541;;10.1145/1409060.1409062;;10.1111/1467-8659.00396;;10.1145/1278780.1278822;;10.1145/1964921.1964965;;10.1145/502348.502379;;10.1109/cvpr.2012.6247761;;10.1109/38.736469;;10.1109/tit.1982.1056489;;10.1145/1141911.1141931;;10.1145/192161.192254;;10.1145/192161.192185;;10.1111/j.1467-8659.2009.01403.x;;10.1109/cvpr.2010.5540159;;10.1145/127719.122752;;10.1145/1833349.1778862;;10.1145/383259.383297;;10.1145/957013.957037;;10.1145/192161.192184;;10.1145/882262.882324,"Automatic thumbnail cropping and its effectiveness Bongwon Suh, Haibin Ling, Benjamin B. Bederson, David W. Jacobs Nov. 2003; Proceedings of the 16th annual ACM symposium on User interface software and technology Publisher: ACM Request Permissions.;;""PatchMatch: A Randomized Correspondence Algorithm for Structural Image Editing,"" ACM Transactions on Graphics, Barnes, C., Shechtman, E., Finkelstein, A. and Goldman, Dan B., Proc. SIGGRAPH 28(3), Aug. 2009, 10 pages.;;Whyte, O., Sivic, J., and Zisserman, A. 2009. Get out of my picture! internet-based inpainting. In BMVC (British Machine Vision Conference), 11 pages.;;U.S. Appl. No. 12/868,519, filed Aug. 25, 2010, Elya Shechtman, et al.;;U.S. Appl. No. 12/857,294, filed Aug. 16, 2010, Dan Goldman, et al.;;P. Bhat, B. Curless, M. Cohen, and C. L. Zitnick. Fourier analysis of the 2d screened poisson equation for gradient domain problems. In ECCV, 2008, 14 pages.;;U.S. Appl. No. 12/394,280, filed Feb. 27, 2009, Dan Goldman, et al.;;Yonatan Wexler, Eli Shechtman, Michal Irani. Space-Time Completion of Video. IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 29, No. 3, Mar. 2007, 14 pages.;;Agarwala, A., Dontcheva, M., Agrawala, M., Drucker, S., Colburn, A., Curless, B., Salesin, D., and Cohen, M. 2004. Interactive digital photomontage. In ACM SIGGRAPH, vol. 23, 294-302.;;Arias, P., Facciolo, G., Caselles, V., and Sapiro, G. 2011. A variational framework for exemplar-based image inpainting. IJCV 93 (July), 319-347.;;U.S. Appl. No. 12/315,038, filed Nov. 26, 2008, Dan Goldman, et al.;;Burt, P. J., and Adelson, E. H. 1983. A multiresolution spline with application to image mosaics. ACM Trans. Graphics 2 (October), 217-236.;;Efros, A. A., and Leung, T. K. 1999. Texture synthesis by non-parametric sampling. IEEE Computer Society, Los Alamitos, CA, USA, 6 pages.;;Fang, H., and Hart, J. C. 2007. Detail preserving shape deformation in image editing. In ACM SIGGRAPH, vol. 26, pp. 1-5.;;Hays, J., and Efros, A. A. 2007. Scene completion using millions of photographs. In ACM SIGGRAPH, vol. 26, 4:1-4: 7 pages.;;Kwatra, V., Essa, I., Bobick, A., and Kwatra, N. 2005. Texture optimization for example-based synthesis. In ACM SIGGRAPH, vol. 24, 795-802.;;Kwatra, V., Sch{umlaut over (0)}odl, A., Essa, I., Turk, G., and Bobick, A. 2003. Graphcut textures: image and video synthesis using graph cuts. In ACM SIGGRAPH, vol. 22, 277-286.;;Perez, P., Gangnet, M., and Blake, A. 2003. Poisson image editing. In ACM SIGGRAPH, vol. 22, 313-318.;;Rother, C., Bordeaux, L., Hamadi, Y., and Blake, A. 2006. AutoCollage. In ACM SIGGRAPH, vol. 25, 847-852.;;Simakov, D., Caspi, Y., Shechtman, E., and Irani, M. 2008. Summarizing visual data using bidirectional similarity. In CVPR, 8 pages.;;Szeliski, R., and Shum, H.-Y. 1997. Creating full view panoramic image mosaics and environment maps. In ACM SIGGRAPH, 251-258.;;Tappen, M., Freeman, W., and Adelson, E. 2005. Recovering intrinsic images from a single image. IEEE Trans. PAMI 27, 9 (Sep.), 1459-1472.;;Wei, L. Y., and Levoy, M. 2000. Fast texture synthesis using tree-structured vector quantization. In ACM SIGGRAPH, 479-488.;;U.S. Appl. No. 12/858,546, filed Aug. 18, 2010, Holger Winnemoeller, et al.;;U.S. Appl. No. 13/565,552, filed Aug. 2, 2012, Elya Shechtman, et al.;;U.S. Appl. No. 12/858,558, filed Aug. 18, 2010, Holger Winnemoeller, et al.;;Kajiya, J. T. and Kay, T. L. 1989. Rendering fur with three dimensional textures. SIGGRAPH Comput. Graph. 23, 3 (Jul. 1989), 271-280.;;Marschner, S. R., Jensen, H. W., Cammarano, M., Worley, S., and Hanrahan, P. 2003. Light scattering from human hair fibers. In ACM SIGGRAPH 2003 Papers (San Diego, California, Jul. 27-31, 2003). SIGGRAPH'03. ACM, New York, NY, 780-791.;;Chen, H. and Zhu, S. 2006. A Generative Sketch Model for Human Hair Analysis and Synthesis. IEEE Trans. Pattern Anal. Mach. Intell. 28, 7 (Jul. 2006), 1025-1040.;;H. Chen and S. C. Zhu, ""A generative model of human hair for hair sketching"", CVPR (IEEE Conference on Computer Vision and Pattern Recognition), 2:74-81, 2005.;;David J. Heeger and James R. Bergen. Pyramid-based texture analysis/synthesis. In SIGGRAPH,95, pp. 229-238, 1995.;;""ArtRage 3"", Ambient Design, http://www.ambientdesign.com/, from web.archive.org on Aug. 23, 2011, (May 25, 2010), 1 page.;;""Auryn Inc. Auryn Ink"", iTunes Preview, retrieved from , (Jul. 20, 2011), 2 pages.;;""Auryn Ink Review"", www.giggleapps.com, (Feb. 10, 2011), 4 pages.;;""Corel Painter 11 Features"", retrieved from <http://web.archive.org/web/20100526115240/http://www.corel.com/servlet/Satellite/us/en/Product/1166553885783#tabview=tab1> on Mar. 23, 2011, 3 pages.;;""Corel Painter 11 Overview"", retrieved from <http://web.archive.org/web/20100526115240/http://www.corel.com/servlet/Satellite/us/en/Product/1166553885783#tabview=tab0> on Aug. 23, 2011, 3 pages.;;""Final Office Action"", U.S. Appl. No. 12/858,558, (Feb. 15, 2013), 14 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/858,546, (Jan. 30, 2013),19 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/858,558, (Aug. 30, 2012),10 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/868,519, (Feb. 7, 2013),16 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/858,546, (May 6, 2013), 12 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/858,552, (Apr. 20, 2012), 8 pages.;;U.S. Appl. No. 12/039,164, filed Feb. 28, 2008, 60 pages.;;Ando, Ryoichi et al., ""Vector Fluid: A Vector Graphics Depiction of Surface Flow"", NPAR '10: Proceedings of the 8th International Symposium on Non-photorealistic Animation and Rendering (pp. 129-135). New York, NY, USA: ACM, (2010), 7 pages.;;Ando, Ryoichi et al., ""Vector Graphics Depicting Marbling Flow"", Computers & Graphics, vol. 35, Issue 1, (Nov. 29, 2010),14 pages.;;Ashikhmin, Michael ""Synthesizing Natural Textures"", Proceedings of the Symposium on Interactive 3D Graphics 2001, 10 pages.;;Barla, et al., ""Stroke Pattern Analysis and Synthesis"", Eurographics 2006, vol. 25 (2006), No. 3, (2006), 9 pages.;;Barnes, Connelly et al., ""The Generalized PatchMatch Correspondence Algorithm"", retrieved from on Sep. 9, 2010, 14 pages.;;Bhat, Pravin et al., ""GradientShop: A Gradient-Domain Optimization Framework for Image and Video Filtering"", ACM Transactions on Graphics 29(2), (2010),15 pages.;;Bugeau, Aurelie et al., ""A Comprehensive Framework Transactions on Image Inpainting"", IEEE Transactions on Image Processing, vol. 19, No. 10, (Oct. 2010),pp. 2634-2645.;;Chen, Xuejin et al., ""Sketch-Based Tree Modeling Using Markov Random Field"", ACM Trans. on Graphics 27, 5, (2008), 9 pages.;;Deussen, Oliver et al., ""Floating Points: A Method for Computing Stipple Drawings"", Eurographics 2000, vol. 19, No. 3, (2000),10 pages.;;Deussen, Oliver et al., ""The Elements of Nature: Interactive and Realistic Techniques"", SIGGRAPH 2004 Course 31, (2004), 64 pages.;;Diverdi, et al., U.S. Appl. No. 13/219,457, filed Aug. 26, 2011, 104 pages.;;Diverdi, Stephen J., et al., ""U.S. Appl. No. 13/219,453, filed Aug. 26, 2011"", 102 pages.;;Duran, Jonathan ""Deco Tool and Spray Brush for Creating Complex, Geometric Patterns in Flash"", retrieved from on Aug. 31, 2010, (Feb. 2, 2009),19 pages.;;Esch, Greg et al., ""Interactive Procedural Street Modeling"", SIGGRAPH 2007 Sketches, 1 page.;;Hacohen, Yoav et al., ""Non-Rigid Dense Correspondence with Applications for Image Enhancement"", SIGGRAPH, (2011), 9 pages.;;Hang, Chu S., ""Making Digital Painting Organic"", PhD Thesis, Hong Kong University of Science and Technology, (Aug. 2007),126 pages.;;Hertzmann, Aaron et al., ""Curve Analogies"", 13th Eurographics Workshop on Rendering (2002), 13 pages.;;Hertzmann, Aaron et al., ""Image Analogies"",Proceedings of SIGGRAPH 2001, 14 pages.;;Igarashi, Takeo et al., ""A Suggestive Interface for 3D Drawing"", Proceedings of the ACM Symposium on User Interface Software and Technology, UIST 01. 2001, ACM: Orlando, Florida, (2001),9 pages.;;Ijiri, Takashi et al., ""The Sketch L-System: Global Control of Tree Modeling Using Free-Form Strokes"", Proceedings of 6th International Symposium SmartGraphics 2006, 9 pages.;;Jodoin, Pierre-Marc et al., ""Hatching by Example: A Statistical Approach"", Proceedings of NPAR 2002, 8 pages.;;Kaneva, Biliana et al., ""Infinite Images: Creating and Exploring a Large Photorealistic Virtual Space"", Proceeding of the IEEE, vol. 98, No. 8, (Aug. 2010),17 pages.;;Lee, Hyunjoon et al., ""Automatic Upright Adjustment of Photographs"", CVPR, (2012),11 pages.;;Lin, Wen-Yan et al., ""Smoothly Varying Affine Stitching"", Proceedings of Computer Vision and Pattern Recognition (CVPR), (Jun. 2011),13 pages.;;Lintermann, Bernd et al., ""Interactive Modeling of Plants"", IEEE Computer Graphics and Applications, 19 (1999), 1, pp. 2-11;;Lloyd, Stuart P., ""Least Squares Quantization in PCM"", IEEE Transactions on Information Theory, vol. 28, No. 2, (Mar. 1982), pp. 129-137.;;Mansfield, Alex et al., ""Transforming Image Completion"", Proceedings of British Machine Vision Conference (BMVC), (Aug. 29, 2011),11 pages.;;Marks, et al., ""Design Galleries: A General Approach to Setting Parameters for Computer Graphics and Animation"", ACM Computer Graphics (SIGGRAPH '97 Proceedings), (Aug. 1997), 26 pages.;;Matsuda, Okiharu ""U.S. Appl. No. 13/219,848, filed Aug. 29, 2011"", 27 pages.;;McVeigh, Chris ""ArtRage Studio Pro 3"", PCWorld, retrieved from on Aug. 23, 2011 4 pages.;;Mech, Radomir et al., U.S. Appl. No. 12/857,382, filed Aug. 16, 2010, 57 pages.;;Mech, Radomir et al., U.S. Appl. No. 13/029,036, filed Feb. 16, 2011, 69 pages.;;Mech, Radomir et al., ""Visual Models of Plants Interacting with Their Environment"", Proceedings of SIGGRAPH 96 (New Orleans, LA, Aug. 4-9, 1996), Computer Graphics, (1996),15 pages.;;Muller, Matthias et al., ""Meshless Deformations Based on Shape Matching"", ACM Transactions on Computer Graphics, 24, 3 (2005), 8 pages.;;Muller, Pascal et al., ""Procedural Modeling of Buildings"", ACM Trans. Graph., 25 (2006), 3, 10 pages.;;Parish, Yoav I., et al., ""Procedural Modeling of Cities"", Proceedings of ACM SIGGRAPH 2001, 8 pages.;;Pritch, Yael et al., ""Shift-Map Image Editing"", ICCV '09, Kyoto, Japan, (Sep. 2009), 8 pages.;;Prusinkiewicz, et al., ""Phyllotaxis"", The Algorithmic Beauty of Plants, Springer-Verlag, Chapter 4, ISBN 978-0387972978, (1990), pp. 99-118.;;Prusinkiewicz, et al., ""Synthetic Topiary"", Proceedings of ACM SIGGRAPH, (1994), 8 pages.;;Ruiters, Roland et al., ""Patch-Based Texture Interpolation"", Eurographics Symposium on Rendering, vol. 29, No. 4, (2010), 9 pages.;;Salisbury, Michael P., et al., ""Interactive Pen-and-Ink Illustration"", Proceedings of SIGGRAPH 1994, 8 pages.;;Shapira, et al., ""Image Appearance Exploration by Model-Based Navigation"", Computer Graphics Forum, Eurographics, vol. 28 (2009), No. 2, (Mar. 30 to Apr. 3, 2009), 10 pages.;;Shechtman, Eli et al., ""Regenerative Morphing"", CVPR, (2010), 8 pages.;;Shechtman, et al., ""U.S. Appl. No. 12/868,540, filed Aug. 25, 2010"", 34 pages.;;Sims, Karl ""Artificial Evolution for Computer Graphics"", Computer Graphics 25,4, (Aug. 1991), 9 pages.;;Sunkavalli, Kalyan et al., ""Multi-Scale Image Harmonization"", ACM SIGGRAPH, vol. 29 (2010), 10 pages.;;Turk, Greg ""Texture Synthesis on Surfaces"", Proceedings of SIGGRAPH 2001, 8 pages.;;Van Laerhoven, Tom ""An Extensible Simulation Framework Supporting Physically-based Interactive Painting"", PhD thesis, University of Limburg, (Jun. 21, 2006), 171 pages.;;Wang, et al., ""MobiPicture-Browsing Pictures on Mobile Devices"", Proceedings of the eleventh ACM international conference on Multimedia, (Nov. 2, 2003), pp. 106-107.;;Winkenbach, Georges et al., ""Computer-Generated Pen-and-Ink Illustration"", Proceedings of SIGGRAPH 1994, 11 pages.;;Winnemoeller, et al., ""U.S. Appl. No. 12/858,552, filed Aug. 18, 2010"", 70 pages.;;Wong, Michael T., et al., ""Computer-Generated Floral Ornament"", Proceedings of SIGGRAPH 1998, (1998),12 pages.;;Wonka, Peter et al., ""Instant Architecture"", ACM Trans. Graph., 22 (2003), 3, 9 pages.;;""Corrected Notice of Allowance"", U.S. Appl. No. 12/858,546, (Jun. 6, 2013), 8 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/868 519 (Jun. 17, 2013), 10 pages.",ACTIVE
536,US,B1,US 8527478 B1,197-580-552-623-504,2013-09-03,2013,US 97318010 A,2010-12-20,US 97318010 A,2010-12-20,Handling bulk and incremental updates while maintaining consistency,"Aspects of the invention relate generally to updating of interconnected features stored in a repository while maintaining highly consisting views of the repository data. More specifically, the invention relates to updating some features in bulk while providing for incremental updates for other features which are not completely independent of the bulk edits. The bulk edits are grouped into stages or “epochs” associated with various manageable states, including, for example, a building state, an approval state, a live state, and an abandoned state. The current view of the data is thus based on the status of each of the epochs. At the same time, incremental edits may be performed where the incremental edits are independent of the current live bulk epoch. This allows the system to maintain consistent views of the data until an entire group of features moves into the live state.",GOLDMAN SETH;;EUSTIS DAVID;;HULUBEI TUDOR;;DANAHER JOHN;;GOOGLE INC,GOLDMAN SETH;;EUSTIS DAVID;;HULUBEI TUDOR;;DANAHER JOHN,GOOGLE LLC (2010-12-17),https://lens.org/197-580-552-623-504,Granted Patent,yes,10,5,1,1,0,G06F16/29;;G06F16/29,G06F17/30,707/695;;707/694;;707/737,4,2,078-499-466-631-273;;137-292-579-653-532,10.1016/s1389-1286(00)00063-3;;10.1145/1327452.1327492,"""Distributed Lock Manager"" [online] [Retrieved Jul. 21, 2010] Retrieved from the internet: , 4 pages.;;WebBase: A Repository of Web Pages, Jun Hirai, Sriram Raghavan, Hector Garcia-Molina and Andreas Paepcke, 1999, 20 pages.;;The Chubby Lock Service for Loosely-Coupled Distributed Systems, Mike Burrows, Nov. 2006, 16 pages.;;Jeffrey Dean and Sanjay Ghemawat, MapReduce: Simplified Data Processing on Large Clusters, Dec. 2004, 13 pages.",INACTIVE
537,EC,A,EC SP14033163 A,055-748-327-626-474,2015-09-30,2015,EC PI201433163 A,2014-12-24,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS INC,GOLDMAN ERICK;;PURRO NORBERT;;WIRTH DAVID;;SMYTH MARK,,https://lens.org/055-748-327-626-474,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
538,US,A1,US 2022/0054742 A1,065-168-218-742-873,2022-02-24,2022,US 202017001330 A,2020-08-24,US 202017001330 A,2020-08-24,PORTABLE INFUSION PUMP WITH PINCH/SQUEEZE PUMPING ACTION,"A device for infusing a medicament into a patient includes a disposable component having a collapsible reservoir for holding the medicament, a cannula, and an elastomeric tube connected in fluid communication between the reservoir and the cannula. A manipulator is mounted on a chassis for engagement with the elastomeric tube. The manipulator includes a piston and respective pinchers upstream and downstream from the piston for a close/open open/close changeover operation. In concert therewith, the piston cyclically advances and withdraws relative to a platen to thereby alternatingly dilate/constrict the tube section. When the upstream pincher is open, the piston withdraws to create a low fluid pressure, p Lo , in the tube section to draw medicament into the tube. Alternately, when the downstream pincher is open, the piston is advanced to create a high fluid pressure, p Hi , on the tube to infuse medicament into the patient.",MODULAR MEDICAL INC,NEESE DAVID;;DIPERNA PAUL M;;GOLDMAN MARC D,MODULAR MEDICAL INC (2021-03-04),https://lens.org/065-168-218-742-873,Patent Application,yes,3,0,3,3,0,A61M5/14244;;A61M5/14216;;A61M2205/10;;A61M2205/106;;A61M5/14216;;A61M2205/8275;;A61M5/14244;;A61M5/1452,A61M5/142;;A61M5/145,,2,0,,,"“Cohesive.” Merriam-Webster.com Dictionary, Merriam-Webster, https://www.merriam-webster.com/dictionary/cohesive. (Year: 2023);;“Cohesion.” Merriam-Webster.com Dictionary, Merriam-Webster, https://www.merriam-webster.com/dictionary/cohesion. (Year: 2023)",PENDING
539,WO,A1,WO 2010/062342 A1,165-256-009-555-524,2010-06-03,2010,US 2009/0005853 W,2009-10-27,US 25917608 A;;US 36364609 A,2008-10-27,AUTOMATED LASER TUNING,"In exemplary embodiments, an ultra short pulse system comprises a laser platform which includes an optical source configured to generate an optical pulse, an optical amplifier configured to amplify the optical pulse, and a compressor configured to temporally compress the amplified optical pulse. The ultra short pulse system further comprises monitor circuitry configured to monitor one or more performance aspects of the laser platform. Additionally, the ultra short pulse system may comprise logic configured to control the one or more performance aspects of the laser platform in response to at least the monitored one or more performance aspects.",RAYDIANCE INC;;STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,,https://lens.org/165-256-009-555-524,Patent Application,yes,6,0,4,4,0,H01S3/10015;;H01S3/10015;;H01S3/0057;;H01S3/0057;;H01S3/0085;;H01S3/0085;;H01S3/1301;;H01S3/1301;;H01S3/2316;;H01S3/2316,H01S3/10,,0,0,,,,PENDING
540,US,A,US 5712050 A,168-326-266-772-028,1998-01-27,1998,US 41191995 A,1995-03-28,US 41191995 A;;US 18577594 A;;US 95651592 A;;US 75694791 A,1991-09-09,Superalloy component with dispersion-containing protective coating,"A coated superalloy component includes a substrate article formed of a superalloy and an adherent coating over the substrate. The coating is a nickel-base superalloy containing 0.3 volume percent or more of a dispersed oxide of yttrium, hafnium and/or a rare earth, and, preferably, grain boundary strengthening elements such as carbon, zirconium, and boron. The oxide dispersoids improve the performance of the coating in service, reducing the incidence failures due to thermal fatigue, oxidation, and corrosion damage. The dispersoid-containing coating may be formed by directly depositing the oxide-containing coating, or by depositing a metallic coating under conditions which permit the formation of such dispersoids during the deposition process.",GEN ELECTRIC,GOLDMAN EDWARD HARVEY;;DAROLIA RAMGOPAL;;WORTMAN DAVID JOHN,,https://lens.org/168-326-266-772-028,Granted Patent,yes,28,36,1,4,0,C23C4/12;;C23C4/12;;C23C4/06;;C23C4/06;;C23C30/00;;C23C30/00;;Y10T428/12486;;Y10T428/12486;;Y10T428/12931;;Y10T428/12931;;Y10T428/12944;;Y10T428/12944,C23C4/06;;C23C4/12;;C23C30/00,428/680;;428/678;;428/614;;X416241 R,5,1,071-256-899-285-336,10.1016/0040-6090(89)90542-7,"Metals Handbook, Tenth Edition TA 459 M43, 1990, pp. 950 957.;;Databook , 1978, Metal Progress Mid Jun. 1978, p. 106, (No Month).;;East, Handbook of Chemistry and Physics , 57th Ed, CRC Press Inc, QD 65 C4 1976 1977, pp. 116, 135, 175 (No Month).;;Thin Solid Films, vol. 173, No. 1, Jun. 1, 1989, Lausanne, CH, pp. 99 107; B. Gudmundsson Yttrium Oxides in Vacuum Plasma Sprayed CoNiCrALY Coatings p. 100, paragraph 2.3.;;WO A 8 706 273, Publication Date Oct. 22, 1987. Title: Coating to Protect Against Wear and Fretting Corrosion of, in Particular, Metal Mechanical Components Held Together by Frictional Adherence.",EXPIRED
541,US,A1,US 2013/0120438 A1,147-119-503-266-679,2013-05-16,2013,US 86851910 A,2010-08-25,US 86851910 A;;US 24393209 P,2009-09-18,Methods and Apparatuses for Generating Co-Salient Thumbnails for Digital Images,"Methods and apparatus for generating context-sensitive, co-salient thumbnails are described. Co-salient thumbnails may effectively convey more useful information than conventional thumbnails while using the same or similar display space. As such, co-salient thumbnails may make it easier for a user to locate a particular image in a large collection of similar images. In some embodiments, for each of a plurality of patches in a first image, an illustrative method may identify a corresponding similar patch in a second image based on one or more similarity measures. The method may then determine a distance from each of the plurality of patches to its corresponding similar patch and select a crop in the first image relative to the second image based on the determined distance. Optionally, the method may repeat these operations in the opposite direction to select a crop in the second image relative to the first image.",SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,ADOBE INC (2010-08-19),https://lens.org/147-119-503-266-679,Patent Application,yes,0,17,2,2,0,H04N1/3875;;G06T11/60;;G06T2210/22;;G06V10/759;;G06V10/751;;G06T3/04;;H04N1/3875;;G06T11/60;;G06T2210/22;;G06V10/751;;G06V10/759;;G06T3/04;;G09G5/14,G09G5/00,345/611;;345/620,0,0,,,,ACTIVE
542,EP,A1,EP 2380250 A1,048-134-247-550-537,2011-10-26,2011,EP 09829443 A,2009-10-27,US 2009/0005853 W;;US 25917608 A;;US 36364609 A,2008-10-27,AUTOMATED LASER TUNING,,RAYDIANCE INC,STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,,https://lens.org/048-134-247-550-537,Patent Application,yes,0,0,4,4,0,H01S3/10015;;H01S3/10015;;H01S3/0057;;H01S3/0057;;H01S3/0085;;H01S3/0085;;H01S3/1301;;H01S3/1301;;H01S3/2316;;H01S3/2316,H01S3/10,,1,0,,,See references of WO 2010062342A1,DISCONTINUED
543,NZ,A,NZ 731932 A,082-505-433-667-408,2018-09-28,2018,NZ 73193213 A,2013-06-03,US 201261655381 P;;NZ 71382813 A,2012-06-04,Crystalline forms of a bruton’s tyrosine kinase inhibitor,"Disclosed herein is a crystalline Form B of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising 2-Theta peaks at about 5.2°, about 10.2°, about 16.5°, about 18.5°, and about 20.8°. Also disclosed is a crystalline Form B of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, wherein the crystalline form has an infrared (IR) spectrum with peaks at about 1586 cm-1, about 1573 cm-1, about 1562 cm-1, about 1229 cm-1, about 1141 cm-1, about 1103 cm-1, about 1056 cm-1, and about 1033 cm-1, and crystalline Form B of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, wherein the crystalline form has a differential scanning calorimetry (DSC) thermogram having an endotherm having an onset at about 99 °C to about 106 °C with a peak at about 115 °C to about 118 °C. Further disclosed are formulations and medical uses of crystalline Form B.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID,,https://lens.org/082-505-433-667-408,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
544,EP,A1,EP 4199995 A1,090-006-431-583-36X,2023-06-28,2023,EP 21862342 A,2021-08-03,US 202017001330 A;;US 2021/0044301 W,2020-08-24,PORTABLE INFUSION PUMP WITH PINCH/SQUEEZE PUMPING ACTION,,MODULAR MEDICAL INC,NEESE DAVID;;DIPERNA PAUL M;;GOLDMAN MARC D,,https://lens.org/090-006-431-583-36X,Patent Application,yes,0,0,3,3,0,A61M5/14244;;A61M5/14216;;A61M2205/10;;A61M2205/106;;A61M5/14216;;A61M2205/8275;;A61M5/14244;;A61M5/1452,A61M5/142,,0,0,,,,PENDING
545,EP,A1,EP 0532252 A1,129-173-690-737-273,1993-03-17,1993,EP 92308099 A,1992-09-08,US 75694791 A,1991-09-09,"Superalloy component with dispersion-containing protective coating, and method of preparation.","A coated superalloy component includes a substrate article formed of a superalloy and an adherent coating over the substrate. The coating is a nickel-base superalloy containing at least about 0.1 volume percent or more of a dispersed oxide of yttrium, hafnium and/or a rare earth, and, preferably, grain boundary strengthening elements such as carbon, zirconium, and boron. The oxide dispersoids improve the performance of the coating in service, reducing the incidence failures due to thermal fatigue, oxidation, and corrosion damage. The dispersoid-containing coating may be formed by directly depositing the oxide-containing coating, or by depositing a metallic coating and then forming the dispersoids by subsequent heat treatment.",GEN ELECTRIC,GOLDMAN EDWARD HARVEY;;WORTMAN DAVID JOHN;;DAROLIA RAMGOPAL,,https://lens.org/129-173-690-737-273,Patent Application,yes,5,9,3,4,0,C23C4/06;;C23C4/12;;C23C4/18;;C23C30/00,C23C4/04;;C23C4/06;;C23C4/12;;C23C4/18;;C23C30/00,,1,1,071-256-899-285-336,10.1016/0040-6090(89)90542-7,"THIN SOLID FILMS vol. 173, no. 1, 1 June 1989, LAUSANNE,CH pages 99 - 107 B. GUDMUNDSSON 'yttrium oxides in vacuum-plasma-sprayed CoNiCrAlY coatings'",DISCONTINUED
546,WO,A1,WO 2010/051022 A1,057-264-829-470-336,2010-05-06,2010,US 2009/0005854 W,2009-10-27,US 25917608 A;;US 36363609 A,2008-10-27,NETWORK LASER SYSTEM WITH REMOTE DIAGNOSTICS,"In exemplary embodiments, a network laser system comprises a laser platform including an optical source configured to generate an optical pulse, an optical amplifier configured to amplify the optical pulse, and a compressor configured to temporally compress the amplified optical pulse. The network laser system may also comprise monitor circuitry (e.g., sensors) configured to monitor one or more performance aspects of the laser platform. The network laser system may further comprise logic configured to transmit data to a remote computing device over a network. The network laser system may be configured to perform a diagnostic test and/or maintenance in response to instructions received from the remote computing device.",RAYDIANCE INC;;STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,,https://lens.org/057-264-829-470-336,Patent Application,yes,4,0,3,3,0,H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/149;;H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/147,H01S3/10,,0,0,,,,PENDING
547,US,A1,US 2022/0177382 A1,114-380-793-521-35X,2022-06-09,2022,US 202217678811 A,2022-02-23,US 202217678811 A;;US 202117521022 A;;US 201514856663 A;;US 201462060911 P,2014-10-07,BULK ANIMAL BEDDING,"A bulk animal bedding material is presented comprising shredded and fiberized natural lignocellulosic material vigorously blended with a solvent and small grain particles (SGPs) to form twisted, curled, clumped, and rolled fibers with the SGPs integrated within and/or encasing said fibers.",PITTMOSS LLC,SCOTT BRIAN;;BETHKE CHARLES LEE;;GOLDMAN MARK DAVID,PITTMOSS LLC (2022-04-26),https://lens.org/114-380-793-521-35X,Patent Application,yes,10,1,2,7,0,C05F11/00;;A01K1/0155;;C05F3/00;;Y02A40/20;;Y02P20/145;;C05F11/00;;C05G5/12;;A01K1/015;;A01K1/0155;;A01K1/0154,C05F11/00;;C05G5/12,,0,0,,,,ACTIVE
548,AU,A1,AU 2002/313582 A1,002-811-956-662-968,2003-02-17,2003,AU 2002/313582 A,2002-07-23,IL 14449501 A;;IL 0200611 W,2001-07-23,Cutlery polishing apparatus,,MAOF INNOVATION AND TECHNOLOGI,ENGEL RAMI;;GOLDMAN NITAI;;DAN YARIV;;GELES DAVID,,https://lens.org/002-811-956-662-968,Patent Application,no,0,0,4,4,0,A46B13/001;;B24B19/001;;B24B29/005;;B24B29/10;;B24D13/10,A46B13/00;;B24B19/00;;B24B29/10;;B24D13/10,,0,0,,,,DISCONTINUED
549,EP,A1,EP 2377210 A1,015-454-793-103-254,2011-10-19,2011,EP 09823931 A,2009-10-27,US 2009/0005854 W;;US 25917608 A;;US 36363609 A,2008-10-27,NETWORK LASER SYSTEM WITH REMOTE DIAGNOSTICS,,RAYDIANCE INC,STADLER ANDREW;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,,https://lens.org/015-454-793-103-254,Patent Application,yes,0,0,3,3,0,H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/149;;H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/147,H01S3/10,,0,0,,,,DISCONTINUED
550,WO,A2,WO 2003/009965 A2,078-015-264-408-539,2003-02-06,2003,IL 0200611 W,2002-07-23,IL 14449501 A,2001-07-23,CUTLERY POLISHING APPARATUS,"An apparatus (10) for automatically polishing kitchen utensils. The apparatus (10) comprise one or more entry ports (12), through which the ustensils are loaded onto said tracks, to a collection point, from which ustensils are retrieved in a dry, polished state, wherein each of the one or more conveyor tracks (16) comprises a plurality of rotatable drive wheels (18) for moving said ustensils along the tracks together with means (38) for causing the drive wheels to rotate, and a plurality of rotatable brushes (20) together with means (34) for rotating said brushes, such that the rotating brushes dry and polish said utensils, and means (14) for spaying polishing medium onto said utensils.",MAOF INNOVATION AND TECHNOLOGI;;ENGEL RAMI;;DAN YARIV;;GELES DAVID;;GOLDMAN NITAI,ENGEL RAMI;;DAN YARIV;;GELES DAVID;;GOLDMAN NITAI,,https://lens.org/078-015-264-408-539,Patent Application,yes,0,0,4,4,0,A46B13/001;;B24B19/001;;B24B29/005;;B24B29/10;;B24D13/10,A46B13/00;;B24B19/00;;B24B29/10;;B24D13/10,,0,0,,,,PENDING
551,CA,A,CA 240794 A,056-630-762-700-58X,1924-06-17,1924,CA 240794D A,,CA 240794T A,,NEWSPAPER VENDING MACHINE,,ULLIAN HYMAN BENJAMIN;;GERMAIN DAVID RAYMOND;;GOLDMAN SAM,GERMAIN DAVID RAYMOND;;GOLDMAN SAM;;ULLIAN HYMAN BENJAMIN,,https://lens.org/056-630-762-700-58X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
552,US,B2,US 8619098 B2,176-615-679-641-756,2013-12-31,2013,US 86851910 A,2010-08-25,US 86851910 A;;US 24393209 P,2009-09-18,Methods and apparatuses for generating co-salient thumbnails for digital images,"Methods and apparatus for generating context-sensitive, co-salient thumbnails are described. Co-salient thumbnails may effectively convey more useful information than conventional thumbnails while using the same or similar display space. As such, co-salient thumbnails may make it easier for a user to locate a particular image in a large collection of similar images. In some embodiments, for each of a plurality of patches in a first image, an illustrative method may identify a corresponding similar patch in a second image based on one or more similarity measures. The method may then determine a distance from each of the plurality of patches to its corresponding similar patch and select a crop in the first image relative to the second image based on the determined distance. Optionally, the method may repeat these operations in the opposite direction to select a crop in the second image relative to the first image.",SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E;;ADOBE SYSTEMS INC,SHECHTMAN ELYA;;GOLDMAN DANIEL R;;JACOBS DAVID E,ADOBE INC (2010-08-19),https://lens.org/176-615-679-641-756,Granted Patent,yes,72,5,2,2,0,H04N1/3875;;G06T11/60;;G06T2210/22;;G06V10/759;;G06V10/751;;G06T3/04;;H04N1/3875;;G06T11/60;;G06T2210/22;;G06V10/751;;G06V10/759;;G06T3/04;;G09G5/14,G09G5/02;;G09G5/14,345/635;;345/629;;345/204;;345/2.1;;345/156;;345/168;;345/2.2;;345/1.3;;345/1.1;;345/173;;345/169,99,46,164-611-077-215-676;;010-584-229-002-827;;064-348-768-458-019;;171-563-516-927-107;;047-321-294-726-555;;042-689-645-533-661;;036-712-812-707-784;;006-569-037-594-733;;138-886-667-508-17X;;197-763-750-194-941;;075-286-905-404-93X;;002-904-180-765-355;;086-164-816-979-110;;013-759-719-034-849;;091-368-519-826-690;;042-579-334-928-167;;192-540-347-759-682;;007-057-842-134-091;;030-777-962-603-795;;046-559-636-039-311;;090-847-908-435-564;;100-174-955-372-516;;123-534-977-219-353;;082-859-022-686-637;;051-388-541-746-459;;008-386-133-216-987;;036-158-814-512-635;;053-138-689-081-378;;060-048-731-801-602;;080-004-418-421-532;;029-656-348-079-894;;033-815-104-020-861;;079-200-603-418-338;;125-285-578-163-901;;091-929-151-553-061;;043-814-218-233-994;;134-183-246-339-631;;045-689-670-465-33X;;176-820-572-106-65X;;081-749-474-301-124;;045-981-655-378-439;;173-061-018-421-050;;127-871-225-096-269;;014-842-060-437-773;;091-660-617-416-933;;023-498-194-066-134,10.5244/c.23.116;;10.1007/978-3-540-88688-4_9;;17224616;;10.1109/tpami.2007.60;;10.1145/1186562.1015718;;10.21236/ada540639;;10.1145/245.247;;10.1145/1275808.1276392;;10.1145/1275808.1276382;;10.1145/1186822.1073263;;10.1145/882262.882264;;10.1145/1201775.882269;;10.1145/1179352.1141965;;10.1109/cvpr.2008.4587842;;10.1145/258734.258861;;16173188;;10.1109/tpami.2005.185;;10.1145/344779.345009;;10.1145/74334.74361;;10.1145/1201775.882345;;16792093;;10.1109/tpami.2006.131;;10.1109/cvpr.2005.31;;10.1145/218380.218446;;10.1145/1576246.1531330;;10.1145/1809939.1809954;;10.1016/j.cag.2010.11.002;;10.1145/364338.364405;;10.1145/1731047.1731048;;10.1109/tip.2010.2049240;;20435541;;10.1145/1409060.1409062;;10.1111/1467-8659.00396;;10.1145/1278780.1278822;;10.1145/1964921.1964965;;10.1145/502348.502379;;10.1109/38.736469;;10.1109/tit.1982.1056489;;10.1145/1141911.1141931;;10.1145/192161.192254;;10.1145/192161.192185;;10.1111/j.1467-8659.2009.01403.x;;10.1109/cvpr.2010.5540159;;10.1145/127719.122752;;10.1145/964696.964707;;10.1145/1833349.1778862;;10.1145/383259.383297;;10.1145/192161.192184;;10.1145/882262.882324;;10.1109/cvpr.2012.6247761,"MobiPicture: browsing pictures on mobile devices; Ming-Yu Wang, Xing Xie, Wei-Ying Ma, Hong-Jiang Zhang Nov. 2003.;;Whyte, O., Sivic, J., and Zisserman, A. 2009. Get out of my picture! internet-based inpainting. In BMVC (British Machine Vision Conference), 11 pages.;;U.S. Appl. No. 12/868,540, filed Aug. 25, 2010, Elya Shechtman, et al.;;U.S. Appl. No. 12/857,294, filed Aug. 16, 2010, Dan Goldman, et al.;;P. Bhat, B. Curless, M. Cohen, and C. L. Zitnick. Fourier analysis of the 2d screened poisson equation for gradient domain problems. In ECCV, 2008, 14 pages.;;U.S. Appl. No. 12/394,280, filed Feb. 27, 2009, Dan Goldman, et al.;;Yonatan Wexler, Eli Shechtman, Michel Irani. Space-Time Completion of Video. IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 29, No. 3, Mar. 2007, 14 pages.;;Agarwala, A., Dontcheva, M., Agrawala, M., Drucker, S., Colburn, A., Curless, B., Salesin, D., and Cohen, M. 2004. Interactive digital photomontage. In ACM SIGGRAPH, vol. 23, 294-302.;;Arias, P., Facciolo, G., Caselles, V., and Sapiro, G. 2011. A variational framework for exemplar-based image inpainting. IJCV 93 (July), 319-347.;;U.S. Appl. No. 12/315,038, filed Nov. 26, 2008, Dan Goldman, et al.;;Burt, P. J., and Adelson, E. H. 1983. A multiresolution spline with application to image mosaics. ACM Trans. Graphics 2 (October), 217-236.;;Efros, A. A., and Leung, T. K. 1999. Texture synthesis by non-parametric sampling. IEEE Computer Society, Los Alamitos, CA, USA, 6 pages.;;Fang, H., and Hart, J. C. 2007. Detail preserving shape deformation in image editing. In ACM SIGGRAPH, vol. 26, pp. 1-5.;;Hays, J., and Efros, A. A. 2007. Scene completion using millions of photographs. In ACM SIGGRAPH, vol. 26, 4:1-4: 7 pages.;;Kwatra, V., Essa, I., Bobick, A., and Kwatra, N. 2005. Texture optimization for example-based synthesis. In ACM SIGGRAPH, vol. 24, 795-802.;;Kwatra, V., Schödl, A., Essa, I., Turk, G., and Bobick, A. 2003. Graphcut textures: image and video synthesis using graph cuts. In ACM SIGGRAPH, vol. 22, 277-286.;;Perez, P., Gangnet, M., and Blake, A. 2003. Poisson image editing. In ACM SIGGRAPH, vol. 22, 313-318.;;Rother, C., Bordeaux, L., Hamadi, Y., and Blake, A. 2006. AutoCollage. In ACM SIGGRAPH, vol. 25, 847-852.;;Simakov, D., Caspi, Y., Shechtman, E., and Irani, M. 2008. Summarizing visual data using bidirectional similarity. In CVPR, 8 pages.;;Szeliski, R., and Shum, H.-Y. 1997. Creating full view panoramic image mosaics and environment maps. In ACM SIGGRAPH, 251-258.;;Tappen, M., Freeman, W., and Adelson, E. 2005. Recovering intrinsic images from a single image. IEEE Trans. PAMI 27, 9 (Sep.), 1459-1472.;;Wei, L. Y., and Levoy, M. 2000. Fast texture synthesis using tree-structured vector quantization. In ACM SIGGRAPH, 479-488.;;U.S. Appl. No. 12/858,546, filed Aug. 18, 2010, Holger Winnemoeller, et al.;;U.S. Appl. No. 13/565,552, filed Aug. 2, 2012, Elya Shechtman, et al.;;U.S. Appl. No. 12/858,558, filed Aug. 18, 2010, Holger Winnemoeller, et al.;;Kajiya, J. T. and Kay, T. L. 1989. Rendering fur with three dimensional textures. SIGGRAPH Comput. Graph. 23, 3 (Jul. 1989), 271-280.;;Marschner, S. R., Jensen, H. W., Cammarano, M., Worley, S., and Hanrahan, P. 2003. Light scattering from human hair fibers. In ACM SIGGRAPH 2003 Papers (San Diego, California, Jul. 27-31, 2003). SIGGRAPH '03. ACM, New York, NY, 780-791.;;Chen, H. and Zhu, S. 2006. A Generative Sketch Model for Human Hair Analysis and Synthesis. IEEE Trans. Pattern Anal. Mach. Intell. 28, 7 (Jul. 2006), 1025-1040.;;H. Chen and S. C. Zhu, ""A generative model of human hair for hair sketching"", CVPR (IEEE Conference on Computer Vision on and Pattern Recognition), 2:74-81, 2005.;;David J. Heeger and James R. Bergen. Pyramid-based texture analysis/synthesis. In SIGGRAPH 95, pp. 229-238, 1995.;;""PatchMatch: A Randomized Correspondence Algorithm for Structural Image Editing,"" ACM Transactions on Graphics, Barnes, C., Shechtman, E., Finkelstein, A. and Goldman, Dan B., Proc. SIGGRAPH 28(3), Aug. 2009, 10 pages.;;""ArtRage 3"", Ambient Design, http://www.ambientdesign.com/, from web.archive.org on Aug. 23, 2011, (May 25, 2010), 1 page.;;""Auryn Inc. Auryn Ink"", iTunes Preview, retrieved from , (Jul. 20, 2011), 2 pages.;;""Auryn Ink Review"", www.giggleapps.com, (Feb. 10, 2011), 4 pages.;;""Auryn Releases ""Auryn Ink"" Watercolor App; Named One of the Seven Most Innovative iPad Apps of 2010 by fast Company"", www.marketwire.com, (Jan. 4, 2011), 2 pages.;;""Corel Painter 11 Features"", retrieved from <http://web.archive.org/web/20100526115240/http://www.corel.com/servlet/Satellite/us/en/Product/1166553885783#tabview=tab1> on Mar. 23, 2011, 3 pages.;;""Corel Painter 11 Overview"", retrieved from <http://web.archive.org/web/20100526115240/http://www.corel.com/servlet/Satellite/us/en/Product/1166553885783#tabview=tab0> on Aug. 23, 2011, 3 pages.;;""Final Office Action"", U.S. Appl. No. 12/858,558, (Feb. 15, 2013), 14 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/858,546, (Jan. 30, 2013), 19 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/858,558, (Aug. 30, 2012), 10 pages.;;""Non-Final Office Action"", U.S. Appl. No. 12/868,540, (Feb. 22, 2013), 12 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/858,552, (Apr. 20, 2012), 8 pages.;;""U.S. Application as Filed"", U.S. Appl. No. 12/039,164, filed Feb. 28, 2008, 60 pages.;;Ando, Ryoichi et al., ""Vector Fluid: A Vector Graphics Depiction of Surface Flow"", NPAR '10: Proceedings of the 8th International Symposium on Non-photorealistic Animation and Rendering (pp. 129-135). New York, NY, USA: ACM, (2010), 7 pages.;;Ando, Ryoichi et al., ""Vector Graphics Depicting Marbling Flow"", Computers & Graphics, vol. 35 Issue 1, (Nov. 29, 2010), 14 pages.;;Ashikhmin, Michael ""Synthesizing Natural Textures"", Proceedings of the Symposium on Interactive 3D Graphics 2001, (2001), 10 pages.;;Barla, et al., ""Stroke Pattern Analysis and Synthesis"", EUROGRAPHICS 2006, vol. 25 (2006), No. 3, (2006), 9 pages.;;Barnes, Connelly et al., ""The Generalized Patch Match Correspondence Algorithm"", retrieved from on Sep. 9, 2010, 14 pages.;;Bhat, Pravin et al., ""GradientShop: A Gradient-Domain Optimization Framework for Image and Video Filtering"", ACM Transactions on Graphics 29(2), (2010), 15 pages.;;Bugeau, Aurelie et al., ""A Comprehensive Framework for Image Inpainting"", IEEE Transactions on Image Processing, vol. 19 No. 10, (Oct. 2010), pp. 2634-2645.;;Chen, Xuejin et al., ""Sketch-Based Tree Modeling Using Markov Random Field"", ACM Trans. on Graphics 27, 5, (2008), 9 pages.;;Deussen, Oliver et al., ""Floating Points: A Method for Computing Stipple Drawings"", EUROGRAPHICS 2000, vol. 19 (2000), No. 3, (2000), 10 pages.;;Deussen, Oliver et al., ""The Elements of Nature: Interactive and Realistic Techniques"", SIGGRAPH 2004 Course 31, (2004), 64 pages.;;Diverdi, et al., ""U.S. Application as Filed"", U.S. Appl. No. 13/219,457, filed Aug. 26, 2011, 104 pages.;;Diverdi, Stephen J., et al., ""U.S. Application as Filed"", U.S. Appl. No. 13/219,453, filed Aug. 26, 2011, 102 pages.;;Duran, Jonathan ""Deco Tool and Spray Brush for retrieved from Creating Complex, Geometric Patterns in Flash"", retrieved from on Aug. 31, 2010, (Feb. 2, 2009), 19 pages.;;Esch, Greg et al., ""Interactive Procedural Street Modeling"", SIGGRAPH 2007 Sketches, (2007), 1 page.;;Hacohen, Yoav et al., ""Non-Rigid Dense Correspondence with Applications for Image Enhancement"", SIGGRAPH, (2011), 9 pages.;;Hang, Chu S., ""Making Digital Painting Organic"", PhD Thesis, Hong Kong Universityof Science and Technology, (Aug. 2007), 126 pages.;;Hertzmann, Aaron et al., ""Curve Analogies"", 13th Eurographics Workshop on Rendering (2002), 13 pages.;;Hertzmann, Aaron et al., ""Image Analogies"", Proceedings of SIGGRAPH 2001, (2001), 14 pages.;;Igarashi, Takeo et al., ""A Suggestive Interface for 3D Drawing"", Proceedings of the ACM Symposium on User Interface Software and Technology, UIST 01. 2001, ACM: Orlando, Florida, (2001), 9 pages.;;Ijiri, Takashi et al., ""The Sketch L-System: Global Control of Tree Modeling Using Free-Form Strokes"", Proceedings of 6th International Symposium SmartGraphics 2006, (2006), 9 pages.;;Jodoin, Pierre-Marc et al., ""Hatching by Example: A Statistical Approach"", Proceedings of NPAR 2002, (2002), 8 pages.;;Kaneva, Biliana et al., ""Infinite Images: Creating and Exploring a Large Photorealistic Virtual Space"", Proceeding of the IEEE, vol. 98, No. 8, (Aug. 2010), 17 pages.;;Lin, Wen-Yan et al., ""Smoothly Varying Affine Stitching"", Proceedings of Computer Vision and Pattern Recognition (CVPR), (Jun. 2011), 13 pages.;;Lintermann, Bernd et al., ""Interactive Modeling of Plants"", IEEE Computer Graphics and Applications, 19 (1999), 1, (1999), pp. 2-11.;;Lloyd, Stuart P., ""Least Squares Quantization in PCM"", IEEE Transactions on Information Theory, vol. 28, No. 2, (Mar. 1982), pp. 129-137.;;Mansfield, Alex et al., ""Transforming Image Completion"", Proceedings of British Machine Vision Conference (BMVC), (Aug. 29, 2011), 11 pages.;;Marks, et al., ""Design Galleries: A General Approach to Setting Parameters for Computer Graphics and Animation"", ACM Computer Graphics (SIGGRAPH '97 Proceedings), (Aug. 1997), 26 pages.;;Matsuda, Okiharu ""U.S. Application as Filed"", U.S. Appl. No. 13/219,848, filed Aug. 29, 2011, 27 pages.;;McVeigh, Chris ""ArtRage Studio Pro 3"", PCWorld, retrieved from on Aug. 23, 2011, 4 pages.;;Mech, Radomir et al., ""U.S. Application as Filed"", U.S. Appl. No. 12/857,382, filed Aug. 16, 2010, 57 pages.;;Mech, Radomir et al., ""U.S. Application as Filed"", U.S. Appl. No. 13/029,036, filed Feb. 16, 2011, 69 pages.;;Mech, Radomir et al., ""Visual Models of Plants Interacting with Thier Environment"", Proceedings of SIGGRAPH 96 (New Orleans, LA, Aug. 4-9, 1996), Computer Graphics, (1996), 15 pages.;;Muller, Matthias et al., ""Meshless Deformations Based on Shape Matching"", ACM Transactions on Computer Graphics, 24, 3 (2005), (2005), 8 pages.;;Muller, Pascal et al., ""Procedural Modeling of Buildings"", ACM Trans. Graph., 25 (2006), 3, (2006), 10 pages.;;Parish, Yoav I., et al., ""Procedural Modeling of Cities"", Proceedings of ACM SIGGRAPH 2001, (2001), 8 pages.;;Pritch, Yael et al., ""Shift-Map Image Editing"", ICCV '09, Kyoto, Japan, (Sep. 2009), 8 pages.;;Prusinkiewicz, et al., ""Phyllotaxis"", The Algorithmic Beauty of Plants, Springer-Verlag, Chapter 4, ISBN 978-0387972978, (1990), pp. 99-118.;;Prusinkiewicz, et al., ""Synthetic Topiary"", Proceedings of ACM SIGGRAPH, (1994), 8 pages.;;Ruiters, Roland et al., ""Patch-Based Texture Interpolation"", Eurographics Symposium on Rendering, vol. 29, No. 4, (2010), 9 pages.;;Salisbury, Michael P., et al., ""Interactive Pen-and-Ink Illustration"", Proceedings of SIGGRAPH 1994, (1994), 8 pages.;;Shapira, et al., ""Image Appearance Exploration by Model-Based Navigation"", Computer Graphics Forum, Eurographics, vol. 28 (2009), No. 2, (Mar. 30-Apr. 3, 2009), (Mar. 30, 2009), 10 pages.;;Shechtman, Eli et al., ""Regenerative Morphing"", CVPR, (2010), 8 pages.;;Shechtman, Elya et al., ""U.S. Application as Filed"", U.S. Appl. No. 12/868,519, filed Aug. 25, 2010, 45 pages.;;Sims, Karl ""Artificial Evolution for Computer Graphics"", Computer Graphics 25,4, (Aug. 1991), 9 pages.;;Suh, et al., ""Automatic Thumbnail Cropping and its Effectivenenss"", UIST '03: Proceedings of the 16th annual ACM symposium on User interface software and technology, ACM Press, New York, NY, USA, (Nov. 2003), pp. 95-104.;;Sunkavalli, Kalyan et al., ""Multi-Scale Image Harmonization"", ACM SIGGRAPH, vol. 29 (2010), 10 pages.;;Turk, Greg ""Texture Synthesis on Surfaces"", Proccedings of SIGGRAPH 2001, (2001), 8 pages.;;Van Laerhoven, Tom ""An Extensible Simulation Framework Supporting Physically-based Interactive Painting"", PhD thesis, University of Limburg, (Jun. 21, 2006), 171 pages.;;Winkenbach, Georges et al., ""Computer-Generated Pen-and-Ink Illustration"", Proceedings of SIGGRAPH 1994, (1994), 11 pages.;;Winnemoeller, et al., ""U.S. Application as Filed"", U.S. Appl. No. 12/858,552, filed Aug. 18, 2010, 70 pages.;;Wong, Michael T., et al., ""Computer-Generated Floral Ornament"", Proceedings of SIGGRAPH 1998, (1998), 12 pages.;;Wonka, Peter et al., ""Instant Architecture"", ACM Trans. Graph., 22 (2003), 3, (2003), 9 pages.;;""Corrected Notice of Allowance"", U.S. Appl. No. 12/858,546, (Jun. 6, 2013), 8 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/858,546, (May 6, 2013), 12 pages.;;Lee, Hyunjoon et al., ""Automatic Upright Adjustment of Photographs"", CVPR (2012), 11 pages.;;""Notice of Allowance"", U.S. Appl. No. 12/868,540, (Jul. 22, 2013), 10 pages.",ACTIVE
553,US,B2,US 11597687 B2,007-616-707-293-901,2023-03-07,2023,US 202217678811 A,2022-02-23,US 202217678811 A;;US 202117521022 A;;US 201514856663 A;;US 201462060911 P,2014-10-07,Bulk animal bedding,"A bulk animal bedding material is presented comprising shredded and fiberized natural lignocellulosic material vigorously blended with a solvent and small grain particles (SGPs) to form twisted, curled, clumped, and rolled fibers with the SGPs integrated within and/or encasing said fibers.",PITTMOSS LLC,SCOTT BRIAN;;BETHKE CHARLES LEE;;GOLDMAN MARK DAVID,PITTMOSS LLC (2022-04-26),https://lens.org/007-616-707-293-901,Granted Patent,yes,23,0,2,7,0,C05F11/00;;A01K1/0155;;C05F3/00;;Y02A40/20;;Y02P20/145;;C05F11/00;;C05G5/12;;A01K1/015;;A01K1/0155;;A01K1/0154,C05F11/00;;A01K1/015;;C05G5/12,,0,0,,,,ACTIVE
554,CA,A1,CA 2076091 A1,007-204-954-444-948,1993-03-10,1993,CA 2076091 A,1992-08-13,US 75694791 A,1991-09-09,"SUPERALLOY COMPONENT WITH DISPERSION-CONTAINING PROTECTIVE COATINGS, AND METHOD OF PREPARATION","13DV-8682 SUPERALLOY COMPONENT WITH DISPERSION-CONTAINING PROTECTIVE COATING, AND METHOD OF PREPARATION A coated superalloy component includes a substrate article formed of a superalloy and an adherent coating over the substrate. The coating is a nickel-base superalloy containing at least about 0.3 volume percent or more of a dispersed oxide of yttrium, hafnium and/or a rare earth, and, preferably, grain boundary strengthening elements such as carbon, zirconium, and boron. The oxide dispersoids improve the performance of the coating in service, reducing the incidence failures due to thermal fatigue, oxidation, and corrosion damage. The dispersoid-containing coating may be formed by directly depositing the oxide-containing coating, or by depositing a metallic coating and then forming the dispersoids by subsequent heat treatment.",GOLDMAN EDWARD H;;WORTMAN DAVID J;;DAROLIA RAMGOPAL,GOLDMAN EDWARD H;;WORTMAN DAVID J;;DAROLIA RAMGOPAL,,https://lens.org/007-204-954-444-948,Patent Application,no,0,0,3,4,0,C23C4/06;;C23C4/12;;C23C4/18;;C23C30/00,C23C4/04;;C23C4/06;;C23C4/12;;C23C4/18;;C23C30/00,,0,0,,,,DISCONTINUED
555,SG,A,SG 10202101389T A,077-735-535-682-513,2021-03-30,2021,SG 10202101389T A,2013-06-03,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON’S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID;;PURRO NORBERT,,https://lens.org/077-735-535-682-513,Unknown,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,PENDING
556,EC,A,EC SP19015794 A,157-431-682-979-314,2019-03-29,2019,EC DI201915794 A,2019-03-06,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS LLC,WIRTH DAVID;;PURRO NORBERT;;GOLDMAN ERICK;;SMYTH MARK,,https://lens.org/157-431-682-979-314,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
557,US,A1,US 2014/0279271 A1,048-863-766-472-040,2014-09-18,2014,US 201313835503 A,2013-03-15,US 201313835503 A,2013-03-15,Systems and Methods for Configuring a Group Order and Automatic Generation of Group Order Notification and Feedback Conforming to Pre-Specified Feedback Constraints,"Systems, methods and tools facilitate efficient and convenient e-commerce based group ordering. A group order organizer tool allows a group order organizer to create and configure a group order, specify group members, specify and configure information to be solicited from group members, and customize various details of the group order. The group order tool automatically generates member-specific group order notification documents containing member-specific input controls to allow individual group members to input solicited information. Group order notification and management tools send out the group order notification documents to the group members and manage the responses.",VISTAPRINT TECHNOLOGIES LTD,GOLDMAN DAVID A;;HSU EUGENE;;RICE SUSAN C;;YUKNAT DAVID A,VISTAPRINT TECHNOLOGIES LIMITED (2013-07-18);;CIMPRESS SCHWEIZ GMBH (2013-10-08);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/048-863-766-472-040,Patent Application,yes,10,4,3,3,0,G06Q30/0635;;G06Q30/0635,G06Q30/06,705/26.81,9,0,,,"GroupOrderForm1, ""2012 Ladycat Softball T-Shirt Order Form"", pulled from internet, dated, circa 2012.;;GroupOrderForm2, ""Elementrary Class T-Shirt Order Form"", pulled from internet, dated, circa 2012.;;JotForm, Form Templates web page, dated May 21, 2012, see reference U on page 2 of this PTO 892;;GroupOrderForm3, ""T-Shirt Order Form"", pulled from internet, dated, circa 12012.;;Google PDF dates page, https://www.google.com/search?q=tee+shirt+order+form&biw=1920&bih=1077&source=... 5/10/2016;;Cafepress.com1, https://web.archive.org/web/20130115180504/http://www.teamsportswear.com/aboutus_about.htm, dated 1/15/2013.;;cafepress.com2,https://web.archive.org/web/20130116132749/http://www.logosoftwear.com/custom-made/t-shirt/category.php[, dated 1/16/2013cafepress.com3,;;Cafepress.com3,https://web.archive.org/web/20120715040543/http://www.logosoftwear.com/help_system/index.php?category=10, dated 7/15/2012.;;Cafepress.com4,https://web.archive.org/web/20130116132356/http://www.logosoftwear.com/shareandsell.php, dated 1/16/2013.",DISCONTINUED
558,WO,A2,WO 2012/006553 A2,195-269-368-796-929,2012-01-12,2012,US 2011/0043402 W,2011-07-08,US 83379710 A,2010-07-09,METHOD AND APPARATUS FOR SIMULTANEOUS SWITCHING NOISE OPTIMIZATION,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value assignments or as a list of possible value assignments. Further, the method includes an operation for determining the minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin. Additionally, other method operations are included for routing paths to the I/O pins to meet the actual switching times and for creating a design for the IC that meets the actual switching times.",ALTERA CORP;;KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/195-269-368-796-929,Patent Application,yes,1,0,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,,2,1,087-161-701-056-669,10.1007/11847083_36,"LIN ET AL.: ""IR-drop Reduction Through Combinational Circuit Partitioning"", INTEGRATED CIRCUIT AND SYSTEM DESIGN. POWER AND TIMING MODELING, OPTIMIZATION AND SIMULATION, vol. 4148, 2006, pages 370 - 381, XP019040203;;See also references of EP 2591429A4",PENDING
559,EP,A4,EP 2591429 A4,087-599-811-961-025,2015-02-25,2015,EP 11804423 A,2011-07-08,US 83379710 A;;US 2011/0043402 W,2010-07-09,METHOD AND APPARATUS FOR SIMULTANEOUS SWITCHING NOISE OPTIMIZATION,,ALTERA CORP,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/087-599-811-961-025,Search Report,no,1,0,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,,3,1,087-161-701-056-669,10.1007/11847083_36,"HAI LIN ET AL: ""IR-drop Reduction Through Combinational Circuit Partitioning"", 1 January 2006, INTEGRATED CIRCUIT AND SYSTEM DESIGN. POWER AND TIMING MODELING, OPTIM IZATION AND SIMULATION LECTURE NOTES IN COMPUTER SCIENCE;LNCS, SPRINGER, BERLIN, DE, PAGE(S) 370 - 381, ISBN: 978-3-540-39094-7, XP019040203;;MUKHERJEE A ED - SMAILAGIC A ET AL: ""On the reduction of simultaneous switching in SoCs"", VLSI, 2004. PROCEEDINGS. IEEE COMPUTER SOCIETY ANNUAL SYMPOSIUM ON LAFAYETTE, LA, USA 19-20 FEB. 2004, LOS ALAMITOS, CA, USA,IEEE COMPUT. SOC, US, 19 February 2004 (2004-02-19), pages 262 - 263, XP010726416, ISBN: 978-0-7695-2097-1, DOI: 10.1109/ISVLSI.2004.1339549;;See also references of WO 2012006553A2",DISCONTINUED
560,CN,A,CN 103080938 A,084-659-607-339-389,2013-05-01,2013,CN 201180033590 A,2011-07-08,US 2011/0043402 W;;US 83379710 A,2010-07-09,Method and apparatus for simultaneous switching noise optimization,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value assignments or as a list of possible value assignments. Further, the method includes an operation for determining the minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin. Additionally, other method operations are included for routing paths to the I/O pins to meet the actual switching times and for creating a design for the IC that meets the actual switching times.",ALTERA CORP,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/084-659-607-339-389,Patent Application,no,4,2,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,,2,0,,,"何剑春等: ""超深亚微米芯片互连线电感提取技术及应用"", 《浙江大学学报（工学版）》;;韩海涛: ""高速数字PCB板互连噪声建模与仿真研究"", 《中国优秀博硕士学位论文全文数据库（硕士）》",ACTIVE
561,US,B2,US 8627254 B2,098-887-864-618-840,2014-01-07,2014,US 201213618176 A,2012-09-14,US 201213618176 A;;US 83379710 A,2010-07-09,Method and apparatus for simultaneous switching noise optimization,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value. The minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block are determined such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin.",KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL;;ALTERA CORP,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/098-887-864-618-840,Granted Patent,yes,6,2,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,716/115,0,0,,,,INACTIVE
562,WO,A3,WO 2012/006553 A3,199-795-157-431-685,2012-04-19,2012,US 2011/0043402 W,2011-07-08,US 83379710 A,2010-07-09,METHOD AND APPARATUS FOR SIMULTANEOUS SWITCHING NOISE OPTIMIZATION,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value assignments or as a list of possible value assignments. Further, the method includes an operation for determining the minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin. Additionally, other method operations are included for routing paths to the I/O pins to meet the actual switching times and for creating a design for the IC that meets the actual switching times.",ALTERA CORP;;KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/199-795-157-431-685,Search Report,yes,3,0,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,,0,0,,,,PENDING
563,WO,A1,WO 2015/023622 A1,160-735-245-609-172,2015-02-19,2015,US 2014/0050621 W,2014-08-12,US 201361866587 P,2013-08-16,REMOTELY CONTROLLING ASPECTS OF POOLS AND SPAS,"Systems and methods of (remotely) controlling aspects of pools and spas and of modifying water contained therein are detailed. The Wi- Fi Protected Setup (WPS) standard may be employed to facilitate formation of networks including networking devices associated with controllers of pool and spa equipment. A controller (14) may be accessed via wired and/or wireless data connection (18, 22, 38, 42) from a browser (30) or a mobile device (26). The controller (14) may store data for analysis and evaluation in a remote located server (34)",ZODIAC POOL SYSTEMS INC,UY DINDO;;GOLDMAN DAVID ANDREW;;NIBLER DAVID;;MC QUEEN E KEITH,,https://lens.org/160-735-245-609-172,Patent Application,yes,5,9,2,2,0,G05B15/02;;G05B19/048;;G05B23/0216;;G05B2219/163;;G05B2219/25011;;G05B2219/25168;;G05B2219/2642;;H04W4/38;;G08C17/02;;H04W4/38;;G05B2219/163;;G05B23/0216;;G05B15/02;;G05B2219/25011;;G05B19/048;;G05B2219/25168;;G05B2219/2642;;G08C17/02;;H04L12/282;;H04L67/125;;H04L2012/2841,G05B15/02;;G05B19/048;;G05B23/02;;H04W4/38,,0,0,,,,PENDING
564,US,A1,US 2013/0080987 A1,167-726-179-447-872,2013-03-28,2013,US 201213618176 A,2012-09-14,US 201213618176 A;;US 83379710 A,2010-07-09,METHOD AND APPARATUS FOR SIMULTANEOUS SWITCHING NOISE OPTIMIZATION,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value. The minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block are determined such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin.",KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/167-726-179-447-872,Patent Application,yes,6,7,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,716/113,0,0,,,,INACTIVE
565,EP,A2,EP 2591429 A2,096-515-625-917-915,2013-05-15,2013,EP 11804423 A,2011-07-08,US 83379710 A;;US 2011/0043402 W,2010-07-09,METHOD AND APPARATUS FOR SIMULTANEOUS SWITCHING NOISE OPTIMIZATION,,ALTERA CORP,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,,https://lens.org/096-515-625-917-915,Patent Application,yes,0,0,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,,0,0,,,,DISCONTINUED
566,US,B1,US 8296704 B1,184-591-917-223-821,2012-10-23,2012,US 83379710 A,2010-07-09,US 83379710 A,2010-07-09,Method and apparatus for simultaneous switching noise optimization,"Methods and apparatus for reducing simultaneous switching noise (SSN) in an integrated circuit (IC) designed with a computer aided design (CAD) tool are presented. In one method, value assignments for parameters of the IC are received by the CAD tool. The value assignments are entered as a range of value assignments or as a list of possible value assignments. Further, the method includes an operation for determining the minimum and the maximum path delays for each Input/Output (I/O) pin in an I/O block such that the received value assignments are satisfied. The actual switching times of the I/O pins are spread out in time to decrease SSN in the I/O pins. The switching times are spread out so that the switching times fall between the minimum and the maximum path delay for the corresponding I/O pin. Additionally, other method operations are included for routing paths to the I/O pins to meet the actual switching times and for creating a design for the IC that meets the actual switching times.",KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL;;ALTERA CORP,KIPPER MICHAEL HOWARD;;FENDER JOSHUA DAVID;;AZIZI NAVID;;GOLDMAN DAVID SAMUEL,ALTERA CORPORATION (2010-07-29),https://lens.org/184-591-917-223-821,Granted Patent,yes,6,13,9,9,0,G06F30/3312;;G06F30/34;;G06F30/394;;G06F2119/10;;G06F30/398;;G06F30/34;;G06F30/394;;G06F30/3312;;G06F2119/10;;G06F30/31;;G06F2119/12,G06F17/50,716/115,3,1,012-642-345-507-529,10.1109/iccad.2004.1382691,"International Search Report (PCT/US2011/043402), dated Dec. 27, 2011.;;Azizi et al, ""Incorporating SSN Analysis in Constraint-Based System Design"", Feb. 2009, Design Con.;;Fung et al., ""Simultaneous Short-Path and Long-Path Timing Optimization for FPGAs"", Proceedings of the 2004 IEEE/ACM International conference on Computer-aided design.",ACTIVE
567,WO,A2,WO 2014/150443 A2,059-867-257-422-536,2014-09-25,2014,US 2014/0023280 W,2014-03-11,US 201313835503 A,2013-03-15,SYSTEM AND METHODS FOR CONFIGURING A GROUP ORDER AND AUTOMATIC GENERATION OF GROUP ORDER NOTIFICATION AND FEEDBACK CONFORMING TO PRE-SPECIFIED FEEDBACK CONSTRAINTS,"Systems, methods and tools facilitate efficient and convenient e-commerce based group ordering. A group order organizer tool allows a group order organizer to create and configure a group order, specify group members, specify and configure information to be solicited from group members, and customize various details of the group order. The group order tool automatically generates member-specific group order notification documents containing member-specific input controls to allow individual group members to input solicited information. Group order notification and management tools send out the group order notification documents to the group members and manage the responses.",VISTAPRINT SCHWEIZ GMBH;;GOLDMAN DAVID A;;HSU EUGENE;;RICE SUSAN C;;YUKNAT DAVID A,GOLDMAN DAVID A;;HSU EUGENE;;RICE SUSAN C;;YUKNAT DAVID A,,https://lens.org/059-867-257-422-536,Patent Application,yes,0,0,3,3,0,G06Q30/0635;;G06Q30/0635,,,0,0,,,,PENDING
568,WO,A3,WO 2014/150443 A3,151-695-540-286-812,2015-01-29,2015,US 2014/0023280 W,2014-03-11,US 201313835503 A,2013-03-15,SYSTEMS AND METHODS FOR CONFIGURING A GROUP ORDER AND AUTOMATIC GENERATION OF GROUP ORDER NOTIFICATION,"Systems, methods and tools facilitate efficient and convenient e-commerce based group ordering. A group order organizer tool allows a group order organizer to create and configure a group order, specify group members, specify and configure information to be solicited from group members, and customize various details of the group order. The group order tool automatically generates member-specific group order notification documents containing member-specific input controls to allow individual group members to input solicited information. Group order notification and management tools send out the group order notification documents to the group members and manage the responses.",VISTAPRINT SCHWEIZ GMBH;;GOLDMAN DAVID A;;HSU EUGENE;;RICE SUSAN C;;YUKNAT DAVID A,GOLDMAN DAVID A;;HSU EUGENE;;RICE SUSAN C;;YUKNAT DAVID A,,https://lens.org/151-695-540-286-812,Search Report,yes,8,0,3,3,0,G06Q30/0635;;G06Q30/0635,G06Q30/06,,0,0,,,,PENDING
569,PE,A1,PE 20150174 A1,014-096-968-567-285,2015-02-12,2015,PE 2014002374 A,2013-06-03,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Referida a una forma cristalina A de un compuesto inhibidor de tirosina quinasa (Btk) de Bruton tal como 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona que presenta un patron de difraccion de polvo de rayos X (XRPD) con picos caracteristicos (+/- 0,1�, 2-theta) a 5,7, 13,6, 16,1, 18,9, 21,3 y 21,6. Tambien esta referida a una preparacion farmaceutica que comprende al compuesto en forma amorfa o en su forma cristalina A. Dichas composiciones son utiles en el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cancer, incluyendo linfoma, asi como enfermedades o condiciones inflamatorias",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/014-096-968-567-285,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K47/38;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,DISCONTINUED
570,AU,B2,AU 2013/271918 B2,023-589-943-316-844,2016-08-04,2016,AU 2013/271918 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/023-589-943-316-844,Granted Patent,no,1,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
571,US,B2,US 8184271 B2,030-644-479-523-163,2012-05-22,2012,US 95191110 A,2010-11-22,US 95191110 A;;US 86268007 A;;US 84820006 P,2006-09-29,Differentiation of flow cytometry pulses and applications,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A;;EMD MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2012-01-01);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/030-644-479-523-163,Granted Patent,yes,13,2,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36,356/28;;356/28.5;;73/202.5;;73/204.11,5,3,024-781-884-094-765;;004-776-450-741-441;;110-459-038-028-664,10.1002/0471722731;;10.1002/cyto.1171;;11746105;;10.1021/ac60214a047,"Shapiro, ""Pratical Flow Cytometry,"" 4th Ed., Willey, Hoboken, 2003.;;Westo et al., ""Doublet Discrimination in DNA Cell-Cycle Analysis,"" Cytometry, 2001, vol. 46, pp. 296-306.;;Savitzky et al., ""Smoothing and Differentiation of Data by Simplified Least Squares Procedures,"" Analytical Chemistry, Jul. 1964, vol. 36, No. 8, pp. 1627-1639.;;PCT, International Search Report (PCT/ISA/210) in PCT/US07/79761, Aug. 27, 2008, 2 pages.;;PCT, Written Opinion of the International Searching Authority (PCT/ISA/237) in PCT/US07/79761, Aug. 27, 2008, 2 pages.",ACTIVE
572,KR,A,KR 20170091785 A,015-364-634-958-555,2017-08-09,2017,KR 20177021511 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/015-364-634-958-555,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K31/519;;A61K47/38,,0,0,,,,DISCONTINUED
573,BR,A2,BR PI0923884 A2,017-764-168-984-806,2019-09-03,2019,BR PI0923884 A,2009-12-22,US 2009/0069135 W;;US 34652308 A,2008-12-30,eliminação de contaminação do sinal dinâmico,"""eliminação de contaminação do sinal dinâmico"". a presente invenção refere-se a um amplificador autoconfigurável e a um método de amplificação, incluindo um detector de nível de sinal rf que tem uma entrada conectada a um sinal rf e uma saída configurada para produzir um sinal de controle responsivo a um nível de potência do sinal rf. o sinal de controle é fornecido a um circuito de ajuste paramétrica que inclui uma entrada conectada ao sinal de controle e uma saída configu- rada para fornecer um retorno negativo responsivo ao sinal de controle. o retorno negativo é fornecido a um amplificador de rf que inclui uma entrada que forma uma entrada do amplificador autoconfigurável, uma saída que forma uma saída do amplificador autoconfigurável e uma porta de controle conectada à saída do circuito de ajuste paramétrica, tal que um ou mais parâmetros do amplificador de rf é responsivo ao retorno negativo.",INTEL CORP,DAVID SAWYER;;NADER ROHANI;;NICHOLAS COWLEY;;RICHARD J GOLDMAN,,https://lens.org/017-764-168-984-806,Patent Application,no,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,DISCONTINUED
574,US,A1,US 2011/0271473 A1,058-712-267-686-110,2011-11-10,2011,US 201113101750 A,2011-05-05,US 201113101750 A;;US 33234410 P,2010-05-07,ORAL CARE DEVICE,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,THE GILLETTE COMPANY LLC (2016-09-01);;THE GILLETTE COMPANY (2011-04-21),https://lens.org/058-712-267-686-110,Patent Application,yes,4,4,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04,15/167.1,0,0,,,,ACTIVE
575,GT,A,GT 201400281 A,066-356-668-769-752,2019-08-12,2019,GT 201400281 A,2014-12-04,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"LA PRESENTE INVENCIÓN DESCRIBE AL INHIBIDOR DE TIROSINA QUINASA (BTK) DE BRUTON 1-((R)-3-(4-AMINO-3-(4-FENOXIFENIL)-1H-PIRAZOLO[3, 4-D] PIRIMIDIN-1-IL) PIPERIDIN-1-IL)PROP-2-EN1-ONA, INCLUYENDO LAS FORMAS CRISTALINAS, SOLVATOS Y SUS SALES ACEPTABLES EN EL CAMPO FARMACÉUTICO. SE DESCRIBE TAMBIÉN COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN AL INHIBIDOR BTK, ASÍ COMO MÉTODOS PARA USAR A DICHO INHIBIDOR SOLO O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA EL TRATAMIENTO DE ENFERMEDADES O CONDICIONES AUTOINMUNES, ENFERMEDADES O CONDICIONES HETEROINMUNES, CÁNCER, INCLUYENDO LINFOMA, ASÍ COMO ENFERMEDADES O CONDICIONES INFLAMATORIAS.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/066-356-668-769-752,Amended Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61P35/00,,0,0,,,,PENDING
576,US,A1,US 2007/0253455 A1,076-969-563-583-710,2007-11-01,2007,US 74087407 A,2007-04-26,US 74087407 A;;US 79664606 P,2006-04-26,Intelligent Laser Interlock System,"The present invention comprises, in various embodiments, systems and methods for shutting down a laser system in an intelligent and flexible manner. An intelligent laser interlock system includes both hardwired components, and intelligent components configured to execute computing instructions. The hardwired components and the intelligent components are configured to shutdown the laser system to one or more alternative shutdown states in response to one or more interlock signals.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,RAYDIANCE INC (2007-06-21);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/076-969-563-583-710,Patent Application,yes,99,11,4,4,0,F16P3/20;;H01S3/2308;;H01S3/2308;;H01S3/005;;H01S3/005;;H01S3/0912;;H01S3/0912;;H01S3/10038;;H01S3/10038,H01S3/00;;H02H9/00,372/38.09;;361/52,0,0,,,,ACTIVE
577,ZA,B,ZA 202105175 B,120-046-194-839-677,2022-07-27,2022,ZA 202105175 A,2021-07-22,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/120-046-194-839-677,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
578,GB,A,GB 2451363 A,128-048-589-122-70X,2009-01-28,2009,GB 0817294 A,2007-03-05,US 2007/0005663 W;;US 27807106 A,2006-03-30,Highly responsive master-slave valve positioning,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/128-048-589-122-70X,Patent Application,no,0,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,G05B1/03;;G05D16/20,,1,0,,,Not yet advised.,ACTIVE
579,AU,A1,AU 2013/271918 A1,142-299-062-942-668,2015-01-22,2015,AU 2013/271918 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/142-299-062-942-668,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
580,EP,B1,EP 2062056 B1,158-572-519-604-438,2019-04-10,2019,EP 07843384 A,2007-09-27,US 2007/0079761 W;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,,LUMINEX CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,"CYTEK BIOSCIENCES, INC., FREMONT, US (2023-11-02);;LUMINEX CORPORATION (2019-03-06);;EMD MILLIPORE CORPORATION (2012-04-25);;MILLIPORE CORPORATION (2010-05-19)",https://lens.org/158-572-519-604-438,Granted Patent,yes,7,0,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01N15/14,,0,0,,,,ACTIVE
581,CL,A1,CL 2017000371 A1,172-600-257-727-27X,2017-10-30,2017,CL 2017000371 A,2017-02-13,US 201261655381 P,2012-06-04,Formas cristalinas de un inhibidor de tirosina quinasa de bruton,"<p>SE DESCRIBE AQUÍ AL INHIBIDOR DE TIROSINA QUINASA (BTK) DE BRUTON 1-((R)-3-(4-AMINO-3-(4-FENOXIFENIL)-1 H-PIRALOLO[3,4- D] PIRIMIDIN-1-IL)PIPERIDIN-1-IL)PROP-2-EN-1 -ONA, INCLUYENDO LAS FORMAS CRISTALINAS, SOLVATOS Y SUS SALES ACEPTABLES EN EL CAMPO FARMACÉUTICO. SE DESCRIBE TAMBIÉN COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN AL INHIBIDOR BTK, ASÍ COMO MÉTODOS PARA USAR A DICHO INHIBIDOR SOLO O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA EL  TRATAMIENTO DE ENFERMEDADES O CONDICIONES AUTOINMUNES, ENFERMEDADES O CONDICIONES HETEROINMUNES, CÁNCER, INCLUYENDO LINFOMA, ASÍ COMO ENFERMEDADES O CONDICIONES INFLAMATORIAS.</p>",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/172-600-257-727-27X,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38,,0,0,,,,PENDING
582,AU,A,AU 1996/048278 A,012-370-927-350-457,1996-10-24,1996,AU 1996/048278 A,1996-03-26,US 41920195 A;;US 41920595 A,1995-04-10,"Method and apparatus for conditioning and transporting timed program data, independent of transport timing",,DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,,https://lens.org/012-370-927-350-457,Patent Application,no,0,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,EXPIRED
583,EP,A4,EP 2854859 A4,032-106-283-034-557,2016-01-13,2016,EP 13799982 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2022-05-11),https://lens.org/032-106-283-034-557,Search Report,no,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;A61P29/00;;A61P35/00;;C07D487/04,,1,0,,,See also references of WO 2013184572A1,PENDING
584,JO,B1,JO 3754 B1,063-840-559-265-358,2021-01-31,2021,JO P20130168 A,2013-06-03,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON’S TYROSINE KINASE INHIBITOR,"<p>Described herein is the Bruton’s tyrosine kinase (Btk) inhibitor 1-(®-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or combination with the other threpeutic agents, for the treatment of autoimmune diseases or conditions, heterimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</p>",PHARMACYCLICS LLC,ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO;;MARK SMYTH,,https://lens.org/063-840-559-265-358,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61P29/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;A61P35/00;;C07D487/04,,0,0,,,,ACTIVE
585,US,B2,US 9281653 B2,095-514-991-279-57X,2016-03-08,2016,US 201213553690 A,2012-07-19,US 201213553690 A;;US 74087407 A;;US 79664606 P,2006-04-26,Intelligent laser interlock system,"Systems and methods are disclosed for shutting down a laser system in an intelligent and flexible manner. An intelligent laser interlock system includes both hardwired components, and intelligent components configured to execute computing instructions. The hardwired components and the intelligent components are configured to shutdown the laser system to one or more alternative shutdown states in response to one or more interlock signals.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL;;COHERENT INC,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,RAYDIANCE INC (2007-06-21);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/095-514-991-279-57X,Granted Patent,yes,102,1,4,4,0,F16P3/20;;H01S3/2308;;H01S3/2308;;H01S3/005;;H01S3/005;;H01S3/0912;;H01S3/0912;;H01S3/10038;;H01S3/10038,F16P3/20;;H01S3/00;;H01S3/091;;H01S3/10;;H01S3/23,,76,60,016-042-423-186-246;;034-198-200-102-512;;070-762-457-305-331;;054-553-005-359-274;;107-491-505-742-253;;106-352-588-540-537;;052-988-699-279-649;;141-673-850-199-212;;088-339-132-138-761;;057-872-185-503-276;;058-428-473-536-780;;140-235-674-660-228;;126-512-667-197-138;;109-319-323-316-737;;007-943-533-068-461;;033-492-002-552-396;;044-932-306-406-537;;176-602-037-735-467;;104-896-463-141-607;;049-327-564-862-574;;033-514-707-599-498;;033-514-707-599-498;;172-173-961-881-648;;064-538-387-903-251;;063-273-945-096-013;;064-538-387-903-251;;071-356-742-086-695;;078-630-235-137-447;;055-368-509-124-825;;008-297-618-180-914;;027-044-314-590-758;;007-534-703-329-197;;166-423-940-293-419;;075-065-377-249-833;;003-527-809-444-299;;011-656-550-619-272;;038-776-097-627-86X;;123-241-684-276-697;;007-603-487-033-055;;126-474-490-038-742;;034-344-790-017-571;;145-294-032-372-402;;016-426-124-747-667;;117-744-165-986-432;;145-239-123-381-45X;;060-881-567-032-214;;000-084-545-744-394;;054-499-387-093-074;;026-314-668-625-496;;029-558-780-287-378;;007-610-480-329-043;;018-099-554-374-677;;000-411-739-404-617;;014-781-489-666-564;;001-545-518-386-996;;068-170-005-057-700;;090-225-352-798-75X;;064-013-679-316-815;;072-213-206-454-499;;093-814-694-433-923,20212690;;10.1364/ao.18.002500;;10.1117/12.525748;;10.1364/ol.30.001620;;16075516;;10.1364/opex.12.003888;;19483922;;10.1109/ofc.2005.192643;;10.1364/josab.16.001999;;10.1364/ol.30.001917;;16092218;;19471402;;10.1364/oe.11.002832;;10.1364/ao.36.003375;;18253351;;10.1109/68.769730;;10.1364/oe.11.001175;;19465984;;10.1109/50.802992;;10.1364/ol.30.001446;;16007769;;10.1364/opex.12.000956;;19474907;;10.1049/el:19991505;;18091887;;10.1364/ol.23.001695;;10.1109/jlt.2003.810563;;19730501;;10.1364/ol.10.000609;;10.1063/1.96260;;10.1109/50.618320;;10.1103/physreve.67.046608;;12786510;;10.1364/ol.30.001449;;16007770;;10.1364/ol.30.001449;;16007770;;10.1109/lpt.2004.840999;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;10.1109/lpt.2005.860058;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;15352348;;10.1364/ol.29.001718;;19532735;;10.1364/oe.15.004876;;19471462;;10.1364/oe.11.003332;;19488309;;10.1364/opex.12.006589;;10.1109/cleo.2005.202228;;10.1016/j.addr.2004.12.007;;15757758;;10.1109/lpt.2005.848549;;17041678;;10.1364/ol.31.003191;;10.1109/jlt.1986.1074847;;19730485;;10.1364/ol.10.000562;;10.1109/68.803079;;10.1049/el:19981138;;10.1364/ol.28.001371;;12906093;;10.1117/12.646020;;19498789;;10.1364/opex.13.007621;;10.1364/ao.13.000353;;20125987;;10.1364/oe.14.007125;;19529083;;10.1016/0030-4018(94)90331-x;;10.1016/0030-4018(85)90120-8;;10.1038/nature01275;;12478288;;10.1109/jqe.1986.1073009;;10.1038/418290a;;12124612;;10.1364/ol.11.000153;;19730563;;10.1016/0079-6727(94)00013-o;;10.1364/josab.5.001563;;15295618;;10.1038/sj.gt.3302337;;19823377;;10.1364/ol.18.001343;;10.1016/0030-4018(94)90075-2;;10.1117/12.573681;;10.1364/josa.68.001196;;10.1109/jstqe.2006.884067;;19484030;;10.1364/opex.12.004775;;10.1364/opex.12.002710;;19475112;;10.1364/opex.13.004869;;19498473,"Agostinelli, J. et al., ""Optical Pulse Shaping with a Grating Pair,"" Applied Optics, vol. 18, No. 14, pp. 2500-2504, Jul. 15, 1979.;;Anastassiou et al., ""Photonic Bandgap Fibers Exploiting Omnidirectional Reflectivity Enable Flexible Delivery of Infrared Lasers for Tissue Cutting,"" Proceedings of the SPIE-the International Society for Optical Engineering, SPIE, US, vol. 5317, No. 1, Jan. 1, 2004, pp. 29-38, XP002425586 ISSN: 0277-786X.;;Benoit, G. et al., ""Dynamic All-optical Tuning of Transverse Resonant Cavity Modes in Photonic Bandgap Fibers, ""Optics Letters, vol. 30, No. 13, Jul. 1, 2005, pp. 1620-1622.;;Chen, L. et al., ""Ultrashort Optical Pulse Interaction with Fibre Gratings and Device Applications,"" 1997, Canaga, located at http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq29402.pfd.;;Chen, X. et al., ""Highly Birefringent Hollow-core Photonic Bandgap Fiber,"" Optics Express, vol. 12, No. 16, Aug. 9, 2004, pp. 3888-3893.;;Chen, Y. et al., ""Dispersion-Managed Mode Locking"", Journal of the Optical Society of America B, Nov. 1999, pp. 1999-2004, vol. 16, No. 11, Optical Society of America.;;Dasgupta, S. et al., ""Design of Dispersion-Compensating Bragg Fiber with an Ultrahigh Figure of Merit,"" Optics Letters, Aug. 1, 2005, vol. 30, No. 15, Optical Society of America.;;De Matos et al., ""Multi-kilowatt, Picosecond Pulses from an All-fiber Chirped Pulse Amplification System Using Air-core Photonic Bandgalp Fiber"", Lasers and Electro-optics, 2004, (CLEO), Conference on San Francisco, CA USA, May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. May 17, 2004, pp. 973-974, XP010745448 ISBN: 978-1-55752-777-6.;;De Matos, C.J.S. et al., ""All-fiber Chirped Pulse Amplification using Highly-dispersive Air-core Photonic Bandgap Fiber,"" Nov. 3, 2003, Optics Express, pp. 2832-2837, vol. 11, No. 22.;;Delfyett, P. et al., ""Ultrafast Semiconductor Laser-Diode-Seeded Cr:LiSAF Rengerative Amplifier System"", Applied Optics, May 20, 1997, pp. 3375-3380, vol. 36, No. 15, Octoical Society of America.;;Eggleton, et al., ""Electrically Tunable Power Efficient Dispersion Compensating Fiber Bragg Grating,"" IEEE Photonics Technology Letters, vol., 11, No. 7, pp. 854-856, Jul. 1999.;;Engeness et al., ""Dispersion Tailoring and Compensation by Modal Interations in Omniguide Fibers,"" Optics Express, May 19, 2003, pp. 1175-1196, vol. 11, No. 10.;;Fink et al., ""Guiding Optical Light in Air Using an All-Dielectric Structure,"" Journal of Lightwave Technology, Nov. 1999, pp. 2039-2041, vol. 17, No. 11.;;Folkenberg, J.R., et al., ""Broadband Single-polarization Photonic Crystal Fiber,"" Optics Letters, vol. 30, No. 12, Jun. 15, 2005, pp. 1446-1448.;;Folkenberg, J.R., et al., ""Polarization Maintaining Large Mode Area Photonic Crystal Fiber,"" Optics Express vol. 12, No. 5, Mar. 8, 2004, pp. 956-960.;;Futami, F., et al., ""Wideband Fibre Dispersion Equalisation up to Fourth-order for Long-distance Sub-picosecond Optical Pulse Transmission,"" Electronics Letters, vol. 35, No. 25, Dec. 9, 1999.;;Galvanauskas, A. et al., ""Chirped-pulse-amplification Circuits for Fiber Amplifiers, Based on Chirped-period Quasi-phase, matching gratings"", Optics Letters, Nov. 1, 1998, p. 1695-1697, vol. 23, No. 21, Optical Society of America.;;Hartl et al., ""In-line high energy Yb Fiber Laser Based Chirped Pulse Amplifier System"", Laser and Electro-Optics, 2004, (CLEO) Conference of San Francisco, CA USA May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. 1, May 17, 2004, pp. 563-565, XP010745382, ISBN: 978-1-55752-777-6.;;Hellstrom, E. et al., ""Third-order Dispersion Compensation Using a Phase Modulator"", Journal of Lightwave Technology, vol. 21, No. 5, pp. 1188-1197, May 2003.;;Heritage, J. P. et al., ""Picosecond Pulse Shaping by Spectral Phase and Amplitude Manipulation,"" Optics Letters, vol. 10, No. 12, pp. 609-611, Dec. 1985.;;Heritage, J.P. et al., ""Spectral Windowing of Frequency-Modulated Optical Pulses in a Grating Compressor,"" Applied Physics Letters, vol. 47, No. 2, pp. 87-89, Jul. 15, 1985.;;Hill, K. et al., ""Fiber Bragg Grating Technology Fundamentals and Overview,"" Journal of Lightwave Technology, Aug. 1997, vol. 15, No. 8, pp. 1263-1276.;;Ibanescu et al., ""Analysis of Mode Structure in Hollow Dielctric Waveguide Fibers, ""Physical Review E 67, 2003, The American Physical Society.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Optics Letters, vol. 30, No. 12, pp. 1449-1451, Jun. 15, 2005.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Purdue University ECE Annual Research Summary, Jul. 1, 2004-Jun. 30, 2005.;;Killey, et al., ""Electronic Dispersion Compensation by Signal Predistortion Using Digital Processing and a Dual-Drive Mach-Zehnder Modulator,"" IEEE Photonics Technology Letters, vol. 17, No. 3, pp. 714-716, Mar. 2005.;;Kim, K. et al., ""1.4kW High Peak Power Generation from an All Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Koechner, ""Solid State Laser Engineering"", Oct. 29, 1999, Section 5.5, pp. 270-277, 5th Edition, Springer.;;Kwon, et al., ""Tunable Dispersion Slope Compensator Using a Chirped Fiber Bragg Grating Tuned by a Fan-shaped Thin Metallic Heat Channel,"" IEEE Photonics Technology Letters, vol. 18, No. 1, pp. 118-120, Jan. 1, 2006.;;Kyungbum, Kim et al., ""1.4kW High Peak Power Generation from an all Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Levy et al., ""Engineering Space-Variant Inhomogeneous Media for Polarization Control,"" Optics Letters, Aug. 1, 2004, pp. 1718-1720, vol. 29, No. 15, Optical Society of America.;;Liao, Kai-Hsiu et al., ""Large-aperture Chirped Volume Bragg Grating Based Fiber CPA System, ""Optics Express, Apr. 16, 2007, vol. 15, No. 8, pp. 4876-4882.;;Limpert et al., ""All Fiber Chiped-Pulse Amplification System Based on Compression in Air-Guiding Photonic Bandgap Fiber"", Optics Express, Dec. 1, 2003, vol. 11, No. 24, pp. 3332-3337.;;Lo, S. et al., ""Semiconductor Hollow Optical Waveguides Formed by Omni-directional Reflectors"", Optics Express, vol. 12, No. 26, Dec. 27, 2004, pp. 6589-6593.;;Malinowski A. et al., ""Short Pulse High Power Fiber Laser Systems,"" Proceedings of the 2005 Conference on Lasers and Electro-Optics (CLEO), Paper No. CThG3, pp. 1647-1649, May 26, 2005.;;Mehier-Humbert, S. et al., ""Physical Methods for Gene Transfer: Improving the Kinetics of Gene Delivery Into Cells,"" Advanced Drug Delivery Reviews, vol. 57, pp. 733-753, 2005.;;Mohammed, W. et al., ""Selective Excitation of the TE01 Mode in Hollow-Glass Waveguide Using a Subwavelength Grating,"" IEEE Photonics Technology Letters, Jul. 2005, vol. 17, No. 7, IEEE.;;Nibbering, E.T.J., et al. ""Spectral Determination of the Amplitude and the Phase of Intense Ultrashort Optical Pulses,"" Journal Optical Society of America B, vol. 13, No. 2, pp. 317-329, Feb. 1996.;;Nicholson, J. et al., ""Propagation of Femotsecond Pulses in Large-mode-area, Higher-order-mode Fiber,"" Optics Letters, vol. 31, No. 21, 2005, pp. 3191-3193.;;Nishimura et al., ""In Vivo Manipulation of Biological Systems with Femtosecond Laser Pulses,"" Proc. SPIE 6261, 62611J, pp. 1-10, 2006.;;Noda, J. et al., ""Polarization-maintaining Fibers and Their Applications"", Journal of Lightwave Technology, vol. Lt-4, No. 8 Aug. 1986, pp. 1071-1089.;;Palfrey et al., ""Generation of 16-FSEC Frequency-tunable Pulses by Optical Pulse compression"" Optics Letters, OSA, Optical Society of america, Washington, DC, USA, vol. 10, No. 11, Nov. 1, 1985, pp. 562-564, XP000710358 ISSN: 0146-9592.;;Pelusi, M. et al., ""Electrooptic Phase Modulation of Stretched 250-fs Pulses for Suppression of Third-Order Fiber Disperson in Transmission"", IEEE Photonics Technology Letters, vol. 11, No. 11, Nov. 1999, pp. 1461-1463.;;Pelusi, M. D., et al., ""Phase Modulation of Stretched Optical Pulses for Suppression of Third-order Dispersion Effects in fibre Transmission,"" Electronics Letters, vol. 34, No. 17, pp. 1675-1677, Aug. 20, 1998.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Photonics West 2005, San Jose, California, Jan. 2005, pp. 5709-3720.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Proceedings of SPIE-vol. 5709, Fiber Lasers II: Technology, Systems, and Applications, Apr. 2005, pp. 184-192.;;Ramachandran, S., et al., ""High-power Amplification in a 2040-mum2 Higher Order Mode,"" SPIE Photonics West 2007, Post-deadline.;;Resan et al., ""Dispersion-Managed Semiconductor Mode-Locked Ring Laser"", Optics Letters, Aug. 1, 2003, pp. 1371-1373, vol. 28, No. 15, Optical Society of America.;;Schreiber, T., et al., ""Design and High Power Operation of a Stress-induced single Polarization Single-transverse Mode LMA Yb-doped Photonic Crystal Fiber,"" Fiber Lasers III: Technology, Systems, and Applications, Andrew J.W. Brown, Johan Nilsson, Donald J. Harter, Andreas Tunnermann, eds., Proc. of SPIE, vol. 6102, pp. 61020C-1-61020C-9, 2006.;;Schreiber, T., et al., ""Stress-induced Single-polarization Single-transverse Mode Photonic Crystal Fiber with Low Nonlinearity,"" Optics Express, vol. 13, No. 19, Sep. 19, 2005, pp. 7621-7630.;;Siegman, ""Unstable Optical Resonators"", Applied Optics, Feb. 1974, pp. 353-367, vol. 13, No. 2.;;Stevenson et al., Femtosecond Optical Transfection of Cells: Viability and Efficiency, Optics Express, vol. 14, No. 16, pp. 7125-7133, Aug. 7, 2006.;;Stock et al., ""Chirped Pulse Amplification in an Erbium-doped fiber Oscillator/Erbium-doped Fiber Amplifier System"", Optics Communications, North-Holland Publishing Co., Amsterdam, NL, vol. 106, No. 4/5/06, Mar. 15, 1994, pp. 249-252, XP000429901, ISSN: 0030-4018.;;Strickland et al., ""Compression of Amplified Chirped Optical Pulses"", Optics Communications, North-Holland Publishing Co., Amersterdam, NL, vol. 56, No. 3, Dec. 1, 1985, pp. 219-221, XP024444933 ISSN: 0030-4018 (retrieved on 1985-12-011.;;Temelkuran, B. et al., ""Wavelength-scalable Hollow Optical Fibres with Large Photonic Bandgaps for CO2 Laser Transmission,"" Nature, Dec. 12, 2002, pp. 650-653.;;Thurston, R.N. et al., ""Analysis of Picosecond Pulse Shape Synthesis by Spectral Masking in a Grating Pulse Compressor,"" IEEE Journal of Quantum Electronics, vol. EQ-22, No. 5, pp. 682-696, May 1986.;;Tirlapur et al., ""Targeted Transfection by Femtosecond Laser,"" Nature Publishing Group, vol. 418, pp. 290-291, Jul. 18, 2002.;;Tsai et al., ""Ultrashort Pulsed Laser Light,"" Optics & Photonics News, pp. 25-29, Jul. 2004.;;Vaissie et al., ""Desktop Ultra-Short Pulse Laser at 1552 nm,""Ultrashort Pulse Laser Materials Interaction Workshop (Raydiance)-Directed Energy Professional Society (DEPS), Sep. 28, 2006.;;Weiner, A.M. et al., ""Synthesis of Phase-coherent, Picosecond Optical Square Pulses,"" Optics Letters, vol. 11, No. 3, pp. 153-155, Mar. 1986.;;Weiner, A.M., ""Femtosecond Optical Pulse Shaping and Processing,"" Prog. Quant. Electr. 1995, vol. 19, pp. 161-237, 1995.;;Weiner, A.M., ""High-resolution femtosecond Pulse Shaping,"" Journal of the Optical Society of America B. vol. 5, No. 8, pp. 1563-1572, Aug. 1988.;;Wells, D.J., ""Gene Therapy Progress and Prospects: electroporation and Other Physical Methods,"" Gene Therapy, Nature Publishing Group, vol. 11, pp. 1363-1369, Aug. 5, 2004, (http://www.nature.com/gt).;;White, W.E., et al., ""Compensation of Higher-order Frequency-dependent Phase Terms in Chirped-pulse Amplification Systems,"" Optics Letters, vol. 18, No. 16, pp. 1343-1345, Aug. 15, 1993.;;Yamakawa et al., ""1 Hz, 1 ps, terawatt Nd: glass laser"", Optics Communications, North-Holland Publishing Co. Amsterdam, NL, vol. 112, No. 1-2, Nov. 1, 1994, pp. 37-42, XP024424285.;;Yan et al., Ultrashort Pulse Measurement Using Interferometric Autocorrelator Based on Two-photon-absorbtion Detector at 1.55mum Wavelength Region., 2005, Proceedings of SPIE vol. 5633, Advanced Materials and Devices for Sensing and Imaging II, pp. 424-429.;;Yeh, et al. ""Theory of Bragg Fiber"", Journal of the Optical Society America, Sep. 1978, pp. 1196, vol. 68, No. 9., pp. 1196-1201.;;Yi, Y. et al., ""Sharp Bending of On-Chip silicon Bragg Cladding Waveguide With Light Guiding on Low Index Core Materials"", IEEE Journal of Selected Topics in Quantum Electronics, vol. 12, No. 6, Nov./Dec. 2006, pp. 1345-1348.;;Yi, Y., et al., ""On-chip Si-based Bragg Cladding Waveguide with High Index Contrast Bilayers"", Optics Express, vol. 12, No. 20, Oct. 4, 2004, pp. 4775-4780.;;Yin, D. et al., ""Integrated Arrow Waveguides with Hollow Cores"", Optics Express, vol. 12, No. 12, Jun. 14, 2004, pp. 2710-2715.;;Zhou, S. et al., ""Compensation of nonlinear Phase Shifts with Third-order Dispersion in Short-pulse Fiber Amplifiers,"" Optics Express, vol. 13, No. 13, pp. 4869-2877, Jun. 27, 2005.;;Final Office Action received for U.S. Appl. No. 11/740,874, mailed on Apr. 15, 2010, 18 pages.;;Non-Final Office Action received for U.S. Appl. 11/740,874, mailed on Dec. 13, 2010, 16 pages.;;Non-Final Office Action received for U.S. Appl. 11/740,874, mailed on Oct. 13, 2009, 15 pages.;;Non-Final Office Action received for U.S. Appl. 11/740,874, mailed on Sep. 19, 2011, 11 pages.;;Notice of Allowance received for U.S. Appl. No. 11/740,874, mailed on Mar. 29, 2012, 7 pages.",ACTIVE
586,US,A,US 5819160 A,147-746-442-977-161,1998-10-06,1998,US 71597196 A,1996-09-18,US 71597196 A,1996-09-18,Programmable radio subscription system for receiving selectively defined information,"The radio subscription system of the present invention enables a subscriber to remotely define and identify one or more playlists, each specifying information content selected by the subscriber from a subscription content database, for later transmission to the subscriber's radio. The radio subscription system also permits the subscriber to use the local subscriber radio to remotely request transmission of a particular playlist to the subscriber's radio for storage and playback. The subscriber may then use the local subscriber radio to play back the particular playlist.",AT & T CORP,FOLADARE MARK;;GOLDMAN SHELLEY;;SILVERMAN DAVID PHILLIP;;STURM WALTER,AT&T CORP (1996-08-28),https://lens.org/147-746-442-977-161,Granted Patent,yes,3,392,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,455/45;;455/4.2;;455/186.1,0,0,,,,EXPIRED
587,US,A1,US 2008/0221812 A1,186-606-614-351-318,2008-09-11,2008,US 86268007 A,2007-09-27,US 86268007 A;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2012-01-01);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/186-606-614-351-318,Patent Application,yes,33,49,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G06F19/00;;G01N21/00,702/66;;356/338,0,0,,,,ACTIVE
588,JP,A,JP 2019203008 A,182-773-791-180-911,2019-11-28,2019,JP 2019131481 A,2019-07-16,JP 2017157676 A;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF BRUTON'S TYROSINE KINASE INHIBITOR,"To provide pharmaceutical compositions that include a Btk inhibitor for treatment of autoimmune diseases or disorders, heteroimmune diseases or disorders, cancer including lymphoma, and inflammatory diseases or disorders.SOLUTION: A solid pharmaceutical formulation for oral administration comprises: (a) about 40 mg to about 200 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; (b) about 40 wt.% to about 50 wt.% of a diluent; (c) about 3 wt.% to about 10.wt.% of a disintegrating agent; (d) about 2 wt.% to about 7 wt.% of a surfactant; and (e) about 0.2 wt.% to about 1.0 wt.% of a lubricant. Preferably, the dosage form is a hard gelatin capsule.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/182-773-791-180-911,Patent Application,no,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/02;;A61K47/04;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/28;;A61K47/32;;A61K47/36;;A61K47/38;;A61K47/40;;A61K47/44;;A61P29/00;;A61P35/00;;A61P35/02,,0,0,,,,ACTIVE
589,PH,A1,PH 12020500028 A1,007-555-971-160-052,2022-02-21,2022,PH 12020500028 A,2020-01-02,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON`S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/007-555-971-160-052,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
590,DE,T5,DE 112007000820 T5,003-037-788-418-574,2009-01-29,2009,DE 112007000820 T,2007-03-05,US 27807106 A;;US 2007/0005663 W,2006-03-30,Hochansprechende Master-Slave-Ventileinstellung,,MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/003-037-788-418-574,Patent Application,no,0,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16,,0,0,,,,ACTIVE
591,CL,A1,CL 2014003306 A1,026-801-201-926-365,2015-04-17,2015,CL 2014003306 A,2014-12-03,US 201261655381 P,2012-06-04,Preparacion farmaceutica oral que comprende un inhibidor de tirosina quinasa de bruton y forma cristalina a del mismo.,,PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/026-801-201-926-365,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/5025;;A61K9/48;;A61K47/30;;A61K47/38;;A61P35/00,,0,0,,,,PENDING
592,JP,A,JP 2018012710 A,047-614-187-694-067,2018-01-25,2018,JP 2017157676 A,2017-08-17,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"PROBLEM TO BE SOLVED: To provide compositions for oral administration containing a Bruton's tyrosine kinase (Btk) inhibitor, 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof.SOLUTION: Disclosed herein is a solid pharmaceutical formulation comprising: (a) about 40-200 mg of the above Btk inhibitor; (b) about 40-50 wt% of a diluents; (c) about 3-10 wt% of disintegrator; (d) about 2-7 wt% of a surfactant; and (e) about 0.2-1.0 wt% of a lubricant. A pharmaceutical composition comprising the Btk inhibitor for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer including lymphoma, and inflammatory diseases or conditions is disclosed. Also disclosed is a method for using the Btk inhibitor alone or in combination with other therapeutic agents.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/047-614-187-694-067,Patent Application,no,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61P35/00;;A61P35/02,,0,0,,,,PENDING
593,SU,A1,SU 1138593 A1,047-695-304-119-596,1985-02-07,1985,SU 3490090 A,1982-09-09,SU 3490090 A,1982-09-09,COMPOSITE STRUCTURE,,SP KT B GERMETICHNYKH SKVAZHIN,GOLDMAN ISAAK M;;VERBITSKIJ DAVID I;;SHPRINBERG RUVIM M,,https://lens.org/047-695-304-119-596,Limited Patent,no,0,0,1,1,0,,F16S3/06;;F04B47/00,,0,0,,,,EXPIRED
594,US,A,US 5978671 A,087-827-967-021-074,1999-11-02,1999,US 57638795 A,1995-12-21,US 57638795 A,1995-12-21,Method for updating a caller database in a communication system,"A method for updating a caller database in a communication system by detecting repeat callers during the bridging of calls placed to a called party subscriber and upon such detection, enabling the subscriber to enter corresponding alphanumeric identifiers in the frequent caller database. This method is useful in a communication system that completes a telephone call placed by a caller to a personal telephone number of a called party by bridging that call to a return call originated by the called party in response to a paging signal alerting the subscriber of the telephone call.",AT & T MIDDLETOWN,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,AT&T CORP (1996-03-18),https://lens.org/087-827-967-021-074,Granted Patent,yes,5,29,1,1,0,H04M3/42229;;H04M3/42229;;H04M3/382;;H04M3/382;;H04M3/42042;;H04M3/42042;;H04M3/42059;;H04M3/42059;;H04M3/48;;H04M3/48;;H04M11/022;;H04M11/022;;H04M2201/40;;H04M2201/40;;H04M2242/22;;H04M2242/22;;H04Q3/72;;H04Q3/72;;H04W8/18;;H04W8/18;;H04W8/26;;H04W8/26;;H04W68/00;;H04W68/00;;H04W76/10;;H04W76/10,H04M3/38;;H04M3/42;;H04M3/48;;H04M11/02;;H04Q3/72;;H04W8/18;;H04W8/26;;H04W68/00;;H04W76/02,455/412;;455/461,0,0,,,,EXPIRED
595,CN,B,CN 101611323 B,096-651-936-136-426,2013-02-20,2013,CN 200780043433 A,2007-09-27,US 2007/0079761 W;;US 84820006 P,2006-09-29,Differentiation of flow cytometry pulses and applications,,MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,MILLIPORE CORP. (2010-10-27);;EMD MILLIPORE CORPORATION (2014-08-20),https://lens.org/096-651-936-136-426,Granted Patent,no,0,0,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36;;G01F1/36,,0,0,,,,ACTIVE
596,MX,A,MX 2021012478 A,122-907-150-955-566,2021-11-12,2021,MX 2021012478 A,2014-12-04,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR.,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimid in-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/122-907-150-955-566,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
597,CA,C,CA 3015208 C,144-973-640-088-059,2024-01-02,2024,CA 3015208 A,2013-06-03,US 201261655381 P;;CA 2875986 A,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with the following structure: (see above structure) including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/144-973-640-088-059,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K9/48;;A61K31/519;;A61K47/14;;A61K47/20;;A61K47/38;;A61P35/00,,0,0,,,,PENDING
598,WO,A4,WO 2010/078142 A4,144-922-501-350-897,2010-11-18,2010,US 2009/0069135 W,2009-12-22,US 34652308 A,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP;;COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,,https://lens.org/144-922-501-350-897,Patent Application,yes,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,PENDING
599,CA,A1,CA 2963401 A1,010-461-880-418-645,2016-04-14,2016,CA 2963401 A,2015-09-24,US 201462060911 P;;US 201514856663 A;;US 2015/0051869 W,2014-10-07,MATERIALS SUITABLE AS SUBSTITUTES FOR PEAT MOSSES AND PROCESSES AND APPARATUS THEREFOR,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,HANDLEY MONT ANDREW;;KNAPP MATT COLLINS;;GOLDMAN MARK DAVID,,https://lens.org/010-461-880-418-645,Patent Application,no,0,0,5,7,0,C05F11/00;;C05G5/12;;C05F11/00;;C05G5/12;;C09K17/50;;C09K17/52;;C09K17/16;;C05G3/80,C09K17/00;;C05F11/00,,0,0,,,,DISCONTINUED
600,WO,A2,WO 2010/078142 A2,017-165-127-908-271,2010-07-08,2010,US 2009/0069135 W,2009-12-22,US 34652308 A,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP;;COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,,https://lens.org/017-165-127-908-271,Patent Application,yes,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,PENDING
601,US,A,US 6117188 A,029-767-765-918-339,2000-09-12,2000,US 6765598 A,1998-04-27,US 6765598 A,1998-04-27,System and method using token processing to control software distribution and desktop management in a computer network environment,"A system for controlling the distribution of software in a customized configuration to a plurality of computers in a network environment, comprising console means for creating distribution control information which is both associated with the software and related to said customized configuration, server means responsive to the console means for storing the software and the distribution control information; agent means resident on each computer for downloading the software in accordance with the distribution control information and a token authorization signal from a token server means, and token server means for controlling the number of users simultaneously distributing the software, the token server means responsive to a token request signal from the agent means to provide a token authorization signal to the agent means authorizing the agent means to download the software onto the corresponding computer.",COGNET CORP,ARONBERG DAVID B;;GOLDMAN DOV J;;SPIRO PETER A,COGNET CORP (1998-08-09);;DYNALOG TECHNOLOGIES LTD (1997-11-17);;NORTONLIFELOCK INC (2019-11-04);;CA INC (2019-11-04),https://lens.org/029-767-765-918-339,Granted Patent,yes,10,56,1,1,0,G06F21/105;;G06F21/105;;G06F8/61;;G06F8/61,G06F1/00;;G06F9/445;;G06F21/00,717/11,7,5,087-424-211-414-787;;012-122-068-911-89X;;077-601-118-377-426;;009-078-657-215-135;;094-430-788-375-289,10.1109/35.623994;;10.1109/lcn.1996.558150;;10.1109/noms.1994.644144;;10.1109/icsm.1991.160343;;10.1109/32.55090,"Heilbronner, S.; Managing PC Networks . IEEE/IEE Electronic Library online , IEEE Communications Magazine, vol. 35, Iss. 10, pp. 112 117, Oct. 1997.;;Gumbold, M.; Software Distribution by Reliable Multicast . IEEE/IEE Electronic Library online , Proceedings on the 21st IEEE Conference on Local Computer Networks, pp. 222 231, Oct. 1996.;;Parsons et al.; Intellegent agents in an enterprise management architecture . IEEE/IEE Electronic Library online . 1997 Intl. Conference on Intelligent Processing Systems (ICIPS 97), Oct. 1997.;;Start et al.; The distribution management of service software . Science Server online . Computer Standards and Interfaces, vol. 17, Issue 3, pp. 291 301, Jun. 1995.;;Rozenblit, M.; Secure Software Distribution . IEEE/IEE Electronic Library online . 1994 IEEE Network Operations and Management Symposium. Symposium Record, vol. 2, pp. 486 496, Feb. 1994.;;Perin, C.; Configuration and software distribution in maintenance environments on heterogenous platforms . IEEE/IEE Electronic Library online . Conference on Software Maintenance. Proceedings, pp. 269 274, Oct. 1991.;;White et al.; ABYSS: an architecture for software protection . IEEE/IEE Electronic Library online . IEEE Transactions on Software Engineering, vol. 16, Issue 6, pp. 619 629, Jun. 1990.",EXPIRED
602,US,A1,US 2007/0235668 A1,054-004-753-693-911,2007-10-11,2007,US 27807106 A,2006-03-30,US 27807106 A,2006-03-30,HIGHLY RESPONSIVE MASTER-SLAVE VALVE POSITIONING,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,MKS INSTRUMENTS INC (2006-05-11),https://lens.org/054-004-753-693-911,Patent Application,yes,2,6,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16,251/30.05;;137/624.14,0,0,,,,ACTIVE
603,US,B2,US 8885153 B2,081-147-484-930-612,2014-11-11,2014,US 201213461713 A,2012-05-01,US 201213461713 A;;US 95191110 A;;US 86268007 A;;US 84820006 P,2006-09-29,Differentiation of flow cytometry pulses and applications,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A;;EMD MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2011-12-12);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/081-147-484-930-612,Granted Patent,yes,15,8,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01N15/14,356/28;;356/28.5,5,3,024-781-884-094-765;;004-776-450-741-441;;110-459-038-028-664,10.1002/0471722731;;10.1002/cyto.1171;;11746105;;10.1021/ac60214a047,"Shapiro, ""Pratical Flow Cytometry,"" 4th Ed., Willey, Hoboken, 2003.;;Westo et al., ""Doublet Discrimination in DNA Cell-Cycle Analysis,"" Cytometry, 2001, vol. 46, pp. 296-306.;;Savitzky et al., ""Smoothing and Differentiation of Data by Simplified Least Squares Procedures,"" Analytical Chemistry, Jul. 1964, vol. 36, No. 8, pp. 1627-1639.;;PCT, International Search Report (PCT/ISA/210) in PCT/US07/79761, Aug. 27, 2008, 2 pages.;;PCT, Written Opinion of the International Searching Authority (PCT/ISA/237) in PCT/US07/79761, Aug. 27, 2008, 2 pages.",ACTIVE
604,JO,A1,JO P20200222 A1,102-830-724-824-437,2022-10-30,2022,JO P20200222 A,2020-09-09,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON’S TYROSINE KINASE INHIBITOR,"<p>Described herein is the Bruton’s tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</p>",PHARMACYCLICS LLC,ERICK GOLDMAN;;MARK SMYTH;;NORBERT PURRO;;DAVID D WIRTH,,https://lens.org/102-830-724-824-437,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
605,DE,D1,DE 69633808 D1,165-729-418-120-30X,2004-12-16,2004,DE 69633808 T,1996-03-22,US 41920195 A;;US 41920595 A,1995-04-10,Interaktives Video-auf-Abrufsystem mit Paketübertragung über eine ATM-Fernmeldeleitung,,HEWLETT PACKARD DEVELOPMENT CO,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,,https://lens.org/165-729-418-120-30X,Granted Patent,no,0,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,EXPIRED
606,SU,A1,SU 1038585 A1,182-979-713-071-932,1983-08-30,1983,SU 3357499 A,1981-11-25,SU 3357499 A,1981-11-25,VANE PUMP,,SP KT B GERMETICHNYKH SKVAZHIN,LYASHENKO ANATOLIJ A;;GOLDMAN ISAAK M;;VERBITSKIJ DAVID I,,https://lens.org/182-979-713-071-932,Limited Patent,no,0,0,1,1,0,,F04D29/041;;F04D1/00;;F04D29/04,,0,0,,,,EXPIRED
607,MA,A1,MA 37711 A1,189-957-353-257-596,2017-05-31,2017,MA 37711 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Formes cristallines d'un inhibiteur de tyrosine kinase de bruton,"La présente invention concerne l'inhibiteur de tyrosine kinase de bruton (btk) 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)pipéridin-1-yl)prop-2-èn-1-one, celui-ci comprenant des formes cristallines, des solvates et des sels de qualité pharmaceutique de celui-ci. L'invention concerne également des compositions pharmaceutiques qui comprennent l'inhibiteur de btk, ainsi que des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, du cancer, y compris un lymphome, et de maladies ou d'états inflammatoires.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/189-957-353-257-596,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
608,MA,B2,MA 41654 B2,007-997-242-031-849,2020-12-31,2020,MA 41654 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Formes cristallines d'un inhibiteur de tyrosine kinase de bruton,"La présente invention concerne l'inhibiteur de tyrosine kinase de bruton (btk) 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)pipéridin-1-yl)prop-2-èn-1-one, celui-ci comprenant des formes cristallines, des solvates et des sels de qualité pharmaceutique de celui-ci. L'invention concerne également des compositions pharmaceutiques qui comprennent l'inhibiteur de btk, ainsi que des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, du cancer, y compris un lymphome, et de maladies ou d'états inflammatoires.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/007-997-242-031-849,Amended Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K31/519;;A61K45/06;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
609,BR,A2,BR 112014030424 A2,030-968-561-019-821,2017-06-27,2017,BR 112014030424 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,formas cristalinas de um inibidor de quinase de tirosina de bruton,"resumo formas cristalinas de um inibidor de quinase de tirosina de bruton descreve-se aqui o inibidor de quinase de tirosina de (btk) bruton 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluindo formas cristalinas, solvatos e sais farmaceuticamente aceitáveis dos mesmos. também são reveladas composições farmacêuticas que incluem o inibidor da btk, bem como métodos de utilização do inibidor da btk, sozinho ou em combinação com outros agentes terapêuticos, para o tratamento de doenças auto-imunes ou estados, doenças ou condições hetero-imunes, câncer, incluindo linfomas, e doenças ou patologias inflamatórias.",PHARMACYCLICS INC,DAVID D WIRTH;;ERICK GOLDMAN;;MARK SMYTH;;NORBERT PURRO,PHARMACYCLICS LLC (US) (2023-04-11);;OXFORD AMHERST LLC (US) (2017-07-11),https://lens.org/030-968-561-019-821,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K47/30;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,DISCONTINUED
610,US,A1,US 2011/0063602 A1,035-762-638-446-134,2011-03-17,2011,US 95191110 A,2010-11-22,US 95191110 A;;US 86268007 A;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2012-01-01);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/035-762-638-446-134,Patent Application,yes,12,10,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36,356/28,0,0,,,,ACTIVE
611,US,B2,US 6957178 B2,068-326-660-818-404,2005-10-18,2005,US 1505801 A,2001-10-29,US 1505801 A,2001-10-29,Incremental automata verification,Methods and apparatus for performing formal verification of a system defined by a set of automata are useful in facilitating computing efficiencies during the verification of an incremental system design. The various embodiments permit computing efficiencies by saving information generated during a verification of the system for use in subsequent verification runs. The saved information includes calculation results pertaining to instances or elements of the system that do not require modification for the next subsequent verification.,HONEYWELL INT INC,MUSLINER DAVID J;;GOLDMAN ROBERT P;;PELICAN MICHAEL J,HONEYWELL INTERNATIONAL INC (2001-10-24),https://lens.org/068-326-660-818-404,Granted Patent,yes,22,7,4,4,0,G06F30/3323;;G06F30/3323,G06F17/50,703/15;;714/39,6,2,167-967-698-797-011;;153-888-469-754-794,10.21236/ada359891;;10.7146/brics.v2i2.19504,"R. Alur and D. Dill, ""Automata-theoretic Verification of Real-Time Systems"", Nov. 2, 1995, pp. 1-27.;;M. Archer and C. Heirmeyer, ""Mechanical Verification of Timed Automata: A Case Study"", 1996, pp. 1-12.;;R. Goering, ""Design Automation: Breakthrough claimed in functional verification"", EE Times, May 21, 2001, pp. 59-62.;;F. Laroussinie et al., ""From Timed Automata to Logic-and Back"", BRICS-Jan. 1995, 22 pgs.;;N. Lynch and F. Vaandrager, ""Forward and Backward Simulations Part II: Timing-Based Systems"", Apr. 26, 1995, pp. 1-49.;;B. Plateau and W. Stewart, ""Stochastic Automata Networks: Product Forms and Iterative Solutions"", INRIA-1996, pp. 1-38.",EXPIRED
612,US,A,US 5805991 A,075-344-587-607-549,1998-09-08,1998,US 49706095 A,1995-06-30,US 49706095 A,1995-06-30,Technique for eliminating free paging in a personal mobile communication system,"A system and method for processing telephone calls to a personal telephone number, such calls being of the type in which a call to a called party's personal telephone number results in a page to a pager of a called party and the caller's call is held in the network to be bridged to a return telephone call of the called party, employs type-ahead for faster perceived system response while not permitting free paging. In particular, although type-ahead is permitted, the page is not immediately initiated upon receipt of the last character of a valid command string prior to the end of the announcement that is played to the caller upon his call reaching a bridging and signaling unit. Instead, the bridging and signaling unit is arranged to respond so that it appears to have accepted and executed the command, and moves into the next phase of operation, e.g., music on hold. However, the page is not initiated until it is determined that both 1) the entire time for the announcement has elapsed from the receipt of the caller's call, i.e., the time of commencement of billing has arrived, and 2) the caller remains on the call at that time.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,AT&T CORP (1995-09-06),https://lens.org/075-344-587-607-549,Granted Patent,yes,12,13,1,1,0,H04M3/42229;;H04M3/48;;H04M11/022;;H04M2215/00;;H04W68/00;;H04W76/10;;H04M3/42229;;H04M11/022;;H04M2215/00;;H04W68/00;;H04M3/48;;H04W76/10,H04M3/42;;H04M3/48;;H04M11/02;;H04W68/00;;H04W76/02,455/406;;455/81.2;;455/313;;455/458;;455/459;;455/408,0,0,,,,EXPIRED
613,US,A,US 5844969 A,083-087-861-127-237,1998-12-01,1998,US 78742097 A,1997-01-23,US 78742097 A,1997-01-23,"Communication system, method and device for remotely re-transmitting received electronic mail directed to a destination terminal to a new destination terminal","A communication system for remotely re-selecting and re-transmitting received electronic mail at a destination terminal to another destination terminal using a remote communication device, e.g., a two-way pager. The system includes an electronic mail server coupled to an electronic mail network, a backbone and an alert network. The electronic mail server receives electronic mail messages from the electronic mail network or from the backbone network. Each received mail message includes a sender identification, an E-mail identification and a destination terminal. The server generates and transmits over the alert network a select signal and a message summary to the communication device when an E-mail has been received from a destination terminal. A communication device stores the message summaries and displays them as a user scrolls the message summaries. The user through a keyboard in the device may select and revise a message summary by entering a new destination in the message summary. Using a send key, the user transmits the revised message summary to the server coupled to the destination terminal. The server in response to the transmitted revised message summary accesses a database to locate a copy of the received message or contacts and instructs the destination terminal to forward a copy of the received message to the new destination terminal via the server or an alternate server.",AT & T CORP,GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WESTRICH ROBERT S,AT&T CORP (1997-03-05),https://lens.org/083-087-861-127-237,Granted Patent,yes,8,188,1,1,0,H04L51/214;;H04L51/224;;H04L51/58;;H04L51/214;;H04L51/58;;H04L51/224,H04L12/58,379/93.24;;455/412;;395/200.3,1,0,,,"Paul Hurly et al, The Videotex and Teletext Handbook, pp. 216 218 & 388, 1985.",EXPIRED
614,CN,A,CN 1149225 A,081-142-371-547-016,1997-05-07,1997,CN 96111860 A,1996-08-27,US 52042595 A,1995-08-29,Call screening method and apparatus for use in completing telephone calls,,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,,https://lens.org/081-142-371-547-016,Patent Application,no,0,0,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,,0,0,,,,DISCONTINUED
615,DO,A,DO P2017000152 A,081-966-812-240-944,2017-07-31,2017,DO 2017000152 A,2017-06-22,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS LLC,NORBERT PURRO;;MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH,,https://lens.org/081-966-812-240-944,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
616,EP,A4,EP 4069333 A4,102-384-206-314-595,2023-12-20,2023,EP 20896925 A,2020-12-03,US 201962945033 P;;US 201962944999 P;;US 2020/0063151 W,2019-12-06,ROTARY MICROFLUIDIC MEDICAL PUMP,,QUASURAS INC,DIPERNA PAUL M;;GOLDMAN MARC;;NEESE DAVID;;HEARTY PATRICK,,https://lens.org/102-384-206-314-595,Search Report,no,8,0,8,8,0,A61M2005/14288;;A61M5/14248;;A61M2205/273;;A61M2205/3327;;A61M2205/3331;;A61M2205/3553;;A61M2205/6072;;A61M2205/8206;;A61M2205/50;;A61M2205/52;;A61M2005/14268;;A61M5/14586;;A61M5/16809;;A61M2205/581;;A61M2205/584;;A61M2205/3368;;A61M2005/16868;;A61M2205/18;;A61M2205/6018;;A61M2205/6027;;A61M2205/6036;;A61M2205/6045;;A61M2205/6054;;A61M5/142;;A61M2005/14288;;A61M2205/273;;A61M2205/3327;;A61M2205/3553;;A61M2205/6072;;A61M5/145;;A61M2205/3331;;A61M2205/8206;;A61M5/14248;;A61M2205/50;;A61M2205/52;;G09B23/285;;A61M5/1413,A61M5/142;;A61M5/168;;A61M5/172,,1,0,,,See also references of WO 2021113537A1,PENDING
617,CN,B,CN 102883634 B,102-173-119-115-897,2015-07-15,2015,CN 201180022740 A,2011-05-05,US 2011/0035367 W;;US 33234410 P,2010-05-07,Toothbrush,,GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/102-173-119-115-897,Granted Patent,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,ACTIVE
618,WO,A1,WO 2016/057230 A1,098-925-813-066-542,2016-04-14,2016,US 2015/0051869 W,2015-09-24,US 201462060911 P;;US 201514856663 A,2014-10-07,MATERIALS SUITABLE AS SUBSTITUTES FOR PEAT MOSSES AND PROCESSES AND APPARATUS THEREFOR,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,HANDLEY MONT ANDREW;;KNAPP MATT COLLINS;;GOLDMAN MARK DAVID,,https://lens.org/098-925-813-066-542,Patent Application,yes,5,0,5,7,0,C05F11/00;;C05G5/12;;C05F11/00;;C05G5/12;;C09K17/50;;C09K17/52;;C09K17/16;;C05G3/80,C05G5/00;;C05F11/08,,0,0,,,,PENDING
619,ZA,B,ZA 202105174 B,128-192-290-892-108,2022-07-27,2022,ZA 202105174 A,2021-07-22,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/128-192-290-892-108,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
620,WO,A2,WO 2007/126543 A2,159-033-007-296-076,2007-11-08,2007,US 2007/0005663 W,2007-03-05,US 27807106 A,2006-03-30,HIGHLY RESPONSIVE MASTER-SLAVE VALVE POSITIONING,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/159-033-007-296-076,Patent Application,yes,0,2,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16,,0,0,,,,PENDING
621,US,S,US D0335760 S,165-752-592-542-650,1993-05-25,1993,US 52406290 F,1990-05-16,US 52406290 F,1990-05-16,Shoe signage,,EYE D UNLIMITED INC,WARREN DAVID L;;CRANSTON JOYCE L;;GOLDMAN MARGERY J,WRS GROUP LTD (2001-06-28);;GRAFEETIES & COMPANY INTERNATIONAL INC (1996-10-28);;EYE-D UNLIMITED INC. A CORP. OF CO (1990-05-07),https://lens.org/165-752-592-542-650,Design Right,yes,5,19,1,1,0,,,D 2314,0,0,,,,EXPIRED
622,US,A,US 5724416 A,162-233-601-460-670,1998-03-03,1998,US 67276796 A,1996-06-28,US 67276796 A,1996-06-28,Normalization of calling party sound levels on a conference bridge,"A conference call sound level balancing method and system for selectively muting a conferee whose sound environment is loud enough to dominate other conferees of a conference call. The method is operable on a system that includes a network-based conference bridge and a sound equalization platform that is coupled to each telephone of a conference call. If one telephone connected to the conference call has a higher noise level than the other branches of the call, thus making it so the other branches cannot obtain speaking privileges, a predetermined touchtone key is entered at the noisy telephone. The sound equalization platform responds by automatically measuring the ambient sound levels of the respective branches of the conference call and balancing the speaking privileges for the respective call branches of the conference call.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,ACTIVEPOINT CORPORATION (2012-07-10);;AT&T PROPERTIES LLC (2012-05-22);;CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC (2014-01-01);;MICROSOFT TECHNOLOGY LICENSING LLC (2015-04-28);;AT&T INTELLECTUAL PROPERTY II L.P (2012-05-22);;MOSAID TECHNOLOGIES INC (2012-08-07),https://lens.org/162-233-601-460-670,Granted Patent,yes,15,173,1,1,0,H04M3/56;;H04M3/56;;H04M3/40;;H04M3/40;;H04M3/568;;H04M3/568,H04M3/40;;H04M3/56,379/202;;370/260;;370/263;;370/268;;370/269;;379/204,0,0,,,,EXPIRED
623,MY,A,MY 187999 A,186-403-030-617-119,2021-11-08,2021,MY PI2014003370 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/186-403-030-617-119,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,B65D75/36;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/505;;A61K31/519;;A61K47/02;;A61K47/26;;A61K47/36;;A61K47/38,,0,0,,,,ACTIVE
624,US,A,US 5905944 A,182-845-499-815-131,1999-05-18,1999,US 74831296 A,1996-11-13,US 74831296 A,1996-11-13,Secure communication of access information,"A system and method for secure communication of access information codes to access a telecommunications network and use network services, such as a personal reach service. In that regard, the present invention communicates the access information with the network over a secure paging channel. When call for the user is received at a personal reach service node, a paging message is transmitted to the user through a paging system, the paging message indicating that the call has been received. The user then places a call to the personal reach service node. Upon receiving the call from the user, a request for access information is transmitted to the user. The user then transmits a paging signal from a two-way pager, the paging signal including an indicator of the access information. The personal reach service node receives the indicator of the access information from the user through the paging system and validates the indicated access information. If the indicated access information is valid access is granted to the personal reach service and the two calls are connected to each other.",AT & T CORP,GOLDMAN SHELLY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1997-01-06),https://lens.org/182-845-499-815-131,Granted Patent,yes,12,25,1,1,0,H04L63/10;;H04L63/10;;H04W12/08;;H04W12/08;;H04W68/00;;H04W68/00;;H04W74/00;;H04W74/00;;H04W76/10;;H04W76/10;;H04W84/025;;H04W84/025,H04L29/06;;H04W12/08;;H04W68/00;;H04W74/00;;H04W76/02;;H04W84/02,455/31.3;;455/410;;455/414,0,0,,,,EXPIRED
625,US,B2,US 7643909 B2,031-527-410-066-893,2010-01-05,2010,US 27807106 A,2006-03-30,US 27807106 A,2006-03-30,Highly responsive master-slave valve positioning,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,MKS INSTRUMENTS INC (2006-05-11),https://lens.org/031-527-410-066-893,Granted Patent,yes,2,3,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,G06F19/00,700/282;;251/30.05,2,0,,,"Written Opinion for corresponding PCT Appln: PCT/US2007/05663, 5 pp.;;International Search Report for corresponding PCT Appln: PCT/US2007/05663, 2 pp.",ACTIVE
626,CL,A1,CL 2017003496 A1,038-710-041-446-54X,2018-06-22,2018,CL 2017003496 A,2017-12-29,US 201261655381 P,2012-06-04,Formas cristalinas de un inhibidor de tirosina quinasa de bruton.,"<p>SE DESCRIBE AQUÍ AL INHIBIDOR DE TIROSINA QUINASA (BTK) DE BRUTON 1 -((R)-3-(4-AMINO-3-(4-FENOXIFENIL)-1 H-PIRAZOLO[3,4-D] PIRIMIDIN-1 - II)PIPERIDIN-1-II)PROP-2-EN-1-ONA, INCLUYENDO LAS FORMAS CRISTALINAS, SOLVATOS Y SUS SALES ACEPTABLES EN EL CAMPO FARMACÉUTICO. SE DESCRIBE TAMBIÉN COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN AL INHIBIDOR BTK, ASÍ COMO MÉTODOS PARA USAR A DICHO INHIBIDOR SOLO O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA EL TRATAMIENTO DE ENFERMEDADES O CONDICIONES AUTOINMUNES, ENFERMEDADES O CONDICIONES HETEROINMUNES, CÁNCER, INCLUYENDO LINFOMA, ASÍ COMO ENFERMEDADES O CONDICIONES INFLAMATORIAS.</p>",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/038-710-041-446-54X,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38,,0,0,,,,PENDING
627,KR,A,KR 20110091578 A,072-258-130-036-563,2011-08-11,2011,KR 20117015167 A,2009-12-22,US 34652308 A;;US 2009/0069135 W,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,,INTEL CORP,COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,,https://lens.org/072-258-130-036-563,Patent Application,no,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,ACTIVE
628,MX,A,MX 2014014848 A,104-603-918-345-250,2015-07-06,2015,MX 2014014848 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR.,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimid in-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,PHARMACYCLICS LLC (2017-05-15),https://lens.org/104-603-918-345-250,Patent Application,no,0,1,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
629,CO,A2,CO 7240408 A2,103-152-502-701-315,2015-04-17,2015,CO 14276324 A,2014-12-16,US 201261655381 P,2012-06-04,Formas cristalinas de un inhibidor de tirosina quinasa de bruton,"Se describe aquí al inhibidor de tirosina quinasa(Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1Hpirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sussales aceptables en el campo farmacéutico. Se describetambién composiciones farmacéuticas que incluyen alinhibidor Btk, así como métodos para usar a dicho inhibidorsolo o en combinación con otros agentes terapéuticos, parael tratamiento de enfermedades o condiciones autoinmunes,enfermedades o condiciones heteroinmunes, cáncer,incluyendo linfoma, así como enfermedades o condicionesinflamatorias.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/103-152-502-701-315,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;C07D487/04,,0,0,,,,PENDING
630,DO,A,DO P2022000096 A,115-014-188-333-170,2022-07-15,2022,DO 2022000096 A,2022-05-06,US 201261655381 P;;US 2013/0043888 W,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS LLC,NORBERT PURRO;;MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH,,https://lens.org/115-014-188-333-170,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
631,AR,A1,AR 092844 A1,131-406-410-429-089,2015-05-06,2015,AR P130101974 A,2013-06-04,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Reivindicación 1: Una preparación farmacéutica para administración oral que comprende: (a) más o menos 40 a más o menos 200 mgs de 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona; (b) más o menos 40% en peso a más o menos 50% en peso de un diluyente; (c) más o menos 3% en peso a más o menos 10% en peso de un agente desintegrador; (d) más o menos 2% en peso a más o menos 7% en peso de un agente de actividad superficial; y (e) más o menos 0,2% en peso a más o menos 1,0% en peso de un lubricante. Reivindicación 14: Una Forma A cristalina de 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidinil-il)prop-2-en-1-ona que tiene por lo menos una de las siguientes propiedades: (a) un patrón de difracción de polvo por rayos X (XRPD) esencialmente igual al ilustrado en la figura 1; (b) un patrón de difracción de polvo por rayos X con crestas características a 5,7 ± 0,10 2-q, 13,6 ± 0,10 2-q, 16,1 ± 0,10 2-q, 18,9 ± 0,1º 2-q, 21,3 ± 0,1º 2-q y 21,6 ± 0,1º 2-q; (c) esencialmente el mismo patrón de difracción de polvo por rayos X (XRPD) post-almacenamiento a 40ºC y 75% de humedad relativa durante por lo menos una semana; (d) esencialmente el mismo patrón de difracción de polvo por rayos X (XRPD) post-almacenamiento a 25ºC y 97% de humedad relativa durante por lo menos una semana; (e) espectro infrarrojo (IR) esencialmente similar al indicado en la figura 2; (f) crestas débiles de espectro infrarrojo (IR) a más o menos 1584 cm⁻¹, más o menos 1240 cm⁻¹, más o menos 1147 cm⁻¹, más o menos 1134 cm⁻¹, más o menos 1099 cm⁻¹ y más o menos 1067 cm⁻¹; (g) un termograma DSC esencialmente similar al indicado en la figura 3; (h) un termograma de análisis termo-gravimétrico (TGA) esencialmente similar al indicado en la figura 4; (i) un termograma DSC con una endoterma que tiene un comienzo a más o menos 154ºC y una cresta a más o menos 157ºC y una exoterma a más o menos 159ºC; (j) no higroscopicidad; (k) una solubilidad acuosa observada de más o menos 0,013 mg/mL a más o menos pH 8; o (l) sus combinaciones.",PHARMACYCLICS INC,NORBERT PURRO;;MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH,,https://lens.org/131-406-410-429-089,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519;;A61P29/00;;A61P35/00;;A61P37/00,,0,0,,,,PENDING
632,AU,A1,AU 2011/324028 A1,129-927-693-664-610,2013-05-02,2013,AU 2011/324028 A,2011-06-30,US 91146210 A;;US 2011/0042613 W,2010-10-25,Embroidery workstation utility cart,"An embroidery workstation utility cart for optimizing the positioning of supports for the embroidery machine, thread spool rack, monitor, workpiece queue, and other accessories desired for optimal embroidery processing.",VISTAPRINT SCHWEIZ GMBH,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,VISTAPRINT SCHWEIZ GMBH (2013-12-12),https://lens.org/129-927-693-664-610,Patent Application,no,0,0,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05B43/00;;D02H1/00;;D05C11/00,,0,0,,,,DISCONTINUED
633,UA,C2,UA 126959 C2,163-885-380-254-207,2023-03-01,2023,UA A201700877 A,2013-06-03,US 201261655381 P,2012-06-04,"ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР ТИРОЗИНКІНАЗИ БРУТОНА","У даній заявці розкривається інгібітор тирозинкінази Брутона (Btk) 1-((R)-3-(4-аміно-3-(4-феноксифеніл)-1Н-піразоло[3,4-d]піримідин-1-іл)піпередин-1-іл)проп-2-ен-1-он, включаючи його кристалічні форми, сольвати та фармацевтично прийнятні солі. Також розкриваються фармацевтичні композиції, які включають інгібітор Btk, і способи застосування інгібітору Btk, самостійно або в комбінації з іншими терапевтичними агентами, для лікування аутоімунних захворювань або патологічних станів, гетероімунних захворювань або патологічних станів, раку, включаючи лімфому та запальні захворювання або патологічні стани.",PHARMACYCLICS LCC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/163-885-380-254-207,Limited Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,EXPIRED
634,GB,A,GB 2457943 A,177-960-018-816-604,2009-09-02,2009,GB 0803843 A,2008-02-29,GB 0803843 A,2008-02-29,Film coated blank for forming foodstuff container,"The invention relates to a container and associated blank 1, and a method for forming the blank 1. The blank 1 comprises a paperboard layer and a larger film layer to allow improved film to film sealing of a container formed from the folded blank 1. The film layer may be laminated to the paperboard layer, and the paperboard layer may include an aperture which forms a window in the blank 1. The container may be in the form of a sandwich container or a noodle pot. The blank 1 may further have webbing sections 20 provided between two panels 4, 5 to enable the container to be more easily formed. The webbing sections 20 comprise at least two portions 20a, 20b and a fold line 21. The fold line 21 extends to the opening of the container when formed, so that the edges don't interfere inside the container. A hole 8 is provided in one webbing portion 20b spaced from the fold line 21, so that the plastic sheet portion of the webbing can be heat sealed against an adjacent wall.",COLPAC LTD,WRIGHT PHILLIP;;MILLS FRANK DAVID;;GOLDMAN NEIL VERNON HAROLD,,https://lens.org/177-960-018-816-604,Patent Application,no,8,18,4,4,0,B65D5/2047;;B65D5/24;;B65D5/4279;;B65D5/56;;B65D85/36;;B65D81/2069;;B32B3/02;;B32B27/10;;B65D5/241;;B65D5/243,B65D5/56;;B65D5/20;;B65D5/24;;B65D5/42;;B65D85/36,,0,0,,,,DISCONTINUED
635,GB,B,GB 2451363 B,178-521-750-893-282,2011-03-23,2011,GB 0817294 A,2007-03-05,US 2007/0005663 W;;US 27807106 A,2006-03-30,Highly responsive master-slave valve positioning,,MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/178-521-750-893-282,Granted Patent,no,0,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,G05B1/03;;G05D16/20,,1,0,,,Not yet advised.,ACTIVE
636,WO,A2,WO 2003/038690 A2,184-733-440-342-794,2003-05-08,2003,US 0234429 W,2002-10-29,US 1505801 A,2001-10-29,INCREMENTAL AUTOMATA VERIFICATION,Methods and apparatus for performing formal verification of a system defined by a set of automata are useful in facilitating computing efficiencies during the verification of an incremental system design. The various embodiments permit computing efficiencies by saving information generated during a verification of the system for use in subsequent verification runs. The saved information includes calculation results pertaining to instances or elements of the system that do not require modification for the next subsequent verification.,HONEYWELL INT INC,MUSLINER DAVID J;;PELICAN MICHAEL J;;GOLDMAN ROBERT P,,https://lens.org/184-733-440-342-794,Patent Application,yes,0,0,4,4,0,G06F30/3323;;G06F30/3323,G06F17/50,,0,0,,,,PENDING
637,US,A,US 5831860 A,195-110-569-338-815,1998-11-03,1998,US 43122895 A,1995-04-28,US 43122895 A,1995-04-28,Package special delivery service,"It is possible to redirect a package in mid-transit, so as to deliver it to the addressee who will not be at the location to which the package was originally addressed when the package would otherwise be delivered. To do so, a package carrier, prior to delivering a package to an address specified by the sender, determines if the addressee desires the package to be rerouted to a different address. This determination is prompted by detection of the fact that the addressee is not in the vicinity of the address specified by the sender. The location of the addressee is determined from the location of a two-way pager associated with the addressee as detected by a paging antenna, e.g., tower, of a conventional two-way paging. A comparison is made between the location of the addressee and the address specified by the sender. If there is a disparity and the addressee subscribes to the package special delivery redirection service, the package is then processed according to the instructions of the addressee. One instruction that can be left by the addressee is to call the addressee and ask if he wishes the package to be redirected, and, if so, what should be the new address. Another instruction that can be left by the addressee is to automatically reroute the package to a destination which may be determined as a function of the location of the addressee.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,AT&T IPM CORP (1995-05-24);;BALL HORTICULTURAL COMPANY (1995-09-30),https://lens.org/195-110-569-338-815,Granted Patent,yes,8,163,2,2,0,G06Q10/08;;G06Q10/08,G06Q10/08,364/478.07;;364/479.01;;364/200;;364/478.08;;364/478.15;;364/479.06;;364/479.07;;364/479.12;;364/403,0,0,,,,EXPIRED
638,EP,A2,EP 0831608 A2,000-824-121-783-008,1998-03-25,1998,EP 97306100 A,1997-08-11,US 71597196 A,1996-09-18,Programmable radio subscription system for receiving selectively defined information,"The radio subscription system of the present invention enables a subscriber to remotely define and identify one or more playlists, each specifying information content selected by the subscriber from a subscription content database, for later transmission to the subscriber's radio. The radio subscription system also permits the subscriber to use the local subscriber radio to remotely request transmission of a particular playlist to the subscriber's radio for storage and playback. The subscriber may then use the local subscriber radio to play back the particular playlist.",AT & T CORP,FOLADARE MARK;;SILVERMAN DAVID PHILLIP;;GOLDMAN SHELLEY;;STURM WALTER,,https://lens.org/000-824-121-783-008,Patent Application,yes,0,32,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,,0,0,,,,DISCONTINUED
639,US,A1,US 2012/0097081 A1,011-032-621-159-571,2012-04-26,2012,US 91146210 A,2010-10-25,US 91146210 A,2010-10-25,EMBROIDERY WORKSTATION UTILITY CART,"An embroidery workstation utility cart for optimizing the positioning of supports for the embroidery machine, thread spool rack, monitor, workpiece queue, and other accessories desired for optimal embroidery processing.",BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R;;VISTAPRINT TECHNOLOGIES LTD,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,VISTAPRINT SCHWEIZ GMBH (2013-10-08);;VISTAPRINT TECHNOLOGIES LIMITED (2010-10-25);;VISTAPRINT LIMITED (2013-10-08),https://lens.org/011-032-621-159-571,Patent Application,yes,25,2,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05C3/00,112/78,0,0,,,,DISCONTINUED
640,EP,A1,EP 2854859 A1,024-203-492-657-309,2015-04-08,2015,EP 13799982 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2022-05-11),https://lens.org/024-203-492-657-309,Patent Application,yes,0,2,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K9/20;;A61K31/519;;A61K45/06;;A61P29/00;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
641,CN,A,CN 110354132 A,035-311-717-840-225,2019-10-22,2019,CN 201910730441 A,2013-06-03,US 201261655381 P;;CN 201380041392 A,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3, 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/035-311-717-840-225,Patent Application,no,5,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;A61P39/00,,0,0,,,,PENDING
642,UA,C2,UA 114421 C2,025-033-048-196-187,2017-06-12,2017,UA A201414091 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/025-033-048-196-187,Limited Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,EXPIRED
643,MX,B,MX 348290 B,026-491-018-479-64X,2017-06-05,2017,MX 2014014848 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR.,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimid in-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,PHARMACYCLICS LLC (2017-05-15),https://lens.org/026-491-018-479-64X,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;C07D487/04;;A61K47/30;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
644,JP,A,JP 2021183617 A,019-585-622-872-29X,2021-12-02,2021,JP 2021121857 A,2021-07-26,JP 2019163455 A;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF BRUTON'S TYROSINE KINASE INHIBITOR,"To provide pharmaceutical formulations that include a Btk inhibitor, for treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer including lymphoma, and inflammatory diseases or conditions.SOLUTION: A pharmaceutical formulation for oral administration comprises (a) about 140 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, (b) one or more diluents, (c) one or more surfactants, and (d) one or more lubricants.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/019-585-622-872-29X,Patent Application,no,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/28;;A61K47/32;;A61K47/36;;A61K47/38;;A61K47/40;;A61K47/44;;A61P35/00;;A61P35/02;;A61P43/00,,0,0,,,,PENDING
645,JP,A,JP 2023162162 A,076-885-874-276-576,2023-11-08,2023,JP 2023115449 A,2023-07-13,JP 2021121857 A;;US 201261655381 P;;JP 2019163455 A,2012-06-04,CRYSTALLINE FORMS OF BRUTON TYROSINE KINASE INHIBITOR,"To provide crystalline forms of a Bruton tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and preparation methods thereof.SOLUTION: A crystalline form has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 7.0±0.1° 2-Theta, 14.0±0.1° 2-Theta, 15.7±0.1° 2-Theta, 18.2±0.1° 2-Theta, 19.1±0.1° 2-Theta, 19.5±0.1° 2-Theta, 20.3±0.1° 2-Theta, 22.1±0.1° 2-Theta, and 22.9±0.1° 2-Theta.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/076-885-874-276-576,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K9/48;;A61K31/519;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61P35/00;;A61P35/02,,0,0,,,,PENDING
646,EP,A2,EP 0767568 A2,084-391-326-219-204,1997-04-09,1997,EP 96113939 A,1996-08-30,US 53833195 A,1995-10-03,Method and apparatus for processing telephone calls,"A method and apparatus for processing telephone calls based on variable telephone call parameters is disclosed. A telecommunication network node is connected to a database which stores telephone subscriber preference data describing subscriber preferences. In one embodiment, the database contains subscriber preference data defining the type of telephone services to be applied to outgoing telephone calls. Upon receipt of the outgoing call at the node, the node performs a database search using variable telephone call parameters and retrieves a telephone call service description. The telephone call service description describes the type of service to apply to the call. The call is completed with the described services being applied to the call. In another embodiment, the database contains subscriber preference data defining routing instructions for incoming calls. Upon receipt of the incoming call at the node, the node performs a database search using variable telephone call parameters and retrieves routing instructions. The routing instructions indicate whether the call is to be routed to the subscriber or to an alternate destination. The call is completed by routing it according to the retrieved routing instructions.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,,https://lens.org/084-391-326-219-204,Patent Application,yes,0,9,4,4,0,H04Q3/0016;;H04Q2213/13091;;H04Q2213/13097;;H04Q2213/13103;;H04Q2213/13109;;H04Q2213/13141;;H04Q2213/13332;;H04Q2213/13377;;H04Q2213/1338;;H04Q2213/13405,H04M3/42;;H04Q3/00,,0,0,,,,DISCONTINUED
647,KR,A,KR 20080111471 A,082-795-440-068-567,2008-12-23,2008,KR 20087025015 A,2007-03-05,US 27807106 A;;US 2007/0005663 W,2006-03-30,HIGHLY RESPONSIVE MASTER-SLAVE VALVE POSITIONING,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority. ® KIPO & WIPO 2009",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/082-795-440-068-567,Patent Application,no,0,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16;;F16K37/00,,0,0,,,,ACTIVE
648,AU,C1,AU 2013/271918 C1,099-302-709-680-206,2017-02-09,2017,AU 2013/271918 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/099-302-709-680-206,Amended Patent,no,1,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
649,WO,A1,WO 2013/184572 A1,117-572-111-553-430,2013-12-12,2013,US 2013/0043888 W,2013-06-03,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC;;PURRO NORBERT,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/117-572-111-553-430,Patent Application,yes,31,114,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,20,9,139-003-728-595-305;;061-853-363-196-610;;022-380-553-470-498;;090-064-710-132-858;;004-773-466-896-807;;076-854-822-706-827;;000-491-422-018-497;;025-966-522-155-708;;031-902-506-698-766,6896167;;10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2;;10.1056/nejm198412063112303;;6548796;;18097447;;10.1038/nri2217;;pmc2193582;;10.1084/jem.194.12.1861;;11748286;;10.1126/science.1153629;;18323416;;pmc2787092;;10.1016/j.cell.2009.08.041;;19879843;;10.1186/1742-6413-3-24;;pmc1634871;;17069647;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;10.1107/s002188980600731x,"FREEDMAN ET AL.: ""Cancer Medicine"", 2003, AMERICAN CANCER SOCIETY, B.C. DECKER INC., article ""Non-Hodgkin's Lymphomas"";;""The Non-Hodgkin's Lymphoma Pathologic Classification Project"", CANCER, vol. 49, 1982, pages 2112 - 2135;;HORNINGROSENBERG, N. ENGL. J. MED., vol. 311, 1984, pages 1471 - 1475;;U. KLEIN ET AL., NATURE REVIEWS IMMUNOLOGY, vol. 8, 2008, pages 22 - 23;;R.E. DAVIS ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, 2001, pages 1861 - 1874;;G. LENTZ ET AL., SCIENCE, vol. 319, 2008, pages 1676 - 1679;;M. COMPAGNO ET AL., NATURE, vol. 459, 2009, pages 712 - 721;;L. SRINIVASAN ET AL., CELL, vol. 139, 2009, pages 573 - 586;;STAUDT ET AL., NATURE, vol. 463, 7 January 2010 (2010-01-07), pages 88 - 92;;""Harrison's Principles of Internal Medicine"", 2004, THE MCGRAW-HILL COMPANIES, INC;;DEY ET AL., CYTOJOURNAL, vol. 3, no. 24, 2006;;NISITANI ET AL., PROC. NATL. ACAD. SCI, USA, vol. 96, 1999, pages 2221 - 2226;;""Remington: The Science and Practice of Pharmacy"", 1995, MACK PUBLISHING COMPANY;;JOHN E.: ""Remington's Pharmaceutical Sciences"", 2000, MACK PUBLISHING CO.;;LIBERMAN ET AL.: ""Pharmaceutical Dosage Forms"", vol. 1, 1990, MARCEL DECKER, pages: 209 - 214;;""Pharmaceutical Dosage Forms and Drug Delivery Systems"", 1999, LIPPINCOTT WILLIAMS & WILKINS;;LACHMAN ET AL., THE THEORY AND PRACTICE OF INDUSTRIAL PHARMACY, 1986;;SINGH ET AL.: ""Encyclopedia of Pharmaceutical Technology"", 2002, pages: 751 - 753;;C.F. MACRAE ET AL., J. APPL. CRYST., 2006, pages 39 - 3,453-457;;See also references of EP 2854859A4",PENDING
650,EP,A2,EP 2062056 A2,154-538-900-973-078,2009-05-27,2009,EP 07843384 A,2007-09-27,US 2007/0079761 W;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,,GUAVA TECHNOLOGIES INC,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,"CYTEK BIOSCIENCES, INC., FREMONT, US (2023-11-02);;LUMINEX CORPORATION (2019-03-06);;EMD MILLIPORE CORPORATION (2012-04-25);;MILLIPORE CORPORATION (2010-05-19)",https://lens.org/154-538-900-973-078,Patent Application,yes,0,2,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01F1/36;;G01P3/36,,0,0,,,,ACTIVE
651,US,B2,US 8601635 B2,167-627-758-383-080,2013-12-10,2013,US 201113101750 A,2011-05-05,US 201113101750 A;;US 33234410 P,2010-05-07,Oral care device,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT;;GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,THE GILLETTE COMPANY LLC (2016-09-01);;THE GILLETTE COMPANY (2011-04-21),https://lens.org/167-627-758-383-080,Granted Patent,yes,8,24,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04,15/167.1;;15/201,1,0,,,"PCT International Search Report dated Oct. 7, 2011.",ACTIVE
652,EP,A3,EP 0831608 A3,184-593-752-643-738,1999-02-03,1999,EP 97306100 A,1997-08-11,US 71597196 A,1996-09-18,Programmable radio subscription system for receiving selectively defined information,"The radio subscription system of the present invention enables a subscriber to remotely define and identify one or more playlists, each specifying information content selected by the subscriber from a subscription content database, for later transmission to the subscriber's radio. The radio subscription system also permits the subscriber to use the local subscriber radio to remotely request transmission of a particular playlist to the subscriber's radio for storage and playback. The subscriber may then use the local subscriber radio to play back the particular playlist.",AT & T CORP,FOLADARE MARK;;SILVERMAN DAVID PHILLIP;;GOLDMAN SHELLEY;;STURM WALTER,,https://lens.org/184-593-752-643-738,Search Report,yes,1,0,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 016, no. 254 (E - 1213) 9 June 1992 (1992-06-09)",DISCONTINUED
653,WO,A1,WO 2011/140346 A1,196-943-833-361-356,2011-11-10,2011,US 2011/0035367 W,2011-05-05,US 33234410 P,2010-05-07,TOOTHBRUSH,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GILLETTE CO;;GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/196-943-833-361-356,Patent Application,yes,5,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,PENDING
654,AU,B2,AU 685701 B2,004-557-577-183-870,1998-01-22,1998,AU 1996/048278 A,1996-03-26,US 41920195 A;;US 41920595 A,1995-04-10,"Method and apparatus for conditioning and transporting timed program data, independent of transport timing",,DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,,https://lens.org/004-557-577-183-870,Granted Patent,no,3,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,EXPIRED
655,SU,A1,SU 1116218 A1,009-742-501-076-872,1984-09-30,1984,SU 3589726 A,1983-05-06,SU 3589726 A,1983-05-06,PUMP IMPELLER,,SP KT B GERMETICHNYKH SKVAZHIN,VERBITSKIJ DAVID I;;BYCHKOV YURIJ M;;GOLDMAN ISAAK M,,https://lens.org/009-742-501-076-872,Limited Patent,no,0,1,1,1,0,,F04D11/00;;F04D5/00,,0,0,,,,EXPIRED
656,DE,T2,DE 69633808 T2,031-314-153-767-605,2005-11-03,2005,DE 69633808 T,1996-03-22,US 41920195 A;;US 41920595 A,1995-04-10,Interaktives Video-auf-Abrufsystem mit Paketübertragung über eine ATM-Fernmeldeleitung,,HEWLETT PACKARD DEVELOPMENT CO,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,,https://lens.org/031-314-153-767-605,Granted Patent,no,0,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,EXPIRED
657,US,A1,US 2021/0170095 A1,130-296-308-991-605,2021-06-10,2021,US 202017111396 A,2020-12-03,US 202017111396 A;;US 201962945033 P;;US 201962944999 P,2019-12-06,ROTARY MICROFLUIDIC MEDICAL PUMP,"Rotary microfluidic medical pump and pumping method embodiments are discussed herein that may be used for controlled delivery of small and precise volumes of therapeutic or non-therapeutic fluids in a variety of environmental conditions. Certain medical pump and pumping method embodiments discussed herein may also be useful for the controlled delivery of certain therapeutic fluids that may be susceptible to degradation when exposed to high levels of pressure, flow velocity, shear stress or the like.",QUASURAS INC,DIPERNA PAUL M;;GOLDMAN MARC;;NEESE DAVID;;HEARTY PATRICK,QUASURAS INC (2021-02-04),https://lens.org/130-296-308-991-605,Patent Application,yes,5,4,8,8,0,A61M2005/14288;;A61M5/14248;;A61M2205/273;;A61M2205/3327;;A61M2205/3331;;A61M2205/3553;;A61M2205/6072;;A61M2205/8206;;A61M2205/50;;A61M2205/52;;A61M2005/14268;;A61M5/14586;;A61M5/16809;;A61M2205/581;;A61M2205/584;;A61M2205/3368;;A61M2005/16868;;A61M2205/18;;A61M2205/6018;;A61M2205/6027;;A61M2205/6036;;A61M2205/6045;;A61M2205/6054;;A61M5/142;;A61M2005/14288;;A61M2205/273;;A61M2205/3327;;A61M2205/3553;;A61M2205/6072;;A61M5/145;;A61M2205/3331;;A61M2205/8206;;A61M5/14248;;A61M2205/50;;A61M2205/52;;G09B23/285;;A61M5/1413,A61M5/145,,0,0,,,,PENDING
658,KR,A,KR 20220093389 A,156-895-092-109-852,2022-07-05,2022,KR 20227021197 A,2013-06-03,US 201261655381 P;;KR 20217007940 A;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/156-895-092-109-852,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519,,0,0,,,,DISCONTINUED
659,EP,A1,EP 4069333 A1,187-914-865-319-241,2022-10-12,2022,EP 20896925 A,2020-12-03,US 201962945033 P;;US 201962944999 P;;US 2020/0063151 W,2019-12-06,ROTARY MICROFLUIDIC MEDICAL PUMP,,QUASURAS INC,DIPERNA PAUL M;;GOLDMAN MARC;;NEESE DAVID;;HEARTY PATRICK,,https://lens.org/187-914-865-319-241,Patent Application,yes,0,0,8,8,0,A61M2005/14288;;A61M5/14248;;A61M2205/273;;A61M2205/3327;;A61M2205/3331;;A61M2205/3553;;A61M2205/6072;;A61M2205/8206;;A61M2205/50;;A61M2205/52;;A61M2005/14268;;A61M5/14586;;A61M5/16809;;A61M2205/581;;A61M2205/584;;A61M2205/3368;;A61M2005/16868;;A61M2205/18;;A61M2205/6018;;A61M2205/6027;;A61M2205/6036;;A61M2205/6045;;A61M2205/6054;;A61M5/142;;A61M2005/14288;;A61M2205/273;;A61M2205/3327;;A61M2205/3553;;A61M2205/6072;;A61M5/145;;A61M2205/3331;;A61M2205/8206;;A61M5/14248;;A61M2205/50;;A61M2205/52;;G09B23/285;;A61M5/1413,A61M5/142;;A61M5/172,,0,0,,,,PENDING
660,US,A,US 5561791 A,180-665-206-365-130,1996-10-01,1996,US 41920195 A,1995-04-10,US 41920195 A,1995-04-10,Method and apparatus for conditioning timed program independent of transport timing,"In an interactive video-on-demand system, real-time programs are encoded as a transport stream including a plurality of transport stream packets. Some of the transport stream packets include timing signals indicating the real time of the program. The transport stream packets are formatted into transport cells for transport over an asynchronous transfer mode network from a source to a destination. The cells are transported at a transport rate which is determined by a network clock. The transport rate is chosen to deliver the transport stream faster than the real time of the program. While transporting the transport stream, it is determined if the transport stream is being transported ahead of the real time of the program. In this case, idle cells are injected into the transport stream to have the program arrive at the destination in the real time of the program.",DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;DIGITAL EQUIPMENT CORPORATION (1995-04-07);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/180-665-206-365-130,Granted Patent,yes,5,130,1,12,0,H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347;;H04N21/47202;;H04N21/47202;;H04N7/17336;;H04N7/17318;;H04N21/4347;;H04N21/2365,H04N7/173;;H04N21/2365;;H04N21/434;;H04N21/472,395/550;;395/200.13;;370/94.1,0,0,,,,EXPIRED
661,CN,A,CN 104736178 A,193-639-100-564-097,2015-06-24,2015,CN 201380041392 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/193-639-100-564-097,Patent Application,no,1,19,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,DISCONTINUED
662,CA,C,CA 2664456 C,193-743-280-616-228,2013-12-31,2013,CA 2664456 A,2007-09-27,US 84820006 P;;US 2007/0079761 W,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",GUAVA TECHNOLOGIES INC,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,,https://lens.org/193-743-280-616-228,Granted Patent,no,0,0,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01N15/10,,0,0,,,,ACTIVE
663,JP,A,JP H10190594 A,034-667-887-980-045,1998-07-21,1998,JP 21640097 A,1997-08-11,US 71597196 A,1996-09-18,RADIO JOINING AND LISTENING SYSTEM,"PROBLEM TO BE SOLVED: To make a listener able to select the contents of radio broadcasting by himself/herself. SOLUTION: By this radio joining and listening system, a subscriber can remotely define and confirm one or plural play lists. Respective specified information contents are selected by the subscriber from a joining and listening contents data base 18 and transmitted to the radio 12 of the subscriber later. Also, by the radio joining and listening system, the subscriber remotely requests a specified play list for storage or reproduction to be transmitted to the radio of the subscriber by using the radio 12 of a local subscriber. Then, the subscriber can reproduce the specified play list by using the radio 12 of the local subscriber.",AT & T CORP,FOLADARE MARK;;GOLDMAN SHELLEY;;SILVERMAN DAVID PHILLIP;;STURM WALTER,,https://lens.org/034-667-887-980-045,Patent Application,no,0,18,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,,0,0,,,,EXPIRED
664,AU,B2,AU 2020/239751 B2,034-450-295-816-527,2022-10-27,2022,AU 2020/239751 A,2020-09-24,AU 2020/239751 A;;AU 2018/211201 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/034-450-295-816-527,Granted Patent,no,1,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
665,EP,A1,EP 2633111 A1,040-348-179-188-048,2013-09-04,2013,EP 11738873 A,2011-06-30,US 91146210 A;;US 2011/0042613 W,2010-10-25,EMBROIDERY WORKSTATION UTILITY CART,,VISTAPRINT TECHNOLOGIES LTD,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,VISTAPRINT SCHWEIZ GMBH (2013-12-25),https://lens.org/040-348-179-188-048,Patent Application,yes,0,0,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05B43/00;;D02H1/00;;D05C11/00,,0,0,,,,DISCONTINUED
666,CR,A,CR 20140558 A,044-389-443-893-608,2015-03-13,2015,CR 20140558 A,2014-12-04,US 201261655381 P;;US 2013/0043888 W,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/044-389-443-893-608,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
667,US,A1,US 2003/0083858 A1,051-270-291-278-766,2003-05-01,2003,US 1505801 A,2001-10-29,US 1505801 A,2001-10-29,Incremental automata verification,"
   Methods and apparatus for performing formal verification of a system defined by a set of automata are useful in facilitating computing efficiencies during the verification of an incremental system design. The various embodiments permit computing efficiencies by saving information generated during a verification of the system for use in subsequent verification runs. The saved information includes calculation results pertaining to instances or elements of the system that do not require modification for the next subsequent verification. 
",HONEYWELL INT INC,MUSLINER DAVID J;;GOLDMAN ROBERT P;;PELICAN MICHAEL J,HONEYWELL INTERNATIONAL INC (2001-10-24),https://lens.org/051-270-291-278-766,Patent Application,yes,22,10,4,4,0,G06F30/3323;;G06F30/3323,G06F17/50,703/22,0,0,,,,EXPIRED
668,NZ,A,NZ 702548 A,080-488-743-185-848,2015-11-27,2015,NZ 70254813 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a bruton’s tyrosine kinase inhibitor,"Described herein is the Bruton’s tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,"PHARMACYCLICS LLC, US (2015-10-30)",https://lens.org/080-488-743-185-848,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
669,MA,A1,MA 41654 A1,093-903-137-838-092,2018-07-31,2018,MA 41654 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Formes cristallines d'un inhibiteur de tyrosine kinase de bruton,"La présente invention concerne l'inhibiteur de tyrosine kinase de bruton (btk) 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)pipéridin-1-yl)prop-2-èn-1-one, celui-ci comprenant des formes cristallines, des solvates et des sels de qualité pharmaceutique de celui-ci. L'invention concerne également des compositions pharmaceutiques qui comprennent l'inhibiteur de btk, ainsi que des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou d'états auto-immuns, de maladies ou d'états hétéro-immuns, du cancer, y compris un lymphome, et de maladies ou d'états inflammatoires.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/093-903-137-838-092,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
670,AU,B2,AU 2016/250445 B2,100-308-374-820-828,2018-07-26,2018,AU 2016/250445 A,2016-10-28,AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1 -yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/100-308-374-820-828,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
671,US,B2,US 9296753 B2,096-994-582-275-158,2016-03-29,2016,US 201313908949 A,2013-06-03,US 201313908949 A;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (NANOSYN) (2012-07-12),https://lens.org/096-994-582-275-158,Granted Patent,yes,100,76,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06,,100,26,029-381-309-895-477;;038-340-694-023-194;;041-564-787-488-186;;051-773-437-524-806;;084-954-244-635-278;;015-063-415-122-10X;;094-426-452-116-986;;026-602-342-915-043;;070-105-220-366-494;;157-431-722-988-742;;089-560-783-324-399;;039-782-322-629-050;;082-627-792-674-488;;049-401-272-654-645;;062-629-771-597-536;;032-600-458-370-231;;005-264-653-185-294;;032-963-276-412-261;;017-696-456-420-448;;014-599-246-214-415;;008-839-998-512-08X;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;005-576-769-764-004;;069-501-243-828-566,pmc4513941;;23782157;;10.1056/nejmoa1306220;;20166765;;10.2165/11532180-000000000-00000;;15771912;;10.1016/j.cancergencyto.2004.08.012;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;22960555;;10.1097/cco.0b013e3283589950;;10.1016/j.bcp.2012.07.031;;22885287;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.7326/0003-4819-90-5-761;;434676;;23425038;;10.3109/10428194.2013.777837;;10.1016/s1074-7613(00)00002-9;;10933389;;16917004;;10.1182/blood-2006-05-026112;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;10.1182/blood-2005-01-0016;;16123223;;10.1084/jem.20021845;;12810683;;pmc2193950,"Remington's Pharmaceutical Sciences, 1985, Mack Printing Co., 17th ed., p. 185.;;U.S. Appl. No. 14/073,543, filed Nov. 6, 2013, Honigberg et al.;;U.S. Appl. No. 14/073,594, filed Nov. 6, 2013, Honigberg et al.;;U.S. Appl. No. 14/079,508, filed Nov. 14, 2013, Honigberg et al.;;U.S. Appl. No. 14/080,640, filed Nov. 14, 2013, Honigberg et al.;;U.S. Appl. No. 14/080,649, filed Nov. 14, 2013, Honigberg et al.;;U.S. Appl. No. 14/156,247, filed Jan. 15, 2014, Honigberg et al.;;U.S. Appl. No. 14/188,390, filed Feb. 24, 2014, Buggy et al.;;U.S. Appl. No. 13/542,440 Non-Final Office Action mailed Oct. 31, 2013.;;U.S. Appl. No. 13/450,158 Non-Final Office Action mailed Oct. 31, 2013.;;U.S. Appl. No. 13/606,949 Non-Final Office Action mailed Oct. 29, 2013.;;U.S. Appl. No. 13/340,522 Final Office Action mailed Nov. 1, 2013.;;U.S. Appl. No. 12/907,759 Final Office Action mailed Nov. 8, 2013.;;U.S. Appl. No. 13/335,719 Final Office Action mailed Nov. 8, 2013.;;U.S. Appl. No. 13/340,409 Final Office Action mailed Nov. 12, 2013.;;U.S. Appl. No. 13/249,066 Office Action mailed Dec. 11, 2013.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;U.S. Appl. No. 12/907,759 Office Action mailed Aug. 13, 2013.;;U.S. Appl. No. 12/907,759 Office Action mailed Dec. 31, 2013.;;U.S. Appl. No. 13/153,291 Final Office Action mailed Jan. 3, 2014.;;U.S. Appl. No. 13/542,440 Office Action mailed Jan. 7, 2014.;;U.S. Appl. No. 13/341,708 Office Action mailed Jan. 22, 2014.;;PRNewswire, ""Update on Preclinical Finding and Development Timeline for PCI-45292"", Mar. 2, 2011.;;U.S. Appl. No. 13/153,317 Final Office Action mailed Jan. 23, 2014.;;Science Daily ""Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma."" (Jun. 19, 2013), http://www.sciencedaily.com/releases/2013/06/130619195217.htm, last accessed Jan. 30, 2014.;;Wang et al. ""Targeting BTK with ibrutinib in relapsed or refractory mantel-cell lymphoma."" N Engl J Med 369(6):507-516 (Aug. 8, 2013).;;U.S. Appl. No. 13/606,949 Final Office Action mailed Feb. 14, 2014.;;U.S. Appl. No. 13/404,422 Office Action mailed Feb. 21, 2014.;;U.S. Appl. No. 13/410,110 Office Action mailed Feb. 24, 2014.;;U.S. Appl. No. 13/430,173 Office Action mailed Feb. 25, 2014.;;U.S. Appl. No. 13/607,036 Office Action mailed Mar. 6, 2014.;;U.S. Appl. No. 13/439,775 Office Action mailed Mar. 6, 2014.;;U.S. Appl. No. 13/340,621 Office Action mailed Mar. 6, 2014.;;U.S. Appl. No. 13/232,784 Office Action mailed Mar. 6, 2014.;;U.S. Appl. No. 13/340,559 Office Action mailed Mar. 17, 2014.;;U.S. Appl. No. 13/736,812 Office Action mailed Mar. 18, 2014.;;Hagemeister, F. ""Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia,"" Drugs, 70(3):261-272 (2010).;;U.S. Appl. No. 13/747,319 Office Action mailed Mar. 20, 2014.;;U.S. Appl. No. 13/747,322 Office Action mailed Mar. 20, 2014.;;Glassman et al., ""The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,"" Cancer Genetics and Cytogenetics 158:88-91 (2005).;;U.S. Appl. No. 13/543,065 Office Action mailed Mar. 25, 2014.;;U.S. Appl. No. 13/543,394 Office Action mailed Mar. 25, 2014.;;U.S. Appl. No. 13/543,399 Office Action mailed Mar. 26, 2014.;;U.S. Appl. No. 13/654,173 Office Action mailed Apr. 7, 2014.;;U.S. Appl. No. 13/869,700 Office Action mailed May 16, 2014.;;U.S. Appl. No. 13/869,700, filed Apr. 24, 2013, Buggy et al.;;U.S. Appl. No. 13/849,399, filed Mar. 22, 2013, Honigberg et al.;;U.S. Appl. No. 13/654,173, filed Oct. 17, 2012, Honigberg et al.;;U.S. Appl. No. 13/747,319, filed Jan. 22, 2013, Buggy et al.;;U.S. Appl. No. 13/890,498, filed May 9, 2013, Honigberg et al.;;U.S. Appl. No. 13/952,531, filed Jul. 26, 2013, Honigberg et al.;;U.S. Appl. No. 13/965,135, filed Aug. 12, 2013, Buggy et al.;;U.S. Appl. No. 14/033,344, filed Sep. 20, 2013, Honigberg et al.;;Advani et al. ""The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study"", Ann. Oncol., 22(suppl 4): abstract 153 (2011).;;Apsel et al. ""Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases."" Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. ""Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1,"" Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. ""Modern Pharmaceutics,"" p. 596 (1996).;;Brown et al. ""Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)"", J Clin. Oncol. 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: <http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view&confID=114&abstractID=98841>.;;Browning, J.L., ""B cells move to centre stage: novel opportunities for autoimmune disease treatment"", Nature Reviews/Drug Discovery, 5:564-576 (Jul. 2006).;;Burchat et al., ""Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck-a Selectivity Insight,"" Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger, J.A., ""Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape"", Curr. Opin. Oncol. (Epub Sep. 6, 2012), 24(6):643-649 (Nov. 2012).;;Carmi et al. ""Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer,"" Biochem. Pharmacol. (Epub Aug. 4, 2012), 84(11):1388-1399 (Dec. 2012).;;Chang et al. ""The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells."" Arthritis Research & Therapy, 13:R115 (2011).;;Cohen et al. ""Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors,"" Science, 308:1318-1321 (May 27, 2005).;;Czuczman et al. ""Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma"", J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;Davids et al. ""Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia"", Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Desiderio, S., ""Role of Btk in B cell development and signaling,"" Curr. Opin. Imm. 9:534-540 (1997).;;Dorwald, F.Z., Side Reactions in Organic Synthesis, Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005).;;EA200901313 Notification of Office Action mailed Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards, C.M., ""BTK inhibition in myeloma: targeting the seed and the soil"", Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;Fabian et al. ""A small molecule-kinase interaction map for clinical kinase inhibitors."" Nature Biotechnology, 2005, 23(3): 329-336.;;Fisher et al. ""Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse"", Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al. ""The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma"", 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, Abstract 156 (Dec. 8-11, 2012).;;Fruman, D.A., ""Xid-like Phenotypes: A B Cell Signalosome Takes Shape"", Immunity, 13:1-3 (Jul. 2000).;;Giuliani, N., ""Multiple myeloma bone disease: pathophysiology of osteoblast inhibition,"" Blood (Epub Aug. 17, 2006), 108(13):3992-3996 (2006).;;Gold, M.R., ""To make antibodies or not:signaling by the B-cell antigen receptor,"" Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Hantschel et al. ""The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib"", PNAS 104(33):13283-13288 (2007).;;Hata et al. ""Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells,"" J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. ""Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765"", Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. ""Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group"", Blood (Epub Aug. 25, 2005), 106(12):3725-3732 (Dec. 2005).;;Horwood et al. ""Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor alpha Production,"" J. Exp. Med., 197(12):1603-1611 (Jun. 2003).",ACTIVE
672,AU,A1,AU 2011/247997 A1,136-213-391-540-953,2012-11-29,2012,AU 2011/247997 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,Toothbrush,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/136-213-391-540-953,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,DISCONTINUED
673,US,A1,US 2018/0365720 A1,141-852-224-692-716,2018-12-20,2018,US 201816010591 A,2018-06-18,US 201816010591 A;;US 201762521483 P,2017-06-18,CONTROLS MODULE,"Methods for minimizing bandwidth associated with transmission of unnecessary queries to third party vendors is provided. Methods may include transmitting initial queries to the third party vendors. Methods may include receiving a result set corresponding to the initial queries. Methods may further include mapping the initial queries, with the result set to a set of controls. Methods may include creating a personalized set of subsequent queries based on the mapping to the set of controls. Methods may include transmitting the subsequent queries to the third party vendor. Methods may include receiving a result set corresponding to the second set of queries.",HIPEROS LLC,GOLDMAN DOV JOSEPH;;BHIDE SANDEEP DAMODAR;;ANGLE MICHAEL DAVID,HIPEROS LLC (2018-06-15);;COUPA SOFTWARE INCORPORATED (2020-04-06),https://lens.org/141-852-224-692-716,Patent Application,yes,20,197,1,1,0,G06Q30/0203;;G06Q30/0203;;G06F16/903;;G06Q10/0635;;G06Q10/0635,G06Q30/02;;G06F17/30;;G06Q10/06,,0,0,,,,DISCONTINUED
674,CA,C,CA 2991994 C,163-835-233-165-938,2022-06-28,2022,CA 2991994 A,2013-06-03,US 201261655381 P;;CA 2875986 A,2012-06-04,PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING IBRUTINIB,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/163-835-233-165-938,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61P35/00,,0,0,,,,PENDING
675,SU,A2,SU 1348480 A2,182-783-522-172-090,1987-10-30,1987,SU 4048238 A,1986-04-03,SU 4048238 A,1986-04-03,LIQUID LEVEL MONITOR FOR BOREHOLE,,SP KT B GERMETICHNYKH SKVAZHIN,VERBITSKIJ DAVID I;;GOLDMAN ISAAK M;;GRUDKIN EDUARD K,,https://lens.org/182-783-522-172-090,Limited Patent,no,0,0,1,1,0,,E21B7/04,,0,0,,,,EXPIRED
676,TW,B,TW I662963 B,183-552-093-820-392,2019-06-21,2019,TW 107101564 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,,PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/183-552-093-820-392,Granted Patent,no,1,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
677,AU,B2,AU 2018/211201 B2,082-341-742-855-316,2020-06-25,2020,AU 2018/211201 A,2018-07-31,AU 2018/211201 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/082-341-742-855-316,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
678,US,A,US 5930702 A,148-977-946-800-292,1999-07-27,1999,US 73528796 A,1996-10-22,US 73528796 A,1996-10-22,Personal mobility communication system,"The invention provides a mobile communication system in a network that receives a location schedule from a subscriber and directs a call to the subscriber based on the location schedule. The network may include a telephone network, a data network and a cable network interconnected together. Each of the networks connects to communication devices. For example, the cable network is connected to fixed location devices such as cable units conventionally provided to cable subscribers. The fixed location devices may be connected to communication devices such as televisions, stereos or mailboxes. When a subscriber location schedule indicates that the subscriber is reachable at a specific fixed location device, the mobility system pages the subscriber at the specific fixed location device when a call is received for the subscriber during the specified date and time found in the location schedule. The subscriber may respond to the page by either making a reverting call commonly used in paging systems or responding directly through the fixed location device if the connected communication device provides for two-way communication.",AT & T CORP,GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1997-01-03),https://lens.org/148-977-946-800-292,Granted Patent,yes,2,46,1,1,0,H04M3/42229;;H04M7/006;;H04M3/42229;;H04M7/006,H04M3/42;;H04M7/00,455/417;;379/211;;348/9,0,0,,,,EXPIRED
679,CN,A,CN 103180502 A,170-651-181-334-724,2013-06-26,2013,CN 201180051410 A,2011-06-30,US 2011/0042613 W;;US 91146210 A,2010-10-25,Embroidery workstation utility cart,"An embroidery workstation utility cart for optimizing the positioning of supports for the embroidery machine, thread spool rack, monitor, workpiece queue, and other accessories desired for optimal embroidery processing.",VISTAPRINT TECHNOLOGIES LTD,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,,https://lens.org/170-651-181-334-724,Patent Application,no,5,3,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05B43/00;;D02H1/00;;D05C11/00,,0,0,,,,DISCONTINUED
680,US,B2,US 9540382 B2,198-360-081-978-537,2017-01-10,2017,US 201314405317 A,2013-06-03,US 201314405317 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (NANOSYN) (2012-07-12),https://lens.org/198-360-081-978-537,Granted Patent,yes,99,42,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/505;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;C07D487/04,,100,72,080-707-244-949-02X;;051-773-437-524-806;;084-954-244-635-278;;015-063-415-122-10X;;094-426-452-116-986;;026-602-342-915-043;;070-105-220-366-494;;029-307-446-890-335;;157-431-722-988-742;;053-207-920-994-687;;089-560-783-324-399;;039-782-322-629-050;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;062-629-771-597-536;;032-600-458-370-231;;005-264-653-185-294;;032-963-276-412-261;;006-286-861-403-907;;017-696-456-420-448;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;038-340-694-023-194;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;005-576-769-764-004;;026-747-860-569-66X;;069-501-243-828-566;;091-695-878-773-648;;095-118-733-111-972;;090-510-849-756-371;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;014-469-692-721-18X;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;025-965-705-925-299;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;009-072-168-512-123;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;068-224-919-120-455,10.1200/jco.2010.28.15_suppl.8012;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;22960555;;10.1097/cco.0b013e3283589950;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;pmc3239353;;21752263;;10.1186/ar3400;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.7326/0003-4819-90-5-761;;434676;;23425038;;10.3109/10428194.2013.777837;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;20166765;;10.2165/11532180-000000000-00000;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;10.1182/blood-2005-01-0016;;16123223;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1084/jem.20021845;;12810683;;pmc2193950;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;10.1074/jbc.m301484200;;12724322;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;10092645;;10.1074/jbc.274.14.9587;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.1182/blood-2004-07-2708;;15331445;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;22975686;;10.1016/j.cellsig.2012.09.008;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;10.3109/10428190109057962;;11342365,"Mukoyama et al. Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases, retrieved from STN Database Accession No. 2005:299462 Patent No. JP2005089352, Apr. 7, 2005, *abstract*.;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al. The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study, Ann. Oncol. 22(suppl 4): abstract 153 (2011).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Brown et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin. Oncol. 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: <http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view&confID=114&abstractID=98841>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck-a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrie et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Chang et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research & Therapy, 13:R115 (2011).;;Chang et al. PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Rodent Models of Arthritis. ACR/ARNP Scientific Meeting, Nov. 6-11, 2010, Poster #286.;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Co-pending U.S. Appl. No. 14/613,309, filed Feb. 3, 2015.;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signaling in diffuse large B-cell lymphoma. Nature 463(7277):88-92 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Dorwald. A. Side Reactions in Organic Synthesis, Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005).;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, Abstract 156 (Dec. 8-11, 2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia, Cancer Genetics and Cytogenetics 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (lgb, CD79b) and mb1 (lga, CD79a). PNAS 100(7):4126-4131 (2003).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (Epub Aug. 25, 2005) 106(12):3725-3732 (Dec. 2005).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Honigberg et al. Targeting Btk in Lymphoma: PCT-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCT-32765 is an Active-Site Probe that Enables Assessment of Btk Inhibition In Vivo. Blood (Ash Annual Meeting Abstracts). 2007. 110:Abstract 1592.;;Horwood et al. Bruton's Tyrosin Kinase is Required for Lipopolysaccharide-induced Tumor Necrosis Factor alpha Production. J. Exp. Med. 197(12)1 603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jefferies et al. Bruton's Tyrosine Kinase is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor {acute over (kappa)}B Activation by Toll-like Receptor 4. J. Biol. Chem.278:26258-26264 (2003).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor-ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCE signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosin Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting. Bruton's Tyrosine Kinase (BTK), LFM-A13 [alpha-Cyano-beta-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the ltk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al. Pleiotropic consequences of Bruton tyrosin kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;Merged Markush Service Search, Jun. 27, 2005.;;Middendorp et al. Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity. Blood 105(1):259-261 (2005).;;Niiro et al. Regulation of B-Cell Fate by Antigen-Receptor Signals. Nature Reviews 2:945-956 (2002).;;Nisitani et al. In situ detection of activated Bruton's tyrosine kinase in the lg signaling complex by phosphopeptide-specific monoclonal antibodies. PNAS USA 96:2221-2226 (1999).;;Oligino et al. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res. Ther., 5(Supp1.4):S7-S11 (2002).;;Pagel et al. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin. Cancer Res. (Epub Jul. 6, 2005), 11(13):4857-4866 (2005).;;Pan et al. Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase, ChemMedChem. 2:58-61 (2007).;;PCT/US2006/49626 International Preliminary Report on Patentability Search Report dated Mar. 24, 2009.;;PCT/US2006/49626 International Search Report dated Apr. 9, 2008.;;PCT/US2008/058528 International Search Report and Written Opinion dated Sep. 30, 2008.;;PCT/US2009/50897 International Preliminary Examination Report and Written Opinion dated Jan. 27, 2011.;;PCT/US2009/50897 International Search Report dated Mar. 15, 2010.;;PCT/US2010/52377 International Search Report and Written Opinion mailed Jun. 29, 2011.;;PCT/US2013/043888 International Search Report and Written Opinion dated Sep. 23, 2013.;;Peterson et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group. Br. J. Clin. Oncol., 21(1):5-15 (Jan. 1, 2003).;;Picci. Osteosarcoma (Osteogenic Sarcoma). Orphanet J. Rare Diseases 2(6):1-4 (2007).;;Pollyea et al. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay, Poster Abstract #3713, 51st ASH Annual Meeting and Exposition (Dec. 3, 2009).;;Ponader et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (Epub Dec. 16, 2011), 119(5):1182-1189 (Feb. 2012).;;Powers et al. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. Chem. Rev., 102(12):4639-4750 (2002).;;Prakash et al. Chicken sarcoma to human cancers: a lesson in molecular therapeutics. The Ochsner Journal, 7(2):61-64 (Jan. 1, 2007).;;PRNewswire. Pharmacyclics, Inc. Announces Presentation of Interim Results from Phase I Trial of its First-in-Human Btk Inhibitor PCI-32765. Dec. 7, 2009.;;PRNewswire. Update on Preclinical Finding and Development Timeline for PCI-45292. Mar. 2, 2011.;;Quek et al. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr. Biol. 8(20):1137-1140 (1998).;;Ritter et al. Osteosarcoma. Ann. Oncol. 21(Supplement 7):320-325 (2010).;;Robak et al. A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia. Curr. Med. Chem. (Epub Jul. 24, 2012), 19(31):5294-5318 (2012).;;Robak et al. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin. Investig. Drugs (Epub May 22, 2012), 21(7):921-947 (Jul. 2012).;;Rushworth et al. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal. Sep. 11, 2012. pii: S0898-6568(12)00250-1. doi: 10.1016/j.cellsig.2012.09.008. [Epub ahead of print].;;Sada et al. Protein-Tyrosine Kinases and Adaptor Proteins in FceRI-Mediated Signaling in Mast Cells. Curr. Mol. Med. 3(1):85-94 (2003).;;Schaeffer et al. Tec family kinases in lymphocyte signaling and function. Curr. Op. Imm. 12:282-288 (2000).;;Schnute et al. Bruton's tyrosine kinase (Btk). Anti-Inflammatory Drug Discovery. Ed. J.I. Levin and S. Laufer. (2012), pp. 297-326.;;Schwamb et al. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood (Epub Aug. 27, 2012), 120(19):3978-3985 (Nov. 2012).;;Science Daily. Counting tumor cells in blood predicts treatment benefit in prostate cancer. (Jul. 7, 2008), http://www.sciencedaily.com/releases/2008/07/080706083142.htm. last accessed Jul. 23, 2013.;;Science Daily. Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma. (Jun. 19, 2013), http://www.sciencedaily.com/releases/2013/06/130619195217.htm, last accessed Jan. 30, 2014.;;Science IP CAS Search, Mar. 16, 2006.;;Science IP CAS Search, Sep. 5, 2006.;;Shaffer et al. Lymphoid malignancies: the dark side of B-cell differentiation. Nature Reviews/Immunology 2:920-932 (2002).;;Smaill et al. Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)prido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor. J. Med. Chem. 42(10):1803-1815 (1999).;;Smith et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays 23:436-446 (2001).;;Smolen et al. Therapeutic Strategies for Rheumatoid Arthritis. Nature Reviews 2:473-488 (2003).;;Tinmouth et al. Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma. Leuk. Lymphoma 41(1-2):137-145 (2001).",ACTIVE
681,KR,A,KR 20230170108 A,021-801-395-158-795,2023-12-18,2023,KR 20237041085 A,2013-06-03,US 201261655381 P;;KR 20227021197 A;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/021-801-395-158-795,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K9/20;;A61K31/519;;A61P29/00;;A61P35/02;;A61P37/00,,0,0,,,,PENDING
682,NZ,A,NZ 713828 A,013-437-964-382-853,2017-05-26,2017,NZ 71382813 A,2013-06-03,US 201261655381 P;;NZ 70254813 A,2012-06-04,Crystalline forms of a bruton’s tyrosine kinase inhibitor,"Described herein is the Bruton’s tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1 H-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions that include the Btk inhibitor and methods of using the Btk inhibitor in the treatment of diseases or conditions that would benefit from inhibition of Btk activity.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/013-437-964-382-853,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K47/38;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
683,AU,A1,AU 2023/200435 A1,008-121-031-561-911,2023-03-02,2023,AU 2023/200435 A,2023-01-27,AU 2023/200435 A;;AU 2020/239751 A;;AU 2018/211201 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/008-121-031-561-911,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
684,AR,A2,AR 118108 A2,036-774-755-344-289,2021-09-15,2021,AR P200100425 A,2020-02-14,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias. Reivindicación 1: Una preparación farmacéutica para administración oral caracterizada porque comprende: (a) más o menos 40 a más o menos 200 mgs de 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona; (b) más o menos 40% en peso a más o menos 50% en peso de un diluyente; (c) más o menos 3% en peso a más o menos 10% en peso de un agente desintegrador; (d) más o menos 2% en peso a más o menos 7% en peso de un agente de actividad superficial; y (e) más o menos 0,2% en peso a más o menos 1,0% en peso de un lubricante. Reivindicación 2: La preparación farmacéutica, de acuerdo con la reivindicación 1, caracterizada porque el diluyente está seleccionado a partir del grupo que consiste de lactosa, sucrosa, dextrosa, dextratos, maltodextrin, manitol, xilitol, sorbitol, ciclodextrinas, fosfato de calcio, sulfato de calcio, almidones, almidones modificados, celulosa microcristalina, microcelulosa, etc. Reivindicación 3: La preparación farmacéutica, de acuerdo con la reivindicación 2, caracterizada porque el diluyente es una celulosa microcristalina. Reivindicación 11: La preparación farmacéutica, de acuerdo con cualesquiera reivindicaciones 1 - 10, caracterizada porque la forma de dosificación es una cápsula de gelatina dura.",PHARMACYCLICS LLC,WIRTH DAVID D;;GOLDMAN ERICK;;SMYTH MARK;;PURRO NORBERT,,https://lens.org/036-774-755-344-289,Amended Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/30;;A61K47/38;;A61P29/00;;A61P35/00;;A61P37/00;;C07D487/04,,0,0,,,,PENDING
685,US,A1,US 2016/0096779 A1,044-178-949-584-394,2016-04-07,2016,US 201514856663 A,2015-09-17,US 201514856663 A;;US 201462060911 P,2014-10-07,MATERIALS SUITABLE AS SUBSTITUTES FOR PEAT MOSSES AND PROCESSES AND APPARATUS THEREFOR,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,HANDLEY MONT ANDREW;;KNAPP MATT COLLINS;;GOLDMAN MARK DAVID,PITTMOSS LLC (2015-10-21),https://lens.org/044-178-949-584-394,Patent Application,yes,0,2,5,7,0,C05F11/00;;C05G5/12;;C05F11/00;;C05G5/12;;C09K17/50;;C09K17/52;;C09K17/16;;C05G3/80,C05F11/00;;B02C23/06;;B02C23/20;;C05G3/00,,0,0,,,,ACTIVE
686,TW,A,TW 201402122 A,042-560-789-431-560,2014-01-16,2014,TW 102119583 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3, 4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/042-560-789-431-560,Patent of Addition,no,0,1,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61P35/02;;C07D487/04,,0,0,,,,ACTIVE
687,US,A1,US 2015/0158871 A1,050-063-757-339-869,2015-06-11,2015,US 201314405317 A,2013-06-03,US 201314405317 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/050-063-757-339-869,Patent Application,yes,0,33,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519;;A61K45/06,,0,0,,,,ACTIVE
688,US,A,US 4737582 A,067-417-219-010-823,1988-04-12,1988,US 75056785 A,1985-06-28,US 75056785 A,1985-06-28,Absorbent vegetable materials,"This invention provides novel, highly absorbent pectin-containing vegetable materials, and a process for making these materials by incorporating into pectin-containing vegetable materials substituents which contain cation exchange groups. The present invention further provides absorbent structures containing these materials, as well as disposable absorbent procuts containing the materials or absorbent structures of the present invention.",PROCTER & GAMBLE,GOLDMAN STEPHEN A;;MYHRE DAVID V;;RETZSCH HERBERT L,PROCTER & GAMBLE COMPANY THE CINCINNATI OHIO A CORP OF OHIO,https://lens.org/067-417-219-010-823,Granted Patent,yes,21,48,3,3,0,A61L15/225;;A61L15/225;;A61L15/28;;A61L15/28;;A61L15/40;;A61L15/40;;C08B37/0045;;C08B37/0045;;C08L5/06;;C08L5/06;;Y10S604/904;;Y10S604/904;;Y10T428/249921;;Y10T428/249921;;Y10T428/31504;;Y10T428/31504;;Y10T428/31971;;Y10T428/31971,A61L15/22;;A61L15/28;;A61L15/40;;C08B37/06;;C08L5/06,536/2;;106/162;;428/411.1;;428/221;;428/532;;604/364;;604/368;;604/904,0,0,,,,EXPIRED
689,CA,C,CA 2875986 C,082-747-677-238-046,2020-06-09,2020,CA 2875986 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/082-747-677-238-046,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48,,0,0,,,,ACTIVE
690,US,B2,US 7847923 B2,089-221-040-879-08X,2010-12-07,2010,US 86268007 A,2007-09-27,US 86268007 A;;US 84820006 P,2006-09-29,Differentiation of flow cytometry pulses and applications,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2012-01-01);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/089-221-040-879-08X,Granted Patent,yes,11,8,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36,356/28,5,3,024-781-884-094-765;;004-776-450-741-441;;110-459-038-028-664,10.1002/0471722731;;10.1002/cyto.1171;;11746105;;10.1021/ac60214a047,"Shapiro, ""Pratical Flow Cytometry,"" 4th Ed., Willey, Hoboken, 2003.;;Westo et al., ""Doublet Discrimination in DNA Cell-Cycle Analysis,"" Cytometry, 2001, vol. 46, pp. 296-306.;;Savitzky et al., ""Smoothing and Differentiation of Data by Simplified Least Squares Procedures,"" Analytical Chemistry, Jul. 1964, vol. 36, No. 8, pp. 1627-1639.;;PCT, International Search Report (PCT/ISA/210) in PCT/US07/79761, Aug. 27, 2008, 2 pages.;;PCT, Written Opinion of the International Searching Authority (PCT/ISA/237) in PCT/US07/79761, Aug. 27, 2008, 2 pages.",ACTIVE
691,JP,A,JP 2020015744 A,088-446-683-847-04X,2020-01-30,2020,JP 2019163455 A,2019-09-06,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF BRUTON TYROSINE KINASE INHIBITOR,"To provide pharmaceutical compositions comprising a Bruton tyrosine kinase (Btk) inhibitor for treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer including lymphoma, and inflammatory diseases or conditions.SOLUTION: The invention provides crystalline forms of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one having an XRPD pattern with characteristic peaks at 5.2±0.1°2-Theta, 10.2±0.1°2-Theta, 16.5±0.1°2-Theta, 18.5±0.1°2-Theta, and 20.8±0.1°2-Theta. The invention also provides pharmaceutical formulations comprising the crystalline forms, diluents and lubricants.SELECTED DRAWING: Figure 5",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/088-446-683-847-04X,Patent Application,no,3,1,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K9/48;;A61K31/519;;A61K47/02;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/28;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/40;;A61K47/42;;A61P35/00;;A61P35/02;;A61P43/00,,2,0,,,"平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004616029;;PHARM STAGE, vol. 6, JPN6009053755, 2007, pages 20 - 25, ISSN: 0004616030",PENDING
692,PE,A1,PE 20190390 A1,097-100-147-734-47X,2019-03-13,2019,PE 2019000040 A,2013-06-03,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se refiere al inhibidor de tirosina quinasa de Bruton (Btk) 1-((R) -3-(4-amino-3-(4- amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il) prop-2-en-1-ona, incluyendo sus formas cristalinas, solvatos y sales farmaceuticamente aceptables. Se incluye tambien una formulacion farmaceutica para administracion oral que comprende: (a) aprox. 40 a 200 mg de 1-((R) -3-(4-amino-3-(4- amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il) prop-2-en-1-ona; (b)40 a 50 % en peso de un diluyente; (c) aprox. 3 a 10% en peso de un agente desintegrador; (d) aprox. 2 a 7% en peso de un agente de actividad superficial; y (e ) aprox. 0.2 a 1.0% en peso de un lubricante. Tambien se refiere a una composicion farmaceutica y metodos de uso del inhibidor de Btk en el tratamiento de enfermedades o trastornos afectadas por numerosos tipos de celula de linaje hematopoyetico, las cuales incluyen enfermedades o condiciones autoinmunes, cancer, entre otros.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/097-100-147-734-47X,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
693,TN,A1,TN 2014000492 A1,128-588-935-973-863,2016-03-30,2016,TN 2014000492 A,2014-11-25,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/128-588-935-973-863,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
694,TW,A,TW 201811334 A,128-536-436-956-298,2018-04-01,2018,TW 107101564 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/128-536-436-956-298,Patent of Addition,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/02;;A61K47/26;;A61K47/38;;A61K47/44;;A61P35/00;;C07D487/04,,0,0,,,,ACTIVE
695,US,A1,US 2014/0336203 A1,138-105-728-458-897,2014-11-13,2014,US 201414339363 A,2014-07-23,US 201414339363 A;;US 201313908949 A;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (NANOSYN) (2012-07-12),https://lens.org/138-105-728-458-897,Patent Application,yes,2,42,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,514/262.1;;544/262,0,0,,,,DISCONTINUED
696,SU,A1,SU 1108187 A1,150-244-645-425-613,1984-08-15,1984,SU 3534690 A,1983-01-05,SU 3534690 A,1983-01-05,DEVICE FOR MONITORING FLUID IN BOREHOLE,,SP KT B GERMETICHNYKH SKVAZHIN,GRUDKIN EDUARD K;;GOLDMAN ISAAK M;;VERBITSKIJ DAVID I,,https://lens.org/150-244-645-425-613,Limited Patent,no,0,0,1,1,0,,E21B7/04,,0,0,,,,EXPIRED
697,TW,A,TW 201906612 A,146-870-475-093-989,2019-02-16,2019,TW 107137018 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/146-870-475-093-989,Patent of Addition,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/02;;A61K47/26;;A61K47/38;;A61K47/44;;A61P35/00;;C07D487/04,,0,0,,,,ACTIVE
698,JP,A,JP 2021193095 A,168-117-032-734-511,2021-12-23,2021,JP 2021136489 A,2021-08-24,JP 2019131481 A;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF BRUTON TYROSINE KINASE INHIBITOR,"To provide an oral formulation containing a Bruton tyrosine kinase inhibitor.SOLUTION: A pharmaceutical formulation for oral administration comprises: (a) about 40 mg to about 200 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; (b) about 40 wt.% to about 50 wt.% of a diluent; (c) about 3 wt.% to about 10 wt.% of a disintegrating agent; (d) about 2 wt.% to about 7 wt.% of a surfactant; and (e) about 0.2 wt.% to about 1.0 wt.% of a lubricant.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/168-117-032-734-511,Patent Application,no,4,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61K47/04;;A61K47/12;;A61K47/14;;A61K47/20;;A61K47/26;;A61K47/32;;A61K47/36;;A61K47/38;;A61K47/44,,2,0,,,"平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004883755;;高田則幸: ""創薬段階における原薬Formスクリーニングと選択"", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004883756",PENDING
699,WO,A8,WO 2003/038690 A8,159-770-996-745-27X,2004-02-19,2004,US 0234429 W,2002-10-29,US 1505801 A,2001-10-29,INCREMENTAL AUTOMATA VERIFICATION,,HONEYWELL INT INC,MUSLINER DAVID J;;PELICAN MICHAEL J;;GOLDMAN ROBERT P,,https://lens.org/159-770-996-745-27X,Patent Application,no,0,0,4,4,0,G06F30/3323;;G06F30/3323,G06F17/50,,0,0,,,,PENDING
700,AU,A1,AU 2020/239751 A1,184-443-597-981-011,2020-10-22,2020,AU 2020/239751 A,2020-09-24,AU 2020/239751 A;;AU 2018/211201 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/184-443-597-981-011,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
701,WO,A3,WO 2008/042718 A3,000-661-298-415-004,2008-12-11,2008,US 2007/0079761 W,2007-09-27,US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",GUAVA TECHNOLOGIES INC;;PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,,https://lens.org/000-661-298-415-004,Search Report,yes,4,0,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36;;G01F1/36,,0,0,,,,PENDING
702,EP,B1,EP 2566367 B1,009-216-169-387-280,2017-06-21,2017,EP 11720360 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,TOOTHBRUSH,,GILLETTE CO LLC,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,THE GILLETTE COMPANY LLC (2016-12-07),https://lens.org/009-216-169-387-280,Granted Patent,yes,3,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B5/00;;A46B7/06;;A46B9/02,,0,0,,,,ACTIVE
703,AU,A1,AU 2016/250445 A1,023-637-231-072-187,2016-11-17,2016,AU 2016/250445 A,2016-10-28,AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1 -yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/023-637-231-072-187,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
704,GB,A,GB 2177100 A,023-352-816-333-750,1987-01-14,1987,GB 8615404 A,1986-06-24,US 75056785 A,1985-06-28,ABSORBENT VEGETABLE MATERIALS,,PROCTER & GAMBLE,GOLDMAN STEPHEN ALLEN;;MYHRE DAVID VERNON;;RETZSCH HERBERT LOUIS,,https://lens.org/023-352-816-333-750,Patent Application,no,6,8,3,3,0,A61L15/225;;A61L15/225;;A61L15/28;;A61L15/28;;A61L15/40;;A61L15/40;;C08B37/0045;;C08B37/0045;;C08L5/06;;C08L5/06;;Y10S604/904;;Y10S604/904;;Y10T428/249921;;Y10T428/249921;;Y10T428/31504;;Y10T428/31504;;Y10T428/31971;;Y10T428/31971,A61L15/22;;A61L15/28;;A61L15/40;;C08B37/06;;C08L5/06,C3M MXX           MXX;;C3M M163          MXX;;C3M M163C         MXX;;C3M M164          MXX;;C3U U10B          UNS;;C3U U12A2C        UNS;;C3U U12B1B2       UNS;;C3U U12B1B3A      UNS;;C3U U13           UNS;;C3U U2C6          UDS;;C3U U2C6          UNS;;C3U U3D           UDS;;C3U U3D           UNS;;C3U U4B2B         UDS;;C3U U4B2C         UDS;;C3U U4L           UDS;;U1S S1122;;U1S S3020,0,0,,,,DISCONTINUED
705,CN,A,CN 1138801 A,033-591-283-666-026,1996-12-25,1996,CN 96104612 A,1996-04-08,US 41920195 A;;US 41920595 A,1995-04-10,"Method and apparatus for conditioning and transporting timed program data, independent of transport timing",,DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,,https://lens.org/033-591-283-666-026,Patent Application,no,0,5,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,DISCONTINUED
706,KR,A,KR 20190040370 A,066-672-764-898-540,2019-04-17,2019,KR 20197010159 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/066-672-764-898-540,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K9/48;;A61K31/519;;A61K47/38,,0,0,,,,DISCONTINUED
707,PH,A1,PH 12014502681 A1,095-419-122-899-202,2015-01-26,2015,PH 12014502681 A,2014-12-01,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,MARK SMYTH;;ERICK GOLDMAN;;WIRTH DAVID D;;NORBERT PURRO,,https://lens.org/095-419-122-899-202,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61P35/00;;A61K9/48;;A61K47/30;;A61K47/38;;A61P29/00,,0,0,,,,PENDING
708,EP,A2,EP 0738083 A2,082-131-559-464-75X,1996-10-16,1996,EP 96104623 A,1996-03-22,US 41920195 A;;US 41920595 A,1995-04-10,Interactive video on demand system using packet transmission via ATM network,"In an interactive video-on-demand system, real-time programs are encoded as a transport stream including a plurality of transport stream packets. Some of the transport stream packets include timing signals indicating the real time of the program. The transport stream packets are formatted into transport cells for transport over an asynchronous transfer mode network from a source to a destination. The cells are transported at a transport rate which is determined by a network clock. The transport rate is chosen to deliver the transport stream faster than the real time of the program. While transporting the transport stream, it is determined if the transport stream is being transported ahead of the real time of the program. In this case, idle cells are injected into the transport stream to have the program arrive at the destination in the real time of the program.",DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/082-131-559-464-75X,Patent Application,yes,0,10,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,0,0,,,,EXPIRED
709,UY,A,UY 39740 A,101-534-342-889-937,2022-06-30,2022,UY 39740 A,2013-06-04,US 201261655381 P;;UY 34848 A,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;DAVID D WIRTH;;PURRO NORBERT,,https://lens.org/101-534-342-889-937,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/20;;A61K47/38;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
710,AU,B2,AU 2018/211216 B2,117-867-229-263-023,2020-06-25,2020,AU 2018/211216 A,2018-07-31,AU 2018/211216 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/117-867-229-263-023,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
711,EP,A2,EP 2377242 A2,155-150-561-103-857,2011-10-19,2011,EP 09837005 A,2009-12-22,US 2009/0069135 W;;US 34652308 A,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,,INTEL CORP,COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,,https://lens.org/155-150-561-103-857,Patent Application,yes,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,DISCONTINUED
712,MX,A,MX 2012012869 A,173-184-790-544-822,2012-11-29,2012,MX 2012012869 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,TOOTHBRUSH.,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GUILLETTE COMPANY,SAGEL PAUL ALBERT;;FARRELL MARK EDWARD;;GOLDMAN PAUL DAVID,,https://lens.org/173-184-790-544-822,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,DISCONTINUED
713,US,A1,US 2020/0320179 A1,033-671-900-491-963,2020-10-08,2020,US 202016799201 A,2020-02-24,US 202016799201 A;;US 201962809590 P,2019-02-23,MUSIC AND DIGITAL RIGHTS MANAGEMENT SYSTEMS AND METHODS,"A method and associated system for matching and delivering digital work metadata to one or more digital service providers, including modifying one or more digital work metadata files to remove non-critical data or segment erroneous data from the one or more digital work metadata files; reformatting the one or more digital work metadata files for compatibility with a digital service provider usage report table; performing a first matching operation, in which the one or more digital work metadata files are compared to the digital service provider usage report table on the basis of one or more data points; performing a second matching operation, the second matching operation being an artificial intelligence (AI) matching operation on one or more unmatched digital work metadata files of the one or more digital work metadata files; and transmitting output data from the matching operations to the one or more digital service providers.",MUSERK LLC,GOLDMAN PAUL DAVID;;WHITE COLLIN ROBERT;;BRADLEY QUENTIN NICHOLAS,MUSERK LLC (2020-06-08),https://lens.org/033-671-900-491-963,Patent Application,yes,8,0,4,5,0,G06F21/10;;G06F16/148;;G06N20/00;;G06F16/1748;;G06F16/116;;G06F21/16;;G06F21/10,G06F21/16;;G06F16/11;;G06F16/14;;G06F16/174;;G06N20/00,,0,0,,,,ACTIVE
714,US,A1,US 2013/0338172 A1,102-473-849-009-900,2013-12-19,2013,US 201313908949 A,2013-06-03,US 201313908949 A;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT;;PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (NANOSYN) (2012-07-12),https://lens.org/102-473-849-009-900,Patent Application,yes,1,89,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519;;A61K45/06,514/262.1;;544/262;;206/528,1,0,,,"Remington's Pharmaceutical Sciences, 1985, Mack Printing Co., 17th ed., p. 185",ACTIVE
715,CA,A1,CA 2813720 A1,094-792-281-278-63X,2012-05-10,2012,CA 2813720 A,2011-06-30,US 91146210 A;;US 2011/0042613 W,2010-10-25,EMBROIDERY WORKSTATION UTILITY CART,"An embroidery workstation utility cart for optimizing the positioning of supports for the embroidery machine, thread spool rack, monitor, workpiece queue, and other accessories desired for optimal embroidery processing.",VISTAPRINT TECHNOLOGIES LTD,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,,https://lens.org/094-792-281-278-63X,Patent Application,no,0,0,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05B43/00;;D02H1/00;;D05C11/00,,0,0,,,,DISCONTINUED
716,TW,B,TW I662964 B,103-660-200-010-528,2019-06-21,2019,TW 107137018 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,,PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/103-660-200-010-528,Granted Patent,no,1,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
717,WO,A3,WO 2010/078142 A3,122-000-298-494-625,2010-09-23,2010,US 2009/0069135 W,2009-12-22,US 34652308 A,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP;;COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,COWLEY NICHOLAS;;GOLDMAN RICHARD J;;SAWYER DAVID;;ROHANI NADER,,https://lens.org/122-000-298-494-625,Search Report,yes,5,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/26;;H03F1/34,,0,0,,,,PENDING
718,CA,A1,CA 2875986 A1,106-441-273-013-526,2013-12-12,2013,CA 2875986 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/106-441-273-013-526,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
719,MY,A,MY 194911 A,138-710-608-478-151,2022-12-22,2022,MY PI2018000375 A,2013-06-03,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Fig. 1)",PHARMACYCLICS LLC,NORBERT PURRO;;MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH,,https://lens.org/138-710-608-478-151,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61P29/00;;A61K9/48;;A61K47/30;;A61K47/38;;A61P35/00,,0,0,,,,ACTIVE
720,KR,A,KR 20130018852 A,172-058-206-771-978,2013-02-25,2013,KR 20127029048 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,TOOTHBRUSH,,GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/172-058-206-771-978,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B7/06;;A46B9/04,,0,0,,,,DISCONTINUED
721,US,A,US 5933647 A,193-317-080-111-418,1999-08-03,1999,US 79293897 A,1997-01-24,US 79293897 A,1997-01-24,System and method for software distribution and desktop management in a computer network environment,"A system for distributing software in a customized configuration, to pre-selected computers in a network environment, includes a workstation running a console, a workstation running an agent, and a file server. The workstation running the console creates distribution control information which dictates how the software is distributed and to what agent based workstations under a given set of conditions. The distribution control information is stored on the file server where it is subsequently downloaded from by the agent based workstation which meets the conditions for a particular configuration of the software.",COGNET CORP,ARONBERG DAVID B;;GOLDMAN DOV J;;SPIRO PETER A,COGNET CORP (1998-08-09);;DYNALOG TECHNOLOGIES LTD (1997-01-22);;NORTONLIFELOCK INC (2003-09-23),https://lens.org/193-317-080-111-418,Granted Patent,yes,29,267,1,1,0,G06F8/64;;G06F8/64;;G06F8/61;;G06F8/61,G06F9/445,395/712;;395/200.51,0,0,,,,EXPIRED
722,AU,A1,AU 2018/211201 A1,020-840-046-521-694,2018-08-16,2018,AU 2018/211201 A,2018-07-31,AU 2018/211201 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)prop-2-en- 1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/020-840-046-521-694,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
723,WO,A1,WO 2012/060908 A1,042-038-775-088-069,2012-05-10,2012,US 2011/0042613 W,2011-06-30,US 91146210 A,2010-10-25,EMBROIDERY WORKSTATION UTILITY CART,"An embroidery workstation utility cart for optimizing the positioning of supports for the embroidery machine, thread spool rack, monitor, workpiece queue, and other accessories desired for optimal embroidery processing.",VISTAPRINT TECHNOLOGIES LTD;;BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,BREEN ANTHONY A;;GOLDMAN DAVID A;;FRIAS KRISTEN R,,https://lens.org/042-038-775-088-069,Patent Application,yes,17,2,6,6,0,D05B43/00;;D05C11/00;;D05B43/00;;D05C11/00,D05B43/00;;D02H1/00;;D05C11/00,,0,0,,,,PENDING
724,AU,A1,AU 2018/211216 A1,046-022-621-594-988,2018-08-16,2018,AU 2018/211216 A,2018-07-31,AU 2018/211216 A;;AU 2016/250445 A;;AU 2013/271918 A;;US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin- 1 -yl)piperidin- 1 -yl)prop-2-en- 1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (20992107_1):GGG",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/046-022-621-594-988,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
725,WO,A2,WO 2008/042718 A2,050-218-275-018-230,2008-04-10,2008,US 2007/0079761 W,2007-09-27,US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",GUAVA TECHNOLOGIES INC;;PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,,https://lens.org/050-218-275-018-230,Patent Application,yes,0,2,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01N21/00,,0,0,,,,PENDING
726,EP,A3,EP 0738083 A3,085-426-501-839-456,1998-09-09,1998,EP 96104623 A,1996-03-22,US 41920195 A;;US 41920595 A,1995-04-10,Interactive video on demand system using packet transmission via ATM network,,DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/085-426-501-839-456,Search Report,no,2,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,3,2,010-476-776-826-288;;030-507-621-614-437,10.1117/12.7977033;;10.1109/cmpcon.1996.501744,"CHAO H J ET AL: ""ASYNCHRONOUS TRANSFER MODE PACKET VIDEO TRANSMISSION SYSTEM"", OPTICAL ENGINEERING, vol. 28, no. 7, July 1989 (1989-07-01), pages 781 - 788, XP000033802;;VARMA S: ""MPEG-2 OVER ATM: SYSTEM DESIGN ISSUES"", DIGEST OF PAPERS OF COMPCON (COMPUTER SOCIETY CONFERENCE) 1996, TECHNOLOGIES FOR THE INFORMATION SUPERHIGHWAY SANTA CLARA, FEB. 25 - 28, 1996, no. CONF. 41, 25 February 1996 (1996-02-25), INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 26 - 31, XP000628461;;D'AGOSTINO S: ""UNIVERSAL VIDEOCODEC FOR ATM NETWORKS1"", REVUE HF, vol. 15, no. 3 / 04, 1 January 1991 (1991-01-01), pages 102 - 112, XP000307855",EXPIRED
727,JP,A,JP 2018048182 A,113-791-489-692-63X,2018-03-29,2018,JP 2017207591 A,2017-10-26,US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF BRUTON'S TYROSINE KINASE INHIBITOR,"PROBLEM TO BE SOLVED: To provide novel crystalline forms of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.SOLUTION: A crystalline form has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 5.2±0.1° 2-theta, 10.2±0.1° 2-theta, and 20.8±0.1° 2-theta.SELECTED DRAWING: Figure 1",PHARMACYLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,,https://lens.org/113-791-489-692-63X,Patent Application,no,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519;;A61P7/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P43/00,,2,0,,,"平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004024845;;高田則幸: ""創薬段階における原薬Formスクリーニングと選択"", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004024846",PENDING
728,KR,A,KR 20210033067 A,134-973-822-321-170,2021-03-25,2021,KR 20217007940 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/134-973-822-321-170,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D473/34;;A61K9/48;;A61K31/519;;A61K47/38;;C07D487/04,,0,0,,,,DISCONTINUED
729,CA,A1,CA 2798816 A1,160-061-487-762-390,2011-11-10,2011,CA 2798816 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,TOOTHBRUSH,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/160-061-487-762-390,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,DISCONTINUED
730,US,A1,US 2021/0188473 A1,168-331-747-674-134,2021-06-24,2021,US 202017127892 A,2020-12-18,US 202017127892 A;;US 201962950582 P,2019-12-19,Pre-Filled and Pre-Sealed Beverage Container Sleeve Applicator,A system for labeling a beverage container includes a conveyer structured to receive and transport the beverage container. The beverage container is prefilled with an ingestible content and sealed. The top of the beverage container has a mark that a lid reader uses to determine a orientation position and generate an alignment signal. Can positioning pads use the alignment signal to position the beverage container rotationally until the mark aligns with a reference position. An air blast station may be present to release high pressure air onto an exterior of the beverage container and a sleeve applicator overlay a shrink wrap sleeve around an exterior of the beverage container. A steam tunnel uses steam to cause the shrink wrap sleeve label to shrink onto the beverage container.,ELIQS LLC,SCHWAPPACH JOSEPH PATRICK;;GOLDMAN DAVID MOORE;;BERG MAX JOSEPH,ELIQS LLC (2020-12-18),https://lens.org/168-331-747-674-134,Patent Application,yes,4,0,1,1,0,B65C3/065;;B65C9/067;;B65C9/04;;B65C3/065;;B65C9/04;;B65B53/06;;B65C9/40;;B65C9/06,B65C3/06;;B65B53/06;;B65C9/04;;B65C9/06;;B65C9/40,,0,0,,,,DISCONTINUED
731,US,B2,US 11912632 B2,168-758-297-034-57X,2024-02-27,2024,US 201514856663 A,2015-09-17,US 201514856663 A;;US 201462060911 P,2014-10-07,Materials suitable as substitutes for peat mosses and processes and apparatus therefor,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to Sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,HANDLEY MONT ANDREW;;KNAPP MATT COLLINS;;GOLDMAN MARK DAVID,PITTMOSS LLC (2015-10-21),https://lens.org/168-758-297-034-57X,Granted Patent,yes,18,0,5,7,0,C05F11/00;;C05G5/12;;C05F11/00;;C05G5/12;;C09K17/50;;C09K17/52;;C09K17/16;;C05G3/80,C05F11/00;;C05G3/80;;C05G5/12;;C09K17/16;;C09K17/50;;C09K17/52,,1,0,,,"Abuhashim, M. and Abdel-Fattah, M. K., “Impact of Gypsum Particle Size on Soil Physical Properties of a Saline-Sodic Soil from North Sinai, Egypt”, Egypt. J. Soil Sci. vol. 53, No. 1, pp. 89-103 (2013). (Year: 2013).",ACTIVE
732,DO,A,DO P2014000274 A,185-267-967-284-659,2015-03-31,2015,DO 2014000274 A,2014-11-27,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,"Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.",PHARMACYCLICS INC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/185-267-967-284-659,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/30;;A61K9/48;;A61K47/38;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
733,AU,A8,AU 2013/271918 A8,198-957-398-724-174,2015-02-26,2015,AU 2013/271918 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/198-957-398-724-174,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,ACTIVE
734,CA,A1,CA 2186922 A1,009-925-829-262-312,1997-04-04,1997,CA 2186922 A,1996-10-01,US 53833195 A,1995-10-03,METHOD AND APPARATUS FOR PROCESSING TELEPHONE CALLS,"A method and apparatus for processing telephone calls based on variable telephone call parameters is disclosed. A telecommunication network node is connected to a database which stores telephone subscriber preference data describing subscriber preferences. In one embodiment, the database contains subscriber preference data defining the type of telephone services to be applied to outgoing telephone calls. Upon receipt of the outgoing call at the node, the node performs a database search using variable telephone call parameters and retrieves a telephone call service description. The telephone call service description describes the type of service to apply to the call. The call is completed with the described services being applied to the call. In another embodiment, the database contains subscriber preference data defining routing instructions for incoming calls. Upon receipt of the incoming call at the node, the node performs a database search using variable telephone call parameters and retrieves routing instructions. The routing instructions indicate whether the call is to be routed to the subscriber or to an alternate destination. The call is completed by routing it according to the retrieved routing instructions.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,,https://lens.org/009-925-829-262-312,Patent Application,no,0,0,4,4,0,H04Q3/0016;;H04Q2213/13091;;H04Q2213/13097;;H04Q2213/13103;;H04Q2213/13109;;H04Q2213/13141;;H04Q2213/13332;;H04Q2213/13377;;H04Q2213/1338;;H04Q2213/13405,H04M3/42;;H04Q3/00,,0,0,,,,DISCONTINUED
735,EP,A4,EP 2062056 A4,087-114-057-211-805,2018-01-10,2018,EP 07843384 A,2007-09-27,US 2007/0079761 W;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,,EMD MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,"CYTEK BIOSCIENCES, INC., FREMONT, US (2023-11-02);;LUMINEX CORPORATION (2019-03-06);;EMD MILLIPORE CORPORATION (2012-04-25);;MILLIPORE CORPORATION (2010-05-19)",https://lens.org/087-114-057-211-805,Search Report,no,3,0,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01N15/14,,0,0,,,,ACTIVE
736,US,A,US 5754783 A,102-699-477-856-464,1998-05-19,1998,US 59508596 A,1996-02-01,US 59508596 A,1996-02-01,Apparatus and method for interleaving timed program data with secondary data,"In a video server a transport stream is generated. The transport stream is to be transported over a circuit of a network signalling at a constant bit rate. During generation, timed program content is encoded as a variable bit rate stream. The variable bit rate stream is transported over a constant bit rate circuit of a network. While transporting the variable bit rate stream, an accumulated difference between the number of bits transported in the variable bit rate stream and the number of bits required for the constant bit rate circuit is measured periodically. In response to the measured difference, a secondary untimed content is supplied to the constant bit rate circuit at a rate which minimizes the accumulated difference, and where the secondary content is evenly distributed over the transport stream.",DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;DIGITAL EQUIPMENT CORPORATION (1996-01-31);;HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/102-699-477-856-464,Granted Patent,yes,5,100,1,1,0,H04N21/23406;;H04N21/23611;;H04N21/2381;;H04N21/242;;H04N21/47202;;H04N21/64307;;H04N21/64307;;H04N21/47202;;H04N21/23406;;H04N21/2381;;H04N21/242;;H04N21/23611,H04N21/234;;H04N21/236;;H04N21/2381;;H04N21/242;;H04N21/472;;H04N21/643,395/200.47,1,0,,,"Final Test for ISO/IEC DIS 13818 1: Information Technology Generic Coding of Moving Pictures and Associated Audio Information: Systems Attachment: Explanatory Report JTC 1/SC 29/WG 11 N 721 (Information Processing Society of Japan/Information Technology Standards Commission of Japan A Standards Organization Accredited by JISC ), Date: Jun. 13,1994.",EXPIRED
737,US,A,US 5745696 A,120-416-920-742-753,1998-04-28,1998,US 41920595 A,1995-04-10,US 41920595 A,1995-04-10,Transport controller for timed program data,"In an interactive video-on-demand system, real-time programs are encoded as a transport stream including a plurality of transport stream packets. Some of the transport stream packets include timing signals indicating the real time of the program. The transport stream packets are formatted into transport cells for transport over an asynchronous transfer mode network from a source to a destination. The cells are transported at a transport rate which is determined by a network clock. The transport rate is chosen to deliver the transport stream faster than the real time of the program. While transporting the transport stream, it is determined if the transport stream is being transported ahead of the real time of the program. In this case, idle cells are injected into the transport stream to have the program arrive at the destination in the real time of the program.",DIGITAL EQUIPMENT CORP,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;DIGITAL EQUIPMENT CORPORATION (1995-04-07);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/120-416-920-742-753,Granted Patent,yes,11,18,1,12,0,H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347;;H04N21/47202;;H04N21/47202;;H04N21/2365;;H04N7/17336;;H04N21/4347;;H04N7/17318,H04N7/173;;H04N21/2365;;H04N21/434;;H04N21/472,395/200.63;;395/200.61;;395/200.66;;370/468,0,0,,,,EXPIRED
738,HK,A1,HK 1177121 A1,139-140-602-084-076,2013-08-16,2013,HK 13104474 A,2013-04-12,US 2011/0035367 W;;US 33234410 P,2010-05-07,TOOTHBRUSH,,GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/139-140-602-084-076,Patent Application,no,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B/,,0,0,,,,DISCONTINUED
739,HK,A1,HK 1208803 A1,145-599-141-307-025,2016-03-18,2016,HK 15109505 A,2015-09-25,US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,,PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/145-599-141-307-025,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61P/;;A61K/,,0,0,,,,PENDING
740,US,B2,US 8232687 B2,182-486-464-609-440,2012-07-31,2012,US 74087407 A,2007-04-26,US 74087407 A;;US 79664606 P,2006-04-26,Intelligent laser interlock system,"The present invention comprises, in various embodiments, systems and methods for shutting down a laser system in an intelligent and flexible manner. An intelligent laser interlock system includes both hardwired components, and intelligent components configured to execute computing instructions. The hardwired components and the intelligent components are configured to shutdown the laser system to one or more alternative shutdown states in response to one or more interlock signals.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL;;RAYDIANCE INC,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,RAYDIANCE INC (2007-06-21);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/182-486-464-609-440,Granted Patent,yes,142,7,4,4,0,F16P3/20;;H01S3/2308;;H01S3/2308;;H01S3/005;;H01S3/005;;H01S3/0912;;H01S3/0912;;H01S3/10038;;H01S3/10038,F16P3/20,307/328;;372/8;;372/29.011;;372/29.014;;372/38.01;;372/38.02;;372/38.03;;372/38.04;;372/38.05;;372/38.06;;372/38.07;;372/38.08;;372/38.09,66,58,117-744-165-986-432;;145-239-123-381-45X;;060-881-567-032-214;;000-084-545-744-394;;026-314-668-625-496;;029-558-780-287-378;;007-610-480-329-043;;018-099-554-374-677;;000-411-739-404-617;;014-781-489-666-564;;001-545-518-386-996;;068-170-005-057-700;;090-225-352-798-75X;;064-013-679-316-815;;072-213-206-454-499;;093-814-694-433-923;;016-042-423-186-246;;034-198-200-102-512;;070-762-457-305-331;;054-553-005-359-274;;107-491-505-742-253;;106-352-588-540-537;;052-988-699-279-649;;141-673-850-199-212;;088-339-132-138-761;;057-872-185-503-276;;058-428-473-536-780;;140-235-674-660-228;;126-512-667-197-138;;109-319-323-316-737;;007-943-533-068-461;;033-492-002-552-396;;044-932-306-406-537;;176-602-037-735-467;;104-896-463-141-607;;049-327-564-862-574;;033-514-707-599-498;;033-514-707-599-498;;172-173-961-881-648;;064-538-387-903-251;;063-273-945-096-013;;064-538-387-903-251;;071-356-742-086-695;;078-630-235-137-447;;008-297-618-180-914;;027-044-314-590-758;;007-534-703-329-197;;166-423-940-293-419;;075-065-377-249-833;;003-527-809-444-299;;011-656-550-619-272;;038-776-097-627-86X;;123-241-684-276-697;;007-603-487-033-055;;126-474-490-038-742;;034-344-790-017-571;;145-294-032-372-402;;055-368-509-124-825,10.1016/0030-4018(94)90331-x;;10.1016/0030-4018(85)90120-8;;10.1038/nature01275;;12478288;;10.1109/jqe.1986.1073009;;10.1364/ol.11.000153;;19730563;;10.1016/0079-6727(94)00013-o;;10.1364/josab.5.001563;;15295618;;10.1038/sj.gt.3302337;;19823377;;10.1364/ol.18.001343;;10.1016/0030-4018(94)90075-2;;10.1117/12.573681;;10.1364/josa.68.001196;;10.1109/jstqe.2006.884067;;19484030;;10.1364/opex.12.004775;;10.1364/opex.12.002710;;19475112;;10.1364/opex.13.004869;;19498473;;20212690;;10.1364/ao.18.002500;;10.1117/12.525748;;10.1364/ol.30.001620;;16075516;;10.1364/opex.12.003888;;19483922;;10.1109/ofc.2005.192643;;10.1364/josab.16.001999;;10.1364/ol.30.001917;;16092218;;19471402;;10.1364/oe.11.002832;;10.1364/ao.36.003375;;18253351;;10.1109/68.769730;;10.1364/oe.11.001175;;19465984;;10.1109/50.802992;;10.1364/ol.30.001446;;16007769;;10.1364/opex.12.000956;;19474907;;10.1049/el:19991505;;18091887;;10.1364/ol.23.001695;;10.1109/jlt.2003.810563;;19730501;;10.1364/ol.10.000609;;10.1063/1.96260;;10.1109/50.618320;;10.1103/physreve.67.046608;;12786510;;10.1364/ol.30.001449;;16007770;;10.1364/ol.30.001449;;16007770;;10.1109/lpt.2004.840999;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;10.1109/lpt.2005.860058;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;15352348;;10.1364/ol.29.001718;;19532735;;10.1364/oe.15.004876;;19488309;;10.1364/opex.12.006589;;10.1109/cleo.2005.202228;;10.1016/j.addr.2004.12.007;;15757758;;10.1109/lpt.2005.848549;;17041678;;10.1364/ol.31.003191;;10.1109/jlt.1986.1074847;;19730485;;10.1364/ol.10.000562;;10.1109/68.803079;;10.1049/el:19981138;;10.1364/ol.28.001371;;12906093;;10.1117/12.646020;;19498789;;10.1364/opex.13.007621;;10.1364/ao.13.000353;;20125987;;19471462;;10.1364/oe.11.003332,"Stock et al., ""Chirped Pulse Amplification in an Erbium-doped Diber Oscillator/Erbium-doped Fiber Amplifier System"", Optics Communications, North-Holland Publishing Co., Amsterdam, NL, vol. 106, No. 4/5/06, Mar. 15, 1994, pp. 249-252, XP000429901, ISSN: 0030-4018.;;Strickland et al., ""Compression of Amplified Chirped Optical Pulses"", Optics Communications, North-Holland Publishing Co., Amersterdam, NL, vol. 56, No. 3, Dec. 1, 1985, pp. 219-221, XP024444933 ISSN: 0030-4018 (retrieved on Dec. 11, 1985.;;Temelkuran, B. et al., ""Wavelength-scalable Hollow Optical Fibres with Large Photonic Bandgaps for CO2 Laser Transmission,"" Nature, Dec. 12, 2002, pp. 650-653.;;Thurston, R.N. et al., ""Analysis of Picosecond Pulse Shape Synthesis by Spectral Masking in a Grating Pulse Compressor,"" IEEE Journal of Quantum Electronics, vol. EQ-22, No. 5, pp. 682-696, May 1986.;;Weiner, A.M. et al., ""Synthesis of Phase-coherent, Picosecond Optical Square Pulses,"" Optics Letters, vol. 11, No. 3, pp. 153-155, Mar. 1986.;;Weiner, A.M., ""Femtosecond Optical Pulse Shaping and Processing,"" Prog. Quant. Electr. 1995, vol. 19, pp. 161-237, 1995.;;Weiner, A.M., ""High-resolution femtosecond Pulse Shaping,"" Journal of the Optical Society of America B. vol. 5, No. 8, pp. 1563-1572, Aug. 1988.;;Wells, D.J., ""Gene Therapy Progress and Prospects: electroporation and Other Physical Methods,"" Gene Therapy, Nature Publishing Group, vol. 11, pp. 1363-1369, Aug. 5, 2004, (http://www.nature.com/gt).;;White, W.E., et al., ""Compensation of Higher-order Frequency-dependent Phase Terms in Chirped-pulse Amplification Systems,"" Optics Letters, vol. 18, No. 16, pp. 1343-1345, Aug. 15, 1993.;;Yamakawa et al., ""1 Hz, 1 ps, terawatt Nd: glass laser"", Optics Communications, North-Holland Publishing Co. Amsterdam, NL, vol. 112, No. 1-2, Nov. 1, 1994, pp. 37-42, XP024424285.;;Yan et al., Ultrashort Pulse Measurement Using Interferometric Autocorrelator Based on Two-photon-absorbtion Detector at 1.55mum Wavelength Region., 2005, Proceedings of SPIE vol. 5633, Advanced Materials and Devices for Sensing and Imaging II, pp. 424-429.;;Yeh, et al. ""Theory of Bragg Fiber"", Journal of the Optical Society America, Sep. 1978, pp. 1196, vol. 68, No. 9., pp. 1196-1201.;;Yi, Y. et al., ""Sharp Bending of On-Chip silicon Bragg Cladding Waveguide With Light Guiding on Low Index Core Materials"", IEEE Journal of Selected Topics in Quantum Electronics, vol. 12, No. 6, Nov./Dec. 2006, pp. 1345-1348.;;Yi, Y., et al., ""On-chip Si-based Bragg Cladding Waveguide with High Index Contrast Bilayers"", Optics Express, vol. 12, No. 20, Oct. 4, 2004, pp. 4775-4780.;;Yin, D. et al., ""Integrated ARROW Waveguides with Hollow Cores"", Optics Express, vol. 12, No. 12, Jun. 14, 2004, pp. 2710-2715.;;Zhou, S. et al., ""Compensation of nonlinear Phase Shifts with Third-order Dispersion in Short-pulse Fiber Amplifiers,"" Optics Express, vol. 13, No. 13, pp. 4869-2877, Jun. 27, 2005.;;Agostinelli, J. et al., ""Optical Pulse Shaping with a Grating Pair,"" Applied Optics, vol. 18, No. 14, pp. 2500-2504, Jul. 15, 1979.;;Anastassiou et al., ""Photonic Bandgap Fibers Exploiting Omnidirectional Reflectivity Enable Flexible Delivery of Infrared Lasers for Tissue Cutting,"" Proceedings of the SPIE-the International Society for Optical Engineering, SPIE, US, vol. 5317, No. 1, Jan. 1, 2004, pp. 29-38, XP002425586 ISSN: 0277-786X.;;Benoit, G. et al., ""Dynamic All-optical Tuning of Transverse Resonant Cavity Modes in Photonic Bandgap Fibers,""Optics Letters, vol. 30, No. 13, Jul. 1, 2005, pp. 1620-1622.;;Chen, L. et al., ""Ultrashort Optical Pulse Interaction with Fibre Gratings and Device Applications,"" 1997, Canaga, located at http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq29402.pfd.;;Chen, X. et al., ""Highly Birefringent Hollow-core Photonic Bandgap Fiber,"" Optics Express, vol. 12, No. 16, Aug. 9, 2004, pp. 3888-3893.;;Chen, Y. et al., ""Dispersion-Managed Mode Locking"", Journal of the Optical Society of America B, Nov. 1999, pp. 1999-2004, vol. 16, No. 11, Optical Society of America.;;Dasgupta, S. et al., ""Design of Dispersion-Compensating Bragg Fiber with an Ultrahigh Figure of Merit,"" Optics Letters, Aug. 1, 2005, vol. 30, No. 15, Optical Society of America.;;De Matos et al., ""Multi-kilowatt, Picosecond Pulses from an All-fiber Chirped Pulse Amplification System Using Air-core Photonic Bandgalp Fiber"", Lasers and Electro-optics, 2004, (CLEO), Conference on San Francisco, CA USA, May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. May 17, 2004, pp. 973-974, XP010745448 ISBN: 978-1-55752-777-6.;;De Matos, C.J.S. et al., ""All-fiber Chirped Pulse Amplification using Highly-dispersive Air-core Photonic Bandgap Fiber,"" Nov. 3, 2003, Optics Express, pp. 2832-2837, vol. 11, No. 22.;;Delfyett, P. et al., ""Ultrafast Semiconductor Laser-Diode-Seeded Cr:LiSAF Rengerative Amplifier System"", Applied Optics, May 20, 1997, pp. 3375-3380, vol. 36, No. 15, Octoical Society of America.;;Eggleton, et al., ""Electrically Tunable Power Efficient Dispersion Compensating Fiber Bragg Grating,"" IEEE Photonics Technology Letters, vol. 11, No. 7, pp. 854-856, Jul. 1999.;;Engeness et al., ""Dispersion Tailoring and Compensation by Modal Interations in Omniguide Fibers,"" Optics Express, May 19, 2003, pp. 1175-1196, vol. 11, No. 10.;;Fink et al., ""Guiding Optical Light in Air Using an All-Dielectric Structure,"" Journal of Lightwave Technology, Nov. 1999, pp. 2039-2041, vol. 17, No. 11.;;Folkenberg, J.R., et al., ""Broadband Single-polarization Photonic Crystal Fiber,"" Optics Letters, vol. 30, No. 12, Jun. 15, 2005, pp. 1446-1448.;;Folkenberg, J.R., et al., ""Polarization Maintaining Large Mode Area Photonic Crystal Fiber,"" Optics Express vol. 12, No. 5, Mar. 8, 2004, pp. 956-960.;;Futami, F., et al., ""Wideband Fibre Dispersion Equalisation up to Fourth-order for Long-distance Sub-picosecond Optical Pulse Transmission,"" Electronics Letters, vol. 35, No. 25, Dec. 9, 1999.;;Galvanauskas, A. et al., ""Chirped-pulse-amplification Circuits for Fiber Amplifiers, Based on Chirped-period Quasi-phase, matching gratings"", Optics Letters, Nov. 1, 1998, p. 1695-1697, vol. 23, No. 21, Optical Society of America.;;Hartl et al., ""In-line high energy Yb Fiber Laser Based Chirped Pulse Amplifier System"", Laser and Electro-Optics, 2004, (CLEO) Conference of San Francisco, CA USA May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. 1, May 17, 2004, pp. 563-565, XP010745382, ISBN: 978-1-55752-7777-.;;Hellstrom, E. et al., ""Third-order Dispersion Compensation Using a Phase Modulator"", Journal of Lightwave Technology, vol. 21, No. 5, pp. 1188-1197, May 2003.;;Heritage, J. P. et al., ""Picosecond Pulse Shaping by Spectral Phase and Amplitude Manipulation,"" Optics Letters, vol. 10, No. 12, pp. 609-611, Dec. 1985.;;Heritage, J.P. et al., ""Spectral Windowing of Frequency-Modulated Optical Pulses in a Grating Compressor,"" Applied Physics Letters, vol. 47, No. 2, pp. 87-89, Jul. 15, 1985.;;Hill, K. et al., ""Fiber Bragg Grating Technology Fundamentals and Overview,"" Journal of Lightwave Technology, Aug. 1997, vol. 15, No. 8, pp. 1263-1276.;;Ibanescu et al., ""Analysis of Mode Structure in Hollow Dielctric Waveguide Fibers,""Physical Review E 67, 2003, The American Physical Society.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Optics Letters, vol. 30, No. 12, pp. 1449-1451, Jun. 15, 2005.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Purdue University ECE Annual Research Summary, Jul. 1, 2004-Jun. 30, 2005.;;Killey, et al., ""Electronic Dispersion Compensation by Signal Predistortion Using Digital Processing and a Dual-Drive Mach-Zehnder Modulator,"" IEEE Photonics Technology Letters, vol. 17, No. 3, pp. 714-716, Mar. 2005.;;Kim, K. et al., ""1.4kW High Peak Power Generation from an All Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Koechner, ""Solid State Laser Engineering"", Oct. 29, 1999, Section 5.5, pp. 270-277, 5th Edition, Springer.;;Kwon, et al., ""Tunable Dispersion Slope Compensator Using a Chirped Fiber Bragg Grating Tuned by a Fan-shaped Thin Metallic Heat Channel,"" IEEE Photonics Technology Letters, vol. 18, No. 1, pp. 118-120, Jan. 1, 2006.;;Kyungbum, Kim et al., ""1.4kW High Peak Power Generation from an all Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Levy et al., ""Engineering Space-Variant Inhomogeneous Media for Polarization Control,"" Optics Letters, Aug. 1, 2004, pp. 1718-1720, vol. 29, No. 15, Optical Society of America.;;Liao, K. et al.., ""Large-aperture Chirped Volume Bragg Grating Based Fiber CPA System,"" Optics Express, Apr. 16, 2007, vol. 15, No. 8, pp. 4876-4882.;;Lo, S. et al., ""Semiconductor Hollow Optical Waveguides Formed by Omni-directional Reflectors"", Optics Express, vol. 12, No. 26, Dec. 27, 2004, pp. 6589-6593.;;Malinowski A. et al., ""Short Pulse High Power Fiber Laser Systems,"" Proceedings of the 2005 Conference on Lasers and Electro-Optics (CLEO), Paper No. CThG3, pp. 1647-1649, May 26, 2005.;;Mehier-Humbert, S. et al., ""Physical Methods for Gene Transfer: Improving the Kinetics of Gene Delivery Into Cells,"" Advanced Drug Delivery Reviews, vol. 57, pp. 733-753, 2005.;;Mohammed, W. et al., ""Selective Excitation of the TE01 Mode in Hollow-Glass Waveguide Using a Subwavelength Grating,"" IEEE Photonics Technology Letters, Jul. 2005, vol. 17, No. 7, IEEE.;;Nibbering, E.T.J., et al. ""Spectral Determination of the Amplitude and the Phase of Intense Ultrashort Optical Pulses,"" Journal Optical Society of America B, vol. 13, No. 2, pp. 317-329, Feb. 1996.;;Nicholson, J. et al., ""Propagation of Femotsecond Pulses in Large-mode-area, Higher-order-mode Fiber,"" Optics Letters, vol. 31, No. 21, 2005, pp. 3191-3193.;;Noda, J. et al., ""Polarization-maintaining Fibers and Their Applications"", Journal of Lightwave Technology, vol. Lt-4, No. 8 Aug. 1986, pp. 1071-1089.;;Palfrey et al., ""Generation of 16-FSEC Frequency-tunable Pulses by Optical Pulse compression"" Optics Letters, OSA, Optical Society of america, Washington, DC, USA, vol. 10, No. 11, Nov. 1, 1985, pp. 562-564, XP000710358 ISSN: 0146-9592.;;Pelusi, M. D. et al., ""Electrooptic Phase Modulation of Stretched 250-fs Pulses for Suppression of Third-Order Fiber Disperson in Transmission,"" IEEE Photonics Technology Letters, vol. 11, No. 11, pp. 1461-1463, Nov. 1999.;;Pelusi, M. D. et al., ""Phase Modulation of Stretched Optical Pulses for Suppression of Third-order Dispersion Effects in fibre Transmission,"" Electronics Letters, vol. 34, No. 17, pp. 1675-1677, Aug. 20, 1998.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Proceedings of SPIE-vol. 5709, Fiber Lasers II: Technology, Systems, and Applications, Apr. 2005, pp. 184-192.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Photonics West 2005, San Jose, California, Jan. 2005, pp. 5709-3720.;;Ramachandran, S., et al., ""High-power Amplification in a 2040-mum2 Higher Order Mode,"" SPIE Photonics West 2007, Post-deadline.;;Resan et al., ""Dispersion-Managed Semiconductor Mode-Locked Ring Laser"", Optics Letters, Aug. 1, 2003, pp. 1371-1373, vol. 28, No. 15, Optical Society of America.;;Schreiber, T., et al., ""Design and High Power Operation of a Stress-induced single Polarization Single-transverse Mode LMA Yb-doped Photonic Crystal Fiber,"" Fiber Lasers III: Technology, Systems, and Applications, Andrew J.W. Brown, Johan Nilsson, Donald J. Harter, Andreas Tünnermann, eds., Proc. of SPIE, vol. 6102, pp. 61020C-1-61020C-9, 2006.;;Schreiber, T., et al., ""Stress-induced Single-polarization Single-transverse Mode Photonic Crystal Fiber with Low Nonlinearity,"" Optics Express, vol. 13, No. 19, Sep. 19, 2005, pp. 7621-7630.;;Siegman, ""Unstable Optical Resonators"", Applied Optics, Feb. 1974, pp. 353-367, vol. 13, No. 2.;;Limpert et al., ""All Fiber Chiped-Pulse Amplification System Based on Compression in Air-Guiding Photonic Bandgap Fiber"", Optics Express, Dec. 1, 2003, vol. 11, No. 24, pp. 3332-3337.",ACTIVE
741,US,A,US 5390734 A,195-163-508-230-13X,1995-02-21,1995,US 7008893 A,1993-05-28,US 7008893 A,1993-05-28,Heat sink,"A heat sink is provided having a bundle of thermally conductive fibers that extend from a heat receiving end to a heat dissipating end where they are splayed as extremely numerous fins of one or plural coalesced fibers to enlarge the effective heat convecting area. The splayed fins are supported or maintained in a splayed array by a structure. Heat dissipation capability is augmented by forcing a cooling fluid such as air through the splayed fins. The fins are initially caused to separate or splay by various techniques including electrostatic spreading, layering, tape rolling, selective coating removal, and elastic rebound, and are maintained in the splayed position by a frame, adhesion, or elastomers.",LYTRON INC,VOORHES DAVID W;;GOLDMAN RICHARD D;;LOPEZ ROBERT R,LYTRON INCORPORATED (1993-06-08),https://lens.org/195-163-508-230-13X,Granted Patent,yes,16,159,1,1,0,F28F13/00;;H01L23/3677;;H05K7/20445;;H01L2924/0002;;H01L23/3677;;F28F13/00;;H05K7/20445;;H01L2924/0002,F28F13/00;;H01L23/367;;H05K7/20,H1K KPDC          PDC;;H1K KPDX          PDX,0,0,,,,EXPIRED
742,TW,B,TW I653041 B,199-447-607-647-256,2019-03-11,2019,TW 102119583 A,2013-06-03,US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,,PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/199-447-607-647-256,Granted Patent,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,ACTIVE
743,CA,A1,CA 3015208 A1,195-489-058-713-408,2013-12-12,2013,CA 3015208 A,2013-06-03,US 201261655381 P;;CA 2875986 A,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/195-489-058-713-408,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K9/48;;A61K31/519;;A61K47/14;;A61K47/20;;A61K47/38;;A61P35/00,,0,0,,,,PENDING
744,US,A1,US 2012/0280578 A1,030-142-188-775-352,2012-11-08,2012,US 201213553690 A,2012-07-19,US 201213553690 A;;US 74087407 A;;US 79664606 P,2006-04-26,INTELLIGENT LASER INTERLOCK SYSTEM,"Systems and methods are disclosed for shutting down a laser system in an intelligent and flexible manner. An intelligent laser interlock system includes both hardwired components, and intelligent components configured to execute computing instructions. The hardwired components and the intelligent components are configured to shutdown the laser system to one or more alternative shutdown states in response to one or more interlock signals.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL,RAYDIANCE INC (2007-06-21);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/030-142-188-775-352,Patent Application,yes,3,4,4,4,0,F16P3/20;;H01S3/2308;;H01S3/2308;;H01S3/005;;H01S3/005;;H01S3/0912;;H01S3/0912;;H01S3/10038;;H01S3/10038,F16P3/20,307/328,0,0,,,,ACTIVE
745,DE,B4,DE 112007000820 B4,045-540-389-327-562,2017-03-16,2017,DE 112007000820 T,2007-03-05,US 27807106 A;;US 2007/0005663 W,2006-03-30,Hochansprechende Master-Slave-Ventileinstellung,"Verfahren (300) zum Steuern bzw. Regeln mehrerer Ventile, wobei das Verfahren (300) umfasst: A. Koppeln eines Master-Ventils (122) und eines Satzes von Slave-Ventilen (122(1)–122(N)) über ein digitales Netzwerk (160); B. Empfangen (310) eines Drucksollwerts (202) oder Druckeinstellwerts, der einen gewünschten Druck darstellt, und eines Rückkopplungsdruckwerts (204), der einen tatsächlichen Druck darstellt, durch das Master-Ventil (122); C. Positionieren (320) eines Master-Ventilschiebers (122C) des Master-Ventils (122) als eine Funktion des Drucksollwerts (202) oder Druckeinstellwerts und des Druckrückkopplungswerts (204); D. Erzeugen (330) eines Positions-Einstellungswerts, der eine relative Position des Master-Ventilschiebers (122C) innerhalb eines Bereichs von Master-Ventil-Aktuatorpositionen darstellt; E. Broadcasten bzw. Rundsenden (340) des Positions-Einstellungswerts an den Satz von Slave-Ventilen (122(1)–122(N)) über das digitale Netzwerk (160); und F. Empfangen (350) des Positions-Einstellungswerts und Positionieren eines Schiebers (122(1)C–122(N)C) jedes Slave-Ventils in dem Satz von Slave-Ventilen (122(1)–122(N)) in oder an einer Position, die der relativen Position des Master-Ventilschiebers (122C) entspricht.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/045-540-389-327-562,Granted Patent,no,5,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16;;G05B1/03;;G05D16/20;;G06F19/00,,0,0,,,,ACTIVE
746,CA,A1,CA 2172565 A1,063-213-972-408-153,1996-10-29,1996,CA 2172565 A,1996-03-25,US 43122895 A,1995-04-28,PACKAGE SPECIAL DELIVERY SERVICE,"It is possible to redirect a package in mid-transit, so as to deliver it to the addressee who will not be at the location to which the package was originally addressed when the package would otherwise be delivered. To do so, a package carrier, prior to delivering a package to an address specified by the sender, determines if the addressee desires the package to be rerouted to a different address. This determination is prompted by detection of the fact that the addressee is not in the vicinity of the address specified by the sender. The location of the addressee is determined from the location of a two-way pager associated with theaddressee as detected by a paging antenna, e.g., tower, of a conventional two-way paging. A comparison is made between the location of the addressee and the address specified by the sender. If there is a disparity and the addressee subscribes to the package special delivery redirection service, the package is then processed according to the instructions of the addressee. One instruction that can be left by the addressee is to call the addressee and ask if he wishes the package to be redirected, and, if so, what should be the new address. Another instruction that can be left by the addressee is to automatically reroute the package to a destination which may be determined as a function of the location of the addressee.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,,https://lens.org/063-213-972-408-153,Patent Application,no,0,0,2,2,0,G06Q10/08;;G06Q10/08,G06Q10/08,,0,0,,,,DISCONTINUED
747,CA,A1,CA 2664456 A1,070-052-996-777-147,2008-04-10,2008,CA 2664456 A,2007-09-27,US 84820006 P;;US 2007/0079761 W,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation an d interact with the electromagnetic radiation to generate signals in the for m of pulses includes generating a time-dependent pulse indicative of the cha racteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by select ing a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with r espect to time over the measurement window.",GUAVA TECHNOLOGIES,GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A;;PITTARO RICHARD,,https://lens.org/070-052-996-777-147,Patent Application,no,0,1,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36;;G01F1/36,,0,0,,,,ACTIVE
748,WO,A3,WO 2007/126543 A3,072-780-991-104-822,2009-05-07,2009,US 2007/0005663 W,2007-03-05,US 27807106 A,2006-03-30,HIGHLY RESPONSIVE MASTER-SLAVE VALVE POSITIONING,"A master valve and at least one slave valve are connected via a network, wherein upon broadcast of a position setpoint of the master valve the at least one slave valve achieves a corresponding position within a shortened period of time, such network being a dedicated network or high speed shared network with position setpoint priority.",MKS INSTR INC,GOLDMAN DAVID J;;RYAN MARTIN;;DAVIDKOVICH VLADISLAV;;HILL GORDON,,https://lens.org/072-780-991-104-822,Search Report,yes,2,0,13,13,0,G05D16/2046;;Y10T137/86413;;G05B1/03;;G05D16/2093;;F16K31/12;;A01G25/16;;F16K37/00;;Y10T137/86413;;G05D16/2046,F16K31/12;;A01G25/16,,0,0,,,,PENDING
749,CN,A,CN 102883634 A,107-347-168-862-273,2013-01-16,2013,CN 201180022740 A,2011-05-05,US 2011/0035367 W;;US 33234410 P,2010-05-07,Toothbrush,"An oral care implement having a handle and a toothbrush head is disclosed. The head includes a base portion and a cleaning portion. The cleaning portion includes a plurality of cleaning elements, wherein the cleaning portion is attached to the base portion at a first end and a second end. A mid-section of the cleaning portion is elevated above the base portion such that an opening is created between the base portion and the cleaning portion, and wherein the opening extends along a longitudinal axis of the head.",GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,,https://lens.org/107-347-168-862-273,Patent Application,no,8,2,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B9/04;;A46B7/06,,0,0,,,,ACTIVE
750,KR,A,KR 20200017549 A,103-994-687-107-427,2020-02-18,2020,KR 20207003793 A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"본원에 개시된 것은 브루톤 타이로신 키나아제(Bruton's tyrosine kinase; Btk) 저해제 1-((R)-3-(4-아미노-3-(4-페녹시페닐)-1H-피라졸로[3,4-d]피리미딘-1-일)피페리딘-1-일)프로프-2-엔-1-온이며, 이것은 이의 결정 형태, 용매화물 및 약학적으로 허용가능한 염을 포함한다. 또한 개시된 것은 Btk 저해제를 포함하는 약학 제제와, Btk 저해제를 단독으로 또는 다른 치료제와 조합하여 이용하는 방법인데, 이는 자가면역 질환 또는 병태, 이종면역 질환 또는 병태, 림프종을 포함하는 암, 및 염증성 질환 또는 병태의 치료를 위한 것이다.",PHARMACYCLICS LLC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/103-994-687-107-427,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D473/34;;A61K9/48;;A61K31/519;;A61K47/38;;C07D487/04,,0,0,,,,DISCONTINUED
751,CA,A1,CA 3218491 A1,101-729-574-760-876,2013-12-12,2013,CA 3218491 A,2013-06-03,US 201261655381 P;;CA 3015208 A,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yppiperidin-1-ypprop-2-en-1-one, with the following structure: including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/101-729-574-760-876,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,,,0,0,,,,PENDING
752,US,B2,US 11919830 B2,133-052-515-400-597,2024-03-05,2024,US 17521022,2021-11-08,,,Materials suitable as substitutes for peat mosses and processes and apparatus therefor,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,Mont Andrew Handley;;Matt Collins Knapp;;Mark David Goldman,PITTMOSS LLC (2015-10-21),https://lens.org/133-052-515-400-597,Granted Patent,yes,15,0,1,1,0,C05F11/00;;C05G3/80;;C05G5/12;;C09K17/16;;C09K17/50;;C09K17/52,C05F11/00;;C05G3/80;;C05G5/12;;C09K17/16;;C09K17/50;;C09K17/52,,0,0,,,,UNKNOWN
753,CA,A1,CA 2991994 A1,130-683-766-329-053,2013-12-12,2013,CA 2991994 A,2013-06-03,US 201261655381 P;;CA 2875986 A,2012-06-04,PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING IBRUTINIB,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/130-683-766-329-053,Patent Application,no,0,4,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61K9/48;;A61P35/00,,0,0,,,,PENDING
754,UY,A,UY 34848 A,130-044-072-161-582,2013-10-31,2013,UY 34848 A,2013-06-04,US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UN INHIBIDOR DE TIROSINA QUINASA DE BRUTON,escanear Estructura de pag. 107/267,PHARMACYCLICS INC,MARK SMYTH;;ERICK GOLDMAN;;WIRTH DAVID D;;NORBERT PURRO,,https://lens.org/130-044-072-161-582,Patent Application,no,0,1,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/4162;;A61K9/20;;A61K31/519;;A61K47/38;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
755,MX,A,MX 9604351 A,132-989-512-761-844,1997-04-30,1997,MX 9604351 A,1996-09-26,US 53833195 A,1995-10-03,METHOD AND APPARATUS FOR PROCESSING TELEPHONE CALLS.,"A method and apparatus for processing telephone calls based on variable telephone call parameters is disclosed. A telecommunication network node is connected to a database which stores a telephone subscriber preference data describing subscriber preference data defining the type of telephone services to be applied to outgoing telephone calls. Upon receipt of the outgoing call at the node, the node performs a database search using variable telephone calls parameters and retrieves a telephone call service description. The telephone call service description describes the type of service to apply to the call. The call is completed with the described services being applied to the call. In another embodiment, the database contains subscriber preference data defining routing instructions for incoming calls. Upon receipt of the incoming call at the node, the node performs a database search using variable telephone call parameters and retrieves routing instructions. The routing instructions indicate whether the call is to be routed to the subscriber or to an alternate destination. The call is completed by routing it according to the retrieved routing instructions.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP,,https://lens.org/132-989-512-761-844,Patent Application,no,0,0,4,4,0,H04Q3/0016;;H04Q2213/13091;;H04Q2213/13097;;H04Q2213/13103;;H04Q2213/13109;;H04Q2213/13141;;H04Q2213/13332;;H04Q2213/13377;;H04Q2213/1338;;H04Q2213/13405,H04M3/42;;H04Q3/00,,0,0,,,,PENDING
756,BR,A8,BR 112014030424 A8,140-206-804-159-544,2017-07-11,2017,BR 112014030424 A,2013-06-03,US 2013/0043888 W;;US 201261655381 P,2012-06-04,FORMAS CRISTALINAS DE UM INIBIDOR DE QUINASE DE TIROSINA DE BRUTON,"FORMAS CRISTALINAS DE UM INIBIDOR DE TIROSINA-QUINASE DE BRUTON. É aqui descrito um inibidor de tirosina quinase de Bruton (Btk) 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1Hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluindo formas cristalinas, solvatos e sais farmaceuticamente aceitáveis dos mesmos. Também são reveladas composições farmacêuticas que incluem o inibidor de Btk, bem como métodos de utilização do inibidor de Btk, sozinho ou em combinação com outros agentes terapêuticos, para o tratamento de doenças ou condições autoimunes, doenças ou condições heteroimmune, câncer, incluindo linfomas e doenças ou condições inflamatórias.",PHARMACYCLICS INC;;OXFORD AMHERST LLC;;PHARMACYCLICS LLC,MARK SMYTH;;ERICK GOLDMAN;;DAVID D WIRTH;;NORBERT PURRO,PHARMACYCLICS LLC (US) (2023-04-11);;OXFORD AMHERST LLC (US) (2017-07-11),https://lens.org/140-206-804-159-544,Patent Application,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,DISCONTINUED
757,EP,A1,EP 2566367 A1,147-271-130-787-418,2013-03-13,2013,EP 11720360 A,2011-05-05,US 33234410 P;;US 2011/0035367 W,2010-05-07,TOOTHBRUSH,,GILLETTE CO,GOLDMAN PAUL DAVID;;FARRELL MARK EDWARD;;SAGEL PAUL ALBERT,THE GILLETTE COMPANY LLC (2016-12-07),https://lens.org/147-271-130-787-418,Patent Application,yes,0,0,14,14,0,A46B5/0008;;A46B7/06;;A46B9/026;;A46B9/04;;A46B7/06;;A46B9/026;;A46B7/06;;A46B5/0008,A46B5/00;;A46B7/06;;A46B9/02,,0,0,,,,ACTIVE
758,US,A1,US 2012/0236291 A1,159-339-712-133-346,2012-09-20,2012,US 201213461713 A,2012-05-01,US 201213461713 A;;US 95191110 A;;US 86268007 A;;US 84820006 P,2006-09-29,DIFFERENTIATION OF FLOW CYTOMETRY PULSES AND APPLICATIONS,"A method of analyzing pulses from a flow cytometer in which particles in a fluid pass through an excitation volume of an electromagnetic radiation and interact with the electromagnetic radiation to generate signals in the form of pulses includes generating a time-dependent pulse indicative of the characteristics of one or more particles passing through the excitation volume of the electromagnetic radiation, determining a measurement window by selecting a portion of the pulse with a starting point and an ending point above a predetermined value, and calculating a first derivative of the pulse with respect to time over the measurement window.",PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A;;EMD MILLIPORE CORP,PITTARO RICHARD;;GOLDMAN BRUCE;;LEFEBVRE RAY;;KING DAVID A,GUAVA TECHNOLOGIES INC (2008-05-16);;LUMINEX CORPORATION (2019-01-03);;EMD MILLIPORE CORPORATION (2011-12-12);;CYTEK BIOSCIENCES INC (2023-02-28),https://lens.org/159-339-712-133-346,Patent Application,yes,2,15,17,17,0,G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14;;G01N15/1429;;G01N2015/1477;;G01N2015/1486;;G01N2015/1006;;G01N15/1459;;G01N15/14,G01P3/36,356/28,0,0,,,,ACTIVE
759,EP,B1,EP 0738083 B1,181-618-661-471-108,2004-11-10,2004,EP 96104623 A,1996-03-22,US 41920195 A;;US 41920595 A,1995-04-10,Interactive video on demand system using packet transmission via ATM network,,HEWLETT PACKARD DEVELOPMENT CO,MENDELSON JEFFREY B;;GOLDMAN MATTHEW S;;MORRIS DAVID E,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/181-618-661-471-108,Granted Patent,yes,2,0,10,12,0,H04N21/47202;;H04N7/17318;;H04N7/17336;;H04N21/2365;;H04N21/4347,H04N7/26;;H04M11/08;;H04N7/10;;H04N7/173,,3,0,,,"CHAO H J ET AL: ""ASYNCHRONOUS TRANSFER MODE PACKET VIDEO TRANSMISSION SYSTEM"" OPTICAL ENGINEERING, vol. 28, no. 7, July 1989, pages 781-788, XP000033802;;VARMA S: ""MPEG-2 OVER ATM: SYSTEM DESIGN ISSUES"" DIGEST OF PAPERS OF COMPCON (COMPUTER SOCIETY CONFERENCE) 1996, TECHNOLOGIES FOR THE INFORMATION SUPERHIGHWAY SANTA CLARA, FEB. 25 - 28, 1996, no. CONF. 41, 25 February 1996, INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS, pages 26-31, XP000628461;;D'AGOSTINO S: ""UNIVERSAL VIDEOCODEC FOR ATM NETWORKS1"" REVUE HF, vol. 15, no. 3 / 04, 1 January 1991, pages 102-112, XP000307855",EXPIRED
760,US,A1,US 2022/0055959 A1,192-212-669-808-800,2022-02-24,2022,US 202117521022 A,2021-11-08,US 202117521022 A;;US 201514856663 A;;US 201462060911 P,2014-10-07,MATERIALS SUITABLE AS SUBSTITUTES FOR PEAT MOSSES AND PROCESSES AND APPARATUS THEREFOR,"Processes capable of producing bulk materials suitable for use by the horticulture industry, resulting bulk materials produced thereby, and applications for these processes and materials. Preferred bulk materials have physical properties similar to peat moss and comprise individual materials, each at least partially having a twisted, curled, clumped and rolled structure. The individual materials may further comprise small granular particles dispersed throughout the twisted, curled, clumped and rolled structure. The individual materials may be rolled fibers such that the bulk material has physical properties similar to sphagnum peat moss so as to be particularly suitable as, for example, a soil conditioner, an absorbent material, a chemical carrier, or a filtering material. Alternatively, the individual materials may be rolled particles such that the bulk material has physical properties similar to milled peat moss so as to be particularly suitable as propagation media.",PITTMOSS LLC,HANDLEY MONT ANDREW;;KNAPP MATT COLLINS;;GOLDMAN MARK DAVID,PITTMOSS LLC (2015-10-21),https://lens.org/192-212-669-808-800,Patent Application,yes,15,2,5,7,0,C05F11/00;;C05G5/12;;C05F11/00;;C05G5/12;;C09K17/50;;C09K17/52;;C09K17/16;;C05G3/80,C05F11/00;;C05G5/12,,0,0,,,,ACTIVE
761,SG,A,SG 11201408067Y A,192-317-060-769-566,2015-01-29,2015,SG 11201408067Y A,2013-06-03,US 201261655381 P;;US 2013/0043888 W,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,,PHARMACYCLICS INC,SMYTH MARK;;GOLDMAN ERICK;;WIRTH DAVID D;;PURRO NORBERT,,https://lens.org/192-317-060-769-566,Unknown,no,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K47/38;;A61K9/48;;A61K47/30;;A61P29/00;;A61P35/00,,0,0,,,,PENDING
762,US,A1,US 2023/0237129 A1,070-630-344-864-060,2023-07-27,2023,US 202318117575 A,2023-03-06,US 202318117575 A;;US 202016799201 A;;US 201962809590 P,2019-02-23,MUSIC AND DIGITAL RIGHTS MANAGEMENT SYSTEMS AND METHODS,"A method and associated system for matching and delivering digital work metadata to one or more digital service providers including modifying one or more digital work metadata files, which includes removing non-critical data or segment-erroneous data or performing a language translation; reformatting the one or more digital work metadata files for compatibility with a transformer model-based AI matching operation; performing a block grouping operation on the one or more digital work metadata files, where data associated with the one or more digital work metadata files is grouped in blocks and analyzed for one or more pairs of data records; performing the transformer model-based AI matching operation to determine whether each pair of the one or more pairs of data records comprise a matching pair of data records; and transmitting output data from the transformer model-based artificial intelligence matching operation to the one or more digital service providers.",MUSERK LLC,GOLDMAN PAUL DAVID;;WHITE COLLIN ROBERT;;BRADLEY QUENTIN NICHOLAS;;AHMANSON JUSTIN DAVID,MUSERK LLC (2023-03-20),https://lens.org/070-630-344-864-060,Patent Application,yes,0,0,1,5,0,G06F21/1012;;G06F21/12;;G06F21/12;;G06F16/65;;G06F16/116;;G06F21/1012,G06F21/12;;G06F16/11;;G06F16/65,,0,0,,,,PENDING
763,EP,A2,EP 1852206 A2,051-778-486-615-926,2007-11-07,2007,EP 07107403 A,2007-05-03,US 79779806 P;;US 82160606 P;;US 74210807 A,2006-05-04,Cordless Welding Machines and Cordless Plasma Cutters,"A cordless welding machine (100) includes first (B1) and second (B2) batteries being connected in parallel, a ground clamp (GC) connected to the first and second batteries, and a first welding electrode (SC) connected to the first and second batteries. The batteries providing a current output of at least about 40 amps.
",BLACK & DECKER INC,CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,,https://lens.org/051-778-486-615-926,Patent Application,yes,5,23,5,5,0,B23K9/10;;B23K9/10;;B23K9/1081;;B23K9/1081;;B23K10/003;;B23K10/003;;Y10T29/53135;;Y10T29/53135,B23K9/10;;B23K10/00,,0,0,,,,ACTIVE
764,EP,B1,EP 1852206 B1,073-659-298-561-808,2020-05-13,2020,EP 07107403 A,2007-05-03,US 79779806 P;;US 82160606 P;;US 74210807 A,2006-05-04,Cordless Welding Machines and Cordless Plasma Cutters,,BLACK & DECKER INC,CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,,https://lens.org/073-659-298-561-808,Granted Patent,yes,3,0,5,5,0,B23K9/1081;;B23K10/003;;Y10T29/53135;;B23K9/10;;Y10T29/53135;;B23K9/1081;;B23K10/003;;B23K9/10,B23K9/10;;B23K10/00,,0,0,,,,ACTIVE
765,US,A1,US 2007/0257084 A1,171-401-786-073-904,2007-11-08,2007,US 74210807 A,2007-04-30,US 74210807 A;;US 79779806 P;;US 82160606 P,2006-05-04,Cordless Welding Machines,"A cordless welding machine includes first and second batteries being connected in parallel, a ground clamp connected to the first and second batteries, and a first welding electrode connected to the first and second batteries. The batteries providing a current output of at least about 40 amps.",CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,BLACK & DECKER INC (2007-05-15),https://lens.org/171-401-786-073-904,Patent Application,yes,65,26,5,5,0,B23K9/10;;B23K9/10;;B23K9/1081;;B23K9/1081;;B23K10/003;;B23K10/003;;Y10T29/53135;;Y10T29/53135,B23K37/00,228/44.3;;29/730,4,2,137-359-656-574-445;;002-314-304-894-600,10.1016/s0378-7753(00)00486-9;;10.1016/s0378-7753(00)00487-0,"Bhardwaj et al. , ""Lead Acid with thin metal film (TMF) technology for high power applications"", 12/2000, Journal of Power Sources, Volume, 91, pages 51-61.;;Gruenstein et al., ""Inspira- an enabling battery technology for high voltage automotive electrical systems""12/2000, Journal of Power Sources, Volume 91, pages 62-67.;;Glen R., article ""Broco Inc.'s GOWELDO: Portable Mig Welder"" 07/2003, on website www.off-road.com/trucks, pages 1-3.;;Suzuki et al., ""High Power and Long Life Lithium-ion Battery for Backup Power Sources"", 10/2003, Telecommunications Energy Conferences, IEICE/IEEE INTELEC '03, pages 317-322.",ACTIVE
766,US,B2,US 11599502 B2,146-549-994-116-504,2023-03-07,2023,US 202016799201 A,2020-02-24,US 202016799201 A;;US 201962809590 P,2019-02-23,Music and digital rights management systems and methods,"A method and associated system for matching and delivering digital work metadata to one or more digital service providers, including modifying one or more digital work metadata files to remove non-critical data or segment erroneous data from the one or more digital work metadata files; reformatting the one or more digital work metadata files for compatibility with a digital service provider usage report table; performing a first matching operation, in which the one or more digital work metadata files are compared to the digital service provider usage report table on the basis of one or more data points; performing a second matching operation, the second matching operation being an artificial intelligence (AI) matching operation on one or more unmatched digital work metadata files of the one or more digital work metadata files; and transmitting output data from the matching operations to the one or more digital service providers.",MUSERK LLC,GOLDMAN PAUL DAVID;;WHITE COLLIN ROBERT;;BRADLEY QUENTIN NICHOLAS;;AHMANSON JUSTIN DAVID,MUSERK LLC (2020-06-08),https://lens.org/146-549-994-116-504,Granted Patent,yes,11,0,4,5,0,G06F21/10;;G06F16/148;;G06N20/00;;G06F16/1748;;G06F16/116;;G06F21/16;;G06F21/10,G06F16/14;;G06F16/11;;G06F16/174;;G06F21/16;;G06N20/00,,4,0,,,"Exactuals Webinar: Perfecting Music Metadata Through Machine Learning, “https://vimeo.com/293427917/86ede8e532” https://vimeo.com/293427917/86ede8e532 Release date Oct. 29, 2015 (Year: 2015).;;Written Opinion of the International Searching Authority in PCT/US2020/019460 (dated Sep. 25, 2020).;;International Search Report in PCT/US2020/019460 (dated Sep. 25, 2020).;;Exactuals Webinar: Perfecting Music Metadata Through Machine Learning, Exactuals (2018).",ACTIVE
767,US,B2,US 9533367 B2,187-731-500-534-772,2017-01-03,2017,US 74210807 A,2007-04-30,US 74210807 A;;US 79779806 P;;US 82160606 P,2006-05-04,Cordless welding machine and plasma cutter,"A cordless welding machine includes first and second batteries being connected in parallel, a ground clamp connected to the first and second batteries, and a first welding electrode connected to the first and second batteries. The batteries providing a current output of at least about 40 amps.",CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A;;BLACK & DECKER INC,CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,BLACK & DECKER INC (2007-05-15),https://lens.org/187-731-500-534-772,Granted Patent,yes,88,2,5,5,0,B23K9/10;;B23K9/10;;B23K9/1081;;B23K9/1081;;B23K10/003;;B23K10/003;;Y10T29/53135;;Y10T29/53135,B23K9/10;;B23K10/00,,7,2,137-359-656-574-445;;002-314-304-894-600,10.1016/s0378-7753(00)00486-9;;10.1016/s0378-7753(00)00487-0,"""Genesis PURELEAD, Application Manual"", sixth edition, Jun. 2005, Publication No. US-GPL-AM-002,pp. 1-28.;;Bhardwaj et al. , ""Lead Acid with thin metal film (TMF) technology for high power applications"", Dec. 2000, Journal of Power Sources, vol. 91, pp. 51-61.;;Gruenstein et al., ""Inspira-an enabling battery technology for high voltage automotive electrical systems"" Dec. 2000, Journal of Power Sources, vol. 91, pp. 62-67.;;Glen R., article ""Broco Inc.'s GOWELDO: Portable Mig Welder"" Jul. 2003, on website www.off-road.com/trucks, pp. 1-3.;;Suzuki et al., ""High Power and Long Life Lithium-ion Battery for Backup Power Sources"", Oct. 2003, Telecommunications Energy Conferences, IEICE/IEEE INTELEC '03, pp. 317-322.;;Adam Piekarski, European Search Report, Jun. 5, 2008, The Hague.;;Annex to the European Search Report on European Patent Application No. EP 07 10 7403.",ACTIVE
768,EP,A3,EP 1852206 A3,096-097-640-458-447,2008-10-15,2008,EP 07107403 A,2007-05-03,US 79779806 P;;US 82160606 P;;US 74210807 A,2006-05-04,Cordless Welding Machines and Cordless Plasma Cutters,"A cordless welding machine (100) includes first (B1) and second (B2) batteries being connected in parallel, a ground clamp (GC) connected to the first and second batteries, and a first welding electrode (SC) connected to the first and second batteries. The batteries providing a current output of at least about 40 amps.
",BLACK & DECKER INC,CARRIER DAVID A;;HOWARD GEOFFREY S;;STARKS SHELBY K;;GOLDMAN DAVID A,,https://lens.org/096-097-640-458-447,Search Report,yes,5,1,5,5,0,B23K9/1081;;B23K10/003;;Y10T29/53135;;B23K9/10;;Y10T29/53135;;B23K9/1081;;B23K10/003;;B23K9/10,B23K9/10;;B23K10/00,,0,0,,,,ACTIVE
769,US,A1,US 2018/0319805 A1,027-972-573-569-613,2018-11-08,2018,US 201816036207 A,2018-07-16,US 201816036207 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/027-972-573-569-613,Patent Application,yes,8,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61J1/03;;C07D487/04;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
770,US,A1,US 2018/0319806 A1,053-132-990-420-781,2018-11-08,2018,US 201816036258 A,2018-07-16,US 201816036258 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/053-132-990-420-781,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
771,AT,T1,AT E553034 T1,089-968-506-961-823,2012-04-15,2012,AT 07812670 T,2007-07-06,US 2007/0072923 W,2007-07-06,VERFAHREN ZUR HANDHABUNG VON EIN TEILCHENFÖRMIGES ALIQUOT ENTHALTENDEN KLAPPSCHALENBEHÄLTERN,"A method for handling package assemblies in an automated aliquot and/or dispersal processes is provided. Embodiments of the present invention include, but are not limited to, a method of handling a package assembly containing a particulate aliquot (such as a selected type of agricultural seed) that includes first and second portions which cooperate to contain the aliquot, the method including receiving the package assembly in a package assembly handling device (50), and applying a force to the package assembly using the package assembly handling device so that the first and second portions at least partially separate in response to the force.",PIONEER HI BRED INT,GOLDMAN DANIEL;;HARTMAN MICHAEL;;HUNTER JAMES;;JOHNSON DAVID;;TUCKER GRIFFITHS,,https://lens.org/089-968-506-961-823,Granted Patent,no,0,1,10,10,0,B65B69/00;;B65B69/00,,,0,0,,,,ACTIVE
772,US,A1,US 2006/0056480 A1,096-541-208-647-474,2006-03-16,2006,US 22930205 A,2005-09-15,US 22930205 A;;US 60986604 P,2004-09-15,Actively stabilized systems for the generation of ultrashort optical pulses,"A system and method for generating an optical laser pulse train of constant ultrashort pulse duration and low timing jitter in a fiber ring laser system (resonator) while keeping the laser resonator resilient to environmental conditions like temperature, humidity and pressure. The laser resonator may be actively mode-locked with a periodic electrically driven modulation at a specific frequency that corresponds to the inverse of the transit time inside the resonator. The optical pulse train quality may be monitored in real time, and the frequency of the modulation may be dynamically tuned in real time to compensate for resonator length changes due to changes in the environmental conditions.",MIELKE MICHAEL M;;YILMAZ ISMAIL T;;GOLDMAN DAVID;;FARLEY MARK,MIELKE MICHAEL M;;YILMAZ ISMAIL T;;GOLDMAN DAVID;;FARLEY MARK,RAYDIANCE INC (2005-11-17),https://lens.org/096-541-208-647-474,Patent Application,yes,9,46,1,1,0,H01S3/06791;;H01S3/107;;H01S3/1109;;H01S3/1121;;H01S3/136;;H01S3/06791;;H01S3/107;;H01S3/136;;H01S3/1121;;H01S3/1109,H01S3/083,372/94,0,0,,,,DISCONTINUED
773,US,A1,US 2018/0362534 A1,141-085-337-532-298,2018-12-20,2018,US 201816110969 A,2018-08-23,US 201816110969 A;;US 201816036258 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/141-085-337-532-298,Patent Application,yes,8,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
774,WO,A1,WO 2023/149975 A1,148-557-774-656-173,2023-08-10,2023,US 2022/0080469 W,2022-11-25,US 202217591435 A,2022-02-02,SYSTEM FOR DRAWING FLUID FROM A BAG UNDER SUB-AMBIENT CONDITIONS,A portable system and method for infusing liquid medicaments to a patient through an elastomeric fluid channel includes an airtight pressure shell for holding a collapsible bag of the fluid medicament to be infused. A pressure sensor connected to the pressure shell monitors decreases below ambient pressure inside the shell to determine when the sub-ambient pressure becomes insufficient to continue assisting the withdrawal of fluid from the collapsible bag to an external pinch/squeeze unit. An equilibration valve is synchronized with the pinch/squeeze unit to reestablish ambient pressure in the pressure shell for continued operation as the pinch/squeeze unit acts to sequentially push liquid medicament for infusion into the patient.,MODULAR MEDICAL INC,DIPERNA PAUL M;;GOLDMAN MARC D;;NEESE DAVID;;HEARTY PATRICK,,https://lens.org/148-557-774-656-173,Patent Application,yes,4,0,1,4,0,F04B43/082;;A61M5/14228;;A61M5/16854;;A61M2205/3351,A61M5/148;;A61M5/142;;A61M5/168;;F04B43/08,,0,0,,,,PENDING
775,US,B2,US 10537034 B2,148-152-288-131-421,2020-01-14,2020,US 201816170355 A,2018-10-25,US 201816170355 A;;US 201762580221 P,2017-11-01,Control boxes principally for use with equipment of swimming pools and spas,"Control boxes with segregated low- and high-voltage components are described. Service technicians (or others) requiring access to one set of components may do so without necessarily accessing the other set. Dual user interfaces may be utilized, further, with one interface being present at the control box and the other being remote therefrom.",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2017-11-02),https://lens.org/148-152-288-131-421,Granted Patent,yes,9,2,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,H05K5/02;;A61H33/00;;E04H4/12;;H02G3/08;;H04B1/3827,,1,0,,,"International Application No. PCT/US2018/057496, International Search Report and Written Opinion dated Feb. 18, 2019, 14 pages.",ACTIVE
776,US,B1,US 9725455 B1,178-288-097-904-71X,2017-08-08,2017,US 201715497896 A,2017-04-26,US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/178-288-097-904-71X,Granted Patent,yes,286,24,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/00;;C07D295/00;;C07D487/04,,309,130,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;038-340-694-023-194;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;028-709-531-330-282;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;031-216-361-201-391;;025-966-522-155-708;;084-480-509-946-521;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;20166765;;10.2165/11532180-000000000-00000;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;25276427;;10.1155/2014/852748;;pmc4170925;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;pmc2833438;;15180891;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099,"ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al., Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4): abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al., Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al., Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al., Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al., Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bharate, S.S., et al., “Interactions and incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, J. Excipients and Food Chem., 2010, vol. 1 (3), pp. 3-26.;;Biospace, Dec. 8, 2009, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning, B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al., Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al., CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al., High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger, Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al., Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al., Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon, Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al., Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al., Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al., Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arthritis Res Ther, 13:R115 (2011).;;Chavez et al., Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al., SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Cohen et al., Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al., Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al., Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature, 463(7277):88-92 (2010).;;Desiderio, Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al., Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action mailed Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards, BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report mailed Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, mailed on Nov. 10, 2015.;;Fabian et al., A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;Fedorak et al., A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al., Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman, Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Grosheck et al. Molecular Target Class Is Predictive of in vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al., Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al., Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al., Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al., A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al., Targeting Btk in Lymphoma: PCT-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCT-32765 Is an Active-Site Probe that Enables Assessment of Btk Inhibition in Vivo. Blood (Ash Annual Meeting Abstracts). 2007. 110: Abstract 1592.;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al., Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, mailed on May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;Iqbal, N. et al., “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.” Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants with Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib with Nivolumab in Participants with Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb, What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al., Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al., Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al., Development of a Bruton's tyrosine kinase (BTK) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al., Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers, Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki, Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al., Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al., Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al., Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al., Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al., Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al., Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al., Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al., Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination with Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;Macpartlin et al., Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al., Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al., Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al., Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994).;;Memorial Sloan-Kettering Cancer Center. Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 9, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02315326?term=NCT02315326 NLM Identifier: NCT02315326.;;Mendel et al., “In vivo Antitumor Activity of SU11248, A Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/pharmacodynamic Relationship,” Clin Cancer Res, 9(1): 327-337 (2003).;;Merged Markush Service Search, Jun. 27, 2005.;;Middendorp et al., Function of Bruton's Tyrosine Kinase during B Cell Development is Partially Independent of its Catalytic Activity. J Immunol 171:5988-5996 (2003).;;Middendorp et al., Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity. Blood 105(1):259-261 (2005).;;Mukoyama et al., “Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases,” retrieved from STN Database Accession No. 2005:299462 Patent No. JP2005089352, Abstract (2005).;;National Cancer Institute (NCI). A multicenter phase 2 study of the Bruton's tyrosine kinase inhibitor PCI-32765 for treatment of relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 2, 2013 [cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01981512 NLM Identifier: NCT01981512. et al.",ACTIVE
777,US,B2,US 9713617 B2,181-804-468-937-585,2017-07-25,2017,US 201615386118 A,2016-12-21,US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/181-804-468-937-585,Granted Patent,yes,284,27,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/505;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;B65D75/36,,488,130,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;070-623-826-082-605;;000-593-425-035-61X;;070-105-220-366-494;;029-307-446-890-335;;157-431-722-988-742;;025-716-535-208-301;;053-207-920-994-687;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;032-963-276-412-261;;006-286-861-403-907;;017-696-456-420-448;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;038-340-694-023-194;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;005-576-769-764-004;;026-747-860-569-66X;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;009-072-168-512-123;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;108-465-833-398-743;;012-047-319-657-391;;028-709-531-330-282;;016-289-303-702-626;;088-154-228-885-728,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;pmc3239353;;21752263;;10.1186/ar3400;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;23425038;;10.3109/10428194.2013.777837;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;20166765;;10.2165/11532180-000000000-00000;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;10.1182/blood-2005-01-0016;;16123223;;12652460;;10.1053/sonc.2003.50024;;28140216;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;22975686;;10.1016/j.cellsig.2012.09.008;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;24464309;;10.1007/s40265-014-0178-8;;pmc3662532;;23717217;;10.2147/ce.s34068;;25276427;;10.1155/2014/852748;;pmc4170925;;10.1016/0378-5173(88)90220-7;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249,"ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al. The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study, Ann. Oncol. 22(suppl 4): abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 21, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Biospace, 20091208, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al. Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin. Oncol. 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: <http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst—detail—view&confID=114&abstractID=98841>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of The T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrd, J.C., et al., 2013, “Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia”, New England Journal of Medicine, vol. 369, No. 1, pp. 32-42.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Chang et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Research & Therapy, 13:R115 (2011).;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al. PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Rodent Models of Arthritis. ACR/ARHP Scientific Meeting, Nov. 6-11, 2010, Poster #286.;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Co-pending U.S. Appl. No. 14/605,857, filed Jan. 26, 2015.;;Co-pending U.S. Appl. No. 14/613,309, filed Feb. 3, 2015.;;Co-pending U.S. Appl. No. 14/703,750, filed May 4, 2015.;;Co-pending U.S. Appl. No. 14/793,366, filed Jul. 7, 2015.;;Co-pending U.S. Appl. No. 14/794,685, filed Jul. 8, 2015.;;Co-pending U.S. Appl. No. 14/855,270, filed Sep. 15, 2015.;;Co-pending U.S. Appl. No. 14/856,217, filed Sep. 16, 2015.;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-92 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dorwald. A. Side Reactions in Organic Synthesis, Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005).;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, mailed on Nov. 10, 2015.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, Abstract 156 (Dec. 8-11, 2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia, Cancer Genetics and Cytogenetics 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Grosheck et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (Epub Aug. 25, 2005) 106(12):3725-3732 (Dec. 2005).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al., Targeting Btk in Lymphoma: PCT-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCT-32765 Is an Active-Site Probe that Enables Assessment of Btk Inhibition in Vivo. Blood (Ash Annual Meeting Abstracts). 2007. 110: Abstract 1592.;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide -induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al. Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor ?B Activation by Toll-like Receptor 4. J. Biol. Chem. 278:26258-26264 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Larsen et al., “Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs,” Int. J. Pharmaceutics. 47:103-10 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim S.H., et al., “Asymmetric Syntheses of Fused Bicyclic Lactams,” Journal of Organic Chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Indentifier: NCT0110567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;MacPartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994).;;Memorial Sloan-Kettering Cancer Center. Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 9, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02315326?term=NCT02315326 NLM Identifier: NCT02315326.;;Mendel et al., “In vivo Antitumor Activity of SU11248, A Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/pharmacodynamic Relationship,” Clin Cancer Res, 9(1): 327-337 (2003).;;Merged Markush Service Search, Jun. 27, 2005.;;Middendorp et al. Function of Bruton's Tyrosine Kinase during B Cell Development is Partially Independent of its Catalytic Activity. J Immunol 171:5988-5996 (2003).;;Middendorp et al. Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity. Blood 105(1):259-261 (2005).;;Mukoyama et al. Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases, retrieved from STN Database Accession No. 2005:299462 Patent No. JP2005089352, Apr. 7, 2005, *abstract*.;;National Cancer Institute (NCI). A multicenter phase 2 study of the Bruton's tyrosine kinase inhibitor PCI-32765 for treatment of relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (D): National Library of Medicine (US). Nov. 2, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01981512 NLM Identifier: NCT01981512.;;National Cancer Institute (NCI). Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 27, 2014—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02048813 NLM Identifier: NCT02048813.;;National Cancer Institute (NCI). Ibrutinib in treating patients with relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01841723 NLM Identifier: NCT01841723.;;National Cancer Institute (NCI). Ibrutinib in treating patients with relapsed or refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01849263 NLM Identifier: NCT01849263.;;National Cancer Institute (NCI). Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-Cell non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 27, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01955499 NLM Identifier: NCT01955499.;;National Cancer Institute (NCI). Rituximab and bendamustine hydrochloride, rituximab and ibrutinib, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01886872 NLM Identifier: NCT01886872.;;National Cancer Institute (NCI). Rituximab, lenalidomide, and ibrutinib in treating patients with previously untreated stage II-IV follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 9, 2013—[cited Nov. 22, 20134]. Available from: http://clinicaltrials.gov/ct2/show/NCT01829568 NLM Identifier: NCT01829568.;;National Cancer Institute. Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02219737?term=NCT02219737 NLM Identifier: NCT02219737.;;National Cancer Institute. Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 9, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02159755?term=NCT02159755 NLM Identifier: NCT02159755. et al.",ACTIVE
778,WO,A1,WO 2019/028004 A1,165-994-446-456-633,2019-02-07,2019,US 2018/0044574 W,2018-07-31,US 201762539167 P,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/165-994-446-456-633,Patent Application,yes,6,8,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G06N3/02;;G06T7/00,,1,0,,,See also references of EP 3662271A4,PENDING
779,US,A1,US 2019/0248798 A1,005-437-815-553-014,2019-08-15,2019,US 201916393775 A,2019-04-24,US 201916393775 A;;US 201815900660 A;;US 201816111014 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/005-437-815-553-014,Patent Application,yes,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61J1/03;;C07D487/04;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
780,US,A1,US 2018/0155352 A1,053-402-464-443-278,2018-06-07,2018,US 201815887744 A,2018-02-02,US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,"PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (""NANOSYN"") (2012-07-12);;PHARMACYCLICS INC (2015-05-26)",https://lens.org/053-402-464-443-278,Patent Application,yes,0,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519,,0,0,,,,DISCONTINUED
781,US,A1,US 2019/0248799 A1,049-025-035-237-470,2019-08-15,2019,US 201916393797 A,2019-04-24,US 201916393797 A;;US 201816110999 A;;US 201816035449 A;;US 201815901118 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/049-025-035-237-470,Patent Application,yes,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
782,US,S,US D0718339 S,067-031-239-985-474,2014-11-25,2014,US 201429485710 F,2014-03-21,US 201429485710 F,2014-03-21,Self-powered robotic lawn mower,,F ROBOTICS ACQUISITIONS LTD;;ROBOTICS ACQUISTIONS LTD F,DAMSHAK DAVID;;GOLDMAN IZIKIM;;ZUR ERAN;;LITVAK RAN;;TIKOCHINSKY YOAV,MTD PRODUCTS INC (2021-03-30);;F ROBOTICS ACQUISITIONS LTD (2014-07-20);;TIKO PRODUCT DESIGN LTD (2014-07-20),https://lens.org/067-031-239-985-474,Design Right,no,0,45,1,1,0,,,1503;;D15/14;;D15/17,0,0,,,,ACTIVE
783,US,A1,US 2020/0231595 A1,126-369-319-137-500,2020-07-23,2020,US 202016824630 A,2020-03-19,US 202016824630 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/126-369-319-137-500,Patent Application,yes,5,2,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
784,US,B2,US 10294231 B2,000-411-884-163-346,2019-05-21,2019,US 201816110999 A,2018-08-23,US 201816110999 A;;US 201816035449 A;;US 201815901118 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/000-411-884-163-346,Granted Patent,yes,353,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K45/06;;B65D75/36;;C07D487/04,,347,149,104-949-654-022-72X;;080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163;;050-012-520-524-900;;018-287-130-409-862;;017-226-063-911-434;;063-283-230-106-299;;082-955-679-125-981;;020-377-752-587-998;;071-449-828-437-743,10.1007/3-540-69178-2_5;;10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047;;15939795;;pmc2213268;;10.1084/jem.20042101;;pmc2868342;;18202907;;10.1007/s10865-007-9147-y;;11527964;;10.1074/jbc.m104828200;;10.3322/caac.20004;;19147869;;10.5402/2012/195727;;22830056;;pmc3399483;;10.1016/s1097-2765(00)80357-3;;10360180;;10.2210/pdb1qcf/pdb;;10.1016/j.bcp.2003.09.035;;14757163,"Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).;;Extended European Search Report for European Application No. 16773859.0 dated Oct. 4, 2018, 9 pages.;;Extended European Search Report for European Application No. EP 16773865.7 dated Oct. 23, 2018, 55 pages.;;“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, 20091208, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone, “Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for IMBRUVICA® (ibrutinib), revised Feb. 2018.;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective ltk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;MacPartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [a-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003). et al.",ACTIVE
785,US,A1,US 2012/0227026 A1,041-804-955-664-143,2012-09-06,2012,US 201113040255 A,2011-03-03,US 201113040255 A,2011-03-03,Method and Apparatus for Placement and Routing of Partial Reconfiguration Modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS;;ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/041-804-955-664-143,Patent Application,yes,2,18,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,716/128,1,0,,,"Koester et al., Design Optimization to Improve Placeability of Partial Reconfiguration Module, 2009, EDAA, pages 1-6",ACTIVE
786,DE,D1,DE 60139496 D1,149-149-701-352-412,2009-09-17,2009,DE 60139496 T,2001-06-15,US 21525400 P;;US 0119198 W,2000-06-30,GESUNDHEITS- UND KRANKHEITSVERWALTUNGSSYSTEM ZUR VERBESSERTEN PATIENTENVERSORGUNG,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/149-149-701-352-412,Granted Patent,no,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,EXPIRED
787,WO,A9,WO 2002/002004 A9,163-858-967-574-206,2003-05-30,2003,US 0119198 W,2001-06-15,US 21525400 P,2000-06-30,A HEALTH OUTCOMES AND DISEASE MANAGEMENT NETWORK AND RELATED METHOD FOR PROVIDING IMPROVED PATIENT CARE,A health outcomes and disease management network (100) and related method is provided for efficiently and effectively monitoring patient status and providing recommendations for patient healthcare. The system and method deploys a plurality of monitoring stations and a computer network. Each of the monitoring stations includes a measuring device. Healthcare managers coordinate with each other to develop patient treatment programs based in part on data received from the monitoring stations.,BECTON DICKINSON CO;;UNIV DUKE;;VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/163-858-967-574-206,Patent Application,no,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,PENDING
788,US,A1,US 2022/0112196 A1,194-922-166-713-577,2022-04-14,2022,US 202117328644 A,2021-05-24,US 202117328644 A;;US 202017066192 A;;US 202016824630 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201414405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/194-922-166-713-577,Patent Application,yes,2,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,PENDING
789,AT,T1,AT E438338 T1,000-074-079-567-247,2009-08-15,2009,AT 01946393 T,2001-06-15,US 21525400 P;;US 0119198 W,2000-06-30,GESUNDHEITS- UND KRANKHEITSVERWALTUNGSSYSTEM ZUR VERBESSERTEN PATIENTENVERSORGUNG,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/000-074-079-567-247,Granted Patent,no,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021,,0,0,,,,EXPIRED
790,US,A1,US 2021/0070759 A1,031-796-778-983-986,2021-03-11,2021,US 202016951796 A,2020-11-18,US 202016951796 A;;US 202016824630 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/031-796-778-983-986,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
791,US,A1,US 2009/0216494 A1,063-541-073-549-609,2009-08-27,2009,US 36363609 A,2009-01-30,US 36363609 A;;US 74087407 A;;US 25917608 A;;US 61588306 A;;US 79664606 P;;US 76173606 P;;US 76228406 P;;US 76300206 P;;US 76279106 P;;US 76279006 P,2006-01-23,Network Laser System with Remote Diagnostics,"In exemplary embodiments, a network laser system comprises a laser platform including an optical source configured to generate an optical pulse, an optical amplifier configured to amplify the optical pulse, and a compressor configured to temporally compress the amplified optical pulse. The network laser system may also comprise monitor circuitry (e.g., sensors) configured to monitor one or more performance aspects of the laser platform. The network laser system may further comprise logic configured to transmit data to a remote computing device over a network. The network laser system may be configured to perform a diagnostic test and/or maintenance in response to instructions received from the remote computing device.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M,RAYDIANCE INC (2009-04-17),https://lens.org/063-541-073-549-609,Patent Application,yes,4,9,3,3,0,H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/149;;H04B10/0773;;H04L43/06;;H04L43/50;;H04Q2213/1301;;H04L41/147,G21C17/00;;H01S3/00,702/183;;372/38.1,0,0,,,,DISCONTINUED
792,EP,A1,EP 1331874 A1,149-584-257-099-583,2003-08-06,2003,EP 01946393 A,2001-06-15,US 0119198 W;;US 21525400 P,2000-06-30,A HEALTH OUTCOMES AND DISEASE MANAGEMENT NETWORK FOR PROVIDING IMPROVED PATIENT CARE,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/149-584-257-099-583,Patent Application,yes,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,EXPIRED
793,WO,A1,WO 2003/018847 A1,171-086-533-742-586,2003-03-06,2003,US 0228086 W,2002-08-30,US 31673601 P,2001-08-31,EFFECT OF BDNF GENOTYPE ON HIPPOCAMPAL FUNCTION AND VERBAL MEMORY AND RISK FOR SCHIZOPHRENIA,The invention is related to the discovery that a met66val polymorphism in the gene for brain-derived neurotrophic factor (BDNF) is correlated with hippocampal function and verbal memory and risk for neuropsychiatric disorders such as schizophrenia.,US GOV HEALTH & HUMAN SERV;;WEINBERGER DANIEL;;EGAN MICHAEL F;;KOLACHANA BHASKAR S;;GOLDMAN DAVID,WEINBERGER DANIEL;;EGAN MICHAEL F;;KOLACHANA BHASKAR S;;GOLDMAN DAVID,,https://lens.org/171-086-533-742-586,Patent Application,yes,0,0,2,2,0,A61K38/00;;C07K14/475;;C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C07K14/475;;A61K38/00;;C12Q2600/156,A61K38/00;;C07K14/475;;C12Q1/68;;C12Q1/6883,,1,1,089-311-659-522-809,10.1038/35075076;;11333982,"GUILLIN O. ET AL.: ""BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization"", NATURE, vol. 411, 3 May 2001 (2001-05-03), pages 86 - 89, XP002960699",PENDING
794,ES,T3,ES 2953808 T3,195-581-347-604-285,2023-11-16,2023,ES 18801160 T,2018-10-25,US 201762580221 P;;US 2018/0057496 W,2017-11-01,Cajas de control principalmente para uso con equipo de piscinas y spas,"Se describen cajas de control (10) con componentes segregados de baja y alta tensión. Los técnicos de servicio (u otros) que requieran acceso a un conjunto de componentes pueden hacerlo sin necesariamente acceder al otro conjunto. Además, se pueden utilizar interfaces de usuario duales, estando una interfaz presente en la caja de control y la otra remota a la misma. (Traducción automática con Google Translate, sin valor legal)",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,,https://lens.org/195-581-347-604-285,Granted Patent,no,0,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,E04H4/12;;A61H33/00,,0,0,,,,ACTIVE
795,US,A1,US 2009/0213879 A1,048-730-755-255-260,2009-08-27,2009,US 36364609 A,2009-01-30,US 36364609 A;;US 74087407 A;;US 25917608 A;;US 61588306 A;;US 79664606 P;;US 76173606 P;;US 76228406 P;;US 76300206 P;;US 76279106 P;;US 76279006 P,2006-01-23,Automated Laser Tuning,"In exemplary embodiments, an ultra short pulse system comprises a laser platform which includes an optical source configured to generate an optical pulse, an optical amplifier configured to amplify the optical pulse, and a compressor configured to temporally compress the amplified optical pulse. The ultra short pulse system further comprises monitor circuitry configured to monitor one or more performance aspects of the laser platform. Additionally, the ultra short pulse system may comprise logic configured to control the one or more performance aspects of the laser platform in response to at least the monitored one or more performance aspects.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M,RAYDIANCE INC (2009-04-28);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/048-730-755-255-260,Patent Application,yes,103,18,4,4,0,H01S3/10015;;H01S3/10015;;H01S3/0057;;H01S3/0057;;H01S3/0085;;H01S3/0085;;H01S3/1301;;H01S3/1301;;H01S3/2316;;H01S3/2316,H01S3/10,372/20;;372/25,0,0,,,,INACTIVE
796,WO,A1,WO 2002/002004 A1,105-352-992-954-065,2002-01-10,2002,US 0119198 W,2001-06-15,US 21525400 P,2000-06-30,A HEALTH OUTCOMES AND DISEASE MANAGEMENT NETWORK AND RELATED METHOD FOR PROVIDING IMPROVED PATIENT CARE,A health outcomes and disease management network (100) and related method is provided for efficiently and effectively monitoring patient status and providing recommendations for patient healthcare. The system and method deploys a plurality of monitoring stations and a computer network. Each of the monitoring stations includes a measuring device. Healthcare managers coordinate with each other to develop patient treatment programs based in part on data received from the monitoring stations.,BECTON DICKINSON CO;;UNIV DUKE;;VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;CONNOR CHRISTOPHER O;;GOLDMAN GEORGE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/105-352-992-954-065,Patent Application,yes,6,1,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,PENDING
797,US,A1,US 2018/0362535 A1,107-365-636-113-513,2018-12-20,2018,US 201816110999 A,2018-08-23,US 201816110999 A;;US 201816035449 A;;US 201815901118 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/107-365-636-113-513,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
798,WO,A2,WO 1999/026606 A2,053-606-663-977-525,1999-06-03,1999,EP 9807198 W,1998-11-11,US 6669897 P,1997-11-25,SUSTAINED RELEASE FORMULATIONS COMPRISING alpha -GLUCOSIDASE-INHIBITORS,"The present invention relates to pharmaceutical sustained release formulations of alpha -glucosidase inhibitors as for example acarbose, miglitol, emiglitate or voglibose leading to a reduction of side effects.",BAYER AG;;GOLDMAN DAVID;;AMATRUDA JOHN;;POERTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,GOLDMAN DAVID;;AMATRUDA JOHN;;POERTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,,https://lens.org/053-606-663-977-525,Patent Application,no,0,10,6,6,0,A61K31/702;;A61K9/2054;;A61K9/209;;A61K31/13;;A61K31/445;;A61P3/04;;A61P3/10;;A61P9/10,A61K9/20;;A61K9/22;;A61K9/24;;A61K31/13;;A61K31/133;;A61K31/445;;A61K31/7032;;A61K45/00;;A61K47/12;;A61K47/38;;A61P3/04;;A61P3/10;;A61P9/10,,0,0,,,,PENDING
799,US,B2,US 10242146 B2,087-636-603-585-248,2019-03-26,2019,US 201615132163 A,2016-04-18,US 201615132163 A;;US 201414152624 A;;US 201113040255 A,2011-03-03,Method and apparatus for placing and routing partial reconfiguration modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/087-636-603-585-248,Granted Patent,yes,14,2,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,,14,6,116-073-370-377-993;;054-723-856-561-402;;105-422-478-223-412;;006-583-227-587-543;;019-810-060-216-685;;100-615-693-454-511,10.1049/ip-cdt:20000498;;10.1049/iet-cdt:20060056;;10.1109/date.2009.5090806;;10.1109/edac.1992.205948;;10.1145/993396.993399;;10.1109/newcas.2008.4606394,"Communication Pursuant to Article 94(3) EPC for European Patent Application No. 12 156 571.7, dated Oct. 23, 2017.;;Japanese Laid-Open Publication No. 11-17524 and English translation of abstract.;;CN101179271A English translation of abstract.;;Chinese Search Report.;;Extended European Search Report for Application No. EP 12 15 6571.7.;;Robinson, et al.; “Methods of Exploiting Simulation Technology for Simulating the Timing of Dynamically Reconfigurable Logic”; IEE Proceedings E. Computers & Digital Techniques, Institution of Electrical Engineers, Stevenage, GB, vol. 147, No. 3, pp. 175-180, May 30, 2000.;;Silva, et al.; “Generation of Hardware Modules for Run-Time Reconfigurable Hybrid CPU/FPGA Systems”, IET Comput. Digit. Tech., vol. 1, No. 5, pp. 461-471, Sep. 4, 2007.;;Koester, et al., “Design Optimization to Improve Placeability of Partial Reconfiguration Module”, 2009, EDAA, pp. 1-6.;;U.S. Appl. No. 14/152,624, filed Jan. 10, 2014, in Re Application of David Samuel Goldman, et al.;;Japanese Laid-Open Publication No. 11-17524.;;Brouwer R J et al: “Paragraph: a parallel algorithm for simultaneous placement and routing using hierarchy”, Design Automation, 1992. Proceedings., 3rd European Conference on Brussels, Belgium Mar. 16-19, Los Alamitos, CA, USA, IEEE Comput. Soc, US, Mar. 16, 1992 (Mar. 16, 1992).;;Ian Robertson et al: “A design flow for partially reconfigurable hardware”, ACM Transactions on Embedded Computing Systems, vol. 3, No. 2, May 1, 2004 (May 1, 2004), pp. 257-283.;;Julien Delorme et al: “A FPGA partial reconfiguration design approach for cognitive radio based on NoC architecture”, Circuits and Systems and Taisa Conference, 2008. Newcas-Taisa 2008. 2008 Joint 6th International IEEE Northeast Workshop on, IEEE, Piscataway, NJ, USA, Jun. 22, 2008 (Jun. 22, 2008), pp. 355-358.;;Summons to Attend Oral Proceedings for Patent Application No. 1215671.7, dated Jun. 11, 2018, 13 pages.",ACTIVE
800,US,A1,US 2018/0362536 A1,110-045-752-367-313,2018-12-20,2018,US 201816111014 A,2018-08-23,US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/110-045-752-367-313,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
801,US,A1,US 2018/0170940 A1,056-762-857-201-147,2018-06-21,2018,US 201815887712 A,2018-02-02,US 201815887712 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/056-762-857-201-147,Patent Application,yes,0,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61K31/519,,0,0,,,,DISCONTINUED
802,AU,A,AU 2001/068450 A,085-381-556-143-863,2002-01-14,2002,AU 2001/068450 A,2001-06-15,US 21525400 P;;US 0119198 W,2000-06-30,A health outcomes and disease management network and related method for providing improved patient care,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/085-381-556-143-863,Patent Application,no,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,PENDING
803,US,A,US 5763183 A,111-645-288-870-200,1998-06-09,1998,US 74526996 A,1996-11-08,US 74526996 A;;US 639495 P,1995-11-09,Allelic variation of the serotonin 5HT7 receptor,"An allelic variant of the 5HT7 serotonin receptor was discovered. Family study data indicate that this variant can be correlated to alchoholic offerders. DNA encoding the variant protein, the protein itself, vectors containing the variant gene and cell lines carrying a vector with the variant gene are part of the invention.",US ARMY,PESONEN ULLAMARI;;KOULU MARKKU;;LINNOILA MARKKU;;GOLDMAN DAVID;;VIRKKUNEN MATTI,DEPARTMENT OF HEALTH AND HUMAN SERVICES AS REPRESENTED BY THE UNITED STATES OF AMERICA SECRETARY OF THE (1997-03-11),https://lens.org/111-645-288-870-200,Granted Patent,yes,0,22,1,1,6,C07K14/70571;;C12Q1/6883;;C12Q2600/156;;C12Q1/6883;;C07K14/70571;;C12Q2600/156,C07K14/705;;C12Q1/68,435/6;;435/91.1;;435/91.2;;435/4;;435/320.1;;435/240.2;;435/252.3;;435/240.4;;435/254.11;;435/254.9;;530/350;;204/182.8;;536/23.1;;536/24.3;;536/24.32,10,6,016-882-836-075-810;;073-228-397-156-555;;020-875-853-845-740;;004-516-100-691-228;;006-318-984-924-386;;044-700-164-648-094,10.1001/archpsyc.1974.01760180027003;;4441246;;10.1001/archpsyc.1991.01810250031003;;1984759;;10.1016/0278-5846(87)90056-x;;2442799;;1714508;;10.1002/jnr.490280402;;007908055;;7908055;;7557992;;10.1006/geno.1995.1042,"Pesonen et al. Neurosci. abstr., 21, Part 2, p. 1121, 1995.;;Bard et al. Genbank Sequence Listing, Accession No. L 21195, 1993.;;U. Pesonen, et al., Rare non conservative amino acid substitution in the 5 HT 7 receptor gene found in alcoholics with antisocial personaltiy disorder, Soc. Neurosci, Abstr., 21, p. 1121, 1995.;;Crowe, Arch. Gen. Psychiatry 31:785, 1974.;;Roy et al., Arch. Gen. psychiatry 48:29, 1991.;;Roy et al., Prog. Neuro Psychopharmacol. Psychiatry 11:173, 1987.;;Stoll and Goldman, J. Neurosci. Res. 28:457, 1991.;;Roth B.L., et al. J. Pharmacol. Exp. Ther. 268:1403, 1994.;;Linnoila, et al., J. Clin Psychiatry 53:10 (suppl), 1992.;;Lappalainen, et al., Genomics 27, 274 279, 1995.",EXPIRED
804,US,A1,US 2017/0226112 A1,124-901-923-524-174,2017-08-10,2017,US 201715497896 A,2017-04-26,US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/124-901-923-524-174,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,,0,0,,,,ACTIVE
805,EP,A1,EP 3704330 A1,178-620-660-956-722,2020-09-09,2020,EP 18801160 A,2018-10-25,US 201762580221 P;;US 2018/0057496 W,2017-11-01,CONTROL BOXES PRINCIPALLY FOR USE WITH EQUIPMENT OF SWIMMING POOLS AND SPAS,,ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,,https://lens.org/178-620-660-956-722,Patent Application,yes,0,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,E04H4/12;;A61H33/00,,0,0,,,,ACTIVE
806,WO,A1,WO 2019/089340 A1,180-131-220-526-328,2019-05-09,2019,US 2018/0057496 W,2018-10-25,US 201762580221 P,2017-11-01,CONTROL BOXES PRINCIPALLY FOR USE WITH EQUIPMENT OF SWIMMING POOLS AND SPAS,"Control boxes (10) with segregated low- and high-voltage components are described. Service technicians (or others) requiring access to one set of components may do so without necessarily accessing the other set. Dual user interfaces may be utilized, further, with one interface being present at the control box and the other being remote therefrom.",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,,https://lens.org/180-131-220-526-328,Patent Application,yes,6,1,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,A61H33/00;;E04H4/12,,0,0,,,,PENDING
807,US,B2,US 9361421 B2,198-330-876-640-559,2016-06-07,2016,US 201414152624 A,2014-01-10,US 201414152624 A;;US 201113040255 A,2011-03-03,Method and apparatus for placing and routing partial reconfiguration modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/198-330-876-640-559,Granted Patent,yes,8,3,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,,6,3,116-073-370-377-993;;054-723-856-561-402;;105-422-478-223-412,10.1049/ip-cdt:20000498;;10.1049/iet-cdt:20060056;;10.1109/date.2009.5090806,"Extended European Search Report for Application No. EP 12 15 6571.7.;;Robinson, et al.; ""Methods of Exploiting Simulation Technology for Simulating the Timing of Dynamically Reconfigurable Logic""; IEE Proceedings E. Computers & Digital Techniques, Institution of Electrical Engineers, Stevenage, GB, vol. 147, No. 3, pp. 175-180, May 30, 2000.;;Silva, et al.; ""Generation of Hardware Modules for Run-Time Reconfigurable Hybrid CPU/FPGA Systems"", IET Comput. Digit. Tech., vol. 1, No. 5, pp. 461-471, Sep. 4, 2007.;;Koester, et al., ""Design Optimization to Improve Placeability of Partial Reconfiguration Module"", 2009, EDAA, pp. 1-6.;;U.S. Appl. No. 13/040,255, filed Mar. 3, 2011, in Re Application of David Samuel Goldman, et al.;;Japanese Laid-Open Publication No. 11-17524 (a document showing well-known technology). [Translator's note: *No English language counterpart could be located].",ACTIVE
808,US,A1,US 2020/0148691 A1,007-551-450-810-429,2020-05-14,2020,US 202016744007 A,2020-01-15,US 202016744007 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/007-551-450-810-429,Patent Application,yes,10,3,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
809,WO,A1,WO 2016/051127 A1,011-448-782-178-799,2016-04-07,2016,GB 2015051848 W,2015-06-25,GB 201417274 A,2014-09-30,VIDEO DATA ENCODING AND DECODING,"A video data encoding method is operable with respect to successive source images each comprising a set of encoded regions, each region being separately encoded as an independently decodable network abstraction layer (NAL) unit having associated encoding parameter data. The method comprises identifying a subset of the regions representing at least a portion of each source image that corresponds to a required display image; allocating regions of the subset of regions for a source image to respective composite frames of a set of one or more composite frames so that the set of composite frames, taken together, provides image data representing the subset of regions; and modifying the encoding parameter data associated with the regions allocated to each composite frame so that the encoding parameter data corresponds to that of a frame comprising those regions allocated to that composite frame.",SONY CORP;;SONY EUROPE LTD,GOLDMAN MICHAEL;;WAGG DAVID;;WILLIAMS MICHAEL JOHN;;SHARMAN KARL JAMES,,https://lens.org/011-448-782-178-799,Patent Application,yes,3,4,5,5,0,H04N19/70;;H04N19/174;;H04N19/46;;H04N19/167;;H04N21/4728;;H04N19/17;;H04N19/46;;H04N19/70;;H04N19/88;;H04N19/46;;H04N19/174;;H04N19/167;;H04N19/70;;H04N21/4728;;H04L65/762;;H04N19/177;;H04N19/188,H04N19/167;;H04N19/70;;H04N19/17;;H04N19/174;;H04N19/46;;H04N21/41,,0,0,,,,PENDING
810,US,A1,US 2018/0179214 A1,037-022-212-769-146,2018-06-28,2018,US 201815900660 A,2018-02-20,US 201815900660 A;;US 201715497896 A;;US 201815887744 A;;US 201715645319 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/037-022-212-769-146,Patent Application,yes,0,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,,0,0,,,,ACTIVE
811,US,B2,US 10294232 B2,088-030-145-437-925,2019-05-21,2019,US 201816111014 A,2018-08-23,US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/088-030-145-437-925,Granted Patent,yes,351,7,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K45/06;;B65D75/36;;C07D487/04,,349,151,104-949-654-022-72X;;080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;069-501-243-828-566;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;084-480-509-946-521;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163;;050-012-520-524-900;;018-287-130-409-862;;017-226-063-911-434;;063-283-230-106-299;;082-955-679-125-981;;020-377-752-587-998;;071-449-828-437-743,10.1007/3-540-69178-2_5;;10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1084/jem.20021845;;12810683;;pmc2193950;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;pmc2833438;;15180891;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047;;15939795;;pmc2213268;;10.1084/jem.20042101;;pmc2868342;;18202907;;10.1007/s10865-007-9147-y;;11527964;;10.1074/jbc.m104828200;;10.3322/caac.20004;;19147869;;10.5402/2012/195727;;22830056;;pmc3399483;;10.1016/s1097-2765(00)80357-3;;10360180;;10.2210/pdb1qcf/pdb;;10.1016/j.bcp.2003.09.035;;14757163,"US 10,085,944 B2, 10/2018, Chong et al. (withdrawn);;US 10,105,368 B2, 10/2018, Alturi et al. (withdrawn);;Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).;;Extended European Search Report for European Application No. 16773859.0 dated Oct. 4, 2018, 9 pages.;;Extended European Search Report for European Application No. EP 16773865.7 dated Oct. 23, 2018, 55 pages.;;“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, 20091208, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CDI9+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (Pci-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley—VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“ Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Supp1.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor a Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available From: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for IMBRUVICA® (ibrutinib), revised Feb. 2018.;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective ltk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Noiv. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;Macpartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [a-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the ltk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004). et al.",ACTIVE
812,US,A1,US 2020/0223856 A1,072-768-418-097-98X,2020-07-16,2020,US 202016837665 A,2020-04-01,US 202016837665 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/072-768-418-097-98X,Patent Application,yes,0,2,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61J1/03;;C07D487/04;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
813,EP,B1,EP 1331874 B1,087-403-789-561-801,2009-08-05,2009,EP 01946393 A,2001-06-15,US 0119198 W;;US 21525400 P,2000-06-30,A HEALTH OUTCOMES AND DISEASE MANAGEMENT NETWORK FOR PROVIDING IMPROVED PATIENT CARE,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/087-403-789-561-801,Granted Patent,yes,10,2,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,EXPIRED
814,ZA,B,ZA 9810710 B,101-419-282-521-183,1999-06-14,1999,ZA 9810710 A,1998-11-24,US 6669897 P,1997-11-25,Sustained release formulations comprising alpha-glucosidase-inhibitors,,BAYER AG,GOLDMAN DAVID;;AMATRUDA JOHN;;PORTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,,https://lens.org/101-419-282-521-183,Granted Patent,no,0,0,6,6,0,A61K31/702;;A61K9/2054;;A61K9/209;;A61K31/13;;A61K31/445;;A61P3/04;;A61P3/10;;A61P9/10,A61K9/20;;A61K9/22;;A61K9/24;;A61K31/13;;A61K31/133;;A61K31/445;;A61K31/7032;;A61K45/00;;A61K47/12;;A61K47/38;;A61P3/04;;A61P3/10;;A61P9/10,,0,0,,,,EXPIRED
815,US,B2,US 10752634 B2,006-848-029-053-496,2020-08-25,2020,US 202016837665 A,2020-04-01,US 202016837665 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a brutons tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/006-848-029-053-496,Granted Patent,yes,360,2,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K45/06;;B65D75/36;;C07D487/04,,363,162,009-735-793-164-974;;080-707-244-949-02X;;084-786-079-037-150;;089-192-146-880-951;;051-773-437-524-806;;084-954-244-635-278;;064-285-126-440-946;;026-345-282-332-596;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;104-949-654-022-72X;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;089-402-914-639-064;;144-738-232-611-859;;050-012-520-524-900;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;051-261-371-269-486;;001-779-883-672-562;;091-695-878-773-648;;018-287-130-409-862;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;036-444-505-098-001;;016-289-303-702-626;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;068-519-192-122-633;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;017-226-063-911-434;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;016-064-084-746-508;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;001-645-453-115-842;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;063-283-230-106-299;;009-072-168-512-123;;191-922-716-579-909;;112-113-906-517-885;;082-955-679-125-981;;011-434-537-008-254;;020-377-752-587-998;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;132-576-696-875-962;;005-625-687-439-249;;051-308-600-980-390;;071-449-828-437-743;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;006-736-845-251-70X;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163,10.1016/j.ejpb.2008.07.014;;18715549;;10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1182/blood.v110.11.2559.2559;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10602208;;10.1002/(sici)1521-3773(19991203)38:23<3440::aid-anie3440>3.0.co;2-;;10.1002/(sici)1521-3773(19991203)38:23<3440::aid-anie3440>3.0.co;2-#;;10.1093/acprof:oso/9780199236565.003.0003;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.5270/esa-p89agpo;;12356095;;10.1002/9781118971147.ch16;;10.1152/ajpgi.1995.269.2.g210;;7653560;;15939795;;pmc2213268;;10.1084/jem.20042101;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;10.1182/blood.v110.11.1592.1592;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;pmc2868342;;18202907;;10.1007/s10865-007-9147-y;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(87)90012-3;;10.1016/0378-5173(88)90220-7;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;10.1155/2001/28962;;11785667;;pmc2276078;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;11527964;;10.1074/jbc.m104828200;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1111/j.1600-065x.2008.00741.x;;19290921;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;10.3109/03639045.2010.488647;;20545515;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.3322/caac.20004;;19147869;;22975686;;10.1016/j.cellsig.2012.09.008;;10.2174/1566524033361618;;12558077;;10.1016/s0960-894x(01)80549-7;;10.5402/2012/195727;;22830056;;pmc3399483;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1016/s1097-2765(00)80357-3;;10360180;;10.2210/pdb1qcf/pdb;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1002/0470025077.chap84b;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;10.1016/j.bcp.2003.09.035;;14757163;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.1039/an9952002435;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047,"US 10,085,944 B2, 10/2018, Chong et al. (withdrawn);;US 10,105,368 B2, 10/2018, Atluri et al. (withdrawn);;“API form screening and selection in drug discovery stage,” Pharm. Stage, 6(10): 20-25, (2007).;;“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;Aaltonen et al., “Solid Form Screening—A Review,” Eur J Pharm Biopharm, 71(1):23-37 (2008).;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al., “Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia,” Blood (ASH Annual Meeting Abstracts) 110(Abstract):2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al., “Michael acceptors as a tool for anticancer drug design,” Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al., “Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases,” Nature Chem. Bio 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Concomitant Polymorphs,” Angew Chem Int Ed, 38(23):3440-3461 (1999).;;Bernstein, “Controlling the Polymorphic Form Obtained,” Polymorphism in Molecular Crystals, Clarendon Press, Oxford (2002).;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, Dec. 8, 2009, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Borka, “Crystal Polymorphism of Pharmaceuticals,” Acta Pharm Jugosl, 40:71-94 (1990).;;Boyle et al., “Enhancing Patient Adherence to Improve Outcomes with Oral Chemotheraphy,” US Pharm Oncology Suppl, 32(10):1-8 (2007).;;Brittain ed., Guillory, “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids,” Chapter 5 in Polymorphism in Pharmaceutical Solids, 183-226 (1999).;;Brown et al., “Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al., “Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight,” Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al., “CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers,” Leukemia 23:43-52 (2009).;;Burger et al., “High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation,” Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al., “Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer,” Biochem. Pharmacol. 84(11):1388-1399 (2012).;;Carrle et al., “Current Strategies of Chemotherapy in Osteosarcoma,” International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al., “Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients,” Blood 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al., “SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma,” Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;CHMP assessment report: Imbruvica, European Medicines Agency (2014).;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al., “Novel Bruton's tyrosine kinase inhibitors currently in development,” OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dolgin, “A Life Changing Innovation: How the success of one targeted therapy ushered in a new era of lymphoma treatment,” Nature 563(7731):S46-S47 (2018).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards, “BTK inhibition in myeloma: targeting the seed and the soil,” Blood 120(9):1757-1759 (2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Extended European Search Report for European Application No. 16773859.0 dated Oct. 4, 2018, 9 pages.;;Extended European Search Report for European Application No. EP 16773865.7 dated Oct. 23, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA Guidelines: “Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances,” (Feb. 1987).;;FDA Guidelines: “International Conference on Harmonisation; Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances,” Federal Register, vol. 65, No. 251 (2000).;;FDA Guidelines: “Q6A Specfications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances,” (Dec. 2000).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis,” Am. J. Physiol. 269:G210-218 (1995).;;Feldhahn et al., “Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells,” J Exp Med, 201(11):1837-1853 (2005).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al., “Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia,” Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al., “Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors,” J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani, “Multiple myeloma bone disease: pathophysiology of osteoblast inhibition,” Blood 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al., “Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a),” PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“ Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al., “The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib,” PNAS 104(33):13283-13288 (2007).;;Hata et al., “Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells,” J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. “Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765,” Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series 14: (1975).;;Hochhaus et al., “A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids,” Biomed. Chrom. 6:283-286 (1992).;;Honigberg et al., “A Clinical Trial of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in naturally occuring canine lymphoma,” Cancer Res, AACR Ann Meeting, 69:Abstract 3740 (2009).;;Honigberg et al., “Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo,” ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;Imbruvica Prescribing Information, available at <http://www.accessdata.fda.gov/drugsatfda_docs/labe1/2018/205552s025lbl.pdf> (2018).;;Ingersoll et al., “The impact of medication regimen factors on adherence to chronic treatment: a review of literature,” J Behav Med, 31(3):213-224 (2008).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013-[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012-[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013- [cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012- [cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:2625864 (2003).;;Kamb, “What's wrong with our cancer models?” Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al., “Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase,” PNAS USA 96:2227-2232 (1999).;;Khadka et al., “Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability,” Asian J Pharma Sci, 9:304-316 (2014).;;Kojima et al., Effective Solid Form Selection for the Pharmaceutical Development, Journal of Pharmaceutical Science and Technology, Japan, 2008 , 68(5):344-349.;;Korade-Mirnics et al., “Src kinase-mediated signaling in leukocytes,” J. Leukoc. Bio. 68(5):603-613 (2000).;;Kozaki et al., “Development of a Bruton's tyrosine kinase (Btk) inhibitor -ONO-WG-307, a potential treatment for B-cell malignancies,” 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al., “Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures,” Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers, “Mechanisms of B-cell lymphoma pathogenesis,” Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki, “Functional dissection of BCR signaling pathways,” Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al., “Pharmacological uses and perspective of heavy water and deuterated compounds,” Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for IMBRUVICA® (ibrutinib), revised Feb. 2018.;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” Int. J. Pharmaceutics 37:87-95 (1987).;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Le Tourneau et al., “Dose Escalation Methods in Phase I Cancer Clinical Trials,” J. Natl Cancer 101:708-720 (2009).;;Li et al., “Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain,” Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective ltk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos, “Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma,” J. Clin. Oncol. 23(26):6351-6357 (2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al., “Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases,” Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085. et al.",ACTIVE
816,US,B2,US 10065968 B2,004-881-849-478-731,2018-09-04,2018,US 201815901118 A,2018-02-21,US 201815901118 A;;US 201715497896 A;;US 201815887744 A;;US 201715645319 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,"PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (""NANOSYN"") (2012-07-12);;PHARMACYCLICS INC (2015-05-26)",https://lens.org/004-881-849-478-731,Granted Patent,yes,329,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;C07D295/023,,331,145,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;069-501-243-828-566;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;014-469-692-721-18X;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;009-072-168-512-123;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;058-496-535-660-125;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163;;074-225-865-565-732,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1084/jem.20021845;;12810683;;pmc2193950;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10092645;;10.1074/jbc.274.14.9587;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;22975686;;10.1016/j.cellsig.2012.09.008;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.3109/10428190309178781;;14565661;;10.1080/1042819031000097447;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047;;18061887;;10.1016/j.drudis.2007.09.005,"Acs 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodg kin lymphoma).;;Advani et al. Effect of Btk inhibitor Pci-32765 monotherapy on responses in patients with relapsed aggressive Nhl: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 Asco Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor Pci-32765 is highly active and well tolerated in patients (Pts) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (Pci-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/Ii Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (Ash Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism - a Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: a Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, 20091208, pharmacyclics, Inc. (Pcyc) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor Pci-32765.;;Brown et al., “Phase lb trial of Avl-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (Cll) and B-non-Hodgkin lymphoma (B-Nhl),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on 01/14/16] Retrieved from the Internet: < http://meeti ng I ibrary.asco.o rg/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck - a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After Bcr Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (2014 Jul. 21) (pii: Jco.2014.55.8262).;;Byrd et al. Targeting Btk with Ibrutinib in relapsed chronic lymphocytic leukemia, Nejm 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with Cll and Sll receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: a Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb 2014, vol. 74 (2), pp. 263271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:24122424 (2013).;;Chang et al., “Pci-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” Acr/Arhp Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor Pci-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: an Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. Syk-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase Ii Study of Ibrutinib Plus Fcr in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Sept 23 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02251548?term=NCT02251548 Nlm Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (Pci-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 May 17-[cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 Nlm Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature, 463(7277):88-92 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. In Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (Btk) inhibitor, ibrutinib (Pci-32765), has preferential activity in the activated B cell-like (Abc) subtype of relapsed/refractory (Rr) Dlbcl: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: a New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:Vch, Weinheim pg. Ix of Preface, Wiley-Vch Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action mailed Oct. 31, 2011.;;EA201000599 Search Report dated 15 Nov. 2010.;;Edwards. Btk inhibition in myeloma: targeting the seed and the soil. Blood 120(9):17571759 (Aug. 2012).;;Ep 06850039.6 Search Report and Written Opinion dated 15 Feb. 2010.;;Ep 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;Ep 08744513.6 Examination Report dated 16 Jan. 2013.;;Ep 08744513.6 Search Report and Written Opinion dated 18 Mar. 2010.;;Ep 09798770.5 Search Report and Written Opinion dated 28 Oct. 2011.;;Ep 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;Ep 10823966 Supplementary European Search Report mailed Oct. 17, 2011.;;Ep 10823966.6 Search Report dated 17 Oct. 2011.;;Ep 10823966.6 Written Opinion dated 6 Dec. 2011.;;Ep 12151943.3 Examination Report dated 05 Feb. 2013.;;Ep 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;Ep 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;Ep 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;Ep 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;Ep 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;Ep 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;Ep 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;Ep 12166305.8 Examination Report dated 3 Dec. 2013.;;Ep 12166305.8 Search Report and Written Opinion dated 6 Nov. 2012.;;Ep 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;Ep 12172840.6 Search Report and Written Opinion dated 12 Dec. 2012.;;Ep 12172841.4 Search Report and Written Opinion dated 2 Jan. 2013.;;Ep 12172842.2 Extended Search Report dated 14 May 2013.;;Ep 12172842.2 Partial Search Report dated 24 Jan. 2013.;;Ep 12172843.0 Search Report and Written Opinion dated 18 Jan. 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 09, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, mailed on Nov. 10, 2015.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;Fda, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (Ich), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Adminstration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with Mopp reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (Pci-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: a B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). Pnas 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of in vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“ Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. Pnas 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by Pci-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (Chop) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with Chop alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the a.C.S. Symposium Series (1975).;;Hochhaus et al. A selective Hplc/Ria for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: Pci-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of Pci-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. Ash Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor Pci-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” Pnas Usa, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor a Production. J. Exp. Med. 197(12)1 603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, mailed on 23 May 2016, 10 pp.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 mailed Jun. 27, 2016 (our reference Pir-331.25).;;International Search Report for International Application No. PCT/US2016/024321 mailed Jun. 28, 2016 (our reference Pir-332.25).;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article Id 852748, 9 pp.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRl-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 Who classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Apr 06- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01833039 Nlm Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor Pci-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Oct 09- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01704963 Nlm Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Jun. 19- [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02169180?term=NCT02169180 Nlm Identifier: NCT02169180.;;Janssen Research & Development, Llc. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Oct 20 [cited 2015 Feb 5] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 Nlm Identifier: NCT02271438.;;Janssen Research & Development, Llc. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Dec 30 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02329847?term=NCT02329847 Nlm Identifier: NCT02329847.;;Janssen Research and Development, Llc. A long-term extension study of Pci-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Mar 04- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 Nlm Identifier: NCT01804686.;;Janssen Research and Development, Llc. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of Pci-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Aug 19- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01969266 Nlm Identifier: NCT01969266.;;Janssen Research and Development, Llc. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Mar 30- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01569750 Nlm Identifier: NCT01569750.;;Janssen Research and Development, Llc. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 May 15- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01611090 Nlm Identifier: NCT01611090.;;Janssen Research and Development, Llc. A study of Pci-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Oct 28- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01974440 Nlm Identifier: NCT01974440.;;Janssen Research and Development, Llc. A study of Pci-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Jan 25- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 Nlm Identifier: NCT01779791.;;Janssen Research and Development, Llc. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Jan 24- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01776840 Nlm Identifier: NCT01776840.;;Janssen Research and Development, Llc. A study of the Bruton's tyrosine kinase inhibitor Pci-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Oct 25- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 Nlm Identifier: NCT01973387.;;Janssen Research and Development, Llc. A study on the Bruton's tyrosine kinase inhibitor, Pci-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 May 14- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01855750 Nlm Identifier: NCT01855750.;;Janssen Research and Development, Llc. A study to assess the absolute bioavailability of Oral Pci-32765 and the effect of grapefruit juice on the bioavailability of Pci-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 May 28- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 Nlm Identifier: NCT01866033.;;Janssen Research and Development, Llc. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Jun 18- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 Nlm Identifier: NCT01626651.;;Janssen Research and Development, Llc. A study to assess the effect of rifampin on the pharmacokinetics of Pci-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Jan 4- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01763021 Nlm Identifier: NCT01763021.;;Janssen Research and Development, Llc. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Aug 9-[cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 Nlm Identifier: NCT01674322.;;Janssen Research and Development, Llc. A study to determine the effect of food on the pharmacokinetics of Pci-32765. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Mar 04- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01820936 Nlm Identifier: NCT01820936.;;Janssen Research and Development, Llc. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 May 14-[cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01599949 Nlm Identifier: NCT01599949.;;Janssen Research and Development, Llc. A study to evaluate the pharmacokinetics of Pci-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Jan 09- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01767948 Nlm Identifier: NCT01767948.;;Janssen Research and Development, Llc. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Jul 18- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01646021 Nlm Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. Pnas Usa 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor -Ono-Wg-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, Ca, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251262 (2005).;;Kurosaki. Functional dissection of Bcr signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for Tasigna® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. Ii. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (Btk) by a Point Mutation in its Pleckstrin Homology (Ph) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by Ppi. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. 2012 May 24;55(10):4539-50 Publication Date (Web): 06 Mar 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/Ii Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Dec 17 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02321540?term=NCT02321540 Nlm Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/Ii Trial of Pci-32765 (Btk Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Oct 16 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02269085?term=NCT02269085 Nlm Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (Sct) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Oct 21 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02272686?term=NCT02272686 Nlm Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (Cll). In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Dec 5- [cited 2014 Apr 15]. Available from: http://clinicaltrials.govict2/show/NCT02007044 Nlm Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R Mcl). In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2013 Jun 14- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 Nlm Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor Pci-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Jan 25- [cited 2013 Nov 22]. Available from: http://clinicaltrials.govict2/show/NCT01520519 Nlm Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor Pci-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with Cll and Sll. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2012 Dec 13- [cited 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 Nlm Identifier: NCT01752426.;;Macpartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: 1 Feb. 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (Btk), Lfm-A13 [a-Cyano-R-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. Of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;Mcconathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994).;;Memorial Sloan-Kettering Cancer Center. Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (Pcnsl) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (Scnsl). In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). 2014 Dec 9 [cited 2015 Feb 5] Available from: https://clinicaltrial.govict2/show/NCT02315326?term=NCT02315326 Nlm Identifier: NCT02315326. et al.",ACTIVE
817,US,B2,US 10266540 B2,154-491-064-483-202,2019-04-23,2019,US 201816035449 A,2018-07-13,US 201816035449 A;;US 201815901118 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/154-491-064-483-202,Granted Patent,yes,351,4,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,349,149,050-012-520-524-900;;018-287-130-409-862;;017-226-063-911-434;;063-283-230-106-299;;082-955-679-125-981;;020-377-752-587-998;;071-449-828-437-743;;104-949-654-022-72X;;080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163,15939795;;pmc2213268;;10.1084/jem.20042101;;pmc2868342;;18202907;;10.1007/s10865-007-9147-y;;11527964;;10.1074/jbc.m104828200;;10.3322/caac.20004;;19147869;;10.5402/2012/195727;;22830056;;pmc3399483;;10.1016/s1097-2765(00)80357-3;;10360180;;10.2210/pdb1qcf/pdb;;10.1016/j.bcp.2003.09.035;;14757163;;10.1007/3-540-69178-2_5;;10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047,"US 10,085,944 B2, 10/2018, Chong et al. (withdrawn);;US 10,105,368 B2, 10/2018, Alturi et al. (withdrawn);;Boyle et al., “Enhancing Patient Adherence to Improve Outcomes with Oral Chemotheraphy,” US Pharm Oncology Suppl, 32(10):1-8 (2007).;;CHMP assessment report: Imbruvica, European Medicines Agency (2014).;;Feldhahn et al.,“Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells,” J Exp Med, 201(11):1837-1853 (2005).;;Honigberg et al., “A Clinical Trial of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in naturally occuring canine lymphoma,” Cancer Res, AACR Ann Meeting, 69:Abstract 3740 (2009).;;Ingersoll et al., “The impact of medication regimen factors on adherence to chronic treatment: a review of literature,” J Behav Med, 31(3):213-224 (2008).;;Mao et al., “Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Moleculer Basis of X-linked Agammaglobulinema,” J Biol Chem, 276(44):41435-41443 (2001).;;Miller et al., “Solvent Systems for Crystallization and Polymorph Selection,” Biotech Pharm Aspect, 6:53-109 (2007).;;PR Newswire, “Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma,” Pharmacyclics (Apr. 13, 2009).;;Ruddy et al., “Patient Adherences and Persistence With Oral Anticancer Treatment,” CA Cancer J Clin, 59(1):56-66 (2009).;;Savjani et al., Drug Solubility: Importance and Enhancement Techniques, ISRN Pharmaceutics (2012).;;Schindler et al., “Crystal Structure of Hck in Complex with a Src Family-Selective Tyrosine Kinase Inhibitor,” Mol Cell, 3(5):639-648 (1999).;;Sissi et al., “Antitumor AZA-anthrapyrazoles: biophysical and biochemical studies on 8- and 9-aza regioisomers,” Biochem Pharmacol, 67(4):631-642 (2004).;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).;;Extended European Search Report for European Application No. 16773859.0 dated Oct. 4, 2018, 9 pages.;;Extended European Search Report for European Application No. EP 16773865.7 dated Oct. 23, 2018, 55 pages.;;“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, Dec. 8, 2009, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of in vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor -ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for IMBRUVICA® (ibrutinib), revised Feb. 2018.;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 203—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567. et al.",ACTIVE
818,US,A1,US 2017/0201757 A1,181-159-151-095-333,2017-07-13,2017,US 201515324747 A,2015-06-25,GB 201417274 A;;GB 2015051848 W,2014-09-30,VIDEO DATA ENCODING AND DECODING,"A video data encoding method is operable with respect to successive source images each including a set of encoded regions, each region being separately encoded as an independently decodable network abstraction layer (NAL) unit having associated encoding parameter data. The method includes: identifying a subset of the regions representing at least a portion of each source image that corresponds to a required display image; allocating regions of the subset of regions for a source image to respective composite frames of a set of one or more composite frames so that the set of composite frames, taken together, provides image data representing the subset of regions; and modifying the encoding parameter data associated with the regions allocated to each composite frame so that the encoding parameter data corresponds to that of a frame comprising those regions allocated to that composite frame.",SONY CORP,GOLDMAN MICHAEL;;WAGG DAVID;;WILLIAMS MICHAEL JOHN;;SHARMAN KARL JAMES,SONY CORPORATION (2016-12-13),https://lens.org/181-159-151-095-333,Patent Application,yes,5,9,5,5,0,H04N19/70;;H04N19/174;;H04N19/46;;H04N19/167;;H04N21/4728;;H04N19/17;;H04N19/46;;H04N19/70;;H04N19/88;;H04N19/46;;H04N19/174;;H04N19/167;;H04N19/70;;H04N21/4728;;H04L65/762;;H04N19/177;;H04N19/188,H04N19/169;;H04L29/06;;H04N19/177;;H04N19/46,,0,0,,,,DISCONTINUED
819,AT,T1,AT E494237 T1,008-363-400-432-86X,2011-01-15,2011,AT 07799348 T,2007-07-06,US 80666006 P;;US 2007/0072935 W,2006-07-06,KNICKKLAPPBEHÄLTER FÜR AUTOMATISIERTE ALIQUOTIER- UND VERTEILUNGSVERFAHREN,"A package assembly for automated aliquot and/or dispersal processes is provided. Embodiments of the present invention include, but are not limited to: first and second portions which cooperate to contain the aliquot, wherein a pair of flexure channels are defined in opposing sides of at least one of the first or second portions, the flexure channels cooperating to define a flexure axis extending through the pair of flexure channels. Thus, embodiments of the present invention may allow at least one of first and second portions of the package assembly to flex about the flexure axis in response to a force exerted on the package assembly such that the first and second portions separate in response to the force.",PIONEER HI BRED INT,GOLDMAN DANIEL;;HARTMAN MICHAEL;;HUNTER JAMES;;JOHNSON DAVID;;TUCKER GRIFFITHS,,https://lens.org/008-363-400-432-86X,Granted Patent,no,0,1,14,17,0,A01C7/02;;A01C15/006;;B65D75/22;;A01C7/02;;B65D75/22;;A01C15/006,,,0,0,,,,ACTIVE
820,EP,A1,EP 2495676 A1,034-966-085-884-959,2012-09-05,2012,EP 12156571 A,2012-02-22,US 201113040255 A,2011-03-03,Method and apparatus for placement and routing of partial reconfiguration modules,"A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.
",ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;HERRMANN ALAN LOUIS;;BETZ VAUGHN,,https://lens.org/034-966-085-884-959,Patent Application,yes,0,0,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,,2,2,116-073-370-377-993;;054-723-856-561-402,10.1049/ip-cdt:20000498;;10.1049/iet-cdt:20060056,"ROBINSON D ET AL: ""Methods of exploiting simulation technology for simulating the timing of dynamically reconfigurable logic"", IEE PROCEEDINGS E. COMPUTERS & DIGITAL TECHNIQUES, INSTITUTION OF ELECTRICAL ENGINEERS. STEVENAGE, GB, vol. 147, no. 3, 30 May 2000 (2000-05-30), pages 175 - 180, XP006013909, ISSN: 0143-7062, DOI: 10.1049/IP-CDT:20000498;;SILVA M L ET AL: ""Generation of hardware modules for run-time reconfigurable hybrid CPU/FPGA systems"", 20070904, vol. 1, no. 5, 4 September 2007 (2007-09-04), pages 461 - 471, XP006029523",DISCONTINUED
821,ES,T3,ES 2359098 T3,063-658-587-956-200,2011-05-18,2011,ES 07799348 T,2007-07-06,US 80666006 P,2006-07-06,ENVASE TIPO CLAMSHELL ARTICULADO PARA PROCESOS AUTOMATIZADOS DE ALICUOTA Y DISPERSION.,"A package assembly for automated aliquot and/or dispersal processes is provided. Embodiments of the present invention include, but are not limited to: first and second portions which cooperate to contain the aliquot, wherein a pair of flexure channels are defined in opposing sides of at least one of the first or second portions, the flexure channels cooperating to define a flexure axis extending through the pair of flexure channels. Thus, embodiments of the present invention may allow at least one of first and second portions of the package assembly to flex about the flexure axis in response to a force exerted on the package assembly such that the first and second portions separate in response to the force.",PIONEER HI BRED INT,GOLDMAN DANIEL;;HARTMAN MICHAEL;;HUNTER JAMES;;JOHNSON DAVID;;TUCKER GRIFFITHS,,https://lens.org/063-658-587-956-200,Granted Patent,no,0,1,14,17,0,A01C7/02;;A01C15/006;;B65D75/22;;A01C7/02;;B65D75/22;;A01C15/006,B65D75/22;;A01C15/00;;B65D43/02;;B65D43/16;;B65D83/06,,0,0,,,,ACTIVE
822,US,B1,US 9828383 B1,056-763-077-084-589,2017-11-28,2017,US 201715670614 A,2017-08-07,US 201715670614 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC;;PHARMACYCLIC S LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/056-763-077-084-589,Granted Patent,yes,325,20,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/505;;C07D487/04,,320,135,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;029-457-630-175-079;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;038-340-694-023-194;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;088-509-847-283-89X;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;031-216-361-201-391;;025-966-522-155-708;;084-480-509-946-521;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;018-172-072-188-474;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;068-667-081-666-931;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;066-008-649-663-708;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;10.1172/jci75328;;25271622;;pmc4347242;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;20166765;;10.2165/11532180-000000000-00000;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1158/1535-7163.mct-06-0686;;17406031;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;pmc2833438;;15180891;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;11505401;;10.1002/1097-0142(20010801)92:3<569::aid-cncr1356>3.0.co;2-d;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;25259922;;pmc4177038;;10.1016/j.cell.2014.08.007;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;pmc1413718;;10.1073/pnas.0510565103;;16461460;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047,"ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, Dec. 8, 2009, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature, 463(7277):88-92 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;Dubovsky, J. A., et al., “Ibrutinib Treatment Ameliorates Murine Chronic Graft-Versus-Host Disease,” Journal of Clinical Investigation, vol. 124 (11), 10 pages. (Nov. 2014) DOI: 10.1172/JCI75328.;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;Ep 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Grosheck et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report and Written Opinion for PCT/US15/63475 dated Mar 28, 2016.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.govict2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 29, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013 Nov 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (Md): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;MacPartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahadevan, D et al. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Molecular Cancer Therapy, vol. 6, No. 4, Apr. 2007, pp, 1186-1197, p. 1192.;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994).;;Memorial Sloan-Kettering Cancer Center. Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 9, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02315326?term=NCT02315326 NLM Identifier: NCT02315326.;;Mendel et al., “In vivo Antitumor Activity of SU11248, A Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/pharmacodynamic Relationship,” Clin Cancer Res, 9(1): 327-337 (2003).;;Merged Markush Service Search, Jun. 27, 2005.;;Middendorp et al. Function of Bruton's Tyrosine Kinase during B Cell Development is Partially Independent of its Catalytic Activity. J Immunol 171:5988-5996 (2003).;;Middendorp et al. Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity. Blood 105(1):259-261 (2005).;;Mukoyama et al., “Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases,” retrieved from STN Database Accession No. 2005:299462 Patent No. JP2005089352, Abstract (2005).;;National Cancer Institute (NCI). A multicenter phase 2 study of the Bruton's tyrosine kinase inhibitor PCI-32765 for treatment of relapsed hairy cell leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Nov. 2, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01981512 NLM Identifier: NCT01981512. et al.",ACTIVE
823,US,S,US D0718340 S,058-329-431-235-652,2014-11-25,2014,US 201429485714 F,2014-03-21,US 201429485714 F,2014-03-21,Self-powered robotic lawn mower,,F ROBOTICS ACQUISITIONS LTD;;F ROBOTICS ACQUISITIONS LTD,DAMSHAK DAVID;;GOLDMAN IZIKIM;;ZUR ERAN;;LITVAK RAN;;TIKOCHINSKY YOAV,F ROBOTICS ACQUISITIONS LTD (2014-07-20);;TIKO PRODUCT DESIGN LTD (2014-07-20),https://lens.org/058-329-431-235-652,Design Right,no,0,27,1,1,0,,,1503;;D15/14,0,0,,,,ACTIVE
824,AU,A1,AU 2018/358912 A1,081-521-982-614-871,2020-06-11,2020,AU 2018/358912 A,2018-10-25,US 201762580221 P;;US 2018/0057496 W,2017-11-01,Control boxes principally for use with equipment of swimming pools and spas,"Control boxes (10) with segregated low- and high-voltage components are described. Service technicians (or others) requiring access to one set of components may do so without necessarily accessing the other set. Dual user interfaces may be utilized, further, with one interface being present at the control box and the other being remote therefrom.",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,,https://lens.org/081-521-982-614-871,Patent Application,no,0,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,E04H4/12;;A61H33/00,,0,0,,,,DISCONTINUED
825,US,B1,US 10961251 B1,115-272-261-300-802,2021-03-30,2021,US 202016951796 A,2020-11-18,US 202016951796 A;;US 202016824630 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/115-272-261-300-802,Granted Patent,yes,375,2,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K45/06;;B65D75/36;;C07D487/04,,359,162,009-735-793-164-974;;080-707-244-949-02X;;084-786-079-037-150;;089-192-146-880-951;;051-773-437-524-806;;084-954-244-635-278;;064-285-126-440-946;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;104-949-654-022-72X;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;089-402-914-639-064;;144-738-232-611-859;;050-012-520-524-900;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;051-261-371-269-486;;001-779-883-672-562;;091-695-878-773-648;;018-287-130-409-862;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;036-444-505-098-001;;016-289-303-702-626;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;068-519-192-122-633;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;017-226-063-911-434;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;016-064-084-746-508;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;084-480-509-946-521;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;001-645-453-115-842;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;063-283-230-106-299;;009-072-168-512-123;;191-922-716-579-909;;112-113-906-517-885;;082-955-679-125-981;;011-434-537-008-254;;020-377-752-587-998;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;132-576-696-875-962;;005-625-687-439-249;;051-308-600-980-390;;071-449-828-437-743;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;006-736-845-251-70X;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163,10.1016/j.ejpb.2008.07.014;;18715549;;10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1182/blood.v110.11.2559.2559;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10602208;;10.1002/(sici)1521-3773(19991203)38:23<3440::aid-anie3440>3.0.co;2-;;10.1002/(sici)1521-3773(19991203)38:23<3440::aid-anie3440>3.0.co;2-#;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.5270/esa-p89agpo;;12356095;;10.1002/9781118971147.ch16;;10.1152/ajpgi.1995.269.2.g210;;7653560;;15939795;;pmc2213268;;10.1084/jem.20042101;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;10.1182/blood.v110.11.1592.1592;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;pmc2868342;;18202907;;10.1007/s10865-007-9147-y;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(87)90012-3;;10.1016/0378-5173(88)90220-7;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;10.1155/2001/28962;;11785667;;pmc2276078;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;11527964;;10.1074/jbc.m104828200;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1111/j.1600-065x.2008.00741.x;;19290921;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;pmc2833438;;15180891;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;10.3109/03639045.2010.488647;;20545515;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.3322/caac.20004;;19147869;;22975686;;10.1016/j.cellsig.2012.09.008;;10.2174/1566524033361618;;12558077;;10.1016/s0960-894x(01)80549-7;;10.5402/2012/195727;;22830056;;pmc3399483;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1016/s1097-2765(00)80357-3;;10360180;;10.2210/pdb1qcf/pdb;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1002/0470025077.chap84b;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;10.1016/j.bcp.2003.09.035;;14757163;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.1039/an9952002435;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047,"“API form screening and selection in drug discovery stage,” Pharm. Stage, 6(10): 20-25, (2007).;;“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;Aaltonen et al., “Solid Form Screening—A Review,” Eur J Pharm Biopharm, 71(1):23-37 (2008).;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al., “Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia.” Blood (ASH Annual Meeting Abstracts) 110(Abstract):2559 (2007).;;Agency For Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al.. “Michael acceptors as a tool for anticancer drug design,” Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al., “Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases,” Nature Chem. Bio 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Concomitant Polymorphs,” Angew Chem Int Ed, 38(23):3440-3461 (1999).;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, 20091208, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Borka, “Crystal Polymorphism of Pharmaceuticals,” Acta Pharm Jugosl, 40:71-94 (1990).;;Boyle et al., “Enhancing Patient Adherence to Improve Outcomes with Oral Chemotheraphy,” US Pharm Oncology Suppl, 32(10):1-8 (2007).;;Brown et al., “Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al., “Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight,” Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al., “CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers,” Leukemia 23:43-52 (2009).;;Burger et al., “High-Level Expression Of The T-Cell Chemokines CCL3 And CCL4 By Chronic Lymphocytic Leukemia B Cells In Nurselike Cell Cocultures And After BCR Stimulation,” Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198:163-208 (1998).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al., “Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer,” Biochem. Pharmacol. 84(11):1388-1399 (2012).;;Carrle et al., “Current Strategies of Chemotherapy in Osteosarcoma,” International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al., “Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients,” Blood 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review Of Its Potential In The Treatment Of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al., “SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma,” Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;CHMP assessment report: Imbruvica, European Medicines Agency (2014).;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al., “Novel Bruton's tyrosine kinase inhibitors currently in development,” OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier In The Treatment Of Chronic Lymphocytic Leukemia By Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents In Medicinal Chemistry 11:265-271 (2013).;;Dolgin, “A Life Changing Innovation: How the success of one targeted therapy ushered in a new era of lymphoma treatment,” Nature 563(7731):S46-S47 (2018).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards, “BTK inhibition in myeloma: targeting the seed and the soil.” Blood 120(9):1757-1759 (2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Extended European Search Report for European Application No. 16773859.0 dated Oct. 4, 2018, 9 pages.;;Extended European Search Report for European Application No. EP 16773865.7 dated Oct. 23, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA Guidelines: “Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances,” (Feb. 1987).;;FDA Guidelines: “International Conference on Harmonisation; Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances,” Federal Register, vol. 65, No. 251 (2000).;;FDA Guidelines: “Q6A Specfications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances,” (Dec. 2000).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis.” Am. J. Physiol. 269:G210-218 (1995).;;Feldhahn et al., “Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells,” J Exp Med, 201(11):1837-1853 (2005).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al., “Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia,” Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al., “Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors,” J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani, “Multiple myeloma bone disease: pathophysiology of osteoblast inhibition,” Blood 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al., “Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a),” PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone, “Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al., “The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib,” PNAS 104(33):13283-13288 (2007).;;Hata et al., “Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells,” J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. “Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765,” Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series 14: (1975).;;Hochhaus et al., “A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids,” Biomed. Chrom. 6:283-286 (1992).;;Honigberg et al., “A Clinical Trial of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in naturally occuring canine lymphoma,” Cancer Res, AACR Ann Meeting, 69:Abstract 3740 (2009).;;Honigberg et al., “Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo,” ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;Imbruvica Prescribing Information, available at <http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205552s025lbl.pdf> (2018).;;Ingersoll et al., “The impact of medication regimen factors on adherence to chronic treatment: a review of literature,” J Behav Med, 31(3):213-224 (2008).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014. Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRl-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180 .;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013 Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb, “What's wrong with our cancer models?” Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al., “Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase,” PNAS USA 96:2227-2232 (1999).;;Khadka et al., “Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability,” Asian J Pharma Sci, 9:304-316 (2014).;;Kojima et al., Effective Solid Form Selection for the Pharmaceutical Development, Journal of Pharmaceutical Science and Technology, Japan, 2008 , 68(5):344-349.;;Korade-Mirnics et al., “Src kinase-mediated signaling in leukocytes,” J. Leukoc. Bio. 68(5):603-613 (2000).;;Kozaki et al., “Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies,” 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al., “Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures,” Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers, “Mechanisms of B-cell lymphoma pathogenesis,” Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki, “Functional dissection of BCR signaling pathways,” Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al., “Pharmacological uses and perspective of heavy water and deuterated compounds,” Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for Imbruvica® (ibrutinib), revised Feb. 2018.;;Label for Tasigna® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” Int. J. Pharmaceutics 37:87-95 (1987).;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Le Tourneau et al., “Dose Escalation Methods in Phase I Cancer Clinical Trials,” J. Natl Cancer 101:708-720 (2009).;;Li et al., “Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain,” Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective ltk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos, “Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma,” J. Clin. Oncol. 23(26):6351-6357 (2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al., “Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases,” Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013 Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567. et al.",ACTIVE
826,US,A1,US 2011/0053681 A1,126-258-393-938-881,2011-03-03,2011,US 87028710 A,2010-08-27,US 87028710 A;;US 27539509 P,2009-08-28,System and Method for Fantasy Sports Gambling,"A method and system provides an interactive gaming system for a plurality of users connected via a communication network. At least one community is created for the interactive gaming system including rules defining parameters for the gaming system, the community including a plurality of players. An initial bankroll is allocated to each of the plurality of players and each of the plurality of players is enabled to wager at least a portion of their allocated bankroll in accordance with the rules. Information is provided to a requesting one of the plurality of players for assisting the requesting player in making a wager and each of the plurality of players is ranked based on success in wagering by each of the plurality of players.",GOLDMAN JUSTIN EDWARD;;SHEDD JR ROBERT DANIEL;;DELEVIE ALAN DAVID,GOLDMAN JUSTIN EDWARD;;SHEDD JR ROBERT DANIEL;;DELEVIE ALAN DAVID,PADDY POWER PLC (2010-09-01);;THREE SCREEN GAMES INC (2010-09-01),https://lens.org/126-258-393-938-881,Patent Application,yes,1,91,1,1,0,G07F17/3274;;G07F17/3274,A63F9/24,463/25;;463/42;;463/43,0,0,,,,DISCONTINUED
827,CN,A,CN 110998286 A,033-820-519-094-631,2020-04-10,2020,CN 201880050360 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutionalneural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/033-820-519-094-631,Patent Application,no,9,1,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/25;;G01N21/35;;G01N21/65;;G01N27/62;;G06N3/04;;G06N3/08;;G06T7/00,,1,0,,,"孙晓等: ""基于ROI-KNN卷积神经网络的面部表情识别"", 《自动化学报》",ACTIVE
828,US,A1,US 2018/0179215 A1,044-304-807-188-315,2018-06-28,2018,US 201815901118 A,2018-02-21,US 201815901118 A;;US 201715497896 A;;US 201815887744 A;;US 201715645319 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,"PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (""NANOSYN"") (2012-07-12);;PHARMACYCLICS INC (2015-05-26)",https://lens.org/044-304-807-188-315,Patent Application,yes,0,9,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,,0,0,,,,ACTIVE
829,CN,A,CN 102708221 A,065-815-109-604-875,2012-10-03,2012,CN 201210046153 A,2012-02-23,US 201113040255 A,2011-03-03,Method and apparatus for placement and routing of partial reconfiguration modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,ALTERA CORP,SAMUEL GOLDMAN DAVID;;MARK BOURGEAULT;;LOUIS HERRMANN ALAN;;VAUGHN BETZ,,https://lens.org/065-815-109-604-875,Patent Application,no,2,3,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,,1,1,105-422-478-223-412,10.1109/date.2009.5090806,"MARKUS KOESTER AND WAYNE LUK,JENS HAGEMEYER AND MARIO PORRMANN: ""《Design Optimizations to Improve Placeability of Partial Reconfiguration Modules》"", 《2009,EDAA》, 24 April 2009 (2009-04-24)",ACTIVE
830,GB,A,GB 2530751 A,079-517-542-446-559,2016-04-06,2016,GB 201417274 A,2014-09-30,GB 201417274 A,2014-09-30,Video data encoding and decoding,"Video data encoding of a series of successive source images 0-3, each comprising an array of encoded tiles, each tile being separately encoded as an independently decodable network abstraction layer (NAL) unit NAL0.0-NAL5.3 having associated encoding parameter data. The method comprises identifying a sub-array Tile1-Tile5 of the tiles representing at least a portion of each source image that corresponds to a required display image; allocating each tile of the sub-array to one of a set of one or more so called composite frames, each composite frame comprising a collection of p tiles, where p is an integer greater than one; and modifying the encoding parameter data associated with the tiles allocated to each composite frame such that the encoding parameter data corresponds to the case in which the composite frame is an array 1 tile wide and p tiles high. Metadata associated with each tile in a composite frame may also reflect the position of the tile in the image to be displayed. Associated decoding method and apparatus claims are included.",SONY CORP,WAGG DAVID;;GOLDMAN MICHAEL;;WILLIAMS MICHAEL JOHN;;SHARMAN KARL JAMES,,https://lens.org/079-517-542-446-559,Patent Application,no,2,2,5,5,0,H04N19/70;;H04N19/174;;H04N19/46;;H04N19/167;;H04N21/4728;;H04N19/17;;H04N19/46;;H04N19/70;;H04N19/88;;H04N19/46;;H04N19/174;;H04N19/167;;H04N19/70;;H04N21/4728;;H04L65/762;;H04N19/177;;H04N19/188,H04N19/88;;H04N19/17;;H04N19/46;;H04N19/70,,0,0,,,,DISCONTINUED
831,EP,A4,EP 1331874 A4,131-395-828-144-119,2005-09-14,2005,EP 01946393 A,2001-06-15,US 0119198 W;;US 21525400 P,2000-06-30,A HEALTH OUTCOMES AND DISEASE MANAGEMENT NETWORK AND RELATED METHOD FOR PROVIDING IMPROVED PATIENT CARE,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/131-395-828-144-119,Search Report,no,4,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,EXPIRED
832,US,A1,US 2014/0237441 A1,169-030-611-876-084,2014-08-21,2014,US 201414152624 A,2014-01-10,US 201414152624 A;;US 201113040255 A,2011-03-03,Method and Apparatus for Placing and Routing Partial Reconfiguration Modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/169-030-611-876-084,Patent Application,yes,3,1,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,716/128,0,0,,,,ACTIVE
833,US,A1,US 2017/0334921 A1,184-394-371-179-466,2017-11-23,2017,US 201715670614 A,2017-08-07,US 201715670614 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/184-394-371-179-466,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,,0,0,,,,ACTIVE
834,CH,A,CH 282714 A,017-413-647-706-710,1952-05-15,1952,CH 282714D A,1950-01-16,CH 282714T A,1950-01-16,Reissverschlussschieber.,,SCHWARTZ JOHN;;GOLDMAN DAVID;;ALEXANDER LOUIS R;;TREBILCOCK GLADYS J,JOHN SCHWARTZ;;DAVID GOLDMAN;;LOUIS R ALEXANDER;;GLADYS J TREBILCOCK,,https://lens.org/017-413-647-706-710,Granted Patent,no,0,4,1,1,0,A44B19/28,A44B19/28,25C,0,0,,,,EXPIRED
835,US,A1,US 2021/0032258 A1,010-383-978-718-215,2021-02-04,2021,US 202017066192 A,2020-10-08,US 202017066192 A;;US 202016824630 A;;US 201916690788 A;;US 201916393775 A;;US 201816111014 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,,https://lens.org/010-383-978-718-215,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,DISCONTINUED
836,US,A1,US 2017/0305919 A1,082-134-462-374-014,2017-10-26,2017,US 201715645319 A,2017-07-10,US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,"PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC. (""NANOSYN"") (2012-07-12);;PHARMACYCLICS INC (2015-05-26)",https://lens.org/082-134-462-374-014,Patent Application,yes,0,14,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04,,0,0,,,,DISCONTINUED
837,ES,T3,ES 2329547 T3,104-031-438-164-564,2009-11-27,2009,ES 01946393 T,2001-06-15,US 21525400 P,2000-06-30,RED DE GESTION DE DESENLACES SANITARIOS Y DE ENFERMEDADES PARA PROPORCIONAR MEJOR ASISTENCIA AL PACIENTE.,"A health outcomes and disease management network and related method is provided for efficiently and effectively monitoring patient status as well as providing recommendations for improved patient healthcare. The system and method employs, among other things, a plurality of remote monitoring stations and a computer network. Each of the remote monitoring stations includes at least one measuring device, adapted to measure a physiological condition of a respective patient, and to provide data representative of the physiological condition for inclusion among patient health-related data pertaining to a respective patient. The health-related data can include, for example, data relating to a patient's heart. The computer network comprises a database containing accumulated health-related data pertaining to health-related conditions and treatment. The computer network is adapted to receive the patient health-related data from the remote monitoring stations via, for example, the Internet. Healthcare managers, each assigned to groups of patients, along with primary care providers, coordinate with each other to establish treatments programs for the patients based on their respective patient health-related data and the accumulated health-related data, and to revise the accumulated health-related data based on the patient health-related data. The computer network is further adapted to provide the accumulated health-related data stored in the database to organizations financing at least a portion of the treatment programs, and is adapted to receive financial data pertaining to the treatment programs from the organizations and to store the financial data in the database.",BECTON DICKINSON CO;;UNIV DUKE,VONK GLENN;;FRANTZ ANN;;WHELLAN DAVID;;O'CONNOR CHRISTOPHER;;GOLDMAN GEORGE,,https://lens.org/104-031-438-164-564,Granted Patent,no,0,0,10,10,0,A61B5/0002;;A61B5/02055;;A61B5/021;;A61B5/14532;;A61B2560/0271;;G16H20/60;;G16H10/20;;G16H15/00;;G16H40/67;;A61B5/0002;;A61B2560/0271;;A61B5/021;;A61B5/02055;;A61B5/14532;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,A61B5/00;;A61B5/0205;;A61B5/021;;G16H10/20;;G16H15/00;;G16H20/60;;G16H40/67,,0,0,,,,EXPIRED
838,JP,A,JP 2012185818 A,133-527-530-860-459,2012-09-27,2012,JP 2012037429 A,2012-02-23,US 201113040255 A,2011-03-03,METHOD AND DEVICE FOR INSTALLING AND ROUTING PARTIALLY RECONFIGURED MODULE,"PROBLEM TO BE SOLVED: To provide a method and a device for installing and routing a partially reconfigured (PR) module on a target device.SOLUTION: There is provided a method for designing a system on the target device, the method including allocating resources on the target device to a static logical module and a partially reconfigurable (PR) module of the system, or installing one instance of the PR module on the target device in parallel and routing it using the allocated resources.",ALTERA CORP,DAVID SAMUEL GOLDMAN;;MARK BOGART;;ALAN LOUIS HERRMANN;;BETZ VAUGHN,,https://lens.org/133-527-530-860-459,Patent Application,no,3,0,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50;;H03K19/173,,0,0,,,,INACTIVE
839,US,B2,US 9130344 B2,159-020-545-003-522,2015-09-08,2015,US 36364609 A,2009-01-30,US 36364609 A;;US 74087407 A;;US 25917608 A;;US 61588306 A;;US 79664606 P;;US 76173606 P;;US 76228406 P;;US 76300206 P;;US 76279106 P;;US 76279006 P,2006-01-23,Automated laser tuning,"In exemplary embodiments, an ultra short pulse system comprises a laser platform which includes an optical source configured to generate an optical pulse, an optical amplifier configured to amplify the optical pulse, and a compressor configured to temporally compress the amplified optical pulse. The ultra short pulse system further comprises monitor circuitry configured to monitor one or more performance aspects of the laser platform. Additionally, the ultra short pulse system may comprise logic configured to control the one or more performance aspects of the laser platform in response to at least the monitored one or more performance aspects.",STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M;;RAYDIANCE INC,STADLER ANDREW D;;GOLDMAN DAVID;;FARLEY MARK;;MIELKE MICHAEL M,RAYDIANCE INC (2009-04-28);;COHERENT INC (2015-07-22);;RAYD LLC (2015-07-23),https://lens.org/159-020-545-003-522,Granted Patent,yes,104,4,4,4,0,H01S3/10015;;H01S3/10015;;H01S3/0057;;H01S3/0057;;H01S3/0085;;H01S3/0085;;H01S3/1301;;H01S3/1301;;H01S3/2316;;H01S3/2316,H01S3/10;;H01S3/00;;H01S3/13;;H01S3/23,,71,60,145-294-032-372-402;;016-426-124-747-667;;117-744-165-986-432;;145-239-123-381-45X;;060-881-567-032-214;;000-084-545-744-394;;054-499-387-093-074;;026-314-668-625-496;;029-558-780-287-378;;007-610-480-329-043;;018-099-554-374-677;;000-411-739-404-617;;014-781-489-666-564;;001-545-518-386-996;;068-170-005-057-700;;090-225-352-798-75X;;064-013-679-316-815;;072-213-206-454-499;;093-814-694-433-923;;016-042-423-186-246;;034-198-200-102-512;;070-762-457-305-331;;054-553-005-359-274;;107-491-505-742-253;;106-352-588-540-537;;052-988-699-279-649;;141-673-850-199-212;;088-339-132-138-761;;057-872-185-503-276;;058-428-473-536-780;;140-235-674-660-228;;126-512-667-197-138;;109-319-323-316-737;;007-943-533-068-461;;033-492-002-552-396;;044-932-306-406-537;;176-602-037-735-467;;104-896-463-141-607;;049-327-564-862-574;;033-514-707-599-498;;033-514-707-599-498;;172-173-961-881-648;;064-538-387-903-251;;063-273-945-096-013;;064-538-387-903-251;;071-356-742-086-695;;078-630-235-137-447;;055-368-509-124-825;;008-297-618-180-914;;027-044-314-590-758;;007-534-703-329-197;;166-423-940-293-419;;075-065-377-249-833;;003-527-809-444-299;;011-656-550-619-272;;038-776-097-627-86X;;123-241-684-276-697;;007-603-487-033-055;;126-474-490-038-742;;034-344-790-017-571,10.1364/ao.13.000353;;20125987;;10.1364/oe.14.007125;;19529083;;10.1016/0030-4018(94)90331-x;;10.1016/0030-4018(85)90120-8;;10.1038/nature01275;;12478288;;10.1109/jqe.1986.1073009;;10.1038/418290a;;12124612;;10.1364/ol.11.000153;;19730563;;10.1016/0079-6727(94)00013-o;;10.1364/josab.5.001563;;15295618;;10.1038/sj.gt.3302337;;19823377;;10.1364/ol.18.001343;;10.1016/0030-4018(94)90075-2;;10.1117/12.573681;;10.1364/josa.68.001196;;10.1109/jstqe.2006.884067;;19484030;;10.1364/opex.12.004775;;10.1364/opex.12.002710;;19475112;;10.1364/opex.13.004869;;19498473;;20212690;;10.1364/ao.18.002500;;10.1117/12.525748;;10.1364/ol.30.001620;;16075516;;10.1364/opex.12.003888;;19483922;;10.1109/ofc.2005.192643;;10.1364/josab.16.001999;;10.1364/ol.30.001917;;16092218;;19471402;;10.1364/oe.11.002832;;10.1364/ao.36.003375;;18253351;;10.1109/68.769730;;10.1364/oe.11.001175;;19465984;;10.1109/50.802992;;10.1364/ol.30.001446;;16007769;;10.1364/opex.12.000956;;19474907;;10.1049/el:19991505;;18091887;;10.1364/ol.23.001695;;10.1109/jlt.2003.810563;;19730501;;10.1364/ol.10.000609;;10.1063/1.96260;;10.1109/50.618320;;10.1103/physreve.67.046608;;12786510;;10.1364/ol.30.001449;;16007770;;10.1364/ol.30.001449;;16007770;;10.1109/lpt.2004.840999;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;10.1109/lpt.2005.860058;;10.1109/cleo.2005.202253;;10.1364/opex.13.004600;;19495375;;15352348;;10.1364/ol.29.001718;;19532735;;10.1364/oe.15.004876;;19471462;;10.1364/oe.11.003332;;19488309;;10.1364/opex.12.006589;;10.1109/cleo.2005.202228;;10.1016/j.addr.2004.12.007;;15757758;;10.1109/lpt.2005.848549;;17041678;;10.1364/ol.31.003191;;10.1109/jlt.1986.1074847;;19730485;;10.1364/ol.10.000562;;10.1109/68.803079;;10.1049/el:19981138;;10.1364/ol.28.001371;;12906093;;10.1117/12.646020;;19498789;;10.1364/opex.13.007621,"Siegman, ""Unstable Optical Resonators"", Applied Optics, Feb. 1974, pp. 353-367, vol. 13, No. 2.;;Stevenson et al., Femtosecond Optical Transfection of Cells: Viability and Efficiency, Optics Express, vol. 14, No. 16, pp. 7125-7133, Aug. 7, 2006.;;Stock et al., ""Chirped Pulse Amplification in an Erbium-doped fiber Oscillator/Erbium-doped Fiber Amplifier System"", Optics Communications, North-Holland Publishing Co., Amsterdam, NL, vol. 106, No. 4/5/06, Mar. 15, 1994, pp. 249-252, XP000429901, ISSN: 0030-4018.;;Strickland et al., ""Compression of Amplified Chirped Optical Pulses"", Optics Communications, North-Holland Publishing Co., Amersterdam, NL, vol. 56, No. 3, Dec. 1, 1985, pp. 219-221, XP024444933 ISSN: 0030-4018 (retrieved on Dec. 11, 1985.;;Temelkuran, B. et al., ""Wavelength-scalable Hollow Optical Fibres with Large Photonic Bandgaps for CO2 Laser Transmission,"" Nature, Dec. 12, 2002, pp. 650-653.;;Thurston, R.N. et al., ""Analysis of Picosecond Pulse Shape Synthesis by Spectral Masking in a Grating Pulse Compressor,"" IEEE Journal of Quantum Electronics, vol. EQ-22, No. 5, pp. 682-696, May 1986.;;Tirlapur et al., ""Targeted Transfection by Femtosecond Laser,"" Nature Publishing Group, vol. 418, pp. 290-291, Jul. 18, 2002.;;Tsai et al., ""Ultrashort Pulsed Laser Light,"" Optics & Photonics News, pp. 25-29, Jul. 2004.;;Vaissie et al., ""Desktop Ultra-Short Pulse Laser at 1552 nm,""Ultrashort Pulse Laser Materials Interaction Workshop (Raydiance)-Directed Energy Professional Society (DEPS), Sep. 28, 2006.;;Weiner, A.M. et al., ""Synthesis of Phase-coherent, Picosecond Optical Square Pulses,"" Optics Letters, vol. 11, No. 3, pp. 153-155, Mar. 1986.;;Weiner, A.M., ""Femtosecond Optical Pulse Shaping and Processing,"" Prog. Quant. Electr. 1995, vol. 19, pp. 161-237, 1995.;;Weiner, A.M., ""High-resolution femtosecond Pulse Shaping,"" Journal of the Optical Society of America B. vol. 5, No. 8, pp. 1563-1572, Aug. 1988.;;Wells, D.J., ""Gene Therapy Progress and Prospects: electroporation and Other Physical Methods,"" Gene Therapy, Nature Publishing Group, vol. 11, pp. 1363-1369, Aug. 5, 2004, (http://www.nature.com/gt).;;White, W.E., et al., ""Compensation of Higher-order Frequency-dependent Phase Terms in Chirped-pulse Amplification Systems,"" Optics Letters, vol. 18, No. 16, pp. 1343-1345, Aug. 15, 1993.;;Yamakawa et al., ""1 Hz, 1 ps, terawatt Nd: glass laser"", Optics Communications, North-Holland Publishing Co. Amsterdam, NL, vol. 112, No. 1-2, Nov. 1, 1994, pp. 37-42, XP024424285.;;Yan et al., Ultrashort Pulse Measurement Using Interferometric Autocorrelator Based on Two-photon-absorbtion Detector at 1.55 mum Wavelength Region., 2005, Proceedings of SPIE vol. 5633, Advanced Materials and Devices for Sensing and Imaging II, pp. 424-429.;;Yeh, et al. ""Theory of Bragg Fiber"", Journal of the Optical Society America, Sep. 1978, pp. 1196, vol. 68, No. 9., pp. 1196-1201.;;Yi, Y. et al., ""Sharp Bending of On-Chip silicon Bragg Cladding Waveguide With Light Guiding on Low Index Core Materials"", IEEE Journal of Selected Topics in Quantum Electronics, vol. 12, No. 6, Nov./Dec. 2006, pp. 1345-1348.;;Yi, Y., et al., ""On-chip Si-based Bragg Cladding Waveguide with High Index Contrast Bilayers"", Optics Express, vol. 12, No. 20, Oct. 4, 2004, pp. 4775-4780.;;Yin, D. et al., ""Integrated ARROW Waveguides with Hollow Cores"", Optics Express, vol. 12, No. 12, Jun. 14, 2004, pp. 2710-2715.;;Zhou, S. et al., ""Compensation of nonlinear Phase Shifts with Third-order Dispersion in Short-pulse Fiber Amplifiers,"" Optics Express, vol. 13, No. 13, pp. 4869-2877, Jun. 27, 2005.;;Agostinelli, J. et al., ""Optical Pulse Shaping with a Grating Pair,"" Applied Optics, vol. 18, No. 14, pp. 2500-2504, Jul. 15, 1979.;;Anastassiou et al., ""Photonic Bandgap Fibers Exploiting Omnidirectional Reflectivity Enable Flexible Delivery of Infrared Lasers for Tissue Cutting,"" Proceedings of the SPIE-the International Society for Optical Engineering, SPIE, US, vol. 5317, No. 1, Jan. 1, 2004, pp. 29-38, XP002425586 ISSN: 0277-786X.;;Benoit, G. et al., ""Dynamic All-optical Tuning of Transverse Resonant Cavity Modes in Photonic Bandgap Fibers, ""Optics Letters, vol. 30, No. 13, Jul. 1, 2005, pp. 1620-1622.;;Chen, L. et al., ""Ultrashort Optical Pulse Interaction with Fibre Gratings and Device Applications,"" 1997, Canaga, located at http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq29402.pfd.;;Chen, X. et al., ""Highly Birefringent Hollow-core Photonic Bandgap Fiber,"" Optics Express, vol. 12, No. 16, Aug. 9, 2004, pp. 3888-3893.;;Chen, Y. et al., ""Dispersion-Managed Mode Locking"", Journal of the Optical Society of America B, Nov. 1999, pp. 1999-2004, vol. 16, No. 11, Optical Society of America.;;Dasgupta, S. et al., ""Design of Dispersion-Compensating Bragg Fiber with an Ultrahigh Figure of Merit,"" Optics Letters, Aug. 1, 2005, vol. 30, No. 15, Optical Society of America.;;De Matos et al., ""Multi-kilowatt, Picosecond Pulses from an All-fiber Chirped Pulse Amplification System Using Air-core Photonic Bandgalp Fiber"", Lasers and Electro-optics, 2004, (CLEO), Conference on San Francisco, CA USA, May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. May 17, 2004, pp. 973-974, XP010745448 ISBN: 978-1-55752-777-6.;;De Matos, C.J.S. et al., ""All-fiber Chirped Pulse Amplification using Highly-dispersive Air-core Photonic Bandgap Fiber,"" Nov. 3, 2003, Optics Express, pp. 2832-2837, vol. 11, No. 22.;;Delfyett, P. et al., ""Ultrafast Semiconductor Laser-Diode-Seeded Cr:LiSAF Rengerative Amplifier System"", Applied Optics, May 20, 1997, pp. 3375-3380, vol. 36, No. 15, Octoical Society of America.;;Eggleton, et al., ""Electrically Tunable Power Efficient Dispersion Compensating Fiber Bragg Grating,"" IEEE Photonics Technology Letters, vol. 11, No. 7, pp. 854-856, Jul. 1999.;;Engeness et al., ""Dispersion Tailoring and Compensation by Modal Interations in Omniguide Fibers,"" Optics Express, May 19, 2003, pp. 1175-1196, vol. 11, No. 10.;;Fink et al., ""Guiding Optical Light in Air Using an All-Dielectric Structure,"" Journal of Lightwave Technology, Nov. 1999, pp. 2039-2041, vol. 17, No. 11.;;Folkenberg, J.R., et al., ""Broadband Single-polarization Photonic Crystal Fiber,"" Optics Letters, vol. 30, No. 12, Jun. 15, 2005, pp. 1446-1448.;;Folkenberg, J.R., et al., ""Polarization Maintaining Large Mode Area Photonic Crystal Fiber,"" Optics Express vol. 12, No. 5, Mar. 8, 2004, pp. 956-960.;;Futami, F., et al., ""Wideband Fibre Dispersion Equalisation up to Fourth-order for Long-distance Sub-picosecond Optical Pulse Transmission,"" Electronics Letters, vol. 35, No. 25, Dec. 9, 1999.;;Galvanauskas, A. et al., ""Chirped-pulse-amplification Circuits for Fiber Amplifiers, Based on Chirped-period Quasi-phase, matching gratings"", Optics Letters, Nov. 1, 1998, p. 1695-1697, vol. 23, No. 21, Optical Society of America.;;Hartl et al., ""In-line high energy Yb Fiber Laser Based Chirped Pulse Amplifier System"", Laser and Electro-Optics, 2004, (CLEO) Conference of San Francisco, CA USA May 20-21, 2004, Piscataway, NJ, USA, IEEE, vol. 1, May 17, 2004, pp. 563-565, XP010745382, ISBN: 978-1-55752-7777.;;Hellstrom, E. et al., ""Third-order Dispersion Compensation Using a Phase Modulator"", Journal of Lightwave Technology, vol. 21, No. 5, pp. 1188-1197, May 2003.;;Heritage, J. P. et al., ""Picosecond Pulse Shaping by Spectral Phase and Amplitude Manipulation,"" Optics Letters, vol. 10, No. 12, pp. 609-611, Dec. 1985.;;Heritage, J.P. et al., ""Spectral Windowing of Frequency-Modulated Optical Pulses in a Grating Compressor,"" Applied Physics Letters, vol. 47, No. 2, pp. 87-89, Jul. 15, 1985.;;Hill, K. et al., ""Fiber Bragg Grating Technology Fundamentals and Overview,"" Journal of Lightwave Technology, Aug. 1997, vol. 15, No. 8, pp. 1263-1276.;;Ibanescu et al., ""Analysis of Mode Structure in Hollow Dielctric Waveguide Fibers,"" Physical Review E 67, 2003, The American Physical Society.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Optics Letters, vol. 30, No. 12, pp. 1449-1451, Jun. 15, 2005.;;Jiang, et al., ""Fully Dispersion Compensated ~500 fs Pulse Transmission Over 50 km Single Mode Fiber,"" Purdue University ECE Annual Research Summary, Jul. 1, 2004-Jun. 30, 2005.;;Killey, et al., ""Electronic Dispersion Compensation by Signal Predistortion Using Digital Processing and a Dual-Drive Mach-Zehnder Modulator,"" IEEE Photonics Technology Letters, vol. 17, No. 3, pp. 714-716, Mar. 2005.;;Kim, K. et al., ""1.4kW High Peak Power Generation from an All Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Koechner, ""Solid State Laser Engineering"", Oct. 29, 1999, Section 5.5, pp. 270-277, 5th Edition, Springer.;;Kwon, et al., ""Tunable Dispersion Slope Compensator Using a Chirped Fiber Bragg Grating Tuned by a Fan-shaped Thin Metallic Heat Channel,"" IEEE Photonics Technology Letters, vol. 18, No. 1, pp. 118-120, Jan. 1, 2006.;;Kyungbum, Kim et al., ""1.4kW High Peak Power Generation from an all Semiconductor Mode-locked Master Oscillator Power Amplifier System Based on eXtreme Chirped Pulse Amplification (X-CPA)"", Optics Express, Jun. 2, 2005, pp. 4600-4606, vol. 13, No. 12.;;Levy et al., ""Engineering Space-Variant Inhomogeneous Media for Polarization Control,"" Optics Letters, Aug. 1, 2004, pp. 1718-1720, vol. 29, No. 15, Optical Society of America.;;Liao, Kai-Hsiu et al., ""Large-aperture Chirped Volume Bragg Grating Based Fiber CPA System,"" Optics Express, Apr. 16, 2007, vol. 15, No. 8, pp. 4876-4882.;;Limpert et al., ""All Fiber Chiped-Pulse Amplification System Based on Compression in Air-Guiding Photonic Bandgap Fiber"", Optics Express, Dec. 1, 2003, vol. 11, No. 24, pp. 3332-3337.;;Lo, S. et al., ""Semiconductor Hollow Optical Waveguides Formed by Omni-directional Reflectors"", Optics Express, vol. 12, No. 26, Dec. 27, 2004, pp. 6589-6593.;;Malinowski A. et al., ""Short Pulse High Power Fiber Laser Systems,"" Proceedings of the 2005 Conference on Lasers and Electro-Optics (CLEO), Paper No. CThG3, pp. 1647-1649, May 26, 2005.;;Mehier-Humbert, S. et al., ""Physical Methods for Gene Transfer: Improving the Kinetics of Gene Delivery Into Cells,"" Advanced Drug Delivery Reviews, vol. 57, pp. 733-753, 2005.;;Mohammed, W. et al., ""Selective Excitation of the TE01 Mode in Hollow-Glass Waveguide Using a Subwavelength Grating,"" IEEE Photonics Technology Letters, Jul. 2005, vol. 17, No. 7, IEEE.;;Nibbering, E.T.J., et al. ""Spectral Determination of the Amplitude and the Phase of Intense Ultrashort Optical Pulses,"" Journal Optical Society of America B, vol. 13, No. 2, pp. 317-329, Feb. 1996.;;Nicholson, J. et al., ""Propagation of Femotsecond Pulses in Large-mode-area, Higher-order-mode Fiber,"" Optics Letters, vol. 31, No. 21, 2005, pp. 3191-3193.;;Nishimura et al., ""In Vivo Manipulation of Biological Systems with Femtosecond Laser Pulses,"" Proc. SPIE 6261, 62611J, pp. 1-10, 2006.;;Noda, J. et al., ""Polarization-maintaining Fibers and Their Applications"", Journal of Lightwave Technology, vol. Lt-4, No. 8 Aug. 1986, pp. 1071-1089.;;Palfrey et al., ""Generation of 16-FSEC Frequency-tunable Pulses by Optical Pulse compression"" Optics Letters, OSA, Optical Society of america, Washington, DC, USA, vol. 10, No. 11, Nov. 1, 1985, pp. 562-564, XP000710358 ISSN: 0146-9592.;;Pelusi, M. et al. ""Electrooptic Phase Modulation of Stretched 250-fs Pulses for Suppression of Third-Order Fiber Disperson in Transmission"", IEEE Photonics Technology Letters, vol. 11, No. 11, Nov. 1999, pp. 1461-1463.;;Pelusi, M. D. et al., ""Phase Modulation of Stretched Optical Pulses for Suppression of Third-order Dispersion Effects in fibre Transmission,"" Electronics Letters, vol. 34, No. 17, pp. 1675-1677, Aug. 20, 1998.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Photonics West 2005, San Jose, California, Jan. 2005, pp. 5709-3720.;;Price et al., ""Advances in High Power, Short Pulse, Fiber Laser Systems and Technology"", Proceedings of SPIE-vol. 5709, Fiber Lasers II: Technology, Systems, and Applications, Apr. 2005, pp. 184-192.;;Ramachandran, S., et al., ""High-power Amplification in a 2040-mum2 Higher Order Mode,"" SPIE Photonics West 2007, Post-deadline.;;Resan et al., ""Dispersion-Managed Semiconductor Mode-Locked Ring Laser"", Optics Letters, Aug. 1, 2003, pp. 1371-1373, vol. 28, No. 15, Optical Society of America.;;Schreiber, T., et al., ""Design and High Power Operation of a Stress-induced single Polarization Single-transverse Mode LMA Yb-doped Photonic Crystal Fiber,"" Fiber Lasers III: Technology, Systems, and Applications, Andrew J.W. Brown, Johan Nilsson, Donald J. Harter, Andreas Tünnermann, eds., Proc. of SPIE, vol. 6102, pp. 61020C-1-61020C-9, 2006.;;Schreiber, T., et al., ""Stress-induced Single-polarization Single-transverse Mode Photonic Crystal Fiber with Low Nonlinearity,"" Optics Express, vol. 13, No. 19, Sep. 19, 2005, pp. 7621-7630.",INACTIVE
840,US,A1,US 2020/0146163 A1,041-590-287-479-418,2020-05-07,2020,US 201916708980 A,2019-12-10,US 201916708980 A;;US 201816170355 A;;US 201762580221 P,2017-11-01,CONTROL BOXES PRINCIPALLY FOR USE WITH EQUIPMENT OF SWIMMING POOLS AND SPAS,"Control boxes with segregated low- and high-voltage components are described. Service technicians (or others) requiring access to one set of components may do so without necessarily accessing the other set. Dual user interfaces may be utilized, further, with one interface being present at the control box and the other being remote therefrom.",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2017-11-02),https://lens.org/041-590-287-479-418,Patent Application,yes,2,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,H05K5/02;;A61H33/00;;E04H4/12;;H02G3/08,,0,0,,,,DISCONTINUED
841,US,A1,US 2018/0327415 A1,047-867-852-027-80X,2018-11-15,2018,US 201816035449 A,2018-07-13,US 201816035449 A;;US 201815901118 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/047-867-852-027-80X,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,0,0,,,,ACTIVE
842,US,B1,US 10125140 B1,085-851-555-477-988,2018-11-13,2018,US 201816036258 A,2018-07-16,US 201816036258 A;;US 201815900660 A;;US 201815887744 A;;US 201715645319 A;;US 201715497896 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;PHARMACYCLICS INC (2015-05-26);;NANOSCALE COMBINATORIAL SYTHESIS INC (2012-07-12),https://lens.org/085-851-555-477-988,Granted Patent,yes,337,17,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K45/06;;B65D75/36;;C07D487/04,,332,141,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;074-225-865-565-732;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;18061887;;10.1016/j.drudis.2007.09.005;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047,"“Imbruvica,” EPAR Summary for the Public, European Medicines Agency Science Medicines Health last updated Aug. 2016, retrieved from: <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124>.;;ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R.H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, 20091208, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al. Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88-94 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Extended European Search Report for EP Application No. 16759417 dated Jun. 29, 2018.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Administration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor-ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for IMBRUVICA® (ibrutinib), revised Feb. 2018.;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 Dec. 17, 2014[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;Macpartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [a-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994). et al.",ACTIVE
843,US,A1,US 2023/0088574 A1,057-109-774-075-40X,2023-03-23,2023,US 202217591435 A,2022-02-02,US 202217591435 A;;US 202117482848 A,2021-09-23,SYSTEM FOR DRAWING FLUID FROM A BAG UNDER SUB-AMBIENT CONDITIONS,A portable system and method for infusing liquid medicaments to a patient through an elastomeric fluid channel includes an airtight pressure shell for holding a collapsible bag of the fluid medicament to be infused. A pressure sensor connected to the pressure shell monitors decreases below ambient pressure inside the shell to determine when the sub-ambient pressure becomes insufficient to continue assisting the withdrawal of fluid from the collapsible bag to an external pinch/squeeze unit. An equilibration valve is synchronized with the pinch/squeeze unit to reestablish ambient pressure in the pressure shell for continued operation as the pinch/squeeze unit acts to sequentially push liquid medicament for infusion into the patient.,MODULAR MEDICAL INC,DIPERNA PAUL M;;GOLDMAN MARC D;;NEESE DAVID;;HEARTY PATRICK,MODULAR MEDICAL INC (2022-05-10),https://lens.org/057-109-774-075-40X,Patent Application,yes,0,0,1,4,0,A61M5/1483;;A61M5/14228;;A61M5/16854;;A61M5/152;;A61M5/16881;;A61M2005/16872;;A61M2005/16868;;A61M2205/3331,A61M5/152;;A61M5/168,,0,0,,,,PENDING
844,US,B2,US 8671377 B2,076-109-350-818-15X,2014-03-11,2014,US 201113040255 A,2011-03-03,US 201113040255 A,2011-03-03,Method and apparatus for placement and routing of partial reconfiguration modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS;;ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/076-109-350-818-15X,Granted Patent,yes,2,2,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,716/121;;716/116;;716/117;;716/128;;326/37;;326/38;;326/39;;326/40;;326/41,4,3,105-422-478-223-412;;116-073-370-377-993;;054-723-856-561-402,10.1109/date.2009.5090806;;10.1049/ip-cdt:20000498;;10.1049/iet-cdt:20060056,"Koester et al., Design Optimization to Improve Placeability of Partial Reconfiguration Module, 2009, EDAA, pp. 1-6.;;Extended European Search Report for Application No. EP 12 15 6571.7.;;Robinson, et al.; ""Methods of Exploiting Simulation Technology for Simulating the Timing of Dynamically Reconfigurable Logic""; IEE Proceedings E. Computers & Digital Techniques, Institution of Electrical Engineers, Stevenage, GB, vol. 147, No. 3, pp. 175-180, May 30, 2000.;;Silva, et al.; ""Generation of Hardware Modules for Run-Time Reconfigurable Hybrid CPU/FPGA Systems"", IET Comput. Digit. Tech., vol. 1, No. 5, pp. 461-471, Sep. 4, 2007.",ACTIVE
845,AU,A,AU 1999/012343 A,115-186-316-445-523,1999-06-15,1999,AU 1999/012343 A,1998-11-11,EP 9807198 W;;US 6669897 P,1997-11-25,Sustained release formulations comprising alpha-glucosidase-inhibitors,,BAYER AG,GOLDMAN DAVID;;AMATRUDA JOHN;;PORTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,,https://lens.org/115-186-316-445-523,Patent Application,no,0,0,6,6,0,A61K31/702;;A61K9/2054;;A61K9/209;;A61K31/13;;A61K31/445;;A61P3/04;;A61P3/10;;A61P9/10,A61K9/20;;A61K9/22;;A61K9/24;;A61K31/13;;A61K31/133;;A61K31/445;;A61K31/7032;;A61K45/00;;A61K47/12;;A61K47/38;;A61P3/04;;A61P3/10;;A61P9/10,,0,0,,,,DISCONTINUED
846,EP,B1,EP 3704330 B1,149-016-547-331-031,2023-07-26,2023,EP 18801160 A,2018-10-25,US 201762580221 P;;US 2018/0057496 W,2017-11-01,CONTROL BOXES PRINCIPALLY FOR USE WITH EQUIPMENT OF SWIMMING POOLS AND SPAS,,ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,,https://lens.org/149-016-547-331-031,Granted Patent,yes,5,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,E04H4/12;;A61H33/00,,0,0,,,,ACTIVE
847,US,A,US 5502076 A,187-452-640-052-589,1996-03-26,1996,US 20816494 A,1994-03-08,US 20816494 A,1994-03-08,Dispersing agents for use with hydrofluoroalkane propellants,"Vitamin E acetate, C.sub.3 -linked triesters, glycerin, t-butanol, and transesterified oil/polyethylene glycol are effective dispersing agents for use with hydrofluoroalkanes. Effective amounts of the above are effective in suspending medicaments which are useful in inhalation aerosols, and especially meter-dose inhalers.",HOFFMANN LA ROCHE,DIXIT SURESH C;;GOLDMAN DAVID;;HU JOHN J;;SETHACHUTKUL KRISH,HOFFMANN-LA ROCHE INC (1994-03-04),https://lens.org/187-452-640-052-589,Granted Patent,yes,12,78,1,1,0,A61K9/008;;A61K31/426;;A61K9/008;;A61K31/426,A61K9/00;;A61K31/426,514/510;;424/43;;424/45;;424/46;;514/458;;514/772;;514/786;;514/975,0,0,,,,EXPIRED
848,US,A1,US 2019/0132972 A1,044-878-371-206-780,2019-05-02,2019,US 201816170355 A,2018-10-25,US 201816170355 A;;US 201762580221 P,2017-11-01,CONTROL BOXES PRINCIPALLY FOR USE WITH EQUIPMENT OF SWIMMING POOLS AND SPAS,"Control boxes with segregated low- and high-voltage components are described. Service technicians (or others) requiring access to one set of components may do so without necessarily accessing the other set. Dual user interfaces may be utilized, further, with one interface being present at the control box and the other being remote therefrom.",ZODIAC POOL SYSTEMS LLC,UY DINDO;;BAUCKMAN MARK;;HENG HWA;;DESAI KRISHNA;;GOLDMAN DAVID,ZODIAC POOL SYSTEMS LLC (2017-11-02),https://lens.org/044-878-371-206-780,Patent Application,yes,3,0,8,8,0,A61H33/005;;E04H4/12;;A61H2033/0058;;A61H2201/5097;;H05K5/0217;;H04B1/3827;;H02G3/081;;A61H2201/5097;;A61H2033/0058;;E04H4/12;;A61H33/005,H05K5/02;;H02G3/08,,0,0,,,,ACTIVE
849,US,A1,US 2016/0267212 A1,079-568-115-299-427,2016-09-15,2016,US 201615132163 A,2016-04-18,US 201615132163 A;;US 201414152624 A;;US 201113040255 A,2011-03-03,Method and Apparatus for Placing and Routing Partial Reconfiguration Modules,A method for designing a system on a target device includes assigning resources on the target device to static logic modules and partial reconfigurable (PR) modules in the system. The instances of one of the PR modules are placed and routed in parallel utilizing resources from those that are assigned. Other embodiments are also disclosed.,ALTERA CORP,GOLDMAN DAVID SAMUEL;;BOURGEAULT MARK;;BETZ VAUGHN;;HERRMANN ALAN LOUIS,ALTERA CORPORATION (2011-06-03),https://lens.org/079-568-115-299-427,Patent Application,yes,3,1,11,11,0,G06F30/34;;G06F2117/06;;G06F30/394;;G06F30/34;;G06F30/392;;G06F2117/06;;G06F30/347;;G06F30/3953,G06F17/50,,0,0,,,,ACTIVE
850,FR,A,FR 1008375 A,114-918-813-472-965,1952-05-16,1952,FR 1008375D A,1950-01-14,FR 1008375T A,1950-01-14,Fermeture à curseur,,,SCHWARTZ JOHN;;GOLDMAN DAVID;;ALEXANDER LOUIS ROSENTHAL;;TREBILCOCK GLADYS JANET,,https://lens.org/114-918-813-472-965,Granted Patent,no,0,0,1,1,0,A44B19/28,A44B19/28,,0,0,,,,EXPIRED
851,WO,A3,WO 1999/026606 A3,090-291-309-081-281,1999-08-12,1999,EP 9807198 W,1998-11-11,US 6669897 P,1997-11-25,SUSTAINED RELEASE FORMULATIONS COMPRISING alpha -GLUCOSIDASE-INHIBITORS,"The present invention relates to pharmaceutical sustained release formulations of α-glucosidase inhibitors as for example acarbose, miglitol, emiglitate or voglibose leading to a reduction of side effects.",BAYER AG;;GOLDMAN DAVID;;AMATRUDA JOHN;;POERTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,GOLDMAN DAVID;;AMATRUDA JOHN;;POERTNER CAROLA;;BRENDEL ERICH;;BOSCHE PATRICK,,https://lens.org/090-291-309-081-281,Search Report,yes,4,0,6,6,0,A61K31/702;;A61K9/2054;;A61K9/209;;A61K31/13;;A61K31/445;;A61P3/04;;A61P3/10;;A61P9/10,A61K9/20;;A61K9/22;;A61K9/24;;A61K31/13;;A61K31/133;;A61K31/445;;A61K31/7032;;A61K45/00;;A61K47/12;;A61K47/38;;A61P3/04;;A61P3/10;;A61P9/10,,0,0,,,,PENDING
852,US,A1,US 2023/0093674 A1,097-700-136-799-357,2023-03-23,2023,US 202117482848 A,2021-09-23,US 202117482848 A,2021-09-23,PORTABLE INFUSION PUMP WITH NEGATIVE PRESSURE CONTROL,"A portable system and method for infusing fluid medicaments to a patient through an elastomeric fluid channel includes an airtight pressure shell for holding a collapsible bag of the fluid medicament to be infused. A pressure sensor connected to the pressure shell monitors decreases below ambient pressure inside the shell to determine when the ambient pressure becomes insufficient to continue assisting the withdrawal of fluid from the collapsible bag, to an external pinch/squeeze unit. At this point, an equilibrator operates to reestablish ambient pressure in the pressure shell for continued operation. In operation, the pinch/squeeze unit exerts radial forces on the elastomeric fluid channel. These forces act to sequentially push fluid medicament for infusion to the patient when the elastomeric fluid channel is occluded and stressed, and draw fluid medicament from the collapsible bag as the elastomeric fluid channel is unstressed.",MODULAR MEDICAL INC,DIPERNA PAUL M;;GOLDMAN MARC D;;NEESE DAVID;;HEARTY PATRICK,MODULAR MEDICAL INC (2021-10-12),https://lens.org/097-700-136-799-357,Patent Application,yes,3,0,2,4,0,A61M5/16854;;A61M5/14228;;A61M5/148;;A61M5/14244;;A61M5/16854;;A61M2205/3331;;A61M5/16813;;A61M5/1483;;A61M5/14216,A61M5/142;;A61M5/148;;A61M5/168,,0,0,,,,PENDING
853,EP,A1,EP 3202152 A1,114-333-583-864-192,2017-08-09,2017,EP 15732920 A,2015-06-25,GB 201417274 A;;GB 2015051848 W,2014-09-30,VIDEO DATA ENCODING AND DECODING,,SONY CORP,GOLDMAN MICHAEL;;WAGG DAVID;;WILLIAMS MICHAEL JOHN;;SHARMAN KARL JAMES,SONY GROUP CORPORATION (2021-07-28),https://lens.org/114-333-583-864-192,Patent Application,yes,0,0,5,5,0,H04N19/70;;H04N19/174;;H04N19/46;;H04N19/167;;H04N21/4728;;H04N19/17;;H04N19/46;;H04N19/70;;H04N19/88;;H04N19/46;;H04N19/174;;H04N19/167;;H04N19/70;;H04N21/4728;;H04L65/762;;H04N19/177;;H04N19/188,H04N19/70;;H04N19/167;;H04N19/17;;H04N19/174;;H04N19/46;;H04N21/41,,0,0,,,,DISCONTINUED
854,US,A1,US 2017/0100404 A1,156-825-823-269-275,2017-04-13,2017,US 201615386118 A,2016-12-21,US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK STEPHEN;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/156-825-823-269-275,Patent Application,yes,0,0,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,A61K31/519;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;B65D75/36,,0,0,,,,ACTIVE
855,WO,A1,WO 2023/048916 A1,199-013-578-655-530,2023-03-30,2023,US 2022/0042132 W,2022-08-31,US 202117482848 A,2021-09-23,PORTABLE INFUSION PUMP WITH NEGATIVE PRESSURE CONTROL,"A portable system and method for infusing fluid medicaments to a patient through an elastomeric fluid channel includes an airtight pressure shell for holding a collapsible bag of the fluid medicament to be infused. A pressure sensor connected to the pressure shell monitors decreases below ambient pressure inside the shell to determine when the ambient pressure becomes insufficient to continue assisting the withdrawal of fluid from the collapsible bag, to an external pinch/squeeze unit. At this point, an equilibrator operates to reestablish ambient pressure in the pressure shell for continued operation. In operation, the pinch/squeeze unit exerts radial forces on the elastomeric fluid channel. These forces act to sequentially push fluid medicament for infusion to the patient when the elastomeric fluid channel is occluded and stressed, and draw fluid medicament from the collapsible bag as the elastomeric fluid channel is unstressed.",MODULAR MEDICAL INC,DIPERNA PAUL M;;GOLDMAN MARC D;;NEESE DAVID;;HEARTY PATRICK,,https://lens.org/199-013-578-655-530,Patent Application,yes,4,0,2,4,0,A61M5/16854;;A61M5/14228;;A61M5/148;;A61M5/14244;;A61M5/16854;;A61M2205/3331;;A61M5/16813;;A61M5/1483;;A61M5/14216,A61M5/155;;A61M5/14;;A61M5/142;;A61M5/145;;A61M5/148;;A61M5/168;;A61M5/172,,0,0,,,,PENDING
856,US,B2,US 10106548 B2,197-495-963-127-787,2018-10-23,2018,US 201815900660 A,2018-02-20,US 201815900660 A;;US 201715497896 A;;US 201815887744 A;;US 201715645319 A;;US 201615386118 A;;US 201314405317 A;;US 2013/0043888 W;;US 201261655381 P,2012-06-04,Crystalline forms of a Bruton's tyrosine kinase inhibitor,"Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",PHARMACYCLICS LLC,PURRO NORBERT;;SMYTH MARK S;;GOLDMAN ERICK;;WIRTH DAVID D,PHARMACYCLICS LLC (2015-05-26);;NANOSCALE COMBINATORIAL SYNTHESIS INC (2012-07-12);;PHARMACYCLICS INC (2015-05-26),https://lens.org/197-495-963-127-787,Granted Patent,yes,335,11,135,135,0,A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07D487/04;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P3/10;;C07D487/04;;A61K47/30;;A61K47/38;;A61K9/48;;A61K9/20;;A61P35/00;;A61P29/00;;A61K9/4866;;C07B2200/13;;A61K9/4858;;A61K9/0053;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4825;;A61J1/035;;A61K31/519;;A61K45/06;;A61P1/00;;A61P1/02;;A61P1/16;;A61P3/10;;A61P7/02;;A61P7/06;;A61P9/00;;A61P11/00;;A61P11/02;;A61P11/04;;A61P11/06;;A61P13/08;;A61P13/10;;A61P13/12;;A61P15/00;;A61P15/02;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/08;;A61P21/04;;A61P27/02;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P39/00;;A61P43/00;;B65D75/36;;A61K31/519;;A61K9/4866;;A61K9/4858;;A61K9/2054;;A61K9/2013;;A61K9/2018;;A61P37/00;;A61P35/02;;A61P29/00;;C07D487/04;;A61K31/519;;A61K45/06;;A61K9/2013;;A61K9/2018;;A61K9/2054;;A61K9/4858;;A61K9/4866;;C07B2200/13;;A61J1/035;;A61K9/0053;;A61K9/4825;;B65D75/36,C07D487/04;;A61J1/03;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/519;;A61K45/06;;B65D75/36,,332,142,080-707-244-949-02X;;084-786-079-037-150;;051-773-437-524-806;;084-954-244-635-278;;133-008-924-022-912;;015-063-415-122-10X;;094-426-452-116-986;;019-086-481-958-666;;016-756-423-575-588;;026-602-342-915-043;;052-987-643-482-301;;000-593-425-035-61X;;070-623-826-082-605;;009-214-187-079-899;;030-078-557-734-49X;;108-465-833-398-743;;070-105-220-366-494;;029-307-446-890-335;;025-716-535-208-301;;157-431-722-988-742;;012-047-319-657-391;;053-207-920-994-687;;065-757-732-229-525;;089-560-783-324-399;;039-782-322-629-050;;006-237-773-846-459;;082-627-792-674-488;;002-823-958-702-458;;049-401-272-654-645;;127-667-896-531-817;;062-629-771-597-536;;032-600-458-370-231;;144-738-232-611-859;;005-264-653-185-294;;006-286-861-403-907;;017-696-456-420-448;;130-520-749-136-034;;017-180-533-571-083;;060-343-162-821-76X;;014-599-246-214-415;;041-564-787-488-186;;008-839-998-512-08X;;009-587-718-018-713;;021-015-269-040-421;;063-939-931-828-787;;038-340-694-023-194;;045-702-131-023-464;;064-910-620-122-530;;048-878-332-994-257;;027-352-729-896-964;;026-747-860-569-66X;;005-576-769-764-004;;031-154-802-869-32X;;001-779-883-672-562;;091-695-878-773-648;;095-118-733-111-972;;121-296-934-601-962;;090-510-849-756-371;;099-968-706-681-044;;071-972-043-147-865;;011-802-005-769-016;;021-664-364-889-319;;023-472-875-871-416;;067-329-295-915-800;;040-081-313-970-111;;150-148-996-303-597;;016-289-303-702-626;;036-444-505-098-001;;059-482-814-808-136;;055-695-667-155-81X;;009-759-792-847-227;;018-213-579-233-535;;097-932-790-996-155;;016-349-850-586-099;;092-206-243-195-30X;;095-216-091-651-510;;078-075-117-694-648;;008-901-941-428-068;;005-306-184-480-970;;161-837-503-145-387;;111-426-070-855-26X;;095-231-661-033-366;;023-435-886-035-592;;014-515-164-887-404;;055-518-308-228-557;;025-965-705-925-299;;020-435-634-003-86X;;031-216-361-201-391;;025-966-522-155-708;;084-480-509-946-521;;035-702-515-879-920;;002-420-701-504-492;;011-062-027-245-140;;008-704-730-686-021;;074-837-993-593-196;;005-487-928-510-286;;076-762-219-398-50X;;053-850-839-388-180;;055-664-614-571-543;;011-345-778-561-064;;027-560-773-936-958;;078-433-586-645-301;;121-700-133-762-637;;098-286-411-734-482;;034-183-816-393-504;;191-922-716-579-909;;011-434-537-008-254;;007-136-598-472-085;;079-212-142-898-751;;007-669-468-009-211;;015-697-459-371-25X;;005-625-687-439-249;;051-308-600-980-390;;088-154-228-885-728;;061-108-963-183-979;;039-514-711-341-930;;018-279-218-509-454;;136-130-263-709-642;;003-189-258-374-984;;073-610-944-546-606;;068-224-919-120-455;;051-636-999-417-614;;052-771-855-232-379;;091-682-755-938-948;;070-621-773-794-721;;083-061-642-764-097;;062-723-120-023-708;;053-715-226-174-129;;001-516-175-552-397;;135-208-479-541-78X;;029-381-309-895-477;;046-028-122-231-872;;028-090-690-606-278;;027-792-295-168-159;;060-193-751-138-888;;012-242-145-790-208;;003-889-397-643-299;;031-303-044-777-026;;101-396-698-814-503;;039-524-906-996-098;;085-572-707-424-163;;074-225-865-565-732,10.1200/jco.2010.28.15_suppl.8012;;23045577;;10.1200/jco.2012.42.7906;;pmc5505166;;10.3410/f.717959990.793468443;;10.3410/f.717959990.793469902;;10.1038/nchembio.117;;pmc2880455;;18849971;;11012021;;10.1016/s0960-894x(00)00441-8;;10.1021/cg1013335;;10.1038/nrd2085;;16816838;;12039591;;10.1016/s0960-894x(02)00196-8;;10.1038/leu.2008.299;;18987663;;19074730;;pmc4916945;;10.1182/blood-2008-07-170415;;22960555;;10.1097/cco.0b013e3283589950;;25513467;;25049322;;pmc4162500;;10.1200/jco.2014.55.8262;;10.1056/nejmoa1215637;;23782158;;pmc3772525;;pmc4400288;;25700432;;10.1182/blood-2014-10-606038;;10.1023/a:1016241927429;;7494814;;12039590;;10.1016/s0960-894x(02)00195-6;;24464309;;10.1007/s40265-014-0178-8;;10.1016/j.bcp.2012.07.031;;22885287;;16896870;;pmc3172747;;10.1007/s00264-006-0192-x;;10.1182/blood-2013-02-482125;;10.3410/f.718073986.793497271;;pmc3790509;;23940282;;pmc3239353;;21752263;;10.1186/ar3400;;pmc3662532;;23717217;;10.2147/ce.s34068;;18006696;;pmc2234057;;10.1182/blood-2007-07-100115;;10.1182/blood.v97.1.321;;11133777;;pmc3641834;;15919995;;10.1126/science1108367;;15681517;;10.1200/jco.2005.02.172;;23493945;;pmc3594038;;10.2147/ott.s33732;;22616724;;pmc4557770;;10.3109/10428194.2012.695781;;pmc2845535;;20054396;;10.1038/nature08638;;10.1016/s0952-7915(97)80107-0;;9287186;;0009287186;;pmc4010045;;24433470;;10.2174/1871525712666140115143914;;22936735;;10.1182/blood-2012-07-439216;;15711537;;10.1038/nbt1068;;10.1152/ajpgi.1995.269.2.g210;;7653560;;10.7326/0003-4819-90-5-761;;434676;;10.1182/blood-2009-08-236471;;19965662;;pmc2852362;;10.1016/s1074-7613(00)00002-9;;10933389;;10.1073/pnas.95.20.12022;;pmc21758;;9751783;;10.1089/152581601750098453;;11276370;;10.1016/s1470-2045(14)70388-2;;25150799;;16917004;;10.1182/blood-2006-05-026112;;15771912;;10.1016/j.cancergencyto.2004.08.012;;12119152;;10.1016/s0165-6147(02)02045-x;;pmc153059;;10.1073/pnas.0735266100;;12651942;;10.1158/0008-5472.can-09-3788;;20406975;;10.1002/jps.1137;;10.1002/jps.1137.abs;;11745745;;20166765;;10.2165/11532180-000000000-00000;;10.1002/jps.2600580802;;4899118;;pmc1940229;;10.1073/pnas.0702654104;;17684099;;10.1074/jbc.273.18.10979;;9556577;;10.1182/blood-2011-01-328484;;pmc3122947;;21422473;;12652460;;10.1053/sonc.2003.50024;;28140216;;10.1182/blood-2005-01-0016;;16123223;;1286285;;10.1002/bmc.1130060607;;pmc2919935;;10.1073/pnas.1004594107;;20615965;;10.1182/blood.v98.5.1326;;11520778;;16176929;;10.1074/jbc.m506063200;;20008237;;10.1182/asheducation-2009.1.523;;pmc6324557;;10.1074/jbc.m301484200;;12724322;;15688078;;10.1038/nrd1635;;10.1073/pnas.96.5.2227;;10051623;;pmc26765;;11073097;;10.1002/pro.575;;pmc3048427;;21280133;;10.1038/nrc1589;;15803153;;10781408;;10.1016/s0952-7915(00)00087-x;;10.1139/cjpp-77-2-79;;10535697;;10.1139/y99-005;;10.1016/s0515-3700(09)70422-7;;10.1016/0378-5173(88)90220-7;;10.1016/0378-5173(87)90012-3;;10.1093/jnci/djp079;;pmc2684552;;19436029;;7538439;;10.1016/1074-7613(95)90026-8;;11749647;;10.1021/jo0108865;;15323564;;10.1021/bi049428r;;10.1016/s1074-5521(99)80118-5;;10467133;;10.1200/jco.2005.05.012;;16155019;;22394077;;10.1021/jm300035p;;15180535;;10.2174/1381612043384538;;18548107;;10.1038/leu.2008.126;;10.1007/s11864-014-0274-8;;24481980;;10.1038/nsb864;;12402030;;15117762;;10.1182/blood-2004-01-0207;;10.1634/theoncologist.9-4-422;;15266096;;10.4088/pcc.v05n0202;;pmc353039;;15156233;;10.1016/0016-5085(94)90599-1;;7507873;;12538485;;14634110;;10.4049/jimmunol.171.11.5988;;10.1182/blood-2004-07-2708;;15331445;;10.1016/j.addr.2003.10.020;;14962582;;10.1038/nri955;;12461567;;pmc26764;;10.1073/pnas.96.5.2221;;10051622;;pmc2833438;;15180891;;16000584;;10.1158/1078-0432.ccr-04-2352;;10.1002/cmdc.200600221;;17154430;;12506163;;10.1200/jco.2003.05.128;;10.1186/1750-1172-2-6;;pmc1794406;;17244349;;10.3324/haematol.2009.013359;;19880776;;pmc2770958;;10.1182/blood-2011-10-386417;;22180443;;pmc4916557;;12475205;;10.1021/jm0600141.s001;;10.1021/cr010182v;;21603517;;pmc3096390;;9778529;;10.1016/s0960-9822(98)70471-3;;16170032;;10.1158/1535-7163.mct-05-0082;;pmc1343495;;14746532;;10.1146/annurev.med.55.091902.104249;;10.1016/j.addr.2003.10.011;;14962589;;10.1093/annonc/mdq276;;20943636;;10.2174/092986712803833371;;22830347;;10.1517/13543784.2012.685650;;22612424;;10.2174/1566524033361618;;12558077;;10.1016/s0952-7915(00)00088-1;;10781397;;10.1039/9781849735346-00297;;22927247;;10.1182/blood-2012-05-431783;;12461565;;10.1038/nri953;;25158606;;10.1586/17474086.2014.951323;;10.1016/b978-0-08-057123-2.50012-0;;10.1002/jps.2600640203;;1127579;;21115978;;pmc3318778;;10.1182/blood-2010-09-307249;;10.1021/jm990482t;;10753475;;10.1021/jm9806603;;10346932;;11340625;;10.1002/bies.1062;;10.1038/nrd1109;;12776222;;16178558;;10.1021/ol0516869;;10.1097/coh.0b013e32833ed177;;20978388;;pmc3078627;;10.3109/10428190109057962;;11342365;;10.1021/jm970124v;;9357527;;9751072;;10.1016/s0006-2952(98)00122-1;;10.1517/13543776.2010.517750;;20831363;;8688094;;10.1126/science.273.5278.1096;;12006542;;10.1074/jbc.274.3.1646;;9880544;;15180538;;10.2174/1381612043384475;;10.1016/s0169-409x(01)00097-7;;11325474;;22615102;;10.1002/ajh.23176;;pmc4513941;;23782157;;10.1056/nejmoa1306220;;10.1517/14728214.5.3.287;;10.1007/s00277-012-1534-y;;22926531;;19805688;;10.1200/jco.2008.21.1169;;24869598;;10.1056/nejmoa1400029;;pmc4144824;;12766258;;10.1124/jpet.103.052316;;18596745;;10.1038/leu.2008.163;;10.1158/1538-7445.am2012-2021;;10.1002/cncr.25005;;pmc2861142;;20166206;;10873099;;10.1021/acs.cgd.7b00047;;18061887;;10.1016/j.drudis.2007.09.005,"ACS 2015 (http://www.cancer.org/cancer/non-hodgkinlymphoma/detailedguide/non-hodgkin-lymphoma-types-of-non-hodgkinlymphoma).;;Advani et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 28(15 Supp):8012 (2010).;;Advani et al., “The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study,” Ann Oncol, 22(Supp 4):abstract 153 (2011).;;Advani, R. H., et al., 2013, “Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) ha significant activity in patients with relapsed/refractory B-cell malignancies”, Journal of Clinical Oncology, vol. 31, No. 1 ,pp. 88-94.;;Agathocleous et al. Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia. Blood (ASH Annual Meeting Abstracts) 110:Abstract 2559 (2007).;;Agency for Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005).;;Ahn et al. Michael acceptors as a tool for anticancer drug design. Current Pharmaceutical Design 2(3):247-262 (1996).;;Apsel et al. Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases. Nature Chem. Bio., 4(11):691-699 (2008).;;Arnold et al. Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1. Bioorg. Med. Chem. Ltrs. 10:2167-2170 (2000).;;Banker et al. Modern Pharmaceutics, 3ed., Marcel Dekker, New York 1996, p. 596.;;Bernstein, “Polymorphism—A Perspective,” Crystal Growth & Design, 11: 632-650 (2011).;;Bharate S.S., et al., “Incompatibilities of Pharmaceutical Excipients with Active Pharmaceutical Ingredients: A Comprehensive Review”, Journal of Excipients and Food Chemicals, 2010, vol. 1 (3), pp. 3-26.;;Biospace, Dec. 8, 2009, pharmacyclics, Inc. (PCYC) announces presentation of interim results from phase I trial of its first-in-human btk inhibitor PCI-32765.;;Brown et al., “Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL),” J Clin Oncol, 30(supp):abstract 8032 (2012); [online][retrieved on Jan. 14, 2016] Retrieved from the Internet: <http://meetinglibrary.asco.org/content/98841-114>.;;Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews/Drug Discovery 5:564-576 (Jul. 2006).;;Burchat et al. Pyrazolo[3,4-d]pyrimidines Containing an Extended 3-Substituent as Potent Inhibitors of Lck—a Selectivity Insight. Bioorg. Med. Chem. Ltrs. 12:1687-1690 (2002).;;Burger et al. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers, Leukemia 23:43-52 (2009).;;Burger et al. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and After BCR Stimulation. Blood 113(13):3050-3058 (2008).;;Burger. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 24(6):643-649 (Epub Sep. 6, 2012/Nov. 2012).;;Byrd et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clinical Oncology (Jul. 21, 2014) (pii: JCO.2014.55.8262).;;Byrd et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia, NEJM 369(1):32-42 (Jul. 4, 2013).;;Byrd J.C., et al., “Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib”, Blood, Apr. 16, 2015, vol. 125 (16), pp. 2497-2506.;;Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12: 945-954 (1995).;;Calderwood et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lcks,” Bioorg Med Chem Lett, 12: 1683-1686 (2002).;;Cameron F., et al., “Ibrutinib: first global approval,” Drugs, Feb. 2014, vol. 74 (2), pp. 263-271.;;Cannon. Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, Wiley-Interscience 1995, pp. 783-802.;;Carmi et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. (Epub Aug. 4, 2012) 84(11):1388-1399 (Dec. 2012).;;Carrle et al. Current Strategies of Chemotherapy in Osteosarcoma. International Orthopaedics 30:445-451 (2006).;;Certified Translation of CN103121999A, dated Sep. 29, 2016.;;Certified Translation of CN103923084A, dated Sep. 29, 2016.;;Certified Translation of CN103923084B, dated Sep. 29, 2016.;;Certified Translation of CN104523695A, dated Nov. 14, 2016.;;Chang et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor inbrutinib in mantel cell lymphoma patients. Blood, 122:2412-2424 (2013).;;Chang et al., “PCI-45292, a novel Btk inhibitor with optimized pharmaceutical properties, demonstrates potent activities in rodent models of arthritis,” ACR/ARHP Scientific Meeting, Poster #286 (2010).;;Chang et al., “The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells,” Arhtritis Res Ther, 13:R115 (2011).;;Chavez et al. Ibrutinib: An Evidence-Based Review of Its Potential in the Treatment of Advanced Chronic Lymphocytic Leukemia. Core Evidence 8:37-45 (2013).;;Chen et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111(4):2230-2237 (2008) [E-pub Nov. 15, 2007].;;Ciric et al., “Clonal Evolution in Waldenstrom macroglobulinemia Highlights Functional Role of B-Cell Receptor,” Blood, 97: 321-323 (2001).;;Cohen et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors. Science 308:1318-1321 (May 27, 2005).;;Czuczman et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. 23(4):694-704 (Feb. 1, 2005).;;D'Cruz et al. Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy 6:161-176 (2013).;;Dana-Farber Cancer Institute. A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Sep. 23, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02251548?term=NCT02251548 NLM Identifier: NCT02251548.;;Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 17, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01614821 NLM Identifier: NCT01614821.;;Davids et al. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Leuk. Lymphoma (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).;;Davis et al., “Chronic active B-cell receptor signalling in diffuse large B-cell lymphoma,” Nature, 463(7277):88-92 (2010).;;Desiderio. Role of Btk in B cell development and signaling. Curr. Op. in Immunology 1997, 9:534-540.;;Devos et al., “The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapsed/refractory (RR) DLBCL: interim phase 2 results,” Haematologica 98(s1):490 (2013).;;Dias et al. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition. Cardiovascular & Hematological Agents in Medicinal Chemistry 11:265-271 (2013).;;Dorwald, F.Z., “Side Reactions in Organic Synthesis,” Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & C KGaA (2005).;;EA200901313 Notification of Office Action dated Oct. 31, 2011.;;EA201000599 Search Report dated Nov. 15, 2010.;;Edwards. BTK inhibition in myeloma: targeting the seed and the soil. Blood 120(9):1757-1759 (Aug. 2012).;;EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.;;EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.;;EP 08744513.6 Examination Report dated Jan. 16, 2013.;;EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.;;EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.;;EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.;;EP 10823966 Supplementary European Search Report dated Oct. 17, 2011.;;EP 10823966.6 Search Report dated Oct. 17, 2011.;;EP 10823966.6 Written Opinion dated Dec. 6, 2011.;;EP 12151943.3 Examination Report dated Feb. 5, 2013.;;EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.;;EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.;;EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.;;EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166305.8 Examination Report dated Dec. 3, 2013.;;EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.;;EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.;;EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.;;EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.;;EP 12172842.2 Extended Search Report dated May 14, 2013.;;EP 12172842.2 Partial Search Report dated Jan. 24, 2013.;;EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.;;EP06850039 Supplemental Search Report dated Feb. 15, 2010.;;EP06850039 Supplemental Search Report dated Feb. 9, 2010.;;EP11790524.0 Extended European Search Report dated Oct. 9, 2013.;;EP12172840.6 Office Action dated Jun. 12, 2014.;;EP12172841.4 Office action dated Jun. 12, 2014.;;EP12172842.2 Office Action dated Jul. 1, 2014.;;EP12172843.0 Office action dated Jul. 1, 2014.;;EP15170739.5 Extended European Search Report, dated Nov. 10, 2015.;;Fabian et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 23(3): 329-336 (2005).;;FDA, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Federal Register of Nov. 25, 1997, draft of “Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.” endorsed final guidance Oct. 6, 1999.;;Federal Drug Adminstration, Draft Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism at 3 (Dec. 2004).;;Fedorak et al. A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. Am. J. Physiol. 269:G210-218 (1995).;;Fisher et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann. Intern. Med., 90(5):761-763 (1979).;;Fowler et al., “The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma,” 54th American Society of Hematology Annual Meeting and Exposition, Abstract 156 (2012).;;Friedberg et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13):2578-2585 (2010) [E-pub Nov. 17, 2009].;;Fruman. Xid-like Phenotypes: A B Cell Signalosome Takes Shape. Immunity 13:1-3 (Jul. 2000).;;Fry et al., “Specific Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor,” Proc Natl Acad Sci, 95: 12022-12027 (1998).;;Gazitt et al. Differential mobilization of CD34+ Cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors, J of Hematotherapy & Stem Cell Research 10:167-176 (2001).;;Ghia. Ibrutinib: better combined with other drugs? Lancet 15:1043-1044 (2014).;;Giuliani. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood (Epub Aug. 17, 2006) 108(13):3992-3996 (2006).;;Glassman et al., “The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia,” Cancer Genet Cytogen, 158:88-91 (2005).;;Gold. To make antibodies or not:signaling by the B-cell antigen receptor. Trends in Pharmacological Sciences, 23(7):316-324 (Jul. 2002).;;Gordon et al. Somatic hypermutation of the B cell receptor genes B29 (Igb, CD79b) and mb1 (Iga, CD79a). PNAS 100(7):4126-4131 (2003).;;Groshock et al. Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Res. 70:3677-3686 (2010).;;Gu et al., “Polymorph Screening: Influence of Solvent on the Rate of Solvent-Mediated Polymorphic Transformation,” Journal of Pharmaceutical Sciences 90, 11: 1878-1890 (2001).;;Hagemeister. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 70(3):261-272 (2010).;;Haleblian and McCrone,“Pharmaceutical Applications of Polymorphism,” 58(8): 911-929 (1969).;;Hantschel et al. The Btk Tyrosine Kinase is a Major Target of the Bcr-Ab1 Inhibitor Dasatinib. PNAS 104(33):13283-13288 (2007).;;Hata et al. Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells. J. Biol. Chem. 273(18): 10979-10987 (1998).;;Herman et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (Epub Mar. 21, 2011), 117(23):6287-6296 (Jun. 2011).;;Hiddeman et al. Rituximab Plus Chemotherapy in Follicular and Mantle Cell Lymphomas, Seminars in Oncology 30(1)Suppl.2:16-20 (Feb. 2003).;;Hiddeman et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group,” Blood, 106(12):3725-32 (2005).;;Higuchi et al. Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (1975).;;Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed. Chrom., 6:283-286 (1992).;;Honigberg et al. Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo. ASH Annual Meeting Abstracts 1592. 110(11): 475A (2007).;;Honigberg et al., “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-Cell Activation and is Efficacious in Models of Autoimmune Disease and B-Cell Malignancy,” PNAS USA, 107: 13075-13080 (2010).;;Horwood et al. Bruton's Tyrosine Kinase Is Required for Lipopolysaccharide-induced Tumor Necrosis Factor α Production. J. Exp. Med. 197(12):1603-1611 (Jun. 2003).;;http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7, last accessed Feb. 16, 2011.;;Huhn et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331 (Sep. 1, 2001).;;International Search Report and Written Opinion for Application No. PCT/US2016/020467, dated May 23, 2016, 10 pages.;;International Search Report for International Application No. PCT/US2006/049626 dated Apr. 9, 2008.;;International Search Report for International Application No. PCT/US2009/050897 dated Mar. 15, 2010.;;International Search Report for International Application No. PCT/US2016/024305 dated Jun. 27, 2016.;;International Search Report for International Application No. PCT/US2016/024321 dated Jun. 28, 2016.;;Iqbal et al., on pp. 2-4 (Molecular Biology International, 2014, Article ID 852748, 9 pages.;;Iwaki et al. Btk Plays a Crucial Role in the Amplification of FceRI-mediated Mast Cell Activation by Kit. J. Biol. Chem. 280(48):40261-40270 (Dec. 2, 2005).;;Jaffe. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 1:523-531 (2009).;;Janssen Biotech, Inc. An open label treatment use protocol for ibrutinib in subjects with relapsed or refractory mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Apr. 6, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01833039 NLM Identifier: NCT01833039.;;Janssen Pharmaceutical K.K. A study to evaluate the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01704963 NLM Identifier: NCT01704963.;;Janssen Pharmaceutical K.K. Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 19, 2014—[cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02169180?term=NCT02169180 NLM Identifier: NCT02169180.;;Janssen Research & Development, LLC. A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 20, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02271438?term=NCT02271438 NLM Identifier: NCT02271438.;;Janssen Research & Development, LLC. Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 30, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02329847?term=NCT02329847 NLM Identifier: NCT02329847.;;Janssen Research and Development, LLC. A long-term extension study of PCI-32765 (Ibrutinib). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01804686 NLM Identifier: NCT01804686.;;Janssen Research and Development, LLC. A pharmacokinetic study in healthy participants to assess the pharmacokinetics and safety of a supratherapeutic dose of PCI-32765 (Ibrutinib) capsule and solution formulations administered with food. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 19, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01969266 NLM Identifier: NCT01969266.;;Janssen Research and Development, LLC. A study combining Ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with CD20-positive B-cell non Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 30, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01569750 NLM Identifier: NCT01569750.;;Janssen Research and Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 15, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090 NLM Identifier: NCT01611090.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01974440 NLM Identifier: NCT01974440.;;Janssen Research and Development, LLC. A study of PCI-32765 (Ibrutinib) in patients with refractory follicular lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01779791 NLM Identifier: NCT01779791.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantel cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 24, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01776840 NLM Identifier: NCT01776840.;;Janssen Research and Development, LLC. A study of the Bruton's tyrosine kinase inhibitor PCI-32765 (Ibrutinib) versus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 25, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01973387 NLM Identifier: NCT01973387.;;Janssen Research and Development, LLC. A study on the Bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01855750 NLM Identifier: NCT01855750.;;Janssen Research and Development, LLC. A study to assess the absolute bioavailability of Oral PCI-32765 and the effect of grapefruit juice on the bioavailability of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 28, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01866033 NLM Identifier: NCT01866033.;;Janssen Research and Development, LLC. A study to assess the effect of ketoconazole on the pharmacokinetics of ibrutinib in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01626651 NLM Identifier: NCT01626651.;;Janssen Research and Development, LLC. A study to assess the effect of rifampin on the pharmacokinetics of PCI-32765 in healthy participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01763021 NLM Identifier: NCT01763021.;;Janssen Research and Development, LLC. A study to determine the absorption, metabolism, and routes of excretion of (14C) radiolabeled ibrutinib in healthy male participants. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Aug. 9, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674322 NLM Identifier: NCT01674322.;;Janssen Research and Development, LLC. A study to determine the effect of food on the pharmacokinetics of PCI-32765. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Mar. 4, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01820936 NLM Identifier: NCT01820936.;;Janssen Research and Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantel cell lymphoma who progress after bortezomib therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). May 14, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01599949 NLM Identifier: NCT01599949.;;Janssen Research and Development, LLC. A study to evaluate the pharmacokinetics of PCI-32765 in participants with varying degrees of hepatic impairment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 9, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01767948 NLM Identifier: NCT01767948.;;Janssen Research and Development, LLC. Study of ibrutinib (a Bruton's tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantel cell lymphoma who have received at least one prior therapy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jul. 18, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01646021 NLM Identifier: NCT01646021.;;Jefferies et al., “Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kB activation by toll-like receptor 4,” J Biol Chem, 278:26258-64 (2003).;;Kamb. What's wrong with our cancer models? Nature Reviews Drug Discovery 4:161-165 (2005).;;Kawakami et al. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. PNAS USA 96:2227-2232 (1999).;;Korade-Mirnics et al. Src kinase-mediated signaling in leukocytes. J. Leukoc. Bio., 68(5):603-613 (Nov. 2000).;;Kozaki et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor—ONO-WG-307, a potential treatment for B-cell malignancies. 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).;;Kuglstatter et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Science 20(2):428-436 (2011) [E-pub Dec. 17, 2010].;;Kuppers. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews/Cancer 5:251-262 (2005).;;Kurosaki. Functional dissection of BCR signaling pathways. Curr. Op. Imm. 12:276-281 (2000).;;Kushner et al. Pharmacological uses and perspective of heavy water and deuterated compounds. Canadian Journal of Physiology and Pharmacology 77(2):79-88 (1999).;;Label for TASIGNA® (nilotinib), revised Aug. 2009.;;Larsen et al., “Prodrug Forms for the Sulfonamide Group. II. Water-soluble Amino Acid Derivatives of N-methylsulfonamides as Possible Prodrugs,” Int J Pharmaceutics, 47: 103-110 (1988).;;Larsen et al.Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivatives, N-sulfonylamindes, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharmaceutics 37:87-95 (1987).;;Le Tourneau et al. Dose Escalation Methods in Phase I Cancer Clinical Trials. J. Natl Cancer 101:708-720 (2009).;;Li et al. Activation of Bruton's Tyrosine Kinase (BTK) by a Point Mutation in its Pleckstrin Homology (PH) domain. Immunity 2:451-460 (1995).;;Lim et al. Asymmetric syntheses of fused bicyclic lactams. Journal of Organic chemistry 66(26):9056-9062 (2001).;;Lin et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation, Biochemistry 43:11056-11062 (2004).;;Liu et al. Structural Basis for selective inhibition of Src family kinases by PPI. Chemistry and Biology 6:671-678, in particular table 1, p. 671 (1999).;;Lossos. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 23(26):6351-6357 (Sep. 10, 2005).;;Lou et al. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. May 24, 2012;55(10):4539-50 Publication Date (Web): Mar. 6, 2012.;;Luskova et al. Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases. Curr. Pharmaceutical Design 10:1727-1737 (2004).;;M.D. Anderson Cancer Center. A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 17, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02321540?term=NCT02321540 NLM Identifier: NCT02321540.;;M.D. Anderson Cancer Center. A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 16, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02269085?term=NCT02269085 NLM Identifier: NCT02269085.;;M.D. Anderson Cancer Center. Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Oct. 21, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02272686?term=NCT02272686 NLM Identifier: NCT02272686.;;M.D. Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab (i vs iR) in patients with relapsed chronic lymphocytic leukemia (CLL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 5, 2013—[cited Apr. 15, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT02007044 NLM Identifier: NCT02007044.;;M.D. Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed/refractory mantel cell lymphoma (R/R MCL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jun. 14, 2013—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01880567 NLM Identifier: NCT01880567.;;M.D. Anderson Cancer Center. Phase 2 study of the combination of Bruton's tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Jan. 25, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01520519 NLM Identifier: NCT01520519.;;M.D. Anderson Cancer Center. Pilot study to determine effects of the Btk inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using heavy water labeling in subjects with CLL and SLL. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 13, 2012—[cited Nov. 22, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01752426 NLM Identifier: NCT01752426.;;MacPartlin et al. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22:1354-1360 (2008).;;Maddocks et al. Ibrutinib in B-cell lymphomas. Current Treatment Options in Oncology 15:226-237 (2014) (Epub: Feb. 1, 2014).;;Mahajan et al. Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [a-Cyano-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]. J. of Biol. Chem. 274(14):9587-9599 (1999).;;Mallis et al. Structural characterization of a proline-driven conformational switch within the Itk SH2 domain. Nat. Struct. Biol., 9(12):900-905 (2002).;;Mangla et al., “Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses,” Blood, 104(4):1191-1197 (2004).;;Marina et al. Biology and Therapeutic Advances for Pediatric Osteosarcoma. The Oncologist 9:422-441 (2004).;;McConathy et al. Stereochemistry in Drug Action. J Clinical Psychiatry. 5:70-73 (2003).;;McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterol, 106:405-413 (1994).;;Memorial Sloan-Kettering Cancer Center. Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Dec. 9, 2014 [cited Feb. 5, 2015] Available from: https://clinicaltrial.gov/ct2/show/NCT02315326?term=NCT02315326 NLM Identifier: NCT02315326. et al.",ACTIVE
857,WO,A3,WO 2003/042851 A3,126-362-703-956-840,2003-10-09,2003,US 0234926 W,2002-10-31,US 99083101 A,2001-11-09,"DISPLAY, INPUT AND FORM FACTOR FOR PORTABLE INSTRUMENTS","A compact appliance providing high resolution display capability in an ergonomically designed package. Subassemblies of the device are mechanically coupled to avoid interference between a user's hands and face while the device is used, while concurrently providing ergonomically located control for substantially all functions of the device.",SYNERDYNE,KNIGHTON MARK S;;GOLDMAN MARC;;AGABRA DAVID S;;DROBNIS DAVID D;;HAYNIE JILL E,,https://lens.org/126-362-703-956-840,Search Report,yes,2,0,4,4,0,H04N23/531;;H04N23/661;;H04N23/632;;H04N23/531;;H04N23/632;;H04N23/661,H04N5/225;;H04N5/232,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 1999, no. 04 30 April 1999 (1999-04-30)",PENDING
858,US,A1,US 2002/0109038 A1,021-453-373-150-663,2002-08-15,2002,US 78082801 A,2001-02-09,US 78082801 A,2001-02-09,INTERNAL FLUID COOLED WINDOW ASSEMBLY,"
   An interceptor missile including an infrared radiation detection subsystem and a window assembly in the hull of the missile optically coupled to the infrared radiation detection subsystem. The window assembly includes an inner window, an outer window, and a support subsystem between the inner and the outer windows defining a plurality of infrared transparent fluid flow cooling channels between the inner and outer windows. A source of fluid coupled to the cooling channels for cooling the outer window without adversely affecting the optical properties of either window. 
",GOLDMAN LEE M.;;COLLINS STEVEN R.;;JAMES DAVID B.;;BLANCHARD DAVID M.;;WIRTH STEVEN,GOLDMAN LEE M;;COLLINS STEVEN R;;JAMES DAVID B;;BLANCHARD DAVID M;;WIRTH STEVEN,RAYTHEON COMPANY (2000-12-18),https://lens.org/021-453-373-150-663,Patent Application,yes,0,8,2,2,0,F41G7/2253;;F41G7/2293;;F42B15/01;;F42B15/34;;F41G7/2293;;F42B15/01;;F41G7/2253;;F42B15/34,F41G7/22;;F42B15/01;;F42B15/34,244/3.16,0,0,,,,EXPIRED
859,US,B2,US 6530539 B2,063-272-166-675-361,2003-03-11,2003,US 78082801 A,2001-02-09,US 78082801 A,2001-02-09,Internal fluid cooled window assembly,"
    An interceptor missile including an infrared radiation detection subsystem and a window assembly in the hull of the missile optically coupled to the infrared radiation detection subsystem. The window assembly includes an inner window, an outer window, and a support subsystem between the inner and the outer windows defining a plurality of infrared transparent fluid flow cooling channels between the inner and outer windows. A source of fluid coupled to the cooling channels for cooling the outer window without adversely affecting the optical properties of either window. 
",RAYTHEON CO,GOLDMAN LEE M;;COLLINS STEVEN R;;JAMES DAVID B;;BLANCHARD DAVID M;;WIRTH STEVEN,RAYTHEON COMPANY (2000-12-18),https://lens.org/063-272-166-675-361,Granted Patent,yes,12,17,2,2,0,F41G7/2253;;F41G7/2293;;F42B15/01;;F42B15/34;;F41G7/2293;;F42B15/01;;F41G7/2253;;F42B15/34,F41G7/22;;F42B15/01;;F42B15/34,244/3.16;;244/3.15;;359/845;;359/894;;313/17;;313/22,0,0,,,,EXPIRED
860,US,B1,US 7359003 B1,144-379-610-656-981,2008-04-15,2008,US 99083101 A,2001-11-09,US 99083101 A,2001-11-09,"Display, input and form factor for portable instruments","A compact appliance providing high resolution display capability in an ergonomically designed package. Subassemblies of the device are mechanically coupled to avoid interference between a user's hands and face while the device is used, while concurrently providing ergonomically located control for substantially all functions of the device.",SYNERDYNE CORP,KNIGHTON MARK S;;GOLDMAN MARC;;AGABRA DAVID S;;DROBNIS DAVID D;;HAYNIE JILL E,SYNERDYNE (2001-11-08),https://lens.org/144-379-610-656-981,Granted Patent,yes,17,28,4,4,0,H04N23/531;;H04N23/661;;H04N23/632;;H04N23/531;;H04N23/632;;H04N23/661,H04N5/225;;H04N5/232,348/376;;348/373;;348/375,1,0,,,"Shimadzu Corp., Patent Abstracts of Japan, vol. 1999, No. 04, Apr. 30, 1999.",EXPIRED
861,AU,A1,AU 2002/350086 A1,075-711-584-087-420,2003-05-26,2003,AU 2002/350086 A,2002-10-31,US 99083101 A;;US 0234926 W,2001-11-09,"Display, input and form factor for portable instruments",,SYNERDYNE,KNIGHTON MARK S;;AGABRA DAVID S;;HAYNIE JILL E;;GOLDMAN MARC;;DROBNIS DAVID D,,https://lens.org/075-711-584-087-420,Patent Application,no,0,0,4,4,0,H04N23/531;;H04N23/661;;H04N23/632;;H04N23/531;;H04N23/632;;H04N23/661,H04N5/225;;H04N5/232,,0,0,,,,DISCONTINUED
862,WO,A2,WO 2003/042851 A2,174-209-970-145-671,2003-05-22,2003,US 0234926 W,2002-10-31,US 99083101 A,2001-11-09,"DISPLAY, INPUT AND FORM FACTOR FOR PORTABLE INSTRUMENTS","A compact appliance providing high resolution display capability in an ergonomically designed package. Subassemblies of the device are mechanically coupled to avoid interference between a user's hands and face while the device is used, while concurrently providing ergonomically located control for substantially all functions of the device.",SYNERDYNE,KNIGHTON MARK S;;GOLDMAN MARC;;AGABRA DAVID S;;DROBNIS DAVID D;;HAYNIE JILL E,,https://lens.org/174-209-970-145-671,Patent Application,yes,0,0,4,4,0,H04N23/531;;H04N23/661;;H04N23/632;;H04N23/531;;H04N23/632;;H04N23/661,H04N5/225;;H04N5/232,,0,0,,,,PENDING
863,WO,A1,WO 2013/158153 A1,018-325-796-763-002,2013-10-24,2013,US 2012/0069912 W,2012-12-14,US 201261625836 P,2012-04-18,SYSTEMS AND METHODS FOR PRIORITIZING LOCAL SHOPPING OPTIONS,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W,,https://lens.org/018-325-796-763-002,Patent Application,yes,3,4,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,H04W4/02;;G06Q30/00;;H04W4/024;;H04W4/029,,0,0,,,,PENDING
864,US,A1,US 2005/0177118 A1,088-194-899-395-769,2005-08-11,2005,US 5687905 A,2005-02-12,US 5687905 A;;US 83026704 A;;US 19996102 A;;US 20660498 A;;US 24255794 A;;US 38619101 P,1994-05-13,Resorbable polymeric device for localized drug delivery,"An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. A preferred embodiment includes a cartilage region comprising a polyelectrolytic complex joined with a subchondral bone region. The cartilage region, of this embodiment, enhances the environment for chondrocytes to grow articular cartilage; while the subchondral bone region enhances the environment for cells which migrate into that region's macrostructure and which differentiate into osteoblasts. Another embodiment is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.",HOGANSON DAVID M.;;BRADICA GINO;;GOLDMAN SCOTT M.;;BREKKE JOHN H.,HOGANSON DAVID M;;BRADICA GINO;;GOLDMAN SCOTT M;;BREKKE JOHN H,KENSEY NASH CORPORATION (2005-08-15),https://lens.org/088-194-899-395-769,Patent Application,yes,62,105,2,38,0,A61L27/3839;;A61L27/3839;;A61K35/16;;A61K35/16;;A61K35/28;;A61K35/28;;A61K38/15;;A61K38/15;;A61L27/3641;;A61L27/507;;A61L27/58;;A61L27/58;;A61L2430/20,A61K35/16;;A61K35/28;;A61K38/15;;A61L27/38;;A61L27/58,604/288.01;;623/1.42;;424/424,0,0,,,,EXPIRED
865,US,B2,US 9117238 B2,151-757-402-172-359,2015-08-25,2015,US 201213686195 A,2012-11-27,US 201213686195 A;;US 201261625836 P,2012-04-18,"Method, system, and medium for generating a mobile interface indicating traffic level for local merchants","Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W;;EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/151-757-402-172-359,Granted Patent,yes,12,8,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/00;;G01C21/20;;G01C21/34;;G06Q30/06;;H04W4/02;;H04W4/024;;H04W4/029,,4,0,,,"""Ford's Sync Destinations App Plans Your Route Before You Get in the Car"". Dec. 29, 2010. Devin Coldewey.;;""International Application Serial No. PCT/US2012/069912, International Search Report mailed Feb. 8, 2013"", 2 pgs.;;""International Application Serial No. PCT/US2012/069912, Written Opinion mailed Feb. 8, 2013"", 5 pgs.;;""International Application Serial No. PCT/US2012/069912, International Preliminary Report on Patentability mailed Oct. 30, 2014"", 7 pgs.",INACTIVE
866,EP,A1,EP 3662271 A1,188-636-325-203-175,2020-06-10,2020,EP 18841659 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,,SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/188-636-325-203-175,Patent Application,yes,0,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G06N3/02;;G01N21/84;;G06T7/00,,0,0,,,,ACTIVE
867,US,A1,US 2003/0170859 A1,032-624-458-586-91X,2003-09-11,2003,US 36937803 A,2003-02-19,US 36937803 A;;US 59624800 A;;US 13954399 P,1999-06-16,Human poly (ADP-ribose) polymerase 2 materials and methods,"
   The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided. 
",CHRISTENSON ERIK;;DEMAGGIO ANTHONY J.;;GOLDMAN PHYLLIS S.;;MCELLIGOTT DAVID L.,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/032-624-458-586-91X,Patent Application,yes,25,6,12,12,68,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;G01N33/50;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,435/199;;435/6;;435/69.1;;435/320.1;;435/325;;536/23.2,0,0,,,,EXPIRED
868,PL,T3,PL 3662271 T3,061-322-793-054-513,2024-02-19,2024,PL 18841659 T,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,,SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/061-322-793-054-513,Patent Application,no,0,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G01N21/31;;G01N21/35;;G01N21/65;;G06N3/02;;G06N3/04;;G06N3/045;;G06N3/08;;G06N3/084;;G06T7/00,,0,0,,,,PENDING
869,US,A1,US 2003/0190739 A1,072-957-284-347-607,2003-10-09,2003,US 19993702 A,2002-07-22,US 19993702 A;;US 60603500 A;;US 14158299 P,1999-06-29,Tankyrase2 materials and methods,"
   The invention provides novel tankyrase polypeptides designated tankyrase2, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the tankyrase2 polypeptides, antibodies that are immunoreactive with the tankyrase2 polypeptides. In addition, there are provided methods for identifying specific binding partners of tankyrase2, and more particularly methods for identifying binding partners that modulate biological activity of tankyrase2. Methods of modulating biological activity of tankyrase2 in vitro and in vivo are also provided. 
",CHRISTENSON ERIK;;DEMAGGIO ANTHONY J.;;GOLDMAN PHYLLIS S.;;MCELLIGOTT DAVID L.,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/072-957-284-347-607,Patent Application,yes,1,1,8,8,178,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P35/00;;A61P35/02;;C12N9/10;;C12Y204/0203;;C12N9/1077;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P35/00;;A61P35/02;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/00;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/25;;G01N33/15;;G01N33/53;;G01N33/566,435/226;;435/69.1;;435/6;;435/320.1;;435/325;;536/23.2,0,0,,,,DISCONTINUED
870,US,A1,US 2021/0133538 A1,020-658-037-850-313,2021-05-06,2021,US 201816635633 A,2018-07-31,US 201816635633 A;;US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,SMITHS DETECTION INC (2020-01-08),https://lens.org/020-658-037-850-313,Patent Application,yes,0,5,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G06N3/04;;G06N3/08;;H01J49/00;;H01J49/02,,0,0,,,,ACTIVE
871,AU,A,AU 2000/057439 A,033-103-823-905-919,2001-01-02,2001,AU 2000/057439 A,2000-06-16,US 13954399 P;;US 0016629 W,1999-06-16,Human poly(adp-ribose) polymerase 2 materials and methods,,ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/033-103-823-905-919,Patent Application,no,0,0,12,12,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,0,0,,,,EXPIRED
872,US,B2,US 11379709 B2,075-185-225-866-476,2022-07-05,2022,US 201816635633 A,2018-07-31,US 201816635633 A;;US 201762539167 P;;US 2018/0044574 W,2017-07-31,System for determining the presence of a substance of interest in a sample,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,SMITHS DETECTION INC (2020-01-08),https://lens.org/075-185-225-866-476,Granted Patent,yes,10,1,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G06N3/04;;G06N3/08;;H01J49/00;;H01J49/02,,4,2,006-885-964-534-912;;024-132-705-961-908,10.1109/lpt.2015.2465132;;10.1109/tgrs.2017.2693346,"Dutta, Sibasish, et al., “Dye-Assisted pH Sensing Using aSmartphone,” IEEE Photonics Technology Letters, vol. 27, No. 22, Nov. 15, 2015, pp. 2363-2366.;;Mei, Shaohui, et al., Learning Sensor-Specific Spatial-Spectral Features of Hyperspectral Images via Convolutional Neural Networks, IEEE Transactions on Geoscience and Remote Sensing, vol. 55, No. 8, Aug. 2017, pp. 4520-4533.;;Extended Search Report for European Application No. 18841659.8, dated Mar. 12, 2021.;;International Search Report and the Written Opinion for Application No. PCT/US2018/0445/4, dated Nov. 16, 2018, 13 Pages.",ACTIVE
873,CA,C,CA 2034458 C,131-038-927-051-051,2000-10-24,2000,CA 2034458 A,1991-01-17,US 49877790 A,1990-03-23,MOLDED CASE CIRCUIT BREAKER CONTACT AND CONTACT ARM ARRANGEMENT,A molded case circuit breaker movable contact arm electrically connects with the circuit breaker load terminal requiring only a small diameter auxiliary electrical conducting braid by pivotally arranging the contact arm within its support. The contact arm is nickel-plated prior to attachment of the contact to insure high current circuit interruption without damage to the contact or the contact arm.,GEN ELECTRIC,BELLINO JOSEPH PAUL;;O'BRIEN DEXTER THOMAS;;GOLDMAN IRA BERNARD;;ARNOLD DAVID,,https://lens.org/131-038-927-051-051,Granted Patent,no,0,0,3,3,0,H01H1/023;;H01H1/5822;;H01H1/5833;;H01H11/045;;H01H1/023;;H01H11/045;;H01H1/5833;;H01H1/5822,H01H1/023;;H01H1/58;;H01H11/04,,0,0,,,,EXPIRED
874,US,A1,US 2021/0334885 A1,079-681-680-145-898,2021-10-28,2021,US 202117317933 A,2021-05-12,US 202117317933 A;;US 201815970112 A;;US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,SYSTEMS AND METHODS FOR PRIORITIZING LOCAL SHOPPING OPTIONS,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATTHEW LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/079-681-680-145-898,Patent Application,yes,5,0,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/06;;G01C21/20;;G01C21/34;;H04W4/02;;H04W4/024;;H04W4/029,,0,0,,,,ACTIVE
875,CA,A1,CA 3070850 A1,101-806-424-401-938,2019-02-07,2019,CA 3070850 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/101-806-424-401-938,Patent Application,no,0,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G06N3/02;;G06T7/00,,0,0,,,,PENDING
876,EP,A4,EP 3662271 A4,151-789-188-324-820,2021-04-14,2021,EP 18841659 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,,SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/151-789-188-324-820,Search Report,no,5,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G01N21/31;;G01N21/35;;G01N21/65;;G06N3/02;;G06N3/04;;G06N3/08;;G06T7/00,,3,2,024-132-705-961-908;;006-885-964-534-912,10.1109/tgrs.2017.2693346;;10.1109/lpt.2015.2465132,"MEI SHAOHUI ET AL: ""Learning Sensor-Specific Spatial-Spectral Features of Hyperspectral Images via Convolutional Neural Networks"", IEEE TRANSACTIONS ON GEOSCIENCE AND REMOTE SENSING, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 55, no. 8, 20 July 2017 (2017-07-20) - 20 July 2017 (2017-07-20), pages 4520 - 4533, XP011657296, ISSN: 0196-2892, [retrieved on 20170720], DOI: 10.1109/TGRS.2017.2693346;;DUTTA SIBASISH ET AL: ""Dye-Assisted pH Sensing Using a Smartphone"", IEEE PHOTONICS TECHNOLOGY LETTERS, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 27, no. 22, 15 November 2015 (2015-11-15), pages 2363 - 2366, XP011670549, ISSN: 1041-1135, [retrieved on 20150930], DOI: 10.1109/LPT.2015.2465132;;See also references of WO 2019028004A1",ACTIVE
877,US,A1,US 2013/0282520 A1,172-711-078-087-782,2013-10-24,2013,US 201213686195 A,2012-11-27,US 201213686195 A;;US 201261625836 P,2012-04-18,SYSTEMS AND METHODS FOR PRIORITIZING LOCAL SHOPPING OPTIONS,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W;;EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/172-711-078-087-782,Patent Application,yes,8,28,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,H04W4/02;;G06Q30/06;;H04W4/024;;H04W4/029,705/26.8,1,0,,,"""Ford's Sync Destinations App Plans Your Route Before You Get In The Car"". Dec 29, 2010. Devin Coldewey.",INACTIVE
878,NO,D0,NO 963100 D0,000-066-533-584-128,1996-07-25,1996,NO 963100 A,1996-07-25,US 52342295 A,1995-09-05,Vertikal-integrert sensor,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,,https://lens.org/000-066-533-584-128,Patent Application,no,0,0,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,0,0,,,,EXPIRED
879,NO,B1,NO 318404 B1,035-124-567-440-387,2005-03-14,2005,NO 963100 A,1996-07-25,US 52342295 A,1995-09-05,Vertikal-integrert sensor,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,,https://lens.org/035-124-567-440-387,Granted Patent,no,0,0,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,0,0,,,,EXPIRED
880,US,B2,US 11030676 B2,102-524-501-377-566,2021-06-08,2021,US 201815970112 A,2018-05-03,US 201815970112 A;;US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,Systems and methods for prioritizing local shopping options,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATTHEW LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/102-524-501-377-566,Granted Patent,yes,21,1,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/06;;G01C21/20;;G01C21/34;;H04W4/02;;H04W4/024;;H04W4/029,,22,0,,,"312 Amendment filed for U.S. Appl. No. 13/686,195, dated Jul. 15, 2015, 10 pages.;;Applicant Initiated Interview Summary Received for U.S. Appl. No. 13/686,195, dated Oct. 9, 2014, 3 pages.;;Devin, “Ford's Sync Destination App Plans Your Route Before You Get in the Car”, Dec. 29, 2010, 7 pages.;;Final Office Action received for U.S. Appl. No. 13/686,195, dated Nov. 25, 2014, 17 pages.;;Non-Final Office Action received for U.S. Appl. No. 13/686,195, dated Jul. 30, 2014, 16 pages.;;Notice of Allowance received for U.S. Appl. No. 13/686,195, dated Apr. 15, 2015, 17 pages.;;PTO Response to Rule 312 Communication for U.S. Appl. No. 13/686,195 dated Jul. 23, 2015, 2 pages.;;Response to Final Office Action filed on Feb. 24, 2015 for U.S. Appl. No. 13/686,195, dated Nov. 25, 2014, 20 pages.;;Response to Non-Final Office Action filed on Oct. 30, 2014 for U.S. Appl. No. 13/686,195, dated Jul. 30, 2014, 17 pages.;;International Preliminary Report on Patentability received for PCT Application No. PCT/US2012/069912, dated Oct. 30, 2014, 7 pages.;;International Search Report received for PCT Application No. PCT/US2012/069912, dated Feb. 8, 2013, 2 pages.;;Written Opinion received for PCT Application No. PCT/US2012/069912 dated Feb. 8, 2013, 5 pages.;;U.S. Appl. No. 13/686,195, filed Nov. 27, 2012, Issued.;;U.S. Appl. No. 14/806,505, filed Jul. 22, 2015, Issued.;;Applicant Initiated Interview Summary received for U.S. Appl. No. 14/806,505, dated Aug. 24, 2017, 4 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/806,505, dated Jul. 18, 2017, 13 pages.;;Notice of Allowance Received for U.S. Appl. No. 14/806,505, dated Mar. 13, 2018, 11 pages.;;Preliminary Amendment received for U.S. Appl. No. 14/806,505, filed on Nov. 6, 2015, 8 pages.;;Response to Non-Final Office Action filed on Dec. 18, 2017 for U.S. Appl. No. 14/806,505, dated Jul. 18, 2017, 16 pages.;;Applicant Initiated Interview Summary received for U.S. Appl. No. 13/686,195, dated Jan. 15, 2015, 3 pages.;;U.S. Appl. No. 13/686,195 U.S. Pat. No. 9,117,238, filed Nov. 27, 2012, Method, System, and Medium for Generating a Mobile Interface Indicating Traffic Level For Local Merchants (as amended).;;U.S. Appl. No. 14/806,505 U.S. Pat. No. 10,019,751, filed Jul. 22, 2015, Systems and Methods for Prioritizing Local Shopping Options.",ACTIVE
881,CA,A1,CA 2212762 A1,134-941-147-799-624,1998-03-18,1998,CA 2212762 A,1997-08-12,US 71597196 A,1996-09-18,PROGRAMMABLE RADIO SUBSCRIPTION SYSTEM FOR RECEIVING SELECTIVELY DEFINED INFORMATION,,AT & T CORP,GOLDMAN SHELLEY B;;STURM WALTER;;FOLADARE MARK JEFFREY;;SILVERMAN DAVID PHILLIP,,https://lens.org/134-941-147-799-624,Patent Application,no,0,0,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,,0,0,,,,EXPIRED
882,US,A,US 5600071 A,062-644-352-966-689,1997-02-04,1997,US 68472396 A,1996-07-22,US 68472396 A;;US 52342295 A,1995-09-05,Vertically integrated sensor structure and method,A vertically integrated sensor structure (60) includes a base substrate (71) and a cap substrate (72) bonded to the base substrate (71). The base substrate (71) includes a transducer (78) for sensing an environmental condition. The cap substrate (72) includes electronic devices (92) formed on one surface to process output signals from the transducer (78). The sensor structure (60) provides an integrated structure that isolates sensitive components from harsh environments.,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,FREESCALE SEMICONDUCTOR INC (2004-04-04),https://lens.org/062-644-352-966-689,Granted Patent,yes,13,142,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,73/721,3,1,015-244-319-739-057,10.1109/t-ed.1985.22099,"Motorola Sensor Device Data , 3rd Edition, 1995, pp. iii vi.;;Ljubisa Ristic, Sensor Technology and Devices , Artech House (Boston London), 1994, pp. vii xii, 386 390, 446 447.;;Tanigawa et al., Mos Integrated Silicon Pressure Sensor , Reprinted from IEEE Trans, Electron Devices, vol. ED 32, No. 7, pp. 1191 1195 (165 169), Jul. 1985.",EXPIRED
883,CA,A1,CA 2034458 A1,075-988-189-952-383,1991-09-24,1991,CA 2034458 A,1991-01-17,US 49877790 A,1990-03-23,MOLDED CASE CIRCUIT BREAKER CONTACT AND CONTACT ARM ARRANGEMENT,,GEN ELECTRIC,BELLINO JOSEPH P;;O'BRIEN DEXTER T;;GOLDMAN IRA B;;ARNOLD DAVID,,https://lens.org/075-988-189-952-383,Patent Application,no,0,0,3,3,0,H01H1/023;;H01H1/5822;;H01H1/5833;;H01H11/045;;H01H1/023;;H01H11/045;;H01H1/5833;;H01H1/5822,H01H1/023;;H01H1/58;;H01H11/04,D33060349    M,0,0,,,,EXPIRED
884,US,A,US 4999464 A,082-348-408-207-374,1991-03-12,1991,US 49877790 A,1990-03-23,US 49877790 A,1990-03-23,Molded case circuit breaker contact and contact arm arrangement,A molded case circuit breaker movable contact arm electrically connects with the circuit breaker load terminal requiring only a small diameter auxiliary electrical conducting braid by pivotally arranging the contact arm within its support. The contact arm is nickel-plated prior to attachment of the contact to insure high current circuit interruption withtout damage to the contact or the contact arm.,GEN ELECTRIC,BELLINO JOSEPH P;;ARNOLD DAVID;;O'BRIEN DEXTER T;;GOLDMAN IRA B,GENERAL ELECTRIC COMPANY A CORP. OF NY (1990-03-15),https://lens.org/082-348-408-207-374,Granted Patent,yes,18,10,3,3,0,H01H1/023;;H01H1/5822;;H01H1/5833;;H01H11/045;;H01H1/023;;H01H11/045;;H01H1/5833;;H01H1/5822,H01H1/023;;H01H1/58;;H01H11/04,200/267;;200/401;;200/268;;200/269;;200/271;;200/275,0,0,,,,EXPIRED
885,TW,B,TW I404328 B,156-207-249-960-206,2013-08-01,2013,TW 98145005 A,2009-12-25,US 34652308 A,2008-12-30,Dynamic signal contamination suppression,,INTEL CORP,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,,https://lens.org/156-207-249-960-206,Granted Patent,no,3,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,,,1,1,022-235-121-400-065,10.1109/jssc.2002.806280,"Kang-Yoon Lee; Seung-Wook Lee; Yido Koo; Hyoung-Ki Huh; Hee- Young Nam; Jeong-Woo Lee; Joonbae Park; Kyeongho Lee; Deog- Kyoon Jeong; Wonchan Kim; , ""Full-CMOS 2-GHz WCDMA direct conversion transmitter and receiver,"" Solid-State Circuits, IEEE Journal of , vol.38, no.1, pp. 43- 53, Jan 2003",INACTIVE
886,EP,A1,EP 1192259 A1,181-003-819-715-141,2002-04-03,2002,EP 00943257 A,2000-06-28,US 0017827 W;;US 14158299 P,1999-06-29,TANKYRASE2 MATERIALS AND METHODS,,ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,ICOS CORPORATION (2006-04-12),https://lens.org/181-003-819-715-141,Patent Application,yes,0,0,8,8,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P35/00;;A61P35/02;;C12N9/10;;C12Y204/0203;;C12N9/1077;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P35/00;;A61P35/02;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/00;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/25;;G01N33/15;;G01N33/53;;G01N33/566,,0,0,,,,DISCONTINUED
887,EP,A2,EP 1192258 A2,188-541-067-019-663,2002-04-03,2002,EP 00942875 A,2000-06-16,US 0016629 W;;US 13954399 P,1999-06-16,HUMAN POLY(ADP-RIBOSE) POLYMERASE 2 MATERIALS AND METHODS,,ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,ICOS CORPORATION (2006-04-12),https://lens.org/188-541-067-019-663,Patent Application,yes,0,0,12,12,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,0,0,,,,DISCONTINUED
888,CN,B,CN 101854148 B,197-491-252-415-928,2014-08-13,2014,CN 200911000102 A,2009-12-26,US 34652308 A,2008-12-30,Dynamic signal contamination suppression,,INTEL CORP,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,,https://lens.org/197-491-252-415-928,Granted Patent,no,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/34;;G05F1/10,,0,0,,,,ACTIVE
889,US,A1,US 2023/0004784 A1,195-344-680-997-618,2023-01-05,2023,US 202217857256 A,2022-07-05,US 202217857256 A;;US 202016635633 A;;US 2018/0044574 W;;US 201762539167 P,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/195-344-680-997-618,Patent Application,yes,3,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G06N3/04;;G06N3/08;;H01J49/00;;H01J49/02,,0,0,,,,ACTIVE
890,CN,A,CN 101854148 A,029-438-268-155-732,2010-10-06,2010,CN 200911000102 A,2009-12-26,US 34652308 A,2008-12-30,Dynamic signal contamination suppression,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;NADER ROHANI,,https://lens.org/029-438-268-155-732,Patent Application,no,1,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/34;;G05F1/10,,0,0,,,,ACTIVE
891,EP,A1,EP 0762096 A1,137-740-979-008-715,1997-03-12,1997,EP 96113883 A,1996-08-30,US 52342295 A,1995-09-05,Vertically integrated sensor structure and method for making same,A vertically integrated sensor structure (60) includes a base substrate (71) and a cap substrate (72) bonded to the base substrate (71). The base substrate (71) includes a transducer (78) for sensing an environmental condition. The cap substrate (72) includes electronic devices (92) formed on one surface to process output signals from the transducer (78). The sensor structure (60) provides an integrated structure that isolates sensitive components from harsh environments.,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,,https://lens.org/137-740-979-008-715,Patent Application,yes,3,11,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,1,1,015-244-319-739-057,10.1109/t-ed.1985.22099,"TANIGAWA H. ET AL.: ""MOS integrated silicon pressure sensor"", IEEE TRANSACTIONS ON ELECTRON DEVICES, vol. ED-32, no. 7, July 1985 (1985-07-01), (USA), pages 1191 - 1195, XP000604685",EXPIRED
892,US,A1,US 2010/0164617 A1,017-462-546-399-740,2010-07-01,2010,US 34652308 A,2008-12-30,US 34652308 A,2008-12-30,DYNAMIC SIGNAL CONTAMINATION SUPPRESSION,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,INTEL CORPORATION (2009-08-07),https://lens.org/017-462-546-399-740,Patent Application,yes,8,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/34,330/75,0,0,,,,ACTIVE
893,US,A1,US 2021/0015597 A1,023-815-466-025-907,2021-01-21,2021,US 201716067928 A,2017-01-05,US 201716067928 A;;US 201662276521 P;;US 2017/0012328 W,2016-01-08,URETERAL STENTS AND METHODS OF USING THE SAME,"Embodiments disclosed herein relate to ureteral stents having an elongated stent body and one or more deformable bladders secured thereto, and methods of using the same.",BARD INC C R,GOLDMAN DAVID MATTHEW;;CURRY PETER;;URBAN JOSEPH ANTHONY;;WISTE JEREMY M,C.R. BARD INC (2016-04-20),https://lens.org/023-815-466-025-907,Patent Application,yes,0,0,3,3,0,A61F2/04;;A61M5/00;;A61M27/008;;A61F2002/047;;A61F2/04;;A61F2002/047,A61F2/04,,0,0,,,,ACTIVE
894,WO,A3,WO 2008/032319 A3,018-638-974-170-208,2009-05-07,2009,IL 2007001127 W,2007-09-11,US 84342306 P;;US 82990306 P,2006-09-11,MEDIA PLAYING ON ANOTHER DEVICE,A method includes initiating the playing of a user selected media clip on a buddy communication device through a community server. The method may include playing a buddy selected media clip on a user communication device. The community server brokers the media exchange. Another method includes receiving an SMS with a phone number of the buddy communication device after a conversation has concluded and then playing a buddy media clip.,VRINGO INC;;KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,,https://lens.org/018-638-974-170-208,Search Report,yes,1,0,3,3,0,H04L12/66;;H04L12/66;;H04M3/02;;H04M3/02;;H04M3/42017;;H04M3/42017;;H04M3/42051;;H04M3/42051;;H04M3/42093;;H04M3/42093,H04M3/42;;H04B1/38,,0,0,,,,PENDING
895,EP,B1,EP 3662271 B1,086-536-942-948-184,2023-10-11,2023,EP 18841659 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,,SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/086-536-942-948-184,Granted Patent,yes,10,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G01N21/31;;G01N21/35;;G01N21/65;;G06N3/02;;G06N3/04;;G06N3/045;;G06N3/08;;G06N3/084;;G06T7/00,,2,0,,,"MEI SHAOHUI ET AL: ""Learning Sensor-Specific Spatial-Spectral Features of Hyperspectral Images via Convolutional Neural Networks"", IEEE TRANSACTIONS ON GEOSCIENCE AND REMOTE SENSING, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 55, no. 8, 20 July 2017 (2017-07-20), - 20 July 2017 (2017-07-20), pages 4520-4533, XP011657296, ISSN: 0196-2892, DOI: 10.1109/TGRS.2017.2693346 [retrieved on 2017-07-20];;DUTTA SIBASISH ET AL: ""Dye-Assisted pH Sensing Using a Smartphone"", IEEE PHOTONICS TECHNOLOGY LETTERS, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 27, no. 22, 15 November 2015 (2015-11-15), pages 2363-2366, XP011670549, ISSN: 1041-1135, DOI: 10.1109/LPT.2015.2465132 [retrieved on 2015-09-30]",ACTIVE
896,WO,A1,WO 2001/000849 A1,118-721-966-762-118,2001-01-04,2001,US 0017827 W,2000-06-28,US 14158299 P,1999-06-29,TANKYRASE2 MATERIALS AND METHODS,"The invention provides novel tankyrase polypeptides designated tankyrase2, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the tankyrase2 polypeptides, antibodies that are immunoreactive with the tankyrase2 polypeptides. In addition, there are provided methods for identifying specific binding partners of tankyrase2, and more particularly methods for identifying binding partners that modulate biological activity of tankyrase2. Methods of modulating biological activity of tankyrase2 in vitro and in vivo are also provided.",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/118-721-966-762-118,Patent Application,yes,2,4,8,8,178,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P35/00;;A61P35/02;;C12N9/10;;C12Y204/0203;;C12N9/1077;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P35/00;;A61P35/02;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/00;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/25;;G01N33/15;;G01N33/53;;G01N33/566,,1,1,029-759-013-024-068,9822378;;10.1126/science.282.5393.1484,"SMITH S ET AL: ""Tankyrase, a poly(ADP-ribose) polymerase at human telomeres"", SCIENCE, vol. 282, no. 5393, 20 November 1998 (1998-11-20), pages 1484 - 1487, XP002118903, ISSN: 0036-8075",PENDING
897,US,B1,US 8434044 B1,136-520-383-851-110,2013-04-30,2013,US 96812810 A,2010-12-14,US 96812810 A;;US 29929310 P,2010-01-28,Specifying placement and routing constraints for security and redundancy,"A programmable chip design tool is provided to enumerate and specify the security and/or redundancy constraints of a programmable chip design. A design is implemented with a high-level security or redundancy scheme, and the programmable chip design tool applies the scheme while simultaneously optimizing for desired metrics (logic density, routability, timing, power, etc.). An underlying assignment scheme as well as user interface components used to enter this assignment scheme are provided.",GOLDMAN DAVID SAMUEL;;PEDERSEN BRUCE B;;QUAN GABRIEL;;CHOI YUEN HO;;ALTERA CORP,GOLDMAN DAVID SAMUEL;;PEDERSEN BRUCE B;;QUAN GABRIEL;;CHOI YUEN HO,ALTERA CORPORATION (2010-12-02),https://lens.org/136-520-383-851-110,Granted Patent,yes,2,4,1,1,0,G06F30/392;;G06F30/392,G06F17/50;;G06F13/14,716/116;;716/100;;716/110;;710/305,2,0,,,"Huffinire, Ted, et al., ""Moats and Drawbridges: An Isolation Primitive for Reconfigurable Hardware Based Systems,"" University of California, Santa Barbara, Department of Computer Science, printed Feb. 2010, 15 pages.;;McLean, Mark, et al., ""FPGA-Based Single Chip Cryptographic Solution (U),"" Proceeding of the SDR 06 Technical Conference and Product Exposition, 2006, 4 pages.",ACTIVE
898,WO,A2,WO 2008/032319 A2,015-230-328-888-380,2008-03-20,2008,IL 2007001127 W,2007-09-11,US 84342306 P;;US 82990306 P,2006-09-11,MEDIA PLAYING ON ANOTHER DEVICE,A method includes initiating the playing of a user selected media clip on a buddy communication device through a community server. The method may include playing a buddy selected media clip on a user communication device. The community server brokers the media exchange. Another method includes receiving an SMS with a phone number of the buddy communication device after a conversation has concluded and then playing a buddy media clip.,VRINGO INC;;KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,,https://lens.org/015-230-328-888-380,Patent Application,yes,0,0,3,3,0,H04L12/66;;H04L12/66;;H04M3/02;;H04M3/02;;H04M3/42017;;H04M3/42017;;H04M3/42051;;H04M3/42051;;H04M3/42093;;H04M3/42093,G06F15/16;;H04L12/66;;H04M3/42,,0,0,,,,PENDING
899,AU,B2,AU 779689 B2,057-218-243-628-733,2005-02-03,2005,AU 2000/057439 A,2000-06-16,US 13954399 P;;US 0016629 W,1999-06-16,Human poly(ADP-ribose) polymerase 2 materials and methods,,ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/057-218-243-628-733,Granted Patent,no,0,0,12,12,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,0,0,,,,EXPIRED
900,EP,C0,EP 3662271 C0,116-235-023-120-519,2023-10-11,2023,EP 18841659 A,2018-07-31,US 201762539167 P;;US 2018/0044574 W,2017-07-31,SYSTEM FOR DETERMINING THE PRESENCE OF A SUBSTANCE OF INTEREST IN A SAMPLE,,SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/116-235-023-120-519,Unknown,no,0,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G01N21/84;;G01N21/31;;G01N21/35;;G01N21/65;;G06N3/02;;G06N3/04;;G06N3/045;;G06N3/08;;G06N3/084;;G06T7/00,,0,0,,,,ACTIVE
901,US,A1,US 2008/0064378 A1,160-637-877-553-606,2008-03-13,2008,US 85311707 A,2007-09-11,US 85311707 A;;US 84342306 P;;US 82990306 P,2006-09-11,MEDIA PLAYING ON ANOTHER DEVICE,A method includes initiating the playing of a user selected media clip on a buddy communication device through a community server. The method may include playing a buddy selected media clip on a user communication device. The community server brokers the media exchange. Another method includes receiving an SMS with a phone number of the buddy communication device after a conversation has concluded and then playing a buddy media clip.,KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,KAHAN ARIEL YEHOSHUA;;GOLDFARB DAVID ELLIOT;;GOLDMAN ANDREW;;MEDVED JONATHAN WILLIAM,VRINGO INC (2007-09-23),https://lens.org/160-637-877-553-606,Patent Application,yes,46,9,3,3,0,H04L12/66;;H04L12/66;;H04M3/02;;H04M3/02;;H04M3/42017;;H04M3/42017;;H04M3/42051;;H04M3/42051;;H04M3/42093;;H04M3/42093,H04M3/42;;G06F15/16;;H04L12/66,455/414.1;;370/352;;709/205,0,0,,,,DISCONTINUED
902,DE,T2,DE 69605876 T2,174-957-667-891-739,2000-07-20,2000,DE 69605876 T,1996-08-30,US 52342295 A,1995-09-05,Vertikal integrierte Sensorstruktur und Verfahren zu deren Herstellung,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,"FREESCALE SEMICONDUCTOR, INC., AUSTIN, TEX., US (2006-10-12)",https://lens.org/174-957-667-891-739,Granted Patent,no,0,1,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,0,0,,,,EXPIRED
903,AU,A,AU 2000/057753 A,039-182-922-081-632,2001-01-31,2001,AU 2000/057753 A,2000-06-25,US 14158299 P;;US 0017827 W,1999-06-29,Tankyrase2 materials and methods,,ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/039-182-922-081-632,Patent Application,no,0,0,8,8,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P35/00;;A61P35/02;;C12N9/10;;C12Y204/0203;;C12N9/1077;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P35/00;;A61P35/02;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/00;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/25;;G01N33/15;;G01N33/53;;G01N33/566,,0,0,,,,PENDING
904,US,A1,US 2015/0324891 A1,062-219-049-874-100,2015-11-12,2015,US 201514806505 A,2015-07-22,US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,SYSTEMS AND METHODS FOR PRIORITIZING LOCAL SHOPPING OPTIONS,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/062-219-049-874-100,Patent Application,yes,0,8,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,H04W4/02;;G06Q30/06;;H04W4/024;;H04W4/029,,0,0,,,,ACTIVE
905,US,A1,US 2019/0050604 A1,140-197-393-888-395,2019-02-14,2019,US 201816020805 A,2018-06-27,US 201816020805 A;;US 201762585522 P,2017-11-13,ON-DEVICE BITSTREAM VALIDATION,"A programmable logic device verifies that configuration data permissibly programs the programmable logic device. The programmable logic device includes a programmable fabric having partitions to be programmed by the configuration data, a secure device manager that may generate masks based on the configuration data, and a local sector manager. The masks determine that the configuration data is configured to permissibly program the permitted partitions or that the permitted partitions have been permissibly programmed. The local sector manager applies the masks to generate an interleaved result, compares the interleaved result to an expected result, and sends an indication that the configuration data is configured to permissibly program the permitted partitions or permissibly programmed the permitted partitions in response to determining that the interleaved result is the expected result, or sends an alert to stop programming in response to determining that the interleaved result is not the expected result.",INTEL CORP,WEBER SCOTT J;;ATSATT SEAN R;;DRAPER ANDREW MARTYN;;GOLDMAN DAVID,ALTERA CORPORATION (2023-12-19);;INTEL CORPORATION (2019-01-02),https://lens.org/140-197-393-888-395,Patent Application,yes,3,21,2,2,0,G06F21/76;;G06F21/73;;G06F21/76;;H03M13/27;;G06F7/584;;G06F21/73,G06F21/76;;G06F7/58;;G06F21/73;;H03M13/27,,0,0,,,,ACTIVE
906,US,B2,US 7907008 B2,020-168-957-776-724,2011-03-15,2011,US 34652308 A,2008-12-30,US 34652308 A,2008-12-30,Dynamic signal contamination suppression,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,INTEL CORPORATION (2009-08-07),https://lens.org/020-168-957-776-724,Granted Patent,yes,10,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/36,330/86,1,0,,,"Search Report in Related Application PCT/US2009/069135 mailed Jul. 29, 2010.",ACTIVE
907,NO,L,NO 963100 L,033-518-366-774-021,1997-03-06,1997,NO 963100 A,1996-07-25,US 52342295 A,1995-09-05,Vertikal-integrert sensor,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,,https://lens.org/033-518-366-774-021,Abstract,no,0,0,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,0,0,,,,EXPIRED
908,US,B2,US 11224502 B2,127-455-686-930-161,2022-01-18,2022,US 201716067928 A,2017-01-05,US 201716067928 A;;US 201662276521 P;;US 2017/0012328 W,2016-01-08,Ureteral stents and methods of using the same,"Embodiments disclosed herein relate to ureteral stents having an elongated stent body and one or more deformable bladders secured thereto, and methods of using the same.",BARD INC C R,GOLDMAN DAVID MATTHEW;;CURRY PETER;;URBAN JOSEPH ANTHONY;;WISTE JEREMY M,C.R. BARD INC (2016-04-20),https://lens.org/127-455-686-930-161,Granted Patent,yes,3,0,3,3,0,A61F2/04;;A61M5/00;;A61M27/008;;A61F2002/047;;A61F2/04;;A61F2002/047,A61F2/04,,2,0,,,"International Search Report and Written Opinion from International Application No. PCT/US2017/012328 dated Apr. 14, 2017.;;U.S. Appl. No. 62/276,521, filed Jan. 8, 2016.",ACTIVE
909,EP,B1,EP 0762096 B1,141-948-621-690-737,1999-12-29,1999,EP 96113883 A,1996-08-30,US 52342295 A,1995-09-05,Vertically integrated sensor structure and method for making same,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,,https://lens.org/141-948-621-690-737,Granted Patent,yes,3,0,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,1,0,,,"IEEE TRANSACTIONS ON ELECTRON DEVICES, vol. ED-32, no. 7, July 1985, (USA), pages 1191-1195, XP000604685 TANIGAWA H. ET AL.: ""MOS integrated silicon pressure sensor""",EXPIRED
910,US,B2,US 11769039 B2,055-350-410-879-878,2023-09-26,2023,US 202217857256 A,2022-07-05,US 202217857256 A;;US 202016635633 A;;US 2018/0044574 W;;US 201762539167 P,2017-07-31,System for determining the presence of a substance of interest in a sample,"A detection device for detecting the presence of a substance of interest in a sample is described. The device can include a data store comprising executable instructions for at least one convolutional neural network, CNN, configured to process images: and a processor coupled to the data store and configured to execute the instructions to operate the at least one CNN. The detection device can be configured to: obtain spectrometry data, operate a first one of the CNNs to process the spectrometry data to obtain a first CNN output; apply a mask to the spectrometry data to obtain masked data; operate a second one of the CNNs to process the masked data to obtain a second CNN output; and determine if the substance of interest is present in the sample based on both the first CNN output and the second CNN output.",SMITHS DETECTION INC,TROY JEROME;;EDWARDS JOHN W;;GOLDMAN HEATHER;;JOINER DAVID;;MILLER WILLIAM,,https://lens.org/055-350-410-879-878,Granted Patent,yes,11,0,13,13,0,G01N21/31;;G01N21/65;;G01N2021/3595;;G01N2201/1296;;G06N3/084;;G06N3/045;;G06N3/08;;H01J49/0036;;H01J49/025;;G06N3/045,G06N3/045;;G06N3/08;;H01J49/00;;H01J49/02,,4,2,006-885-964-534-912;;024-132-705-961-908,10.1109/lpt.2015.2465132;;10.1109/tgrs.2017.2693346,"Dutta, Sibasish, et al., “Dye-Assisted pH Sensing Using aSmartphone,” IEEE Photonics Technology Letters, vol. 27, No. 22, Nov. 15, 2015, pp. 2363-2366.;;Extended Search Report for European Application No. 18841659.8, dated Mar. 12, 2021.;;International Search Report and the Written Opinion for Application No. PCT/US2018/044574, dated Nov. 16, 2018, 13 Pages.;;Mei, Shaohui, et al., Learning Sensor-Specific Spatial-Spectral Features of Hyperspectral Images via Convolutional Neural Networks, IEEE Transactions on Geoscience and Remote Sensing, vol. 55, No. 8, Aug. 2017, pp. 4520-4533.",ACTIVE
911,US,A,US 3192513 A,083-032-192-398-161,1965-06-29,1965,US 5777660 A,1960-09-22,US 5777660 A,1960-09-22,Data processing and display system,,GEN PRECISION INC,GOLDMAN DAVID A;;GRAY JOHN W;;HAYEK ARTHUR F;;ERNEST MORGER,,https://lens.org/083-032-192-398-161,Granted Patent,no,10,1,5,6,0,G06F13/22;;G06F13/22,G06F3/12;;G06F13/22;;G09G3/00,,0,0,,,,EXPIRED
912,US,B2,US 6989260 B2,099-352-490-431-234,2006-01-24,2006,US 36937803 A,2003-02-19,US 36937803 A;;US 59624800 A;;US 13954399 P,1999-06-16,Human poly(ADP-ribose) polymerase 2 materials and methods,"The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/099-352-490-431-234,Granted Patent,yes,35,4,12,12,68,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,C12N9/12;;A61K38/00;;G01N33/50;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,435/194;;435/183;;435/69.1;;435/91.1;;530/350,78,70,047-412-705-131-649;;039-963-391-480-782;;083-134-714-159-81X;;019-810-335-711-889;;006-425-837-980-429;;046-932-386-266-45X;;097-054-908-093-394;;072-949-785-529-986;;074-642-937-557-342;;109-483-663-253-044;;006-911-122-969-908;;019-945-212-491-079;;069-695-832-958-551;;025-954-384-311-910;;006-404-118-185-928;;078-103-235-114-224;;034-331-211-704-877;;007-352-622-097-788;;163-788-771-394-077;;159-979-502-911-862;;152-520-430-306-466;;002-704-208-517-091;;001-457-304-553-947;;130-646-047-491-369;;147-062-750-223-41X;;025-184-307-709-716;;084-165-674-357-915;;042-698-945-240-62X;;014-865-054-842-811;;033-797-614-829-293;;001-353-633-462-687;;096-888-948-974-772;;106-753-778-592-300;;025-750-184-554-753;;028-034-587-475-584;;109-553-992-963-291;;058-771-693-926-316;;007-033-051-621-962;;063-470-457-658-358;;020-855-322-534-259;;034-969-377-310-344;;082-564-722-938-120;;082-543-396-197-802;;019-064-411-799-850;;001-817-808-080-115;;028-256-285-071-051;;097-292-830-422-322;;175-789-684-520-039;;034-498-409-269-879;;085-764-009-624-439;;036-326-129-640-399;;094-281-238-066-178;;116-193-705-533-609;;098-624-565-383-08X;;112-484-994-901-950;;015-578-927-490-646;;020-246-828-683-936;;042-820-480-710-105;;022-580-468-420-943;;072-965-139-142-787;;030-443-500-754-783;;007-472-573-688-608;;029-759-013-024-068;;077-529-901-893-533;;000-466-280-529-149;;008-523-783-671-744;;086-901-555-374-478;;009-198-726-656-230;;009-893-901-432-942;;042-865-977-623-92X,3029772;;10.1073/pnas.84.5.1224;;pmc304399;;3118181;;10.1074/jbc.274.25.17860;;10364231;;9579858;;10.1046/j.1365-313x.1998.00240.x;;9778846;;1530940;;10.1016/s0021-9258(18)45983-2;;1842922;;10.1101/gr.1.1.5;;10.1016/s0021-9258(19)70491-8;;6253477;;10338144;;10.1016/s0014-5793(99)00448-2;;10.1016/s0167-7799(98)01236-0;;9807841;;8783501;;10.1016/0167-5699(96)10025-6;;10.1126/science.282.5386.63;;9756477;;10.1126/science.2660260;;2660260;;10.1126/science.3863253;;3863253;;10.1016/0076-6879(92)11003-2;;1406312;;2891139;;pmc299544;;10.1073/pnas.84.23.8370;;10.1038/352624a0;;1907718;;10.1093/nar/24.18.3546;;8836181;;pmc146123;;9729735;;10.1016/s0959-440x(98)80121-8;;10.1006/abio.1997.2153;;9193717;;4360349;;10.1021/bi00702a028;;9255788;;10.1038/nbt0897-751;;10.1146/annurev.biochem.60.1.631;;10.1146/annurev.bi.60.070191.003215;;1715680;;10.1016/0027-5107(94)90147-3;;7518039;;10.1038/336577a0;;3200306;;9219227;;10.1007/bf02761748;;10.1126/science.270.5235.410;;7569995;;9425665;;10.1016/s0958-1669(97)80128-0;;10.1038/194495a0;;14450081;;2531466;;10.1126/science.2531466;;9353232;;10.1016/s0958-1669(97)80040-7;;10329013;;10.1006/geno.1999.5799;;1172191;;10.1038/256495a0;;10.1101/gr.1.2.111;;1842928;;6402547;;10.1016/0022-1759(83)90415-5;;10.1126/science.3413476;;3413476;;9367793;;10.1006/bmme.1997.2631;;10.1073/pnas.80.13.4045;;pmc394197;;6191328;;9550519;;10.1161/01.str.29.4.830;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/0003-2697(84)90808-x;;6204550;;10.1007/978-1-4419-8718-1_1;;10.1016/s0958-1669(97)80123-1;;9425660;;10.1016/s0021-9258(20)65111-0;;6281257;;6300662;;pmc368532;;10.1128/mcb.3.2.280;;10.1128/mcb.3.2.280-289.1983;;10.1111/j.1423-0410.1998.tb05424.x;;9704449;;10.1016/0022-1759(94)90051-5;;8308291;;10.4049/jimmunol.131.6.2895;;6358356;;2057362;;pmc328270;;10.1093/nar/19.11.3055;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10322503;;10.1016/s0165-6147(99)01292-4;;1422221;;10.1016/1046-5928(92)90001-d;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1093/nar/12.8.3435;;6328421;;pmc318760;;10.1093/nar/11.18.6167;;6194506;;pmc326365;;10.1126/science.7618080;;7618080;;pmc223251;;10.1073/pnas.47.12.1981;;14038788;;8391890;;10.1101/gr.2.4.318;;10.1038/356356a0;;1549180;;9804757;;10.1074/jbc.273.46.30069;;6317018;;10.1021/bi00291a019;;pmc341163;;10.1093/nar/13.7.2399;;4000959;;9822378;;10.1126/science.282.5393.1484;;10.1016/s0014-2999(98)00249-0;;09683009;;9683009;;10.1016/s0165-6147(98)01193-6;;9703762;;3047679;;pmc338531;;10.1093/nar/16.16.8186;;10.1111/j.1432-1033.1978.tb12610.x;;213276;;6272129;;10.1038/294284a0;;5027125;;10.1016/s0006-291x(72)80018-4;;8417366;;10.1128/mcb.13.1.98-104.1993;;pmc358889;;10.1128/mcb.13.1.98,"Alkhatid, et al., ""Cloning and Expression of cDNA for Human Poly(ADP-ribose) Polymerase,"" Proc. Natl. Acad. Sci. USA, vol. 84, pp. 1224-1228, Mar. 1987.;;Althaus and Richter, ""ADP-Ribosylation of Proteins: Enzymology and Biochemical Significance,"" Molecular Biochemistry and Biophysics, Springer-Verlag (1987).;;Amé, J.C., et al., ""PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-Ribose) Polymerase,"" J. Biol. Chem., 274(25):17860-17868 (1999).;;Anderson, W.F., ""Human Gene Therapy,"" Nature, 392 (6679 Suppl.):25-30 (1998).;;Ausubel, et al., (Eds.), ""Screening of Recombinant DNA Libraries,"" Current Protocols in Molecular Biology, John Wiley & Son, Chapter 6, pp. 6.0.3-6.4.10 (1994).;;Babiychuk, et al., ""Higher Plants Possess Two Structurally Different Poly(ADP-ribose) Polymerases,"" The Plant Journal, vol. 15(5) pp. 635-645, Sep. 1998.;;Banasik, et al., ""Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase,"" J. Biol. Chem., 267:1569-1575 (1992).;;Barany, F., ""The Ligase Chain Reaction in a PCR World,"" PCR Methods and Applications, 1:5-16 (1991).;;Benjamin and Gill, ""Poly(ADP-ribose) Synthesis In Vitro Programmed by Damaged DNA,"" J. Biol. Chem., 255:10502-8 (1980).;;Berger and Kimmel, (Eds.) ""Guide to Molecular Cloning Techniques, "" Methods in Enzymology, vol. 152, Title Page and Table of Contents Academic Press, San Diego, California (1987).;;Berghammer, et al., ""pADPRT-2: A Novel Mammalian Polymerizing (ADP-ribosyl) Transferase Gene Related to Truncated pADPRT Homologues in Plants and Caenorhabditis elegans,"" FEBS Lett. 449:259-263 (1999).;;Bramlage, et al., ""Designing Ribozymes for the Inhibition of Gene Expression,"" Trends Biotechnol., 16:434-438 (1998).;;Brüggemann, et al., ""Strategies for Expressing Human Antibody Repertoires in Transgenic Mice,"" Immunol. Today, 17:391-397 (1996).;;Cane, et al., ""Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations,"" Science, 282:63-68 (1998).;;Capecchi, M.R., ""Altering the Genome by Homologous Recombination,"" Science, 244:1288-1292 (1989).;;Caruthers, M.H., ""Gene Synthesis Machines: DNA Chemistry and Its Uses,"" Science, 230:281-285 (1985).;;Caruthers, et al., ""Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs,"" Methods Enzymol., 211:3-20 (1992).;;Cherney, et al., ""cDNA Sequence, Protein Structure, and Chronosomal Location of the Human Gene for Poly(ADP-ribose) Polymerase,"" Proc. Natl. Acad. Sci. USA, vol. 84, pp. 8370-8374, Dec. 1987.;;Clackson, et al., ""Making Antibody Fragments Using Phage Display Libraries,"" Nature, 352:624-628 (1991).;;Cline, et al., ""PCR Fidelity of Pfu DNA Polymerase and Other Thermostable DNA Polymerases,"" Nucleic Acids. Res., 24:3546-3551 (1996).;;Dall'Acqua, et al., ""Antibody Engineering,"" Curr. Opin. Struct. Biol., 8:443-450 (1998).;;D'Amours, et al., ""Purification of the Death Substrate Poly(ADP-ribose) Poymerase,"" Anal. Biochem., 249:106-108 (1997).;;David, et al., ""Protein Iodination with Solid State Lactoperoxidase,"" Biochemistry, 13:1014-1021 (1974).;;Dayhoff in Atlas of Protein Sequence and Structure, National Biochemical Research Foundation, Washington, D.C. 5:124 (1972).;;Delihas, et al., ""Natural Antisense RNA/target RNA Interactions: Possible Models for Antisense Oligonucleotide Drug Design,"" Nat. Biotechnol., 15:751-753 (1997).;;Eguchi, Y., ""Antisense RNA,"" Annu. Rev. Biochem., 60:631-652 (1991).;;Fritz, et al., ""Effect of Transfection of Human Poly(ADP-ribose) Polymerase in Chinese Hamster Cells on Mutagen Resistance,"" Mutation Res., 308:127-133 (1994).;;Gatti, et al., ""Localization of an Ataxia-telangiectasia Gene to Chromosome 11q22-23,"" Nature, 336:577-580 (1988).;;Gibson and Shillitoe, ""Ribozymes: Their Functions and Strategies for Their Use,"" Mol. Biotechnol., 7:125-137 (1997).;;Harlow, et al., (Eds.) Antibodies: A Laboratory Manual, Chapter 6, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, pp. 139-243 (1988).;;Hodgkin, et al., ""The Nematode Casnorhabditis elegans and Its Genome,"" Science, 270:410 (1995).;;Houston and Banks, ""The Chemical-Biological Interface: Developments in Automated and Miniaturised Screening Technology,"" Curr. Opin. Biotechnol., 8:734-740 (1997).;;Hunter, et al., ""Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity,"" Nature, 194:495-496 (1962).;;Huse, et al., ""Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,"" Science, 246:1275-1281 (1989).;;Jayawickreme and Kost, ""Gene Expression Systems in the Development of High-Throughput Screens,"" Curr. Opin. Biotechnol., 8:629-634 (1997).;;Johansson, M., ""A Human Poly(ADP-Ribose) Polymerase Gene Family (ADPRTL): cDNA Cloning of Two Novel Poly(ADP-ribose) Polymerase Homologues,"" Genomics, 57(3):442-445 (1999).;;Johansson, M., EMBL/Genbank Data Libraries, Accession No. AF085734, Dec. 1999.;;Köhler and Milstein, ""Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,"" Nature, 256:495-497 (1975).;;Lagerström, et al., ""Capture PCR: Efficient Amplification of DNA Fragments Adjacent to a Known Sequence in Human and YAC DNA,"" PCR Methods Applic., 1:111-119 (1991).;;Lamoyi, et al., ""Preparation of F(ab')<SUB>2 </SUB>Fragments From Mouse IgG of Various Subclasses,"" J. Immunol. Meth., 56:235-243 (1983).;;Landegren, et al., ""A Ligase-Mediated Gene Detection Technique,"" Science, 241:1077-1080 (1988).;;Lavrovsky, et al., ""Therapeutic Potential and Mechanism of Action of Oligonucleotides and Ribozymes,"" Biochem. Mol. Med., 62:11-22 (1997).;;Leary, et al., ""Rapid and Sensitive Colorimetric Method for Visualizing Biotin-Labeled DNA Probes Hybridized to DNA or RNA Immobilized on Nitrocellulose: Bio-Blots,"" Proc. Nat'l. Acad. Sci. USA, 80:4045-4049 (1983).;;Lo, et al., ""Inhibition of Poly(ADP-Ribose) Polymerase: Reduction of Ischemic Injury and Attenuation of N-Methy-D-Aspartate-Induced Neurotransmitter Dysregulation,"" Stroke, 29:830-6 (1998).;;Marks, et al., ""By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,"" J. Mol. Biol., 222:581-597 (1991).;;Meinkoth and Wahl, ""Hybridization of Nucleic Acids Immobilized on Solid Supports,"" Anal. Biochem., 138:267-284 (1984).;;Molinete, et al., ""Structure and Function of the Human Poly (ADP-ribose) Polymerase,"" ADP-Ribosylation Reactions, Poirier and Moreau (Eds.), Springer-Verlag, New York, p. 3-13 (1992).;;Myers, P.L., ""Will Combinatorial Chemistry Deliver Real Medicines?"", Curr. Opin. Biotechnol., 8:701-707 (1997).;;Nishikimi, et al., ""Poly(ADP-ribose) Synthetase-The DNA Binding Domain and the Automodification Domain,"" J. Biol. Chem., 257:6102-6105 (1982).;;Okayama and Berg, ""A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells,"" Molecular and Cellular Biology, 3:280-289 (Feb. 1983).;;Ouwehand, et al., ""Novel Diagnostic and Therapeutic Strategies with Genetically Engineered Human Antibodies,"" Vox Sang, 74 (Suppl. 2), 223-232 (1998).;;Owens and Young, ""The Genetic Engineering of Monoclonal Antibodies,"" J. Immunological Methods, 168:149-165 (1994).;;Parham, P., ""On the Fragmentation of Monoclonal IgG1, IgG2a, and IgG2b from BALB/c Mice,"" J. Immunol., 131:2895-2902 (1983).;;Parker, et al., ""Targeted Gene Walking Polymerase Chain Reaction,"" Nucleic Acids. Res., 19(11):3055-3060 (1991).;;Pearson, et al., ""Improved Tools for Biological Sequence Comparison,"" Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 (1988).;;Pieper, et al., ""Poly (ADP-ribose) Polymerase, Nitric Oxide and Cell Death,"" Trends Pharmacol. Sci., 20:171-181 (1999).;;Porath, J., ""Immobilized Metal Ion Affinity Chromatography,"" Protein Expr. Purif., 3:263-281 (1992).;;Rader, et al., ""A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries,"" Proc. Nat'l Acad. Sci. USA, 95:8910-8915 (1998).;;Renz and Kurz, ""A Colorimetric Method for DNA Hybridization,"" Nucleic Acids. Res., 12:3435-3444 (1984).;;Richardson and Gumport, ""Biotin and Fluorescent Labeling of RNA Using T4 RNA Ligase,"" Nucleic Acids. Res., 11:6167-6184 (1983).;;Roberge, et al., ""A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support,"" Science, 269:202-204 (1995).;;Rossomando, E.F., ""Ion-Exchange Chromatography,"" Methods Enzymol. (Guide to Protein Chemistry, Section VII) Deutscher (Eds.) 182:309-421 (1990).;;Rotman, B., ""Measurement of Activity of Single Molecules of beta-D-Galactosidase,"" Proc. Nat'l. Acad. Sci. USA, 47:1981-1991 (1961).;;Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, NY, 9:47-9.50 (1989).;;Sarkar, et al., ""Restriction-site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers,"" PCR Methods Applic., 2:319-322 (1993).;;Satoh and Lindahl, ""Role of Poly(ADP-ribose) Formation in DNA Repair,"" Nature, 356(6367):356-358 (1992).;;Shieh, et al., ""Poly(ADP-ribose) Polymerase Null Mouse Cells Synthesize ADP-ribose Polymers,"" J. Biol. Chem., 273(46):30069-30072 (1998).;;Sims, et al., ""Poly(ADP-ribose) Polymerase Inhibitors Preserve Nicotinamide Adenine Dinucleotide and Adenosine 5'-Triphosphate Pools in DNA-Damaged Cells; Mechanism of Stimulation of Unscheduled DNA Synthesis,"" Biochemistry, 22(22):5188-5194 (1983).;;Smith, et al., ""The Synthesis of Oligonucleotides Containing an Aliphatic Amino Group at the 5' Terminus: Synthesis of Fluorescent DNA Primers for Use in DNA Sequence Analysis,"" Nucleic Acids Res., 13(7):2399-2412 (1985).;;Smith, et al., ""Tankyrase, a Poly(ADP-Ribose) Polymerase at Human Telomeres,"" Science, 282:1484-1487 (1998).;;Szabó, C., ""Role of Poly(ADP-ribose) Synthetase in Inflammation,"" Eur. J. Pharmacol., 350(1):1-19 (1998).;;Szabó and Dawson, ""Role of Poly(ADP-ribose) Synthetase in Inflammation and Ischaemia-Reperfusion,"" Trends Pharmacol. Sci., 19(7):287-298 (1998).;;Triglia, et al., ""A Procedure for In Vitro Amplification of DNA Segments That Lie Outside the Boundaries of Known Sequences,"" Nucleic Acids Res., 16:8186 (1988).;;Tsopanakis, et al., ""Purification and Properties of Poly(ADP-ribose) Polymerase from Pig-Thymus Nuclei,"" Eur. J. Biochem., 90:337-345 (1978).;;Yamamoto, et al., ""Streptozotocin and Alloxan Induce DNA Strand Breaks and Poly(ADP-ribose) Synthetase in Pancreatic Islets,"" Nature, 294(5838):284-286 (1981).;;Yoshihara, K., ""Complete Dependency of Poly(ADP-ribose) Synthesis on DNA and its Inhibition by Actinomycin D,"" Biochem. Biophys. Res. Commun., 47:119-125 (1972).;;Youssoufian and Lodish, ""Transcriptional Inhibition of the Murine Erythropoietin Receptor Gene by an Upstream Repetitive Element,"" Mol., Cell Biol., 13(1):98-104 (1993).;;GenBank No. AJ007780; Jan. 7, 1999.",EXPIRED
913,CA,A1,CA 2376717 A1,027-361-325-652-212,2000-12-21,2000,CA 2376717 A,2000-06-16,US 13954399 P;;US 0016629 W,1999-06-16,HUMAN POLY(ADP-RIBOSE) POLYMERASE 2 MATERIALS AND METHODS,"The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression construc ts comprising the polynucleotides, and host cells transformed with the expressi on constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition , there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro andin vivo are also provided.",ICOS CORP,MCELLIGOTT DAVID L;;GOLDMAN PHYLLIS S;;DEMAGGIO ANTHONY J;;CHRISTENSON ERIK,,https://lens.org/027-361-325-652-212,Patent Application,no,0,0,12,12,67,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,0,0,,,,DISCONTINUED
914,AU,A1,AU 2005/202977 A1,056-276-897-324-228,2005-08-04,2005,AU 2005/202977 A,2005-07-07,AU 2005/202977 A;;AU 2000/057753 A,2000-06-25,Tankyrase2 Materials and Methods,,ICOS CORP,MCELLIGOTT DAVID L;;GOLDMAN PHYLLIS S;;DEMAGGIO ANTHONY J;;CHRISTENSON ERIK,,https://lens.org/056-276-897-324-228,Patent Application,no,0,0,1,1,0,,A61K38/45;;A61P35/00;;C07K16/40;;C12N9/10;;C12N15/54;;C12Q1/48;;C12Q1/68,,0,0,,,,DISCONTINUED
915,TW,A,TW 201101675 A,125-249-029-583-606,2011-01-01,2011,TW 98145005 A,2009-12-25,US 34652308 A,2008-12-30,Dynamic signal contamination suppression,"A self-configurable amplifier and method of amplification, including an RF signal level detector having an input connected to an RF signal, and an output configured to produce a control signal responsive to a power level of the RF signal. The control signal is supplied to a parametric adjustment circuit that includes an input connected to the control signal, and an output configured to provide a negative feedback responsive to the control signal. The negative feedback is supplied to an RF amplifier that includes an input forming an input of the self-configurable amplifier, an output forming an output of the self-configurable amplifier, and a control port connected to the output of the parametric adjustment circuit, such that one or more parameters of the RF amplifier is responsive to the negative feedback.",INTEL CORP,COWLEY NICHOLAS P;;GOLDMAN RICHARD J;;SAWYER DAVID A;;ROHANI NADER,,https://lens.org/125-249-029-583-606,Patent of Addition,no,0,0,15,15,0,H03F1/0272;;H03F1/34;;H03F3/189;;H03F2200/105;;H03F2200/294;;H03F2200/451;;H03G3/3036;;H03F1/26;;H03F1/34;;H03F1/34;;H03F3/189;;H03F1/0272;;H03G3/3036;;H03F2200/294;;H03F2200/105;;H03F2200/451,H03F1/02;;H03F1/34;;H03F3/189;;H03G3/30,,0,0,,,,INACTIVE
916,WO,A3,WO 2000/077179 A3,163-225-328-057-755,2001-02-22,2001,US 0016629 W,2000-06-16,US 13954399 P,1999-06-16,HUMAN POLY(ADP-RIBOSE) POLYMERASE 2 MATERIALS AND METHODS,"The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/163-225-328-057-755,Search Report,yes,1,0,12,12,0,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,A61K38/00;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;G01N33/50;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,6,6,074-642-937-557-342;;096-888-948-974-772;;072-965-139-142-787;;036-326-129-640-399;;000-466-280-529-149;;083-134-714-159-81X,10338144;;10.1016/s0014-5793(99)00448-2;;10329013;;10.1006/geno.1999.5799;;9804757;;10.1074/jbc.273.46.30069;;10322503;;10.1016/s0165-6147(99)01292-4;;10.1016/s0165-6147(98)01193-6;;9703762;;10.1074/jbc.274.25.17860;;10364231,"BERGHAMMER H ET AL: ""PADPRT-2: A NOVEL MAMMALIAN POLYMERIZING (ADP-RIBOSYL) TRANSFERASE GENE RELATED TO TRUNCATED PADPRT HOMOLOGUES IN PLANTS AND CAENORHABDITIS ELEGANS"", FEBS LETTERS, vol. 449, 23 April 1999 (1999-04-23), pages 259 - 263, XP000867424, ISSN: 0014-5793;;JOHANSSON M: ""A HUMAN POLY(ADP-RIBOSE) POLYMERASE GENE FAMILY (ADPRTL) CDNA CLONING OF TWO NOVEL POLY(ADP-RIBOSE) POLYMERASE HOMOLOGUES"", GENOMICS, vol. 57, no. 3, 1 May 1999 (1999-05-01), pages 442 - 445, XP000870418, ISSN: 0888-7543;;SHIEH W MELISSA ET AL: ""Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers."", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30069 - 30072, XP002154243, ISSN: 0021-9258;;PIEPER, A. ET AL.: ""Poly (ADP-ribose) polymerase, nitric oxide and cell death."", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 20, no. 4, April 1999 (1999-04-01), pages 171 - 181, XP004172564, ISSN: 0165-6147;;SZABO C ET AL: ""Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion"", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 19, no. 7, 1 July 1998 (1998-07-01), pages 287 - 298, XP004131514, ISSN: 0165-6147;;AME J-C ET AL: ""PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 25, 18 June 1999 (1999-06-18), pages 17860 - 17868, XP002129094, ISSN: 0021-9258",PATENTED
917,US,B2,US 11687996 B2,157-588-933-297-373,2023-06-27,2023,US 202117317933 A,2021-05-12,US 202117317933 A;;US 201815970112 A;;US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,Systems and methods for prioritizing local shopping options,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATTHEW LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/157-588-933-297-373,Granted Patent,yes,28,0,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/0601;;G01C21/20;;G01C21/34;;G06Q10/047;;G06Q30/0201;;G06Q50/00;;H04W4/024;;H04W4/029,,16,0,,,"Final Office Action received for U.S. Appl. No. 13/686,195, dated Nov. 25, 2014, 17 pages.;;Non-Final Office Action received for U.S. Appl. No. 13/686,195, dated Jul. 30, 2014, 16 pages.;;Notice of Allowance received for U.S. Appl. No. 13/686,195, dated Apr. 15, 2015, 16 pages.;;Non-Final Office Action received for U.S. Appl. No. 14/806,505, dated Jul. 18, 2017, 13 pages.;;Notice of Allowance Received for U.S. Appl. No. 14/806,505, dated Mar. 13, 2018, 10 pages.;;Final Office Action Received for U.S. Appl. No. 15/970,112, dated May 19, 2020, 20 pages.;;Non Final Office Action Received for U.S. Appl. No. 15/970,112, dated Dec. 2, 2019, 21 pages.;;Non Final Office Action Received for U.S. Appl. No. 15/970,112, dated Oct. 8, 2020, 14 pages.;;Notice of Allowance Received for U.S. Appl. No. 15/970,112, dated Feb. 5, 2021, 5 pages.;;Devin,“Ford's Sync Destination App Plans Your Route Before You Get In The Car”, Dec. 29, 2010, 7 Pages.;;International Preliminary Report on Patentability received for PCT Application No. PCT/US2012/069912, dated Oct. 30, 2014, 7 pages.;;International Search Report received for PCT Application No. PCT/US2012/069912, dated Feb. 8, 2013, 2 pages.;;Written Opinion received for PCT Application No. PCT/US2012/069912 dated Feb. 8, 2013, 5 pages.;;U.S. Appl. No. 13/686,195 U.S. Pat. No. 9,117,238, Nov. 27, 2012, Method, System, and Medium for Generating a Mobile Interface Indicating Traffic Level for Local Merchants (as amended).;;U.S. Appl. No. 14/806,505 U.S. Pat. No. 10,019,751, Jul. 22, 2015, Systems and Methods for Prioritizing Local Shopping Options.;;U.S. Appl. No. 15/970,112 U.S. Pat. No. 11,030,676, May 3, 2018, Systems and Methods for Prioritizing Local Shopping Options.",ACTIVE
918,CA,A1,CA 2370568 A1,164-310-464-551-54X,2001-01-04,2001,CA 2370568 A,2000-06-28,US 14158299 P;;US 0017827 W,1999-06-29,TANKYRASE2 MATERIALS AND METHODS,"The invention provides novel tankyrase polypeptides designated tankyrase2, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the tankyrase2 polypeptides, antibodies that are immunoreactive with the tankyrase2 polypeptides. In addition, there are provided methods for identifying specif ic binding partners of tankyrase2, and more particularly methods for identifyin g binding partners that modulate biological activity of tankyrase2. Methods of modulating biological activity of tankyrase2 in vitroand in vivoare also provided.",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;MCELLIGOTT DAVID L;;GOLDMAN PHYLLIS S,,https://lens.org/164-310-464-551-54X,Patent Application,no,0,0,8,8,178,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P35/00;;A61P35/02;;C12N9/10;;C12Y204/0203;;C12N9/1077;;A61K38/00,G01N33/50;;A61K38/00;;A61K45/00;;A61P35/00;;A61P35/02;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/00;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/25;;G01N33/15;;G01N33/53;;G01N33/566,,0,0,,,,DISCONTINUED
919,DE,D1,DE 69605876 D1,164-553-483-864-679,2000-02-03,2000,DE 69605876 T,1996-08-30,US 52342295 A,1995-09-05,Vertikal integrierte Sensorstruktur und Verfahren zu deren Herstellung,,MOTOROLA INC,SOORIAKUMAR K;;MONK DAVID J;;CHAN WENDY K;;GOLDMAN KENNETH G,"FREESCALE SEMICONDUCTOR, INC., AUSTIN, TEX., US (2006-10-12)",https://lens.org/164-553-483-864-679,Granted Patent,no,0,0,10,10,0,G01L19/148;;G01L19/148;;G01L9/0055;;G01L9/0055;;G01L19/0084;;G01L19/0084;;G01L19/0627;;G01L19/0627;;G01L19/143;;G01L19/143;;G01L19/147;;G01L19/147;;H01L24/45;;H01L24/45;;H01L2224/45124;;H01L2224/45124;;H01L2224/45144;;H01L2224/45144;;H01L2224/48091;;H01L2224/48091;;H01L2224/48465;;H01L2224/48465;;H01L2224/73265;;H01L2224/73265;;H01L2924/01322;;H01L2924/01322;;H01L2924/12042;;H01L2924/12042;;H01L2924/1305;;H01L2924/1305;;H01L2924/13062;;H01L2924/13062;;H01L2924/14;;H01L2924/14,G01L9/04;;G01L9/00;;G01L19/06;;H01L29/84,,0,0,,,,EXPIRED
920,US,A1,US 2007/0288367 A1,199-580-164-313-638,2007-12-13,2007,US 76049307 A,2007-06-08,US 76049307 A;;US 41575906 A;;US 67632705 P,2005-04-30,REVENUE MANAGEMENT SYSTEMS AND METHODS WITH BILL AND ACCOUNT SUPPRESSION,"A revenue management system for telecommunication systems is disclosed. The revenue management system can have multiple integrated modules. The modules can include a revenue generation module, a revenue capture module, a revenue collection module, a revenue intelligence module, and others. The revenue management system can also be configured to simultaneously manage revenue for prepaid, postpaid, now-paid payment models.",ORACLE INT CORP,KRISHNAMOORTHY JAYAPRAKASH;;LABUDA DAVID S;;HADDOCK JAMES R;;GOLDMAN MARK S,ORACLE INTERNATIONAL CORPORATION (2007-05-16),https://lens.org/199-580-164-313-638,Patent Application,yes,99,14,12,12,0,G06Q20/102;;G06Q40/00;;G06Q40/00;;G06Q20/102,G06Q40/00,705/40,0,0,,,,ACTIVE
921,US,B2,US 10019751 B2,111-857-351-823-672,2018-07-10,2018,US 201514806505 A,2015-07-22,US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,Systems and methods for prioritizing local shopping options,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATT LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/111-857-351-823-672,Granted Patent,yes,14,2,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/00;;G01C21/20;;G01C21/34;;G06Q30/06;;H04W4/02;;H04W4/024;;H04W4/029,,13,0,,,"“Ford's Sync Destination App Plans Your Route Before You Get in the Car”. Dec 29, 2010. Devin Coldweway. (Year: 2010).;;“U.S. Appl. No. 13/686,195, Examiner Interview Summary dated Oct. 9, 2014”, 3 pgs.;;“U.S. Appl. No. 13/686,195, Final Office Action dated Nov. 25, 2014”, 17 pgs.;;“U.S. Appl. No. 13/686,195, Non Final Office Action dated Jul. 30, 2014”, 16 pgs.;;“U.S. Appl. No. 13/686,195, Notice of Allowance dated Apr. 15, 2015”, 17 pgs.;;“U.S. Appl. No. 13/686,195, PTO Response to Rule 312 Communication dated Jul. 23, 2015”, 2 pgs.;;“U.S. Appl. No. 13/686,195, Response dated Feb. 24, 2015 to Non Final Office Action dated Nov. 25, 2014”, 20 pgs.;;“U.S. Appl. No. 13/686,195, Response dated Oct. 30, 2014 to Non Final Office Action dated Jul. 30, 2014”, 17 pgs.;;“Ford's Sync Destinations App Plans Your Route Before You Get in the Car”, Devin Coldewey, (Dec. 29, 2010), 7 pgs.;;“International Application Serial No. PCT/US2012/069912, International Preliminary Report on Patentability dated Oct. 30, 2014”, 7 pgs.;;“International Application Serial No. PCT/US2012/069912, International Search Report dated Feb. 8, 2013”, 2 pgs.;;“International Application Serial No. PCT/US2012/069912, Written Opinion dated Feb. 8, 2013”, 5 pgs.;;“U.S. Appl. No. 13/686,195, 312 Amendment dated Jul. 15, 2015”, 10 pgs.",ACTIVE
922,CA,C,CA 2212762 C,120-188-676-316-709,2000-11-14,2000,CA 2212762 A,1997-08-12,US 71597196 A,1996-09-18,PROGRAMMABLE RADIO SUBSCRIPTION SYSTEM FOR RECEIVING SELECTIVELY DEFINED INFORMATION,"The radio subscription system of the present invention enables a subscriber to remotely define and identify one or more playlists, each specifying information content selected by the subscriber from a subscription content database, for later transmission to the subscriber's radio. The radio subscription system also permits the subscriber to use the local subscriber radio to remotely request transmission of a particular playlist to the subscriber's radio for storage and playback. The subscriber may then use the local subscriber radio to playback the particular playlist.",AT & T CORP,FOLADARE MARK JEFFREY;;STURM WALTER;;SILVERMAN DAVID PHILLIP;;GOLDMAN SHELLEY B,,https://lens.org/120-188-676-316-709,Granted Patent,no,0,0,7,7,0,H04H20/72;;H04H60/82;;H04H20/72;;H04H60/82,H04B1/06;;H04H20/72;;H04H60/82,,0,0,,,,EXPIRED
923,WO,A1,WO 2017/120332 A1,168-202-434-949-669,2017-07-13,2017,US 2017/0012328 W,2017-01-05,US 201662276521 P,2016-01-08,URETERAL STENTS AND METHODS OF USING THE SAME,"Embodiments disclosed herein relate to ureteral stents having an elongated stent body and one or more deformable bladders secured thereto, and methods of using the same.",BARD INC C R,GOLDMAN DAVID MATTHEW;;CURRY PETER;;URBAN JOSEPH ANTHONY;;WISTE JEREMY M,,https://lens.org/168-202-434-949-669,Patent Application,yes,3,1,3,3,0,A61F2/04;;A61M5/00;;A61M27/008;;A61F2002/047;;A61F2/04;;A61F2002/047,A61F2/00;;A61F2/06;;A61F2/82;;A61F2/95;;A61M5/00;;A61M27/00,,0,0,,,,PENDING
924,US,B2,US 8795242 B2,160-410-846-554-474,2014-08-05,2014,US 5687905 A,2005-02-12,US 5687905 A;;US 83026704 A;;US 19996102 A;;US 20660498 A;;US 24255794 A;;US 38619101 P,1994-05-13,Resorbable polymeric device for localized drug delivery,"An implantable device for facilitating the healing of voids in bone, cartilage and soft tissue is disclosed. In one embodiment, the device is arranged for the local delivery of therapeutic agent. A preferred embodiment is a porous resorbable implant, wherein the therapy delivery may be localized in nature, rather than systemic, such that higher doses at the target site may be allowed than would be tolerable by the body systemically.",HOGANSON DAVID M;;BRADICA GINO;;GOLDMAN SCOTT M;;BREKKE JOHN H;;KENSEY NASH CORP,HOGANSON DAVID M;;BRADICA GINO;;GOLDMAN SCOTT M;;BREKKE JOHN H,KENSEY NASH CORPORATION (2005-08-15),https://lens.org/160-410-846-554-474,Granted Patent,yes,75,5,2,38,0,A61L27/3839;;A61L27/3839;;A61K35/16;;A61K35/16;;A61K35/28;;A61K35/28;;A61K38/15;;A61K38/15;;A61L27/3641;;A61L27/507;;A61L27/58;;A61L27/58;;A61L2430/20,A61M37/00;;A61K35/16;;A61K35/28;;A61K38/15;;A61L27/38;;A61L27/58,604/288.01,5,5,049-796-345-602-58X;;049-197-689-646-784;;005-694-776-353-905;;062-503-070-341-884;;046-664-886-831-410,14623805;;10.1161/01.cir.0000103131.70301.4f;;12760978;;10.1213/01.ane.0000063922.90966.3a;;10.1001/jama.291.14.1720;;15082699;;1381779;;10881816;;10.1016/s0003-4975(00)01180-2,"Aviles, MD, Ronnier J., et al., ""Inflammation as a Risk Factor for Atrial Fibrillation"", Circulation, 108, (2003),3006-3010.;;Halvorsen, MD, Per , et al., ""The Effect of Dexamethasone on Side Effects After Coronary Revascularization Procedures"", Anesth Analg 2003, 96, (2003),1578-83.;;Mathew, MD, Joseph P., ""A Multicenter Risk Index for Atrial Fibrillation"", JAMA, 291(14), (Apr. 14, 2005), 1720-1729.;;Siden, Rivka , et al., ""Epicardial Controlled-Release Verapamil Prevents Ventricular Tahcycardia Episodes Induced by Acute Ischemia in a Canine Model"", J Cardiovascular Pharmacology, 19, Raven Press Ltd., New York, (1992),798-809.;;Yared, MD, Jean-Pierre , et al., ""Effects of Single Dose, Postinduction Dexamethasone on Recovery After Cardiac Surgery"", Ann Thorac Surg 2000, 69, (2000),1420-1424.",EXPIRED
925,US,A1,US 2018/0253784 A1,165-803-503-470-040,2018-09-06,2018,US 201815970112 A,2018-05-03,US 201815970112 A;;US 201514806505 A;;US 201213686195 A;;US 201261625836 P,2012-04-18,SYSTEMS AND METHODS FOR PRIORITIZING LOCAL SHOPPING OPTIONS,"Systems and methods to provide a prioritized shopping system are discussed. For example, a method can include receiving a list of target items, receiving busyness data for a plurality of local merchants, developing a prioritized shopping plan, and communicating the prioritized shopping plan to a mobile device. Each target item in the list of target items can represents a product or service that a user has indicated an interest in purchasing. The prioritized shopping plan is based at least in part on the busyness data and the list of target items. Busyness data provides an indication of traffic levels within at least a portion of the plurality of local merchants.",EBAY INC,TAPLEY JOHN;;HIGGINS KRYSTAL ROSE;;GIGER MATTHEW LEE;;GOLDMAN DAVID W,EBAY INC (2012-10-31),https://lens.org/165-803-503-470-040,Patent Application,yes,6,4,9,9,0,H04W4/029;;G06Q30/0633;;G06Q30/0641;;H04W4/024;;G06Q30/0639;;H04W4/02;;G06Q30/0633;;G06Q30/0641;;G01C21/34;;G01C21/206;;H04W4/024;;H04W4/029;;G06Q10/047;;G06Q30/0201;;G06Q50/01;;G06Q30/0639,G06Q30/06;;H04W4/02;;H04W4/024;;H04W4/029,,0,0,,,,ACTIVE
926,WO,A2,WO 2000/077179 A2,003-000-126-202-644,2000-12-21,2000,US 0016629 W,2000-06-16,US 13954399 P,1999-06-16,HUMAN POLY(ADP-RIBOSE) POLYMERASE 2 MATERIALS AND METHODS,"The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,,https://lens.org/003-000-126-202-644,Patent Application,yes,0,0,12,12,67,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,A61K38/00;;G01N33/50;;A61K45/00;;A61P1/00;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,,0,0,,,,PATENTED
927,US,B2,US 8102980 B2,084-224-996-289-502,2012-01-24,2012,US 76049307 A,2007-06-08,US 76049307 A;;US 41575906 A;;US 67632705 P,2005-04-30,Revenue management systems and methods with bill and account suppression,"A revenue management system for telecommunication systems is disclosed. The revenue management system can have multiple integrated modules. The modules can include a revenue generation module, a revenue capture module, a revenue collection module, a revenue intelligence module, and others. The revenue management system can also be configured to simultaneously manage revenue for prepaid, postpaid, now-paid payment models.",KRISHNAMOORTHY JAYAPRAKASH;;LABUDA DAVID S;;HADDOCK JAMES R;;GOLDMAN MARK S;;ORACLE INT CORP,KRISHNAMOORTHY JAYAPRAKASH;;LABUDA DAVID S;;HADDOCK JAMES R;;GOLDMAN MARK S,ORACLE INTERNATIONAL CORPORATION (2007-05-16),https://lens.org/084-224-996-289-502,Granted Patent,yes,102,8,12,12,0,G06Q20/102;;G06Q40/00;;G06Q40/00;;G06Q20/102,G06Q40/00;;H04M15/00,379/114.05;;379/114.03;;379/121.02,99,3,037-154-416-104-386;;010-327-131-725-683;;056-991-806-777-524,10.1145/79204.79213;;10.1147/sj.352.0172;;10.1145/74877.74898,"U.S. Appl. No. 11/415,759, filed May 1, 2006, Final Office Action mailed Nov. 17, 2010, 9 pages.;;U.S. Appl. No. 11/496,057, filed Jul. 28, 2006, Final Office Action mailed Jan. 4, 2011,17 pages.;;U.S. Appl. No. 11/496,057, filed Jul. 28, 2006, Advisory Action mailed Mar. 9, 2011, 3 pages.;;Agarwal et al., ""Architecting Object Applications for High Performance With Relational Databases"", Aug. 10, 1995, pp. 1-8.;;Black, ""Real-Time Fraud Management"", Billing World, Jul./Aug. 1999; pp. 3.;;Blaha, Michael R. et al., ""Relational Database Design Using an Object Oriented Methodology"", Communication of the ACM, Apr. 1988, vol. 31, No. 4, pp. 414-427.;;Borland's Paradox for Windows User Guide, Version 5.0, Borland International, Inc., 1994, 185 pages.;;Chenho, Kung, ""Object Subclass Hierarchy in SQL: A Simple Approach"", Jul. 1990, Communications of the ACM, vol. 33, No. 7, pp. 117-125.;;Chester, Thomas et al., Mastering Excel 97, 4th Ed., Sybex Inc., Alameda, CA, 1997, 200 pages.;;Davis, Charles, ""Online Financing to Boost Procurement"", Electronic Payments International, p. 14, Feb. 2000, 3 pages total.;;Derfler, Frank J. et al., ""How Networks Work"", Millenium Ed., Que Corporation, Jan. 2000, 249 pages (2 pdf attachments).;;Gavron, Jacquelyn et al., ""How to Use Microsoft Windows NT 4 Workstation"", MacMillan Computer Publishing, USA, 1996, 25 pages.;;Gomez-Perez et al., ""Towards a Method to Conceptualize Domain Ontologies"", Workshop on Ontological Engineering, ECAI'96, Budapest, Aug. 12, 1996, pp. 41-51.;;Gralla, Preston, ""How the Internet Works"", Millenium Ed., Que Corporation, Aug. 1999, 357 pages (2 pdf attachments).;;Horngren, Charles T. et al., ""Introduction to Financial Accounting"", Revised 3rd Ed., Prentice-Hall, Inc., 1988, 561 pages.;;Iannella et al., ""Metadata: Enabling the Internet"", Jan. 1997, Research Data Network CRC, pp. 1-7.;;Muller, Nathan J., ""Desktop Encyclopedia of the Internet"", Artech House, Inc., 1998, 602 pgs (2 pdf attachments).;;Peachtree, ""Using General Ledger User Guide"", Peachtree Software, Inc., 1989, 319 pages.;;St. Pierre et al., ""Issues in Crosswalking Content Metadata Standards"", Oct. 15, 1998, National Information Standards Organization, pp. 1-8.;;PR Newswire, ""Regions to Offer Secure Internet Banking from Security First Technologies"", Apr. 3, 1997, p. 0403ATTH003, 3 pgs.;;Reinwald et al., ""Storing and Using Objects in a Relational Database"", IBM Systems Journal, vol. 35, No. 2, May 1996, pp. 172-191.;;Riley, David D., ""Data Abstraction and Structures: An Introduction to Computer Science II"", Boyd and Fraser Publishing Company, 1987, 30 pages.;;Search Report and Written Opinion for Application PCT/US06/29571, mailed on Apr. 16, 2007; 10 pages.;;Search Report for Application PCT/US06/25405, mailed on Apr. 3, 2008, 2 pages.;;Shah, Ashwin V. et al., ""DSM: An Object-Relationship Modeling Language"", OOPSLA '89, Oct. 1-6, 1989, pp. 181-202.;;Syverson, Nancy, ""Inside Graybar: A Profile of the Nation's Top Electrical Distributor"", Industrial Maintenance and Plant Operation, vol. 61, No. 11, p. 14, Nov. 2000, 4 pages total.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Advisory Action mailed May 11, 2009, 3 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Advisory Action mailed May 6, 2008, 3 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Advisory Action mailed Jun. 24, 2004, 2 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Final Office Action mailed Jan. 28, 2004, 8 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Final Office Action mailed Feb. 11, 2008, 6 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Final Office Action mailed Mar. 4, 2009, 8 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Final Office Action mailed Jun. 16, 2005, 16 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Notice of Allowance mailed Mar. 5, 2010, 9 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Oct. 7, 2002, 6 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Oct. 7, 2004, 12 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Jul. 3, 2003, 7 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Aug. 9, 2007, 8 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Sep. 1, 2009, 6 pages.;;U.S. Appl. No. 09/569,097, filed May 10, 2000, Office Action mailed Sep. 3, 2008, 6 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Advisory Action mailed Jan. 9, 2009, 3 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Advisory Action mailed Dec. 28, 2009, 3 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Final Office Action mailed Oct. 16, 2009, 19 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Final Office Action mailed Oct. 23, 2008, 21 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Office Action mailed Mar. 24, 2009, 16 pages.;;U.S. Appl. No. 11/414,072, filed Apr. 27, 2006, Office Action mailed Apr. 24, 2008, 33 pages.;;U.S. Appl. No. 11/415,759, filed May 1, 2006, Office Action mailed Mar. 30, 2010, 9 pages.;;U.S. Appl. No. 11/559,969, filed Nov. 15, 2006, Office Action mailed Oct. 2, 2009, 11 pages.;;U.S. Appl. No. 11/559,969, filed Nov. 15, 2006, Office Action mailed Mar. 31, 2010, 13 pages.;;U.S. Appl. No. 11/559,969, filed Nov. 15, 2006, Office Action mailed Mar. 5, 2009, 11 pages.;;U.S. Appl. No. 11/760,427, filed Jun. 8, 2007, Office Action mailed Dec. 11, 2009, 13 pages.;;U.S. Appl. No. 11/760,519, filed Jun. 8, 2007, Office Action mailed Jan. 21, 2010, 9 pages.;;White, Ron, ""How Computers Work"", Millenium Ed., Que Corporation, Sep. 1999, 322 pages (2 pdf attachments).;;Oracle Applications, Concepts, Release 11 for UNX, Apr. 1998, 90 pgs.;;Oracle Server Distribution Systems, vol. II: Replicated Data, Release 7.3, Feb. 1996, 469 pgs.;;Skold, Martin, ""QDB-A Query Processor for the High Performance, Parallel Data Server NDB Cluster"", Linkopings University, Sweden, Apr. 1999, 28 pgs.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Office Action mailed Jan. 14, 2004, 15 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Office Action mailed Oct. 2, 2004, 22 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Final Office Action mailed Aug. 19, 2005, 23 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Office Action mailed May 16, 2006, 26 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Petition Decision mailed Dec. 18, 2006, 1 page.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Final Office Action mailed Dec. 19, 2006, 33 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Office Action mailed Sep. 11, 2007, 15 pages.;;U.S. Appl. No. 09/967,493, filed Sep. 27, 2001, Notice of Allowance mailed Apr. 11, 2008, 12 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Office Action mailed Sep. 1, 2006, 9 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Final Office Action mailed Feb. 22, 2007, 13 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Advisory Action mailed May 2, 2007, 3 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Office Action mailed Aug. 3, 2007, 11 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Office Action mailed Feb. 21, 2008, 21 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Final Office Action mailed Sep. 29, 2008, 19 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Advisory Action mailed Jan. 23, 2009, 3 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Office Action mailed Mar. 4, 2009, 13 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Final Office Action mailed Aug. 19, 2009, 11 pages.;;U.S. Appl. No. 10/394,409, filed Mar. 21, 2003, Advisory Action mailed Oct. 23, 2009, 3 pages.;;U.S. Appl. No. 10/375,694, filed Feb. 26, 2003, Office Action mailed Sep. 7, 2004, 12 pages.;;U.S. Appl. No. 10/375,694, filed Feb. 26, 2003, Final Office Action mailed May 13, 2005, 13 pages.;;U.S. Appl. No. 10/375,694, filed Feb. 26, 2003, Office Action mailed Oct. 13, 2005, 9 pages.;;U.S. Appl. No. 10/375,694, filed Feb. 26, 2003, Notice of Allowance mailed Apr. 3, 2006, 4 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Office Action mailed Oct. 20, 2004, 4 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Final Office Action mailed May 13, 2005, 6 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Office Action mailed Sep. 16, 2005, 7 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Final Office Action mailed Mar. 23, 2006, 9 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Office Action mailed Oct. 10, 2007, 5 pages.;;U.S. Appl. No. 10/706,151, filed Feb. 26, 2003, Notice of Allowance mailed Apr. 18, 2008, 8 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Office Action mailed Feb. 17, 2004, 10 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Final Office Action mailed Sep. 27, 2004, 18 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Office Action mailed Jul. 25, 2006, 18 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Final Office Action mailed Jan. 11, 2007, 17 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Advisory Action mailed Mar. 26, 2007, 3 pages.;;U.S. Appl. No. 09/562,785, filed May 2, 2000, Notice of Allowance mailed May 21, 2007, 7 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Office Action mailed Feb. 17, 2004, 10 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Office Action mailed Nov. 16, 2004, 11 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Final Office Action mailed Jun. 14, 2005, 10 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Office Action mailed Jul. 25, 2006, 9 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Office Action mailed Sep. 27, 2006, 9 pages.;;U.S. Appl. No. 09/617,590, filed Jul. 18, 2000, Notice of Allowance mailed Mar. 27, 2006, 10 pages.;;U.S. Appl. No. 11/478,558, filed Jun. 28, 2006, Office Action mailed Oct. 21, 2010, 12 pages.;;U.S. Appl. No. 11/496,057, filed Jul. 28, 2006, Office Action mailed Jul. 21, 2010, 23 pages.;;U.S. Appl. No. 11/760,427, filed Jun. 8, 2007, Advisory Action mailed Aug. 30, 2010, 3 pages.",ACTIVE
928,US,B1,US 6599727 B1,144-327-195-409-224,2003-07-29,2003,US 59624800 A,2000-06-16,US 59624800 A;;US 13954399 P,1999-06-16,Human poly (ADP-ribose) polymerase 2 materials and methods,"
    The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided. 
",ICOS CORP,CHRISTENSON ERIK;;DEMAGGIO ANTHONY J;;GOLDMAN PHYLLIS S;;MCELLIGOTT DAVID L,ICOS CORPORATION (2000-09-18),https://lens.org/144-327-195-409-224,Granted Patent,yes,35,0,12,12,68,A61K38/00;;C12N9/1077;;C12Y204/0203;;A61P1/00;;A61P1/16;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;A61P9/00;;A61P9/10;;A61P3/10;;C07K14/435;;C12N9/1077;;C12Y204/0203;;A61K38/00,A61K38/00;;A61K45/00;;A61P1/00;;G01N33/50;;A61P1/16;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08;;C07K16/40;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N9/10;;C12N15/09;;C12N15/54;;C12P21/08;;C12Q1/68;;G01N33/15;;G01N33/566,435/194;;435/183;;435/69.1;;435/252.3;;435/254.11;;435/320.1;;536/23.1;;536/23.2;;536/23.5;;530/350,77,70,078-103-235-114-224;;047-412-705-131-649;;001-817-808-080-115;;006-425-837-980-429;;039-963-391-480-782;;083-134-714-159-81X;;019-810-335-711-889;;046-932-386-266-45X;;097-054-908-093-394;;072-949-785-529-986;;074-642-937-557-342;;109-483-663-253-044;;006-911-122-969-908;;019-945-212-491-079;;069-695-832-958-551;;025-954-384-311-910;;006-404-118-185-928;;034-331-211-704-877;;007-352-622-097-788;;163-788-771-394-077;;159-979-502-911-862;;152-520-430-306-466;;002-704-208-517-091;;001-457-304-553-947;;130-646-047-491-369;;147-062-750-223-41X;;042-820-480-710-105;;025-184-307-709-716;;042-698-945-240-62X;;014-865-054-842-811;;033-797-614-829-293;;001-353-633-462-687;;096-888-948-974-772;;106-753-778-592-300;;025-750-184-554-753;;028-034-587-475-584;;109-553-992-963-291;;058-771-693-926-316;;007-033-051-621-962;;063-470-457-658-358;;020-855-322-534-259;;034-969-377-310-344;;082-564-722-938-120;;082-543-396-197-802;;019-064-411-799-850;;028-256-285-071-051;;097-292-830-422-322;;175-789-684-520-039;;034-498-409-269-879;;085-764-009-624-439;;036-326-129-640-399;;094-281-238-066-178;;116-193-705-533-609;;098-624-565-383-08X;;112-484-994-901-950;;015-578-927-490-646;;020-246-828-683-936;;022-580-468-420-943;;072-965-139-142-787;;030-443-500-754-783;;007-472-573-688-608;;029-759-013-024-068;;077-529-901-893-533;;000-466-280-529-149;;008-523-783-671-744;;086-901-555-374-478;;009-198-726-656-230;;009-893-901-432-942;;042-865-977-623-92X;;084-165-674-357-915,2891139;;pmc299544;;10.1073/pnas.84.23.8370;;3029772;;10.1073/pnas.84.5.1224;;pmc304399;;6300662;;pmc368532;;10.1128/mcb.3.2.280;;10.1128/mcb.3.2.280-289.1983;;10.1046/j.1365-313x.1998.00240.x;;9778846;;3118181;;10.1074/jbc.274.25.17860;;10364231;;9579858;;1530940;;10.1016/s0021-9258(18)45983-2;;1842922;;10.1101/gr.1.1.5;;10.1016/s0021-9258(19)70491-8;;6253477;;10338144;;10.1016/s0014-5793(99)00448-2;;10.1016/s0167-7799(98)01236-0;;9807841;;8783501;;10.1016/0167-5699(96)10025-6;;10.1126/science.282.5386.63;;9756477;;10.1126/science.2660260;;2660260;;10.1126/science.3863253;;3863253;;10.1016/0076-6879(92)11003-2;;1406312;;10.1038/352624a0;;1907718;;10.1093/nar/24.18.3546;;8836181;;pmc146123;;9729735;;10.1016/s0959-440x(98)80121-8;;10.1006/abio.1997.2153;;9193717;;4360349;;10.1021/bi00702a028;;9255788;;10.1038/nbt0897-751;;10.1146/annurev.biochem.60.1.631;;10.1146/annurev.bi.60.070191.003215;;1715680;;10.1016/0027-5107(94)90147-3;;7518039;;10.1038/336577a0;;3200306;;8391890;;10.1101/gr.2.4.318;;9219227;;10.1007/bf02761748;;9425665;;10.1016/s0958-1669(97)80128-0;;10.1038/194495a0;;14450081;;2531466;;10.1126/science.2531466;;9353232;;10.1016/s0958-1669(97)80040-7;;10329013;;10.1006/geno.1999.5799;;1172191;;10.1038/256495a0;;10.1101/gr.1.2.111;;1842928;;6402547;;10.1016/0022-1759(83)90415-5;;10.1126/science.3413476;;3413476;;9367793;;10.1006/bmme.1997.2631;;10.1073/pnas.80.13.4045;;pmc394197;;6191328;;9550519;;10.1161/01.str.29.4.830;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/0003-2697(84)90808-x;;6204550;;10.1007/978-1-4419-8718-1_1;;10.1016/s0958-1669(97)80123-1;;9425660;;10.1016/s0021-9258(20)65111-0;;6281257;;10.1111/j.1423-0410.1998.tb05424.x;;9704449;;10.1016/0022-1759(94)90051-5;;8308291;;10.4049/jimmunol.131.6.2895;;6358356;;2057362;;pmc328270;;10.1093/nar/19.11.3055;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;10322503;;10.1016/s0165-6147(99)01292-4;;1422221;;10.1016/1046-5928(92)90001-d;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1093/nar/12.8.3435;;6328421;;pmc318760;;10.1093/nar/11.18.6167;;6194506;;pmc326365;;10.1126/science.7618080;;7618080;;pmc223251;;10.1073/pnas.47.12.1981;;14038788;;10.1038/356356a0;;1549180;;9804757;;10.1074/jbc.273.46.30069;;6317018;;10.1021/bi00291a019;;pmc341163;;10.1093/nar/13.7.2399;;4000959;;9822378;;10.1126/science.282.5393.1484;;10.1016/s0014-2999(98)00249-0;;09683009;;9683009;;10.1016/s0165-6147(98)01193-6;;9703762;;3047679;;pmc338531;;10.1093/nar/16.16.8186;;10.1111/j.1432-1033.1978.tb12610.x;;213276;;6272129;;10.1038/294284a0;;5027125;;10.1016/s0006-291x(72)80018-4;;8417366;;10.1128/mcb.13.1.98-104.1993;;pmc358889;;10.1128/mcb.13.1.98;;10.1126/science.270.5235.410;;7569995,"Johansson, M.,EMBL/Genbank Data Libraries, Accession No. AF085734, Dec. 1999.*;;Cherney et al., cDNA sequence, Protein Structure, and Chromosomal Location of the Human Gene for Poly(ADP-ribose) Polymerase, Proc. Natl. Acad. Sci. USA vol. 84, pp. 8370-8374, Dec. 1987.*;;Alkhatid et al., Cloning and expression of cDNA for Human Poly(ADP-ribose) Polymerase, Proc. Natl. Acad. Sci. USA vol. 84, pp. 1224-1228, Mar. 1987.*;;Okayama and Berg, A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells, Molecular and Cellular Biology, vol. 3, pp. 280-289, Feb. 1983.*;;Babiychuk et al., Higher Plants Possess Two Structurally Different Poly(ADP-ribose) Polymerases, The Plant Journal, vol. 15 (5) pp. 635-645, Sep. 1998.*;;Althaus and Richter, ADP-Ribosylation of Proteins: Enzymology and Biochemical Significance, Molecular Biochemistry and Biophysics, Springer-Verlag (1987).;;Amé, J.C. et al. ""PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-Ribose) Polymerase"", J. Biol. Chem. 274(25):17860-17868 (1999).;;Anderson, W.F., ""Human gene therapy"", Nature, 392 (6679 Suppl.):25-30.;;Ausubel et al., (Eds.), ""Screening of Recombinant DNA Libraries"", Current Protocols in Molecular Biology, John Wiley & Son , Chapter 6, pp. 6.0.3-6.4.10 (1994).;;Banasik et al., ""Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase"", J. Biol. Chem., 267:1569-1575 (1992).;;Barany, F., ""The Ligase Chain Reaction in a PCR World"", PCR Methods and Applications, 1:5-16 (1991).;;Benjamin and Gill, ""Poly(ADP-ribose) Synthesis In Vitro Programmed by Damaged DNA"", J. Biol. Chem., 255:10502-8 (1980).;;Berger and Kimmel, (Eds.) ""Guide to Molecular Cloning Techniques,"" Methods in Enzymology, vol. 152, Title Page and Table of Contents Academic Press, San Diego, California (1987).;;Berghammer et al. ""pADPRT-2: A Novel mammalian polymerizing (ADP-ribosyl) transfer gene related to truncated pADPRT Homologues in plants and Caenorhabditis elegans"", FEBS Lett. 449:259-263 (1999).;;Bramlage et al., ""Designing ribozymes for the inhibition of gene expression"", Trends Biotechnol., 16:434-438 (1998).;;Brüggemann et al., ""Strategies for expressing human antibody repertoires in transgenic mice"", Immunol. Today, 17:391-397 (1996).;;Cane et al., ""Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations"", Science, 282:63-68 (1998).;;Capecchi, M.R., ""Altering the Genome by Homologous Recombination"", Science, 244:1288-1292 (1989).;;Caruthers, M.H., ""Gene Synthesis Machines: DNA Chemistry and Its Uses"", Science, 230:281-285 (1985).;;Caruthers, et al., ""Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs"", Methods Enzymol., 211:3-20 (1992).;;Clackson et al., ""Making antibody fragments using phage display libraries"", Nature, 352:624-628 (1991).;;Cline et al., ""PCR fidelity of Pfu DNA polymerase and other thermostable DNA polymerases"", Nucleic Acids. Res., 24:3546-3551 (1996).;;Dall'Acqua et al., ""Antibody Engineering"", Curr. Opin. Struct. Biol., 8:443-450 (1998).;;D'Amours et al., ""Purification of the Death Substrate Poly(ADP-ribose) Polymerase"", Anal. Biochem., 249:106-108 (1997).;;David et al., ""Protein Iodination with Solid State Lactoperoxidase"", Biochemistry, 13:1014-1021 (1974).;;Dayhoff in Atlas of Protein Sequence and Structure, National Biochemical Research Foundation, Washington, D.C. 5:124 (1972).;;Delihas et al., ""Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design"", Nat. Biotechnol., 15:751-753 (1997).;;Rossomando, E. F., ""Ion-Exchange Chromatography"", Methods Enzymol. (Guide to Protein Chemistry, Section VII) Deutscher, (Eds.) 182:309-421 (1990).;;Eguchi, Y., ""Antisense RNA"", Annu. Rev. Biochem., 60:631-652 (1991).;;Fritz et al., ""Effect of transfection of human poly(ADP-ribose) polymerase in Chinese hamster cells on mutagen resistance"", Mutation Res., 308:127-133 (1994).;;Gatti et al., ""Localization of an ataxia-telangiectasia gene to chromosome 11q22-23"", Nature, 336:577-580 (1988).;;Sarkar et al., ""Restriction-site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers"", PCR Methods Applic. 2:319-322 (1993).;;Gibson and Shillitoe, ""Ribozymes: Their Functions and Strategies for Their Use"", Mol. Biotechnol., 7:125-137 (1997).;;Harlow, et al., (Eds.) Antibodies: A Laboratory Manual, Chapter 6, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY, pp. 139-243 (1988).;;Houston and Banks, ""The chemical-biological interface: developments in automated and miniaturised screening technology"", Curr. Opin. Biotechnol., 8:734-740 (1997).;;Hunter et al., ""Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity"", Nature, 194:495-496 (1962).;;Huse et al., ""Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda"", Science, 246:1275-1281 (1989).;;Jayawickreme and Kost, ""Gene expression systems in the development of high-throughput screens"", Curr. Opin. Biotechnol., 8:629-634 (1997).;;Johansson,M. ""A Human Poly(ADP-Ribose) Polymerase Gene Family (ADPRTL): cDNA Cloning of Two Novel Poly(ADP-ribose) Polymerase Homologues"", Genomics 57 (3):442-445 (1999).;;Köhler and Milstein, ""Continuous cultures of fused cells secreting antibody of predefined specificity"", Nature, 256:495-497 (1975).;;Lagerström et al., ""Capture PCR: Efficient Amplification of DNA Fragments Adjacent to a Known Sequence in Human and YAC DNA"", PCR Methods Applic., 1:111-119 (1991).;;Lamoyi et al., ""Preparation of F(ab')2 Fragments from Mouse IgG of Various Subclasses"", J. Immunol. Meth., 56:235-243 (1983).;;Landegren et al., ""A Ligase-Mediated Gene Detection Technique"", Science, 241:1077-1080 (1988).;;Lavrovsky et al., ""Therapeutic Potential and Mechanism of Action of Oligonucleotides and Ribozymes"", Biochem. Mol. Med., 62:11-22 (1997).;;Leary et al., ""Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots"", Proc. Nat'l. Acad. Sci. USA, 80:4045-4049 (1983).;;Lo et al., ""Inhibition of Poly(ADP-Ribose) Polymerase: Reduction of Ischemic Injury and Attenuation of N-Methyl-D-Aspartate-Induced Neurotransmitter Dysregulation"", Stroke, 29:830-6 (1998).;;Marks et al., ""By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage"", J. Mol. Biol., 222:581-597 (1991).;;Meinkoth and Wahl, ""Hybridization of Nucleic Acids Immobilized on Solid Supports"", Anal. Biochem., 138:267-284 (1984).;;Molinete et al., ""Structure and Function of the Human poly (ADP-ribose) polymerase"" ADP-Ribosylation Reactions, Poirier andMoreau (Eds.), Springer-Verlag, New York, p. 3-13, (1992).;;Myers, P.L., ""Will combinatorial chemistry deliver real medicines?"", Curr. Opin. Biotechnol., 8:701-707 (1997).;;Nishikimi et al., ""Poly(ADP-ribose) Synthetase-The DNA Binding Domain and the Automodification Domain"", J. Biol. Chem. 257:6102-6105 (1982).;;Ouwehand et al., ""Novel Diagnostic and Therapeutic Strategies with Genetically Engineered Human Antibodies"", Vox Sang, 74 (Suppl. 2), 223-232 (1998).;;Owens and Young, ""The genetic engineering of monoclonal antibodies"", J. Immunological Methods, 168:149-165 (1994).;;Parham, P., ""On the Fragmentation of Monoclonal IgG1, IgG2a, and IgG2b from BALB/c Mice"", J. Immunol., 131:2895-2902 (1983).;;Parker et al., ""Targeted gene walking polymerase chain reaction"", Nucleic Acids. Res., 19(11):3055-3060 (1991).;;Pearson et al., ""Improved tools for biological sequence comparison"", Proc. Nat'l. Acad. Sci., USA, 85:2444-2448 (1988).;;Pieper et al., ""Poly (ADP-ribose) polymerase, nitric oxide and cell death"", Trends Pharmacol Sci., 20:171-181 (1999).;;Porath, J., ""Immobilized Metal Ion Affinity Chromatography"", Protein Expr. Purif., 3:263-281 (1992).;;Rader et al., ""A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries"", Proc. Nat'l. Acad. Sci. USA, 95:8910-8915 (1998).;;Renz and Kurz, ""A colorimetric method for DNA hybridization"", Nucleic Acids. Res., 12:3435-3444 (1984).;;Richardson and Gumport, ""Biotin and fluorescent labeling of RNA using T4 RNA ligase"", Nucleic Acids. Res., 11:6167-6184 (1983).;;Roberge et al., ""A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support"", Science, 269:202-204 (1995).;;Rotman, B., ""Measurement of Activity of Single Molecules of beta-D-Galactosidase"", Proc. Nat'l. Acad. Sci. USA, 47:1981-1991 (1961).;;Sambrook et al., (Eds.), Molecular Cloning:A Laboratory Manual, Cold Spring Harbor Laboratory Press:Cold Spring Harbor, New York, NY (1989), 9:47-9.50.;;Satoh and Lindahl, ""Role of poly(ADP-ribose) formation in DNA repair"", Nature, 356(6367): 356-8 (1992).;;Shieh et al., ""Poly(ADP-ribose) Polymerase Null Mouse Cells Synthesize ADP-ribose Polymers"", J. Biol. Chem., 273(46):30069-30072 (1998).;;Sims et al., ""Poly(ADP-ribose) Polymerase Inhibitors Preserve Nicotinamide Adenine Dinucleotide and Adenosine 5'-Triphosphate Pools in DNA-Damaged Cells: Mechanism of Stimulation of Unscheduled DNA Synthesis"", Biochemistry, 22(22):5188-5194 (1983).;;Smith, et al., ""The synthesis of oligonucleotides containing an aliphatic amino group at the 5' terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis"", Nucleic Acids Res., 13(7):2399-2412 (1985).;;Smith, et al., ""Tankyrase, a Poly(ADP-Ribose) Polymerase at Human Telomeres"", Science, 282:1484-1487 (1998).;;Szabó, C., ""Role of poly(ADP-ribose) synthetase in inflammation"", Eur. J. Pharmacol., 350(1):1-19 (1998).;;Szabó and Dawson, ""Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion"", Trends Pharmacol. Sci., 19(7):287-298 (1998).;;Triglia et al., ""A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences"", Nucleic Acids Res., 16:8186 (1988).;;Tsopanakis et al., ""Purification and Properties of Poly(ADP-ribose) Polymerase from Pig-Thymus Nuclei"", Eur. J. Biochem., 90:337-45 (1978).;;Yamamoto et al., ""Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets"", Nature, 294(5838):284-286 (1981).;;Yoshihara, K., ""Complete Dependency of Poly(ADP-Ribose) Synthesis on DNA and its Inhibition by Actinomycin D"", Biochem. Biophys. Res. Commun., 47:119-125 (1972).;;Youssoufian and Lodish, ""Transcriptional Inhibition of the Murine Erythropoietin Receptor Gene by an Upstream Repetitive Element"", Mol;. Cell Biol., 13(1):98-104(1993).;;Hodgkin et al., ""The Nematode Casnorhabditis elegans and Its Genome"", Science 270:410 (1995).",EXPIRED
929,US,A,US 3056111 A,167-389-449-928-47X,1962-09-25,1962,US 84130559 A,1959-09-21,US 84130559 A,1959-09-21,Display system,,GEN PRECISION INC,FINKLER RONALD A;;NORMAN POMERANCE;;GOLDMAN DAVID A;;ZOLA MEYER J,,https://lens.org/167-389-449-928-47X,Granted Patent,no,3,4,1,1,0,G08G5/0026;;G08G5/0026,G08G5/00,,0,0,,,,EXPIRED
930,WO,A1,WO 2011/053286 A1,187-865-418-921-670,2011-05-05,2011,US 2009/0062350 W,2009-10-28,US 2009/0062350 W,2009-10-28,"AUTOMATED SEED DETECTION AND PLANTING SYNCHRONIZATION APPARATUS, METHOD AND SYSTEM","An automated seed detection and planting synchronization apparatus, method and system is disclosed. The invention includes a seed detection protocol configured to monitor a derived metric equated to timing of movement of a seed carried by a seed metering means from a seed pick-up to seed drop point. For controlling synchronization of planting of seed, a seed metering unit empty notification signal is provided if the derived metric is satisfied and sensor readings confirm the absence of seed in the seed metering unit.",PIONEER HI BRED INT;;GLENDENNING MATTHEW K;;GOLDMAN DANIEL M;;JOHNSON DAVID E;;KELSICK JASON J;;SMITH DAVID C,GLENDENNING MATTHEW K;;GOLDMAN DANIEL M;;JOHNSON DAVID E;;KELSICK JASON J;;SMITH DAVID C,,https://lens.org/187-865-418-921-670,Patent Application,yes,5,22,1,1,0,A01C7/105;;A01C7/046,A01C7/10;;G05B19/042,,0,0,,,,PENDING
931,US,A1,US 2011/0098851 A1,167-163-117-728-525,2011-04-28,2011,US 60737209 A,2009-10-28,US 60737209 A,2009-10-28,"AUTOMATED SEED DETECTION AND PLANTING SYNCHRONIZATION APPARATUS, METHOD AND SYSTEM","An automated seed detection and planting synchronization apparatus, method and system is disclosed. The invention includes a seed detection protocol configured to monitor a derived metric equated to timing of movement of a seed carried by a seed metering unit from a seed pick-up to seed drop point. For controlling synchronization of planting of seed, a seed metering unit empty notification signal is provided if the derived metric is satisfied and sensor readings confirm the absence of seed in the seed metering unit.",PIONEER HI BRED INT,GLENDENNING MATTHEW K;;GOLDMAN DANIEL M;;JOHNSON DAVID E;;KELSICK JASON J;;SMITH DAVID C,PIONEER HI-BRED INTERNATIONAL INC (2009-11-02),https://lens.org/167-163-117-728-525,Patent Application,yes,16,36,2,2,0,A01C7/046;;A01C7/105;;A01C21/005;;Y10S111/90;;Y10S111/903;;A01C7/105;;A01C7/046;;A01C21/005;;Y10S111/903;;Y10S111/90,G06F17/00;;A01C7/08,700/240;;111/130,0,0,,,,ACTIVE
932,US,B1,US 7938075 B1,011-450-341-698-214,2011-05-10,2011,US 60737209 A,2009-10-28,US 60737209 A,2009-10-28,"Automated seed detection and planting synchronization apparatus, method and system","An automated seed detection and planting synchronization apparatus, method and system is disclosed. The invention includes a seed detection protocol configured to monitor a derived metric equated to timing of movement of a seed carried by a seed metering unit from a seed pick-up to seed drop point. For controlling synchronization of planting of seed, a seed metering unit empty notification signal is provided if the derived metric is satisfied and sensor readings confirm the absence of seed in the seed metering unit.",PIONEER HI BRED INT,GLENDENNING MATTHEW K;;GOLDMAN DANIEL M;;JOHNSON DAVID E;;KELSICK JASON J;;SMITH DAVID C,PIONEER HI-BRED INTERNATIONAL INC (2009-11-02),https://lens.org/011-450-341-698-214,Granted Patent,yes,18,29,2,2,0,A01C7/046;;A01C7/105;;A01C21/005;;Y10S111/90;;Y10S111/903;;A01C7/105;;A01C7/046;;A01C21/005;;Y10S111/903;;Y10S111/90,G05B19/042;;A01C7/10,111/200;;111/185;;111/900;;111/903,2,0,,,"International Search Report and Written Opinion for corresponding International Application No. PCT/US2090/062350 mailed Jul. 2, 2010.;;Mater-Macc; Magicsem Seed Distributor; © 2009 MATERMACC S.P.A.; Italy; located at website: http://www.matermacc.it/eng/magicsem-stampa.html on May 22, 2010; 1 sheet.",ACTIVE
933,WO,A3,WO 2009/064850 A3,023-021-053-314-482,2009-08-27,2009,US 2008/0083356 W,2008-11-13,US 98765807 P,2007-11-13,METHOD AND APPARATUS FOR INDIRECT MEDICAL CONSULTATION,A method and apparatus is provided comprising a technology engine designed to facilitate indirect medical consultation with health care providers and create a medical record of this indirect consultation event. In one embodiment is provided a method and apparatus for capturing electronically one or more of the following: (a) patient complaints; (b) health care provider's impression/review; (c) health care provider/patient discussion of complaint symptoms following which a treatment plan is formulated regarding health care strategy; (d) any prescription issued by the health care provider; and/or (e) a set of follow-up visits by the patient.,WASSON DAVID S;;GUILLORY PAUL A;;DOLAK JOHN A;;GOLDMAN MATTHEW A,WASSON DAVID S;;GUILLORY PAUL A;;DOLAK JOHN A;;GOLDMAN MATTHEW A,,https://lens.org/023-021-053-314-482,Search Report,yes,5,0,5,5,0,G06Q10/06;;G06Q30/04;;G06Q40/08;;G16H10/20;;G16H10/60;;G16H80/00;;G16H10/20;;G16H10/60;;G06Q10/06;;G06Q30/04;;G06Q40/08;;G16H80/00,G06Q50/00,,0,0,,,,PENDING
934,US,A,US 5912632 A,080-786-019-096-401,1999-06-15,1999,US 78076597 A,1997-01-08,US 78076597 A,1997-01-08,Single chip RF tag oscillator circuit synchronized by base station modulation frequency,"A Radio Frequency (RF) transponder (tag), method, and system, whereby the tag has a low current tag oscillator, the oscillation frequency of the tag oscillator set by RF signal from a base station.",IBM,DIESKA DAVID E;;FRIEDMAN DANIEL JOSEPH;;GOLDMAN KENNETH ALAN;;HEINRICH HARLEY KENT,INTERMEC IP CORP. A CORPORATION OF DELAWARE (1999-02-05);;IBM CORPORATION (1997-02-01);;UNOVA INC (1997-12-18),https://lens.org/080-786-019-096-401,Granted Patent,yes,4,162,1,1,0,G06K7/0008;;G06K19/0723;;H04W56/0035;;H04W56/0035;;G06K7/0008;;G06K19/0723,G06K7/00;;G06K19/07;;H04B7/26,340/825.54;;455/31.1;;455/37.1;;331/23;;331/10,0,0,,,,EXPIRED
935,CA,A1,CA 2181401 A1,109-834-621-191-457,1997-03-01,1997,CA 2181401 A,1996-07-17,US 52042595 A,1995-08-29,Call screening method and apparatus for use in completing telephone calls,,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/109-834-621-191-457,Patent Application,no,0,0,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,,0,0,,,,EXPIRED
936,EP,A4,EP 3283654 A4,117-674-137-247-236,2018-12-12,2018,EP 16780736 A,2016-04-14,US 201562147547 P;;US 2016/0027503 W,2015-04-14,METHODS FOR TYPING OF LUNG CANCER,,GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,FARUKI HAWAZIN;;LAI-GOLDMAN MYLA;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,,https://lens.org/117-674-137-247-236,Search Report,no,2,0,10,10,0,C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C12Q1/68;;C40B30/04;;C40B40/06;;G01N33/574,,7,6,007-411-143-134-577;;004-671-040-120-895;;034-006-012-963-375;;131-631-815-538-938;;024-097-445-956-270;;114-582-312-821-614,10.1158/1078-0432.ccr-07-4937;;19010856;;18641660;;10.1038/nm.1790;;pmc2667337;;10.1097/jto.0b013e318221f701;;21642859;;10.1016/j.jmoldx.2013.03.007;;pmc3699698;;23701907;;pmc5164925;;10.1038/modpathol.2012.106;;22814311;;pmc4509741;;10.5858/arpa.2012-0263-ra;;22970842,"E.-S. LEE ET AL: ""Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression"", CLINICAL CANCER RESEARCH, vol. 14, no. 22, 15 November 2008 (2008-11-15), US, pages 7397 - 7404, XP055324592, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-4937;;KERBY SHEDDEN ET AL: ""Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study"", NATURE MEDICINE, vol. 14, no. 8, 20 July 2008 (2008-07-20), New York, pages 822 - 827, XP055518110, ISSN: 1078-8956, DOI: 10.1038/nm.1790;;TRAVIS WILLIAM D ET AL: ""International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma."", JOURNAL OF THORACIC ONCOLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER FEB 2011, vol. 6, no. 2, February 2011 (2011-02-01), pages 244 - 285, XP002785976, ISSN: 1556-1380;;MATTHEW D. WILKERSON ET AL: ""Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens"", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, vol. 15, no. 4, 1 July 2013 (2013-07-01), US, pages 485 - 497, XP055518315, ISSN: 1525-1578, DOI: 10.1016/j.jmoldx.2013.03.007;;ERIK THUNNISSEN ET AL: ""Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study"", MODERN PATHOLOGY, vol. 25, no. 12, 20 July 2012 (2012-07-20), GB, pages 1574 - 1583, XP055518092, ISSN: 0893-3952, DOI: 10.1038/modpathol.2012.106;;WILLIAM D. TRAVIS ET AL: ""Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification"", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, vol. 137, no. 5, 1 May 2013 (2013-05-01), US, pages 668 - 684, XP055518091, ISSN: 0003-9985, DOI: 10.5858/arpa.2012-0263-RA;;See also references of WO 2016168446A1",DISCONTINUED
937,US,B1,US 6373852 B1,112-347-748-134-230,2002-04-16,2002,US 67978396 A,1996-07-15,US 67978396 A,1996-07-15,Coupling multiple low data rate lines to effect high data rate communication,"
    Apparatus for linking multiple baseband telephone lines to provide broadband communication. The apparatus includes a broadband port, a plurality of baseband ports, and a controller. The broadband port provides connection to a broadband device or broadband communication line. The baseband ports provide connection to baseband communication lines. The controller integrates baseband data streams accepted at the baseband ports into a broadband data stream for transmission at the broadband port, and/or demultiplexes a broadband data stream received at the broadband port into baseband streams for transmission at the baseband ports. The baseband data include message data corresponding to the message data of the broadband stream, and control data describing an interrelationship among the message data, for controlling integrating of the baseband message data. The invention allows an individual to use multiple plain old telephone service (POTS) lines in combination to emulate the capability of a broadband line. 
",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1996-11-05),https://lens.org/112-347-748-134-230,Granted Patent,yes,30,16,5,5,0,H04L25/14;;H04L25/14,H04L25/14;;H04M11/00;;H04M3/00,370/465;;370/474;;370/524,1,0,,,"Stallings W., ISDN and Broadband ISDN with Frame Relay and ATM, pp. 126-129, 1995.",EXPIRED
938,EP,A1,EP 2454989 A1,123-231-130-831-098,2012-05-23,2012,EP 11195043 A,2006-11-20,EP 06838085 A;;US 75770406 P;;US 47832206 A,2006-01-10,Micro vein enhancer,"The present invention is a Miniature Vein Enhancer that includes a Miniature Projection Head. The Miniature Projection Head may be operated in one of three modes, AFM, DBM, and RTM. The Miniature Projection Head of the present invention projects an image of the veins of a patient, which aids the practitioner in pinpointing a vein for an intravenous drip, blood test, and the like. The Miniature projection head may have a cavity for a power source or it may have a power source located in a body portion of the Miniature Vein Enhancer. The Miniature Vein Enhancer may be attached to one of several improved needle protectors, or the Miniature Vein Enhancer may be attached to a body similar to a flashlight for hand held use. The Miniature Vein Enhancer of the present invention may also be attached to a magnifying glass, a flat panel display, and the like.
",ACCUVEIN LLC,GOLDMAN RON;;HUNT DAVID;;MOCK MARK;;MARSHAL GRAHAM;;CONLON STEPHEN;;ROTH BOB,,https://lens.org/123-231-130-831-098,Patent Application,yes,8,3,48,155,0,A61B5/0059;;A61M5/427;;A61B2090/366;;A61B90/13;;A61B5/0082;;A61B5/0068;;A61B5/0079;;A61B5/743;;A61B5/489;;A61M5/42;;A61B5/00;;A61B2090/366;;A61B5/0059;;A61M5/427;;A61B90/13;;G06T7/50;;G02B27/1006;;A61B5/489;;A61B5/0037;;A61B5/0075;;A61B5/0082;;A61B5/7475;;A61M5/46;;A61B5/0068;;A61B5/0079;;A61B5/743;;A61B5/0062;;A61B5/0071;;A61B5/6824;;A61B5/6831;;A61B2560/0431;;A61B5/6887;;A61B17/3403;;A61B2560/0214;;A61B2560/0425;;A61B2562/028,A61B5/00,,0,0,,,,DISCONTINUED
939,US,A,US 5907811 A,126-961-773-152-869,1999-05-25,1999,US 68697696 A,1996-07-25,US 68697696 A,1996-07-25,Personal reach service with paging and optional point of entry via cellular network,"A personal reach system includes a network, a personal reach unit, a cellular network, and a landline telephone station. The personal reach unit is coupled to the cellular network and the landline telephone through the network. When a first party pages a second party through the personal research unit, the first party is connected to the second party by either the personal reach unit through the landline telephone station or the cellular network through the cellular phone.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1996-07-22),https://lens.org/126-961-773-152-869,Granted Patent,yes,8,20,1,1,0,H04W68/00;;H04W68/00,H04W68/00,455/459;;455/413,0,0,,,,EXPIRED
940,ES,T3,ES 2326976 T3,134-012-780-938-312,2009-10-22,2009,ES 04759878 T,2004-04-16,US 41776303 A,2003-04-17,APARATO Y PROCEDIMIENTO PARA ENSAYAR MUESTRAS LIQUIDAS.,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,GOLDMAN ROSS BRYAN;;TOWNSEND DAVID EDWARD;;SMITH KENNETH E;;MCCARTHY KATHLEEN R,,https://lens.org/134-012-780-938-312,Granted Patent,no,0,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,C12Q1/06;;B01L3/00;;C12M1/22,,0,0,,,,ACTIVE
941,CA,C,CA 2181401 C,167-232-348-466-207,2000-01-04,2000,CA 2181401 A,1996-07-17,US 52042595 A,1995-08-29,CALL SCREENING METHOD AND APPARATUS FOR USE IN COMPLETING TELEPHONE CALLS,"A system and method for providing personal communications services are disclosed. A bridging and signaling unit implements a bridge for connecting telephone calls between a caller, a called party, and an alternate destination. A caller who calls the personal telephone number associated with a called party is held at the bridging and signaling unit while waiting for a return telephone call from the called party. The called party is alerted to the existence of the call through a paging system. If the time period during which the caller is on hold exceeds a time-out period, the caller will be connected to an alternate destination, such as a secretary, an answering service, or a voice messaging system. If the called party places the return telephone call while the caller is connected to the alternate destination, the called party will be connected to the caller and the alternate destination in such a manner that that the called party can hear the conversation between the caller and the alternate destination, but the caller and the alternate destination cannot hear the called party and do not know that the called party has connected, i.e. the called party is on mute mode. After screening the call, the called party may then indicate that he/she wishes to be connected to the caller, at which time the connection to the alternate destination is terminated and the caller and the called party are connected such that they can speak with each other. If the called party does not wish to speak to the caller, he/she may hang up, and the connection between the caller and the alternate destination may continue.",,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/167-232-348-466-207,Granted Patent,no,0,0,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,,0,0,,,,EXPIRED
942,US,B1,US 7664122 B1,171-562-042-331-728,2010-02-16,2010,US 74719303 A,2003-12-30,US 74719303 A;;US 48430503 P,2003-07-03,Call tracking using voice quality measurement probe,"A system for monitoring quality of calls in a network. A server receives information concerning calls which begin or end in a network and at the same time receives measurements of a quality parameter such as bandwidth. This measurement data is provided by a probe, so that the server is able to correlate calls which are placed through the network with the quality of service in the network at that time. When the quality falls below a desired level, the server notifies the customer or the network operator so that appropriate action may be taken.",AT & T CORP,CHEUNG ERIC;;FOLADARE MARK;;GOLDMAN SHELLEY;;PURDY KERMIT H;;SHUR DAVID H,AT&T CORP (2004-05-07),https://lens.org/171-562-042-331-728,Granted Patent,yes,19,7,3,3,0,H04L41/5003;;H04L41/5009;;H04L43/0829;;H04L43/0852;;H04L43/087;;H04L43/106;;H04L41/5003;;H04L43/087;;H04L43/0829;;H04L43/0852;;H04L43/106;;H04L41/5009,H04L12/56;;H04L12/28;;H04L12/66,370/401;;370/352;;379/1.04,1,0,,,"Tom Gallatin, Finding and Fixing VolP Problems, May 2003, Internet Telephony Feature Article, pp. 1-6, May 2003.",INACTIVE
943,DE,B,DE 1263366 B,004-480-087-859-476,1968-03-14,1968,DE G0032947 A,1961-08-16,US 5777660 A,1960-09-22,Anordnung zum Aufzeichnen und Abtasten von digitalen Daten,,GEN PRECISION INC,GOLDMAN DAVID ALEXANDER;;GRAY JOHN WIGHTMAN;;HAYEK ARTHUR FOSTER;;MOERGER ERNEST ARNOLD,,https://lens.org/004-480-087-859-476,Patent Application,no,2,0,5,6,0,G06F13/22;;G06F13/22,G06F3/12;;G06F13/22;;G09G3/00,,0,0,,,,DISCONTINUED
944,WO,A2,WO 1998/046274 A2,015-231-441-258-369,1998-10-22,1998,US 9808053 W,1998-04-15,US 84255597 A,1997-04-15,CATIONIC POLYMERS FOR NUCLEIC ACID TRANSFECTION,"A class of polycationic polymers comprising products obtained by the copolymerization of a diprimary amine and a suitable comonomer, wherein the diprimary amine contains at least two primary amines and at least two secondary amines, and their use for nucleic acid transfection, and the delivery of suitable anionically charged bioactive molecules.",AVANTI POLAR LIPIDS INC;;UAB RESEARCH FOUNDATION,BURGESS STEPHEN W;;CURIEL DAVID T;;GOLDMAN COREY K;;SHAW WALTER A,,https://lens.org/015-231-441-258-369,Patent Application,no,0,3,4,4,0,A61K48/00;;A61K48/00;;A61K47/59;;A61K47/59;;A61K47/595;;A61K47/595;;A61K47/6807;;A61K47/6807;;C12N15/87;;C12N15/87,A61K47/48;;A61K48/00;;C12N15/87,,0,0,,,,PENDING
945,WO,A1,WO 1999/008298 A1,012-505-550-212-585,1999-02-18,1999,US 9816626 W,1998-08-10,US 91014697 A,1997-08-12,NONAQUEOUS ELECTRICAL STORAGE DEVICE,"An electrochemical capacitor is disclosed that features two, separated, high surface area carbon cloth electrodes (16, 18) sandwiched between two current collectors (12, 14) fabricated of a conductive polymer having a flow temperature greater than 130 degrees Celsius, with the perimeter of the electrochemical being sealed with a high temperature gasket (20) to form a single cell device. The gasket material is a thermoplastic stable at temperature greater than 100 degrees Celsius, preferably a polyester or a polyurethane, and having a reflow temperature above 130 degrees Celsius but below the softening temperature of the current collector material. The capacitor packaging has good mechanical integrity over a wide temperature range, contributes little to the device equivalent series resistance, and is designed to be easily manufactured by assembly line methods. The individual cells can be stacked in parallel or series configuration to reach the desired device voltage and capacitance.",COVALENT ASSOCIATES INC,MCEWEN ALAN B;;EVANS DAVID A;;BLAKLEY THOMAS J;;GOLDMAN JAY L,,https://lens.org/012-505-550-212-585,Patent Application,yes,5,7,3,3,0,Y02E60/13;;Y02T10/70;;H01G11/80;;H01G11/68;;H01G11/62;;H01G11/60;;H01G11/32;;Y02E60/13;;Y02T10/70;;H01G11/60;;H01G11/62;;H01G11/32;;H01G11/68;;H01G11/80,H01G9/00;;H01G9/155,,0,0,,,,PENDING
946,EP,A4,EP 3665199 A4,025-054-255-960-427,2021-08-11,2021,EP 18843577 A,2018-08-07,US 201762541960 P;;US 201762608218 P;;US 201862629934 P;;US 2018/0045522 W,2017-08-07,METHODS FOR SUBTYPING OF HEAD AND NECK SQUAMOUS CELL CARCINOMA,,GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,LAI-GOLDMAN MYLA;;FARUKI HAWAZIN;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,,https://lens.org/025-054-255-960-427,Search Report,no,0,0,4,4,0,C12Q1/6886;;G01N33/574;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q1/686;;C12Q1/6886;;C12Q2561/113;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q2600/106;;C12Q2600/112,C07K16/28;;C12Q1/6853;;C12Q1/6886;;C40B40/08;;G01N33/574,,5,4,000-670-622-843-997;;053-541-288-806-884;;068-162-585-789-042;;153-998-060-601-394,10.1016/s1535-6108(04)00112-6;;15144956;;10.1371/annotation/b42f61c5-cb7e-49ca-8cd6-6e1f7903ad08;;10.1016/j.cell.2017.10.044;;pmc5878932;;29198524;;10.1371/journal.pone.0108908,"CHRISTINE H CHUNG ET AL: ""Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression"", CANCER CELL, vol. 5, no. 5, 1 May 2004 (2004-05-01), pages 489 - 500, XP055009602, ISSN: 1535-6108, DOI: 10.1016/S1535-6108(04)00112-6;;VONN WALTER ET AL: ""Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes"", PLOS ONE, vol. 8, no. 2, 22 February 2013 (2013-02-22), pages 1 - 11, XP055674588, DOI: 10.1371/journal.pone.0056823;;SIDHARTH V. PURAM ET AL: ""Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer"", CELL, vol. 171, no. 7, 14 December 2017 (2017-12-14), Amsterdam NL, pages 1611 - 1624, XP055547353, ISSN: 0092-8674, DOI: 10.1016/j.cell.2017.10.044;;WARTA ROLF ET AL: ""Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma"", PLOS ONE, vol. 9, no. 10, 2 October 2014 (2014-10-02), pages e108908, XP055790811, Retrieved from the Internet <URL:https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.pone.0108908/1/pone.0108908.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa@plos-prod.iam.gserviceaccount.com/20210329/auto/storage/goog4_request&X-Goog-Date=20210329T094713Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=ho> DOI: 10.1371/journal.pone.0108908;;See also references of WO 2019032525A1",PENDING
947,EP,A3,EP 0781067 A3,064-938-455-219-260,2000-12-06,2000,EP 96120274 A,1996-12-17,US 57383995 A,1995-12-18,System and method for maintaining personal communications information in a mobile communications system,"The invention is an apparatus and method for updating a communications network (16) from one or more user communications devices (12, 78). The invention uses the electronic scheduling or other time-based features within a communications device to control and/or initiate transmission of information between the communications device and the communications network. Information from one or more communications devices is updated to the communications network in response to time-based components in the information entries corresponding to a timing device (42) associated with the respective communications device. Also, once the network has received this updated information, comparisons of related information entries are initiated to detect discrepancies therebetween. In this manner, user submitted time and geographic location information is compared with similar information automatically retrieved by the communications network using conventional and future network communications technology. Any detected discrepancies are used to initiate appropriate notification to the user and/or retrieve updated information, or to default to existing message delivery systems (79).",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/064-938-455-219-260,Search Report,yes,5,0,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,DISCONTINUED
948,EP,A3,EP 0782362 A3,140-100-760-263-618,1999-05-06,1999,EP 96120762 A,1996-12-23,US 57954095 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number (PTN). The mobile party uses the two-way pager to transmit call control parameters which are used by the telephone network to route calls directed to the party's PTN. The mobile party may also use the pager to transmit a location indicator which specifies the subscriber's location and informs the network of the subscriber's intention to receive calls according to a call examination procedure. To invoke the call examination procedure, the bandwidths and protocols of all possible terminating stations associated with the subscriber's location are stored in the network on a pre-provisioned basis. Thereafter, when a call is placed to the subscriber's PTN, the network determines the bandwidth and protocol of the originating station, selects a terminating station that is located at the subscriber site and has a bandwidth and protocol most closely resembling that of the originating station, and routes the call to the selected terminating station.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/140-100-760-263-618,Search Report,yes,3,0,7,7,0,H04W4/16;;H04W76/10;;H04W4/16;;H04W76/10,H04W4/16;;H04W76/02,,0,0,,,,DISCONTINUED
949,US,A,US 6108521 A,006-299-118-584-564,2000-08-22,2000,US 32575597 A,1997-05-20,US 32575597 A;;US 57954095 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number (PTN). The mobile party uses the two-way pager to transmit call control parameters which are used by the telephone network to route calls directed to the party's PTN. The mobile party may also use the pager to transmit a location indicator which specifies the subscriber's location and informs the network of the subscriber's intention to receive calls according to a call examination procedure. To invoke the call examination procedure, the bandwidths and protocols of all possible terminating stations associated with the subscriber's location are stored in the network on a pre-provisioned basis. Thereafter, when a call is placed to the subscriber's PTN, the network determines the bandwidth and protocol of the originating station, selects a terminating station that is located at the subscriber site and has a bandwidth and protocol most closely resembling that of the originating station, and routes the call to the selected terminating station.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/006-299-118-584-564,Granted Patent,yes,26,25,7,7,0,H04W4/16;;H04W76/10;;H04W4/16;;H04W76/10,H04W4/16;;H04W76/02,455/31.3;;455/417;;455/458,2,0,,,"European Search Report for EP96120762, dated Mar. 15, 1999.;;C. Colavito and M. Saba, The Integrated Mobile Telephone & Paging System , IEEE Conference Proceeding, Jun. 9 11, 1969, Boulder, CO.",EXPIRED
950,CA,A1,CA 2195140 A1,021-837-900-222-079,1997-08-14,1997,CA 2195140 A,1997-01-15,US 60069096 A,1996-02-13,Method of Announcing an Internet Call,,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/021-837-900-222-079,Patent Application,no,0,0,6,6,0,H04M3/382;;H04M7/006;;H04M11/022;;Y10S379/902;;Y10S379/90;;H04L9/40;;H04M11/022;;H04M3/382;;H04M7/006;;Y10S379/90;;Y10S379/902;;H04L9/40,H04W84/02;;H04L29/06;;H04M3/38;;H04M7/00;;H04M11/02,,0,0,,,,EXPIRED
951,SG,A1,SG 73359 A1,024-280-923-823-938,2000-06-20,2000,SG 1996001014 A,1996-02-06,US 38500495 A,1995-02-07,Method and apparatus for prioritizing telephone calls,,AT & T CORP,SILVERMAN DAVID P;;FOLADARE MARK J;;MURRAY NANCY S;;GOLDMAN SHELLEY B,,https://lens.org/024-280-923-823-938,Patent Application,no,0,0,10,10,0,H04M3/38;;H04M3/42059;;H04M3/42102;;H04M3/436;;H04M3/54;;H04M2242/22;;H04Q3/0016;;H04Q3/0029;;H04Q3/72;;H04Q2213/13091;;H04Q2213/13103;;H04Q2213/13141;;H04Q2213/13176;;H04Q2213/13204;;H04Q2213/1325;;H04Q2213/13256;;H04Q2213/13282;;H04Q2213/13547;;H04Q3/0029;;H04Q2213/13547;;H04Q2213/13256;;H04M2242/22;;H04M3/42059;;H04Q2213/1325;;H04Q3/0016;;H04Q2213/13103;;H04M3/436;;H04Q3/72;;H04Q2213/13141;;H04M3/42102;;H04M3/54;;H04Q2213/13091;;H04Q2213/13176;;H04Q2213/13282;;H04Q2213/13204;;H04M3/38,H04M3/38;;H04M3/42;;H04M3/436;;H04M3/54;;H04Q3/00;;H04Q3/72,,0,0,,,,PENDING
952,US,A,US 5950122 A,029-694-789-659-269,1999-09-07,1999,US 63905196 A,1996-04-24,US 63905196 A,1996-04-24,Technique for providing feature information in a personal mobile communication system,"A method for use in completing a caller's telephone call that is placed to the telephone number of a called party, comprises the steps of receiving the caller's call, in response to which selecting a meet-me system from among a plurality of meet-me systems. The method further comprises the steps of routing the caller's call to the selected meet-me system, and, routing a call originated by said called party to this selected meet-me system so as to connect to the caller's call at the selected meet-me system. Thereafter, the method includes the step of transmitting appropriate instructions associated with a plurality of available features to the called party so as to allow the called party to select at least one of the available features.",AT & T CORP,FOLADARE MARK J;;SILVERMAN DAVID P;;GOLDMAN SHELLEY B;;WEBER ROY P,AT&T CORPORATION (1996-04-03),https://lens.org/029-694-789-659-269,Granted Patent,yes,6,5,1,1,0,H04W4/00;;H04W76/00;;H04W76/00;;H04W4/00,H04W4/00,455/414;;455/459;;455/412;;455/403;;455/31.3;;455/31.2,0,0,,,,EXPIRED
953,CA,C,CA 2195140 C,034-752-795-644-497,2000-05-02,2000,CA 2195140 A,1997-01-15,US 60069096 A,1996-02-13,METHOD OF ANNOUNCING AN INTERNET CALL,"A called party is alerted to the presence of a voice call on the Internet (110) by a page that is automatically transmitted to the called party's pager (120) upon initiation of the call by a calling party from his terminal (101) running Internet voice communications software and equipped with a microphone (102) and speaker (103). The page is transmitted in response to a message sent by a service provider (115) on the Internet, which receives from the calling party's terminal on the Internet, information for identifying the called party's pager. The called party, upon receiving the page, connects to the called party on the Internet through his home terminal (105) that is running that same voice communications software and is also equipped with a microphone (106) and speaker (107), or through any such similarly equipped portable or fixed terminal (125) at any location from which the Internet can be accessed. Alternatively, the called party can answer the call on the Internet with a standard station set (131 ) by calling an Internet-savvy platform (130), which converts the packetized voice signal of the calling party into an analog signal and the analog voice signal of the called party into packets for transmission on the Internet.",,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/034-752-795-644-497,Granted Patent,no,0,0,6,6,0,H04M3/382;;H04M7/006;;H04M11/022;;Y10S379/902;;Y10S379/90;;H04L9/40;;H04M11/022;;H04M3/382;;H04M7/006;;Y10S379/90;;Y10S379/902;;H04L9/40,H04W84/02;;H04L29/06;;H04M3/38;;H04M7/00;;H04M11/02,,0,0,,,,EXPIRED
954,JP,A,JP 2007282285 A,049-909-087-757-287,2007-10-25,2007,JP 2007185408 A,2007-07-17,US 57383995 A,1995-12-18,APPARATUS AND METHOD FOR MAINTAINING PERSONAL COMMUNICATION INFORMATION IN MOBILE COMMUNICATIONS SYSTEM,"<P>PROBLEM TO BE SOLVED: To provide an apparatus and a method for updating a communication network from one or more user communication apparatuses. <P>SOLUTION: This invention uses an electronic scheduling or other time-based functions in a communication apparatus to control and/or initiate a transmission of information between the communications apparatus and a communication network. Information from one or more communication apparatuses to the communication network is updated, in response to time-based parts in information entries corresponding to a timer that operates with the corresponding communication apparatus. Once the network receives this updated information, comparison between these is initiated, to detect discrepancies between related information entries. Information about the time and the geographical location submitted by a user is compared with similar information automatically reproduced by the communication network by using a conventional or future network communication technology. Detected discrepancies are used for initiating appropriate notification to the user, reproducing the updated information, or holding an existing message delivery systems in nonuse. <P>COPYRIGHT: (C)2008,JPO&INPIT",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/049-909-087-757-287,Patent Application,no,0,0,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,INACTIVE
955,SU,A1,SU 607118 A1,048-416-093-163-264,1978-05-15,1978,SU 2354803 A,1976-05-06,SU 2354803 A,1976-05-06,FORCE MEASURING DEVICE,,K PT I BYTOVOGO OBSLUZHIVANIYA,GOLDMAN SHMIL O;;LEJBELMAN DAVID L;;BURYAK VASILIJ YA;;GOLTSER ANATOLIJ YA,,https://lens.org/048-416-093-163-264,Limited Patent,no,0,1,1,1,0,,G01L1/04,,0,0,,,,EXPIRED
956,US,B1,US 6343115 B1,055-533-499-486-959,2002-01-29,2002,US 60069096 A,1996-02-13,US 60069096 A,1996-02-13,Method of announcing an internet call,"
    A called party is alerted to the presence of a voice call on the Internet (  110  ) by a page that is automatically transmitted to the called party's pager (  120  ) upon initiation of the call by a calling party from his terminal (  101  ) running Internet voice communications software and equipped with a microphone (  102  ) and speaker (  103  ). The page is transmitted in response to a message sent by a service provider (  115  ) on the Internet, which receives from the calling party's terminal on the Internet, information for identifying the called party's pager. The called party, upon receiving the page, connects to the called party on the Internet through his home terminal (  105  ) that is running that same voice communications software and is also equipped with a microphone (  106  ) and speaker (  107  ), or through any such similarly equipped portable or fixed terminal (  125  ) at any location from which the Internet can be accessed. Alternatively, the called party can answer the call on the Internet with a standard station set (  131  ) by calling an Internet-savvy platform (  130  ), which converts the packetized voice signal of the calling party into an analog signal and the analog voice signal of the called party into packets for transmission on the Internet. 
",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1996-04-03),https://lens.org/055-533-499-486-959,Granted Patent,yes,73,132,6,6,0,H04M3/382;;H04M7/006;;H04M11/022;;Y10S379/902;;Y10S379/90;;H04L9/40;;H04M11/022;;H04M3/382;;H04M7/006;;Y10S379/90;;Y10S379/902;;H04L9/40,H04W84/02;;H04L29/06;;H04M3/38;;H04M7/00;;H04M11/02,379/88.17;;379/88.13;;379/217.01;;379/900;;379/902;;370/349;;370/352,7,3,182-078-123-054-480;;185-093-587-406-821;;006-591-280-158-115,10.1007/978-94-011-4918-1_14;;10.17487/rfc1789;;10.1109/glocom.1996.586126,"""Definition of the Internet"", FNC Resolution, Oct. 24, 1995.*;;Nathan Muller, ""Dial 1-800-Internet"" Byte, 1996, vol. 21, Issue 2, Feb. 1996.;;R. Babbage, I. Moffat, A O'Neill and S. Sivaraj, ""Internet Phone-Changing the Telephony Paradigm"" BT Technol J vol. 15, No. 2, Apr. 1997.;;IBM Technical Disclosure Bulletin ""Workstation Communications System"", IBM Technical Disclosure Bulletin, vol. 37, No. 09, Sep. 1994.;;Cui-Qing Yang, ""INET Phone-Telephone Services and Servers on Internet"", University of North Texas, Apr. 1995.;;S. Harris, N. Psimenatos, P. Richards, I. Ebert, ""Intelligent Network Realization and Evolution: CCITT Capability Set I and Beyond"" International Switching Symposium, Oct. 1992, vol. 2.;;Colin, Low ""The Internet Telephony Red Herring"" HP Laboratories Bristol, Jun. 1996.",EXPIRED
957,US,B1,US 6385453 B1,118-442-439-805-786,2002-05-07,2002,US 55805500 A,2000-04-26,US 55805500 A;;US 89807997 A;;US 57918895 A,1995-12-27,Communication system and method using two-way paging to provide call control,"
    A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number. The mobile party uses the two-way pager to transmit call control parameters which are used by the telephone network to route calls directed to the party's PTN. The mobile party may also use the pager to transmit subsequent routing parameters which are used by the network to reroute calls which have been previously routed. The subsequent routing of a call may be performed at any time following a previous routing, even after the call has received answer supervision. 
",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1996-01-11),https://lens.org/118-442-439-805-786,Granted Patent,yes,31,27,8,8,0,H04W84/025;;H04W84/025;;H04M3/42229;;H04M3/42229,H04B5/04;;H04M3/42;;H04W84/02,455/445;;455/417;;340/7.21;;340/7.28;;379/211.02;;379/211.04;;379/212.01,1,0,,,"C. Colavito and M. Saba, ""The Integrated Mobile Telephone & Paging System"", IEEE Conference Proceedings, Jun. 9-11, 1969, Boulder Co.",EXPIRED
958,US,A,US 6032023 A,119-142-017-210-127,2000-02-29,2000,US 22241698 A,1998-12-29,US 22241698 A;;US 57918495 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number. The mobile party is equipped with a two-way pager which the party may use to provide call control. The pager is periodically queried by a network and/or paging service to determine whether or not the pager is reachable. If the pager becomes unreachable, and thereafter a call is placed to the party's Personal Telephone Number, the network routes the call to a default station. If the pager is reachable, any one of a number of alternative call routing procedures may be invoked including: registration type routing, call-by-call routing, revertive calling, call examination routing, and subsequent routing. In one possible embodiment, a Customer Routing Point is used to store the pager status along with other call routing information, and a Network Control Point is used to carry out the appropriate routing procedure. Other possible embodiments include: using an adjunct to perform the functions of the Customer Routing Point and Network Control Point; and combining an adjunct with a Customer Routing Point and Network Control Point.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/119-142-017-210-127,Granted Patent,yes,29,14,8,8,0,H04W4/16;;H04W88/022;;H04W4/16;;H04W88/022,H04W4/16;;H04W88/02,455/31.3;;455/461;;455/417;;455/414,1,0,,,"C. Colavito and M. Saba, The Integrated Mobile Telephone & Paging System , IEEE Conference Proceeding, Jun. 9 11, 1969, Boulder, Co.",EXPIRED
959,EP,A1,EP 3665199 A1,159-079-851-707-700,2020-06-17,2020,EP 18843577 A,2018-08-07,US 201762541960 P;;US 201762608218 P;;US 201862629934 P;;US 2018/0045522 W,2017-08-07,METHODS FOR SUBTYPING OF HEAD AND NECK SQUAMOUS CELL CARCINOMA,,GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,LAI-GOLDMAN MYLA;;FARUKI HAWAZIN;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,,https://lens.org/159-079-851-707-700,Patent Application,yes,0,0,4,4,144,C12Q1/6886;;G01N33/574;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q1/686;;C12Q1/6886;;C12Q2561/113;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q2600/106;;C12Q2600/112,C07K16/28;;C12Q1/6853;;C40B40/08;;G01N33/574,,0,0,,,,PENDING
960,US,B2,US 11739386 B2,176-906-931-912-299,2023-08-29,2023,US 201816632006 A,2018-07-20,US 201816632006 A;;US 201762535617 P;;US 201762578065 P;;US 2018/0043086 W,2017-07-21,Methods for determining response to PARP inhibitors,"Methods and compositions are provided for determining whether an adenocarcinoma or squamous cell carcinoma patient is likely to respond to PARP inhibitor treatment. Specifically, a method of assessing whether a patient's adenocarcinoma (AD) lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) or a patient's squamous cell carcinoma (SQ) is primitive, classical, secretory or basal is provided herein. The method entails detecting the levels of classifier biomarkers at the nucleic acid level, in an AD or SQ lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the AD lung cancer sample is classified as a TRU, PI, or PP AD sample or the SQ lung cancer sample is classified as primitive, classical, secretory or basal and a determination of whether the patient is likely to respond to PARP inhibitor treatment can be made.",GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,LAI-GOLDMAN MYLA;;FARUKI HAWAZIN;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2021-12-24);;GENECENTRIC THERAPEUTICS INC (2021-12-09),https://lens.org/176-906-931-912-299,Granted Patent,yes,24,0,3,3,0,C12N9/1077;;C12Y204/0203;;G01N33/57423;;G01N2800/52;;C12Q1/6886;;C12Q2600/106;;C12Q2600/158;;C12N9/1077;;C12Q1/6886;;C12Q2600/106;;C12Q2600/158;;C12Y204/0203;;G01N2800/52,C12Q1/6886;;C12N9/10,,58,55,035-724-890-182-700;;004-179-899-782-547;;006-667-562-194-403;;126-591-089-313-608;;104-497-647-494-695;;037-521-858-455-29X;;094-625-294-545-997;;025-130-966-924-512;;018-431-249-663-589;;055-624-421-022-840;;042-033-734-735-562;;117-777-238-559-353;;006-071-937-712-151;;141-972-395-659-749;;040-114-686-060-186;;007-633-003-789-794;;036-911-315-471-370;;027-637-887-931-488;;037-047-957-053-389;;146-606-185-618-094;;117-468-526-611-196;;029-535-767-270-158;;014-524-302-477-134;;109-553-992-963-291;;007-411-143-134-577;;082-440-595-671-19X;;007-073-310-261-903;;047-124-067-028-025;;054-687-629-970-737;;056-901-218-275-024;;009-170-894-352-506;;024-292-907-262-753;;003-097-252-926-399;;032-051-834-238-818;;098-346-650-110-898;;052-411-401-805-559;;112-133-786-248-745;;027-186-782-703-331;;151-092-577-969-999;;004-671-040-120-895;;015-828-439-921-354;;086-676-152-970-357;;068-722-476-531-459;;013-912-515-846-763;;178-658-354-216-914;;055-624-421-022-840;;050-723-935-789-629;;014-854-074-686-015;;085-309-020-554-932;;084-284-233-234-25X;;021-630-366-628-950;;043-885-019-636-545;;063-065-243-819-540;;025-139-768-705-328;;030-948-819-976-189,10.1097/00003246-200212000-00016;;12483063;;10.1126/science.1068996;;11951044;;10.1016/0378-1119(91)90582-v;;1756968;;pmc1618650;;15509548;;10.1016/s0002-9440(10)63435-9;;10.1038/76469;;10835600;;10.1103/physreva.37.5004;;9899654;;15829966;;10.1038/nature03443;;22960745;;pmc3466113;;10.1038/nature11404;;10.1177/34.11.3772081;;3772081;;10.1038/nature13385;;25079552;;pmc4231481;;14695316;;pmc1602211;;10.1016/s0002-9440(10)63093-3;;10.1093/bioinformatics/bti681;;16174683;;10.1007/s10549-012-2188-0;;22875744;;pmc3429780;;pmc479115;;15123585;;10.1101/gr.2167504;;17463023;;10.1093/bioinformatics/btm149;;10.1200/jco.2009.26.9589;;20406929;;10.3410/f.718142782.793485309;;10.1177/33.8.3894502;;3894502;;10.18637/jss.v033.i01;;pmc2929880;;20808728;;10.1038/nbt1385;;18278033;;2308948;;10.1073/pnas.87.5.1874;;pmc53586;;10.1093/biostatistics/4.2.249;;12925520;;10.1200/jco.2009.27.5719;;20547991;;pmc2917311;;pmc286648;;10.1073/pnas.86.4.1173;;2919166;;10.1126/science.3413476;;3413476;;10.1158/1078-0432.ccr-07-4937;;19010856;;10.1016/j.neo.2014.04.003;;pmc4094836;;24862760;;10.1021/bi00677a030;;235286;;28649435;;pmc5445594;;10.1038/s41540-017-0011-6;;10.1373/clinchem.2006.083725;;17525107;;pmc2970720;;10.1158/1078-0432.ccr-10-1282;;20837693;;10873096;;10.1214/aoms/1177704472;;10.1073/pnas.1013715108;;pmc3044391;;21300883;;pmc6506566;;10.1038/srep03544;;24384914;;10.1007/bf00116251;;16885343;;10.1158/0008-5472.can-06-1191;;pmc3068975;;10.1186/1471-2105-12-77;;21414208;;24336214;;pmc3966492;;10.1038/nature12894;;2483655;;18641660;;10.1038/nm.1790;;pmc2667337;;10.1007/0-387-29362-0_23;;10.2202/1544-6115.1027;;16646809;;10.1002/emmm.201000068;;20373286;;pmc3377280;;10.1023/a:1018628609742;;20842279;;pmc2938757;;10.1038/nature13385;;25079552;;pmc4231481;;12011421;;10.1073/pnas.082099299;;pmc124443;;10.1200/jco.2008.19.7053;;19414676;;pmc3146043;;20436464;;10.1038/nbt.1621;;pmc2672628;;19289445;;10.1093/bioinformatics/btp120;;9008165;;10.1016/s0092-8674(00)81845-0;;10.1126/science.270.5235.484;;7570003;;pmc2953768;;20643781;;10.1158/1078-0432.ccr-10-0199;;10.1371/journal.pone.0036530;;pmc3349715;;22590557;;10.1016/0888-7543(89)90280-2;;2744765,"Cobb et al (Crit Care Med 2002 vol. 30 p. 2711) (Year: 2002).;;Enard et al. (Science 2002 vol. 296 p. 340) (Year: 2002).;;International Search Report issued by the International Searching Authority for Application No. PCT/US18/43086, dated Dec. 14, 2018, 15 pages.;;Barany, “Cloning, overexpression and nucleotide sequence of a thermostable DNA ligase-encoding gene,” Proc. Natl. Acad. Sci. USA 88:189-193 (1991).;;Bibikova et al., “Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays,” Am J. Pathol 165:1799-1807 (2004).;;Brenner et al., “Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays,” Nat. Biotech. 18:630-34, 2000.;;Broomhead DS, Jones R, King GP., “Comment on Singular-value decomposition and embedding dimension,” Phys Rev A Gen Phys. Jun. 2015;37(12):5004-5005 (1988).;;Bryant et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917.;;Cancer Genome Atlas Research Network. “Comprehensive genomic characterization of squamous cell lung cancers.” Nature 489.7417 (2012): 519-525.;;Clark et al., “Suppression of nonspecific binding of avidin-biotin complex (ABC) to proteins electroblotted to nitrocellulose paper,” J Histochem Cytochem 34:1509-1512 (1986).;;Collisson E.et al., “Comprehensive Molecular Profiling of Lung Adenocarcinoma,” Nature 511(7511):543-550 (2014).;;Cronin et al., “Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay,” Am. J Pathol. 164(1):35-42 (2004).;;Dabney, “Classification of microarrays to nearest centroids,” Bioinformatics 21(22):4148-4154 (2005).;;Daemen et al., “Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.,” Breast Cancer Res Treat 135(2):505-517 (2012).;;Fan et al., “A Versatile Assay for High-Throughput Gene Expression Profiling on Universal Array Matrices,” Genome Res. 14:878-885 (2004).;;Fishel and Kaufman et al., “Meta-analysis of gene expression data: a predictor-based approach,” Bioinformatics 23(13): 1599-606 (2007).;;Fong et al., “Poly(ADP}-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval,” Journal of Clinical Oncology 28(15):2512-2519 (2010).;;Fox et al., “Formaldehyde Fixation,” J Histochem Cytochem 33:845-853 (1985).;;Friedman et al., “Regularization Paths for Generalized Linear Models via Coordinate Descent,”Journal of statistical software 33(1): 1-22 (2010).;;Geiss et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs,” Nat. Biotechnol. 26:317-325 (2008).;;Guatelli et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication,” Proc Natl Acad Sci USA. 87(5):1874-1878 (1990).;;Irizarry et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics April 4(2): 249-64 (2003).;;Konstantinopoulos et al., “Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer,” JCIin Oncol 28(22):3555-3561 (2010).;;Kwoh et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format (TI RNA polymerase/in vitro nucleic acid amplification),” Proc. Natl. Acad. Sci. USA, 86:1173-1177 (1989).;;Landegren et al., “A ligase-mediated gene detection technique,” Science, 241(4869):1077-1080 (1988).;;Lee ESet al., “Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression.” Clinical Cancer Research 14(22):7397-7404 (2008).;;Lim et al., VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation ofBRCA1 and BRCA2. Neoplasia 16(4):343-353 (2014).;;McGhee and von Hippel, “Formaldehyde as a probe of DNA structure. II. Reaction with endocyclic imino groups of DNA bases,” Biochemistry 14:1281-1296 (1975).;;McGrail et al., “Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm,” Systems Biology and Applications. 3(8):1-12 (2017).;;Meyer D., “Support vector machines: the interface to libsvm in package el071,” 2014, 8 pages (dated Jul. 23, 2018).;;Mullins et al., “Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues,” Clin Chem. 53(7):1273-1279 (2007).;;Nielsen, “A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer,” Clin Cancer Res. Nov. 1, 2010;16(21):5222-32 (2010).;;Niki et al., “Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma,” Clinical Cancer Research 6(6):2431-2439 (2000).;;Parzen, “On Estimation of a Probability Density Function and Mode,” Stanford University, 1065-1076 (1962).;;Patel et al. “Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells” PNAS 108 (8) 3406-3411 (2011).;;Prat et al., Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Scientific Reports. 3(3544): 1-12 (2013).;;Quinlan, “Induction of Decision Trees,” Machine Learning 1(1):81-106 (1986).;;Raponi et al. “Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung,” Cancer Res 66(7): 466-472 (2006).;;Robin etai., “pROC: an open source package for R and S+ to analyze and compare ROC curves,” BMC bioinformatic 12:77 (2011), 8 pages.;;Rouskin et al., “Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo,” Nature 505, pp. 701-705 (2014).;;Rupp G and Locker J., University of Pittsburgh School of Medicine, “Purification and analysis of RNA from paraffin embedded tissues,” BioTechniques 6(1):56-60 (1988).;;Shedden et al., “Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study: director's challenge consortium for the molecular classification of lung adenocarcinoma,” Nat Med 14(8): 822-827 (2008).;;Smyth Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using Rand Bioconductor, R. Gentleman, V. Carey, S. Dudoit, R.Irizarry, W. Huber (eds.), Springer, New York, pp. 397-420 (2005).;;Smyth, “Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments,” Stat. Appi. Genet. Mol. Biol. 3: Article 3 (2004), 28 pages.;;Sourisseau et al., “Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition,” EMBO Mol Med 2:130-142 (2010).;;Suykens JAK, Vandewalle J., “Least Squares Support Vector Machine Classifiers,” Neural Processing Letters 9(3): 293-300 (1999).;;Szumilas, “Explaining odds ratios,” J. Can. Acad. Child Adolesc. Psychiatry 19(3): 227-229 (2010).;;The Cancer Genome Atlas Research Network) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543-550 and p. 546 (2014).;;Tibshirani et al., “Diagnosis of multiple cancer types by shrunken centroids of gene expression,” Proc. Natl. Acad. Sci. USA 99(10):6576-6572) (2002).;;Tomida et al., “Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis,” J Clin Oncol 27(17): 2793-2799 (2009).;;Trapnell et al., “Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation,” Nature biotechnology 28(5):511-515 (2010).;;Trapnell et al., “TopHat: discovering splice junctions with RNA-Seq.,” Bioinformatics 25(9):1105-11 (2009).;;Velculescu et al., “Characterization of the yeast transcriptome,” Cell 88(2):243-251 (1997).;;Velculescu et al., “Serial analysis of gene expression,” Science 270(5235):484-487 (1995).;;Wilkerson et al., Lung Squamous Cell Carcinoma mRNA Expression Subtypes are Reproducible, Clinically Important and Correspond to Different Normal Cell Types. Clinical Clin Cancer Res 16(19):4864-4875 (2010).;;Wilkerson et al., “Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation,” PLoS One. 2012; 7(5) e36530. Doi:10.1371/journal.pone.0036530, 13 pages.;;Wold, H. “Estimation of Principal Components and Related Models by Iterative Least Squares,” in Multivariate Analysis, ed. P. R. Krishnaiah, New York:Academic Press, 391-420 (1966).;;Wu and Wallace, “The ligation amplification reaction (LAR)—amplification of specific DNA sequences using sequential rounds of template dependent ligation.,” Genomics, 4(4):560-569 (1989).",ACTIVE
961,US,A1,US 2022/0243283 A1,182-100-416-295-315,2022-08-04,2022,US 202217725936 A,2022-04-21,US 202217725936 A;;US 202117471716 A;;US 202117144644 A;;US 202016887241 A;;US 201715566363 A;;US 2016/0027503 W;;US 201562147547 P,2015-04-14,METHODS FOR TYPING OF LUNG CANCER,"Methods and compositions are provided for the molecular subtyping of lung cancer samples. Specifically, a method of assessing whether a patient's adenocarcinoma lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) is provided herein. The method entails detecting the levels of the classifier biomarkers of Table 1-Table 6 or a subset thereof at the nucleic acid level, in a lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample is classified as a TRU, PI, or PP sample.",GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,FARUKI HAWAZIN;;LAI-GOLDMAN MYLA;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2017-10-24);;GENECENTRIC THERAPEUTICS INC (2017-10-23),https://lens.org/182-100-416-295-315,Patent Application,yes,0,0,10,10,114,C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C12Q1/6886,,0,0,,,,DISCONTINUED
962,US,A1,US 2010/0098228 A1,007-170-793-651-74X,2010-04-22,2010,US 64748809 A,2009-12-26,US 64748809 A;;US 74719303 A;;US 48430503 P,2003-07-03,CALL TRACKING USING VOICE QUALITY MEASUREMENT PROBE,"A system for monitoring quality of calls in a network. A server receives information concerning calls which begin or end in a network and at the same time receives measurements of a quality parameter such as bandwidth. This measurement data is provided by a probe, so that the server is able to correlate calls which are placed through the network with the quality of service in the network at that time. When the quality falls below a desired level, the server notifies the customer or the network operator so that appropriate action may be taken.",CHEUNG ERIC;;FOLADARE MARK;;GOLDMAN SHELLEY;;PURDY KERMIT H;;SHUR DAVID H,CHEUNG ERIC;;FOLADARE MARK;;GOLDMAN SHELLEY;;PURDY KERMIT H;;SHUR DAVID H,AT&T CORP (2004-05-07),https://lens.org/007-170-793-651-74X,Patent Application,yes,36,1,3,3,0,H04L41/5003;;H04L41/5009;;H04L43/0829;;H04L43/0852;;H04L43/087;;H04L43/106;;H04L41/5003;;H04L43/087;;H04L43/0829;;H04L43/0852;;H04L43/106;;H04L41/5009,H04M15/00,379/112.06,0,0,,,,EXPIRED
963,AU,A,AU 1998/069781 A,012-007-661-406-620,1998-11-11,1998,AU 1998/069781 A,1998-04-15,US 84255597 A;;US 9808053 W,1997-04-15,Cationic polymers for nucleic acid transfection,,AVANTI POLAR LIPIDS INC;;UAB RESEARCH FOUNDATION,BURGESS STEPHEN W;;CURIEL DAVID T;;GOLDMAN COREY K;;SHAW WALTER A,,https://lens.org/012-007-661-406-620,Patent Application,no,0,0,4,4,0,A61K48/00;;A61K48/00;;A61K47/59;;A61K47/59;;A61K47/595;;A61K47/595;;A61K47/6807;;A61K47/6807;;C12N15/87;;C12N15/87,A61K47/48;;A61K48/00;;C12N15/87,,0,0,,,,DISCONTINUED
964,US,A,US 5918179 A,015-156-862-343-011,1999-06-29,1999,US 57953995 A,1995-12-27,US 57953995 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number. In one possible embodiment, the mobile party uses a two-way pager to transmit a terminating number, bandwidth, and protocol to a paging service. The paging service relays the terminating number, bandwidth, and protocol to a Customer Routing Point where the information is stored. Thereafter, when a caller initiates a call to the mobile party by dialing the mobile party's Personal Telephone Number, a Network Control Point is notified. The Network Control Point accesses the Customer Routing Point, cross-references the Personal Telephone Number with the stored terminating number, bandwidth, and protocol, and retrieves the cross-referenced information. The Network Control Point then uses the retrieved information to route the call to a terminating telephone station associated with that information. Other possible embodiments include: using an adjunct to perform the functions of the Customer Routing Point and Network Control Point; and combining an adjunct with a Customer Routing Point and Network Control Point. The call handling services offered through the various hardware embodiments include: registration type routing, call by call type routing, and revertive calling.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1996-01-11);;ISLIP TECHNOLOGIES LLC (2012-11-19);;AT&T PROPERTIES LLC (2012-10-24);;AT&T INTELLECTUAL PROPERTY II L.P (2012-10-24),https://lens.org/015-156-862-343-011,Granted Patent,yes,24,26,1,1,0,H04W84/022;;H04W84/022;;H04M3/42042;;H04M3/42042;;H04M3/42102;;H04M3/42102;;H04M3/42229;;H04M3/42229;;H04M7/12;;H04M7/12;;H04M11/022;;H04M11/022;;H04M2242/22;;H04M2242/22;;H04Q3/005;;H04Q3/005;;H04Q2213/13091;;H04Q2213/13091;;H04Q2213/13095;;H04Q2213/13095;;H04Q2213/13097;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13098;;H04Q2213/13103;;H04Q2213/13103;;H04Q2213/13141;;H04Q2213/13141;;H04Q2213/13204;;H04Q2213/13204;;H04Q2213/13209;;H04Q2213/13209;;H04Q2213/13333;;H04Q2213/13333;;H04Q2213/13374;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13377;;H04W88/185;;H04W88/185,H04M3/42;;H04M7/12;;H04M11/02;;H04Q3/00;;H04W84/02;;H04W88/18,455/445;;455/414;;455/412;;455/31.2;;455/31.3,2,0,,,"Newtons Telecom Dictionary, By Harry Newton, Eight Edition, Nov. 1994, p. 693.;;C. Colavito and M. Saba, The Integrated Mobile Telephone & Paging System , IEEE Conference Proceeding, Jun. 9 11, 1969, Boulder, Co.",EXPIRED
965,WO,A1,WO 2023/148729 A1,024-720-027-650-473,2023-08-10,2023,IL 2023050108 W,2023-01-31,IL 29046622 A,2022-02-02,GEOLOCATION SYSTEM AND METHOD,"A system for determining a geolocation of a mobile object movable through a terrain in a Global Navigation Satellite System (GNSS) signal attenuated environment is provided herein. The system may include: a sensor mountable on the mobile object and configured to obtain a dataset of a scene including three or more scene points; a digital storage unit configured to store a semantically segmented reference dataset representing the scene, the semantically segmented reference dataset having a reference coordinate system; and a processing unit configured to: determine three or more distances between the sensor and the three or more scene points; generate, based on the determined distance, an object semantically segmented projection dataset comprising a projection of the detected three or more scene points in the reference coordinate system; register the semantically segmented projection dataset with respect to the semantically segmented reference dataset; and identify the respective scene points real-world geographical locations.",ELBIT SYSTEMS C4I AND CYBER LTD,GOLDMAN BENYAMIN;;ARIAV IDO;;AVINOAM ASAF;;ZAPHIR DAVID;;VOLVOVITCH OHAD;;MAYEROWICZ YARON,,https://lens.org/024-720-027-650-473,Patent Application,yes,3,0,1,1,0,G06V20/56;;G06N3/0464;;G01S17/89;;G01C21/005,G05D1/02;;G01C21/30;;G01C21/32;;G06F16/23;;G06F16/29;;G06N20/00;;G06T7/11;;G06V20/56,,0,0,,,,PENDING
966,US,B2,US 11291984 B2,028-222-887-521-253,2022-04-05,2022,US 202117209816 A,2021-03-23,US 202117209816 A;;US 202062993145 P,2020-03-23,Dehydrogenation of substrates by transition metal complexes,"Provided herein are transition metal complexes that are useful in the acceptorless dehydrogenation of various substrates, including alkanes. Also provided are methods of dehydrogenating substrates to provide unsaturated products such as olefins.",UNIV RUTGERS;;EXXONMOBIL RES & ENG CO,GOLDMAN ALAN S;;MALAKAR SANTANU;;ZHOU XIAOGUANG;;WANG KUN;;MARLER DAVID O,RUTGERS THE STATE UNIVERSITY OF NEW JERSEY (2021-03-31);;EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-05-07),https://lens.org/028-222-887-521-253,Granted Patent,yes,3,0,2,2,0,C07C5/333;;C07C2531/22;;C07F15/0033;;C07C2/32;;B01J2531/827;;B01J2531/822;;B01J2540/225;;B01J2231/766;;B01J2531/821;;B01J2531/0244;;B01J2531/845;;B01J31/223;;B01J31/182;;B01J31/2273;;C07F15/0033;;C07C2531/22;;C07C2/26;;C07C5/333,B01J31/22;;C07C2/26;;C07C5/333;;C07F15/00,,19,15,022-999-868-980-117;;053-199-988-204-584;;055-568-593-201-403;;092-941-043-079-727;;022-908-334-436-276;;046-378-459-795-972;;116-065-074-035-067;;119-827-725-458-424;;004-189-832-464-519;;139-923-222-102-069;;052-785-886-461-868;;028-070-192-253-846;;101-762-422-155-68X;;042-115-134-908-625;;064-213-934-795-54X,10.1021/om401241e;;10.1021/om500752m;;10.1021/om3002137;;10.1021/om010185y;;10.1021/om2011886;;10.1002/adsc.200606049;;10.1021/om010018y;;10.1039/a807716i;;12489227;;10.1002/1521-3765(20020703)8:13<2968::aid-chem2968>3.0.co;2-6;;10.1021/om020274q;;15884939;;10.1021/ja050698m;;10.1039/b605991k;;17576480;;22456597;;10.1039/c2dt30324h;;10.1002/anie.201100252;;21626620;;10.1016/j.tetlet.2007.03.063,"Allen et al. (“Regeneration of an Iridium(III) Complex Active for Alkane Dehydrogenation Using Molecular Oxygen”, Organometallics 2014, 33, 1337-1340) (Year: 2014).;;Pahls et al. (“Understanding the Effect of Ancillary Ligands on Concerted Metalation-Deprotonation by (dmPhebox)Ir(OAc)2(H2O) Complexes: A DFT Study”, Organometallics 2014, 33, 6413-6419) (Year: 2014).;;Ito et al. (“Intermolecular C—H Bond Activation of Alkanes and Arenes by NCN Pincer Iridium(III) Acetate Complexes Containing Bis (oxazolinyl)phenyl Ligands”, Organometallics 2012, 31,4442-4449) (Year: 2012).;;Yuan et al. (“Effect of Carboxylate Ligands on Alkane Dehydrogenation with (dmPhebox)Ir Complexes”, ACS Catal. 2018, 8, 2326-2329) (Year: 2018).;;Nückel et al. (Transition Metal Complexes with Sterically Demanding Ligands, 3.1 Synthetic Access to Square-Planar Terdentate Pyridine-Diimine Rhodium(I) and Iridium(I) Methyl Complexes: Successful Detour via Reactive Triflate and Methoxide Complexes, Organometallics 2001, 20, 4345-4359) (Year: 2001).;;Adams, et al., “Investigation of CF3 Iridium PCP Pincer Catalytic Dehydrogenation and Decarbonylation Chemistry”, Organometallics, vol. 31, No. 4, 2012, pp. 1439-1447.;;Gao, et al., “Iridium-catalyzed dehydrogenative coupling of ethylene to form 1,3-butadiene”, Rutgers University 2017 Central Regional Meeting (CERM) presentation. Jun. 8, 2017.;;Gao, et al., “β-Hydride Elimination and C-H Activation by an Iridium Acetate Complex, Catalyzed by Lewis Acids. Alkane Dehydrogenation Cocatalyzed by Lewis Acids and [2,6-Bis(4,4-dimethyloxazolinyl)-3,5-dimethylphenyl]iridium”, J. Am. Chem. Soc. 2017, 139, pp. 6338-6350.;;Ito, et al., “Efficient Preparation of New Rhodium- and Iridium-[Bis(oxazo-linyl)-3,5-dimethylphenyl] Complexes by C-H Bond Activation: Applications in Asymmetric Synthesis”, Adv. Synth. Catal. 2006, 348, pp. 1235-1240.;;Motoyama, et al., “Bis(oxazolinyl)phenylrhodium(III) Aqua Complexes: Synthesis, Structure, Enantioselective Allylation of Aldehydes, and Mechanistic Studies”, Organometallics, vol. 28, No. 8, Mar. 22, 2001, pp. 1580-1591.;;Motoyama, et al., “Chiral bis(oxazolinyl)phenylrhodium(III) complexes as Lewis acid catalysts for enantioselective allylation of aldehydes”, Chem Comm (Cambridge), Issue 2, 1999, pp. 131-132.;;Motoyama, et al., “Novel Asymmetric Michael Addition of alpha-Cyanopropionates to Acrolein by the Use of a Bis oxazolinyl)phenylstannane-Derived Rhodium(III) Complex as a Chiral Lewis Acid Catalyst”, Chem Eur J, vol. 8, No. 13, Jun. 24, 2002, pp. 2968-2975.;;Motoyama, et al., “Synthesis and X-ray Crystal Structures of Bis(oxazolinyl)phenyl-Derived Chiral Palladium(II) and Platinum(II) and -(IV) Complexes and Their Use in the Catalytic Asymmetric Aldol-Type Condensation of Isocyanides and Aldehydes”, Organometallics, vol. 21, No. 16, Jul. 3, 2002, pp. 3408-3416.;;Nishiyama, et al., “High Performance of Rh(Phebox) Catalysts in Asymmetric Reductive Aldol Reaction: High Anti-Selectivity”, J Am Chem Soc, vol. 127, No. 19, Apr. 26, 2005, pp. 6972-6973.;;Nishiyama, H., “Synthesis and use of bisoxazolinyl-phenyl pincers”, Chem Soc Rev, vol. 36, No. 7, Jul. 2007, pp. 1133-1141.;;Nobbs, et al., “Thio-Pybox and Thio-Phebox complexes of chromium, iron, cobalt and nickel and their application in athylene and butadiene polymerisation catalysis.”, Dalton Trans., 2012, 41, pp. 5949-5964.;;Ohshima, et al., “C1-Symmetric Rh/Phebox-Catalyzed Asymmetric Alkynylation of alpha-Ketoesters”, Angew Chem Int Ed, vol. 50, 2011, pp. 6296-6300.;;Takemoto, et al., “Highly efficient Suzuki-Miyaura coupling reactions catalyzed by bis(oxazolinyl)henyl-Pd(II) complex”. Tetrahedron Lett, vol. 48, No. 19, May 7, 2007, pp. 3397-3401.;;Zhou, “Computational Study of Pincer Iridium Catalytic Systems: C-H, N-H, and C-C Bond Activation and C-C Coupling Reactions.”, A dissertation submitted to the Graduate School-New Brunswick Rutgers, The State University of New Jersey, May 2017.",ACTIVE
967,EP,A2,EP 0782362 A2,051-192-547-831-422,1997-07-02,1997,EP 96120762 A,1996-12-23,US 57954095 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number (PTN). The mobile party uses the two-way pager to transmit call control parameters which are used by the telephone network to route calls directed to the party's PTN. The mobile party may also use the pager to transmit a location indicator which specifies the subscriber's location and informs the network of the subscriber's intention to receive calls according to a call examination procedure. To invoke the call examination procedure, the bandwidths and protocols of all possible terminating stations associated with the subscriber's location are stored in the network on a pre-provisioned basis. Thereafter, when a call is placed to the subscriber's PTN, the network determines the bandwidth and protocol of the originating station, selects a terminating station that is located at the subscriber site and has a bandwidth and protocol most closely resembling that of the originating station, and routes the call to the selected terminating station.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/051-192-547-831-422,Patent Application,yes,2,0,7,7,0,H04W4/16;;H04W76/10;;H04W4/16;;H04W76/10,H04W4/16;;H04W76/02,,0,0,,,,DISCONTINUED
968,EP,A3,EP 0782352 A3,067-180-572-841-000,1999-04-28,1999,EP 96120761 A,1996-12-23,US 58171095 A,1995-12-26,Method and system for determining location of subscriber of two-way paging service,A method and system for determining the location of a subscriber of a two-way paging service includes a telephone network with a switched network and a paging service operatively connected thereto. The paging service includes a paging receiver for receiving a location parameter from a two-way pager of a subscriber of a paging network. The switched network includes a unit for generating a location message to a caller when the caller queries the network for the subscriber location.,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY P,,https://lens.org/067-180-572-841-000,Search Report,yes,2,0,6,6,0,H04W84/025;;H04W84/025,H04M3/42;;H04M3/50;;H04W84/02,,1,0,,,"GANDILS L: ""TRENSD IN WIDE AREA PAGING"", ERICSSON REVIEW, vol. 71, no. 4, 1 January 1994 (1994-01-01), pages 167 - 171, XP000478225",DISCONTINUED
969,EP,A2,EP 0782363 A2,078-204-465-569-382,1997-07-02,1997,EP 96120784 A,1996-12-23,US 57918895 A,1995-12-27,Communication system and method using two-way paging to provide call control,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number. The mobile party uses the two-way pager to transmit call control parameters which are used by the telephone network to route calls directed to the party's PTN. The mobile party may also use the pager to transmit subsequent routing parameters which are used by the network to reroute calls which have been previously routed. The subsequent routing of a call may be performed at any time following a previous routing, even after the call has received answer supervision.",AT & T CORP,FOLADARE MARK JEFFREY;;SILVERMAN DAVID PHILLIP;;GOLDMAN SHELLEY B;;WEBER ROY PHILIP,,https://lens.org/078-204-465-569-382,Patent Application,yes,0,0,8,8,0,H04W84/025;;H04W84/025;;H04M3/42229;;H04M3/42229,H04B5/04;;H04M3/42;;H04W84/02,,1,0,,,"THE BELL SYSTEM TECHNICAL JOURNAL, vol. 56, no. 7, September 1977 (1977-09-01), pages 1015 - 1320",DISCONTINUED
970,JP,A,JP 2005354675 A,087-915-163-391-889,2005-12-22,2005,JP 2005140679 A,2005-05-13,US 57383995 A,1995-12-18,APPARATUS AND METHOD FOR MAINTAINING PERSONAL COMMUNICATION INFORMATION IN MOBILE COMMUNICATION SYSTEM,"<P>PROBLEM TO BE SOLVED: To provide an apparatus and a method for updating a communication network from one or more user communication devices. <P>SOLUTION: The electronic scheduling or other time-based features are used within a communication device to control and/or initiate transmission of information between the communication device and the communication network. Information from one or more communication devices is updated to the communication network in response to time-based components in the information entries corresponding to a timing device associated with the respective communication devices. Also, once the network has received this updated information, comparisons of related information entries are initiated to detect discrepancies between the entries. Any detected discrepancies are used to initiate appropriate notification to the user, regenerate updated information, and make existing message delivery systems disuse. <P>COPYRIGHT: (C)2006,JPO&NCIPI",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/087-915-163-391-889,Patent Application,no,0,0,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,PENDING
971,AU,A,AU 1989/030957 A,109-142-404-248-747,1989-11-16,1989,AU 1989/030957 A,1989-03-03,US 19300088 A,1988-05-12,THERMALLY EFFICIENT SPLICE JOINT FOR ELECTRICAL DISTRIBUTION BUSWAY,,GEN ELECTRIC,BEBERMAN JULIE ANNE;;GOLDMAN IRA BERNARD;;LARKIN HAROLD FORD;;HIBBERT DAVID ALAN,,https://lens.org/109-142-404-248-747,Patent Application,no,0,0,5,5,0,H02G5/007;;H02B1/00;;H02G5/007,H01B17/18;;H02G5/00;;H02G5/02,,0,0,,,,DISCONTINUED
972,CA,C,CA 1316998 C,108-052-982-779-237,1993-04-27,1993,CA 594602 A,1989-03-23,US 19300088 A,1988-05-12,THERMALLY EFFICIENT SPLICE JOINT FOR ELECTRICAL DISTRIBUTION BUSWAY,41PR-6650 THERMALLY EFFICIENT SPLICE JOINT FOR ELECTRICAL DISTRIBUTION BUSWAY A thermally efficient joint for electrical power distribution busway electrically connects between adjacent busway sections. Each busway joint includes a modular assembly containing spaced metallic splice plates separated by corresponding insulating plates. The module is sandwiched between a pair of joint covers by means of an insulated thru-bolt. The spacing between the splice joint for receiving corresponding busway stabs is accurately set by an apertured depression stamped within each of the splice plates.,GEN ELECTRIC,BEBERMAN JULIE A;;GOLDMAN IRA B;;LARKIN HAROLD F;;HIBBERT DAVID A,,https://lens.org/108-052-982-779-237,Granted Patent,no,0,0,5,5,0,H02G5/007;;H02B1/00;;H02G5/007,H01B17/18;;H02G5/00;;H02G5/02,D23370033    M;;0260131    S,0,0,,,,EXPIRED
973,CA,A1,CA 2200790 A1,184-575-139-065-467,1998-01-15,1998,CA 2200790 A,1997-03-24,US 67978396 A,1996-07-15,COUPLING MULTIPLE LOW DATA RATE LINES TO EFFECT HIGH DATA RATE COMMUNICATION,,AT & T CORP,FOLADARE MARK JEFFREY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP;;GOLDMAN SHELLEY B,,https://lens.org/184-575-139-065-467,Patent Application,no,0,0,5,5,0,H04L25/14;;H04L25/14,H04M3/00;;H04L25/14;;H04M11/00,,0,0,,,,EXPIRED
974,WO,A3,WO 1998/046274 A3,018-192-083-818-222,1998-10-22,1998,US US9808053,1998-04-15,"US 08/8/042,555",1997-04-15,CATIONIC POLYMERS FOR NUCLEIC ACID TRANSFECTION,"A class of polycationic polymers comprising products obtained by the copolymerization of a diprimary amine and a suitable comonomer, wherein the diprimary amine contains at least two primary amines and at least two secondary amines, and their use for nucleic acid transfection, and the delivery of suitable anionically charged bioactive molecules.","AVANTI POLAR LIPIDS, INC.;;THE UAB RESEARCH FOUNDATION","BURGESS, Stephen, W.;;CURIEL, David, T.;;GOLDMAN, Corey, K.;;SHAW, Walter, A.",,https://lens.org/018-192-083-818-222,Search Report,yes,0,0,1,1,0,,A61K47/48;;A61K48/00;;C12N15/87,,0,0,,,,UNKNOWN
975,EP,A3,EP 0760571 A3,047-696-579-689-373,2000-01-05,2000,EP 96111551 A,1996-07-17,US 52042595 A,1995-08-29,Call screening method and apparatus for use in completing telephone calls,"A system and method for providing personal communications services are disclosed. A bridging and signaling unit (109) implements a bridge for connecting telephone calls between a caller, a called party, and an alternate destination. A caller who calls the personal telephone number associated with a called party is held at the bridging and signaling unit (109) while waiting for a return telephone call from the called party. The called party is alerted to the existence of the call through a paging system. If the time period during which the caller is on hold exceeds a time-out period, the caller will be connected to an alternate destination, such as a secretary, an answering service, or a voice messaging system. If the called party places the return telephone call while the caller is connected to the alternate destination, the called party will be connected to the caller and the alternate destination in such a manner that that the called party can hear the conversation between the caller and the alternate destination, but the caller and the alternate destination cannot hear the called party and do not know that the called party has connected, i.e. the called party is on mute mode. After screening the call, the called party may then indicate that he/she wishes to be connected to the caller, at which time the connection to the alternate destination is terminated and the caller and the called party are connected such that they can speak with each other. If the called party does not wish to speak to the caller, he/she may hang up, and the connection between the caller and the alternate destination may continue.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMANN DAVID PHILLIP;;WEB ROY PHILIP,,https://lens.org/047-696-579-689-373,Search Report,yes,4,0,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,,0,0,,,,DISCONTINUED
976,CA,A1,CA 2205332 A1,096-686-383-856-991,1997-12-25,1997,CA 2205332 A,1997-05-14,US 66865996 A,1996-06-25,INTELLIGENT PBX IN-BUILDING AND OUT-OF-BUILDING PERSONAL REACH COMMUNICATIONS SYSTEM,,AT & T CORP,WEBER ROY PHILIP;;SILVERMAN DAVID PHILLIP;;FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B,,https://lens.org/096-686-383-856-991,Patent Application,no,0,0,3,3,0,H04W84/022;;H04W84/022;;H04M3/42229;;H04M3/42229;;H04M7/00;;H04M7/00;;H04Q3/0016;;H04Q3/0016;;H04Q3/622;;H04Q3/622;;H04Q2213/13091;;H04Q2213/13091;;H04Q2213/13095;;H04Q2213/13095;;H04Q2213/13103;;H04Q2213/13103;;H04Q2213/13204;;H04Q2213/13204;;H04Q2213/1322;;H04Q2213/1322;;H04Q2213/1326;;H04Q2213/1326;;H04Q2213/13374;;H04Q2213/13374;;H04Q2213/13405;;H04Q2213/13405;;H04W76/10;;H04W76/10,H04M3/42;;H04M7/00;;H04Q3/00;;H04Q3/62;;H04W76/02;;H04W84/02,,0,0,,,,EXPIRED
977,EP,A2,EP 0781067 A2,136-580-764-320-836,1997-06-25,1997,EP 96120274 A,1996-12-17,US 57383995 A,1995-12-18,System and method for maintaining personal communications information in a mobile communications system,"The invention is an apparatus and method for updating a communications network (16) from one or more user communications devices (12, 78). The invention uses the electronic scheduling or other time-based features within a communications device to control and/or initiate transmission of information between the communications device and the communications network. Information from one or more communications devices is updated to the communications network in response to time-based components in the information entries corresponding to a timing device (42) associated with the respective communications device. Also, once the network has received this updated information, comparisons of related information entries are initiated to detect discrepancies therebetween. In this manner, user submitted time and geographic location information is compared with similar information automatically retrieved by the communications network using conventional and future network communications technology. Any detected discrepancies are used to initiate appropriate notification to the user and/or retrieve updated information, or to default to existing message delivery systems (79).",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/136-580-764-320-836,Patent Application,yes,0,31,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,DISCONTINUED
978,US,A,US 4842533 A,003-695-622-485-878,1989-06-27,1989,US 19300088 A,1988-05-12,US 19300088 A,1988-05-12,Thermally efficient splice joint for electrical distribution busway,A thermally efficient joint for electrical power distribution busway electrically connects between adjacent busway sections. Each busway joint includes a modular assembly containing spaced metallic splice plates separated by corresponding insulating plates. The module is sandwiched between a pair of joint covers by means of an insulated thru-bolt. The spacing between the splice joint for receiving corresponding busway stabs is accurately set by an apertured depression stamped within each of the splice plates.,GEN ELECTRIC,BEBERMAN JULIE A;;GOLDMAN IRA B;;LARKIN HAROLD F;;HIBBERT DAVID A,GENERAL ELECTRIC COMPANY A NY CORP (1988-05-06),https://lens.org/003-695-622-485-878,Granted Patent,yes,6,61,5,5,0,H02G5/007;;H02B1/00;;H02G5/007,H02G5/00;;H01B17/18;;H02G5/02,439/213;;X174 88B,0,0,,,,EXPIRED
979,CA,C,CA 2187385 C,002-805-848-009-565,2001-09-04,2001,CA 2187385 A,1996-10-08,US 57383995 A,1995-12-18,SYSTEM AND METHOD FOR MAINTAINING PERSONAL COMMUNICATIONS INFORMATION INA MOBILE COMMUNICATIONS SYSTEM,"The invention is an apparatus and method for updating a communications network from one or more user communications devices. The invention uses the electronic scheduling or other time-based features within a communications device to control and/or initiate transmission of information between the communications device and the communications network. Information from one or more communications devices is updated to the communications network in response to time-based components in the information entries corresponding to a timing device associated with the respective communications device. Also, once the network has received this updated information, comparisons of related information entries are initiated to detect discrepancies therebetween. In this manner, user submitted time and geographic location information is compared with similar information automatically retrieved by the communications network using conventional and future network communications technology. Any detected discrepancies are used to initiate appropriate notification to the user and/or retrieve updated information, or to default to existing message delivery systems.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/002-805-848-009-565,Granted Patent,no,0,0,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,EXPIRED
980,US,B2,US 7297531 B2,017-052-977-340-87X,2007-11-20,2007,US 41776303 A,2003-04-17,US 41776303 A,2003-04-17,Apparatus and method for testing liquid samples,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,GOLDMAN ROSS BRYAN;;TOWNSEND DAVID EDWARD;;SMITH KENNETH E;;MCCARTHY KATHLEEN R,IDEXX LABORATORIES INC (2003-04-11),https://lens.org/017-052-977-340-87X,Granted Patent,yes,45,2,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,C12M1/24;;B01L3/00;;C12M1/22;;C12M1/32;;C12Q1/06,435/288.2;;435/33;;435/288.4;;435/304.2;;435/305.3;;220/506;;220/526;;422/100;;422/102;;422/942;;422/948;;141/31;;141/286;;141/326,1,0,,,"International Search Report from PCT/US2004/011608, Nov. 26, 2004.",ACTIVE
981,DE,D1,DE 602004022148 D1,083-978-806-789-114,2009-09-03,2009,DE 602004022148 T,2004-04-16,US 41776303 A;;US 2004/0011608 W,2003-04-17,VORRICHTUNG UND VERFAHREN ZUR PRÜFUNG VON FLÜSSIGEN PROBEN,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,GOLDMAN ROSS BRYAN;;TOWNSEND DAVID EDWARD;;SMITH KENNETH E;;MCCARTHY KATHLEEN R,,https://lens.org/083-978-806-789-114,Granted Patent,no,0,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,C12Q1/06;;B01L3/00;;C12M1/22,,0,0,,,,ACTIVE
982,US,A,US 5907547 A,083-387-731-847-257,1999-05-25,1999,US 73615096 A,1996-10-24,US 73615096 A,1996-10-24,System and method for establishing internet communications links,"A technique is provided for establishing data communications links and associated telephone calls between customers and customer service representatives. Customers access the Internet from clients. A merchant provides an on-line catalog using a Web server. When the customer requests that a customer service representative contact the customer, linking information is provided to the client. When one of the customer service representatives is available, the server sends a notification packet to the client to notify the customer and to provide the customer with an opportunity to decide whether or not to continue. If the customer decides to continue, an Internet communications link and telephone call are established between the customer and the customer service representative based on the linking information.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WESTRICH ROBERT S,AT&T CORP (1997-02-06),https://lens.org/083-387-731-847-257,Granted Patent,yes,5,320,1,1,0,H04M3/5191;;H04M7/0033;;H04M7/128;;H04L65/401;;H04M3/5191;;H04M7/0033;;H04M7/128;;H04L65/401;;H04L9/40;;H04L65/1101,H04L29/06;;H04M3/51;;H04M7/00,370/352;;379/309,0,0,,,,EXPIRED
983,WO,A1,WO 2019/032525 A1,098-783-835-786-144,2019-02-14,2019,US 2018/0045522 W,2018-08-07,US 201762541960 P;;US 201762608218 P;;US 201862629934 P,2017-08-07,METHODS FOR SUBTYPING OF HEAD AND NECK SQUAMOUS CELL CARCINOMA,Methods and compositions are provided for determining a subtype of head and neck squamous cell carcinoma (HNSCC) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for HNSCC. Also provided herein are methods and compositions for determining the response of an individual with a HNSCC subtype to a therapy such as immunotherapy.,GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,LAI-GOLDMAN MYLA;;FARUKI HAWAZIN;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,,https://lens.org/098-783-835-786-144,Patent Application,yes,1,5,4,4,144,C12Q1/6886;;G01N33/574;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q1/686;;C12Q1/6886;;C12Q2561/113;;C12Q2600/158;;G01N2800/52;;G01N2800/56;;G01N2800/60;;C12Q2600/106;;C12Q2600/112,C07K16/28;;C12Q1/6853;;C40B40/08;;G01N33/574,,8,7,040-540-783-915-918;;034-778-629-750-089;;072-766-494-709-520;;043-538-376-224-323;;083-762-186-687-690;;053-541-288-806-884;;015-131-113-454-338,27570510;;pmc4982242;;10.3389/fphar.2016.00244;;10.1677/erc.1.00600;;15613446;;10.1128/jcm.44.4.1310-1317.2006;;16597856;;pmc1448674;;27646946;;pmc6804896;;10.1200/jco.2016.68.1478;;10.3410/f.726760169.793525828;;10.1200/jco.2016.34.15_suppl.6012;;10.1371/annotation/b42f61c5-cb7e-49ca-8cd6-6e1f7903ad08;;19582815;;10.1002/dc.21134,"AMINUDDIN, A ET AL.: ""Promising Druggable Target in Head and Neck Squamous Cell Carcinoma: Wnt Signaling"", FRONTIERS IN PHARMACOLOGY, vol. 7, no. 244, 12 August 2016 (2016-08-12), pages 1 - 13, XP055576545;;HARARI, PM: ""Epidermal growth factor receptor inhibition strategies in oncology"", ENDOCRINE -RELATED CANCER, vol. 11, no. 4, 11 December 2004 (2004-12-11), pages 689 - 708, XP007909356, DOI: 10.1677/erc.1.00600;;KRAUS, I ET AL.: ""Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33, and 45 in the Majority of Cervical Carcinomas"", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 44, no. 4, April 2006 (2006-04-01), pages 1310 - 1317, XP055099998, DOI: 10.1128/JCM.44.4.1310-1317.2006;;CHOW, LQM ET AL.: ""Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase lb KEYNOTE-012 Expansion Cohort"", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 32, 10 November 2016 (2016-11-10), pages 3838 - 3845, XP055674580, ISSN: 0732-183X, DOI: 10.1200/JCO.2016.68.1478;;MEHRA, R ET AL.: ""Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012"", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 15, May 2016 (2016-05-01), pages 1 - 5, XP009519270, ISSN: 0732-183X, DOI: 10.1200/JCO.2016.34.15_suppl.6012;;WALTER, V ET AL.: ""Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes data"", PLOS ONE, vol. 8, no. 2, 22 February 2013 (2013-02-22), pages 1 - 11, XP055674588, DOI: 10.1371/journal.pone.0056823;;CHUTE, DJ ET AL.: ""Cytology of Head and Neck Squamous Cell Carcinoma Variants"", DIAGNOSTIC CYTOPATHOLOGY, vol. 38, no. 1, 6 July 2009 (2009-07-06), pages 65 - 80, XP055576563;;See also references of EP 3665199A4",PENDING
984,CA,A1,CA 2191374 A1,123-259-359-989-226,1997-06-27,1997,CA 2191374 A,1996-11-27,US 58171095 A,1995-12-26,Method and System for Determining Location of Subscriber of Two-Way Paging Service,,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/123-259-359-989-226,Patent Application,no,0,0,6,6,0,H04W84/025;;H04W84/025,H04M3/42;;H04M3/50;;H04W84/02,,0,0,,,,EXPIRED
985,EP,A1,EP 1613764 A1,127-848-156-002-314,2006-01-11,2006,EP 04759878 A,2004-04-16,US 2004/0011608 W;;US 41776303 A,2003-04-17,APPARATUS AND METHOD FOR TESTING LIQUID SAMPLES,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,GOLDMAN ROSS BRYAN;;TOWNSEND DAVID EDWARD;;SMITH KENNETH E;;MCCARTHY KATHLEEN R,,https://lens.org/127-848-156-002-314,Patent Application,yes,0,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,B01L3/00;;C12M1/22;;C12Q1/06,,0,0,,,,ACTIVE
986,US,A1,US 2021/0291154 A1,164-259-250-686-886,2021-09-23,2021,US 202117209816 A,2021-03-23,US 202117209816 A;;US 202062993145 P,2020-03-23,DEHYDROGENATION OF SUBSTRATES BY TRANSITION METAL COMPLEXES,"Provided herein are transition metal complexes that are useful in the acceptorless dehydrogenation of various substrates, including alkanes. Also provided are methods of dehydrogenating substrates to provide unsaturated products such as olefins.",UNIV RUTGERS;;EXXONMOBIL RES & ENG CO,GOLDMAN ALAN S;;MALAKAR SANTANU;;ZHOU XIAOGUANG;;WANG KUN;;MARLER DAVID O,RUTGERS THE STATE UNIVERSITY OF NEW JERSEY (2021-03-31);;EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-05-07),https://lens.org/164-259-250-686-886,Patent Application,yes,0,0,2,2,0,C07C5/333;;C07C2531/22;;C07F15/0033;;C07C2/32;;B01J2531/827;;B01J2531/822;;B01J2540/225;;B01J2231/766;;B01J2531/821;;B01J2531/0244;;B01J2531/845;;B01J31/223;;B01J31/182;;B01J31/2273;;C07F15/0033;;C07C2531/22;;C07C2/26;;C07C5/333,B01J31/22;;C07C2/26;;C07C5/333;;C07F15/00,,0,0,,,,ACTIVE
987,US,A,US 5973913 A,185-406-201-057-134,1999-10-26,1999,US 91014697 A,1997-08-12,US 91014697 A,1997-08-12,Nonaqueous electrical storage device,"An electrochemical capacitor is disclosed that features two, separated, high surface area carbon cloth electrodes sandwiched between two current collectors fabricated of a conductive polymer having a flow temperature greater than 130.degree. C., the perimeter of the electrochemical capacitor being sealed with a high temperature gasket to form a single cell device. The gasket material is a thermoplastic stable at temperatures greater than 100.degree. C., preferably a polyester or a polyurethane, and having a reflow temperature above 130.degree. C. but below the softening temperature of the current collector material. The capacitor packaging has good mechanical integrity over a wide temperature range, contributes little to the device equivalent series resistance (ESR), and is stable at high potentials. In addition, the packaging is designed to be easily manufacturable by assembly line methods. The individual cells can be stacked in parallel or series configuration to reach the desired device voltage and capacitance.",COVALENT ASSOCIATES INC,MCEWEN ALAN B;;EVANS DAVID A;;BLAKLEY THOMAS J;;GOLDMAN JAY L,COVALENT ASSOCIATES INC (1997-08-06),https://lens.org/185-406-201-057-134,Granted Patent,yes,10,63,3,3,0,Y02E60/13;;Y02T10/70;;H01G11/80;;H01G11/68;;H01G11/62;;H01G11/60;;H01G11/32;;Y02E60/13;;Y02T10/70;;H01G11/60;;H01G11/62;;H01G11/32;;H01G11/68;;H01G11/80,H01G9/00;;H01G9/155,361/523;;361/525;;361/528;;361/532,36,13,131-632-388-861-195;;121-816-928-958-160;;045-860-684-021-841;;106-403-274-946-435;;081-475-218-604-227;;138-870-155-364-348;;077-833-914-019-809;;087-630-678-370-957;;077-921-395-678-043;;166-891-594-126-550;;071-089-581-183-561;;020-449-442-048-737;;072-378-244-046-934,10.1002/adma.19960080409;;10.1021/ic951325x;;11666305;;10.1149/1.2055041;;10.1149/199216.0386pv;;10.1149/1.2054995;;10.1149/1.2044332;;10.1149/1.1836540;;10.1149/1.2220779;;10.1149/1.1837561;;10.1149/1.1837171;;10.1149/1.1837231;;10.1149/1.2059270;;10.1149/1.2059336,"Arbizzani et al., Electronically Conducting Polymers and Activated Carbon: Electrode Materials in Supercapacitor Technology, Adv. Mater. vol:8 No.4, pp. 331 334 (1996).;;Bonhote et al., Hydrophobic, Highly Conductive Ambient Temperature Molten Salts, Inorg. Chem. vol. 35: pp. 1168 1178 (1996).;;Carlin et al., Dual Intercalating Molten Electrolyte Batteries, J. Electrochem. Soc., vol. 141: No. 7, L73 L76 (1994).;;Conway et al., Characterization of Behavior and Mechanisms of Self Discharge of Electrochemical Capacitors in Relation to that at Batteries, Proceedings of the Fifth International Seminar on Double Layer Capacitors and Similar Energy Devices, Florida Educational Seminars, Dec., 1995.;;Conway et al., The Electrolyte Factor in Supercapacitor Design and Performance: Conductivity, Ion Pairing and Solvation, Proceedings of the Fourth International Seminar on Double Layer Capacitros and Similar Energy Storage Devices, Florida Educational Seminars, Dec., 1994.;;Conway, B.E., in Electrochemcial Capacitors, F.M. Delnick and M. Tomkiewicz, Editors, Supercapacitor behavior resulting from pseudocapacitance associated with redox processes , PV95 29, p. 15, The Electrochemical Society Proceedings Series, Pennington, NJ (1996).;;Cooper et al. Proceedings of the 8th International Symposium on Molten Salts, R.J. Gale, G. Blomgren, and H. Kojima, Editors, PV 92 16, pp. 386 396 New, Stable, Ambient Temperature Molten Salts, The Electrochemical Society: Pennington, NJ (1992).;;Fuller et al., Structure of 1 Ethyl 3 methylimidazolium Hexafluorophosphate: Model for Room Temperature Molten Salts, J. Chem. Soc., Chem. Commun., pp. 299 300 (1994).;;Huggins et al., Three Dimensional Charge Storage Via Topotactic Insertion Reactions, The Electrochemical Society Proceedings vol. 95 29, pp. 1 14.;;Ishikawa et al., Electric Double Layer Capacitor Composed of Activated Carbon Fiber Cloth Electrodes and Solid Polymer Electrolytes Containing Alkylammonium Salts, J. Electrochem. Soc., vol. 141: No. 7, (1994).;;Koch et al., The Interfacial Stability of Li with Two New Solvent Free Ionic Liquids: 1,2 Dimethyl 3 propylimidazolium Imide and Methide J. Electrochem. Soc., vol. 142: No. 7 (1995).;;Koch et al., The Intrinsic Anodic Stability of Several Anions Comprising Solvent Free Ionic Liquids, J. Electrochem. Soc., vol. 143: No. 3 (1996).;;Koch et al., High Voltage, Ionic Liquids For Electrochemical Capacitors, The Fourth International Seminar on Double Layer Capacitors and Similar Energy Storage Devices, Dec. 14, 1994.;;Koch et al., The Performance of Solvent Free Ionic Liquid Electrolytes in Electrochemical Capacitors, The Fifth International Seminar on Double Layer Capacitors and Similar Energy Storage Devices, Dec. 4 6, 1995.;;Koresh et al., Double Layer Capacitance and Charging Rate of Ultramicroporous Carbon Electrode, J. Electrochem. Soc. vol. 124: No. 9 pp. 1379 1385.;;Matsuda et al., New Electric Double Layer Capacitors Using Polymer Solid Electrolytes Containing Tetraalkylammonium Salts, J. Electrochem. Soc., vol. 140: No. 7, L109 L110 (1993).;;McEwen et al., EMIPF 6 Based Nonaqueous Electrolytes For Electrochemical Capacitors, Abstract No. 707, p. 861, The Electrochemical Society Meeting Abstracts, vol. 96 2, San Antonio, TX, Oct. 6 11, 1996.;;McEwen et al., Nonaqueous Electrolytes for Electrochemical Capacitors: Imidazolium Cations and Inorganic Fluorides with Organic Carbonates, J. Electrochemical Society, vol. 144: L84 (1997).;;McEwen et al., Nonaqueous Double Layer Capacitors: Electrolyte and Packaging Considerations For High Voltage Devices, Proceedings of the Sixth International Seminar on Double Layer Capacitors and Similar Energy Storage Devices, Florida Educational Seminars, Dec. 9 11, 1996.;;McEwen et al., EMIPF 6 Based Nonaqueous Electrolytes For Electrochemical Capacitors, Elecrochemical Capacitors II, F.M. Delnick, D. Ingersoll, X. Andrieu, and K. Naoi, Editors PV96 25, p. 313, The Electrochemical Society Proceedings Series, Pennington, NJ (1997).;;Murphy, T.C., Update on Ultracapacitor Development For Transportation Applications, The Electrochemical Society Proceedings vol. 95 29 pp. 269 280.;;Nanjundiah et al., Effect of CO Solvents on Capacitance Measurements in Ionic Liquids, Electrochemical Society Proceedings vol. 96 25 pp. 301 312.;;Papageorgiou et al., The Performance and Stability of Ambient Temperature Molten Salts for Solar Cell Applications, J. Electrochem. Soc. vol. 143: No. 10 pp. 3099 3108 (1996).;;Ren et al., Ultracapacitors Using P and N Dopable poly(3 Arylthiophene)S, The Electrochemical Society Proceedings vol. 95 29 pp. 138 161.;;Takeuchi et al., Solid polymer electrolyte, battery and solid state electric double layer capacitor using this electrolyte as well as processes for their manufacture, CA Selects Plus: Batteries and Fuel Cells, Abstract No. 637063, Issue 23, p. 2 , 1996.;;Ue et al., Properties Of New Quaternary Ammonium Salts For Electrochemical Capacitors, Electrochemical Society Proceedings vol. 96 25 pp. 289 300.;;Ue et al., Ionic Radius of (CF 3 SO 2 ) 3 C and Applicabilty of Stokes Law to Its Propylene Carbonate Solution, J. Electrochem. Soc., vol. 143: No. 11 L270 L272 (1996).;;Ue et al., Electrochemical Properties of Organic Liquid Electrolytes Based on Quanternary Onium Salts for Electrical Double Layer Capacitors, J. Electrochem. Soc., vol. 141, No.11:pp. 2989 2996 (1994).;;Ue et al., Mobility and Ionic Association of Lithium and Quaternary Ammonium Salts in Propylene Carbonate and Butyrolactone, J. Electrochem. Soc., vol. 141, No. 12:pp. 3336 3342 (1994).;;Ue et al., Nonaqueous electrolyte solution with high electric conductivity for electrochemical capacitor, No.: 728245, 1996 CAPLUS, Japanese Patent Application No. 95 48743, Abstract Only.;;Kita et al., Electrochemical devices containing two electrolytes, No.: 428795, 1995 CAPLUS, Japanese Patent Application No. 93 106143, Abstract Only.;;Endo et al., Electric double layer capacitor using nonaqueous electrolyte containing cyclobutane and cyclopropane derived quaternary ammonium salt, No.: 138075, 1993 CAPLUS, Japanese Patent Application No. 90 408585, Abstract Only.;;Endo et al., Electric double layer capacitor using nonaqueous electrolyte containing quaternary ammonium salt derived from pyridazine, pyrimidine, or pyrazine, No.: 138074, 1993 CAPLUS, Japanese Patent Application No. 90 408584, Abstract Only.;;Morimoto, Takeshi, Electrolytic double layer capacitors containing high performance organic solvents, No.: 49936, 1993 CAPLUS, Kagaku Kogyo (1992), 43(12), 998 1004.;;Okamoto et al., Electric double layer capacitors with organic electrolytes, No.: 583103, 1990 CAPLUS, Japanese Patent Application Number 88 313397, Abstract Only.;;Matsuzaki et al., Electric double layer capacitors using a nonaqueous electrolyte, No.: 507627, 1990 CAPLUS, Japanese Patent Application No. 88 230582, Abstract Only.",EXPIRED
988,SU,A1,SU 721081 A1,189-250-351-137-102,1980-03-15,1980,SU 2554199 A,1977-12-06,SU 2554199 A,1977-12-06,DEVICE FOR MEASURING THE HEIGHT OF A PERSON,,K P T I BYTOVOGO OBSLUZHIVANIY,GOLDMAN SHMIL O;;LEJBELMAN DAVID L;;BOGUSH GEORGIJ G;;GOLTSER ANATOLIJ A,,https://lens.org/189-250-351-137-102,Limited Patent,no,0,0,1,1,0,,A61B5/107,,0,0,,,,EXPIRED
989,AU,B2,AU 2004/233067 B2,005-083-276-313-20X,2008-03-13,2008,AU 2004/233067 A,2004-04-16,US 41776303 A;;US 2004/0011608 W,2003-04-17,Apparatus and method for testing liquid samples,,IDEXX LAB INC,TOWNSEND DAVID EDWARD;;MCCARTHY KATHLEEN R;;GOLDMAN ROSS BRYAN;;SMITH KENNETH E,,https://lens.org/005-083-276-313-20X,Granted Patent,no,8,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,C12Q1/06;;B01L3/00;;C12M1/22,,0,0,,,,INACTIVE
990,US,A,US 5960064 A,020-263-007-429-724,1999-09-28,1999,US 52042595 A,1995-08-29,US 52042595 A;;US 26465194 A,1994-06-23,Call screening method and apparatus for use in completing telephone calls,"A system and method for providing personal communications services are disclosed. A bridging and signaling unit implements a bridge for connecting telephone calls between a caller, a called party, and an alternate destination. A caller who calls the personal telephone number associated with a called party is held at the bridging and signaling unit while waiting for a return telephone call from the called party. The called party is alerted to the existence of the call through a paging system. If the time period during which the caller is on hold exceeds a timeout period, the caller will be connected to an alternate destination, such as a secretary, an answering service, or a voice messaging system. If the called party places the return telephone call while the caller is connected to the alternate destination, the called party will be connected to the caller and the alternate destination in such a manner that the called party can hear the conversation between the caller and the alternate destination, but the caller and the alternate destination cannot hear the called party and do not know that the called party has connected, i.e. the called party is on mute mode. After screening the call, the called party may then indicate that he/she wishes to be connected to the caller, at which time the connection to the alternate destination is terminated and the caller and the called party are connected such that they can speak with each other. If the called party does not wish to speak to the caller, he/she may hang up, and the connection between the caller and the alternate destination may continue.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,AT&T CORP (1995-10-05),https://lens.org/020-263-007-429-724,Granted Patent,yes,5,179,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,379/88.26;;379/211;;455/413;;455/459,0,0,,,,EXPIRED
991,US,B1,US 6349209 B1,053-388-388-412-307,2002-02-19,2002,US 93601497 A,1997-09-23,US 93601497 A,1997-09-23,Method for simplified telephone dialing,"
    An easy to use (easy-reach) dialing system that connects a calling party with a called party based on data received over a first communication channel and a second communication channel. A calling party calls an easy-reach device and sends data to the easy-reach device over a second communication channel. The easy-reach device calls the called party based on data received over the second communication channel and connects the calling party with the called party. 
",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WESTRICH ROBERT S,AT&T CORP (1997-10-24),https://lens.org/053-388-388-412-307,Granted Patent,yes,20,7,1,1,0,H04W4/20;;H04M3/42348,H04W4/20,455/445;;455/31.2;;455/458,0,0,,,,EXPIRED
992,WO,A1,WO 2016/168446 A1,074-082-051-496-242,2016-10-20,2016,US 2016/0027503 W,2016-04-14,US 201562147547 P,2015-04-14,METHODS FOR TYPING OF LUNG CANCER,"Methods and compositions are provided for the molecular subtyping of lung cancer samples. Specifically, a method of assessing whether a patient's adenocarcinoma lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) is provided herein. The method entails detecting the levels of the classifier biomarkers of Table 1-Table 6 or a subset thereof at the nucleic acid level, in a lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample is classified as a TRU, PI, or PP sample.",GENECENTRIC DIAGNOSTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,FARUKI HAWAZIN;;LAI-GOLDMAN MYLA;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,,https://lens.org/074-082-051-496-242,Patent Application,yes,4,5,10,10,114,C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C40B30/04;;C12Q1/68;;C40B40/06;;G01N33/574,,1,0,,,See also references of EP 3283654A4,PENDING
993,CA,A1,CA 2190672 A1,073-885-611-576-287,1997-06-28,1997,CA 2190672 A,1996-11-19,US 57918895 A,1995-12-27,Communication System and Method Using Two-Way Paging to Provide Call Control,,AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/073-885-611-576-287,Patent Application,no,0,0,8,8,0,H04W84/025;;H04W84/025;;H04M3/42229;;H04M3/42229,H04B5/04;;H04M3/42;;H04W84/02,,0,0,,,,EXPIRED
994,CA,A,CA 724925 A,072-709-800-233-399,1966-01-04,1966,CA 724925D A,,CA 724925T A,,DATA PROCESSING AND DISPLAY SYSTEM,,GEN PRECISION INC,HAYEK ARTHUR F;;GRAY JOHN W;;GOLDMAN DAVID A;;MORGER ERNEST A,,https://lens.org/072-709-800-233-399,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
995,JP,A,JP 2006246532 A,105-989-060-108-342,2006-09-14,2006,JP 2006136102 A,2006-05-16,US 57383995 A,1995-12-18,MOBILE COMMUNICATIONS SYSTEM AND COMMUNICATIONS METHOD,"<P>PROBLEM TO BE SOLVED: To provide an apparatus and method for updating a communications network from one or more user communications devices. <P>SOLUTION: The invention uses the electronic scheduling or other time-based functions within a communications device to control and/or initiate transmission of information between the communications device and the communications network. Information from one or more communications devices is updated to the communications network in response to time-based components in the information entries corresponding to a timing device associated with the respective communications devices. Also, once the network receives this updated information, comparisons of related information entries are initiated to detect discrepancies therebetween. In this manner, time and geographic location information an user submitted are compared with similar information automatically retrieved by the communications network using conventional and future network communications technology. Any detected discrepancies are used to initiate appropriate notification to the user. <P>COPYRIGHT: (C)2006,JPO&NCIPI",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/105-989-060-108-342,Patent Application,no,0,0,12,14,0,H04M3/4228;;H04M11/022;;H04Q3/0025;;H04L67/1095;;H04W4/02;;H04M1/72451;;H04M1/72457;;H04L67/52;;H04W4/029;;H04Q3/0025;;H04M11/022;;H04M3/4228;;H04L67/1095;;H04M1/72457;;H04M1/72451;;H04L67/52,G06F13/00;;H04B7/26;;H04M1/72451;;H04M1/72457;;H04M3/42;;H04M11/00;;H04M11/02;;H04Q3/00;;H04W4/02;;H04W4/029,,0,0,,,,PENDING
996,US,A1,US 2009/0125326 A1,113-991-177-480-95X,2009-05-14,2009,US 27035708 A,2008-11-13,US 27035708 A;;US 98765807 P,2007-11-13,METHOD AND APPARATUS FOR INDIRECT MEDICAL CONSULTATION,A method and apparatus is provided comprising a technology engine designed to facilitate indirect medical consultation with health care providers and create a medical record of this indirect consultation event. In one embodiment is provided a method and apparatus for capturing electronically one or more of the following: (a) patient complaints; (b) health care provider's impression/review; (c) health care provider/patient discussion of complaint symptoms following which a treatment plan is formulated regarding health care strategy; (d) any prescription issued by the health care provider; and/or (e) a set of follow-up visits by the patient.,WASSON DAVID S;;GUILLORY PAUL A;;DOLAK JOHN A;;GOLDMAN MATTHEW A,WASSON DAVID S;;GUILLORY PAUL A;;DOLAK JOHN A;;GOLDMAN MATTHEW A,RED STICK VENTURES L.L.C (2008-12-01),https://lens.org/113-991-177-480-95X,Patent Application,yes,7,18,5,5,0,G06Q10/06;;G06Q30/04;;G06Q40/08;;G16H10/20;;G16H10/60;;G16H80/00;;G16H10/20;;G16H10/60;;G06Q10/06;;G06Q30/04;;G06Q40/08;;G16H80/00,G06F17/10;;G06Q50/00;;G06Q10/00;;G06Q40/00;;G07F19/00,705/2;;701/300;;705/4;;705/34,0,0,,,,ACTIVE
997,US,A1,US 2021/0147948 A1,148-332-142-865-244,2021-05-20,2021,US 202117144644 A,2021-01-08,US 202117144644 A;;US 202016887241 A;;US 201715566363 A;;US 2016/0027503 W;;US 201562147547 P,2015-04-14,METHODS FOR TYPING OF LUNG CANCER,"Methods and compositions are provided for the molecular subtyping of lung cancer samples. Specifically, a method of assessing whether a patient's adenocarcinoma lung cancer subtype is terminal respiratory unit (TRU), proximal inflammatory (PI), or proximal proliferative (PP) is provided herein. The method entails detecting the levels of the classifier biomarkers of Table 1-Table 6 or a subset thereof at the nucleic acid level, in a lung cancer sample obtained from the patient. Based in part on the levels of the classifier biomarkers, the lung cancer sample is classified as a TRU, PI, or PP sample.",GENECENTRIC THERAPEUTICS INC;;UNIV NORTH CAROLINA CHAPEL HILL,FARUKI HAWAZIN;;LAI-GOLDMAN MYLA;;MAYHEW GREG;;PEROU CHARLES;;HAYES DAVID NEIL,THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2017-10-24);;GENECENTRIC THERAPEUTICS INC (2017-10-23),https://lens.org/148-332-142-865-244,Patent Application,yes,0,2,10,10,114,C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886;;C12Q2600/112;;C12Q2600/118;;C12Q2600/158;;C12Q1/6886,C12Q1/6886,,0,0,,,,DISCONTINUED
998,CA,C,CA 2190670 C,150-487-318-541-47X,2001-01-16,2001,CA 2190670 A,1996-11-19,US 57918495 A,1995-12-27,COMMUNICATION SYSTEM AND METHOD USING TWO-WAY PAGING TO PROVIDE CALL CONTROL,"A system and method of using two-way paging to establish communications with a mobile party having a Personal Telephone Number. The mobile party is equipped with a two-way pager which the party may use to provide call control. The pager is periodically queried by a network and/or paging service to determine whether or not the pager is reachable. If the pager becomes unreachable, and thereafter a call is placed to the party's Personal Telephone Number, the network routes the call to a default station. If the pager is reachable, any one of a number of alternative call routing procedures may be invoked including: registration type routing, call-by-call routing, revertive calling, call examination routing, and subsequent routing. In one possible embodiment, a Customer Routing Point is used to store the pager status along with other call routing information, and a Network Control Point is used to carry out the appropriate routing procedure. Other possible embodiments include: using an adjunct to perform the functions of the Customer Routing Point and Network Control Point; and combining an adjunct with a Customer Routing Point and Network Control Point.",,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY BETTY;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/150-487-318-541-47X,Granted Patent,no,0,0,8,8,0,H04W4/16;;H04W88/022;;H04W4/16;;H04W88/022,H04W4/16;;H04W88/02,,0,0,,,,EXPIRED
999,MX,A,MX 9603640 A,175-985-848-821-953,1997-05-31,1997,MX 9603640 A,1996-08-26,US 52042595 A,1995-08-29,CALL SCREENING METHOD AND APPARATUS FOR USE IN COMPLETING TELEPHONE CALLS.,"A system and method for providing personal communications services are disclosed. A bridging and signaling unit implements a bridge for connecting telephoned calls between a caller, a called party, and an alternate destination. A caller who calls the personal telephone number associated with a called party is held at the bridging an signaling unit while waiting for a return telephoned call from the called party. The called party is alerted to the existence of the call through a paging system. If the time period during which the caller is on hold exceeds a timout period, the caller will be connected to an alternate distination, such as a secretary, an answering service, or a voice messaging system. If the called party places the return telephone call while the caller is connected to the alternate destination, the called party will be connected to the caller and the alternate destination in such a manner that the called party can hear the conversation between the caller and the alternate distination, but the caller and the alternate destination cannot hear the called party and do not know that the called party has connected, i.e. the called party is on mute mode. After screening the call, the called party may then indicate that he/she wishes to be connected to the caller, at which time the connection to the alternate destination is terminated and the caller and the called party are connected such that they can speak with each other. If the called party does not wish to speak to the caller, he/she may hang up, and the connection between the caller and the alternate destination may continue.",AT & T CORP,FOLADARE MARK JEFFREY;;GOLDMAN SHELLEY B;;SILVERMAN DAVID PHILLIP;;WEBER ROY PHILIP,,https://lens.org/175-985-848-821-953,Patent Application,no,0,0,8,8,0,H04M3/20;;H04M3/382;;H04M3/42229;;H04M3/4283;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/022;;H04Q3/002;;H04Q3/005;;H04Q2213/13097;;H04Q2213/13098;;H04Q2213/13173;;H04Q2213/1324;;H04Q2213/13256;;H04Q2213/1328;;H04Q2213/13282;;H04Q2213/13374;;H04Q2213/13377;;H04Q2213/13513;;H04M2201/14;;H04M3/42229;;H04Q2213/13098;;H04Q2213/1324;;H04M3/533;;H04Q3/005;;H04M3/4283;;H04M3/436;;H04M3/382;;H04Q2213/13256;;H04Q2213/13374;;H04Q2213/13097;;H04Q2213/13173;;H04M3/20;;H04Q2213/13282;;H04M3/58;;H04Q2213/1328;;H04M3/56;;H04M3/54;;H04Q2213/13513;;H04Q2213/13377;;H04M11/022;;H04Q3/002;;H04M3/48;;H04M2201/14,H04M3/42;;H04M1/64;;H04M1/658;;H04M3/20;;H04M3/38;;H04M3/428;;H04M3/436;;H04M3/48;;H04M3/533;;H04M3/54;;H04M3/56;;H04M3/58;;H04M11/02;;H04Q3/00;;H04W4/16;;H04W84/02,,0,0,,,,EXPIRED
1000,AU,A1,AU 2004/233067 A1,003-164-287-533-154,2004-11-04,2004,AU 2004/233067 A,2004-04-16,US 41776303 A;;US 2004/0011608 W,2003-04-17,Apparatus and method for testing liquid samples,"An article for holding a liquefied sample for the quantification of biological material in the sample includes a device having a reaction chamber enclosing a volume therein, the reaction chamber having an upper opening through which a liquefied sample can be poured and a plurality of discrete non-permeable compartments, each of the compartments having an upper rim and being configured and dimensioned to hold separate aliquots of a liquefied sample therein; and a gasket lid removably secured to the top of the device, the gasket lid being configured and dimensioned for sealing the upper rim of each compartment to prevent liquid communication between the compartments.",IDEXX LAB INC,TOWNSEND DAVID EDWARD;;MCCARTHY KATHLEEN R;;GOLDMAN ROSS BRYAN;;SMITH KENNETH E,,https://lens.org/003-164-287-533-154,Patent Application,no,0,0,15,15,0,B01L3/502;;B01L3/50853;;B01L2200/0642;;B01L2300/042;;B01L2300/0832;;B01L2300/0864;;C12Q1/06;;C12M41/36;;B01L3/50853;;B01L3/502;;B01L2300/0832;;C12Q1/06;;B01L2300/0864;;B01L2300/042;;B01L2200/0642;;C12M41/36,B01L3/00;;C12M1/22;;C12Q1/06,,0,0,,,,INACTIVE
